



Quest

LABORATORIES LIMITED

QUEST LABORATORIES LIMITED

CIN: U24232MP1998PLC012850.

Registered Office	Corporate Office	Contact Person	Email and Telephone	Website
Plot No. 45, Sector III, Pithampur Industrial Area, Pithampur, Dhar - 454775, Madhya Pradesh, India.	N.A.	Mr. Jayesh Jain Company Secretary & Compliance Officer	Email: investors@questlabltd.com Telephone: + 91 7292292374	www.questlabltd.com

THE PROMOTERS OF OUR COMPANY ARE MR. ANIL KUMAR SABARWAL AND MS. TEJASWINI SABARWAL

DETAILS OF ISSUE TO PUBLIC, PROMOTERS/SELLING SHAREHOLDERS

TYPE	FRESH ISSUE	SIZE OF OFFER FOR SALE	TOTAL ISSUE SIZE	ELIGIBILITY AND SHARE RESERVATION AMONG QIBs, NIIs AND RIIs
Fresh Issue	44,49,600 Equity Shares aggregating to ₹ 4,316.11 Lakhs*	N.A.	44,49,600 Equity Shares aggregating to ₹ 4,316.11 Lakhs*	The Issue is being made in Terms of Regulation 229 (2) of the SEBI ICDR Regulations. For details in relation to share reservation among QIBs, Non-Institutional Bidders and Retail Individual Bidder, see "Issue Structure" beginning on page 255 of this Prospectus.

*Subject to finalisation of Basis of Allotment.

DETAILS OF OFFER FOR SALE, SELLING SHAREHOLDERS AND THEIR WEIGHTED AVERAGE COST OF ACQUISITION – NOTAPPLICABLE AS THE ENTIRE ISSUE CONSTITUTES FRESH ISSUE OF EQUITY SHARES

RISKS IN RELATION TO THE FIRST ISSUE

This being the first public issue of our Company, there has been no formal market for the Equity Shares. The face value of Equity Shares is ₹ 10/- each. The Floor Price, Cap Price and Issue Price (determined by our Company in consultation with the Book Running Lead Manager, in accordance with the SEBI ICDR Regulations), and on the basis of the assessment of market demand for the Equity Shares by way of Book Building Process as stated in "Basis for Issue Price" beginning on page 95 should not be taken to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active and/or sustained trading in the Equity Shares or regarding the price at which the Equity Shares will be traded after listing.

GENERAL RISKS

Investments in equity and equity-related securities involve a degree of risk and Bidders should not invest any funds in the issue unless they can afford to take the risk of losing their investment. Bidders are advised to read the risk factors carefully before taking an investment decision in the issue. For taking an investment decision, Bidders must rely on their own examination of our Company and the Issue, including the risks involved. The Equity Shares in the issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of this Prospectus. Specific attention of the investors is invited to "Risk Factors" on page 30 of this Prospectus.

ISSUER'S ABSOLUTE RESPONSIBILITY

Our Company, having made all reasonable inquiries, accepts responsibility for and confirms that this Prospectus contains all information with regard to our Company and the Issue, which is material in the context of the Issue, that the information contained in this Prospectus is true and correct in all material aspects and is not misleading in any material respect, that the opinions and intentions expressed herein are honestly held and that there are no other facts, the omission of which makes this Prospectus as a whole or any of such information or the expression of any such opinions or intentions misleading in any material respect.

LISTING

The Equity Shares Issued through the Prospectus are proposed to be listed on Emerge Platform of NSE ("NSE EMERGE"). Our Company has received "In-Principle" approval from the NSE Emerge for using its name in the offer document for the listing of the Equity Shares, pursuant to letter dated May 03, 2024. For the purpose of the Issue, the Designated Stock Exchange shall be NSE.

BOOK RUNNING LEAD MANAGER TO THE ISSUE

Name and Logo	Contact Person	Email & Telephone
 SHRENI SHARES LIMITED	Ms. Tanya Goyal	E-mail: shrenishares@gmail.com Telephone: 022 - 2089 7022

REGISTRAR TO THE ISSUE

Name and Logo	Contact Person	Email & Telephone
 BIGSHARE SERVICES PVT LTD	Mr. Vinayak Morbale	E-mail: ipo@bigshareonline.com Telephone: 022 - 6263 8200

BID/ISSUE PROGRAMME

ANCHOR INVESTOR BID/ ISSUE PERIOD: TUESDAY, MAY 14, 2024*	BID/ISSUE OPENS ON: WEDNESDAY, MAY 15, 2024*	BID/ ISSUE CLOSES ON: FRIDAY, MAY 17, 2024*

*The Anchor Investor Bidding Date was one Working Day prior to the Bid/ Offer Opening Date, i.e., Tuesday, May 14, 2024.

(This page is intentionally left blank)



Quest

LABORATORIES LIMITED

QUEST LABORATORIES LIMITED

Our Company was originally incorporated under the name “*Quest Laboratories Private Limited*” under the provisions of the Companies Act, 1956 vide Certificate of Incorporation dated June 01, 1998, issued by the Registrar of Companies Madhya Pradesh, Gwalior. Subsequently, the status of the Company was changed to public limited and the name of our Company was changed to “*Quest Laboratories Limited*” vide Special Resolution passed by the Shareholders at the Extra Ordinary General Meeting of our Company held on January 11, 2024. The fresh certificate of incorporation consequent to conversion was issued on January 23, 2024, by Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies, Centralised Processing Centre. The Corporate Identification Number of our Company is U24232MP1998PLC012850.

Registered Office: Plot No. 45 Sector III Pithampur, Dhar - 454775, Madhya Pradesh, India; **Tel No:** 07292292374; **E-mail:** investors@questlabltd.com;

Website: www.questlabltd.com; **Contact Person:** Mr. Jayesh Jain, Company Secretary and Compliance Officer;

THE PROMOTERS OF OUR COMPANY ARE MR. ANIL KUMAR SABARWAL AND MS. TEJASWINI SABARWAL

INITIAL PUBLIC OFFER OF 44,49,600 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH (THE “EQUITY SHARES”) OF QUEST LABORATORIES LIMITED (“OUR COMPANY” OR “QUEST” OR “THE ISSUER”) FOR CASH AT A PRICE OF ₹ 97/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 87/- PER EQUITY SHARE (THE “ISSUE PRICE”) AGGREGATING TO ₹ 4,316.11 LAKHS (“THE ISSUE”), OF WHICH 2,28,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 97/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 87/- PER EQUITY SHARE AGGREGATING TO ₹ 221.16 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE “MARKET MAKER RESERVATION PORTION”). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E., NET ISSUE OF 42,21,600 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ 97/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 87/- PER EQUITY SHARE AGGREGATING TO ₹ 4,094.95 LAKHS IS HEREIN AFTER REFERRED TO AS THE “NET ISSUE”. THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 27.15% AND 25.76% RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY. THE FACE VALUE OF EQUITY SHARES IS ₹ 10/- EACH. THE ISSUE PRICE IS 9.7 TIMES THE FACE VALUE OF THE EQUITY SHARES.

In case of any revision in the Price Band, the Bid/Issue Period shall be extended for at least three additional Working Days after such revision of the Price Band, subject to the total Bid/Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company in consultation with the Book Running Lead Manager for reasons to be recorded in writing extend the Bid/Issue Period for a minimum of three Working Days, subject to the Bid/Issue Period not exceeding 10 Working Days. Any revision in the Price Band, and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchange by issuing a press release and also by indicating the change on the website of the Book Running Lead Manager and at the terminals of the Syndicate Members and by intimation to Self-Certified Syndicate Banks (“SCSBs”), other Designated Intermediaries and the Sponsor Banks, as applicable.

THE FACE VALUE OF THE EQUITY SHARES IS ₹ 10/- EACH AND THE ISSUE PRICE IS 9.7 TIMES OF THE FACE VALUE

This Issue is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (“SCRR”) read with Regulation 229 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations wherein not more than 50.00% of the Net Issue shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (“QIBs”) (the “QIB Portion”), provided that our Company in consultation with the BRLM may allocate up to 60.00% of the QIB Portion to Anchor Investors on a discretionary basis (“Anchor Investor Portion”). One-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from the domestic Mutual Funds at or above the Anchor Investor Allocation Price in accordance with the SEBI ICDR Regulations. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (other than the Anchor Investor Portion) (“Net QIB Portion”). Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, other than Anchor Investors, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35.00% of the Net Issue shall be available for allocation to Retail Individual Investors in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Issue Price. All Potential Bidders, other than Anchor Investors, are required to participate in the Issue by mandatorily utilising the Application Supported by Blocked Amount (“ASBA”) process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts will be blocked by the Self-Certified Syndicate Banks (“SCSBs”) or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, please refer to the chapter titled “Issue Procedure” on page 259 of this Prospectus.

RISK IN RELATION TO THE FIRST ISSUE

This being the first public offer of our Company, there has been no formal market for the Equity Shares. The face value of the Equity Shares is ₹ 10/- each. The Floor Price, Cap Price and Issue Price (determined by our Company in consultation with the Book Running Lead Manager, in accordance with the SEBI ICDR Regulations), and on the basis of the assessment of market demand for the Equity Shares by way of the Book Building Process as stated in “Basis for Issue Price” beginning on page 95 should not be taken to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active and/or sustained trading in the Equity Shares or regarding the price at which the Equity Shares will be traded after listing.

GENERAL RISKS

Investments in equity and equity-related securities involve a degree of risk and Bidders should not invest any funds in the Issue unless they can afford to take the risk of losing their investment. Bidders are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, Bidders must rely on their own examination of our Company and the Issue, including the risks involved. The Equity Shares in the Issue have not been recommended or approved by the Securities and Exchange Board of India (“SEBI”), nor does SEBI guarantee the accuracy or adequacy of the contents of this Prospectus. Specific attention of the investors is invited to “Risk Factors” on page 30 of this Prospectus.

ISSUER'S ABSOLUTE RESPONSIBILITY

Our Company, having made all reasonable inquiries, accepts responsibility for and confirms that this Prospectus contains all information with regard to our Company and the Issue, which is material in the context of the Issue, that the information contained in this Prospectus is true and correct in all material aspects and is not misleading in any material respect, that the opinions and intentions expressed herein are honestly held and that there are no other facts, the omission of which makes this Prospectus as a whole or any of such information or the expression of any such opinions or intentions misleading in any material respect.

LISTING

The Equity Shares offered through this Prospectus are proposed to be listed on EMERGE Platform of National Stock Exchange of India Limited (“NSE EMERGE”), in terms of the Chapter IX of the SEBI (ICDR) Regulations, 2018, as amended from time to time. Our Company has received an In-Principle Approval letter dated May 03, 2024 from National Stock Exchange of India Limited (“NSE”) for using its name in this offer document for listing our shares on the EMERGE Platform of National Stock Exchange of India Limited (“NSE EMERGE”). For the purpose of this Issue, the designated Stock Exchange is the NSE.

BOOK RUNNING LEAD MANAGER TO THE ISSUE

REGISTRAR TO THE ISSUE



SHRENI SHARES LIMITED (Formerly Known as Shreni Shares Private Limited)

No. 217, Hive 67 Icon, Poisar Gymkhana Road,
Lokmanya Tilak Nagar Poisar, Near Raghulela Mall,
Kandivali West, Mumbai – 400067, Maharashtra, India.

Telephone: 022 - 2089 7022

E-mail: shrenishares@gmail.com

Investors Grievance e-mail: info@shreni.in

Contact Person: Ms. Tanya Goyal

Website: www.shreni.in

SEBI Registration Number: INM000012759

BIGSHARE SERVICES PRIVATE LIMITED

Office No. S6-2, 6th Floor, Pinnacle Business Park,
Next to Ahura Centre, Mahakali Caves Road, Andheri East,
Mumbai – 400 093, Maharashtra, India

Tel: 022 - 6263 8200

E-mail: ipo@bigshareonline.com

Investor grievance e-mail: investor@bigshareonline.com

Website: www.bigshareonline.com

Contact Person: Mr. Vinayak Morbale

SEBI Registration No.: INR000001385

ISSUE PROGRAMME

ANCHOR INVESTOR BID/ ISSUE PERIOD: TUESDAY, MAY 14, 2024*	BID/ISSUE OPENS ON: WEDNESDAY, MAY 15, 2024*	BID/ ISSUE CLOSES ON: FRIDAY, MAY 17, 2024*

*The Anchor Investor Bidding Date was one Working Day prior to the Bid/ Offer Opening Date, i.e., Tuesday, May 14, 2024.

(This page is intentionally left blank)

TABLE OF CONTENTS

SECTION I – GENERAL	1
DEFINITIONS AND ABBREVIATIONS	1
PRESENTATION OF FINANCIAL INDUSTRY AND MARKET DATA	17
FORWARD LOOKING STATEMENTS	19
SECTION II - SUMMARY OF OFFER DOCUMENT	21
SECTION III – RISK FACTORS	30
SECTION IV – INTRODUCTION	59
THE ISSUE	59
SUMMARY OF FINANCIAL INFORMATION	61
GENERAL INFORMATION	64
CAPITAL STRUCTURE	73
SECTION V – PARTICULARS OF THE ISSUE	86
OBJECTS OF THE ISSUE	86
BASIS FOR ISSUE PRICE	95
STATEMENT OF POSSIBLE TAX BENEFITS	102
SECTION VI – ABOUT THE COMPANY	106
INDUSTRY OVERVIEW	106
OUR BUSINESS	128
KEY INDUSTRY REGULATIONS AND POLICIES	162
HISTORY AND CERTAIN CORPORATE MATTERS	172
OUR MANAGEMENT	175
OUR PROMOTERS AND PROMOTER GROUP	190
OUR GROUP COMPANIES	194
DIVIDEND POLICY	195
SECTION VII – FINANCIAL INFORMATION	196
RESTATED FINANCIAL STATEMENTS	196
OTHER FINANCIAL INFORMATION	197
CAPITALISATION STATEMENT	198
FINANCIAL INDEBTEDNESS	199
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	201
SECTION VIII – LEGAL AND OTHER INFORMATION	221
OUTSTANDING LITIGATIONS AND MATERIAL DEVELOPMENTS	221
GOVERNMENT AND OTHER STATUTORY APPROVALS	230
OTHER REGULATORY AND STATUTORY DISCLOSURES	235
SECTION IX – ISSUE INFORMATION	246
TERMS OF THE ISSUE	246
ISSUE STRUCTURE	255
ISSUE PROCEDURE	259
RESTRICTIONS ON FOREIGN OWNERSHIP OF INDIAN SECURITIES	282
SECTION X – MAIN PROVISIONS OF THE ARTICLES OF ASSOCIATION	283
SECTION XI – OTHER INFORMATION	312
MATERIAL CONTRACTS AND DOCUMENTS FOR INSPECTION	312
DECLARATION	314

SECTION I – GENERAL

DEFINITIONS AND ABBREVIATIONS

This Prospectus uses certain definitions and abbreviations which, unless the context otherwise indicates or implies or unless otherwise specified, shall have the meaning as provided below. References to any legislation, act, regulations, rules, guidelines or policies shall be to such legislation, act, regulations, rules, guidelines or policies as amended, supplemented, or re-enacted from time to time and any reference to a statutory provision shall include any subordinate legislation made from time to time under that provision.

The words and expressions used in this Prospectus, but not defined herein shall have, to the extent applicable, the meaning ascribed to such terms under SEBI ICDR Regulations, the Companies Act, the SCRA, the Depositories Act, and the rules and regulations made thereunder.

Notwithstanding the foregoing, the terms not defined but used in the chapters titled “*Statement of Possible Tax Benefits*”, “*Restated Financial Statements*”, “*Outstanding Litigations and Material Developments*”, “*Key Industry Regulations and Policies*” and section titled “*Main Provisions of the Articles of Association*” on page 102, 196, 221, 128 and 283 respectively of this Prospectus, shall have the meanings ascribed to such terms in the respective sections.

GENERAL TERMS

Term	Description
“Quest”, “the Company”, “our Company” and Quest Laboratories Limited	Quest Laboratories Limited, a company incorporated in India under the Companies Act, 1956 having its Registered office at Plot No. 45, Sector – III, Pithampur, Dhar - 454775, Madhya Pradesh, India.
“we”, “us” and “our”	Unless the context otherwise indicates or implies, refers to our Company
“you”, “your” or “yours”	Prospective investors in this Issue

COMPANY RELATED TERMS

Term	Description
AOA / Articles / Articles of Association	The Articles of Association of Quest Laboratories Limited as amended from time to time.
Audit Committee	The Audit Committee of our Company, constituted on February 02, 2023 in accordance with Section 177 of the Companies Act, 2013, as described in “ <i>Our Management</i> ” beginning on page 175 of this Prospectus
Auditors/ Statutory Auditors	The Statutory Auditors of our Company, currently being M/s Shyam S Gupta & Associates, Chartered Accounts, having their office 305, Milindas Maner, 2 RNT Marg, Indore - 425001, Madhya Pradesh, India.
Bankers to the Company	HDFC Bank Limited
Board of Directors / the Board / our Board	The Board of Directors of our Company, including all duly constituted Committees thereof. For further details of our Directors, please refer to section titled “ <i>Our Management</i> ” beginning on page 175 of this Prospectus.
Chairman/ Chairperson	The Chairman of Board of Directors of our Company being Mr. Anil Kumar Sabarwal
CIN	Corporate Identification Number of our Company i.e. U24232MP1998PLC012850
Chief Financial Officer/CFO	The Chief Financial Officer of our Company being Mr. Ram Krishna Sharma
Companies Act / Act	The Companies Act, 2013 and amendments thereto. The Companies Act, 1956, to the extent of such of the provisions that are in force.
Company Secretary and Compliance Officer	The Company Secretary and Compliance Officer of our Company being Mr. Jayesh Jain
Corporate Social Responsibility Committee	The Corporate Social Responsibility Committee of our Company, constituted on February 02, 2023 in accordance with Section 135 of the Companies Act, 2013, as described in “ <i>Our Management</i> ” beginning on page 175 of this Prospectus
DIN	Directors Identification Number.
Director(s) / our Directors	The Director(s) of our Company, unless otherwise specified.
Equity Shares	Equity Shares of our Company of Face Value of ₹10/- each fully paid-up
Equity Shareholders	Persons/ Entities holding Equity Shares of Our Company.
Executive Directors	Executive Directors are the Managing Director & Whole Time Directors of our Company.

Term	Description
Group Company	In terms of SEBI ICDR Regulations, the term “ <i>Group Company</i> ” includes companies (other than our Promoters and Subsidiaries) with which there were related party transactions as disclosed in the Restated Financial Statements as covered under the applicable accounting standards, any other companies as considered material by our Board, in accordance with the Materiality Policy and as disclosed in chapter titled “ <i>Our Group Company</i> ” beginning on page 194 of this Prospectus
Independent Director(s)	Independent Directors on the Board, and eligible to be appointed as an Independent Director under the provisions of Companies Act and SEBI LODR Regulations. For details of the Independent Directors, please refer to chapter titled “ <i>Our Management</i> ” beginning on page 175 of this Prospectus
ISIN	International Securities Identification Number. In this case being INE0TNW01017
Key Management Personnel / KMP	Key Managerial Personnel of our Company in terms of Regulation 2(1)(bb) of the SEBI ICDR Regulations, together with the Key Managerial Personnel of our Company in terms of Section 2(51) of the Companies Act, 2013 and as disclosed in the chapter titled “ <i>Our Management</i> ” beginning on page 175 of this Prospectus
Key Performance Indicators” or “KPIs”	Key financial and operational performance indicators of our Company, as included in “ <i>Basis for Issue Price</i> ” beginning on page 95.
Materiality Policy	The policy on identification of group companies, material creditors and material litigation, adopted by our Board on February 02, 2024 in accordance with the requirements of the SEBI (ICDR) Regulations, 2018.
MD or Managing Director	The Managing Director of our Company being Mr. Anil Kumar Sabarwal.
MOA / Memorandum of Association	The Memorandum of Association of our Company, as amended from time to time
Non-Residents	A person resident outside India, as defined under FEMA Regulations, 2000
Nomination and Remuneration Committee	The Nomination and Remuneration Committee of our Company, constituted on February 02, 2024 in accordance with Section 178 of the Companies Act, 2013, the details of which are provided in “ <i>Our Management</i> ” beginning on page 175 of this Prospectus
Non-Executive Director	A Director not being an Executive Director or an Independent Director
NRIs / Non-Resident Indians	A person resident outside India, as defined under FEMA Regulation and who is a citizen of India or a Person of Indian Origin under Foreign Exchange Management (Transfer or Issue of Security by a Person Resident Outside India) Regulations, 2000.
Peer Review Auditors	Auditor having a valid Peer Review certificate in our case being M/s. Shyam S Gupta & Associates
Person or Persons	Any individual, sole proprietorship, unincorporated association, unincorporated organization, body corporate, corporation, company, partnership, limited liability company, joint venture, or trust or any other entity or organization validly constituted and/or incorporated in the jurisdiction in which it exists and operates, as the context requires.
Promoter(s)	Shall mean promoters of our Company i.e., Mr. Anil Kumar Sabarwal and Ms. Tejaswini Sabarwal. For further details, please refer to section titled “ <i>Our Promoters and Promoter Group</i> ” beginning on page 190 of this Prospectus.
Promoter Group	Includes such Persons and entities constituting our promoter group covered under Regulation 2(1)(pp) of the SEBI (ICDR) Regulations as enlisted in the section titled “ <i>Our Promoters and Promoter Group</i> ” beginning on page 190 of this Prospectus.
Registered Office	The Registered Office of our Company situated at Plot No. 45, Sector – III, Pithampur, Dhar - 454775, Madhya Pradesh, India.
Restated Financial Information	Restated Financial Statements for the period ended December 31, 2023 and Financial Years ended on 2023, 2022, and 2021 (prepared in accordance with the Indian GAAP read with Section 133 of the Companies Act, 2013 and restated in accordance with requirements of Section 26 of Part I of Chapter III of Companies Act 2013, as amended, the SEBI ICDR Regulations, as amended and the Guidance Note on “ <i>Reports in Company Prospectuses (Revised 2019)</i> ” issued by ICAI, as amended) which comprises the restated summary Statement of Assets & Liabilities, the restated summary Statement of Profit and Loss, the restated summary Statement of Cash Flows and restated statement of change in equity along with all the schedules, annexures and notes thereto
RoC/ Registrar of Companies	Registrar of Companies, Gwalior, 3 rd , Floor, A Block, Sanjay Complex, Jayendra Ganj, Gwalior - 474009, Madhya Pradesh, India.
Shareholders	Shareholders of our Company

Term	Description
Stock Exchange	Unless the context requires otherwise, refers to, National Stock Exchange of India Limited
Subscriber to MOA / Initial Promoters	Initial Subscriber to MOA & AOA being Mr. Narendra Pamecha, Mr. Anil Kumar Sabarwal
Stakeholders Relationship Committee	The Stakeholders' Relationship Committee of our Company, constituted on February 02, 2024 in accordance with Section 178 of the Companies Act, 2013, the details of which are provided in " <i>Our Management</i> " beginning on page 175 of this Prospectus
Senior Management	Senior Management of our Company in terms of Regulation 2(1)(bbbb) of the SEBI ICDR Regulations and as disclosed in the chapter titled " <i>Our Management</i> " beginning on page 175 of this Prospectus
Whole Time Director	Whole Time Director of our Company being Ms. Tejaswini Sabarwal and Mr. Rahul Dangi

KEY PERFORMANCE INDICATORS

Key Financial Performance	Explanations
Revenue from Operations	Revenue from Operations is used by the management to track the revenue profile of the business and in turn helps to assess the overall financial performance of the Company and volume of the business.
EBITDA	EBITDA provides information regarding the operational efficiency of the business
EBITDA Margin	EBITDA Margin (%) is an indicator of the operational profitability and financial performance of our business
PAT	Profit after tax provides information regarding the overall profitability of the business
PAT Margin	PAT Margin (%) is an indicator of the overall profitability and financial performance of the business
Return on Equity Ratio	Return on equity (ROE) is a measure of financial performance
Debt-Equity Ratio	Debt / Equity Ratio is used to measure the financial leverage of the Company and provides comparison benchmark against peers
Current Ratio	The current ratio is a liquidity ratio that measures our company's ability to pay short-term obligations or those due within one year

ISSUE RELATED TERMS

Term	Description
Abridged Prospectus	Abridged Prospectus to be issued under Regulation 255 of SEBI ICDR Regulations and appended to the Application Form
Allotment/Allot/Allotted	Unless the context otherwise requires, the issue and allotment of Equity Shares, pursuant to the Issue to the successful applicants.
Acknowledgement Slip	The slip or document issued by the Designated Intermediary to an Applicant as proof of registration of the Application.
Allotment Advice	Note or advice or intimation of Allotment sent to the Applicants who have been allotted Equity Shares after the Basis of Allotment has been approved by the Designated Stock Exchanges
Allotment Date	Date on which allotment is made
Allottee (s)	The successful bidder to whom the Equity Shares are being / have been allotted.
Anchor Investor	A Qualified Institutional Buyer, who applied under the Anchor Investor Portion in accordance with the requirements specified in the SEBI ICDR Regulations and the Red Herring Prospectus
Anchor Investor Allocation Price	The price at which Equity Shares will be allocated to the Anchor Investors in terms of the Prospectus and the Prospectus, which will be decided by our Company in consultation with the Book Running Lead Manager during the Anchor Investor Bid/Issue Period.
Anchor Investor Application Form	The application form used by an Anchor Investor to make a Bid in the Anchor Investor Portion and which will be considered as an application for Allotment in terms of the Prospectus and the Prospectus.
Anchor Investor Bid/Issue Period or Anchor Investor Bidding Date	The date one Working Day prior to the Bid/Issue Opening Date, on which Bids by Anchor Investors shall be submitted, prior to and after which the Book Running Lead Manager will not accept any Bids from Anchor Investors, and allocation to the Anchor Investors shall be completed.
Anchor Investor Issue Price	The final price at which the Equity Shares will be Allotted to the Anchor Investors in terms of the Prospectus and the Prospectus, which price will be equal to or higher than the Issue

Term	Description
	Price but not higher than the Cap Price. The Anchor Investor Issue Price will be decided by our Company in consultation with the Book Running Lead Manager
Anchor Investor Pay-in Date	With respect to Anchor Investor(s), it shall be the Anchor Investor Bidding Date, and in the event the Anchor Investor Allocation Price is lower than the Issue Price, not later than two Working Days after the Bid/ Issue Closing Date
Anchor Investor Portion	Up to 60% of the QIB Portion which may be allocated by our Company, in consultation with the Book Running Lead Manager, to the Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations. One-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price, in accordance with the SEBI ICDR Regulations
Applicant/ Investor	Any prospective investor who makes an application for Equity Shares in terms of this Prospectus.
Application Amount	The amount at which the Applicant makes an application for the Equity Shares of our Company in terms of Prospectus.
Application Form	The form in terms of which the Applicant shall make an Application, including ASBA Form, and which shall be considered as the application for the Allotment pursuant to the terms of this Prospectus.
ASBA Account	A bank account linked with or without UPI ID, maintained with an SCSB and specified in the ASBA Form submitted by the Applicants for blocking the Application Amount mentioned in the ASBA Form.
ASBA Bidders	Any prospective investor who makes a bid pursuant to the terms of the Prospectus and the Bid cum Application Form including through UPI mode (as applicable).
ASBA Form	A bid cum application form, whether physical or electronic, used by ASBA bidders, which will be considered as the bid for Allotment in terms of the Prospectus.
Bidding Centres	Centres at which the Designated Intermediaries shall accept the Application Forms i.e. Designated SCSB Branch for SCSBs, Specified Locations for members of the Syndicate, Broker Centres for Registered Brokers, Designated RTA Locations for RTAs and Designated CDP Locations for CDPs.
Bankers to the Issue	Banks which are clearing members and registered with SEBI as Bankers to an Issue and with whom the Public Issue Account will be opened, in this case being ICICI Bank Limited
Banker to the Issue Agreement	Agreement dated March 26, 2024 entered into amongst the Company, Book Running Lead Manager, the Registrar and the Banker of the Issue.
Basis of Allotment	The basis on which the Equity Shares will be Allotted, described in “Issue Procedure” on page 259 of this Prospectus.
Bid	An indication to make an Issue during the Bid/ Issue Period by an ASBA Bidder pursuant to submission of the ASBA Form, or during the Anchor Investor Bidding Date by an Anchor Investor pursuant to submission of the Anchor Investor Application Form, to subscribe to or purchase the Equity Shares at a price within the Price Band, including all revisions and modifications thereto as permitted under the SEBI ICDR Regulations and in terms of the Prospectus and the relevant Bid cum Application Form. The term “Bidding” shall be construed accordingly.
Bid Lot	1,200 Equity Shares and in multiples of 1,200 Equity Shares thereafter
Bid / Issue Closing Date	Except in relation to any Bids received from the Anchor Investors, the date after which the Designated Intermediaries will not accept any Bids, which shall be notified in all editions of editions of The Financial Express (a widely circulated English national daily newspaper), all editions of Jansatta (a widely circulated Hindi national daily newspaper) and Hamara Swaraj, Hindi regional newspaper (Hindi being the regional language of Madhya Pradesh, where our Registered Office is located). Our Company, in consultation with the BRLM, may, consider closing the Bid/Issue Period for QIBs one Working Day prior to the Bid/ Issue Closing Date in accordance with the SEBI ICDR Regulations. In case of any revision, the extended Bid/ Issue Closing Date shall be widely disseminated by notification to the Stock Exchanges, and also be notified on the websites of the BRLM and at the terminals of the Syndicate Members, if any and communicated to the Designated Intermediaries and the Sponsor Bank, which shall also be notified in an advertisement in same newspapers in which the Bid/ Issue Opening Date was published, as required under the SEBI ICDR Regulations

Term	Description
Bid/Issue Opening Date	Except in relation to any Bids received from the Anchor Investors, the date on which the Designated Intermediaries shall start accepting Bids, being which shall be notified in all editions of editions of The Financial Express (a widely circulated English national daily newspaper), all editions of Jansatta (a widely circulated Hindi national daily newspaper) and a Hamara Swaraj, Hindi regional newspaper (Hindi being the regional language of Madhya Pradesh, where our Registered Office is located).
Bid/ Issue Period	Except in relation to Anchor Investors, the period between the Bid/ Issue Opening Date and the Bid/ Issue Closing Date, inclusive of both days, during which prospective Bidders can submit their Bids, including any revisions thereof in accordance with the SEBI ICDR Regulations and the terms of the Prospectus. Provided, however, that the Bidding shall be kept open for a minimum of three Working Days for all categories of Bidders, other than Anchor Investors. Our Company, in consultation with the Book Running Lead Manager may consider closing the Bid/Issue Period for the QIB Portion One Working Day prior to the Bid/Issue Closing Date which shall also be notified in an advertisement in same newspapers in which the Bid/Issue Opening Date was published, in accordance with the SEBI ICDR Regulations. In cases of force majeure, banking strike or similar circumstances, our Company may, in consultation with the BRLM, for reasons to be recorded in writing, extend the Bid / Issue Period for a minimum of three Working Days, subject to the Bid/ Issue Period not exceeding 10 Working Days
Bidder/ Investor	Any prospective investor who makes a bid for Equity Shares in terms of this Prospectus.
Bidding Centres	Centres at which the Designated Intermediaries shall accept the Bid cum Application Forms i.e. Designated SCSB Branch for SCSBs, Specified Locations for members of the Syndicate, Broker Centres for Registered Brokers, Designated RTA Locations for RTAs and Designated CDP Locations for CDPs.
Bid Amount	The amount at which the bidder makes a bid for the Equity Shares of our Company in terms of Prospectus.
Bid cum Application Form	The form in terms of which the bidder shall make a bid, including ASBA Form, and which shall be considered as the bid for the Allotment pursuant to the terms of this Prospectus.
Book Building Process	Book building process, as provided in Part A of Schedule XIII of the SEBI ICDR Regulations, in terms of which the Issue is being made
BRLM / Book Running Lead Manager	The Book Running Lead Manager to the Issue, namely, Shreni Shares Limited (<i>Formerly Known as Shreni Shares Private Limited</i>)
Broker Centers	Broker Centres notified by the Stock Exchanges where ASBA Bidders can submit the ASBA Forms to a Registered Broker. The details of such Broker Centres, along with the names and contact details of the Registered Broker are available on the respective websites of the Stock Exchange (www.nseindia.com)
Business Day	Monday to Friday (except public holidays).
CAN / Confirmation of Allocation Note	A notice or intimation of allocation of the Equity Shares sent to Anchor Investors, who have been allocated Equity Shares, on or after the Anchor Investor Bid/Issue Period
Cap Price	The higher end of the Price Band, i.e. ₹ 97/- per Equity Share
Client Id	Client Identification Number maintained with one of the Depositories in relation to demat account
Collecting Depository Participants or CDPs	A depository participant as defined under the Depositories Act, 1996, registered with SEBI and who is eligible to procure Bids at the Designated CDP Locations in terms of circular No. GR/CFD/POLICYCELL/11/2015 dated November 10, 2015 issued by SEBI as per the list available on the respective websites of the Stock Exchanges, as updated from time to time
Controlling Branches of the SCSBs	Such branches of the SCSBs which coordinate with the BRLM, the Registrar to the Issue and the Stock Exchange.
Cut-off Price	The Issue Price finalised by our Company in consultation with the Book Running Lead Manager which shall be any price within the Price Band. Only Retail Individual Bidders Bidding in the Retail Portion are entitled to Bid at the Cut-Off Price. QIBs (including the Anchor Investors) and Non-Institutional Bidders are not entitled to Bid at the Cut-off Price
Demographic Details	The demographic details of the Applicants such as their Address, PAN, name of the applicant father/husband, investor status, occupation and Bank Account details.

Term	Description
Depository / Depositories	A depository registered with SEBI under the Securities and Exchange Board of India (Depositories and Participants) Regulations, 1996 as amended from time to time, being NSDL and CDSL.
Designated Date	On the Designated Date, the amounts blocked by SCSBs are transferred from the ASBA Accounts to the Public Issue Account and/ or unblocked in terms of this Prospectus.
Designated SCSB Branches	Such branches of the SCSBs which shall collect the ASBA Application Form from the ASBA Applicant and a list of which is available on the website of SEBI at http://www.sebi.gov.in/sebiweb/home/list/5/33/0/0/ Recognized-Intermediaries or at such other website as may be prescribed by SEBI from time to time
Designated CDP Locations	Such locations of the CDPs where Applicant can submit the Application Forms to Collecting Depository Participants. The details of such Designated CDP Locations, along with names and contact details of the Collecting Depository Participants eligible to accept Application Forms are available on the websites of the Stock Exchange i.e. www.nseindia.com
Designated RTA Locations	Such locations of the RTAs where Applicant can submit the Application Forms to RTAs. The details of such Designated RTA Locations, along with names and contact details of the RTAs eligible to accept Application Forms are available on the websites of the Stock Exchange i.e. www.nseindia.com
Designated Intermediaries / Collecting Agent	Collectively, the members of the Syndicate, sub-syndicate or agents, SCSBs (other than in relation to RIBs using the UPI Mechanism), Registered Brokers, CDPs and RTAs, who are authorised to collect Bid cum Application Forms from the relevant Bidders, in relation to the issue. In relation to ASBA Forms submitted by UPI Bidders where the Bid Amount will be blocked upon acceptance of UPI Mandate Request by such UPI Bidder using the UPI Mechanism, Designated Intermediaries shall mean Syndicate, sub-syndicate/agents, Registered Brokers, CDPs, SCSBs and RTAs. In relation to ASBA Forms submitted by QIBs and Non-Institutional Bidders (not using the UPI Mechanism), Designated Intermediaries shall mean Syndicate, sub-syndicate/agents, SCSBs, Registered Brokers, the CDPs and RTAs
Designated Market Maker	Rikhav Securities Limited will act as the Market Maker and has agreed to receive or deliver the specified securities in the market making process for a period of three years from the date of listing of our Equity Shares or for a period as may be notified by amendment to SEBI ICDR Regulations.
Designated Stock Exchange	National Stock Exchange of India Limited (SME Platform) (“NSE EMERGE”)
DP	Depository Participant
DP ID	Depository Participant’s Identity Number
Draft Red Herring Prospectus	Draft Red Herring Prospectus dated March 01, 2024 filed with Exchange and issued in accordance with Section 23, 26 and 32 of the Companies Act, 2013 and SEBI ICDR Regulation.
Eligible NRI	A Non-Resident Indian in a jurisdiction outside India where it is not unlawful to make an issue or invitation under the Issue and in relation to whom this Prospectus will constitute an invitation to subscribe for the Equity Shares.
Emerge Platform of NSE	The SME Platform of NSE for Listing of Equity Shares offered under Chapter IX of SEBI (ICDR) Regulations which was approved by SEBI as an NSE EMERGE on March 13, 2012.
Equity Shares	Equity Shares of our Company of face value ₹ 10.00 each
Electronic Transfer of Funds	Refunds through ECS, NEFT, Direct Credit or RTGS as applicable.
Eligible QFIs	QFIs from such jurisdictions outside India where it is not unlawful to make an offer or invitation under the Issue and in relation to whom the Prospectus constitutes an invitation to purchase the Equity Shares Issued thereby and who have opened demat accounts with SEBI registered qualified depository participants.
Eligible NRI(s)	An NRI(s) from such a jurisdiction outside India where it is not unlawful to make an Issue or invitation under this Issue and in relation to whom the Application Form and the Prospectus will constitute an invitation to purchase the equity shares.
Escrow Account	Accounts opened with the Banker to the Issue

Term	Description
FII / Foreign Institutional Investors	Foreign Institutional Investor (as defined under SEBI (Foreign Institutional Investors) Regulations, 1995, as amended) registered with SEBI under applicable laws in India.
First/ Sole Applicant	The Applicant whose name appears first in the Application Form or Revision Form.
Floor Price	The lower end of the Price Band, subject to any revision(s) thereto, not being less than the face value of Equity Shares, at or above which the Issue Price and the Anchor Investor Issue Price will be finalised and below which no Bids will be accepted
Foreign Venture Capital Investors	Foreign Venture Capital Investors registered with SEBI under the SEBI (Foreign Venture Capital Investor) Regulations, 2000.
FPI / Foreign Portfolio Investor	A Foreign Portfolio Investor who has been registered pursuant to the of Securities and Exchange Board of India (Foreign Portfolio Investors) Regulations, 2014, provided that any FII or QFI who holds a valid certificate of registration shall be deemed to be a foreign portfolio investor till the expiry of the block of three years for which fees have been paid as per the SEBI (Foreign Institutional Investors) Regulations, 1995, as amended
General Information Document (GID)	The General Information Document for investing in public issues prepared and issued in accordance with the circulars (CIR/CFD/DIL/12/2013) dated October 23, 2013, notified by SEBI and updated pursuant to the circular (CIR/CFD/POLICYCELL/11/2015) dated November 10, 2015 and (SEBI/HO/CFD/DIL/CIR/P/2016/26) dated January 21, 2016 and circular (SEBI/HO/CFD/DIL2/CIR/P/2018/138) dated November 1, 2018 notified by SEBI.
GIR Number	General Index Registry Number.
IPO/ Issue/ Issue Size/ Public Issue	Initial Public Offering
Issue Agreement	The agreement dated February 20, 2024, entered amongst our Company and the Book Running Lead Manager, pursuant to which certain arrangements are agreed to in relation to the Issue.
Issue Closing Date	The date after which the Book Running Lead Manager, Syndicate Member, Designated Branches of SCSBs and Registered Brokers will not accept any Application for this Issue, which shall be notified in a English national newspaper, Hindi national newspaper and a regional newspaper each with wide circulation as required under the SEBI (ICDR) Regulations. In this case being May 17, 2024
Issue Opening Date	The date on which the Book Running Lead Manager, Syndicate Member, Designated Branches of SCSBs and Registered Brokers shall start accepting Application for this Issue, which shall be the date notified in an English national newspaper, Hindi national newspaper and a regional newspaper each with wide circulation as required under the SEBI (ICDR) Regulations. In this case being May 15, 2024
Issue Price	The Price at which the Equity Shares are being issued by our Company under this Prospectus being ₹ 97/- per equity share.
Issue Period	The period between the Issue Opening Date and the Issue Closing Date inclusive of both days and during which prospective Applicants can submit their applications.
Issue Size	The Public Issue of 44,49,600 Equity shares of ₹10/- each at issue price of ₹ 97/- per Equity share, including a premium of ₹ 87/- per equity share aggregating to ₹ 4,316.11 Lakhs
Issue Proceeds	Proceeds to be raised by our Company through this Issue, for further details please refer chapter titled “ <i>Objects of the Issue</i> ” page 86 of this Prospectus
Market Making Agreement	The Market Making Agreement dated April 25, 2024 between our Company, Book Running Lead Manager and Market Maker.
Market Maker Reservation Portion	The reserved portion of 2,28,000 Equity Shares of ₹10 each at an Issue price of ₹ 97/- each aggregating to ₹ 221.16 Lakhs to be subscribed by Market Maker in this issue.
Memorandum of Understanding / MOU	The Memorandum of Understanding dated February 20, 2024 between our Company and BRLM.
Mutual Funds	A mutual fund registered with SEBI under the SEBI (Mutual Funds) Regulations, 1996, as amended from time to time
Net Issue	The Issue (excluding the Market Maker Reservation Portion) of 42,21,600 equity Shares of ₹ 10.00 each at a price of ₹ 97/- per Equity Share (the “ Issue Price ”), including a share premium of ₹ 87/- per equity share aggregating to ₹ 4,094.95 Lakhs.
Net Proceeds	The proceeds from the Issue less the Issue related expenses applicable to the Fresh Issue.
Net QIB Portion	The portion of the QIB Portion less the number of Equity Shares Allocated to the Anchor Investors.

Term	Description
Non-Institutional Investors/ Applicant	Investors other than Retail Individual Investors, NRIs and QIBs who apply for the Equity Shares of a value of more than ₹ 2,00,000/-
Non-Resident	A person resident outside India, as defined under FEMA and includes Eligible NRIs, Eligible QFIs, FIIs registered with SEBI and FVCIs registered with SEBI
NSE	National Stock Exchange of India Limited
Other Investor	Investors other than Retail Individual Investors. These include individual applicants other than retail individual investors and other investors including corporate bodies or institutions irrespective of the number of specified securities applied for.
Overseas Corporate Body/ OCB	Overseas Corporate Body means and includes an entity defined in clause (xi) of Regulation 2 of the Foreign Exchange Management (Withdrawal of General Permission to Overseas Corporate Bodies (OCB's) Regulations 2003 and which was in existence on the date of the commencement of these Regulations and immediately prior to such commencement was eligible to undertake transactions pursuant to the general permission granted under the Regulations. OCBs are not allowed to invest in this Issue.
Pay-in-Period	The period commencing on the Bid/Issue Opening date and extended till the closure of the Anchor Investor Pay-in-Date.
Payment through electronic transfer of funds	Payment through NECS, NEFT or Direct Credit, as applicable
Person/Persons	Any individual, sole proprietorship, unincorporated association, unincorporated organization, body corporate, corporation, company, partnership, limited liability company, joint venture, or trust or any other entity or organization validly constituted and/or incorporated in the jurisdiction in which it exists and operates, as the context requires.
Price Band	Price Band of a minimum price (Floor Price) of ₹ 93/- and the maximum price (Cap Price) of ₹ 97/- and includes revisions thereof. The Price Band will be decided by our Company in consultation with the BRLM and advertised in two national daily newspapers (one each in English and in Hindi) with wide circulation and one daily regional newspaper with wide circulation at least two working days prior to the Bid / Issue Opening Date
Prospectus	This Prospectus dated May 20, 2024 filing with the RoC in accordance with the Companies Act, 2013, and the SEBI ICDR Regulations containing, inter alia, the Issue Price that is determined at the end of the Book Building Process, the size of the Issue and certain other information, including any addenda or corrigenda thereto.
Public Issue Account	Account opened with the Bankers to the Issue to receive monies from the SCSBs from the bank account of the ASBA Applicant, on the Designated Date.
Qualified Foreign Investors / QFIs	Non-resident investors other than SEBI registered FIIs or sub-accounts or SEBI registered FVCIs who meet 'know your client' requirements prescribed by SEBI.
Qualified Institutional Buyers/ QIBs	A Mutual Fund, Venture Capital Fund and Foreign Venture Capital Investor registered with the SEBI, a foreign institutional investor and sub-account (other than a sub-account which is a foreign corporate or foreign individual), registered with the SEBI; a public financial institution as defined in Section 2(72) of the Companies Act, 2013; a scheduled commercial bank; a multilateral and bilateral development financial institution; a state industrial development corporation; an insurance company registered with the Insurance Regulatory and Development Authority; a provident fund with minimum corpus of ₹ 25.00 Crore; a pension fund with minimum corpus of ₹ 25.00 Crore; National Investment Fund set up by resolution No. F. No. 2/3/2005 – DDII dated November 23, 2005 of the Government of India published in the Gazette of India, insurance funds set up and managed by army, navy or air force of the Union of India and insurance funds set up and managed by the Department of Posts, India.
Red Herring Prospectus / RHP	This Red Herring Prospectus dated May 08, 2024 by our company in accordance with Section 32 of the Companies Act, 2013 and the provisions of the SEBI ICDR Regulations, which will not have complete particulars of the price at which the Equity Shares will be Issued and the size of the Issue, including any addenda or corrigenda thereto. This Red Herring Prospectus will be filed with the RoC at least three Working Days before the Bid/ Issue Opening Date and will become the Prospectus upon filing with the RoC on or after the Pricing Date.
Refund Account (s)	Account(s) to which monies to be refunded to the Applicants shall be transferred from the Public Issue Account in case listing of the Equity Shares does not occur.
Registrar/ Registrar to the Issue/RTA/ RTI	Registrar to the Issue being Bigshare Services Private Limited

Term	Description
Registrar Agreement	The agreement dated February 20, 2024 entered into between our Company, and the Registrar to the Issue in relation to the responsibilities and obligations of the Registrar to the Issue pertaining to the Issue.
Reserved Category/ Categories	Categories of persons eligible for making application under reservation portion.
Regulations	SEBI (Issue of Capital and Disclosure Requirement) Regulations, 2018 as amended from time to time.
Retail Individual Investors	Individual investors (including HUFs, in the name of Karta and Eligible NRIs) who apply for the Equity Shares of a value of not more than ₹ 2,00,000.
Registered Broker	Individuals or companies registered with SEBI as “Trading Members”(except Syndicate/ Sub-Syndicate Members) who hold valid membership of either BSE or NSE having right to trade in stocks listed on Stock Exchanges ,through which investors can buy or sell securities listed on stock exchanges,a list of which is available on http://www.nseindia.com/membership/content/cat_of_mem.htm
Reserved Category/ Categories	Categories of persons eligible for making application under reservation portion.
Reservation Portion	The portion of the Issue reserved for category of eligible Applicants as provided under the SEBI (ICDR) Regulations, 2018
Revision Form	The form used by the Applicants to modify the quantity of Equity Shares or the Application Amount in any of their Application Forms or any previous Revision Form(s)
Registrar and Share Transfer Agents or RTAs	Registrar and Share Transfer Agents registered with SEBI and eligible to procure Applications at the Designated RTA Locations in terms of circular No. CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 issued by SEBI and available on the websites of the Stock Exchanges at www.nseindia.com
SEBI Listing Regulations	Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
SCORES	SEBI Complaints Redress System, a centralized web-based complaints redressal system launched by SEBI
Self-Certified Syndicate Bank(s) / SCSB(s)	The banks registered with SEBI, offering services, (i) in relation to ASBA (other than through UPI Mechanism), a list of which is available on the website of SEBI at www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=34 or such other website as updated from time to time, and (ii) in relation to ASBA through the UPI Mechanism, a list of which is available on the website of SEBI at https://sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=40 or such other website as updated from time to time. In relation to Bids (other than Bids by Anchor Investor) submitted to a member of the Syndicate, the list of branches of the SCSBs at the Specified Locations named by the respective SCSBs to receive deposits of Bid cum Application Forms from the members of the Syndicate is available on the website of the SEBI at https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=35 and updated from time to time. In accordance with SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2019/76 dated June 28, 2019 and SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019, UPI Bidders using the UPI Mechanism may apply through the SCSBs and mobile applications whose names appears on the website of the SEBI at https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=40 and https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=43 respectively, as updated from time to time
SME Exchange	SME Platform of the NSE i.e. NSE EMERGE
Specified Locations	The Bidding Centres where the Syndicate shall accept ASBA Forms from Bidders and in case of RIBs only ASBA Forms with UPI
Sponsor Bank	Shall mean a Banker to the Issue registered with SEBI which is appointed by the issuer to act as a conduit between the Stock Exchanges and National Payments Corporation of India in order to push the mandate collect requests and/or payment instructions of the retail investors into the UPI.

Term	Description
Syndicate Agreement	Syndicate agreement to be entered into between our Company, the Registrar and the members of the Syndicate in relation to collection of Bid cum Application Forms by the Syndicate
Syndicate Member(s)	Intermediaries (other than the Book Running Lead Manager) registered with SEBI who are permitted to accept bids, applications and place order with respect to the Issue, namely Shreni Shares Limited (<i>Formerly Known as Shreni Shares Private Limited</i>)
Transaction Registration Slip/ TRS	The slip or document issued by a member of the Syndicate or an SCSB (only on demand), as the case may be, to the applicants, as proof of registration of the Application
Underwriters	The BRLM who has underwritten this Issue pursuant to the provisions of the SEBI (ICDR) Regulations and the Securities and Exchange Board of India (Underwriters) Regulations, 1993, as amended from time to time.
Underwriting Agreement	The Agreement dated April 25, 2024 entered between the Underwriters, BRLM and our Company.
Unified Payments Interface (UPI)	UPI is an instant payment system developed by the NPCI. It enables merging several banking features, seamless fund routing & merchant payments into one hood. UPI allows instant transfer of money between any two person's bank accounts using a payment address which uniquely identifies a person's bank Account.
UPI Bidders	Collectively, individual investors applying as Retail Individual Bidders in the Retail Portion, and individuals applying as Non-Institutional Bidders with a Bid Amount of up to ₹500,000 in the Non-Institutional Portion. Pursuant to SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/P/2022/45 dated April 5, 2022, all individual investors applying in public issues where the application amount is up to ₹500,000 shall use the UPI Mechanism and shall provide their UPI ID in the Bid cum Application Form submitted with: (i) a Syndicate Member, (ii) a stock broker registered with a recognized stock exchange (whose name is mentioned on the website of the stock exchange as eligible for such activity), (iii) a depository participant (whose name is mentioned on the website of the stock exchange as eligible for such activity), and (iv) a registrar to an issue and share transfer agent (whose name is mentioned on the website of the stock exchange as eligible for such activity)
UPI Circulars	The SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 1, 2018, SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2019/50 dated April 3, 2019, SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2019/76 dated June 28, 2019, SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019, SEBI circular no. SEBI/HO/CFD/DCR2/CIR/P/2019/133 dated November 8, 2019, SEBI/HO/CFD/DIL2/CIR/P/2020/50 dated March 30, 2020, SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021, SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021 SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/P/2022/45 dated April 5, 2022, SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/P/2022/51 dated April 20, 2022, SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/2022/75 dated May 30, 2022, SEBI master circular no. SEBI/HO/MIRSD/POD-1/P/CIR/2023/70 dated May 17, 2023 (to the extent that such circulars pertain to the UPI Mechanism), the SEBI Master Circular for Issue of Capital and Disclosure Requirements, SEBI circular no. SEBI/HO/CFD/TPD1/CIR/P/2023/140 dated August 9, 2023, along with the circular issued by NSE bearing reference no. 25/2022 dated August 3, 2022 and the circular issued by NSE bearing reference no. 20220803-40 dated August 3, 2022 and any subsequent circulars or notifications issued by SEBI and Stock Exchanges in this regard.
UPI ID	ID created on Unified Payment Interface (UPI) for single-window mobile payment system developed by the National Payments Corporation of India (NPCI)
UPI Mandate Request	A request (intimating the UPI Bidder by way of a notification on the UPI application and by way of a SMS for directing the UPI Bidder to such UPI mobile application) to the UPI Bidder initiated by the Sponsor Bank to authorise blocking of funds on the UPI application equivalent to Bid Amount and subsequent debit of funds in case of Allotment
UPI mechanism	Process for applications by UPI Bidders submitted with intermediaries with UPI as mode of payment, in terms of the UPI Circulars
UPI PIN	Password to authenticate UPI transaction
U.S. Securities Act	U.S. Securities Act of 1933, as amended
Wilful Defaulter or Fraudulent Borrower	Wilful defaulter or a fraudulent borrower as defined under Regulation 2(1)(III) of the SEBI ICDR Regulations

Term	Description
Working Day	Any day, on which commercial banks in Mumbai are open for business; provided however, with reference to (i) announcement of Price Band; and (ii) Bid / Issue Period, “Working Day” shall mean any day, excluding all Saturdays, Sundays and public holidays, on which commercial banks in Mumbai are open for business; and with reference to (iii) the time period between the Bid / Issue Closing Date and the listing of the Equity Shares on the Stock Exchanges, “Working Day” shall mean all trading days of the Stock Exchanges, excluding Sundays and bank holidays, as per the SEBI circular number SEBI/HO/CFD/DIL/CIR/P/2016/26 dated January 21, 2016 and the SEBI circular number SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 1, 2018, including the UPI Circulars

INDUSTRY RELATED TERMS

Term	Description
AAY	Antodaya Ann Yojna
ABDM	Ayushman Bharat Digital Mission
ACC	advanced chemical cell
ACC	Advanced Chemistry Cell
AFDIL	Anglo French Drugs & Industries Limited
AI	Artificial Intelligence
AIC	Atal Incubation Centre
AIDef	AI in Defence
AIDS	Acquired Immune Deficiency Syndrome
AIF	Alternative Investment Funds
AIFs	Alternative Investment Funds
BG	Bank Guarantee
BMR	Batch Manufacturing Record
BSNL	Bharat Sanchar Nigam Limited
BSR	Batch Release Section
CAD	Current Account Deficit
CAGR	Compound Annual Growth Rate
CAGR	Compound Annual Growth Rate
CAZRI	Central Arid Zone Research Institute
CBER	Center for Biologics Evaluation and Research
CDER	Drug Evaluation and Research
CDI	Clinical Data and Insights
CDP-PS	Assistance to Pharmaceutical Industry
CEPA	Comprehensive Partnership Agreement
CGSS	Credit Guarantee Scheme for Start-ups
CGST	Central Goods and Services Tax
CINV	Chemotherapy-Induced Nausea and Vomiting
CPI	Consumer Price Index
DCGI	Drug Controller General of India
DNDi	Drugs for Neglected Diseases initiative
DPA	Deendayal Port Authority
DPIIT	Department for Promotion of Industry and Internal Trade
DPP	Defense Procurement Procedure
EAC	Experts' Advisory Committee
EPL	Emcure Pharmaceuticals
ESDM	Electronics System Design and Manufacturing
ESIC	Employees State Insurance Corporation
EU	European Union
FAO	Food and Agriculture Organization
FCM	Ferric Carboxymaltose
FDI	Foreign Direct Investment
FICCI	Federation of Indian Chambers of Commerce and Industry
FPI	Foreign Portfolio Investment
FTAs	Free Trade Agreements

Term	Description
FY	Financial Year
GDP	Gross Domestic Product
GII	Global Innovation Index
GMP	Good Manufacturing Practices
G-secs	Government Securities
GST	Goods and Services Tax
GVA	Gross Value Added
HFIs	High-Frequency Indicators
ICAR	Indian Council of Agricultural Research
IIL	Indian Immunologicals Ltd
IISR	Indian Institute of Spices Research
IndAus ECTA	India-Australia Economic Cooperation and Trade Agreement
IoT	Internet of Things
IOT	Internet of Things
IP	Indian Pharmacopoeia
IPC	Indian Pharmacopoeia Commission
IT	Information Technology
KSM	Key Starting Materials
LDL	low-density lipoprotein
LMT	Metric Tonnes
MITRA	The Mega Investment Textiles
MMF	Man-Made Fibre
MoSPI	Ministry of Statistics & Programme Implementation
MoU	Memorandum of Understanding
M-SIPS	Modified Special Incentive Scheme
NABARD	National Bank for Agriculture and Rural Development
NaBFID	National Bank for Financing Infrastructure and Development
NARCL	National Asset Reconstruction Company Limited
NPE 2019	National Policy on Electronics
PHH	Primary Household
PLI	Productivity Linked Incentive
PM-DevINE	Prime Minister's Development Initiative for North-East Region
PMGKAY	Pradhan Mantri Garib Kalyan Ann Yojana
PPDS	Pharmaceutical Promotion and Development Scheme
PPP	Public-Private Partnership
PRIP	Promotion of Research and Innovation in Pharma
PRIP	Promotion of Research and Innovation in Pharma
PTUAS	Pharmaceutical Technology Upgradation Assistance Scheme
ROI	Return on Investment
SDL	State Development Loan
SEBI	Securities and Exchange Board of India
SEZ	Special Economic Zone
SPECS	Scheme for Promotion of Manufacturing of Electronic Components and Semiconductors
SPI	SPI
TTDFS	Telecom Technology Development Fund
TV	Television
UAE	United Arab Emirates
US	United States of America
USFDA	United States Food and Drug Administration
WEO	World Economic Outlook
WHO	World Health Organization

ABBREVIATIONS

Term	Description
AS / Accounting Standard	Accounting Standards as issued by the Institute of Chartered Accountants of India
A/c	Account
ACS	Associate Company Secretary

Term	Description
AGM	Annual General Meeting
ASBA	Applications Supported by Blocked Amount
Amt	Amount
AIF	Alternative Investment Funds registered under the Securities and Exchange Board of India (Alternative Investment Funds) Regulations, 2012, as amended.
AY	Assessment Year
AOA	Articles of Association
Approx	Approximately
B. A	Bachelor of Arts
BBA	Bachelor of Business Administration
B. Com	Bachelor of Commerce
B. E	Bachelor of Engineering
B. Sc	Bachelor of Science
B. Tech	Bachelor of Technology
Bn	Billion
BG/LC	Bank Guarantee / Letter of Credit
BIFR	Board for Industrial and Financial Reconstruction
BRLM	Book Running Lead Manager
BSE	BSE Limited
BSE SENSEX	Sensex in an index; market indicator of the position of stock that is listed in the BSE
Banking Regulation Act	The Banking Regulation Act, 1949
CDSL	Central Depository Services (India) Limited
CAGR	Compounded Annual Growth Rate
CAN	Confirmation of Allocation Note
Category I Alternate Investment Fund / Category I AIF	AIFs who are registered as “Category I Alternative Investment Funds” under the SEBI AIF Regulations
Category I Foreign Portfolio Investor(s) / Category I FPIs	FPIs who are registered as “Category I foreign portfolio investors” under the SEBI FPI Regulations
Category II Alternate Investment Fund / Category II AIF	AIFs who are registered as “Category II Alternative Investment Funds” under the SEBI AIF Regulations
Category II Foreign Portfolio Investor(s) / Category II FPIs	FPIs who are registered as “Category II foreign portfolio investors” under the SEBI FPI Regulations
Category III Alternate Investment Fund / Category III AIF	AIFs who are registered as “Category III Alternative Investment Funds” under the SEBI AIF Regulations
CA	Chartered Accountant
CB	Controlling Branch
CDSL	Central Depository Services (India) Limited
CC	Cash Credit
CIN	Corporate Identification Number
CIT	Commissioner of Income Tax
CS	Company Secretary
CSR	Corporate social responsibility.
CFA	Chartered Financial Analyst
CS & CO	Company Secretary & Compliance Officer
CFO	Chief Financial Officer
CENVAT	Central Value Added Tax
CIBIL	Credit Information Bureau (India) Limited
CST	Central Sales Tax
COVID – 19	A public health emergency of international concern as declared by the World Health Organization on January 30, 2020 and a pandemic on March 11, 2020
CWA/ICWA/CMA	Cost and Works Accountant
CMD	Chairman and Managing Director

Term	Description
Companies Act	Unless specified otherwise, this would imply to the provisions of the Companies Act, 2013 to the extent notified) and /or Provisions of Companies Act, 1956 w.r.t. the sections which have not yet been replaced by the Companies Act, 2013 through any official notification
Depository or Depositories	NSDL and CDSL.
DIN	Director Identification Number
DIPP	Department of Industrial Policy and Promotion, Ministry of Commerce, Government of India
DP	Depository Participant
DP ID	Depository Participant's Identification Number
EBITDA	Earnings Before Interest, Taxes, Depreciation & Amortisation
ECS	Electronic Clearing System
ESIC	Employee's State Insurance Corporation
EPS	Earnings Per Share
EGM /EOGM	Extraordinary General Meeting
ESOP	Employee Stock Option Plan
EXIM/ EXIM Policy	Export – Import Policy
FCNR Account	Foreign Currency Non-Resident Account
FIPB	Foreign Investment Promotion Board
FY / Fiscal/Financial Year	Period of twelve months ended March 31 of that particular year, unless otherwise stated
FEMA	Foreign Exchange Management Act, 1999 as amended from time to time, and the regulations framed there under.
FEMA Regulations	Foreign Exchange Management (Transfer or Issue of Security by a Person Resident Outside India) Regulations, 2017
FCNR Account	Foreign Currency Non-Resident Account
FBT	Fringe Benefit Tax
FDI	Foreign Direct Investment
FIs	Financial Institutions
FIIIs	Foreign Institutional Investors (as defined under Foreign Exchange Management (Transfer or Issue of Security by a Person Resident outside India) Regulations, 2000) registered with SEBI under applicable laws in India
FPIs	Foreign Portfolio Investors as defined under the SEBI FPI Regulations.
FTA	Foreign Trade Agreement.
FVCI	Foreign Venture Capital Investors registered with SEBI under the Securities and Exchange Board of India (Foreign Venture Capital Investors) Regulations, 2000.
FV	Face Value
GOI/Government	Government of India
GDP	Gross Domestic Product
GAAP	Generally Accepted Accounting Principles in India
GST	Goods and Service Tax
GVA	Gross Value Added
HNI	High Net Worth Individual
HUF	Hindu Undivided Family
ICAI	The Institute of Chartered Accountants of India
ICAI/ICMAI (Previously known as ICWAI)	The Institute of Cost Accountants of India
IMF	International Monetary Fund
INR / ₹/ Rupees/Rs.	Indian Rupees, the legal currency of the Republic of India
IIP	Index of Industrial Production
IPO	Initial Public Offer
ICSI	The Institute of Company Secretaries of India
IFRS	International Financial Reporting Standards
i.e	That is
I.T. Act	Income Tax Act, 1961, as amended from time to time
IT Authorities	Income Tax Authorities
IT Rules	Income Tax Rules, 1962, as amended, except as stated otherwise
Indian GAAP	Generally Accepted Accounting Principles in India
IRDA	Insurance Regulatory and Development Authority
KMP	Key Managerial Personnel
Ltd.	Limited

Term	Description
MAT	Minimum Alternate Tax
MCA	Ministry of Corporate Affairs, Government of India
MIDC	Maharashtra Industrial Development Corporation
MSEDCL	Maharashtra State Electricity Distribution Co. Ltd
MoF	Ministry of Finance, Government of India
M-o-M	Month-On-Month
MOU	Memorandum of Understanding
M. A	Master of Arts
M. B. A	Master of Business Administration
M. Com	Master of Commerce
Mn	Million
M. E	Master of Engineering
MRP	Maximum Retail Price
M. Tech	Masters of Technology
Merchant Banker	Merchant Banker as defined under the Securities and Exchange Board of India (Merchant Bankers) Regulations, 1992
MAPIN	Market Participants and Investors Database
MSMEs	Micro, Small and medium Enterprises
MoA	Memorandum of Association
NA	Not Applicable
Networth	The aggregate of paid-up Share Capital and Share Premium account and Reserves and Surplus (Excluding revaluation reserves) as reduced by aggregate of Miscellaneous Expenditure (to the extent not written off) and debit balance of Profit & Loss Account
NEFT	National Electronic Funds Transfer
NECS	National Electronic Clearing System
NAV	Net Asset Value
NPV	Net Present Value
NRIs	Non-Resident Indians
NRE Account	Non-Resident External Account
NRO Account	Non-Resident Ordinary Account
NSE	National Stock Exchange of India Limited
NOC	No Objection Certificate
NSDL	National Securities Depository Limited
OCB	Overseas Corporate Bodies
P.A.	Per Annum
PF	Provident Fund
PG	Post Graduate
PAC	Persons Acting in Concert
P/E Ratio	Price/Earnings Ratio
PAN	Permanent Account Number
PAT	Profit After Tax
PBT	Profit Before Tax
PLI	Postal Life Insurance
POA	Power of Attorney
PSU	Public Sector Undertaking(s)
Pvt.	Private
RBI	The Reserve Bank of India
ROE	Return on Equity
R&D	Research & Development
RONW	Return on Net Worth
RTGS	Real Time Gross Settlement
SCRA	Securities Contracts (Regulation) Act, 1956, as amended from time to time
SCRR	Securities Contracts (Regulation) Rules, 1957, as amended from time to time
SCSB	Self-Certified Syndicate Banks
SEBI	Securities and Exchange Board of India
SEBI Act	The Securities and Exchange Board of India Act, 1992
SEBI AIF Regulations	Securities and Exchange Board of India (Alternative Investments Funds) Regulations, 2012, as amended from time to time

Term	Description
SEBI FII Regulations	Securities and Exchange Board of India (Foreign Institutional Investors) Regulations, 1995, as amended from time to time
SEBI FPI Regulations	Securities and Exchange Board of India (Foreign Portfolio Investors) Regulations, 2019, as amended from time to time
SEBI FVCI Regulations	Securities and Exchange Board of India (Foreign Venture Capital Investor) Regulations, 2000, as amended from time to time
SEBI ICDR Regulations	Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended from time to time
SEBI Insider Trading Regulations	Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time.
SEBI LODR Regulations	Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time
SEBI (PFUTP) Regulations/PFUTP Regulations	SEBI (Prohibition of Fraudulent and Unfair Trade Practices relating to Securities Markets) Regulations, 2003
SEBI SAST Regulations	Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended from time to time
SEBI VCF Regulations	Securities and Exchange Board of India (Venture Capital Fund) Regulations, 1996, as repealed by the SEBI AIF Regulations, as amended
SICA	Sick Industrial Companies (Special provisions) Act, 1985, as amended from time to time
SME	Small and Medium Enterprises
STT	Securities Transaction Tax
Sec.	Section
SPV	Special Purpose Vehicle
Takeover Regulations	Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
TAN	Tax Deduction Account Number
TDS	Tax Deducted at Source
TRS	Transaction Registration Slip
TIN	Taxpayers Identification Number
US/United States	United States of America
UPI	Unified Payments Interface as a payment mechanism through National Payments Corporation of India with Application Supported by Block Amount for applications in public issues by retail individual investors through SCSBs
USD/ US\$/ \$	United States Dollar, the official currency of the United States of America
VCF / Venture Capital Fund	Foreign Venture Capital Funds as defined under the SEBI AIF Regulations
VAT	Value Added Tax
w.e.f.	With effect from
WIP	Work in process
Willful Defaulter	An entity or person categorized as a willful defaulter by any bank or financial institution or consortium thereof, in terms of regulation 2(1)(III) of the SEBI ICDR Regulations
YoY	Year over Year

The words and expressions used but not defined in this Prospectus will have the same meaning as assigned to such terms under the Companies Act, the Securities and Exchange Board of India Act, 1992 (the “SEBI Act”), the SCRA, the Depositories Act and the rules and regulations made thereunder.

Notwithstanding the foregoing, terms in “Description of Equity Shares and Terms of the Articles of Association”, “Statement of Possible Tax Benefits”, “Industry Overview”, “Key Regulations and Policies”, “Financial Information of our Company”, “Outstanding Litigations and Material Developments” and “Issue Procedure”, will have the meaning ascribed to such terms in these respective sections.

PRESENTATION OF FINANCIAL INDUSTRY AND MARKET DATA

CERTAIN CONVENTIONS

All references in this Prospectus to 'India' are to the Republic of India and its territories and possessions and all references herein to the 'Government', 'Indian Government', 'GoI', 'Central Government' or the 'State Government' are to the GoI, central or state, as applicable.

Unless otherwise specified, any time mentioned in this Prospectus is in Indian Standard Time ("IST").

Unless indicated otherwise, all references to a year in this Prospectus are to a calendar year.

Unless stated otherwise, all references to page numbers in this Prospectus are to the page numbers of this Prospectus. In this Prospectus, our Company has presented numerical information in "lakhs" units. One lakh represents 1,00,000.

FINANCIAL DATA

Unless stated otherwise, the financial statements in this Prospectus are derived from our Restated Financial Statements. The Restated Financial Statements comprises of the restated statement of assets and liabilities for the period ended December 31, 2023 and for the financial years ended March 31, 2023, March 31, 2022, March 31, 2021 and the restated statement of profit and loss, the restated statement of cash flows and the restated statement of changes in equity for the period ended December 31, 2023 and for the financial years ended March 31, 2023, March 31, 2022 and March 31, 2021 and the summary of significant accounting policies and explanatory notes, prepared in terms of the requirements of Section 26 of Part I of Chapter III of the Companies Act, 2013, as amended; the SEBI ICDR Regulations, as amended and the Guidance Note on Reports in Company Prospectuses (Revised 2019) issued by the ICAI, as amended from time to time. For further information, see please refer section titled "*Restated Financial Statements*" beginning on page 196 of this Prospectus.

In this Prospectus, any discrepancies in any table between the total and the sums of the amounts listed are due to rounding off. All figures in decimals have been rounded off to the second decimal and all percentage figures have been rounded off to two decimal places.

Our Company's financial year commences on April 1 and ends on March 31 of the next year. Accordingly, all references to a particular financial year, unless stated otherwise, are to the 12-month period ended on March 31 of that year. Unless stated otherwise, or the context requires otherwise, all references to a "year" in this Prospectus are to a calendar year.

There are significant differences between Indian GAAP, IFRS and US GAAP. The Company has not attempted to quantify their impact on the financial data included herein and urges you to consult your own advisors regarding such differences and their impact on the Company's financial data. Accordingly, to what extent, the Restated Financial Statements included in this Prospectus will provide meaningful information is entirely dependent on the reader's level of familiarity with Indian accounting practices, the Companies Act, Ind AS, and the SEBI ICDR Regulations. Any reliance by persons not familiar with Indian Accounting Practices on the financial disclosures presented in this Prospectus should accordingly be limited.

Unless the context otherwise indicates, any percentage amounts, as set forth in "*Risk Factors*", "*Our Business*" and "*Management's Discussion and Analysis of Financial Condition and Results of Operations*" beginning on page 30, 128 and 199 respectively, of this Prospectus, and elsewhere in this Prospectus have been calculated on the basis of the "*Restated Financial statements*" of our Company as beginning on page 196 of this Prospectus.

CURRENCY AND UNITS OF PRESENTATION

All references to "Rupees", "Rs." or "₹" are to Indian Rupees, the official currency of the Republic of India. All references to "US\$" or "US Dollars" or "USD" are to United States Dollars, the official currency of the United States of America, EUR or "€" are Euro currency.

All references to the word "Lakh" or "Lac", means "One hundred thousand" and the word "Million" means "Ten Lakhs" and the word "Crore" means "Ten Million" and the word "Billion" means "One thousand Million".

In this Prospectus, any discrepancies in any table between the total and the sums of the amounts listed are due to rounding off. All figures derived from our Restated Financial Statements in decimals have been rounded off to the second decimal and all percentage figures have been rounded off to two decimal places.

This Prospectus may contain conversions of certain US Dollar and other currency amounts into Indian Rupees that have been presented solely to comply with the requirements of the SEBI ICDR Regulations. These conversions should not be construed as a representation that those US Dollar or other currency amounts could have been, or can be converted into Indian Rupees, at any particular rate.

EXCHANGE RATES

This Prospectus contains conversions of certain other currency amounts into Rupees that have been presented solely to comply with the requirements of SEBI ICDR Regulations. Such conversion should not be considered as a representation that such currency amounts have been, could have been or can be converted into Rupees at any particular rate or at all.

The following table sets forth, for the periods indicated, information with respect to the exchange rate between the Indian Rupee and other foreign currencies:

Currency	Exchange Rate as on December 29, 2023*	Exchange Rate as on March 31, 2023	Exchange Rate as on March 31, 2022	Exchange Rate as on March 31, 2021
1 USD	83.12	82.21	75.80	73.50
1 Euro	92.00	89.61	84.66	86.10

*Since December 31, 2023 was Sunday and a holiday hence, we have taken two-day prior exchange rate

Note: If the reference rate is not available on a particular date due to a public holiday, exchange rates of the previous Working Day has been disclosed. The reference rates are rounded off to two decimal places.

Source: <https://www.rbi.org.in/scripts/referenceratearchive.aspx>

DEFINITIONS

For definitions, please refer the chapter titled “*Definitions and Abbreviations*” beginning on page 1 of this Prospectus. In the section titled “*Main Provisions of the Articles of Association*” beginning on page 283 of this Prospectus, defined terms have the meaning given to such terms in the Articles of Association.

INDUSTRY AND MARKET DATA

Unless stated otherwise, the industry and market data and forecasts used throughout this Prospectus has been obtained from industry sources as well as Government Publications. Industry sources as well as Government Publications generally state that the information contained in those publications has been obtained from sources believed to be reliable but that their accuracy and completeness and underlying assumptions are not guaranteed and their reliability cannot be assured.

Further, the extent to which the industry and market data presented in this Prospectus is meaningful depends on the reader’s familiarity with and understanding of the methodologies used in compiling such data. There are standard data gathering methodologies in the industry in which we conduct our business, and methodologies and assumptions may vary widely among different industry sources.

FORWARD LOOKING STATEMENTS

All statements contained in this Prospectus that are not statements of historical fact constitute forward-looking statements. All statements regarding our expected financial condition and results of operations, business, plans and prospects are forward-looking statements. These forward-looking statements include statements with respect to our business strategy, our revenue and profitability, our projects and other matters discussed in this Prospectus regarding matters that are not historical facts. Investors can generally identify forward-looking statements by the use of terminology such as “aim”, “anticipate”, “believe”, “expect”, “estimate”, “intend”, “objective”, “plan”, “project”, “may”, “will”, “will continue”, “will pursue”, “contemplate”, “future”, “goal”, “propose”, “will likely result”, “will seek to” or other words or phrases of similar import. All forward-looking statements (whether made by us or any third party) are predictions and are subject to risks, uncertainties and assumptions about us that could cause actual results to differ materially from those contemplated by the relevant forward-looking statement.

Forward-looking statements reflect our current views with respect to future events and are not a guarantee of future performance. These statements are based on our management’s beliefs and assumptions, which in turn are based on currently available information. Although we believe the assumptions upon which these forward-looking statements are based are reasonable, any of these assumptions could prove to be inaccurate, and the forward-looking statements based on these assumptions could be incorrect.

Further the actual results may differ materially from those suggested by the forward-looking statements due to risks or uncertainties associated with our expectations with respect to, but not limited to, regulatory changes pertaining to the industries in India in which our Company operates and our ability to respond to them, our ability to successfully implement our strategy, our growth and expansion, technological changes, our exposure to market risks, general economic and political conditions in India and overseas which have an impact on our business activities or investments, the monetary and fiscal policies of India and other jurisdictions in which we operate, inflation, deflation, unanticipated volatility in interest rates, foreign exchange rates, equity prices or other rates or prices, the performance of the financial markets in India and globally, changes in domestic laws, regulations and taxes, changes in competition in our industry and incidence of any natural calamities and/or acts of violence.

- Any slowdown or shutdown in our manufacturing operations;
- Inability to accurately manage our inventory, this may adversely affect our goodwill and business, financial condition and results of operations;
- Dependency on third-party transportation providers for the supply of raw materials and delivery of our finished products;
- Delay in orders placing for the purchase of plant and machinery;
- Failure to acquire new consumers or fail to do so in a cost-effective manner, we may not be able to increase revenue or maintain profitability;
- Our ability to attract and retain qualified personnel;
- Restrictions on import and an increase in shipment cost may adversely impact our business, cash flows and results of operations;
- Orders placed by customers may be delayed, modified or cancelled, which may have an adverse effect on our business, financial condition and results of operations;
- Conflict of interests between our Company and other venture or enterprises promoted by our promoter or directors;
- Volatility of loan interest rates and inflation;
- Natural calamities, climate change and health epidemics could adversely affect the Indian economy and our business, financial condition, and results of operations;
- Changing laws, rules and regulations and legal uncertainties, including adverse application of tax laws, may adversely affect our business, financial condition and results of operations;
- Our inability to maintain or improve our brand image;

- A slowdown in economic growth in India could cause our business to suffer;
- Global economic conditions, especially in the geographies we cater to, which may have an adverse effect on our business, financial condition, results of operations and prospects;

For further discussions of factors that could cause our actual results to differ, please refer the section titled “*Risk Factors*” and chapter titled “*Our Business*” and “*Management’s Discussion and Analysis of Financial Condition and Results of Operations*” beginning on page 30, 128, and 199 of this Prospectus, respectively. By their nature, certain market risk disclosures are only estimating and could be materially different from what actually occurs in the future. As a result, actual gains or losses could materially differ from those that have been estimated.

There can be no assurance to Bidders that the expectations reflected in these forward-looking statements will prove to be correct. Given these uncertainties, Bidders are cautioned not to place undue reliance on such forward-looking statements and not to regard such statements to be a guarantee of our future performance.

Forward-looking statements reflect the current views as of the date of this Prospectus and are not a guarantee of future performance. These statements are based on our management’s beliefs and assumptions, which in turn are based on currently available information. Although we believe the assumptions upon which these forward-looking statements are based are reasonable, any of these assumptions could prove to be inaccurate, and the forward-looking statements based on these assumptions could be incorrect. Neither our Company, our Directors, the Syndicate Members nor any of their respective affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after the date hereof or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.

In accordance with the SEBI ICDR Regulations, our Company, will ensure that the Bidders in India are informed of material developments until the time of the grant of listing and trading permission by the Stock Exchange for the Equity Shares pursuant to the Issue.

SECTION II - SUMMARY OF OFFER DOCUMENT

The following is a general summary of certain disclosures included in this Prospectus and is neither exhaustive, nor purports to contain a summary of all the disclosures in this Prospectus or the Prospectus, when filed, or all details relevant to prospective investors. This summary should be read in conjunction with, and is qualified in its entirety by, the more detailed information appearing elsewhere in this Prospectus, including “Risk Factors”, “The Issue”, “Capital Structure”, “Objects of the Issue”, “Industry Overview”, “Our Business”, “Our Promoters and Promoter Group”, “Restated Financial Information”, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, “Outstanding Litigation and Material Developments”, “Issue Procedure” and “Main Provisions of The Articles Of Association” on pages 30, 59, 73, 86, 106, 128, 190, 196, 199, 221, 259 and 283, respectively.

SUMMARY OF OUR BUSINESS

Our Company, Quest Laboratories Limited is engaged in the business of manufacturing of pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. These formulations fall under the trademark “**Quest Laboratories Limited**”. The company produces a variety of products, comprising ethical drugs, generic drugs, and over-the-counter drugs (OTC). These products are available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids. This comprehensive approach allows our Company to address a wide range of medical needs and preferences among patients.

For more details, please refer chapter titled “Our Business” beginning on page 128 of this Prospectus.

SUMMARY OF OUR INDUSTRY

India's pharmaceutical industry leads globally, renowned for affordable generic drugs and vaccines. With a 9.43% CAGR over nine years, it ranks third in production volume. Diverse segments include generics, OTC meds, bulk drugs, vaccines, biosimilars, and biologics. Notably, India houses the most USFDA-compliant manufacturing facilities and 500 API producers, capturing 8% of the global API market. This industry's growth reflects its adaptability and quality standards, ensuring accessible healthcare solutions worldwide.

For more details, please refer chapter titled “Industry Overview” beginning on page 106 of this Prospectus.

OUR PROMOTERS

The promoters of our company are Mr. Anil Kumar Sabarwal and Ms. Tejaswini Sabarwal.

SIZE OF ISSUE

The following table summarizes the details of the Issue. For further details, see “The Issue” and “Issue Structure” beginning on pages 59 and 255, respectively.

Issue of Equity Shares	44,49,600 Equity shares of ₹10/- each for cash at a price of ₹ 97/- per Equity share (including a premium of ₹ 87/- per Equity Share) aggregating to ₹ 4,316.11 Lakhs*
Of which:	
Market Portion	2,28,000 Equity shares of ₹10/- each for cash at a price of ₹ 97/- per Equity shares aggregating to ₹ 221.16 Lakhs
Net Issue	42,21,600 Equity shares of ₹10/- each for cash at a price of ₹ 97/- per Equity shares aggregating to ₹ ₹ 4,094.95 Lakhs

*The Issue has been authorized by our Board pursuant to resolutions passed at its meetings held on February 02, 2024 and by our Shareholders pursuant to a special resolution passed at their meetings held on February 09, 2024.

The Issue and Net Issue shall constitute 27.15% and 25.76% of the post-Issue paid-up Equity Share capital of our Company.

OBJECTS OF THE ISSUE

Our Company intends to utilize the Net Proceeds for the following objects:

(₹ in Lakhs)

Sr. No	Particulars	Amount
1.	Funding of capital expenditure towards purchase of Plant and Machineries for Expansion and Upgradation at the existing Manufacturing Facility situated at Dhar, Madhya Pradesh.	2,600.00
2.	Funding Working Capital Requirements of our Company	1,000.00
3.	General corporate purposes [#]	337.99
	Total	3,937.99

[#]The amount to be utilised for general corporate will not exceed 25% of the Net Proceeds

For further details, please refer to chapter titled “Objects of the Issue” beginning on page 86 of this Prospectus.

PRE-ISSUE SHAREHOLDING OF OUR PROMOTERS AND PROMOTER GROUP AS A PERCENTAGE OF THE PAID-UP SHARE CAPITAL OF THE COMPANY

Set forth is the Pre-Issue and Post-Issue shareholding of our Promoters and Promoter group as a percentage of the paid-up share capital of the Company:

Category of Promoter	Pre-Issue		Post-Issue	
	No. of Shares	% of Pre-Issue Capital	No. of Shares	% of Post- Issue Capital
Promoters				
Mr. Anil Kumar Sabarwal	1,01,67,250	85.17%	1,01,67,250	62.04%
Ms. Tejaswini Sabarwal	4,07,000	3.41%	4,07,000	2.48%
Promoter Group				
Mr. Vinayak Sabarwal	2,12,650	1.78%	2,12,650	1.30%
Total	1,07,86,900	90.36%	1,07,86,900	65.82%

SUMMARY OF RESTATED FINANCIAL STATEMENTS

(₹ in lakhs other than share data)

Particulars	As on December 31, 2023	For the year ended March 31		
		2023	2022	2021
Share Capital	1078.76	107.88	107.88	107.88
Net worth [#]	2277.15	1,502.21	999.38	588.84
Total Revenue ^{\$}	6217.83	6,186.60	5,954.20	3,043.55
Profit after Tax	774.93	502.85	410.50	65.50
Earnings per share (Basic & diluted) (Post Bonus & Split) (₹) [@]	7.18	4.66	3.81	0.61
Net Asset Value per Equity Share (Post Bonus & Split) (₹) [*]	21.11	13.93	9.26	5.46
Total borrowings [^]	460.66	409.69	312.54	304.03

[#]Net Worth = Restated Equity Share Capital plus Restated Reserves & Surplus

^{\$}Total Revenue = Restated Revenue from operations plus Restated Other Income

[@] Earnings per share (Basic & diluted) = Restated profit after tax for the period divided by Restated number of Equity Shares outstanding during the period

^{*}Net Asset Value per Equity Share = Restated Net worth divided by Restated number of Equity Shares outstanding during the period

[^]Total Borrowings = Restated Long-Term Borrowings plus Restated Short Term Borrowings

Notes:

- (1) Our Board of Directors pursuant to a resolution dated September 04, 2023 and Shareholders pursuant to ordinary resolution dated September 27, 2023, have approved the issuance of 97,08,840 bonus Equity Shares in the ratio of Nine Equity Shares for every one existing fully paid-up Equity Share.
- (2) Our Board of Directors pursuant to a resolution dated November 22, 2023, have approved the Further allotment of 11,50,000 fully paid-up Equity Share.

QUALIFICATIONS OF AUDITORS

There are no qualifications included by the Statutory Auditors in their audit reports and hence no effect is required to be given in the Restated Financial Information.

SUMMARY OF OUTSTANDING LITIGATIONS & MATERIAL DEVELOPMENTS

A summary of pending legal proceedings and other material litigations involving our Company, our Promoters, our Directors and our Group Companies as on the date of this Prospectus is provided below:

Name of Entity	Criminal Proceedings	Tax Proceedings	Statutory or Regulatory Proceedings	Disciplinary actions by the SEBI or Stock Exchanges against our Promoters	Material Civil Litigations	Aggregate amount involved (Rs in Lakhs)
Company						
By the Company	NA	NA	NA	NA	NA	NA
Against the Company	3	5	NA	NA	2	198.89*
Directors						
By our Directors	NA	NA	NA	NA	NA	NA
Against the Directors	NA	NA	NA	NA	NA	NA
Promoters*						
By Promoters	NA	NA	NA	NA	NA	NA
Against Promoters@	2	NA	NA	NA	2	unascertaine@
Subsidiaries						
By Subsidiaries	NA	NA	NA	NA	NA	NA
Against Subsidiaries	NA	NA	NA	NA	NA	NA
Group Companies						
By Group Companies	NA	NA	NA	NA	NA	NA
Against Group Companies	NA	NA	NA	NA	NA	NA

*Amount in respect of all the criminal & Civil matters are unascertained.

@ One of our promoters is also the Managing director on the Board and hence litigation against him have not been included in the directors details to avoid repetition. Further the litigation mentioned here are not directly filed against the promoter cum MD. They are in his capacity as director of the Company

Brief details of top 5 Criminal Case against our Promoters:

Sr. No.	Particulars	Litigation filed by	Current status	Amount involved
1	State of Jharkhand V/s. 1. Anil Sabarwal 2. Kavita Sabarwal <i>208 Case No. C.C. 131/2016 filed with the Judicial Magistrate Courts, Senior Division-II, Jamtara Court, filed u/s. 18(a)(i), 18(a)(vi) & 18(b) of the Drugs and Cosmetics Act.</i> A complaint was filed by Naseem Aslam, the drug inspector at Jamtara district in Jharkhand, against Mr. Anil Sabarwal, after finding that the samples of paracetamol oral suspension he collected from the drug store of Sadar Hospital in Jamtara on March 30, 2015 was not-of-standard-quality. From the details of invoices obtained by the drug inspector, the drugs were allegedly found to have been manufactured by M/s. Quest Laboratories Private Ltd in Indore For	State of Jharkhand	Pending	Unascertained

Sr. No.	Particulars	Litigation filed by	Current status	Amount involved
	substantiating his charges leveled against the company, the Drug Inspector produced the laboratory test report of his samples in the court for evidence. The government drug testing laboratory (DTL) in Ranchi conducted the analytical test and the result was that the drug was Not of Standard Quality (NSQ).. The drug was supplied to the hospital by Mehsuk Enterprises, a pharma dealer at Paredih in Jamtara. Accordingly, the Jamtara court registered a case (131/2016) against Mr. Anil Sabarwal, managing director and Kavita Sabarwal, one of the directors of the company under Section 27 (d) of the D&C Act. In the course of time, the proceedings against Kavita Sabarwal had to be dropped because of her sudden death on February 9, 2021, but the case continued against Anil Sabarwal and he was put for hearing on 28.4.2023. The charges were explained to him and he was questioned by the court under section 313 of the Cr PC. He denied his complicity in the crime and stated that he was falsely implicated in the case. After being found guilty of manufacturing 'NSQ' drug, the Principal Sessions Judge at Jamtara in Jharkhand vide its order dated January 23, 2024, has ordered for conviction of Mr. Anil Sabarwal, the managing director of the Quest Laboratories Private Limited in Indore in Madhya Pradesh, for one year imprisonment and imposed a fine of Rs. 20,000, under Section 27 (d) of the Drugs and Cosmetics Act 1940. However, the court has granted him bail to enable him to appeal to the High Court of Ranchi and Mr. Anil Sabarwal has filed an appeal bearing no. Cr.A(SJ) 5225/2024 has been filed with Jharkhand High Court, Ranchi, on February 26, 2024 and the same is pending.			
2	P.R.C. No. 27/2013 filed and pending with the Honourable Court of III Additional Judicial First-Class Magistrate, Kakinada and later transferred to Honourable District & Sessions Judge, East Godavari, Rajahmahendravaram vide case no. (SC/159/2018) As stated, M/s. Quest Laboratories Pvt. Ltd (the Company) represented by Mr. Anil Sabarwal, director is a manufacturer of Drugs and is having a manufacturing license under Form 25 & 28 bearing no. 25/18/98. The complainant herein claims to have taken a sample on August 19, 2010 of Polyfol Forte tablest, Batch no. 13, Mfg. Date: 07/2010, Exp. Date: 12/2011, manufactured by the company, for test / analysis from the Central Drug Stores, APMHIDC, 23-1-73/A, Old Bus Stand, Kakinada and the sample was sent to Govt. Analyst, drugs Control Laboratory, Vijaywada, as per the provisions of Drugs and Cosmetics Act, 1940. As alleged, the test report of the said sample received on June 29, 2011 declared the sample of non-standard quality for the reason that the sample did not meet the I.P. specifications in respect of Description. Upon	The State of Andhra Pradesh (Represented by Drug Inspector) (Complainant)	Pending	unascertained

Sr. No.	Particulars	Litigation filed by	Current status	Amount involved
	receiving confirmation from the pharmacist of the Central Drug Store in question of having received the said drug from M/s. Quest Laboratories Pvt. Ltd., the Complainant herein alleged to have issued letter dated July 16, 2011 to the Company and several reminders thereof requiring the Company to provide Mfg. & Analytical records, Distribution particulars of the said batch and Drug and Manufacturing license to which the Complainant herein had allegedly not received any response. Resultantly, the instant petition was filed by the complainant, alleging the company to be a. guilty of manufacturing for sale and distribution of not of Standard quality drug, thereby contravening Section 18(a)(i) r/w. Section 16 punishable u/s. 27(d) of Drugs and Cosmetics (Amendment) Act, 2008 by manufacturing “NOT OF STANDARD QUALITY DRUG” ; and b. failure to furnish the constitution particulars and batch manufacturing records of the products as required u/s. 24, 18-B & 22(1) of the Act, thus contravening the provisions of the Sections and punishable u/s. 28, 28-A and 22(3) of the Act, respectively and praying for committal to the Honourable Court of Sessions as per Section 32(2) of the Act and in the interest of Justice. After considering the matter the Honourable ADJFC Magistrate, Kakinada vide its order dated March 08, 2018, considering it fit and proper case for committal to the Honourable Court of Sessions, committed the case to the Court of sessions, East Godavari, Rajamahendravaram under section 209(a) of Criminal Procedure Code with directions that the Accused shall attend before Hon'ble Court of Sessions, East Godavari District, Rajamahendravaram after receipt of Court summons and the same order shall continue until further Orders of the Hon'ble Sessions Court as required under Sec.209 (b) Cr.P.C.			
3	State of Maharashtra (Complainant) V/s. 1) Anilkumar S/o Captain S. P. Sabharwal 2) Deependu Shekhar S/o. Hari Keshav Singh 3) Neha Goverdhan Bairagi; 4) M/s. Quest Laboratories Pvt. Ltd. (Parties 1 to 4 individually referred to as defendant no. 1, 2, 3 & 4 respectively and collectively as defendants) <i>R.C.C./1390/2021; RCC- Reg. Criminal Case filed u/s. 18ai & 18c, 60 of Drugs & Cosmetic Act filed with Akola Dist & Session Court CJM Akola</i> As stated, M/s. Quest Laboratories Pvt. Ltd (the Company) represented by Mr. Anil Sabarwal, director is a manufacturer of Drugs and is having a manufacturing license under Form 25 & 28 bearing no. 25/18/98. The complainant herein claims to have taken a sample of Chlorohexidine Gluconate Solution Hand Sanitizer B.No. E 1705, Mfg. Date: 03/2020, Exp. Date: 08-2021	State Of Maharashtra	Summons Awaiting	Unascertained

Sr. No.	Particulars	Litigation filed by	Current status	Amount involved
	(manufactured by M/s. Quest Laboratories Pvt. Ltd.) from M/s. Goyal Medical & General Store, New Radhakisan Plot, Akola, as per the provisions of Drugs and Cosmetics Act, 1940. As alleged, the test report no. NSQ/AUR/124775/2020 dated August 18, 2020 declared the sample of non-standard quality for the reason that the content of Chlorhexidine in the sample was less than the permissible limits. Further as alleged, the name of the defendant no. 4 having been mentioned as manufacturer of the drugs in question, a detailed report as mentioned above was send to it requiring it to produce certain documents / details before the Complainant. Later the complainant filed the instant petition and the same is pending.			
4	1) State thr. Kishore M. Rajne Drugs Inspector (Complainant) V/s. 1) Rahul Dangi thr. Managing Director M/s. Quest Laboratories Pvt. Ltd.; 2) Anil Kumar Sabarwal thr. Director M/s. Quest Laboratories Pvt. Ltd. 3) Tejaswini Chouhan; 4) Naval Gopal Sharma; 5) Umendra Ramkrishna Suthar; 6) Quest Laboratories Pvt. Ltd. (parties 1 to 6 respectively referred to as respondent no. 1, 2, 3, 4, 5 & 6 and collectively as Respondents) <i>Regular criminal case, RCC/1997/2022 filed u/s. U/s. 18ai & 18c 161 34 under Drugs & Cosmetic Act with Vasai District & Addl sessions civil court, 12-4th JT CIVIL JUDGE J.D. J.M.F.C. Vasai</i> The complainant herein claims to have taken a sample on January 14, 2021 of Lomolok Tablets, Loperamide Hydrochloride Tablets I.P., Batch No. T8838, Mfg. Date: 07/2020, Exp. Date: 11/2023, manufactured by M/s. Quest Laboratories Pvt. Ltd. from the premises of M/s. AERO LIFE PHARMA, situated at shop no. 08, Laxmi Apartment, Waliv, Vasai (East), Dist. Palgarh, for inspection and to draw routine samples for test / analysis. As alleged, the test report of the said sample received on January 24, 2022 bearing no. NSQ/MUM/126825/2022 dated January 20, 2022, declared the samples so collected as of non-standard quality for the reason that the sample did not meet the I.P. specifications for dissolution test. Later, after due enquiry and having received the copy of order from the Joint Commissioner (Head Quarter) and Controlling Authority, Food and Drugs Administration, Mumbai, bearing no. Kathla/MUM/126825/74-22/10 dated February 11, 2022, directions were made to investigate the matter and file prosecution against the manufacturer of the drug and related. Later, a notice bearing no. T Z-2/KMR/NSQ/126825/448/2022/2 dated June 23, 2022 was handed over to factory manager Mr. Gopal Chauhan upon the alleged visit to the premises of M/s.	1) State thr. Kishore M. Rajne Drugs Inspector	Awaiting Summons	Unascertained

Sr. No.	Particulars	Litigation filed by	Current status	Amount involved
	Quest Laboratories Pvt. Ltd., by the Complainant herein along with Drug Inspector, Bhopal (M.P.) for enquiry and investigation. Upon receipt of the said notice, the Respondent no. 1 herein submitted several papers and records with the complainant, which as per the Complainant, were not upto their satisfaction. On the basis of documents received from the respondents, the complainant held the respondent, liable of manufacturing Non-Standard Quality Drugs and accordingly framed several charges against them and filed the instant petition praying to initiate process against the respondents herein, in accordance with the law. The matter is pending with the concerned court of jurisdiction.			

For further details, please refer chapter titled “*Outstanding Litigations and Material Developments*” beginning on page 221 of this Prospectus.

RISK FACTORS

For details relating to risk factors, please refer section titled “*Risk Factors*” beginning on page 30 of this Prospectus.

SUMMARY OF CONTINGENT LIABILITIES OF OUR COMPANY

The following is a summary table of our company’s contingent liabilities as:

(₹ in Lakhs)					
Sr. No.	Particulars	As on December 31, 2023	As on March 31, 2023	As on March 31, 2022	As on March 31, 2021
1.	Bank Guarantee	768.98	682.94	282.94	282.94

For details, please refer to Section titled “*Restated Financial Statements*” beginning on page 196 of this Prospectus.

SUMMARY OF RELATED PARTY TRANSACTIONS

ANNEXURE – XXIX: Restated Standalone Statement of Related Party Disclosures

As required under Accounting Standard 18 “*Related Party Disclosures*” as notified pursuant to Company (Accounting Standard) Rules 2006, following are details of transactions during the year with related parties of the company as defined in AS 18.

List of Related Parties where Control exists and Relationships:

Particulars	Name of Name of Related Parties	Designation/ Position
(a) Key Managerial Personnel (KMP)	Mr. Anil Kumar Sabarwal	Managing Director
	Late. Kavita Sabarwal	Director
	Mr. Rahul Dangi	Whole time Director
	Ms. Tejaswini Sabarwal	Whole time Director
	Mr. Jayesh Jain	Company secretary
	Mr. Ramkrishna Sharma	Chief Financial officer
(b) Promoters & their Relatives having control:	Mr. Vinayak Sabarwal	Relative of Director
	Ms. Sakshi Sabarwal	Relative of Director
	Late. Motiya Rani Sabarwal	Relative of Director
(c) Relatives of Promoters who are under the employment of the company	Mr. Vinayak Sabarwal	Relative of Director
	Ms. Sakshi Sabarwal	Relative of Director

Particulars	Name of Name of Related Parties	Designation/ Position
(d) Companies over which Directors have significant influence or control	Vinayak Meditech Private Limited	Mr. Anil Kumar Sabarwal- Additional Director
(e) Other entities over which there is significant control	N.A	N.A

Details of related party transactions during the year:

(₹ in Lakhs)

Particulars	Relationship	Period/ Year ended on			
		December 31, 2023	March 31, 2023	March 31, 2022	March 31, 2021
Salary Expenses					
Ms. Sakshi Sabarwal	Relative of Director	11.75	12.00	9.00	6.00
Mr. Vinayak Sabarwal	Relative of Director	14.84	18.00	9.00	6.00
Director's Remuneration					
Mr. Anil Kumar Sabarwal	Director	45.00	60.00	42.00	30.00
Ms. Tejaswini Sabarwal	Director	18.00	15.00	-	-
Late. Kavita Sabarwal	Director	-	-	-	12.50
Mr. Rahul Dangi	Director	6.33	5.00	3.00	2.75
Commission					
Ms. Sakshi Sabarwal	Relative of Director	-	-	-	1.50
Mr. Vinayak Sabarwal	Relative of Director	-	-	-	1.50
Loan Repaid					
Mr. Anil Kumar Sabarwal	Director	73.07	-	6.41	23.49
Loans Taken					
Late. Motiya Rani Sabarwal	Relative of Director	-	-	-	0.51
Mr. Anil Kumar Sabarwal	Director	48.00	25.07	-	

For details, please refer to chapter titled “Restated Financial Statements” beginning on page 196 of this Prospectus.

FINANCING ARRANGEMENTS

There have been no financing arrangements whereby our Promoters, members of the Promoter group, our directors and their relatives have financed the purchase by any other person of securities of our Company during a period of six (6) months immediately preceding the date of this Prospectus.

WEIGHTED AVERAGE PRICE OF EQUITY SHARES ACQUIRED BY OUR PROMOTERS

The weighted average cost of acquisition of Equity Shares by our Promoters in the last one (1) year preceding the date of this Prospectus set forth in the table below:

Sr. No.	Name of Promoters	No of Equity Shares held	No of Equity Shares acquired in last one (1) year	Weighted Average cost of Acquisition (in ₹) *
1.	Mr. Anil Kumar Sabarwal	1,01,67,250	91,50,525	Nil
2.	Ms. Tejaswini Sabarwal	4,07,000	3,66,300	Nil

The weighted average cost of acquisition of Equity Shares by our Promoters have been calculated by taking into account the amount paid by them to acquire and Shares allotted to them divided by number of shares acquired in last one (1) year.

*As certified by M/s Shyam S. Gupta & Associates, Chartered Accountants, by way of their certificate dated February 24, 2024.

AVERAGE COST OF ACQUISITION OF PROMOTERS

The average cost of acquisition of Equity Shares by our Promoters is set forth in the table below:

Sr. No.	Name of Promoters	No of Equity Shares held	Average cost of Acquisition (in ₹)*
1.	Mr. Anil Kumar Sabarwal	1,01,67,250	1.16
2.	Ms. Tejaswini Sabarwal	4,07,000	1.00

The average cost of acquisition of Equity Shares by our Promoters have been calculated by taking into account the amount paid by them to acquire and Shares allotted to them as reduced by amount received on sell of shares i.e., net of sale consideration is divided by net quantity of shares acquired.

*As certified by M/s Shyam S. Gupta & Associates, Chartered Accountants, by way of their certificate dated February 24, 2024.

DETAILS OF PRE-IPO PLACEMENT

Our Company does not contemplate any issuance or placement of Equity Shares from the date of this Prospectus till the listing of the Equity Shares.

ISSUE OF EQUITY SHARES FOR CONSIDERATION OTHER THAN CASH IN THE LAST ONE (1) YEAR

Except for the Bonus Issue of 97,08,840 Equity Shares, our company has not issued Equity Shares for consideration other than cash in the one (1) year preceding the date of this Prospectus.

Date of Allotment	No. of Equity Shares	Face Value (₹)	Issue Price (₹)	Reasons of Allotment	Benefits accrued to company	Allottees	No. of Shares Allotted
September 30, 2023	97,08,840	10/-	Nil	Bonus Issue	Capitalization of Reserves & Surplus	Mr. Anil Kumar Sabarwal	91,50,525
						Ms. Tejaswini Sabarwal	3,66,300
						Mr. Ashok Anand	1,92,015

SPLIT / CONSOLIDATION OF EQUITY SHARES IN THE LAST ONE YEAR

Our company has not undertaken a split or consolidation of the Equity Shares in the one (1) year preceding the date of this Prospectus.

EXEMPTION FROM COMPLYING WITH ANY PROVISIONS OF SECURITIES LAWS, IF ANY, GRANTED BY SEBI

Our company has not applied or received any exemption from complying with any provisions of securities laws by SEBI.

SECTION III – RISK FACTORS

An investment in Equity Shares involves a high degree of financial risk. Investors should carefully consider all information in this Prospectus, including the risks described below, before making an investment in our Equity Shares. If any of the following risks, or other risks that are not currently known or are now deemed immaterial, actually occur, our business, results of operations, cash flows and financial condition could suffer, the price of the Equity Shares could decline, and you may lose all or part of your investment. In making an investment decision, prospective investors must rely on their own examination of us and the terms of the Issue including the merits and risks involved. Investors should consult their tax, financial and legal advisors about particular consequences to them of an investment in the Issue. The risk factors set forth below do not purport to be complete or comprehensive in terms of all the risk factors that may arise in connection with our business or any decision to purchase, own or dispose of the Equity Shares. This section addresses general risks associated with the industry in which we operate and specific risks associated with our Company. However, there are certain risk factors where the financial impact is not quantifiable and, therefore, such financial impact cannot be disclosed in such risk factors. Unless specified or quantified in the relevant risk factors below, we are not in a position to quantify the financial or other implications of any of the risks described in this section. Any of the following risks, as well as the other risks and uncertainties discussed in this Prospectus, could have a material adverse effect on our business and could cause the trading price of our Equity Shares to decline and you may lose all or part of your investment.

This Prospectus also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the considerations described below and elsewhere in this Prospectus. See chapter titled “Forward Looking Statements” beginning on page 19 of this Prospectus.

To obtain a better understanding of our business, you should read this chapter in conjunction with other chapters of this Prospectus, including the chapters titled “Our Business”, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, “Industry Overview” and “Restated Financial Statements” on page 128, 199, 106 and 196 respectively of this Prospectus, together with all other Restated Financial Statements contained in this Prospectus. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the considerations described below and elsewhere in this Prospectus.

Unless otherwise stated, the financial data in this chapter is derived from our Restated Financial Statements for the Period ended December 31, 2023 and for the financial years ended March 31, 2023, 2022, and 2021 as included in “Restated Financial Statements” beginning on page 196 of this Prospectus.

MATERIALITY

The Risk factors have been determined on the basis of their materiality. The following factors have been considered for determining the materiality.

- Some events may have material impact quantitatively;
- Some events may have material impact qualitatively instead of quantitatively.
- Some events may not be material individually but may be found material collectively.
- Some events may not be material at present but may be having material impact in future.

INTERNAL RISKS

- 1. Our promoter Mr. Anil Kumar Sabarwal has in one of the matters against him, been sentenced for imprisonment and he has filed an appeal against the said order in the higher court. We are not sure whether the said appeal shall be decided in favour of our promoter and in the event of any adverse decision, the operations of the Company shall be adversely affected.**

Our promoter has been held liable in one of the matters bearing no. 131/2016 wherein he has been sentenced for an imprisonment of 1 (One) year and a fine of Rs. 20,000/-. The matter pertains to manufacturing of Not of Standard Quality (NSQ) Drugs. Our Promoter have however not accepted the allegations and have contested the said order in the Jharkhand High Court, Ranchi on the grounds that the samples were collected from a store where the drugs in question had been supplied by the Company and that for maintaining the quality of the drugs, the storage conditions are also a decisive factor. The appeal has been admitted by the concerned court of law and the same is pending.

However, if the said matter is decided against the Promoter / Company or in case the proceedings are prolonged, this shall divert the attention of the promoters / management of the Company towards the matter which shall adversely affect the business of the Company. Also, any adverse or prolonged decision shall also harm the reputation of the Company which shall in return harm the financials of the Company.

Further in the event of adverse decision, the maximum penalty that can be imposed shall be Rs. 20,000/- with an imprisonment of 1 year in which event our promoter of the company shall be imprisoned in which event, the business of our Company may be adversely affected.

2. We have certain outstanding litigation against us, an adverse outcome of which may adversely affect our business, reputation and results of operations.

A summary of outstanding matters set out below includes details of civil and criminal proceedings, tax proceedings, statutory and regulatory actions and other material pending litigation involving us, Directors, Promoters and Group Company as at the date of this Prospectus.

Cases against our Company:

Nature of Cases	No of Outstanding Cases	Amount involved (In Lakhs)
Criminal Complaints	3	Unascertained
Statutory/ Regulatory Authorities	--	--
Taxation Matters	5	197.83
Other Litigation	2	1.05*

*Amount related to 1 matter is unascertained

Cases against our Director and / or Promoters:

Nature of Cases	No of Outstanding Cases	Amount involved (In Lakhs)
Criminal Complaints	3	Unascertained
Statutory/ Regulatory Authorities	--	--
Taxation Matters	--	--
Other Litigation	2	Unascertained

Cases against our Group Companies and / or Subsidiaries:

Nature of Cases	No of Outstanding Cases	Amount involved (In Lakhs)
Criminal Complaints	--	--
Statutory/ Regulatory Authorities	--	--
Taxation Matters	--	--
Other Litigation	--	--

The amounts claimed in these proceedings have been disclosed to the extent ascertainable and include amounts claimed jointly and severally. If any new developments arise, such as a change in Indian law or rulings against us by appellate courts or tribunals, we may need to make provisions in our financial statements that could increase our expenses and current liabilities.

We cannot assure you that any of the outstanding litigation matters will be settled in our favour or that no additional liabilities will arise out of these proceedings. In addition to the above, we could also be adversely affected by complaints, claims or legal actions brought by persons, including before consumer forums or sector-specific or other regulatory authorities in the ordinary course of business or otherwise, in relation to our business operations, our intellectual property, our branding or marketing efforts or campaigns or our policies. We may also be subject to legal action by our employees and/or former employees in relation to alleged grievances, such as termination of employment. We cannot assure you that such complaints, claims or requests for information will not result in investigations, enquiries or legal actions by any regulatory authority or third persons against us.

Brief details of top 5 Criminal Case against our Promoters:

Sr. No.	Particulars	Litigation filed by	Current status	Amount involved
1	State of Jharkhand V/s. 1. Anil Sabarwal 2. Kavita Sabarwal	State of Jharkhand	Pending	Unascertained

Sr. No.	Particulars	Litigation filed by	Current status	Amount involved
	<i>208 Case No. C.C. 131/2016 filed with the Judicial Magistrate Courts, Senior Division-II, Jamtara Court, filed u/s. 18(a)(i), 18(a)(vi) & 18(b) of the Drugs and Cosmetics Act.</i> A complaint was filed by Naseem Aslam, the drug inspector at Jamtara district in Jharkhand, against Mr. Anil Sabarwal, after finding that the samples of paracetamol oral suspension he collected from the drug store of Sadar Hospital in Jamtara on March 30, 2015 was not-of-standard-quality. From the details of invoices obtained by the drug inspector, the drugs were allegedly found to have been manufactured by M/s. Quest Laboratories Private Ltd in Indore. For substantiating his charges leveled against the company, the Drug Inspector produced the laboratory test report of his samples in the court for evidence. The government drug testing laboratory (DTL) in Ranchi conducted the analytical test and the result was that the drug was Not of Standard Quality (NSQ).. The drug was supplied to the hospital by Mehsuk Enterprises, a pharma dealer at Paredih in Jamtara. Accordingly, the Jamtara court registered a case (131/2016) against Mr. Anil Sabarwal, managing director and Kavita Sabarwal, one of the directors of the company under Section 27 (d) of the D&C Act. In the course of time, the proceedings against Kavita Sabarwal had to be dropped because of her sudden death on February 9, 2021, but the case continued against Anil Sabarwal and he was put for hearing on 28.4.2023. The charges were explained to him and he was questioned by the court under section 313 of the Cr PC. He denied his complicity in the crime and stated that he was falsely implicated in the case. After being found guilty of manufacturing 'NSQ' drug, the Principal Sessions Judge at Jamtara in Jharkhand vide its order dated January 23, 2024, has ordered for conviction of Mr. Anil Sabarwal, the managing director of the Quest Laboratories Private Limited in Indore in Madhya Pradesh, for one year imprisonment and imposed a fine of Rs. 20,000, under Section 27 (d) of the Drugs and Cosmetics Act 1940. However, the court has granted him bail to enable him to appeal to the High Court of Ranchi and Mr. Anil Sabarwal has filed an appeal bearing no. Cr.A(SJ) 5225/2024 has been filed with Jharkhand High Court, Ranchi, on February 26, 2024 and the same is pending.			
2	P.R.C. No. 27/2013 filed and pending with the Honourable Court of III Additional Judicial First-Class Magistrate, Kakinada and later transferred to Honourable District & Sessions Judge, East Godavari, Rajahmahendravaram vide case no. (SC/159/2018) As stated, M/s. Quest Laboratories Pvt. Ltd (the Company) represented by Mr. Anil Sabarwal, director is a manufacturer of Drugs and is having a	The State of Andhra Pradesh (Represented by Drug Inspector) (Complainant)	Pending	unascertained

Sr. No.	Particulars	Litigation filed by	Current status	Amount involved
	manufacturing license under Form 25 & 28 bearing no. 25/18/98. The complainant herein claims to have taken a sample on August 19, 2010 of Polyfol Forte tablest, Batch no. 13, Mfg. Date: 07/2010, Exp. Date: 12/2011, manufactured by the company, for test / analysis from the Central Drug Stores, APMHIDC, 23-1-73/A, Old Bus Stand, Kakinada and the sample was sent to Govt. Analyst, drugs Control Laboratory, Vijaywada, as per the provisions of Drugs and Cosmetics Act, 1940. As alleged, the test report of the said sample received on June 29, 2011 declared the sample of non-standard quality for the reason that the sample did not meet the I.P. specifications in respect of Description. Upon receiving confirmation from the pharmacist of the Central Drug Store in question of having received the said drug from M/s. Quest Laboratories Pvt. Ltd., the Complainant herein alleged to have issued letter dated July 16, 2011 to the Company and several reminders thereof requiring the Company to provide Mfg. & Analytical records, Distribution particulars of the said batch and Drug and Manufacturing license to which the Complainant herein had allegedly not received any response. Resultantly, the instant petition was filed by the complainant, alleging the company to be a. guilty of manufacturing for sale and distribution of not of Standard quality drug, thereby contravening Section 18(a)(i) r/w. Section 16 punishable u/s. 27(d) of Drugs and Cosmetics (Amendment) Act, 2008 by manufacturing “NOT OF STANDARD QUALITY DRUG” ; and b. failure to furnish the constitution particulars and batch manufacturing records of the products as required u/s. 24, 18-B & 22(1) of the Act, thus contravening the provisions of the Sections and punishable u/s. 28, 28-A and 22(3) of the Act, respectively and praying for committal to the Honourable Court of Sessions as per Section 32(2) of the Act and in the interest of Justice. After considering the matter the Honourable ADJFC Magistrate, Kakinada vide its order dated March 08, 2018, considering it fit and proper case for committal to the Honourable Court of Sessions, committed the case to the Court of sessions, East Godavari, Rajamahendravaram under section 209(a) of Criminal Procedure Code with directions that the Accused shall attend before Hon'ble Court of Sessions, East Godavari District, Rajamahendravaram after receipt of Court summons and the same order shall continue until further Orders of the Hon'ble Sessions Court as required under Sec.209 (b) Cr.P.C.			
3	State of Maharashtra (Complainant) V/s. 1) Anilkumar S/o Captain S. P. Sabharwal 2) Deependu Shekhar S/o. Hari Keshav Singh 3) Neha Goverdhan Bairagi; 4) M/s. Quest Laboratories Pvt. Ltd. (Parties 1 to 4 individually referred to as	State Of Maharashtra	Summons Awaiting	Unascertained

Sr. No.	Particulars	Litigation filed by	Current status	Amount involved
	defendant no. 1, 2, 3 & 4 respectively and collectively as defendants) <i>R.C.C./1390/2021; RCC- Reg. Criminal Case filed u/s. 18ai & 18c, 60 of Drugs & Cosmetic Act filed with Akola Dist & Session Court CJM Akola</i> As stated, M/s. Quest Laboratories Pvt. Ltd (the Company) represented by Mr. Anil Sabarwal, director is a manufacturer of Drugs and is having a manufacturing license under Form 25 & 28 bearing no. 25/18/98. The complainant herein claims to have taken a sample of Chlorohexidine Gluconate Solution Hand Sanitizer B.No. E 1705, Mfg. Date: 03/2020, Exp. Date: 08-2021 (manufactured by M/s. Quest Laboratories Pvt. Ltd.) from M/s. Goyal Medical & General Store, New Radhakisan Plot, Akola, as per the provisions of Drugs and Cosmetics Act, 1940. As alleged, the test report no. NSQ/AUR/124775/2020 dated August 18, 2020 declared the sample of non-standard quality for the reason that the content of Chlorhexidine in the sample was less than the permissible limits. Further as alleged, the name of the defendant no. 4 having been mentioned as manufacturer of the drugs in question, a detailed report as mentioned above was send to it requiring it to produce certain documents / details before the Complainant. Later the complainant filed the instant petition and the same is pending.			
4	1) State thr. Kishore M. Rajne Drugs Inspector (Complainant) V/s. 1) Rahul Dangi thr. Managing Director M/s. Quest Laboratories Pvt. Ltd.; 2) Anil Kumar Sabarwal thr. Director M/s. Quest Laboratories Pvt. Ltd. 3) Tejaswini Chouhan; 4) Naval Gopal Sharma; 5) Umendra Ramkrishna Suthar; 6) Quest Laboratories Pvt. Ltd. (parties 1 to 6 respectively referred to as respondent no. 1, 2, 3, 4, 5 & 6 and collectively as Respondents) <i>Regular criminal case, RCC/1997/2022 filed u/s. U/s. 18ai & 18c 161 34 under Drugs & Cosmetic Act with Vasai District & Addl sessions civil court, 12-4th JT CIVIL JUDGE J.D. J.M.F.C. Vasai</i> The complainant herein claims to have taken a sample on January 14, 2021 of Lomolok Tablets, Loperamide Hydrochloride Tablets I.P., Batch No. T8838, Mfg. Date: 07/2020, Exp. Date: 11/2023, manufactured by M/s. Quest Laboratories Pvt. Ltd. from the premises of M/s. AERO LIFE PHARMA, situated at shop no. 08, Laxmi Apartment, Waliv, Vasai (East), Dist. Palgarh, for inspection and to draw routine samples for test / analysis. As alleged, the test report of the said sample received on January 24, 2022 bearing no.	1) State thr. Kishore M. Rajne Drugs Inspector	Awaiting Summons	Unascertained

Sr. No.	Particulars	Litigation filed by	Current status	Amount involved
	NSQ/MUM/126825/2022 dated January 20, 2022, declared the samples so collected as of non-standard quality for the reason that the sample did not meet the I.P. specifications for dissolution test. Later, after due enquiry and having received the copy of order from the Joint Commissioner (Head Quarter) and Controlling Authority, Food and Drugs Administration, Mumbai, bearing no. Kathla/MUM/126825/74-22/10 dated February 11, 2022, directions were made to investigate the matter and file prosecution against the manufacturer of the drug and related. Later, a notice bearing no. T Z-2/KMR/NSQ/126825/448/2022/2 dated June 23, 2022 was handed over to factory manager Mr. Gopal Chauhan upon the alleged visit to the premises of M/s. Quest Laboratories Pvt. LTd., by the Complainant herein along with Drug Inspector, Bhopal (M.P.) for enquiry and investigation. Upon receipt of the said notice, the Respondent no. 1 herein submitted several papers and records with the complainant, which as per the Complainant, were not upto their satisfaction. On the basis of documents received from the respondents, the complainant held the respondent, liable of manufacturing Non-Standard Quality Drugs and accordingly framed several charges against them and filed the instant petition praying to initiate process against the respondents herein, in accordance with the law. The matter is pending with the concerned court of jurisdiction.			

For further details of certain material legal proceedings involving our Company, our Promoters, our directors, see “*Outstanding Litigations and Material Developments*” beginning on page 221 of this Prospectus.

3. Any manufacturing or quality control problems may disrupt our business operations, damage our reputation for high quality production and expose us to potential litigation or other liabilities, which would negatively impact our business, prospects, cash flows, results of operations and financial condition.

Pharmaceutical manufacturers are subject to significant regulatory scrutiny in most jurisdictions. We are required to register our manufacturing facility with regulatory authorities and our products must be made, packaged, labelled and stored in a manner consistent with the standards set by the regulatory authorities under various acts and statutes. For our approved products, modifications, enhancements, or changes in manufacturing processes and sites may require supplemental approval or other governmental authorities, which may be subject to a lengthy application process or which we may be unable to obtain. In addition, regulatory authorities and other agencies may conduct scheduled or unscheduled periodic inspections of our manufacturing facilities to monitor our regulatory compliance. Following an inspection, an agency may issue a notice listing conditions that are believed to violate current good manufacturing practices or other regulations, or a warning letter for violations of regulatory significance that may result in enforcement action if not promptly and adequately cured.

There have been instances in the past where our products have been found to have been of non-standard quality (NSQ) and we have been subjected to litigations in respect of same. Although in other cases we have been able to prove that the deterioration in quality of the products sampled was for the reason of storage conditions, in one of the case, our director have been subjected to punishment and penalty by the concerned district court and an appeal in the matter have been filed and pending with the High Court. For further details, kindly refer to the chapter titled, “*Outstanding Litigation and Material Development*” on page 221 of this Prospectus. There are stringent and restrictive norms in relation to quality standards. Further, entry barriers in regulated markets in which we currently operate and seek to expand are high and have extensive regulations pertaining to research, testing and manufacturing, selling and marketing of pharmaceutical products. In most

regulated markets, pharmaceutical products must be registered after being tested for safety, efficacy and environmental impact and the regulations differ from country to country. Failure of our Company to adapt itself to such regulatory changes, obtain necessary approvals/renewal of products, may adversely affect our operations.

- 4. *Our Company is reliant on the demand from the pharmaceutical industry for a significant portion of our revenue. Any downturn in the pharmaceutical industry or an inability to increase or effectively manage our sales could have an adverse impact on our Company's business and results of operations.***

Our Company is engaged in the business of manufacturing of pharmaceutical products and therefore, our revenues are highly dependent on our customers from the pharmaceutical industry and the loss of any of our customers from any industry which we cater to may adversely affect our sales and consequently on our business and results of operations. Further, in the event, there takes place a shift of practice of developing our products in-house in the pharmaceutical industries, it may have an adverse impact on the demand for our products. Similarly, in the event of any new breakthrough in the development of a novel product or raw material by our competitors or customers, our products may become obsolete or be substituted by such alternatives; thereby impacting our revenues and profitability adversely. It may also happen that our competitors are able to improve the efficiency of their manufacturing process or their distribution or raw materials sourcing process and thereby offer their similar or high-quality products at lower price our Company may be unable to adequately react to such developments which may affect our revenues and profitability.

- 5. *The products that we commercialize may not perform as expected which could adversely affect our business, financial condition and results of operations.***

Our success depends significantly on our ability to commercialize new pharmaceutical products in India and across various markets. Commercialization requires us to successfully develop, test, manufacture and obtain the required regulatory approvals for our products, while complying with applicable regulatory and safety standards. In order to develop a commercially viable product, we must demonstrate, through extensive trials that the products are safe and effective for use in humans. Our product, if and when fully developed and tested, may not perform as we expect, necessary regulatory approvals may not be obtained in a timely manner, if at all, and we may not be able to successfully and profitably produce and market such products. Furthermore, even if we are successful in developing a new product, that product may become subject to litigation by third parties claiming our products infringe on their patents or may be seized in-transit by regulatory authorities for alleged infringement of intellectual property or may be otherwise unsuccessful in the market place due to the introduction of superior products by competitors. Moreover, it may take an extended period of time for our new products to gain market acceptance, if at all.

- 6. *Any manufacturing or quality control problems may damage our reputation for high quality products and expose us to litigation or other liabilities, which could adversely affect our financial results.***

Pharmaceutical manufacturers are subject to significant regulatory scrutiny. Our manufacturing facility must manufacture products in accordance with Good Manufacturing Practices stipulated by WHO, state level food and drug administrations, the DCGI and other regulatory agencies, as applicable. Furthermore, we are liable for the quality of our products for the entire duration of the shelf life of the product. After our products reach the market, certain developments could adversely affect demand for our products, including any contamination of our products by intermediaries, re-review of products that are already marketed, new scientific information, greater scrutiny in advertising and promotion, the discovery of previously unknown side effects or the recall or loss of approval of products that we manufacture, market or sell. Disputes over non-conformity of our products with such quality standards or specifications are generally referred to independent government approved testing laboratories. If any such independent laboratory confirms that our products do not conform to the prescribed or agreed standards and specifications, we would bear the expenses of replacing and testing such products, which could adversely affect our business, results of operations and financial condition.

We also face the risk of loss resulting from, and the adverse publicity associated with, manufacturing or quality problems. Such adverse publicity harms the brand image of our Company and products. We may be subject to claims resulting from manufacturing defects or negligence in storage and handling of our products. Any loss of our reputation or brand image, for whatsoever reason may lead to a loss of existing business contracts and adversely affect our ability to enter into additional business contracts in the future. We currently carry no products liability insurance with respect to our manufactured products.

- 7. *The availability of counterfeit drugs, such as drugs passed off by others as our products, could adversely affect our goodwill and results of operations.***

Entities in India and abroad could pass off their own products as ours, including counterfeit or pirated products. For example, certain entities could imitate our brand name, packaging materials or attempt to create look-alike products. As a result, our market share could be reduced due to replacement of demand for our products and adversely affect our goodwill.

We have also invested in our products to prevent counterfeit versions of our products from being distributed in the markets. Such measures include, monitoring products in the market and initiating actions against counterfeiters, each of which entails incurring significant costs at our end. The proliferation of counterfeit and pirated products, and the time and attention lost to defending claims and complaints about counterfeit products could have an adverse effect on our goodwill and our business, prospects, results of operations and financial condition could suffer.

- 8. *Our business is dependent and will continue to depend on our manufacturing facility, and we are subject to certain risks in our manufacturing process. Any slowdown or shutdown in our manufacturing operations or strikes, work stoppages or increased wage demands by our employees that could interfere with our operations could have an adverse effect on our business, financial condition and results of operations.***

We have one manufacturing facility situated at Madhya Pradesh, India. Our business is dependent upon our ability to manage our manufacturing facility, including productivity of our workforce, which are subject to various operating risks, including those beyond our control, such as the breakdown, failure of equipment or industrial accidents, severe weather conditions and natural disasters. Any significant malfunction or breakdown of our machinery, our equipment, our reactors, our automation systems, our IT systems or any other part of our manufacturing processes or systems (together, our “Manufacturing Assets”) may entail significant repair and maintenance costs and cause delays in our operations. However, we cannot assure you that we shall not experience any malfunction or breakdown of our Manufacturing Assets in the future. If we are unable to repair Manufacturing Assets in a timely manner or at all, our operations may need to be suspended until we procure the appropriate Manufacturing Assets to replace them. Further, there can be no assurance that in future, if we suffer accidents or if we are subject to shutdowns due to malfunctions, that we would be able to recover insurance costs covering all losses. Any uninsured losses in the future would adversely impact our results of operations and profitability. Additionally, any regulatory notices received indicating shortfall in quality or inadequacies of quality control measures or in our products could require us to make unplanned shutdowns to our manufacturing facilities in the future, resulting in losses and operational difficulties. In addition, we may be required to carry out planned shutdowns of our facilities for maintenance, statutory inspections, customer audits and testing, or may shut down certain facilities for capacity expansion and equipment upgrades.

Success of our operations depend on availability of labour and good relationships with our labour force. As of the date of this Prospectus, our employees are not members of any organised labour unions. Strikes and lockouts as a result of disputes with our labour force may adversely affect our operations. While we have not had instance of strikes, lockouts or labour disputes in the past, we cannot assure you that we shall not experience any strikes or lockouts on account of labour disputes in the future. Such events could disrupt our operations and may have a material adverse effect on our business, financial condition and results of operations. In addition, we also may face protests from local citizens at our existing facilities or while setting up new facilities, which may delay or halt our operations.

Further, we may be subject to manufacturing disruptions due to contraventions by us of any of the conditions of our regulatory approvals, which may require our manufacturing facility to cease, or limit, production until the disputes concerning such approvals are resolved.

Although we have not experienced any significant disruptions at our manufacturing facility in the past, we cannot assure you that there will not be any disruptions in our operations in the future. Our inability to effectively respond to such events and rectify any disruption, in a timely manner and at an acceptable cost, could lead to the slowdown or shutdown of our operations or the under-utilization of our manufacturing facility, which in turn may have an adverse effect on our business, financial condition and results of operations.

- 9. *Our existing manufacturing facility are concentrated in a single region i.e., Pithampur, Indore, Madhya Pradesh and the inability to operate and grow our business in this particular region may have an adverse effect on our business, financial condition, results of operations, cash flows and future business prospects.***

Our manufacturing unit is located at Pithampur, Indore, Madhya Pradesh which exposes us to risks of concentration. Our success depends on our ability to successfully manufacture and deliver our products to meet our customer demand. Although in the past we have not experienced instances of operating risks, however our manufacturing facility is susceptible to damage or interruption or operating risks, such as human error, power loss, breakdown or failure of equipment, power supply or processes, performance below expected levels of output or efficiency, obsolescence, loss of services of our external contractors, terrorist attacks, acts of war, break-ins, earthquakes, other natural disasters and industrial accidents and similar events. It is also subject to operating risk arising from compliance with the directives of relevant government authorities. Operating risks may result in personal injury and property damage and in the imposition of civil and criminal penalties. If our Company experiences delays in production or shutdowns at our facility due to any reason, including disruptions caused by disputes with its workforce or any external factors, our Company’s operations will be significantly affected, which in turn would have a material adverse effect on its business, financial condition and results of operations.

Further, any materially adverse social, political or economic development, civil disruptions, or changes in the policies of the state government or state or local governments in this region could adversely affect our manufacturing operations, and require a modification of our business strategy, or require us to incur significant capital expenditure or suspend our operations. Any such adverse development affecting continuing operations at our manufacturing facility could result in significant loss due to an inability to meet customer contracts and production schedules, which could materially affect our business reputation within the industry. The occurrence of or our inability to effectively respond to, any such events or effectively manage the competition in the region, could have an adverse effect on our business, results of operations, financial condition, cash flows and future business prospects. Further, continuous addition of industries in and around our manufacturing facility without commensurate growth of its infrastructural facilities may put pressure on the existing infrastructure therein, which may adversely affect our business.

10. *We highly depend on our major raw materials on many of the suppliers who help us procure the same. Our Company has not entered into long-term agreements with its suppliers for supply of raw materials. In the event we are unable to procure adequate amounts of raw materials, at competitive prices our business, results of operations and financial condition may be adversely affected*

Our business is significantly affected by the availability, cost and quality of the raw materials and components which we need to develop our products. Our principal raw materials include APIs, emulsifying wax, dextrose Our business is significantly affected by the availability, cost and quality of the raw materials and components which we need to develop our products. Our principal raw materials include APIs, emulsifying wax, dextrose anhydride, flavors, pharmaceutical-grade sugar, colorants, aqueous coating materials, and packaging materials etc. We usually do not enter into long-term supply contracts with any of our raw material suppliers. Our raw materials are majorly procured in the domestic market from Uttar Pradesh, Madhya Pradesh, Maharashtra, Himachal Pradesh, Gujarat, Assam, Uttarakhand, Telangana, Delhi, Haryana, Karnataka. We are dependent on external suppliers for certain of the materials /components. The prices and supply of these and other raw materials and components depend on factors beyond our control, including general economic conditions, competition, production levels, transportation costs and duties. If, for any reason, our suppliers of raw materials and components should curtail or discontinue their delivery of such materials to us in the quantities we need or at prices that are competitive or expected by us, our ability to meet the requirements of our customers could be impaired and our earnings and business could suffer.

Further, we may not be able to pass on any increase in the cost of manufacturing our products to our customers, which may adversely affect our results of operations. For the period ended December 31, 2023 and for the financial year ended March 31, 2023, 2022 and 2021, our cost of material consumed was ₹ 3,996.13 Lakhs, ₹ 4,173.79 Lakhs, ₹ 4,427.41 Lakhs and ₹ 2,443.19 Lakhs respectively, which represented 64.37%, 67.71%, 74.43% and 80.46% respectively of our revenue from operations. If we are unable to source raw materials from suppliers in a timely manner, our production processes and results of operations may be adversely impacted. There can be no assurance that we would be able to source required quantities or qualities of raw materials in a cost-effective manner in future periods.

In addition, we usually do not enter into long-term supply contracts with any of our raw material suppliers and typically source raw materials from third-party suppliers under contracts of shorter period or the open market. The absence of long-term contracts at fixed prices exposes us to volatility in the prices of raw materials that we require and we may be unable to pass these costs onto our customers, which may reduce our profit margins.

We face a risk that one or more of our existing suppliers may discontinue their supplies to us, and any inability on our part to procure raw materials from alternate suppliers in a timely fashion, or on commercially acceptable terms, may adversely affect our business, financial condition and results of operations. Purchases made from our top 10 suppliers for the period ended December 31, 2023 and for the financial year ended March 31, 2023, 2022 and 2021, were ₹ 2,526.88 Lakhs, ₹ 1,700.88 Lakhs, ₹ 1,339.98 Lakhs and ₹ 707.81 Lakhs, respectively representing 62.73%, 32.78%, 29.94% and 33.62% respectively of our total raw material purchases.

11. *Too much concentration of our Business is from sale to government which may impact our Business.*

The major portion of our revenue for the period ended December 31, 2023 and Financial Year ended March 31, 2023, March 31, 2022 and March 31, 2021 is from Government Institutions i.e., 77.91% and 61.93 %, 51.11% and 18.05%. Such concentration of our business heightens our exposure to adverse developments related to competition, as well as economic and demographic changes in these regions which may adversely affect our business prospects, financial conditions and results of operations. Factors such as competition, culture, regulatory regimes, business practices and customs, industry needs, transportation, in other markets where we may expand, our operations may differ from those in which we are currently offering. In addition, as we enter new markets and geographical areas, we are likely to compete not only with national players, but also local players who might have an established local presence, are more familiar with local regulations, business practices and industry needs, have stronger relationships with local distributors, dealers, relevant government authorities, and are in a stronger financial position than us, all of which may give them a competitive advantage

over us. Our inability to expand more into areas may adversely affect our business prospects, financial conditions and results of operations.

12. *We depend on the success of our relationships with our customers. We derive a significant part of our revenue from our top 10 customers and we do not have long term contracts with these customers. If one or more of such customers choose not to source their requirements from us, our business, financial condition and results of operations may be adversely affected.*

Our revenue from operations for the Period ended December 31, 2023 and for the financial year ended March 31, 2023, 2022 and 2021, our top 10 customers contributed approximately 97.15 %, 95.13 %, 86.29 % and 55.65 % respectively.

Given the nature of our business, there can be no assurance that we would be able to attract new customers or reduce our dependence on any of our top customers. We expect that we will continue to be reliant on our major customers for the foreseeable future. Accordingly, any failure to retain these customers or to remain suppliers to these customers and/or negotiate and execute contracts on terms that are commercially viable, with these select customers, could adversely affect our business, financial condition and results of operations. In addition, any defaults or delays in payments by a major customer or the insolvency or financial distress by a major customer may have an adverse effect on business, financial condition and results of operations.

Cancellation by customers or delay or reduction in their orders or instances where anticipated orders fail to materialize can result in mismatch between our expectant and existing inventory levels at our unit, thereby increasing our costs relating to maintaining our inventory and reduction of our margins, which may adversely affect our profitability and liquidity. Further, we may not find any customers or purchasers for the surplus or excess capacity, in which case we would be forced to incur a loss. Further, our inability to find customers for surplus products may result in excessive inventories which may become obsolete and may be required to be written off in the future.

Additionally, our customers have high and stringent standards for product quality and quantity as well as delivery schedules. Any failure to meet our customers' expectations could result in the cancellation or non-renewal of contracts or purchase orders. There are also several factors, other than our performance that could cause the loss of a customer, which include those customers who may demand price reductions, set-off any payment obligations, require indemnification for themselves or their affiliates, or replace their existing products with alternative products, any of which may have an adverse effect on our business, financial condition, results of operations and prospects.

13. *We conduct our business activities on a purchase order basis and therefore, have not entered into long-term agreements with our customers except government contracts.*

Our Company is engaged in the business of manufacturing of pharmaceutical products on the basis of orders which are received from our customers. We have not entered into any formal agreements, arrangement or any other understanding with our customers except government or our traders and therefore, our business is dependent upon the continuous relationship with the customers, our traders and the quality of products supplied to us. Further, neither do we have any exclusive agents, dealers, distributors nor have we entered into any agreements with any of the market intermediaries for selling or marketing the products supplied to us. If there occurs any change in the market conditions, market trends, requirements of our customers, or if we fail to identify and understand evolving industry trends, preferences or fail to meet our customers' demands, it might have a direct impact on our revenue and customer base. The inability to procure new orders on a regular basis or at all may adversely affect our business, revenues, cash flows and operations.

14. *If we cannot respond adequately to the increased competition we expect to face, we will lose market share and our profits will decline, which will adversely affect our business, results of operations and financial condition.*

Our products face intense competition from products commercialized or under development by competitors in all of our product portfolios. We compete with local companies, multi-national corporations and companies from the rest of world. If our competitors gain significant market share at our expense, our business, results of operations and financial condition could be adversely affected.

Many of our competitors may have greater financial, manufacturing, research and development, marketing and other resources, more experience in obtaining regulatory approvals, greater geographic reach, broader product ranges and stronger sales forces. Our competitors may succeed in developing products that are more effective, more popular or cheaper than any we may develop, which may render our products obsolete or uncompetitive and adversely affect our business and financial results. Also, we face pressure on our margins due to pricing competition from several small and unorganized local players. Presence of more players in the unorganized sector compared to organized ones has resulted in increasingly competitive environment characterized by stiff price competition.

Our business faces competition from manufacturers of patented brand products that do not face any significant regulatory approvals or barriers to enter into the generics market for the territories where the brand is already approved. These manufacturers sell generic versions of their products to the market directly or by acquiring or forming strategic alliances with our competitors or by granting them rights to sell. Any failure on our part to gain an advantage could adversely affect our profitability and results of operations.

We also operate in a rapidly consolidating industry. The strength of combined companies could affect our competitive position in all of our business areas. Furthermore, if one of our competitors or their customers acquires any of our customers or suppliers, we may lose business from the customer or lose a supplier of a critical raw material, which may adversely affect our business, results of operations and financial condition.

15. We do not own the land on which our manufacturing facility and registered office is situated.

Our Company does not own the land on which our manufacturing facility is located. We have taken the same on lease from a third party. The lease for manufacturing facility is valid till August 12, 2040 and can be extended subject to mutual consent of both the parties. If we are unable to renew the lease or if the lease is not renewed on favourable conditions, it may affect our operations adversely. Also, if we do not comply with certain conditions of the lease agreement, it may lead to termination of the lease. In the event of non-renewal or termination of the lease, we may have to vacate our current premises and shift to new premises. There can be no assurance that we shall be able to find a suitable location, or one at present terms and conditions. Any additional burden due to shifting of premises, or increased capital expenditure, may adversely affect our business operations and financial conditions.

For details on properties taken on lease/rent by us please refer to the heading titled Properties Details in chapter titled “Our Business” beginning on page 155 of this Prospectus.

16. Our Company had negative cash flows in the past years, details of which are given below. Sustained negative cash flow could impact our growth and business.

We have experienced negative cash flows in the past which have been set out below as per the Restated financial statements:

(₹ in Lakhs)				
Particulars	December 31, 2023	March 31, 2023	March 31, 2022	March 31, 2021
Net cash generated from/ (used in) operating activities	0.39	363.07	345.51	104.72
Net cash generated from/ (used in) investing activities	(41.88)	(296.97)	(188.82)	(119.67)
Net cash generated from/ (used in) financing activities	(203.66)	26.67	(41.40)	3.83

Cash flows of a company is a key indicator to show the extent of cash generated from the operations of a company to meet capital expenditure, pay dividends, repay loans and make new investments without raising finance from external resources. If we are not able to generate sufficient cash flows, it may adversely affect our business and financial operations. For further details, see section titled “Restated Financial Statements” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” on pages 179 and 182 respectively of this Prospectus.

17. There are certain discrepancies/errors/delay filings noticed in some of our corporate records relating to forms filed with the Registrar of Companies and other provisions of Companies Act, 2013. Any penalty or action taken by any regulatory authorities in future, for non-compliance with provisions of corporate or any other law could impact the financial position of the Company to that extent.

Our company has not complied with certain statutory provisions in the past including but not limited to the details as mentioned in this risk factor.

Our company faced challenges regarding missing documents spanning the period between 1998 and 2006. In response, we conducted a physical inspection of forms and documents at the Registrar of Companies (ROC) in Gwalior, Madhya Pradesh. During this inspection, we were able to locate and organize some of the required documents. Subsequently, based on the information retrieved during the physical search and the statutory documents maintained by our company, as well as the certificate from our Practicing Company Secretary dated February 26, 2024, the necessary details have been included in the Prospectus.

There have been some instances of delays/ non-filing/ non-compliance with certain statutory authorities with certain provision of statutory regulations applicable to us such as:

- Complete share transfer forms for the share transfers taken place are not traceable. Information in relation to such transfers have been disclosed based on the statutory registers maintained by the Company, we may not be able to furnish any further documents in this regard.
- Certain forms and resolutions filed with Registrar of Companies (prior to 2006) are not traceable by our Company which includes Annual Returns and Financial Statements filed for the Financial Years 1998-99, 1999-00, 2000-01, 2001-02 and further allotment of equity shares made on March 31, 2001 are not traceable by us.

While no legal proceedings or regulatory action has been initiated against our Company in relation to such non-compliance or instances of non-filings or incorrect filings or delays in filing statutory forms with the RoC as of the date of this Prospectus, we cannot assure you that such legal proceedings or regulatory actions will not be initiated against our Company in future and we cannot assure you that we will not be subject to penalties imposed by concerned regulatory authorities in this respect. Therefore, if the authorities impose monetary penalties on us or take certain punitive actions against our Company in relation to the same, our business, financial condition and results of operations could be adversely affected.

18. *Our Company's failure to maintain the quality standards of the products or keep pace with the technological developments could adversely impact our business, results of operations and financial condition.*

Our products depend on recent inventions and developments as we manufacture and market the products as per the market trends. Any failure to maintain the quality standards may affect our business. Although we have put in place strict quality control procedures, we cannot assure that our products will always be able to satisfy our customers quality standards and there have been instances where our products have been found to have been of nonstandard quality (NSQ) and we have been subjected to litigations in respect of same. Although in other cases we have been able to prove that the deterioration in quality of the products sampled was for the reason of storage conditions, in one of the case, our director have been subjected to punishment and penalty by the concerned district court and an appeal in the matter have been filed and pending with the High Court. For further details, kindly refer to the chapter titled, "*Outstanding Litigation and Material Development*" on page 221 of this Prospectus.

Further any negative publicity regarding our Company, or products, including those arising from any deterioration in quality of our products from our vendors, or any other unforeseen events could adversely affect our reputation, our operations and our results from operations. Also, rapid change in our customers expectation on account of changes in technology or introduction of new products or for any other reason and failure on our part to meet their expectation could adversely affect our business, result of operations and financial condition. While, we believe that we have always introduced new products based on consumers need to cater to the growing demand of our customers and also endeavour regularly update our existing technology, our failure to anticipate or to respond adequately to changing technical, market demands and/or client requirements could adversely affect our business and financial results.

19. *Our expansion into new product categories and business verticals and increase in the number of products offered may expose us to new challenges and more risks.*

We may face challenges in inspecting and controlling quality, regulatory requirements, handling, storage and delivery of such new products. We may also need to price aggressively in new categories to obtain traction with consumers improve brand awareness, which may not be possible in instances where a product manufacturer imposes restrictions on our ability to offer such products at a discount and which would adversely affect our gross margins.

We may also make substantial investments in launching such new products on our platform Expansion of our offerings or business verticals may also strain our management and operational resources. It may also be difficult for us to achieve profitability with new products and as a result, our profit margins may be lower than we anticipate, which would adversely affect our results of operations. We cannot assure you that we will be able to recover our investments in introducing any new products or that any such new products will be successful by any measure.

20. *We may not be able to accurately manage our inventory, this may adversely affect our goodwill and business, financial condition and results of operations.*

The results of operations of our business are dependent on our ability to effectively manage our inventory and stocks. To effectively manage our inventory, we must be able to accurately estimate customer demand and supply requirements and manufacture and trade inventory accordingly. If our management has misjudged expected customer demand it could adversely impact the results by causing either a shortage of products or an accumulation of excess inventory. Further, if we

fail to sell the inventory we manufacture, we may be required to write-down our inventory or pay our suppliers without new purchases, or create additional vendor financing, which could have an adverse impact on our income and cash flows. We estimate our sales based on the forecast, demand and requirements and also on the customer specifications. Natural disasters such as earthquakes, extreme climatic or weather conditions such as floods or droughts may adversely impact the supply of raw material and local transportation. Should our supply of raw materials be disrupted, we may not be able to procure an alternate source of supply in time to meet the demands of our customers. Such disruption to supply would materially and adversely affect our business, profitability and reputation. In the past we have not experienced any instances of disruptions to the delivery of product to our customer occurred for reasons such as poor handling, transportation bottlenecks, or labour strikes, which could have led to delayed or lost deliveries or damaged products and disrupt supply of these products., but there is not guarantee that these instances will not happen in future to improve our line capability, we try to stock our inventory at our manufacturing facility. An optimal level of inventory is important to our business as it allows us to respond to customer demand effectively. If we overstock inventory, our capital requirements will increase and we will incur additional financing costs. If we under-stock inventory, our ability to meet customer demand and our operating results may be adversely affected. Any mismatch between our planning and actual consumer consumption could lead to potential excess inventory or out-of-stock situations, either of which could have an adverse effect on our business, financial condition and results of operation.

21. *We are exposed to counterparty credit risk and any delay in receiving payments or non-receipt of payments may adversely impact our results of operations.*

We are subject to counterparty credit risk and a significant delay in receiving large payments or non-receipt of large payments may adversely impact our results of operations. Our operations involve extending credit to our customers in respect of sale of our products and consequently, we face the risk of the uncertainty regarding the receipt of these outstanding amounts. Consequently, we face the risk of the uncertainty regarding the receipt of these outstanding amounts. As a result of such industry conditions, we have and may continue to have high levels of outstanding receivables. For the Period ended December 31, 2023 and financial year ended March 31, 2023, 2022 and 2021 our trade receivables were ₹ 2966.52 Lakhs and ₹ 1,993.80 Lakhs and ₹ 2,206.19 Lakhs and ₹ 915.47 Lakhs, respectively. There is no assurance that we will accurately assess the creditworthiness of our customers. Further, macroeconomic conditions which are beyond our control, such as a potential credit crisis in the global financial system, could also result in financial difficulties for our customers, including limited access to the credit markets, insolvency or bankruptcy. Such conditions could cause our customers to delay payment, request modifications of their payment terms, or default on their payment obligations to us, all of which could increase our receivables. Timely collection of dues from customers also depends on our ability to complete our contractual commitments and subsequently bill for and collect from our clients. While we have not faced such incidents in the past, if we are unable to meet our contractual obligations, we may experience delays in the collection of, or be unable to collect, our customer balances, which could adversely affect our results of operations and cash flows.

22. *We have not placed orders for plant and machinery / Equipments. In case of any escalation in prices of these Equipments, our total project cost may increase which in turn will adversely affect our financials.*

While we have identified the types of plant and machinery necessary for our operations, orders for 100% of the plant & machinery, valued at ₹ 2,600.00 Lakhs respectively, as detailed in the “Objects of the Issue” Chapter starting on page 86 of this Prospectus, have not been placed. These estimates are based on our projections and third-party quotations, which are subject to various variables, including potential cost overruns, changes in management's strategic decisions, alterations in suppliers of plant & machinery equipment, among others. These factors may adversely affect our business and operational results. Furthermore, we cannot guarantee our ability to procure these plant and machinery components, or obtain them within the budgeted costs and timelines. Delays in their acquisition could result in cost and time overruns, leading to a significant adverse impact on our business, operational results, and financial condition.

23. *Within the parameters as mentioned in the chapter titled “Objects of this Issue” beginning on page 86 of this Prospectus, our Company’s management will have flexibility in applying the proceeds of the Issue. The fund requirement and deployment mentioned in the Objects of this Issue have not been appraised by any bank or financial institution.*

We intend to utilize the net proceeds for funding the capital expenditure requirements of our company towards the purchase of plant and machinery for the expansion and upgrading of our existing manufacturing facility and funding working capital requirements, and addressing general corporate purposes. The deployment of the net proceeds is planned for the financial year 2024-25 and is based on certain assumptions and strategies that our company intends to implement in the future. The funds raised from the Issue may remain idle on account of change in assumptions, market conditions, strategy of our Company, etc., For further details on the use of the Net Proceeds, please refer chapter titled “Objects of the Issue” beginning on page 86 of this Prospectus.

The deployment of funds for the purposes described above is at the discretion of our Company’s Board of Directors. The fund requirement and deployment are based on internal management estimates and has not been appraised by any bank or

financial institution. Accordingly, within the parameters as mentioned in the chapter titled “*Objects of the Issue*” beginning on page 86 of this Prospectus, the Management will have significant flexibility in applying the proceeds received by our Company from the Issue. Our Board of Directors will monitor the proceeds of this Issue. However, Audit Committee will monitor the utilization of the proceeds of this Issue and prepare the statement for utilization of the proceeds of this Issue. However, in accordance with Section 27 of the Companies Act, 2013, and relevant provisions of SEBI ICDR Regulations, 2018, a company shall not vary the objects of the Issue without our Company being authorised to do so by our shareholders by way of special resolution and other compliances in this regard. Our Promoter and controlling shareholders shall provide exit opportunity to such shareholders who do not agree to the proposal to vary the objects, at such price, and in such manner, as may be prescribed by SEBI, in this regard.

24. *We are dependent on third-party transportation providers for the supply of raw materials and finished products.*

Our success depends on the supply and transport of the various raw materials required for our manufacturing facility and of our finished products from our manufacturing facility which are subject to various uncertainties and risks. Our company do not completely depend on our own transportation facility and are majorly dependent on third-party transportation providers for the delivery of our products. While transportation restrictions, if any, could have an adverse effect on supplies and deliveries to and from our customers and suppliers. In addition, raw materials and finished products may be lost or damaged in transit for various reasons including occurrence of accidents or natural disasters. There may also be a delay in delivery of raw materials and products which may also affect our business and results of operations negatively. In the event we fail to maintain a sufficient volume of raw materials and delivery of such materials to us is delayed, we may be unable to meet our purchase orders in a timely manner or at all, which may result in loss of sales opportunities that our competitors may capitalize on, thereby adversely affecting our business, financial condition, results of operations, and cash flows. Any compensation received from insurers or third-party transportation providers may be insufficient to cover the cost of any delays and will not repair damage to our relationships with our affected customers and distributors. We may also be affected by an increase in fuel costs, as it will have a corresponding impact on freight charges levied by our third-party transportation providers. This could require us to expend considerable resources in addressing our distribution requirements, including by way of absorbing these excess freight charges to maintain our selling price, which could adversely affect our results of operations, or passing these charges on to our customers, which could adversely affect demand for our products.



25. *Our Company logo “” is not registered with Registrar of Trademark; any infringement of our brand name or failure to get it registered may adversely affect our business. Further, any kind of negative publicity or misuse of our brand name could hamper our brand building efforts and our future growth strategy could be adversely affected.*

Our Company has made an application for registration with the Registrar of Trademark for registration of logo. If we are unable to register the intellectual property in the future in our name or any objection on the same may require us to change our logo and hence may loose on the goodwill created so far. Further, the same may involve costly litigations and penal provisions if some legal consequences arise if someone from outside use our name and logo of the Company. We believe that our future growth and competitiveness would depend on our ability to establish and strengthen our brand. We cannot guarantee that we will be able to make a lasting brand image with our clients and other people in the absence of a logo. Although, we believe that our present systems are adequate to protect our confidential information and intellectual property, there can be no assurance that our intellectual property data, trade secrets or proprietary technology will not be copied, infringed or obtained by third parties. Further, our efforts to protect our intellectual property may not be adequate and may lead to erosion of our business value and our operations could be adversely affected. This may lead to litigations and any such litigations could be time consuming and costly and their outcome cannot be guaranteed. Our Company may not be able to detect any unauthorized use or take appropriate and timely steps to enforce or protect our intellectual property, which may adversely affect our business, financial condition and results of operations.

26. *In case of our inability to obtain, renew or maintain the statutory and regulatory licenses, permits and approvals required to operate our business it may have a material adverse effect on our business.*

We are governed by various laws and regulations for our business and operations. We are required, and will continue to be required, to obtain and hold relevant licenses, approvals and permits at state and central government levels for doing our business. The approvals, licenses, registrations and permits obtained by us may contain conditions. Further we will need to apply for renewal of certain approvals, licenses, registrations and permits, which expire or need to update pursuant to change in name and conversion of company to public Company.

While we have obtained a significant number of approvals, licenses, registrations and permits from the relevant authorities. There can be no assurance that the relevant authority will issue an approval or renew expired approvals within the applicable time period or at all. Any delay in receipt or non-receipt of such approvals, licenses, registrations and permits could result in cost and time overrun or which could affect our related operations.

These laws and regulations governing us are increasingly becoming stringent and may in the future create substantial compliance or liabilities and costs. While we endeavor to comply with applicable regulatory requirements, it is possible that such compliance measures may restrict our business and operations, result in increased cost and onerous compliance measures, and an inability to comply with such regulatory requirements may attract penalty. For further details regarding the material approvals, licenses, registrations and permits, see “Government and Other Approvals” on page 230 of this Prospectus.

27. *There are certain discrepancies and non-compliances noticed in some of our financial reporting and/or records relating to filing of returns and deposit of statutory dues with the taxation and other statutory authorities.*

In the past, our company has at several instances, delayed in filing our GST returns, EPF returns and deposit of statutory dues, as a result of which, we have been required to pay the late filing fees along with interest on delayed deposit of due taxes and statutory dues. Although the late filing fees and interest on late deposits levied are small, if we continue this practice, the accumulated amounts of each delay may adversely affect our cash flows. Further no-show cause notice has been issued against our Company till date, in respect of above. In the event of any cognizance being taken by the concerned authorities in respect of above, actions may be taken against our Company and its directors, in which event the financials of our Company and our directors may be affected.

For further details of certain material legal proceedings involving our Company, our Promoter, our directors, see “Outstanding Litigation and Material Developments” beginning on page 181 of this Prospectus.

28. *We have contingent liabilities, and our financial condition could be adversely affected if any of these contingent liabilities materializes.*

The following table sets forth our contingent liabilities as derived from our Restated Financial Statements:

(₹ in Lakhs)					
Sr. No.	Particulars	As on December 31, 2023	As on March 31, 2023	As on March 31, 2022	As on March 31, 2021
1.	Bank Guarantee	768.98	682.94	282.94	282.94

29. *Our success largely depends upon the knowledge and experience of our Promoters, Directors, our Key Managerial Personnel and Senior Management as well as our ability to attract and retain personnel with technical expertise. Any loss of our Promoter, Directors, Key Managerial Personnel, Senior Management or our ability to attract and retain them and other personnel with technical expertise could adversely affect our business, financial condition and results of operations.*

Our success largely depends upon the knowledge and experience of our Promoters, Directors, Key Managerial Personnel and Senior Management as well as our ability to attract and retain skilled personnel. Any loss of our Promoter, Directors, Key Managerial Personnel and Senior Management or our ability to attract and retain them and other skilled personnel could adversely affect our business, financial condition and results of operations. We depend on the management skills and guidance of our Promoter for development of business strategies, monitoring their successful implementation and meeting future challenges. Further, we also significantly depend on the expertise, experience and continued efforts of our Key Managerial Personnel and Senior Management. Our future performance will depend largely on our ability to retain the continued service of our management team. If one or more of our Key Managerial Personnel or Senior Management are unable or unwilling to continue in his or her present position, it could be difficult for us to find a suitable or timely replacement and our business, financial condition and results of operations could be adversely affected.

In addition, we may require a long period of time to hire and train replacement personnel when personnel with technical expertise terminate their employment with us. We may also be required to increase our levels of employee compensation more rapidly than in the past to remain competitive in attracting and retaining personnel with technical expertise that our business requires. The loss of the services of such persons could have an adverse effect on our business, results of operations, cash flows and financial condition.

There is significant competition for management and other skilled personnel in our industry in which we operate, and it may be difficult to attract and retain the personnel we require in the future. There can be no assurance that our competitors will not offer better compensation packages, incentives and other perquisites to such skilled personnel. If we are not able to attract and retain talented employees as required for conducting our business, or if we experience high attrition levels which are largely out of our control, or if we are unable to motivate and retain existing employees, our business, financial condition and results of operations may be adversely affected. For further information, see “Our Management” on page 159 of this Prospectus.

30. We depend on skilled personnel and if we are unable to recruit and retain skilled personnel, our ability to operate or grow our business could be affected.

Our Business Operation required skilled and creative manpower intensive and we engage a considerable number of skilled personnel every year to sustain our growth. Further, we spend significant time and resources in training the manpower we hire. Our success is substantially dependent on our ability to recruit, train and retain skilled manpower. High attrition and competition for manpower may limit our ability to attract and retain the skilled manpower necessary for our future growth requirements. We cannot assure you that skilled manpower will continue to be available in sufficient numbers suitable to our requirements or that we will be able to grow our workforce in a manner consistent with our growth objectives, which may affect our business, financial condition, results of operations and prospects.

31. Our business involves usage of manpower and any unavailability of our employees or any strikes, work stoppages, increased wage demands by workmen or changes in regulations may have an adverse impact on our cash flows and results of operations.

Our business involves usage of manpower and we are dependent on the availability of our permanent employees and the supply of a sufficient pool of labourers. Unavailability or shortage of such a pool of workmen or any strikes, work stoppages, increased wage demands by workmen or changes in regulations may have an adverse impact on our cash flows and results of operations. We may not be able to secure the required number of labourers required for the timely execution of our functions for a variety of reasons including, but not limited to, possibility of disputes, strikes, less competitive rates. We are subject to laws and regulations relating to employee welfare and benefits such as minimum wage, working conditions, employee insurance, and other such employee benefits and any changes to existing labour legislations, including upward revision of wages required by such state governments, limitations on the number of hours of work or provision of improved facilities. Further, there can be no assurance that disruptions in our business will not be experienced if there are strikes, work stoppages, disputes with labourers deployed at our projects. This may adversely affect our business and cash flows and results of operations.

32. Our business is subject to various operating risks at our sites, the occurrence of which can affect our results of operations and consequently, financial condition of our Company.

Our business operations are subject to operating risks, such as breakdown or failure of equipment's used at the project sites, weather conditions, interruption in power supply, shortage of consumables, performance below expected levels of output or efficiency, natural disasters, obsolescence, labour disputes, accidents, our inability to respond to technological advancements and emerging realty industry standards and practices along with the need to comply with the directives of relevant government authorities. The occurrence of these risks, if any, could result in stoppage of work along with penalty in monetary terms. Any stoppage of work may result in a delay in completing our projects leading to failure to deliver the furniture to the customers within the time frame. Further, any of the aforesaid risks may also result in our contractors compromising on the quality standards in order to finish the work within the given timelines, which may in turn affect our reputation and ability to attract new customers. If any of the above were to occur, it would significantly affect our operating results, and the slowdown of business operations may have a material adverse effect on our business operations and financial conditions.

33. Our Company requires significant amounts of working capital for a continued growth. Our inability to meet our working capital requirements may have an adverse effect on our results of operations.

Our business is working capital intensive. Summary of our working capital position as per our Restated Financial Information is given below: -

(₹. In Lakhs)

Particulars	December 31, 2023	March 31, 2023	March 31, 2022	March 31, 2021
A: Current Assets				
Inventories	1,157.33	1,115.72	108.72	82.80
Trade Receivables	2,966.52	1,993.80	2,206.19	915.47
Short-Term Loans and Advances	134.84	241.35	206.97	152.28
Other Current Assets	5.32	5.31	5.25	15.80
B: Current Liabilities				
Trade Payables	2,294.66	2,460.24	1,704.71	796.67
Other Current Liabilities	79.51	73.14	277.82	103.50
Short Term Provisions	327.37	151.02	132.86	6.46
C: Working Capital (A-B)	1,562.47	671.78	411.74	259.72

We intend to continue growing by expanding our business operations. This may result in increase in the quantum of our current assets. Our inability to maintain sufficient cash flow, credit facility and other sources of fund, in a timely manner, or at all, to meet the requirement of working capital could adversely affect our financial condition and result of our operations. For further details regarding working capital requirement, please refer to the chapter titled “Objects of the Issue” beginning on page 86 of this Prospectus.

34. *As we continue to grow, we may not be able to effectively manage our growth and the increased complexity of our business, which could negatively impact our brand and financial performance.*

The success of our business will depend greatly on our ability to effectively implement our operational and growth strategies. As a part of our growth strategy, we aim to, among other things, continue to grow our businesses as and when opportunities exist including expansion in product base, focus on consistently meeting quality standards, deepen and expand our geographical presence, strengthening up our business through effective branding, promotional and digital activities. In pursuing our growth strategy, we will require additional capital investments and cash outlays, which may have a material impact on our cash flows and results of operations. Our operating expenses and capital requirements may increase significantly pursuant to our expansion and diversification plans. Our ability to manage our growth effectively requires us to forecast accurately our sales, growth and manufacturing capacity and to expend funds to improve our operational, financial and management controls, reporting systems and procedures. An inability to implement our future business plan, manage our growth effectively or failure to secure the required funding on favourable terms or at all could have a material and adverse effect on our business, future financial performance and results of operations.

35. *Our business is dependent on the adequate and uninterrupted supply of electrical power at a reasonable cost. Our Company does not have suitable power back-up to meet power failure exigencies. Failure on account of unavailability of electrical power may restrict us in utilizing our full capacity and, hence, may impact our business and results of operation.*

Adequate and cost-effective supply of electrical power is critical to our operations, which entails significant consumption of electrical power. Our manufacturing process requires uninterrupted supply of electrical power in order to ensure that we are able to manufacture our products. The shortage or non-availability of electrical power may adversely affect our manufacturing process and have an adverse impact on our results of operations and financial condition. Currently, we source our power requirements from the state electricity board. There can be no assurance that electricity supplied will be sufficient to meet our requirements or that we will be able to procure adequate and interrupted power supply in the future at a reasonable cost. If the supply of electricity is not available for any reason, we will need to rely on alternative sources. Any failure on our part to obtain alternate sources of electricity, in a timely manner, and at an acceptable cost, may have an adverse effect on our business, results of operations, cash flows and financial condition.

36. *The orders placed by customers may be delayed, modified or cancelled, which may have an adverse effect on our business, financial condition and results of operations.*

We may encounter problems in executing the orders in relation to our products, or executing it on a timely basis. Moreover, factors beyond our control caused by matters such as acts of God, strikes, civil commotion, riots, war, revolution, acts of governments, lack of adequate production capacity, failure or delay in plant start up, breakdown of machinery, shortage of raw materials, etc. or the control of our customers may postpone the delivery of such products or cause its cancellation. Due to the possibility of cancellations or changes in scope and schedule of delivery of such products, resulting from our customers’ discretion or delay in procurement of raw material or problems we encounter in the delivery of such products or reasons outside our control or the control of our customers, we cannot predict with certainty when, if or to what extent we may be able to deliver the orders placed. Additionally, delays in the delivery of such products can lead to customers delaying or refusing to pay the amount, in part or full, that we expect to be paid in respect of such products. In addition, even where a delivery proceeds as scheduled, it is possible that the customers may default or otherwise fail to pay amounts owed.

37. *Introduction of alternative pharmaceutical products caused by changes in technology or consumer needs may affect demand for our existing products which may adversely affect our financial results and business prospects.*

Our products are mainly used in the healthcare sector to cater to masses. Our business is affected by change in technology, consumer needs, market perception of brand, convenience, health and safety norms. Our ability to anticipate such changes and to continuously develop and introduce new and enhanced products successfully on a timely basis will be a key factor in our growth and business prospects. There can be no assurance that we will be able to keep pace with the technological advances that may be necessary for us to remain competitive. Further, any substantial change in preference of consumers who are end users of our products will affect our customers businesses and, in turn, will affect the demand for our products. Any failure to forecast and/or meet the changing demands of pharmaceutical businesses and consumer needs may have an adverse effect on our business, profitability and growth prospects.

38. *The nature of products we deal into are prone to attracting litigation and long trials. In the event of any checking of our products by the respective authority, we may be drawn up into prolonged litigations thus adversely affecting our operations*

Our products are mainly used in the healthcare sector to cater to masses. To maintain their quality, our products are required to be stored at certain temperature and conditions. However, we do not have any control over the conditions in which our products are stored by our customers. We generally produce generic medicines which are majorly supplied to government dispensaries and are regularly checked for their quality by the drug inspector of respective region on sample basis. In the past we have been subjected to litigations for the reasons that the samples of our products taken from the premises of our customers have not been found of specified quality (NSQ). Although the results of such litigations were in our favour for the reason that the products were not stored at the customers' premises at given conditions, we are not sure if we shall get positive results of any such litigations in future, in which event the goodwill and financials of our company shall be adversely affected. Further we are not sure that any such litigation shall not be lodged against us in the future and in any such future litigation divert the managements' attention from the business thus adversely affecting business.

For further details with respect to pending litigations against our company, please refer chapter "*Outstanding litigations and material developments*" beginning at page 221 of this Prospectus.

39. *The regulatory uncertainty associated with pharmaceutical pricing, reimbursement and related matters could adversely affect the marketing, pricing and demand for our products.*

The existence of price controls can limit the revenues we earn from our products. India enacted the National Pharmaceuticals Pricing Policy in 2012. As a result, a number of drug formulations were identified as essential drugs and were added to India's National List of Essential Medicines and these drugs are subjected to price controls in India. On May 15, 2013, the Department of Pharmaceuticals released the revised DPCO 2013 (which replaced the earlier Drugs (Prices Control) Order, 1995). The Drugs (Price Control Order) 2013 (hereinafter referred as The DPCO 2013) governs the price control mechanism for 509 formulations listed in the National List of Essential Medicines.

As per this order, the prices of each of the formulations are determined based on the average of all drugs having an Indian market share of more than 1% by value. The individual drug price notifications for a majority of the products have been released by the National Pharmaceutical Pricing Authority. The DPCO 2013 also regulates the margin that can be offered to the trade channels including the retailers.

Under terms of the DPCO 2013 non-compliance with the notified ceiling price or breaching the ceiling price would be tantamount to overcharging the consumer under the order, and the amount charged over and above the ceiling price shall be recovered along with interest thereon from the date of overcharging. Further, noncompliance with the price notification issued by National Pharmaceutical Pricing Authority (NPPA) could also attract prosecution of the officers of the Company under the Essential Commodities Act, 1955 including imprisonment for a term up to seven years and shall also be liable for fine. Any action against us or our management for violation of the DPCO 2013 may divert management attention and could adversely affect our business, prospects, results of operations and financial condition.

40. *Stricter marketing norms prescribed by a new code of conduct in India for companies doing business in the pharmaceuticals industry could affect our ability to effectively market our products which may affect our profitability.*

In December 2014, the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers of the Government of India announced details of the UCPMP which became effective across India from January 1, 2015. This code of conduct for marketing practices for the Indian pharmaceutical industry is expected to be voluntarily adopted by pharmaceutical companies for a period of six months (extended by a further period of two months) after which it would be reviewed by the Government.

The UCPMP amongst other things provides detailed guidelines about promotional materials, conduct of medical representatives, physician samples, gifts and relationships with healthcare professionals. For example, under the UCPMP, pharmaceutical companies may not supply or offer any gifts, pecuniary advantages or benefits in kind to persons qualified to prescribe or supply drugs. Further, the Managing Director or the chief executive officer of the company is responsible for ensuring adherence to the UCPMP and a self-declaration is required to be submitted by the managing director or the chief executive officer within two months of the closure of every financial year to the industry association. Although these guidelines are voluntary in nature, they may be codified in the future and we may have to spend a considerable amount of time and resources to conform to the requirements of the UCPMP.

41. *Compliance with, and changes in safety, health and environmental laws and regulations may adversely affect our business, prospects, financial condition and results of operations.*

Due to the nature of our business, we expect to be or continue to be subject to extensive and increasingly stringent environmental, health and safety laws and regulations and various labour, workplace and related laws and regulations. We are also subject to environmental, health and safety laws including but not limited to:

- a. The Pharmacy Act, 1948
- b. The Drugs and Cosmetics Act, 1940 (DCA)
- c. The Drugs and Cosmetics Rules, 1945 (DC Rules)
- d. The Drugs (Price Control) Order, 2013 (DPCO 2013)
- e. Essential Commodities Act, 1955 f. Food Safety and Standard Act, 2006
- g. Good Manufacturing Practice Guidelines (GMP)
- h. The Environment Protection Act, 1986 (Environment Protection Act)
- i. Air (Prevention and Control of Pollution) Act, 1981
- j. Water (Prevention and Control of Pollution) Act, 1974
- k. Hazardous Waste Management & Handling Rules, 2008
- l. Public Liability Insurance Act, 1991

Any failure on our part to comply with any existing or future regulations applicable to us may result in legal proceedings being initiated against us, third party claims or the levy of regulatory fines, which may adversely affect our business, results of operations and financial condition. Further amendments to such statutes may impose additional provisions to be followed by our Company and accordingly our Company may need to avoid use of certain ingredients in preparation of our products, discontinue any range of product, incur clean-up and remediation costs, as well as damages, payment of fines or other penalties, closure of production facilities for non-compliance, other liabilities and related litigation, which could adversely affect our business, prospects, financial condition and results of operations.

42. *Unsecured loans taken by our Company can be recalled by the lenders at any time.*

Our Company has unsecured loans amounting to ₹ 1.68 Lakhs, ₹ 26.75 Lakhs, ₹ 3.36 Lakhs and ₹ 12.95 Lakhs for the period ended December 31, 2023 and for the financial year ending March 31, 2023, 2022 and 2021 as per the restated financial statements from banks that are repayable on demand to the relevant lender. These loans are not repayable in accordance with any agreed repayment schedule and may be recalled by the relevant lender at any time. In such cases, our Company may be required to repay the entirety of the unsecured loans together with accrued interest. Our Company may not be able to generate sufficient funds at short notice to be able to repay such loans and may resort to refinancing such loans at a higher rate of interest and on terms not favourable to it. Failure to repay unsecured loans in a timely manner may have a material adverse effect on our business, cash flows and financial condition. For further details of unsecured loans of our Company, please refer the chapter titled “*Restated Financial Statements*” beginning on page 181 of this Prospectus.

43. *Any increase in interest rates would have an adverse effect on our results of operations and will expose our Company to interest rate risks.*

We are dependent upon the availability of equity, cash balances and debt financing to fund our operations and growth. Any fluctuations in interest rates may directly impact the interest costs of such loans and, in particular, any increase in interest rates could adversely affect our results of operations. Furthermore, our indebtedness means that a material portion of our expected cash flow may be required to be dedicated to the payment of interest on our indebtedness, thereby reducing the funds available to us for use in our general business operations. If interest rates increase, our interest payments will increase and our ability to obtain additional debt and non-fund-based facilities could be adversely affected with a concurrent adverse effect on our business, financial condition and results of operations. For further details, please refer chapter titled “*Financial Indebtedness*” beginning on page of this Prospectus.

44. *Our loan agreements with various lenders have several restrictive covenants and certain unconditional rights in favour of the lenders, which could influence our ability to expand, in turn affecting our business and results of operations.*

We have entered into agreements for short term and long-term borrowings with certain lenders. The total amounts outstanding and payable by us as secured loans and unsecured loans were ₹ 460.66 Lakhs, ₹ 409.69 Lakhs, ₹ 312.54 Lakhs and ₹ 304.03 Lakhs as on December 31, 2023 and March 31, 2023, 2022 and 2021 as per the restated financial statements. The credit facilities availed by our Company are secured by way of mortgage of fixed assets, hypothecation of assets. There may have been instances of delay in payment of our dues in time to the banks, in case we are not able to pay our dues in time, the same may amount to a default under the loan documentation and all the penal and termination provisions therein would get triggered and the loans granted to the Company may be recalled with penal interest. This could severely affect our operations and financial condition. In addition to the above, our loan documentation includes certain conditions and covenants that require us to obtain consents from the aforesaid banks prior to carrying out certain activities like entering into any amalgamation, demerger, merger and corporate reconstruction, changing our management and operating structure, making any fresh borrowings or creating fresh charges on assets, etc. Any failure to comply with any condition or covenant under our financing agreements that is not waived by the lending banks or is not otherwise cured by us, may lead to a termination of our credit facilities, acceleration of all amounts due under the said credit facility, which may adversely affect our ability to conduct our business and operations or implement our business plans. Further, the said credit facilities can be renewed/enhanced/cancelled/suspended/reduced and the terms and conditions of the same can be altered by the lending banks, at their discretion. In the event, the lending banks refuse to renew / enhance the credit facilities and/or cancels / suspends / reduces the said credit facilities and/or alters the terms and conditions to the derogation of our Company, our existing operations as well as our future business prospects and financial condition may be severely affected.

45. *We have taken guarantees from our directors in relation to debt facilities provided to us.*

We have taken guarantees from our directors in relation to our secured debt facilities availed from our Bankers. In an event any of these persons withdraw or terminate its/their guarantees, the lender for such facilities may ask for alternate guarantees, repayment of amounts outstanding under such facilities, or even terminate such facilities. We may not be successful in procuring guarantees satisfactory to the lender and as a result may need to repay outstanding amounts under such facilities or seek additional sources of capital, which could adversely affect our financial condition. For more information, please see the chapter titled “*Financial Indebtedness*” beginning on page 199 of this Prospectus.

46. *Our business may expose us to potential product liability claims, which could adversely affect our results operation, goodwill and the marketability of our products.*

While we are not directly exposed to potential product liability claims given the nature of our business, we may be exposed to certain risks associated with the purchase orders issued by us, and the severity and timing of such claims are unpredictable. We face the risk of loss resulting from, and the adverse publicity associated with, lawsuits, whether or not such claims are valid. We may also be subject to claims resulting from manufacturing defects or negligence in storage or handling which may lead to the deterioration of our products. Such claims, regardless of their merits or the ultimate success of the defence against them, are expensive. Even unsuccessful claims would likely require us to incur substantial amounts on litigation and require our management’s time and focus. Any loss of our reputation or brand image may lead to a loss of existing business contracts and affect our ability to enter into additional business contracts in the future, which may have an adverse effect on our business, results of operations, financial condition and cash flows. Accordingly, such claims, may adversely affect our results of operation, goodwill and the marketability of our products.

47. *Failure or disruption of our IT, manufacturing automation systems may adversely affect our business, financial condition and results of operations.*

We have implemented various information technology (“IT”) systems to cover key areas of our operations, procurement, dispatch and accounting. We also have various automation systems and software that automate our manufacturing and production. These systems are potentially vulnerable to damage or interruption from a variety of sources, which could result from (among other causes) cyber-attacks on or failures of such infrastructure or compromises to its physical security, as well as from damaging weather or other acts of nature. A significant or large-scale malfunction or interruption of one or more of our IT systems or manufacturing automation systems could adversely affect our ability to keep our operations running efficiently and affect product availability, particularly in the country, region or functional area in which the malfunction occurs, and wider or sustained disruption to our business cannot be excluded. In addition, it is possible that a malfunction of our data system security measures could enable unauthorized persons to access sensitive business data, including information relating to our intellectual property or business strategy or those of our customers. While we have not faced significant disruptions in past, any such malfunction or disruptions in future could cause economic losses for which we could be held liable or cause damage to our reputation. Any of these developments, alone or in combination, could have a material adverse effect on our business, financial condition and results of operations. Further, unavailability of, or failure to retain, well trained employees capable of constantly servicing our IT, manufacturing automation systems may lead to inefficiency or disruption of our operations and thereby adversely affecting our business, financial condition and results of operations.

48. Our ability to pay dividends will depend upon future earnings, financial condition, cash flows, working capital requirements, capital expenditures and other factors.

We may retain all our future earnings, if any, for use in the operations and expansion of our business. As a result, we may not declare dividends in the foreseeable future. Any future determination as to the declaration and payment of dividends will be at the discretion of our Board of Directors and will depend on factors that our Board of Directors deem relevant, including among others, our results of operations, financial condition, cash requirements, business prospects and any other financing arrangements. Additionally, under some of our loan agreements, we may not be permitted to declare any dividends, if there is a default under such loan agreements or unless our Company has paid all the dues to the lender up to the date on which the dividend is declared or paid or has made satisfactory provisions thereof. Accordingly, realization of a gain on shareholders' investments may largely depend upon the appreciation of the price of our Equity Shares. There can be no assurance that our Equity Shares will appreciate in value. For details of our dividend history, see "Dividend Policy" on page 195 of this Prospectus.

49. Our Promoter and members of the Promoter Group will continue jointly to retain majority control over our Company after the Issue, which will allow them to determine the outcome of matters submitted to shareholders for approval.

After completion of the Issue, Our Promoter and Promoter Group will collectively own 65.82% of the Equity Shares. As a result, our Promoter together with the members of the Promoter Group will be able to exercise a significant degree of influence over us and will be able to control the outcome of any proposal that can be approved by a majority shareholder vote, including, the election of members to our Board, in accordance with the Companies Act and our AOA. Such a concentration of ownership may also have the effect of delaying, preventing or deterring a change in control of our Company.

In addition, our Promoter will continue to have the ability to cause us to take actions that are not in, or may conflict with, our interests or the interests of some or all of our creditors or minority shareholders, and we cannot assure you that such actions will not have an adverse effect on our future financial performance or the price of our Equity Shares.

50. We might infringe upon the intellectual property rights of others and any misappropriation of our intellectual property could harm our competitive position.

While we take care to ensure that we comply with the intellectual property rights of others, we cannot determine with certainty as to whether we are infringing on any existing third-party intellectual property rights, which may require us to alter our technologies, obtain licenses or cease some of our operations. We may also be susceptible to claims from third parties asserting infringement and other related claims. If such claims are raised, those claims could: (a) adversely affect our relationships with current or future customers; (b) result in costly litigation; (c) cause product shipment delays or stoppages; (d) divert management's attention and resources; (e) subject us to significant liabilities; (f) require us to enter into potentially expensive royalty or licensing agreements and (g) require us to cease certain activities. While in the last three financial year we have not been involved in litigation or incurred litigation expenses in connection with our trademarks or intellectual property rights, in the case of an infringement claim made by a third party, we may be required to defend such claims at our own cost and liability and may need to indemnify and hold harmless our customers. Furthermore, necessary licenses may not be available to us on satisfactory terms, if at all. In addition, we may decide to settle a claim or action against us, which settlement could be costly. We may also be liable for any past infringement that we are not aware of. Any of the foregoing could adversely affect our business, financial condition and results of operations.

51. Employee misconduct including misuse of confidential data and failure to maintain confidentiality of information could harm us and is difficult to detect and deter.

We could be harmed by employee misconduct if our customers' confidential information is misappropriated by us or our employees, our customers may consider us liable for that act and seek damages and compensation from us, in addition, to seeking termination of the contract. While there have been no instances during the last three financial year of information technology breach or instances of cyber-attack, assertions of misappropriation of confidential information or the intellectual property of our customers against us, if successful, could have a material adverse effect on our business, financial condition and results of operations. Even if such assertions against us are unsuccessful, they may cause us to incur reputational harm and substantial cost.

Although we closely monitor our employees, misconduct, including acts of bribery, corruption or fraud by employees or executives, such acts could include binding us to transactions that exceed authorized limits or present unacceptable risks, or they may hide unauthorized or unlawful activities from us, which may result in substantial financial losses and damage to our reputation and loss of business from our customers. Employee or executive misconduct could also involve the improper use or disclosure of confidential information, which could result in regulatory sanctions and serious reputational or financial harm, including harm to our brand. While we have not experienced any such employee misconduct in the past,

it is not always possible to deter employee or executive misconduct and the precautions taken and systems put in place to prevent and detect such activities may not be effective in all cases. Any instances of such misconduct could adversely affect our business and our reputation.

52. *Industry information included in this Prospectus has been derived from industry reports. There can be no assurance that such third-party statistical, financial and other industry information is either complete or accurate.*

We have relied on the reports of certain independent third party for purposes of inclusion of such information in this Prospectus. These reports are subject to various limitations and based upon certain assumptions that are subjective in nature. We have not independently verified data from such industry reports and other sources. Although, we believe that the data may be considered to be reliable, their accuracy, completeness and underlying assumptions are not guaranteed and their dependability cannot be assured. While we have taken reasonable care in the reproduction of the information, the information has not been prepared or independently verified by us, or any of our respective affiliates or advisors and, therefore, we make no representation or warranty, express or implied, as to the accuracy or completeness of such facts and statistics. Due to possibly flawed or ineffective collection methods or discrepancies between published information and market practice and other problems, the statistics herein may be inaccurate or may not be comparable to statistics produced for other economies and should not be unduly relied upon. Further, there is no assurance that they are stated or compiled on the same basis or with the same degree of accuracy as may be the case elsewhere. Statements from third parties that involve estimates are subject to change, and actual amounts may differ materially from those included in this Prospectus.

53. *Information relating to the installed manufacturing capacity of our manufacturing facilities included in this Prospectus are based on various assumptions and estimates and future production and capacity may vary.*

Information relating to the historical installed capacity and estimated capacity utilization of our manufacturing facility included in this Prospectus is based on various assumptions and estimates of our management and the Chartered Engineer, please refer to “Our Business” on page 128 of this Prospectus for further details. Actual production volumes and capacity utilization rates, however, may differ significantly from the estimated production capacities and historical capacity utilization of our manufacturing facilities. Investors should therefore not place undue reliance on our historical installed capacity information for our existing manufacturing facilities included in this Prospectus.

54. *If we are unable to establish and maintain an effective internal controls and compliance system, our business and reputation could be adversely affected.*

We are responsible for establishing and maintaining adequate internal measures commensurate with the size and complexity of operations. Our internal audit functions make an evaluation of the adequacy and effectiveness of internal systems on an ongoing basis so that our operations adhere to our policies, compliance requirements and internal guidelines. We periodically test and update our internal processes and systems and there have been no past material instances of failure to maintain effective internal controls and compliance system. However, we are exposed to operational risks arising from the potential inadequacy or failure of internal processes or systems, and our actions may not be sufficient to ensure effective internal checks and balances in all circumstances.

We take reasonable steps to maintain appropriate procedures for compliance and disclosure and to maintain effective internal controls over our financial reporting so that we produce reliable financial reports and prevent financial fraud. As risks evolve and develop, internal controls must be reviewed on an ongoing basis. While our code of conduct requires our employees and intermediaries to comply with all applicable laws, and we continue to enhance our policies and procedures in an effort to ensure compliance with applicable laws and regulations. If we are not in compliance with applicable laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition and results of operations. Likewise, any investigation of any potential violations of laws by the relevant authorities could also have an adverse impact on our business and reputation.

55. *Our Directors, Key Managerial Personnel and Senior Management may have interests other than reimbursement of expenses incurred and normal remuneration or benefits in our Company.*

Our Directors, Key Managerial Personnel and Senior Management may be interested in our Company, in addition to regular remuneration, sitting fees or benefits and reimbursement of expenses, to the extent of the Equity Shares held by them in our Company, and bonuses, dividend payable or other distributions on such Equity Shares. Our directors may be regarded as interested to the extent of the transactions entered into in the ordinary course of business with the companies in which our directors hold directorship and also in the Equity Shares held by them or by their relatives, if any, or that may be subscribed by or allotted to them or the companies, firms and trusts, in which they are interested as directors, members, partners, trustees and promoter, pursuant to this Issue. Further, our Promoter, are interested in promotion and formation of the Company. Further, our Executive Directors are also directors on the boards, or are shareholders, and trustees of entities

with which our Company has had related party transactions and may be deemed to be interested to the extent of the payments made by our Company, if any, to these entities.

56. *The deployment of funds raised through this Issue shall not be subject to any Monitoring Agency and shall be purely dependent on the discretion of the management of our Company.*

Since, the Proceeds from Issue is less than Rs.10,000 lakh, there is no mandatory requirement of appointing an Independent Monitoring Agency for overseeing the deployment of utilization of funds raised through this Issue. The deployment of these funds raised through this Issue, is hence, at the discretion of the management and the Board of Directors of our Company and will not be subject to monitoring by any independent agency. Any inability on our part to effectively utilize the Issue proceeds could adversely affect our financials. However, as per the Section 177 of the Companies Act, 2013 and applicable laws, the Audit Committee of our Company would be monitoring the utilization of the Issue Proceeds.

57. *Our Company has entered into related party transactions in the past and may continue to enter into related party transactions in the future, which may potentially involve conflicts of interest with the equity shareholders.*

Our Company have entered into certain related party transactions with our Promoters, members of the promoter group, Directors and our Group Companies in the past which are in compliance with applicable provisions of Companies Act, 2013 and all other applicable laws. While our Company believes that all such transactions have been conducted on arm's length basis, there can be no assurance that it could not have been achieved on more favourable terms and that such transactions have not been entered into with unrelated parties. Further, it is likely that we may enter into related party transactions in the future and such transactions may potentially involve conflicts of interest. In terms of the Companies Act, 2013 and SEBI LODR Regulations, we are required to adhere to various compliance requirements such as obtaining prior approvals from our Audit Committee, Board and Shareholders for certain party transactions and our undertakes that such related party transactions shall not be done against the interests of the Company and its shareholders as prescribed in the SEBI LODR Regulations. There can be no assurance that such transactions, individually or in the aggregate, will not have an adverse effect on our financial condition and results of operations.

58. *We may not be fully insured for all losses we may incur.*

Although we attempt to limit and mitigate our liability for damages arising from negligent acts, errors or omissions through contractual provisions, limitations of liability set forth in our contracts may not be enforceable in all instances or may not otherwise protect us from liability for damages.

In addition, certain liabilities, such as claims of third parties for which we may be required to indemnify our clients, are generally not limited under those agreements. We face the risk of loss resulting from, and the adverse publicity associated with, lawsuits, whether or not such claims are valid. We have taken various insurance policies, details of which is mentioned in the section titled, "Insurance" under the chapter titled, "Our Business" on page 128 of the Prospectus. Although we believe we have adequate insurance coverage but that coverage may not continue to be available on reasonable terms or to be available in sufficient amounts to cover one or more large claims, and our insurers may disclaim coverage as to any future claim. Insurance coverage may be an inadequate remedy where the loss suffered is not easily quantifiable, for example, in the event of severe damage to our reputation. The successful assertion of one or more large claims against us that exceed available insurance coverage, or changes in our insurance policies (including premium increases or the imposition of large deductible or co-insurance requirements), could have a material adverse effect on our business, reputation, results of operations, financial condition and cash flows.

59. *An investment in the Equity Shares is subject to general risk related to investments in Indian Companies.*

Our Company is incorporated in India and all of our assets and employees are located in India. Consequently, our business, results of operations, financial condition and the market price of the Equity Shares will be affected by changes in interest rates in India, policies of the Government of India, including taxation policies along with policies relating to industry, political, social and economic developments affecting India.

60. *The determination of the Price Band is based on various factors and assumptions and the Issue Price of the Equity Shares may not be indicative of the market price of the Equity Shares upon listing on the Stock Exchange.*

The determination of the Price Band is based on various factors and assumptions, and will be determined by our Company in consultation with the Book Running Lead Manager. Furthermore, the Issue Price of our Equity Shares has been determined by book building method. These will be based on numerous factors (For further information, please refer chapter titled "Basis for Issue Price" beginning on page 95 of this Prospectus) and may not be indicative of the market price of our Equity Shares upon listing on the Stock Exchange. The price of our Equity Shares upon listing on the Stock Exchange will be determined by the market and may be influenced by many factors outside of our control.

61. *Our Equity Shares have never been publicly traded, and may experience price and volume fluctuations following the completion of the Issue. Further, our Equity Shares may not result in an active or liquid market and the price of our Equity Shares may be volatile and you may be unable to resell your Equity Shares at or above the Issue Price or at all.*

Prior to the Issue, there has been no public market for our Equity Shares, and an active trading market may not develop or be sustained after the Issue. Listing and quotation do not guarantee that a market for our Equity Shares will develop or, if developed, does not guarantee the liquidity of such market for the Equity Shares. Investors might not be able to rapidly sell the Equity Shares at the quoted price if there is no active trading in the Equity Shares. The Issue Price of the Equity Shares has been determined by our Company in consultation with the BRLM through the Book Building Process. The market price of the Equity Shares may be subject to significant fluctuations in response to, among other factors, variations in our operating results of our Company, market conditions specific to the industry we operate in, developments relating to India, volatility in securities markets in jurisdictions other than India, variations in the growth rate of financial indicators, variations in revenue or earnings estimates by research publications, and changes in economic, legal and other regulatory factors.

62. *We have issued Equity Shares during the last one year at a price below the Issue Price.*

Our Company had issued Bonus shares of 97,08,840 equity shares on September 30, 2023 in the ratio of 9:1 and Right Issue of 11,50,000 in the last 12 months which may be at lower than the Issue Price. The Equity Shares allotted to shareholders pursuant to this Issue may be priced significantly higher due to various reasons including better performance by the Company, better economic conditions, and passage of time. For further details, see “Capital Structure” on page 73 of this Prospectus.

63. *There is no guarantee that the Equity Shares issued pursuant to the Issue will be listed on the NSE Emerge in a timely manner or at all.*

In accordance with Indian law and practice, permission for listing and trading of the Equity Shares issued pursuant to the Issue will not be granted until after the Equity Shares have been issued and allotted. Approval for listing and trading will require all relevant documents authorizing the issuing of Equity Shares to be submitted. There could be a failure or delay in listing the Equity Shares on the NSE Emerge. Any failure or delay in obtaining the approval would restrict your ability to dispose of your Equity Shares.

64. *Any future issuance of Equity Shares may dilute your shareholding and sale of our Equity Shares by our Promoters or other shareholders may adversely affect the trading price of the Equity Shares.*

Any future equity issuances by us, including in a primary offering, may lead to the dilution of investors’ shareholdings in our Company. Any future equity issuances by us or sales of our Equity Shares by our Promoters or other major shareholders may adversely affect the trading price of the Equity Shares. In addition, any perception by investors that such issuances or sales might occur could also affect the trading price of our Equity Shares.

65. *There are restrictions on daily weekly monthly movement in the price of the equity shares, which may adversely affect the shareholder’s ability to sell for the price at which it can sell, equity shares at a particular point in time.*

Once listed, we would be subject to circuit breakers imposed by the stock exchange, which does not allow transactions beyond specified increases or decreases in the price of the Equity Shares. This circuit breaker operates independently of the index-based market-wide circuit breakers generally imposed by SEBI. The percentage limit on circuit breakers is said by the stock exchange based on the historical volatility in the price and trading volume of the Equity Shares. The stock exchange does not inform us of the percentage limit of the circuit breaker in effect from time to time, and may change it without our knowledge. This circuit breaker limits the upward and downward movements in the price of the Equity Shares. As a result of the circuit breaker, no assurance may be given regarding your ability to sell your Equity Shares or the price at which you may be able to sell your Equity Shares at any time.

66. *Investors may be subject to Indian taxes arising out of capital gains on the sale of the Equity Shares*

Under current Indian tax laws and regulations, unless specifically exempted, capital gains arising from the sale of equity shares in an Indian company are generally taxable in India. A securities transaction tax (“STT”) is levied on and collected by an Indian stock exchange on which equity shares are sold. Any capital gain exceeding Rs.1,00,000, realized on the sale of equity shares held for more than 12 months immediately preceding the date of transfer, which are sold using any other platform other than on a recognized stock exchange and on which no STT has been paid, are subject to long gains tax in India.

Term capital The Finance Act, 2019 amended the Indian Stamp Act, 1899 with effect from July 1, 2020 and clarified that, in the absence of a specific provision under an agreement, the liability to pay stamp duty in case of sale of securities through stock exchanges will be on the buyer, while in other cases of transfer for consideration through a depository, the onus will be on the transferor. The stamp duty for transfer of securities other than debentures on a delivery basis is specified at 0.015% and on a nondelivered basis is specified at 0.003% of the consideration amount. The Finance Act, 2020, has, among o others things, provided a number of amendments to the direct and indirect tax regime, including, without limitation, a simplified alternate direct tax regime and that dividend distribution tax will not be payable in respect of dividends declared, distributed or paid by a domestic company after March 31, 2020, and accordingly, that such dividends not be exempt in the hands of the shareholders, both resident as well as non-resident, and that such dividends likely be subject to tax deduction at source. The Comp any may or may not grant the benefit of a tax treaty (where applicable) to a non-resident shareholder for the purposes of deducting tax at source from such dividend. Investors should consult their own tax advisors about the consequences of investing or trading in the Equity Shares.

Further, any gain realized on the sale of listed equity shares held for a period of 12 months or less will be subject to short term capital gains tax in India. In cases where the seller is a non-resident, capital gains arising from the sale of the equity shares will be partially or wholly exempt from taxation in India in cases where the exemption from taxation in India is provided under a treaty between India and the country of which the seller is resident. Historically, Indian tax treaties do not limit India's ability to impose tax on capital gains. As a result, residents of other countries may be liable for tax in India as well as in their own jurisdiction on a gain upon the sale of the equity shares.

Further, we cannot predict whether any tax laws or other regulations impacting it will be enacted, or predict the nature and impact of any such laws or regulations or whether, if at all, any laws or regulations would have a material adverse effect on our business, financial condition, results of operations and cash flows. The Government of India had announced the union budget for financial year 2023 and the Finance Act, 2023 received assent from the President of India on March 31, 2023. There is no certainty on the impact that the Finance Act, 2023 may have on our business and operations or in the industry we operate in.

67. *Significant differences exist between Indian GAAP and other accounting principles, such as US GAAP and IFRS, which may be material to investors assessments of Our Company's financial condition. Our failure to successfully adopt IFRS may have an adverse effect on the price of our Equity Shares. The proposed adoption of IFRS could result in our financial condition and results of operations appearing materially different than under Indian GAAP.*

Our restated financial statements, including the financial statements provided in this Prospectus, are prepared in accordance with Indian GAAP. We have not attempted to quantify the impact of IFRS or U.S. GAAP on the financial data included in this Prospectus, nor do we provide a reconciliation of our financial statements to those of U.S. GAAP or IFRS. U.S. GAAP and IFRS differ in significant respects from Indian GAAP. For details, refer chapter titled “*Presentation of Financial Industry and Market Data*” beginning on Page 106 of this Prospectus.

Accordingly, the degree to which the Indian GAAP financial statements included in this Prospectus will provide meaningful information is entirely dependent on the reader's level of familiarity with Indian accounting practices. Any reliance by persons not familiar with Indian accounting practices on the financial disclosures presented in this Prospectus should accordingly be limited. India has decided to adopt the “Convergence of its existing standards with IFRS” and not the “International Financial Reporting Standards” (“IFRS”), which was announced by the MCA, through the press note dated January 22, 2010. These “IFRS based / synchronized Accounting Standards” are referred to in India as IND (AS). Public companies in India, including our Company, may be required to prepare annual and interim financial statements under IND (AS). The MCA, through a press release dated February 25, 2011, announced that it will implement the converged accounting standards in a phased manner after various issues, including tax related issues, are resolved. Further, MCA Notification dated February 16, 2015, has provided an exemption to the Companies proposing to list their shares on the SME Exchange as per Chapter IX of the SEBI ICDR Regulations and hence the adoption of IND (AS) by a SME exchange listed Company is voluntary. Accordingly, we have made no attempt to quantify or identify the impact of the differences between Indian GAAP and IFRS or to quantify the impact of the difference between Indian GAAP and IFRS as applied to its financial statements. There can be no assurance that the adoption of IND-AS will not affect our reported results of operations or financial condition. Any failure to successfully adopt IND-AS may have an adverse effect on the trading price of our Equity Shares. Currently, it is not possible to quantify whether our financial results will vary significantly due to the convergence to IND (AS), given that the accounting principles laid down in the IND (AS) are to be applied to transactions and balances carried in books of accounts as on the date of the applicability of the converged standards, i.e., IND (AS) and for future periods.

Moreover, if we volunteer for transition to IND (AS) reporting, the same may be hampered by increasing competition and increased costs for the relatively small number of IND (AS)-experienced accounting personnel available as more Indian companies begin to prepare IND (AS) financial statements. Any of these factors relating to the use of converged Indian Accounting Standards may adversely affect our financial condition.

68. *Foreign investors are subject to foreign investment restrictions under Indian law that limits our ability to attract foreign investors, which may adversely impact the market price of the Equity Shares.*

Under the foreign exchange regulations currently in force in India, transfers of shares between non-residents and residents are freely permitted (subject to certain exceptions) if they comply with the pricing guidelines and reporting requirements specified by the RBI. If the transfer of shares, which are sought to be transferred, is not in compliance with such pricing guidelines or reporting requirements or fall under any of the exceptions referred to above, then the prior approval of the RBI will be required. Additionally, shareholders who seek to convert the Rupee proceeds from a sale of shares in India into foreign currency and repatriate that foreign currency from India will require a no objection/ tax clearance certificate from the income tax authority. There can be no assurance that any approval required from the RBI or any other government agency can be obtained on any particular terms or at all.

EXTERNAL RISKS

69. *A slowdown in economic growth in India could cause our business to suffer.*

Our performance and the growth of our business are necessarily dependent on the health of the overall Indian economy. Any slowdown or perceived slowdown in the Indian economy or future volatility in global commodity prices could adversely affect our business. Additionally, an increase in trade deficit, a downgrading in India's sovereign debt rating or a decline in India's foreign exchange reserves could negatively affect interest rates and liquidity, which could adversely affect the Indian economy and our business. In particular, the COVID-19 pandemic caused an economic downturn in India and globally. Any downturn in the macroeconomic environment in India could also adversely affect our business, financial condition, results of operations and prospects.

India's economy could be adversely affected by a general rise in interest rates or inflation, adverse weather conditions affecting agriculture, commodity and energy prices as well as various other factors. A slowdown in the Indian economy could adversely affect the policy of the GOI towards our industry, which may in turn adversely affect our financial performance and our ability to implement our business strategy.

The Indian economy is also influenced by economic and market conditions in other countries, particularly emerging market conditions in Asia. A decline in India's foreign exchange reserves and exchange rate fluctuations may also affect liquidity and interest rates in the Indian economy, which could adversely impact our financial condition. A loss of investor confidence in other emerging market economies or any worldwide financial instability may adversely affect the Indian economy, which could materially and adversely affect our business, financial condition, results of operations and prospects.

Further, other factors which may adversely affect the Indian economy are scarcity of credit or other financing in India, resulting in an adverse impact on economic conditions in India and scarcity of financing of our expansions; volatility in, and actual or perceived trends in trading activity on, India's principal stock exchanges; changes in India's tax, trade, fiscal or monetary policies, like application of GST; political instability, terrorism or military conflict in India or in countries in the region or globally, including in India's various neighbouring countries; occurrence of natural or man-made disasters; infectious disease outbreaks or other serious public health concerns; prevailing regional or global economic conditions, including in India's principal export markets; and other significant regulatory or economic developments in or affecting India or its financial services sectors.

70. *Our business is substantially affected by prevailing economic, political and other conditions.*

We are incorporated in and substantially all our operations are located in India. As a result, we are highly dependent on prevailing economic conditions in India and our results of operations and cash flows are significantly affected by factors influencing the Indian economy. Factors that may adversely affect the Indian economy, and hence our results of operations and cash flows, may include:

- any increase in Indian interest rates or inflation;
- any exchange rate fluctuations;
- any scarcity of credit or other financing in India, resulting in an adverse impact on economic conditions in India and scarcity of financing for our expansions;
- prevailing income conditions among Indian consumers and Indian corporates;
- volatility in, and actual or perceived trends in trading activity on India's principal stock exchanges;
- changes in India's tax, trade, fiscal or monetary policies;
- political instability, terrorism or military conflict in India or in countries in the region or globally, including in India's various neighbouring countries;
- occurrence of natural or man-made disasters;

- prevailing regional or global economic conditions, including in India's principal export markets;
- any downgrading of India's debt rating by a domestic or international rating agency;
- financial instability in financial markets; and
- other significant regulatory or economic developments in or affecting India or its construction sector.

On February 24, 2022, Russian military forces invaded Ukraine. Although the length, impact and outcome of the ongoing military conflict in Ukraine is highly unpredictable, this conflict and responses from international communities could lead to significant market and other disruptions, including significant volatility in commodity prices and supply of energy resources, instability in financial markets, supply chain interruptions, political and social instability, changes in consumer or purchaser preferences as well as increase in cyberattacks and espionage.

To date, we have not experienced any material interruptions in our supply chain, manufacturing facility and distribution network in connection with these conflicts. We have no way to predict the progress or outcome of the conflict in Ukraine as the conflict, and any resulting government reactions, are rapidly developing and beyond our control. The extent and duration of the military action, sanctions and resulting market disruptions could be significant and could potentially have a substantial impact on the global economy and our business for an unknown period of time. Any of the abovementioned factors could affect our business, financial condition and results of operations.

71. *Our business is affected by global economic conditions, especially in the geographies we cater to, which may have an adverse effect on our business, financial condition, results of operations and prospects.*

The Indian market and the Indian economy are influenced by economic and market conditions in other countries, particularly emerging market countries in Asia. Financial turmoil in Asia, U.S. and elsewhere in the world in recent years has affected the Indian economy. Although economic conditions are different in each country, investors' reactions to developments in one country can have adverse effects on the securities of companies in other countries, including India. Financial disruptions may occur again and could harm our business, financial condition and results of operations.

The global credit and equity markets have experienced substantial dislocations, liquidity disruptions and market corrections in recent years. Financial markets and the supply of credit could continue to be negatively impacted by ongoing concerns surrounding the sovereign debts and/or fiscal deficits of several countries in Europe, the possibility of further downgrades of, or defaults on, sovereign debt, concerns about a slowdown in growth in certain economies and uncertainties regarding the stability and overall standing of the European Monetary Union.

A loss of investor confidence in the financial systems of other emerging markets may cause increased volatility in the Indian financial markets and indirectly in the Indian economy in general. Any worldwide financial instability could influence the Indian economy. In response to such developments, legislators and financial regulators in the United States, Europe and other jurisdictions, including India, have implemented several policy measures designed to add stability to the financial markets. In addition, any increase in interest rates by the United States Federal Reserve will lead to an increase in the borrowing costs in the United States which may in turn impact global borrowing as well. Furthermore, in several parts of the world, there are signs of increasing retreat from globalization of goods, services and people, as pressure for the introduction of a protectionist regime is building and such developments could adversely affect Indian exports. However, the overall impact of these and other legislative and regulatory efforts on the global financial markets is uncertain, and they may not have the intended stabilizing effects. In the event that the current adverse conditions in the global credit markets continue or if there is any significant financial disruption, this could have an adverse effect on our business, financial condition and results of operations.

In February 2022, hostilities between Russia and the Ukraine commenced, which has led stock, commodities and foreign exchange markets worldwide to fluctuate. In addition, the market price of oil has risen sharply since the commencement of hostilities in the Ukraine, which may have an inflationary effect in India and other countries. A prolonged war or a protracted period of hostilities in the Ukraine may lead to global economic disturbances.

If we are unable to successfully anticipate and respond to changing economic and market conditions, our business, financial condition, results of operations and prospects may be adversely affected.

72. *Changing regulations in India could lead to new compliance requirements that are uncertain. The regulatory environment in which we operate is evolving and is subject to change.*

The Government of India may implement new laws or other regulations that could affect the manufacturing industry or the sectors we serve, which could lead to new compliance requirements. New compliance requirements could increase our costs or otherwise adversely affect our business, financial condition and results of operations. Further, the manner in which new requirements will be enforced or interpreted can lead to uncertainty in our operations and could adversely affect our

operations. Our business and financial performance could be adversely affected by any unexpected or onerous requirements or regulations resulting from any changes in laws or interpretation of existing laws, or the promulgation of new laws, rules and regulations. Any such changes and the related uncertainties with respect to the implementation or change in the legal framework may have a material adverse effect on our business, financial condition and results of operations.

73. *A slowdown in our exports due to tariffs and trade barriers and international sanctions could adversely affect our business, financial condition and results of operations.*

A significant portion of our revenue is derived from exports. From time to time, tariffs, quotas and other tariff and non-tariff trade barriers may be imposed on our products in jurisdictions in which we operate or seek to sell our products. There can be no assurance that the European Community and the United States, among others, where we seek to sell our products will not impose trade restrictions on us in future. We may also be prohibited from exporting to certain restricted countries that may be added to a sanctions list maintained by the Government of India or other foreign governments, such as the Specially Designated Nationals and Blocked Persons list maintained by the Office of Foreign Assets Control of the US Department of Treasury in the United States. In February 2022, hostilities between Russia and the Ukraine commenced, which has led to the imposition of sanctions of various Russian interests (and in some cases Belarus) by the European Union, Australia, Canada, Japan, New Zealand, Switzerland, South Korea, the United Kingdom and the United States. Any such imposition of trade barriers or international sanctions may have an adverse effect on our business, financial condition and results of operations.

74. *Natural calamities, climate change and health epidemics could adversely affect the Indian economy and our business, financial condition, and results of operations. In addition, hostilities, terrorist attacks, civil unrest and other acts of violence could adversely affect our business, financial condition and results of operations.*

Our operations including our manufacturing facilities and research and development activities may be damaged or disrupted as a result of natural calamities. Such events may lead to the disruption of information systems and telecommunication services for sustained periods. They also may make it difficult or impossible for employees to reach our business locations. Damage or destruction that interrupts our provision of services could adversely affect our reputation, our relationships with our customers, our Senior Management team's ability to administer and supervise our business or it may cause us to incur substantial additional expenditure to repair or replace damaged equipment or rebuild parts of our facilities. Any of the above factors may adversely affect our business, financial condition and results of operations.

India has from time-to-time experienced instances of social, religious and civil unrest and hostilities between neighbouring countries. Present relations between India and Pakistan continue to be fragile on the issues of terrorism, armaments and Kashmir. In April 2019, skirmishes along India's border with Pakistan and the downing of an Indian military jet fighter plane significantly escalated tensions between the two countries. India has also experienced terrorist attacks in some parts of the country. Military activity or terrorist attacks in the future could influence the Indian economy by disrupting communications and making travel more difficult and such political tensions could create a greater perception that investments in Indian companies involve higher degrees of risk. Events of this nature in the future, as well as social and civil unrest within other countries in Asia, could influence the Indian economy and could have a material adverse effect on the market for securities of Indian companies.

75. *Foreign investors are subject to foreign investment restrictions under Indian laws that may limit our ability to attract foreign investors, which may have a material adverse impact on the market price of the Equity Shares.*

Under the foreign exchange regulations currently in force in India, transfers of shares between non-residents and residents are freely permitted (subject to certain exceptions) if they comply with the pricing guidelines and reporting requirements specified by the RBI. For further details, see "*Restrictions on Foreign Ownership of Indian Securities*" on page 282 of this Prospectus. If the transfer of shares is not in compliance with such pricing guidelines or reporting requirements or falls under any of the exceptions referred to above, then the prior approval of the RBI will be required. Additionally, shareholders who seek to convert the Rupee proceeds from a sale of shares in India into foreign currency and repatriate that foreign currency from India will require a no objection or a tax clearance certificate from the income tax authority. Further, in accordance with Press Note No. 3 (2020 Series), dated April 17, 2020, issued by the DPIIT, Government of India, investments where the beneficial owner of the Equity Shares is situated in or is a citizen of a country which shares land border with India, can only be made through the Government approval route, as prescribed in FDI Policy. These investment restrictions shall also apply to subscribers of offshore derivative instruments. We cannot assure you that any required approval from the RBI or any other governmental agency can be obtained on any particular terms or at all.

76. *Financial instability in other countries may cause increased volatility in Indian financial markets.*

The Indian financial market and the Indian economy are influenced by economic and market conditions in other countries, particularly in emerging market in Asian countries. Financial turmoil in Asia, Europe, the United States and elsewhere in

the world in recent years has affected the Indian economy. Although economic conditions are different in each country, investors' reactions to developments in one country can have an adverse effect on the securities of companies in other countries, including India. A loss in investor confidence in the financial systems of other emerging markets may cause increased volatility in Indian financial markets and, indirectly, in the Indian economy in general. Any global financial instability, including further deterioration of credit conditions in the U.S. market, could also have a negative impact on the Indian economy. Financial disruptions may occur again and could harm our results of operations and financial condition.

The Indian economy is also influenced by economic and market conditions in other countries. This includes, but is not limited to, the conditions in the United States, Europe and certain economies in Asia. Financial turmoil in Asia and elsewhere in the world in recent years has affected the Indian economy. Any worldwide financial instability may cause increased volatility in the Indian financial markets and, directly or indirectly, adversely affect the Indian economy and financial sector and its business.

Although economic conditions vary across markets, loss of investor confidence in one emerging economy may cause increased volatility across other economies, including India. Financial instability in other parts of the world could have a global influence and thereby impact the Indian economy. Financial disruptions in the future could adversely affect our business, prospects, financial condition and results of operations. The global credit and equity markets have in the past experienced substantial dislocations, liquidity disruptions and market corrections.

77. The ability of Indian companies to raise foreign capital may be constrained by Indian law.

As an Indian Company, we are subject to exchange controls that regulate borrowing in foreign currencies, including those specified under FEMA. Such regulatory restrictions limit our financing sources for our projects under development and hence could constrain our ability to obtain financing on competitive terms and refinance existing indebtedness. In addition, we cannot assure you that the required approvals will be granted to us without onerous conditions, or at all. Limitations on foreign debt may adversely affect our business growth, results of operations and financial condition.

78. QIBs and Non-Institutional Investors are not permitted to withdraw or lower their Bids (in terms of quantity of Equity Shares or the Bid Amount) at any stage after submitting a Bid, and Retail Individual Investors are not permitted to withdraw their Bids after Bid/ Issue Closing Date.

Pursuant to the SEBI ICDR Regulations, Qualified Institutional Buyers and Non-Institutional Investors are required to pay the Bid Amount on submission of the Bid and are not permitted to withdraw or lower their Bids (in terms of quantity of Equity Shares or the Bid Amount) at any stage after submitting a Bid. Similarly, Retail Individual Investors can revise or withdraw their Bids at any time during the Bid/ Issue Period and until the Bid/ Issue Closing Date, but not thereafter. Therefore, Qualified Institutional Buyers and Non-Institutional Investors will not be able to withdraw or lower their Bids following adverse developments in international or national monetary policy, financial, political or economic conditions, our business, results of operations or otherwise at any stage after the submission of their Bids.

SECTION IV – INTRODUCTION

THE ISSUE

PRESENT ISSUE OF EQUITY SHARES BY OUR COMPANY IN TERMS OF THIS PROSPECTUS	
Equity Shares Issued ⁽¹⁾⁽²⁾⁽³⁾	44,49,600*, Equity Shares of face value of ₹10/- each fully paid for cash at a price of ₹ 97/- per Equity Share aggregating ₹ 4,316.11 Lakhs
Out of which:	
Issue Reserved for the Market Maker	2,28,000 Equity Shares of face value of ₹10/- each fully-paid up for cash at a price of ₹ 97/- per Equity Share aggregating ₹ 221.16 Lakhs
Net Issue to the Public	42,21,600 Equity Shares of having face value of ₹10/- each fully paid-up for cash at a price of ₹ 97/- per Equity Share aggregating ₹ 4,094.95 Lakhs
Out of which*	
A. QIB Portion ⁽⁴⁾	20,67,600 Equity Shares aggregating up to ₹ 2,005.57 Lakhs.
Of which:	
i) Anchor Investor Portion	12,36,000 Equity Shares aggregating to ₹ 1,198.92 Lakhs
ii) Net QIB Portion (Assuming Anchor Investor Portion is fully subscribed)	8,31,600 Equity Shares aggregating to ₹ 806.652 Lakhs
Of which:	
(a) Available for allocation to Mutual Funds only (5% of the Net QIB Portion)	44,400 Equity Shares aggregating to ₹ 43.07 Lakhs
(b) Balance of QIB Portion for all QIBs including Mutual Funds	7,87,200 Equity Shares aggregating to ₹ 763.58 Lakhs
B. Non-Institutional Portion	6,55,200 Equity Shares aggregating up to ₹ 635.54 Lakhs
C. Retail Portion	14,98,800 Equity Shares aggregating up to ₹ 1,453.84 Lakhs
Pre and Post – Issue Equity Shares	
Equity shares outstanding prior to the Issue	1,19,37,600 Equity Shares of face value of ₹10/- each fully paid-up
Equity shares outstanding after the Issue	1,63,87,200 Equity Shares of face value of ₹10/- each fully paid-up
Use of Net Proceeds	Please refer to the chapter titled “Objects of the Issue” beginning on page 86 of this Prospectus

*Subject to finalization of the Basis of Allotment. Number of shares may need to be adjusted for lot size upon determination of Issue price.

Notes:

- (1) The Issue is being made in terms of Chapter IX of the SEBI ICDR Regulations, as amended from time to time. This Issue is being made by our company in terms of Regulation of 229 (2) of SEBI ICDR Regulations read with Rule 19(2)(b)(i) of SCRR wherein not less than 25% of the post – issue paid up equity share capital of our company are being issued to the public for subscription.
- (2) The Issue including has been approved by our Board pursuant to the resolutions passed at its meetings held on February 02, 2024 and by our Shareholders pursuant to a special resolution passed at their meetings held on February 09, 2024.
- (3) The SEBI ICDR Regulations permit the issue of securities to the public through the Book Building Process, which states that: (a) not less than 35% of the Net Issue shall be available for allocation on a proportionate basis to Retail Individual Bidders; (b) not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders; and (c) not more than 50% of the Net Issue shall be allotted on a proportionate basis to QIBs, subject to valid Bids being received at or above the Issue Price. Provided that the unsubscribed portion in either of the categories specified in clauses (a) or (b) may be allocated to bidders in the other category. Accordingly, we have allocated the Net Issue i.e., not less than 35% of the Net Issue shall be available for allocation to Retail Individual Bidders; not less than 15% of the Net Issue shall be available for allocation to Non-Institutional Bidders and not more than 50% of the Net Issue to QIBs.
- (4) Subject to valid Bids being received at or above the Issue Price, under subscription, if any, in any category, except in the QIB Portion, would be allowed to be met with spill-over from any other category or combination of categories of

Bidders at the discretion of our Company in consultation with the Book Running Lead Manager and the Designated Stock Exchange, subject to applicable laws.

Our Company in consultation with the Book Running Lead Manager, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations. One-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription in the Anchor Investor Portion, the remaining Equity Shares shall be added to the QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors), including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allotment in the Mutual Fund Portion will be added to the Net QIB Portion and allocated proportionately to the QIB Bidders (other than Anchor Investors) in proportion to their Bids. For further details, please refer section titled “*Issue Procedure*” beginning on page 259 of this Prospectus.

SUMMARY OF FINANCIAL INFORMATION

ANNEXURE – I: RESTATED STATEMENT OF ASSETS AND LIABILITIES

(₹ in Lakhs)

Particulars	Annexure	As at December 31, 2023	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
EQUITY AND LIABILITIES					
Shareholders' funds					
(a) Share capital	V	1078.76	107.88	107.88	107.88
(b) Reserves and surplus	VI	1198.39	1,394.33	891.50	480.96
		2277.15	1,502.21	999.38	588.84
Share Application Money		345.00			
Non-current liabilities					
(a) Long-term Borrowings	VIIA	148.76	212.69	133.48	115.42
(b) Deferred tax liabilities (net)	XIII	73.93	59.84	45.89	35.10
(c) Long term provisions	VIII	10.81	8.58	6.66	5.03
		233.50	281.11	186.03	155.55
Current liabilities					
(a) Short term borrowings	VIIA	311.90	197.00	179.06	188.61
(b) Trade payables	IX				
(i) total outstanding dues of micro and small enterprises			-	-	-
(ii) total outstanding dues of creditors other than micro and small enterprises		2294.66	2,460.24	1,704.71	796.67
(c) Other current liabilities	X	79.51	73.14	277.82	103.50
(d) Short-term provisions	XI	327.37	151.02	132.86	6.46
		3013.44	2,881.40	2,294.45	1,095.24
TOTAL		5869.09	4,664.72	3,479.86	1,839.63
ASSETS					
Non-current assets					
(a) Property, plant and equipment	XII	988.50	983.94	737.55	593.63
(b) Non-Current Investments	XV	8.75	8.75	8.75	8.75
(c) Deferred tax assets (net)	XIII		-	-	-
(d) Long-term loans and advances	XIV	603.29	66.16	49.52	29.26
		1600.54	1,058.85	795.82	631.64
Current assets					
(a) Inventories	XVI	1157.33	1,115.72	108.72	82.80
(b) Trade receivables	XVII	2966.52	1,993.80	2,206.19	915.47
(c) Cash and bank balance	XVIII	4.54	249.69	156.91	41.64
(d) Short-term loans and advances	XIX	134.84	241.35	206.97	152.28
(e) Other Current Assets	XX	5.32	5.31	5.25	15.80
		4268.55	3,605.87	2,684.04	1,207.99
TOTAL		5869.09	4,664.72	3,479.86	1,839.63

ANNEXURE – II: STATEMENT OF PROFIT & LOSS, AS RESTATED

(₹ in Lakhs)

Particulars	Annexure	For the period/ year ended			
		December 31, 2023	March 31, 2023	March 31, 2022	March 31, 2021
Income					
Revenue from operations	XXI	6207.98	6,164.06	5,948.39	3,036.35
Other income	XXII	9.85	22.54	5.81	7.20
TOTAL INCOME		6217.83	6,186.60	5,954.20	3,043.55
Expenses					
(a) Cost of Material Consumed	XXIII	3996.13	4,173.79	4,427.41	2,443.19
(b) Purchase of stock-in-trade			-	-	-
(c) Increase/Decrease in Stock in trade	XXIV	(9.65)	7.77	21.97	3.28
(d) Employee benefits expense	XXV	329.96	356.79	346.44	253.08
(e) Finance costs	XXVI	62.50	53.84	29.65	30.71
(f) Depreciation and amortisation expense	XII	41.61	54.98	46.03	39.38
(g) Other expenses	XXVII	682.91	843.47	506.02	194.95
TOTAL EXPENSES		5103.46	5,490.64	5,377.52	2,964.59
Profit / (Loss) before tax		1114.37	695.96	576.68	78.95
Tax expenses:					
(a) Current tax expense		325.36	179.16	155.39	14.74
(b) Earlier year Tax			-	-	-
(c) Deferred tax expense / (benefit)		14.08	13.95	10.79	(1.29)
Net tax expense/(benefit)		339.44	193.11	166.18	13.45
Profit / (Loss) for the year		774.93	502.85	410.50	65.50
Earnings per share (of Rs. 10 each)					
(a) Basic & Diluted		7.18	4.66	3.81	0.61

ANNEXURE – III: STATEMENT OF CASH FLOW, AS RESTATED

(₹ in Lakhs)

Particulars		December 31, 2023	March 31, 2023	March 31, 2022	March 31, 2021
A	Cash flow from operating activities:				
	Net profit before tax	1114.37	695.96	576.68	78.95
	Adjustments:				
	Depreciation & Amortisation	41.61	54.98	46.03	39.38
	Profit on sale of Fixed Assets		(0.40)	-	(0.17)
	Interest Income	(9.64)	(9.75)	(3.70)	(1.03)
	Finance cost	62.50	53.84	29.65	30.71
	Provision for Gratuity	2.94	2.20	1.84	5.84
		97.41	100.87	73.82	74.73
	Operating cash flow before working capital changes	1211.78	796.83	650.50	153.68
	Movement in working capital				
	I. Adjustments for (Increase)/decrease in operating assets				
	Trade receivables	(972.72)	212.39	(1,290.72)	(181.19)
	Inventories	(41.61)	(1,007.00)	(25.92)	341.17
	Short-term loans & advance	136.01	(33.68)	(54.69)	5.82
	Other Current Assets	(0.01)	(0.06)	10.55	(0.99)
	II. Adjustments for (Increase)/decrease in operating liabilities:				
	Trade payables	(165.58)	755.53	908.04	(153.73)
	Other current liabilities	6.37	(204.68)	174.32	(19.02)
		(1037.54)	(277.50)	(278.42)	(7.94)
	Cash generated from operations	174.24	519.33	372.08	145.74
	Net income taxes paid	(173.85)	(156.26)	(26.58)	(41.02)
	Net cash (used in) / provided by operating activities - (A)	0.39	363.07	345.51	104.72
B	Cash flows from investing activities:				
	Purchase of fixed assets & including intangible assets	(51.52)	(306.72)	(193.07)	(120.70)
	Sale of fixed assets & including intangible assets		-	0.55	-
	Interest Received	9.64	9.75	3.70	1.03
	Net cash provided by / (used in) investing activities (B)	(41.88)	(296.97)	(188.82)	(119.67)
C	Cash flows from Financing activities:				
	Proceeds from Long Term Borrowings	(63.93)	79.21	18.06	4.77
	Issue of Shares Capital	345.00			
	Security Deposits paid	(537.13)	(16.64)	(20.26)	5.79
	Proceeds from/(Repayment) of Short-Term Borrowings	114.90	17.94	(9.55)	23.98
	Interest paid	(62.50)	(53.84)	(29.65)	(30.71)
	Net cash flow from/ (used in) financing activities (C)	(203.66)	26.67	(41.40)	3.83
	Net increase / (decrease) in cash & cash equivalents (A+B+C)	(245.15)	92.77	115.29	(11.12)
	Cash & cash equivalents as at the beginning of the year	249.69	156.92	41.63	52.75
	Cash & cash equivalents as at the end of the year	4.54	249.69	156.92	41.63
	Notes to Cash Flow Statement				
1	Component of cash and cash equivalent:				
	- Cash in hand	0.44	9.33	3.20	5.99
	- Balance with Bank	4.10	240.36	153.72	35.64
		4.54	249.69	156.92	41.63

GENERAL INFORMATION

REGISTERED OFFICE OF OUR COMPANY

Quest Laboratories Limited

Plot No. 45 Sector III Pithampur,
Dhar - 454775, Madhya Pradesh, India.

Tel No: 07292-292374

Email: investors@questlabltd.com

Website: www.questlabltd.com

CIN: U24232MP1998PLC012850

Registration Number: 012850

For further details and details of changes in the registered office of our company, please refer to the chapter titled “History and Certain Corporate Matters” beginning on page 172 of this Prospectus.

REGISTRAR OF COMPANIES

Registrar of Companies, Gwalior

3rd Floor, A Block, Sanjay Complex,
Jayendra Ganj, Gwalior - 474009,
Madhya Pradesh, India.

Tel No: 0751-2321907

Fax: 0751-2331853

Email: roc.gwalior@mca.gov.in

Website: www.mca.gov.in

DESIGNATED STOCK EXCHANGE

NSE Emerge**National Stock Exchange of India Limited**

Exchange Plaza, Plot no. C/1,
G Block Bandra – Kurla Complex,
Bandra (E), Mumbai – 400 051,
Maharashtra, India

Tel No: 022 – 2659 8100 / 8114

Website: www.nseindia.com

BOARD OF DIRECTORS

As on the date of this Prospectus, the Board of Directors of our Company comprises of the following:

Name	Designation	DIN	Residential Address
Mr. Anil Kumar Sabarwal	Chairman & Managing Director	00646133	121, Amitesh Nagar, Scheme No. 59, IDA, Indore -452 014, Madhya Pradesh, India.
Ms. Tejaswini Sabarwal	Whole Time Director	09088283	121, Amitesh Nagar, Scheme No. 59, IDA, Indore -452 014, Madhya Pradesh, India.
Mr. Rahul Dangi	Whole Time Director	09088127	Gram Banshiya, Baronda Rehli, Sagar - 470228, Madhya Pradesh, India
Mr. Gautam Kothari	Non-Executive Independent Director	00115063	231, Saket Nagar, Tilaknagar, Indore - 452018, Madhya Pradesh, India
Mr. Amit Ramesh Chandak	Non-Executive Independent Director	09419479	302, Varad Vinayak Apartment, Siddheshwar Nagar, Dighori, Narsala, Nagpur - 440034 Maharashtra, India
Mr. Basant Lal Menghwani	Non-Executive Independent Director	10459081	12/5 Jeevan Deep Colony, Indore - 452001, Madhya Pradesh, India.

For detailed profile of our Board of Directors, please see chapter titled “Our Management” beginning on page 175 of this Prospectus.

COMPANY SECRETARY AND COMPLIANCE OFFICER

Mr. Jayesh Jain is our Company Secretary and Compliance Officer. His contact details are as follows:

Mr. Jayesh Jain

Plot No. 45 Sector III Pithampur,
Dhar - 454775, Madhya Pradesh, India.

Tel No: 07292292374

Email: cs@questlabltd.com

Website: www.questlabltd.com

Investor grievances:

Bidders may contact the Company Secretary and Compliance Officer, BRLM or the Registrar to the Issue in case of any pre-issue or post-issue related queries, grievances and for redressal of complaints including non-receipt of letters of Allotment, non-credit of allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders or non-receipt of funds by electronic mode, etc.

All Issue-related grievances, other than that of Anchor Investors, may be addressed to the Registrar to the Issue with a copy to the relevant Designated Intermediary(ies) with whom the Bid cum Application Form was submitted, giving full details such as name of the sole or First Bidder, Bid cum Application Form number, Bidder's DP ID, Client ID, UPI ID, PAN, address of Bidder, number of Equity Shares applied for, ASBA Account number in which the amount equivalent to the Bid Amount was blocked or the UPI ID (for UPI Bidders who make the payment of Bid Amount through the UPI Mechanism), date of Bid cum Application Form and the name and address of the relevant Designated Intermediary(ies) where the Bid was submitted. Further, the Bidder shall enclose a copy of the Acknowledgment Slip or provide the application number received from the Designated Intermediary(ies) in addition to the documents or information mentioned hereinabove. All grievances relating to Bids submitted through Registered Brokers may be addressed to the Stock Exchanges with a copy to the Registrar to the Issue.

All Issue-related grievances of the Anchor Investors may be addressed to the Registrar to the Issue, giving full details such as the name of the sole or First Bidder, Anchor Investor Application Form number, Bidders' DP ID, Client ID, PAN, date of the Anchor Investor Application Form, address of the Bidder, number of the Equity Shares applied for, Bid Amount paid on submission of the Anchor Investor Application Form and the name and address of the BRLMs where the Anchor Investor Application Form was submitted by the Anchor Investor.

BOOK RUNNING LEAD MANAGER

Shreni Shares Limited

(Formerly Known as Shreni Shares Private Limited)

No. 217, Hive 67 Icon, Poisar Gymkhana Road,
Lokmanya Tilak Nagar Poisar, Near Raghuleela Mall,
Kandivali West, Mumbai – 400067, Maharashtra, India.

Tel No: 022 - 2089 7022

Email: shrenishares@gmail.com

Website: www.shreni.in

Investor Grievance E-mail: info@shreni.in

Contact Person: Ms. Tanya Goyal

SEBI Registration No.: INM000012759

REGISTRAR TO THE ISSUE

Bigshare Services Private Limited

S6-2, 6th Floor, Pinnacle Business Park,
Next to Ahura Centre, Mahakali Caves Road,
Andheri (East) Mumbai – 400 093,
Maharashtra, India

Tel No: 022 – 6263 8200

Email: ipo@bigshareonline.com

Website: www.bigshareonline.com

Investor Grievance E-mail: investor@bigshareonline.com

Contact Person: Mr. Vinayak Morbale

SEBI Registration No.: INR000001385

LEGAL ADVISOR TO THE ISSUE

Asha Agarwal & Associates

118, Shila Vihar, Gokulpura,
Kalwar Road, Jhotwara,
Jaipur – 302 012, Rajasthan, India
Tel No: +91 99509 33137
Email: ashaagarwalassociates@gmail.com
Contact Person: Ms. Nisha Agarwal

BANKERS TO THE COMPANY

HDFC Bank Limited

Brilliant Avenue, Scheme No 94,
Sector-B, Behind Bombay Hospital, Ring Road,
Indore 452010, Madhya Pradesh, India
Tel No.: 9407590823
Email: priyanshi.laddha@hdfcbank.com
Website: www.hdfcbank.com
Contact Person: Ms. Priyanshi Laddha

STATUTORY & PEER REVIEWED AUDITORS OF OUR COMPANY

Shyam S Gupta & Associates, Chartered Accountants

305, Milindas Maner, 2 RNT Marg,
Indore - 425001, Madhya Pradesh, India.
Tel No.: 0731-4065978
Email: sguptaca2004@rediffmail.com
Contact Person: 07314065978
Membership No.: 075255
Firm Registration No.: 007309C
Peer Review Registration No.: 015111

M/s. Shyam S Gupta & Associates, Chartered Accountants hold a peer review certificate dated March 27, 2023 issued by the Institute of Chartered Accountants of India.

BANKERS TO THE ISSUE / ESCROW COLLECTION BANK, REFUND BANK AND PUBLIC ISSUE BANK

ICICI Bank Limited Capital Market Division,

5th Floor, HT Parekh Marg,
Churchgate, Mumbai - 400020,
Maharashtra, India
Tel No.: 022-68052182
Email: ipocmg@icicibank.com
Website: www.icicibank.com
Contact Person: Mr. Varun Badai
SEBI Registration Number: INBI00000004

SYNDICATE MEMBER

Shreni Shares Limited

(Formerly Known as Shreni Shares Private Limited)

No. 217, Hive 67 Icon,
Poisar Gymkhana Road, Lokmanya Tilak
Nagar Poisar, Near Raghuleela Mall, Kandivali West,
Mumbai – 400067, Maharashtra, India.
Tel No: 022 - 20897022
Email: shrenisharespytltd@yahoo.in
Website: www.shreni.in
Contact Person: Mr. Hitesh Punjani
SEBI Registration No.: INZ000268538

STATEMENT OF INTER-SE ALLOCATION OF RESPONSIBILITIES

Shreni Shares Limited (*Formerly Known as Shreni Shares Private Limited*) is the sole Book Running Lead Manager to this Issue and all the responsibilities relating to co-ordination and other activities in relation to the Issue shall be performed by them and hence a statement of inter-se allocation of responsibilities is not required.

SELF-CERTIFIED SYNDICATE BANKS (“SCSBs”)

The list of recognised intermediaries notified by SEBI is available at <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=34>, or at such other website as may be prescribed by SEBI from time to time. A list of the Designated SCSB branches with which an ASBA Bidder (other than a UPI Bidder using the UPI Mechanism), not Bidding through Syndicate/Sub Syndicate or through a Registered Broker, RTA or CDP may submit the Bid cum Application Forms, is available at <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=34>, or at such other websites as may be prescribed by SEBI from time to time.

SCSBS AND MOBILE APPLICATIONS ENABLED FOR UPI MECHANISM

The banks registered with SEBI, which offer the facility of ASBA services, (i) in relation to ASBA, where the Bid Amount will be blocked by authorising an SCSB, a list of which is available on the website of SEBI at <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=34> and updated from time to time and at such other websites as may be prescribed by SEBI from time to time, (ii) in relation to UPI Bidders using the UPI Mechanism, a list of which is available on the website of SEBI at <https://sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=40> or such other website as updated from time to time.

In accordance with SEBI RTA Master Circular, SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2022/45 dated April 5, 2022, and SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2022/51 dated April 20, 2022, read with other applicable UPI Circulars, UPI Bidders Bidding through UPI Mechanism may apply through the SCSBs and mobile applications, using UPI handles, whose name appears on the SEBI website. A list of SCSBs and mobile applications, which, are live for applying in public offers using UPI mechanism is provided in the list available on the website of SEBI at www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=43 and updated from time to time and at such other websites as may be prescribed by SEBI from time to time.

SYNDICATE SCSB BRANCHES

In relation to Bids (other than Bids by Anchor Investors and RIBs) submitted to a member of the Syndicate, the list of branches of the SCSBs at the Specified Locations named by the respective SCSBs to receive deposits of Bid cum Application Forms from the members of the Syndicate is available on the website of the SEBI (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=35>) and updated from time to time or any such other website as may be prescribed by SEBI from time to time.

REGISTERED BROKERS

Bidders (other than RIBs) can submit ASBA Forms in the Issue using the stockbroker network of the stock exchange, i.e., through the Registered Brokers at the Broker Centers. The list of the Registered Brokers, including details such as postal address, telephone number and e-mail address, is provided on the websites of the Stock Exchange at <https://www.nseindia.com>, as updated from time to time.

REGISTRAR AND SHARE TRANSFER AGENTS (“RTA”)

The list of the RTAs eligible to accept ASBA Forms (other than RIBs) at the Designated RTA Locations, including details such as address, telephone number and e-mail address, is provided on the websites of the Stock Exchange at <https://www.nseindia.com/products-services/initial-public-offerings-asba-procedures>, as updated from time to time.

COLLECTING DEPOSITORY PARTICIPANTS (“CDP”)

The list of the CDPs eligible to accept ASBA Forms at the Designated CDP Locations, including details such as name and contact details, is provided on the websites of the Stock Exchange at <https://www.nseindia.com/products-services/initial-public-offerings-asba-procedures>, as updated from time to time.

CREDIT RATING

This being an Issue of Equity Shares, credit rating is not required.

IPO GRADING

Since the Issue is being made in terms of Chapter IX of the SEBI ICDR Regulations, there is no requirement of appointing an IPO Grading agency.

DEBENTURE TRUSTEES

Since this is not a debenture issue, appointment of debenture trustee is not required.

MONITORING AGENCY

Since our Issue size does not exceed ₹ 10,000 Lakhs, we are not required to appoint monitoring agency for monitoring the utilization of Net Proceeds in accordance with Regulation 262(1) of SEBI ICDR Regulations. Our Company has not appointed any monitoring agency for this Issue. However, as per Section 177 of the Companies Act, 2013, the Audit Committee of our Company, would be monitoring the utilization of the proceeds of the Issue.

FILING OF THE PROSPECTUS

The Prospectus shall be filed on NSE Emerge situated at National Stock Exchange of India Limited, Exchange Plaza, Plot no. C/1, G Block Bandra – Kurla Complex, Bandra (E), Mumbai – 400 051, Maharashtra, India.

Pursuant to Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) (Amendment) Regulations, 2022, Prospectus shall not be submitted to SEBI, however, soft copy of Prospectus shall be submitted to SEBI pursuant to SEBI Circular Number SEBI/HO/CFD/DIL1/CIR/P/2018/011 dated January 19, 2018, through SEBI Intermediary Portal at <https://siportal.sebi.gov.in>. SEBI will not issue any observation on the offer document in terms of Regulation 246 (2) of the SEBI ICDR Regulations.

A copy of the Prospectus along with the material contracts and documents referred elsewhere in the Prospectus required to be filed under Section 26 of the Companies Act, 2013 will be delivered to the Registrar of Companies, Gwalior situated at 3rd Floor, A Block, Sanjay Complex, Jayendra Ganj, Gwalior-474009, Madhya Pradesh, India at least (3) three working days prior from the date of opening of the Issue.

APPRAISING ENTITY

No appraising entity has been appointed in respect of any objects of this Issue.

TYPE OF ISSUE

The present Issue is considered to be 100% Book-Building Issue.

GREEN SHOE OPTION

No green shoe option is contemplated under the Issue.

EXPERTS TO THE ISSUE

Except as stated below, our Company has not obtained any expert opinions:

Our Company has received written consent from Peer Reviewed Auditor namely, Shyam S Gupta & Associates, Chartered Accountants, to include their name in respect of the reports on the Restated Financial Statements dated April 17, 2024 and the Statement of Possible Tax Benefits dated February 24, 2024 issued by them and included in this Prospectus, as required under section 26(1)(a)(v) of the Companies Act, 2013 in this Prospectus and as “Expert” as defined under section 2(38) of the Companies Act, 2013 and such consent has not been withdrawn as on the date of this Prospectus. However, the term “expert” shall not be construed to mean an “expert” as defined under the U.S. Securities Act.

CHANGES IN AUDITORS

There has been no change in the Statutory Auditors during the three years immediately preceding the date of this Prospectus.

BOOK BUILDING PROCESS

Book building, in the context of the Issue, refers to the process of collection of Bids from bidders on the basis of the Prospectus, the Bid Cum Application Forms and the Revision Forms, if any, within the Price Band and the minimum Bid Lot, which will be decided by our Company in consultation with the Book Running Lead Manager, and will be advertised in all editions of English national daily newspaper, The Financial Express (a widely circulated English national daily newspaper), all editions of Jansatta (a widely circulated Hindi national daily newspaper) and Hamara Swaraj, a Hindi regional newspaper (Hindi being the regional language of Madhya Pradesh, where our Registered Office is located) each with wide circulation at least two Working Days prior to the Bid/Issue Opening Date and shall be made available to the Stock Exchange for the purpose of uploading on their respective website. The Issue Price shall be determined by our Company in consultation with the Book Running Lead Manager, after the Bid/ Issue Closing Date. For details, see “Issue Procedure” beginning on page 259 of this Prospectus.

All Bidders other than Anchor Investors participated through the ASBA process by providing the details of their respective ASBA Account in which the corresponding Bid Amount was blocked by the SCSBs. In addition to this, the Retail Individual Investors participated through the ASBA process by providing the details of their respective ASBA Account in which the corresponding Bid Amount was blocked by the SCSBs or by using the UPI Mechanism. Non-Institutional Investors with an application size of up to ₹ 5.00 lakhs could use the UPI Mechanism and could also provide their UPI ID in the Bid cum Application Form submitted with Syndicate Members, Registered Brokers, Collecting Depository Participants and Registrar and Share Transfer Agents. Anchor Investors were not permitted to participate in the Issue through the ASBA process.

In terms of the SEBI ICDR Regulations, QIBs and Non-Institutional Investors are not permitted to withdraw their Bid(s) or lower the size of their Bid(s) (in terms of the number of Equity Shares or the Bid Amount) at any stage. RIBs can revise their Bid(s) during the Bid/ Issue Period and withdraw their Bid(s) until Bid/ Issue Closing Date. Anchor Investors are not allowed to withdraw their Bids after the Anchor Investor Bidding Date. Except for Allocation to RIBs, NIIs and the Anchor Investors, allocation in the Issue will be on a proportionate basis. Further, allocation to Anchor Investors will be on a discretionary basis.

Each Bidder by submitting a Bid in the Issue, will be deemed to have acknowledged the above restrictions and the terms of the Issue.

For further details, see “Terms of the Issue”, “Issue Structure” and “Issue Procedure” beginning on pages 246, 255 and 259 of this Prospectus, respectively.

The process of Book Building under the SEBI ICDR Regulations and the Bidding Process are subject to change from time to time and the investors are advised to make their own judgment about investment through this process prior to submitting a Bid in the Issue.

Bidders should note that, the Issue is also subject to obtaining (i) the final approval of the RoC after the Prospectus is filed with the RoC; and (ii) final listing and trading approvals of the Stock Exchange, which our Company shall apply for after Allotment.

UNDERWRITING AGREEMENT

This Issue is 100% Underwritten by Shreni Shares Limited (*Formerly Known as Shreni Shares Private Limited*) in the capacity of Underwriter to the Issue. The Underwriting agreement is dated April 25, 2024. Pursuant to the terms of the Underwriting Agreement, the obligations of the Underwriters are several and are subject to certain conditions specified therein. The Underwriters have indicated their intention to underwrite the following number of specified securities being issued through this issue:

(₹ in Lakhs)

Details of the Underwriter	No. of Equity Shares Underwritten*	Amount Underwritten	% of total Issue size underwritten
Shreni Shares Limited (Formerly Known as Shreni Shares Private Limited) Office No. 217, Hive 67 Icon, Poisar Gymkhana Road Lokmanya Tilak Nagar, Poisar, Near Raghuleela Mall, Kandivali West, Mumbai - 400067, Maharashtra, India Tel No: 022 - 2089 7022 Email: shrenishares@gmail.com	44,49,600*	₹ 4,316.11	100%

Details of the Underwriter	No. of Equity Shares Underwritten*	Amount Underwritten	% of total Issue size underwritten
Website: www.shreni.in Investor Grievance E-mail: info@shreni.in Contact Person: Ms. Tanya Goyal SEBI Registration No.: INM000012759			

**Includes 2,28,000 Equity Shares of the Market Maker Reservation Portion which are to be subscribed by the Market Maker in its own account in order to claim compliance with the requirements of Regulation 261 of the SEBI ICDR Regulations, as amended.*

In the opinion of the Board of Directors of our Company, the resources of the above-mentioned Underwriter are sufficient to enable them to discharge their respective obligations in full.

MARKET MAKER

Rikhav Securities Limited

B/501-502, O2 Commercial Building,

Asha Nagar, Mulund (W),

Mumbai – 400080, Maharashtra, India

Tel No: 022-69078300/400

Email: info@rikhav.net

Website: www.rikhav.net

Contact Person: Mr. Hitesh H Lakhani

SEBI Registration No.: INZ000157737

DETAILS OF THE MARKET MAKING AGREEMENT

In accordance with Regulation 261 of the SEBI ICDR Regulations, we have entered into an agreement with the Book Running Lead Manager and the Market Maker (duly registered with NSE to fulfil the obligations of Market Making) dated April 25, 2024 to ensure compulsory Market Making for a minimum period of three years from the date of listing of equity shares issued in this issue.

Rikhav Securities Limited registered with NSE Emerge will act as the Market Maker and has agreed to receive or deliver of the specified securities in the market making process for a period of three years from the date of listing of our Equity Shares or for a period as may be notified by any amendment to SEBI ICDR Regulations.

The Market Maker shall fulfil the applicable obligations and conditions as specified in the SEBI ICDR Regulations, as amended from time to time and the circulars issued by NSE and SEBI in this matter from time to time.

Following is a summary of the key details pertaining to the Market Making arrangement:

1. The Market Maker shall be required to provide a 2-way quote for 75% of the time in a day. The same shall be monitored by the Stock Exchange. The spread (difference between the sell and buy quote) shall not be more than 10% or as specified by the Stock Exchange from time to time. Further, the Market Maker shall inform the exchange in advance for each and every black out period when the quotes are not being issued by the Market Maker.
2. The prices quoted by the Market Maker shall be in compliance with the Market Maker Spread requirements and other particulars as specified or as per the requirements of NSE and SEBI from time to time.
3. The minimum depth of the quote shall be ₹1,00,000. However, the investors with holdings of value less than ₹1.00 Lakh shall be allowed to Issue their holding to the Market Maker in that scrip provided that he sells his entire holding in that scrip in one lot along with a declaration to the effect to the selling broker. Based on the IPO price of ₹ 97/- per share the minimum application lot size is 1,200 Equity Shares thus minimum depth of the quote shall be 1,200 until the same, would be revised by NSE.
4. After a period of three (3) months from the market making period, the market maker would be exempted to provide quote if the Equity Shares of market maker in our Company reaches to 25%. Or upper limit (Including the 5% of Equity Shares ought to be allotted under this Issue). Any Equity Shares allotted to Market Maker under this Issue over and above 25% equity shares would not be taken into consideration of computing the threshold of 25%. As soon as the Shares of market maker in our Company reduce to 24%, the market maker will resume providing 2-way quotes.

5. There shall be no exemption/threshold on downside. However, in the event the market maker exhausts his inventory through market making process, the concerned stock exchange may intimate the same to SEBI after due verification.
6. On the first day of the listing, there will be pre-opening session (call auction) and there after the trading will happen as per the equity market hours. The circuits will apply from the first day of the listing on the discovered price during the pre-open call auction. The securities of the company will be placed in Special Pre-Open Session (SPOS) and would remain in Trade for Trade settlement for 10 days from the date of listing of Equity shares on the Stock Exchange.
7. There will be special circumstances under which the Market Maker may be allowed to withdraw temporarily/fully from the market for instance due to system problems, any other problems. All controllable reasons require prior approval from the Exchange, while force-majeure will be applicable for non-controllable reasons. The decision of the Exchange for deciding controllable and non- controllable reasons would be final.
8. The Inventory Management and Buying/Selling Quotations and its mechanism shall be as per the relevant circulars issued by SEBI and NSE from time to time.
9. Execution of the order at the quoted price and quantity must be guaranteed by the Market Maker, for the quotes given by them.
10. There would not be more than five Market Makers for the Company's Equity Shares at any point of time and the Market Makers may compete with other Market Makers for better quotes to the investors.
11. The shares of the company will be traded in continuous trading session from the time and day the company gets listed on NSE EMERGE and market maker will remain present as per the guidelines mentioned under NSE and SEBI circulars.
12. There will be special circumstances under which the Market Maker may be allowed to withdraw temporarily/ fully from the market – for instance due to system problems, any other problems. All controllable reasons require prior approval from the Exchange, while force-majeure will be applicable for non-controllable reasons. The decision of the Exchange for deciding controllable and non-controllable reasons would be final.
13. The price band shall be 20% and the Market Maker Spread (difference between the sell and the buy quote) shall be within 10% or as intimated by Exchange from time to time.
14. The Market Maker shall have the right to terminate said arrangement by giving one month notice or on mutually acceptable terms to the Company, who shall then be responsible to appoint a replacement Market Maker.
15. In case of termination of the abovementioned Market Making Agreement prior to the completion of the compulsory Market Making period, it shall be the responsibility of the Company to arrange for another Market Maker(s) in replacement during the term of the notice period being served by the Market Maker but prior to the date of releasing the existing Market Maker from its duties in order to ensure compliance with the requirements of Regulation 261 of the SEBI ICDR Regulations. Further, the Company reserve the right to appoint other Market Maker(s) either as a replacement of the current Market Maker or as an additional Market Maker subject to the total number of Designated Market Makers does not exceed 5 (five) or as specified by the relevant laws and regulations applicable at that particular point of time.
16. **Risk containment measures and monitoring for Market Maker:** NSE will have all margins which are applicable on the Main Board viz., Mark-to-Market, Value-At-Risk (VAR) Margin, Extreme Loss Margin, Special Margins and Base Minimum Capital etc. NSE can impose any other margins as deemed necessary from time-to-time.
17. **Punitive Action in case of default by Market Maker:** NSE will monitor the obligations on a real time basis and punitive action will be initiated for any exceptions and / or non-compliances. Penalties / fines may be imposed by the Exchange on the Market Maker, in case he is not able to provide the desired liquidity in a particular security as per the specified guidelines. These penalties / fines will be set by the Exchange from time to time. The Exchange will impose a penalty on the Market Maker in case he is not present in the market (issuing two-way quotes) for at least 75% of the time. The nature of the penalty will be monetary as well as suspension in market making activities / trading membership. The Department of Surveillance and Supervision of the Exchange would decide and publish the penalties / fines / suspension for any type of misconduct / manipulation / other irregularities by the Market Maker from time to time.
18. **Price Band and Spreads:** SEBI Circular bearing reference no: CIR/MRD/DP/ 02/2012 dated January 20, 2012, has laid down that for Issue size up to ₹250 Crores, the applicable price bands for the first day shall be:

- In case equilibrium price is discovered in the Call Auction, the price band in the normal trading session shall be 5% of the equilibrium price.
- In case equilibrium price is not discovered in the Call Auction, the price band in the normal trading session shall be 5% of the Issue price.

Additionally, the trading shall take place in TFT segment for first 10 days from commencement of trading. The price band shall be 20% and the Market Maker Spread (difference between the sell and the buy quote) shall be within 10% or as intimated by Exchange from time to time.

19. The following spread will be applicable on the NSE Emerge:

Sr. No.	Market Price Slab (in ₹)	Proposed spread (in % to sale price)
1.	Up to 50	9
2.	50 to 75	8
3.	75 to 100	6
4.	Above 100	5

20. Pursuant to SEBI Circular number CIR/MRD/DSA/31/2012 dated November 27, 2012, limits on the upper side for Market Maker during market making process has been made applicable, based on the issue size and as follows:

Issue Size	Buy quote exemption threshold (Including mandatory initial inventory of 5% of the Issue Size)	Re-Entry threshold for buy quote (Including mandatory initial inventory of 5% of the Issue Size)
Up to ₹20 Crore	25%	24%
₹20 Crore to ₹50 Crore	20%	19%
₹50 Crore to ₹80 Crore	15%	14%
Above ₹80 Crore	12%	11%

21. The Market Making arrangement, trading and other related aspects including all those specified above shall be subject to the applicable provisions of law and / or norms issued by SEBI/ NSE from time to time.
22. All the above-mentioned conditions and systems regarding the Market Making Arrangement are subject to change based on changes or additional regulations and guidelines from SEBI and Stock Exchange from time to time.
23. On the first day of listing, there will be a pre-open session (call auction) and there after trading will happen as per the equity market hours. The circuits will apply from the first day of the listing on the discovered price during the pre-open call auction. The securities of the Company will be placed in SPOS and would remain in Trade for Trade settlement for 10 days from the date of listing of Equity Shares on the Stock Exchange.

CAPITAL STRUCTURE

The Equity Share capital of our Company, as on the date of this Prospectus and after giving effect to this Issue, is set forth below:

(₹ in lakhs except share data)

Sr. No.	Particulars	Aggregate Value at Face Value	Aggregate Value at Issue Price*
A.	Authorized Share Capital⁽¹⁾		
	2,00,00,000 Equity Shares of face value of ₹10/- each	2,000.00	-
B.	Issued, Subscribed and Paid-Up Equity Capital before the Issue		
	1,19,37,600 Equity Shares of face value of ₹10/- each	1193.76	-
C.	Present Issue in Terms of this Prospectus		
	Issue of 44,49,600 Equity Shares of face value of ₹10/- each aggregating to ₹ 4,316.11 Lakhs ⁽¹⁾⁽²⁾	444.96	4,316.11
	of which		
	Fresh Issue of 44,49,600 Equity Shares of face value of ₹10/- each aggregating to ₹ 4,316.11 Lakhs	444.96	4,316.11
	Which Includes:		
	2,28,000 Equity Shares of face value of ₹10/- each at a price of ₹97/- per Equity Share reserved as Market Maker Portion	22.80	221.16
	Net issue to Public of 42,21,600 Equity Shares of ₹10/- each at a price of ₹97/- per Equity Share to the Public	422.16	4,094.95
	Of Which		
	At least 14,98,800 Equity Shares aggregating to ₹ 1,453.84 Lakhs will be available for allocation to Retail Individual Investors	149.88	1,453.84
	At least 6,55,200 Equity Shares aggregating to ₹ 635.54 Lakhs will be available for allocation to Non-Institutional Investors	65.52	635.54
	Not more than 20,67,600 Equity Shares aggregating to ₹ 2,005.57 Lakhs will be available for allocation to Qualified Institutional Buyers, five per cent of which shall be allocated to mutual funds	206.76	2,005.57
D.	Issued, Subscribed and Paid-Up Capital After the Issue		
	1,63,87,200 Equity Shares of face value of ₹10/- each	1,638.72	-
E.	Securities Premium Account		
	Before the Issue ⁽³⁾		Nil
	After the Issue		3,871.15

⁽¹⁾ For details in relation to the changes in the authorised share capital of our Company, see “History and Certain Corporate Matters – Amendments to our Memorandum of Association” on page 283.

⁽²⁾ The Issue has been authorized by our Board pursuant to resolutions passed at its meetings held on February 02, 2024 and by our Shareholders pursuant to a special resolution passed at their meetings held on February 09, 2024.

⁽³⁾ Securities Premium before the issue as on December 31, 2023.

CLASS OF SHARES

As on the date of Prospectus, our Company has only one class of share capital i.e., Equity Shares of ₹10/- each. All Equity Shares issued are fully paid-up. Our Company has no outstanding convertible instruments as on the date of this Prospectus.

NOTES TO THE CAPITAL STRUCTURE

1. Changes in Authorized Share Capital

Since incorporation, the capital structure of our Company has been altered in the following manner:

a) The initial authorized share capital of ₹ 2,00,000 /- divided into 20,000 Equity Shares of ₹10/- each.

- b) The Authorized Share Capital was increased from ₹ 2,00,000 /- divided into 20,000 Equity Shares of ₹10/- each to ₹ 15,00,000 /- divided into 1,50,000 Equity Shares of ₹10/- each vide Shareholders' Resolution dated March 25, 2004.
- c) The Authorized Share Capital was increased from ₹ 15,00,000 /- divided into 1,50,000 Equity Shares of ₹10/- each to ₹ 45,00,000 /- divided into 4,50,000 equity shares of ₹10/- each vide Shareholders' Resolution dated February 01, 2008.
- d) The Authorized Share Capital was increased from ₹ 45,00,000 /- divided into 4,50,000 Equity Shares of ₹10/- each to ₹ 1,00,00,000 /- divided into 10,00,000 equity shares of ₹10/- each vide Shareholders' Resolution dated March 25, 2010.
- e) The Authorized Share Capital was increased from ₹ 1,00,00,000 /- divided into 10,00,000 Equity Shares of ₹10/- each to ₹ 2,00,00,000 /- divided into 20,00,000 equity shares of ₹10/- each vide Shareholders' Resolution dated June 30, 2016.
- f) The Authorized Share Capital was increased from ₹ 2,00,00,000 /- divided into 20,00,000 Equity Shares of ₹10/- each to ₹ 12,00,00,000 /- divided into 1,20,00,000 equity shares of ₹10/- each vide Shareholders' Resolution dated August 19, 2023
- g) The Authorized Share Capital was increased from ₹ 12,00,00,000 /- divided into 1,20,00,000 Equity Shares of ₹10/- each to ₹ 20,00,00,000 /- divided into 2,00,00,000 equity shares of ₹10/- each vide Shareholders' Resolution dated January 11, 2024

2. Equity Share Capital History of our Company

The following table sets forth details of the history of the Equity Share capital of our Company:

Date of Allotment	No. of Equity Shares allotted	Face Value (₹)	Issue Price (₹)	Nature of Consideration	Nature of Allotment	Cumulative No. of Equity Shares	Cumulative Paid Up Equity Share Capital (₹)
Upon Incorporation	1,000	10/-	10/-	Cash	Subscription to MOA ⁽ⁱ⁾	1,000	10,000
March 31, 2001	9,000	10/-	10/-	Cash	Further Allotment ⁽ⁱⁱ⁾	10,000	1,00,000
March 25, 2004	1,40,000	10/-	10/-	Cash	Further Allotment ⁽ⁱⁱⁱ⁾	1,50,000	15,00,000
February 13, 2008	3,00,000	10/-	10/-	Cash	Further Allotment ^(iv)	4,50,000	45,00,000
March 31, 2010	1,30,000	10/-	50/-	Cash	Further Allotment ^(v)	5,80,000	58,00,000
December 31, 2011	35,760	10/-	100/-	Cash	Further Allotment ^(vi)	6,15,760	61,57,600
March 31, 2014	1,50,000	10/-	10/-	Cash	Further Allotment ^(vii)	7,65,760	76,57,600
October 10, 2015	16,500	10/-	30/-	Cash	Further Allotment ^(viii)	7,82,260	78,22,600
November 23, 2015	36,500	10/-	30/-	Cash	Further Allotment ^(ix)	8,18,760	81,87,600
December 05, 2015	45,000	10/-	30/-	Cash	Further Allotment ^(x)	8,63,760	86,37,600
January 02, 2016	39,500	10/-	30/-	Cash	Further Allotment ^(xi)	9,03,260	90,32,600
January 28, 2016	45,500	10/-	30/-	Cash	Further Allotment ^(xii)	9,48,760	94,87,600
August 19, 2016	17,500	10/-	40/-	Cash	Further Allotment ^(xiii)	9,66,260	96,62,600
September 28, 2016	1,12,500	10/-	40/-	Cash	Further Allotment ^(xiv)	10,78,760	1,07,87,600
September 30, 2023	97,08,840	10/-	Nil/-	Other Than Cash	Bonus Issue ^(xv)	1,07,87,600	10,78,76,000

Date of Allotment	No. of Equity Shares allotted	Face Value (₹)	Issue Price (₹)	Nature of Consideration	Nature of Allotment	Cumulative No. of Equity Shares	Cumulative Paid Up Equity Share Capital (₹)
January 01, 2024	11,50,000	10/-	30/-	Cash	Further Allotment ^(xvi)	1,19,37,600	11,93,76,000

(i) Initial Subscribers to the Memorandum of Association of our company:

Sr. No	Name	No of Equity Shares
1.	Mr. Anil Kumar Sabarwal	500
2.	Mr. Narendra Kumar Pamecha	500
	Total	1,000

(ii) Further Allotment of 9,000 Equity Shares of face value of ₹10/- at a price of ₹10/- each:

Sr. No	Name	No of Equity Shares
1.	Late. Motiya Rani Sabarwal	9,000
	Total	9,000

(iii) Further Allotment of 1,40,000 Equity Shares of face value of ₹10/- at a price of ₹10/- each

Sr. No	Name	No of Equity Shares
1.	Mr. Anil Kumar Sabarwal	49,500
2.	Late. Kavita Sabarwal	39,500
3.	Late. Motiya Rani Sabarwal	31,000
4.	Mr. Ashok Anand	20,000
	Total	1,40,000

(iv) Further Allotment of 3,00,000 Equity Shares of face value of ₹10/- at a price of ₹10/- each

Sr. No	Name	No of Equity Shares
1.	Mr. Anil Kumar Sabarwal	1,10,000
2.	Late. Kavita Sabarwal	1,10,000
3.	Late. Motiya Rani Sabarwal	80,000
	Total	3,00,000

(v) Further Allotment of 1,30,000 Equity Shares of face value of ₹10/- at a price of ₹50/- each

Sr. No	Name	No. of Equity Shares
1.	Marquise Builders Private limited	70,000
2.	Murti Teal Estate Private Limited	20,000
3.	Macro Holdings Private Limited	40,000
	Total	1,30,000

(vi) Further Allotment of 35,760 Equity Shares of face value of ₹10/- at a price of ₹100/- each

Sr. No	Name	No. of Equity Shares
1.	Mr. Anil Kumar Sabarwal	8,675
2.	Late. Kavita Sabarwal	3,750
3.	Mr. Ashok Anand	1,335
4.	M/s Anil Sabarwal HUF	5,000
5.	Mr. Sunil Narang	8,000
6.	Suyash Constructions Private Limited	9,000
	Total	35,760

(vii) Further Allotment of 1,50,000 Equity Shares of face value of ₹10/- at a price of ₹10/- each

Sr. No	Name	No. of Equity Shares
1.	Late. Kavita Sabarwal	70,000

Sr. No	Name	No. of Equity Shares
2.	M/s. Sunil Brothers (Prop - Mr. Sunil Narang)	80,000
	Total	1,50,000

(viii) Further Allotment of 16,500 Equity Shares of face value of ₹10/- at a price of ₹30/- each

Sr. No	Name	No. of Equity Shares
1.	Mr. Anil Kumar Sabarwal	16,500
	Total	16,500

(ix) Further Allotment of 36,500 Equity Shares of face value of ₹10/- at a price of ₹30/- each

Sr. No	Name	No. of Equity Shares
1.	Mr. Anil Kumar Sabarwal	36,500
	Total	36,500

(x) Further Allotment of 45,000 Equity Shares of face value of ₹10/- at a price of ₹30/- each

Sr. No	Name	No. of Equity Shares
1.	Mr. Anil Kumar Sabarwal	45,000
	Total	45,000

(xi) Further Allotment of 39,500 Equity Shares of face value of ₹10/- at a price of ₹30/- each

Sr. No	Name	No. of Equity Shares
1.	Mr. Anil Kumar Sabarwal	39,500
	Total	39,500

(xii) Further Allotment of 45,500 Equity Shares of face value of ₹10/- at a price of ₹30/- each

Sr. No	Name	No. of Equity Shares
1.	Mr. Anil Kumar Sabarwal	45,500
	Total	45,500

(xiii) Further Allotment of 17,500 Equity Shares of face value of ₹10/- at a price of ₹40/- each

Sr. No	Name	No. of Equity Shares
1.	Mr. Anil Kumar Sabarwal	17,500
	Total	17,500

(xiv) Further Allotment of 1,12,500 Equity Shares of face value of ₹10/- at a price of ₹40/- each

Sr. No	Name	No. of Equity Shares
1.	Mr. Anil Kumar Sabarwal	50,000
2.	Late. Kavita Sabarwal	62,500
	Total	1,12,500

(xv) Bonus Issue of 97,08,840 Equity Shares of face value of ₹10/- each in the ratio of 9:1 i.e., 9 Bonus equity shares for 1 Equity Shares held:

Sr. No	Name	No. of Equity Shares
1.	Mr. Anil Kumar Sabarwal	91,50,525
2.	Mr. Ashok Anand	1,92,015
3.	Ms. Tejaswini Sabarwal	3,66,300
	Total	97,08,840

(xvi) Further Allotment of 11,50,000 Equity Shares of face value of ₹10/- at a price of ₹30/- each

Sr. No	Name	No. of Equity Shares
1.	Ms. Bhavya Jain	66,666

Sr. No	Name	No. of Equity Shares
2.	1955 Venture Fund	1,00,000
3.	Mr. Sandeep Bhandari	66,666
4.	Mr. Gaurav Singh	66,666
5.	Ms. Pooja Narshana	83,337
6.	Mr. Sagar Haresh Doshi	83,333
7.	Ms. Dhara Shah	66,666
8.	Ms. Meghna Rajan Vora	66,666
9.	Mr. Kamlesh Gandhi	2,00,000
10.	Ms. Priti Gandhi	2,00,000
11.	Ms. Pooja Bansal	1,00,000
12.	Mr. Mahendra Verma	50,000
	Total	11,50,000

3. Except as disclosed below, we have not issued any Equity Shares for consideration other than cash, at any point of time since Incorporation:

Date of Allotment	No. of Equity Shares	Face Value (₹)	Issue Price (₹)	Reasons of Allotment	Benefits accrued to company	Allottees	No. of Shares Allotted
September 30, 2023	97,08,840	10/-	Nil	Bonus Issue	Capitalization of Reserves & Surplus	Mr. Anil Kumar Sabarwal	91,50,525
						Ms. Tejaswini Sabarwal	3,66,300
						Mr. Ashok Anand	1,92,015

4. No equity shares have been allotted in terms of any scheme approved under sections 391-394 of the Companies Act, 1956 and sections 230-234 of the Companies Act, 2013.
5. Our Company has not issued any shares pursuant to an Employee Stock Option Scheme/ Employee Stock Purchase Scheme for our employees.
6. We have not re-valued our assets since inception and have not issued any equity shares (including bonus shares) by capitalizing any revaluation reserves.
7. Except as disclosed below, we have not issued any Equity Shares at price below Issue price within last one year from the date of this Prospectus:

Date of Allotment	No. of Equity Shares	Face Value (₹)	Issue Price (₹)	Reasons of Allotment	Benefits accrued to company	Allottees	No. of Shares Allotted
September 30, 2023	97,08,840	10/-	Nil	Bonus Issue	Capitalization of Reserves & Surplus	Mr. Anil Kumar Sabarwal	91,50,525
						Ms. Tejaswini Sabarwal	3,66,300
						Mr. Ashok Anand	1,92,015

8. Shareholding Pattern of our Company

The table below presents the current shareholding pattern of our Company as on the date of this Prospectus.

Category (I)	Category of shareholder (II)	Nos. of shareholders (III)	No. of fully paid-up equity shares held (IV)	No. of Partly paid-up equity shares held (V)	No. of shares underlying Depository Receipts (VI)	Total nos. shares held (VII) = (IV)+(V)+(VI)	Shareholding as a % of total no. of shares (calculated as per SCRR, 1957) (VIII) As a % of (A+B+C2)	Number of Voting Rights held in each class of securities (IX)				No. of Underlying Outstanding convertible securities (including Warrants) (X)	Shareholding as a % assuming full convertible securities (as a percentage of diluted share capital) (XI) = (VII)+(X) As a % of (A+B+C2)	Number of Locked in shares (XII)		Number of Shares pledged or otherwise encumbered (XIII)		Number of equity shares held in dematerialized form (XIV)*
								Class-Equity	Class	Total	Total as a % of (A+B+C)			No (a)	As a % of total Shares held (b)	No (a)	As a % of total Shares held (b)	
A	Promoters & Promoter group	3	1,07,86,900	-	-	1,07,86,900	90.36%	1,07,86,900	-	1,07,86,900	90.36%	-	90.36%	-	-	-	-	1,07,86,900
B	Public	20	11,50,700	-	-	11,50,700	9.64%	11,50,700	-	11,50,700	9.64%	-	9.64%	-	-	-	-	11,50,700
C	Non - Promoters Non - Public	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C 1	Shares underlying DRs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C 2	Shares held by Employee Trusts	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Total	23	1,19,37,600	-	-	1,19,37,600	100.00	1,19,37,600	-	1,19,37,600	100.00	-	100.00%	-	-	-	-	1,19,37,600

9. Set forth below is a list of Shareholders holding 1% or more of the paid-up Share Capital of our Company as on the date of this Prospectus:

Sr. No.	Name of the Shareholder	Number of Equity shares	Percentage of the pre- Issue Equity Share Capital (%)
1.	Mr. Anil Kumar Sabarwal	10,167,250	85.17%
2.	Ms. Tejaswini Sabarwal	4,07,000	3.41%
3.	Mr. Vinayak Sabarwal	2,12,650	1.78%
4.	Mr. Kamlesh Gandhi	2,00,000	1.68%
5.	Ms. Priti Gandhi	2,00,000	1.68%
6.	Mr. Sagar Haresh Doshi	1,56,663	1.31
	Total	1,13,43,563	95.02%

10. Set forth below is a list of Shareholders holding 1% or more of the paid-up Share Capital of our Company two years prior to this Prospectus:

Sr. No.	Name of the Shareholder	Number of Equity shares	Percentage of then pre-Issue Equity Share Capital (%)
1.	Mr. Anil Kumar Sabarwal	9,27,425	85.97%

Sr. No.	Name of the Shareholder	Number of Equity shares	Percentage of then pre-Issue Equity Share Capital (%)
2.	Mr. Ashok Anand	21,335	1.98%
3.	Mr. Ghanshyam Gupta	1,30,000	12.05%
	Total	10,78,760	100.00%

11. Set forth below is a list of Shareholders holding 1% or more of the paid-up Share Capital of our Company as of one year prior to the date of this Prospectus:

Sr. No.	Name of the Shareholder	Number of Equity shares	Percentage of then pre-Issue Equity Share Capital (%)
1.	Mr. Anil Kumar Sabarwal	10,16,725	94.25%
2.	Mr. Ashok Anand	21,335	1.98%
3.	Ms. Tejaswini Sabarwal	40,700	3.77%
	Total	10,78,760	100.00%

12. Set forth below is a list of Shareholders holding 1% or more of the paid-up Share Capital of our Company as of 10 days prior to the date of this Prospectus:

Sr. No.	Name of the Shareholder	Number of Equity shares	Percentage of the pre- Issue Equity Share Capital (%)
1.	Mr. Anil Kumar Sabarwal	10,16,725	85.17%
2.	Ms. Tejaswini Sabarwal	4,07,000	3.41%
3.	Mr. Vinayak Sabarwal	2,12,650	1.78%
4.	Mr. Kamlesh Gandhi	2,00,000	1.68%
5.	Ms. Priti Gandhi	2,00,000	1.68%
6.	Mr. Sagar Hareesh Doshi	1,56,663	1.31%
	Total	1,13,43,563	95.02%

13. Our Company has not made any public Issue (including any rights issue to the public) since its incorporation, except as stated above.
14. Our Company does not have any intention or proposal to alter our capital structure within a period of six (6) months from the date of opening of the by way of split/consolidation of the denomination of Equity Shares or further Issue of Equity Shares (including issue of securities convertible into exchangeable, directly or indirectly, for our Equity Shares) whether preferential or bonus, rights, further public issue or qualified institutions placement or otherwise., except that if our Company may further issue Equity Shares (including issue of securities convertible into Equity Shares) whether preferential or otherwise after the date of the listing of equity shares to finance an acquisition, merger or joint venture or for regulatory compliance or such other scheme of arrangement or any other purpose as the Board may deem fit, if an opportunity of such nature is determined by its Board of Directors to be in the interest of our Company.

15. Shareholding of our Promoters

As on the date of this Prospectus, our Promoters hold 88.58% of the pre- Issued, subscribed and paid-up Equity Share capital of our Company.

Build-up of the shareholding of our Promoters in our Company since incorporation:

Date of Allotment / Transfer	Nature of Issue / Transaction	Nature of Consideration	No. of Equity Shares	Cumulative No. of Equity Shares	F V (₹)	Acquisition /Transfer Price (₹)	% of Pre-Issue Equity Share Capital	% of Post Issue Equity Share Capital	Pledge
1. Mr. Anil Kumar Sabarwal									
On Incorporation	Subscription to MOA	Cash	500	500	10/-	10/-	0.00%	0.00%	No
March 25, 2004	Further Allotment	Cash	49,500	50,000	10/-	10/-	0.41%	0.30%	No

Date of Allotment / Transfer	Nature of Issue / Transaction	Nature of Consideration	No. of Equity Shares	Cumulative No. of Equity Shares	F V (₹)	Acquisition /Transfer Price (₹)	% of Pre-Issue Equity Share Capital	% of Post Issue Equity Share Capital	Pledge
March 13, 2008	Further Allotment	Cash	1,10,000	1,60,000	10/-	10/-	0.92%	0.67%	No
December 31, 2011	Further Allotment	Cash	8,675	1,68,675	10/-	100/-	0.07%	0.05%	No
April 24, 2013	Transfer from Anil Sabarwal HUF	Cash	5,000	1,73,675	10/-	1/-	0.04%	0.03%	No
April 24, 2013	Transfer from Suyash Construction Private Limited	Cash	9,000	1,82,675	10/-	1/-	0.08%	0.05%	No
April 02, 2014	Transfer from Sunil Narang	Cash	40,000	2,22,675	10/-	10/-	0.34%	0.24%	No
April 02, 2014	Transfer from Sunil Narang	Cash	4,000	2,26,675	10/-	1/-	0.03%	0.02%	No
October 10, 2015	Further Allotment	Cash	16,500	2,43,175	10/-	30/-	0.14%	0.10%	No
October 31, 2015	Transfer to Late Motiya Sabarwal	Cash	(500)	2,42,675	10/-	1/-	0.00%	0.00%	No
October 31, 2015	Transfer to Late Motiya Sabarwal	Cash	(49,500)	1,93,175	10/-	1/-	-0.41%	-0.30%	No
October 31, 2015	Transfer to Late Kavita Sabarwal	Cash	(1,10,000)	83,175	10/-	1/-	-0.92%	-0.67%	No
November 23, 2015	Further Allotment	Cash	36,500	1,19,675	10/-	30/-	0.31%	0.22%	No
December 05, 2015	Further Allotment	Cash	45,000	1,64,675	10/-	30/-	0.38%	0.27%	No
January 02, 2016	Further Allotment	Cash	39,500	2,04,175	10/-	30/-	0.33%	0.24%	No
January 28, 2016	Further Allotment	Cash	45,500	2,49,675	10/-	30/-	0.38%	0.28%	No
August 19, 2016	Further Allotment	Cash	17,500	2,67,175	10/-	40/-	0.15%	0.11%	No
September 28, 2016	Further Allotment	Cash	50,000	3,17,175	10/-	40/-	0.42%	0.31%	No
August 14, 2021	Transfer from Late Motiya Sabarwal	Transmission	500	3,17,675	10/-	Nil	0.00%	0.00%	No
August 14, 2021	Transfer from Late Kavita Sabarwal	Transmission	500	3,18,175	10/-	Nil	0.00%	0.00%	No
August 14, 2021	Transfer from Late	Transmission	9,000	3,27,175	10/-	Nil	0.08%	0.05%	No

Date of Allotment / Transfer	Nature of Issue / Transaction	Nature of Consideration	No. of Equity Shares	Cumulative No. of Equity Shares	F V (₹)	Acquisition /Transfer Price (₹)	% of Pre-Issue Equity Share Capital	% of Post Issue Equity Share Capital	Pledge
	Motiya Sabarwal								
August 14, 2021	Transfer from Late Motiya Sabarwal	Transmission	49,500	3,76,675	10/-	Nil	0.41%	0.30%	No
August 14, 2021	Transfer from Late Kavita Sabarwal	Transmission	39,500	4,16,175	10/-	Nil	0.33%	0.24%	No
August 14, 2021	Transfer from Late Motiya Sabarwal	Transmission	31,000	4,47,175	10/-	Nil	0.26%	0.19%	No
August 14, 2021	Transfer from Late Kavita Sabarwal	Transmission	1,10,000	5,57,175	10/-	Nil	0.92%	0.67%	No
August 14, 2021	Transfer from Late Kavita Sabarwal	Transmission	1,10,000	6,67,175	10/-	Nil	0.92%	0.67%	No
August 14, 2021	Transfer from Late Motiya Sabarwal	Transmission	80,000	7,47,175	10/-	Nil	0.67%	0.49%	No
August 14, 2021	Transfer from Late Kavita Sabarwal	Transmission	3,750	7,50,925	10/-	Nil	0.03%	0.02%	No
August 14, 2021	Transfer from Late Kavita Sabarwal	Transmission	70,000	8,20,925	10/-	Nil	0.59%	0.43%	No
August 14, 2021	Transfer from Late Kavita Sabarwal	Transmission	40,000	8,60,925	10/-	Nil	0.34%	0.24%	No
August 14, 2021	Transfer from Late Kavita Sabarwal	Transmission	62,500	9,23,425	10/-	Nil	0.52%	0.38%	No
August 14, 2021	Transfer from Late Kavita Sabarwal	Transmission	4,000	9,27,425	10/-	Nil	0.03%	0.02%	No
December 09, 2022	Transfer from Ghanshyam Gupta	Cash	70,000	9,97,425	10/-	10/-	0.59%	0.43%	No
December 09, 2022	Transfer from Ghanshyam Gupta	Cash	19,300	10,16,725	10/-	10/-	0.16%	0.12%	No

Date of Allotment / Transfer	Nature of Issue / Transaction	Nature of Consideration	No. of Equity Shares	Cumulative No. of Equity Shares	FV (₹)	Acquisition / Transfer Price (₹)	% of Pre-Issue Equity Share Capital	% of Post Issue Equity Share Capital	Pledge
September 30, 2023	Bonus Issue	Other than cash	91,50,525	1,01,67,250	10/-	Nil	76.65%	55.84%	No
Total				1,01,67,250			85.17%	62.04%	

Date of Allotment / Transfer	Nature of Issue / Transaction	Nature of Consideration	No. of Equity Shares	Cumulative No. of Equity Shares	FV (₹)	Acquisition / Transfer Price (₹)	% of Pre-Issue Equity Share Capital	% of Post Issue Equity Share Capital	Pledge
Ms. Tejaswini Sabarwal									
December 09, 2022	Transfer from Ghanshyam Gupta	Cash	40,000	40,000	10/-	10/-	0.34%	0.24%	No
December 09, 2022	Transfer from Ghanshyam Gupta	Cash	700	40,700	10/-	10/-	0.01%	0.00%	No
September 30, 2023	Bonus Issue	Other than cash	3,66,300	4,07,000	10/-	Nil	3.07%	2.24%	No
Total	4,07,000						3.41%	2.48%	

All the Equity Shares held by our Promoters were fully paid-up on the respective dates of acquisition of such Equity Shares. Further, our Promoters have not pledged any of the Equity Shares that they hold in our Company.

16. Pre-Issue and Post-Issue Shareholding of our Promoters and Promoter Group.

Category of Promoter	Pre-Issue		Post-Issue	
	No. of Shares	% of Pre-Issue Capital	No. of Shares	% of Post-Issue Capital
Promoters				
Mr. Anil Kumar Sabarwal	1,01,67,250	85.17%	1,01,67,250	62.04%
Ms. Tejaswini Sabarwal	4,07,000	3.41%	4,07,000	2.48%
Promoter Group				
Mr. Vinayak Sabarwal	2,12,650	1.78%	2,12,650	1.30%
Total	1,07,86,900	90.36%	1,07,86,900	65.82%

17. None of our Directors or Key Managerial Personnel or senior management hold any Equity Shares other than as set out below:

Name	Designation	No. of Equity Shares held	% of pre-Issue paid up capital	% of post Issue paid up capital
Mr. Anil Kumar Sabarwal	Chairman & Managing Director	1,01,67,250	85.17%	62.04%
Ms. Tejaswini Sabarwal	Whole Time Director	4,07,000	3.41%	2.48%

18. Except as mentioned below, there were no equity shares purchased/sold by the Promoter(s) and Promoter Group, Directors of our Company and their relatives and partners of our body corporate promoter during last six months from the date of this Prospectus.

Sr. No	Name of Shareholder	Date of Transaction	Promoter/ Promoter Group/ Director	Number of Equity Shares Subscribed to/ Acquired	Number of Equity Shares Sold	Subscribed/ Acquired/ Transferred
1.	Mr. Anil Kumar Sabarwal	December 09, 2022	Promoter, Chairman & Managing Director	70,000	-	Transfer from Ghanshyam Gupta
				19,300	-	Transfer from Ghanshyam Gupta
2.	Ms. Tejaswini Sabarwal	December 09, 2022	Promoter, Whole Time Director	40,000	-	Transfer from Ghanshyam Gupta
				700	-	Transfer from Ghanshyam Gupta
3.	Mr. Anil Kumar Sabarwal	September 30, 2023	Promoter, Chairman & Managing Director	91,50,525	-	Bonus Issue
4.	Ms. Tejaswini Sabarwal	September 30, 2023	Promoter, Whole Time Director	3,66,300	-	Bonus Issue
5.	Mr. Vinayak Sabarwal	January 01, 2024	Promoter Group	2,12,650	-	Transfer from Ashok Anand

19. None of our Promoters, Promoter Group, Directors and their relatives has entered into any financing arrangement or financed the purchase of the Equity Shares of our Company by any other person during the period of six months immediately preceding the date of filing of the Prospectus.

20. Promoters' Contribution and Lock-in details

Details of Promoter's Contribution locked-in for three (3) years

Pursuant to the Regulation 236 and 238 of SEBI ICDR Regulations, an aggregate of at least 20% of the post Issue Equity Share capital of our Company held by our Promoter shall be locked-in for a period of three years from the date of Allotment in this Issue. As on date of this Prospectus, our Promoters holds 1,05,74,250 Equity Shares constituting 64.53% of the Post Issued, Subscribed and Paid-up Equity Share Capital of our Company, which are eligible for Promoter's Contribution.

Our Promoters have granted consent to include such number of Equity Shares held by them as may constitute of the post issue Equity Share capital of our Company as Promoters' Contribution and have agreed not to sell or transfer or pledge or otherwise dispose of in any manner, the Promoters' Contribution from the date of filing of this Prospectus until the commencement of the lock-in period specified below.

Details of the Equity Shares forming part of Promoters' Contribution and their lock-in details are as follows:

Name of Promoter	Date of Allotment/Acquisition & when made fully paid up	No of Equity shares	No of Equity shares locked in	Face Value (in ₹)	Issue Price (in ₹)	Nature of Allotment	% Of Post-Issue Paid-up Capital	Lock-in Period
Mr. Anil Kumar Sabarwal	September 30, 2023	91,50,525	33,00,000	10	Nil	Bonus Issue	20.08	3 Years

The Equity Shares that are being locked-in are not, and will not be, ineligible for computation of Promoters' Contribution under Regulation 237 of the SEBI ICDR Regulations. In this computation, as per Regulation 237 of the SEBI ICDR Regulations, our Company confirms that the Equity Shares locked-in do not, and shall not, consist of:

- Equity Shares acquired three years preceding the date of this Prospectus for consideration other than cash and out of revaluation of assets or capitalization of intangible assets or bonus shares out of revaluation reserves or reserves without accrual of cash resources or unrealized profits or against equity shares which are otherwise ineligible for computation of Promoters' Contribution.
- The Equity Shares acquired during the year preceding the date of this Prospectus, at a price lower than the price at which the Equity Shares are being Issued to the public in this Issue is not part of the minimum promoter's contribution.
- The Equity Shares held by the Promoters and issued for minimum 20% Promoter's Contribution are not subject to any pledge or any other form of encumbrances.
- Specific written consent has been obtained from the Promoters for inclusion of 33,00,000 Equity Shares for ensuring lock-in of three years to the extent of minimum 20.00% of post issue Paid-up Equity Share Capital from the date of allotment in the public Issue.
- The minimum Promoters' Contribution has been brought to the extent of not less than the specified minimum lot and from the persons defined as Promoters under the SEBI ICDR Regulations.
- We further confirm that our Promoters' Contribution of minimum 20% of the Post Issue Equity does not include any contribution from Alternative Investment Funds or FVCI or Scheduled Commercial Banks or Public Financial Institutions or Insurance Companies registered with Insurance Regulatory and Development Authority of India.

Equity Shares locked-in for one year other than Minimum Promoters' Contribution

- Pursuant to Regulation 238(b) and 239 of the SEBI ICDR Regulations, other than the Equity Shares held by our Promoters, which will be locked-in as minimum Promoters' contribution for three years, all pre-issue 86,37,600 Equity Shares shall be subject to lock-in for a period of one year from the date of Allotment in this Issue.

Lock-in of the Equity Shares to be Allotted, if any, to the Anchor Investors

- Fifty percent of the Equity Shares allotted to Anchor Investors under the Anchor Investor Portion shall be locked-in for a period of 90 days from the date of Allotment and the remaining Equity Shares allotted to Anchor Investors under the Anchor Investor Portion shall be locked-in for a period of 30 days from the date of Allotment.

Inscription or recording of non-transferability

In terms of Regulation 241 of the SEBI ICDR Regulations, our Company confirms that certificates of Equity Shares which are subject to lock in shall contain the inscription "Non-Transferable" and specify the lock - in period and in case such equity shares are dematerialized, the Company shall ensure that the lock - in is recorded by the Depository.

Pledge of Locked in Equity Shares

Pursuant to Regulation 242 of the SEBI ICDR Regulations, the locked-in Equity Shares held by our Promoters can be pledged with any scheduled commercial bank or public financial institution or systematically important non-banking finance company or a housing finance company as collateral security for loans granted by them, provided that:

- (a) if the equity shares are locked-in in terms of clause (a) of Regulation 238, the loan has been granted to the company or its subsidiary(ies) for the purpose of financing one or more of the objects of the Issue and pledge of equity shares is one of the terms of sanction of the loan;
- (b) if the specified securities are locked-in in terms of clause (b) of Regulation 238 and the pledge of specified securities is one of the terms of sanction of the loan.

Provided that such lock-in shall continue pursuant to the invocation of the pledge and such transferee shall not be eligible to transfer the equity shares till the lock-in period stipulated in these regulations has expired.

Transferability of Locked in Equity Shares

- (a) Pursuant to Regulation 243 of the SEBI ICDR Regulations, Equity Shares held by our Promoters, which are locked in as per Regulation 238 of the SEBI ICDR Regulations, may be transferred to and amongst our Promoters/ Promoter

Group or to a new promoter or persons in control of our Company subject to continuation of the lock-in in the hands of the transferees for the remaining period and compliance with SEBI SAST Regulations as applicable.

- (b) Pursuant to Regulation 243 of the SEBI ICDR Regulations, Equity Shares held by shareholders other than our Promoters, which are locked-in as per Regulation 239 of the SEBI ICDR Regulations, may be transferred to any other person holding shares, subject to continuation of the lock-in in the hands of the transferees for the remaining period and compliance with SEBI SAST Regulations as applicable.
- 21. Neither the Company, nor its Promoters, Directors or the Book Running Lead Manager have entered into any buyback and/or standby arrangements for purchase of Equity Shares of the Company from any person.
- 22. All Equity Shares issued pursuant to the Issue shall be fully paid-up at the time of Allotment and there are no partly paid-up Equity Shares as on the date of this Prospectus. Further, since the entire money in respect of the Issue is being called on application, all the successful Applicants will be issued fully paid-up Equity Shares.
- 23. As on the date of this Prospectus, the Book Running Lead Manager and their respective associates (as defined under the SEBI MB Regulations 1992) do not hold any Equity Shares of our Company. The Book Running Lead Manager and their affiliates may engage in the transactions with and perform services for our Company in the ordinary course of business or may in the future engage in commercial banking and investment banking transactions with our Company for which they may in the future receive customary compensation.
- 24. As on date of this Prospectus, there are no outstanding ESOP's, warrants, options or rights to convert debentures, loans or other instruments convertible into the Equity Shares, nor has the company ever allotted any equity shares pursuant to conversion of ESOPs till date. As and when, options are granted to our employees under the Employee Stock Option Scheme, our Company shall comply with the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.
- 25. Investors may note that in case of over-subscription, allotment will be on proportionate basis as detailed under "*Basis of Allotment*" in the chapter titled "*Issue Procedure*" beginning on page 259 of this Prospectus. In case of over-subscription in all categories the allocation in the Issue shall be as per the requirements of Regulation 253 (2) of SEBI ICDR Regulations, as amended from time to time.
- 26. An over-subscription to the extent of 10% of the Net Issue can be retained for the purpose of rounding off to the nearest integer during finalizing the allotment, subject to minimum allotment, which is the minimum application size in this Issue. Consequently, the actual allotment may go up by a maximum of 10% of the Net Issue, as a result of which, the post issue paid up capital after the Issue would also increase by the excess amount of allotment so made. In such an event, the Equity Shares held by the Promoters and subject to lock-in shall be suitably increased; so as to ensure that 20% of the post Issue paid-up capital is locked in.
- 27. Subject to valid applications being received at or above the Issue Price, under subscription, if any, in any of the categories, would be allowed to be met with spill-over from any of the other categories or a combination of categories at the discretion of our Company in consultation with the Book Running Lead Manager and Designated Stock Exchange. Such inter-se spill over, if any, would be affected in accordance with applicable laws, rules, regulations and guidelines.
- 28. We have 23 (Twenty-Three) Shareholders as on the date of filing of the Prospectus.
- 29. The Equity Shares of our company are in dematerialization form.
- 30. There shall be only one denomination of Equity Shares of our Company unless otherwise permitted by law. Our Company shall comply with disclosure and accounting norms as may be specified by SEBI from time to time.
- 31. No payment, direct, indirect in the nature of discount, commission, and allowance, or otherwise shall be made either by us or by our Promoters to the persons who receive allotments, if any, in this issue.
- 32. Our Company shall ensure that transactions in the Equity Shares by our Promoters and our Promoter Group between the date of this Prospectus and the Issue Closing Date shall be reported to the Stock Exchange within 24 hours of such transaction.
- 33. Our Promoters and Promoter Group will not participate in the Issue.

SECTION V – PARTICULARS OF THE ISSUE

OBJECTS OF THE ISSUE

REQUIREMENT OF FUNDS

The Issue comprises of fresh issue of 44,49,600 Equity Shares by our Company aggregating to ₹ 4,316.11 Lakhs.

Our Company proposes to utilize the Net Proceeds from the Issue towards funding the following objects:

1. Funding of capital expenditure towards purchase of plant and machineries for expansion at the existing manufacturing facility;
2. Funding working capital requirements of our company;
3. General corporate purposes;

(Collectively, referred to herein as the “*Objects of the Issue*”)

The main objects and objects incidental and ancillary to the main objects, as set out in our Memorandum of Association, enable our Company to undertake our existing business activities and the activities for which funds are being raised by us through the Issue. In addition, our Company expects to receive the benefits of listing of Equity Shares on the NSE Emerge including enhancing our visibility and our brand image among our existing and potential customers and creating a public market for our Equity Shares in India.

ISSUE PROCEEDS

The details of the proceeds of the Issue are set forth in the table below:

Particulars	Amount
Gross Proceeds of the Issue	4,316.11
Less: Issue related Expenses	378.12
Net Proceeds of the Issue	3,937.99

UTILISATION OF NET PROCEEDS

The Net Proceeds are proposed to be utilised in the manner set out in the following table:

(₹ in Lakhs)

Sr. No	Particulars	Estimated Amount*	% of Gross Proceeds	% of Net Proceeds
1.	Funding of capital expenditure towards purchase of plant and machineries for expansion at the existing manufacturing facility	2,600.00	60.24	66.02
2.	Funding Working Capital Requirements of our Company	1,000.00	23.17	25.39
3.	General corporate purposes [#]	337.99	7.83	8.58
	Total	3,937.99	91.24	100.00

[#]The amount utilized for general corporate purpose shall not exceed 25% of the gross proceeds of the Issue.

PROPOSED SCHEDULE OF IMPLEMENTATION AND DEPLOYMENT OF THE NET PROCEEDS

The Net Proceeds of the Issue (“**Net Proceeds**”) are currently expected to be deployed in accordance with the schedule as stated below:

(₹ in lakhs)

Sr. No	Object	Amount proposed to be financed from Net Proceeds	Estimated Utilization of Net Proceeds in F. Y. 2024-2025
1.	Funding of capital expenditure towards purchase of plant and machineries for expansion at the existing manufacturing facility	2,600.00	2,600.00
2.	Funding Working Capital Requirements of our Company	1,000.00	1,000.00
3.	General corporate purposes [#]	337.99	337.99

Sr. No	Object	Amount proposed to be financed from Net Proceeds	Estimated Utilization of Net Proceeds in F. Y. 2024-2025
	Total	3,937.99	3,937.99

#The amount utilized for general corporate purpose shall not exceed 25% of the gross proceeds of the issue

The fund requirements, the deployment of funds and the intended use of the Net Proceeds as described herein are based on our current business plan and circumstances, management estimates, prevailing market conditions and other external commercial and technical factors including interest rates, exchange rate fluctuations and other charges, which are subject to change from time to time. However, such fund requirements and deployment of funds have not been verified or appraised by any bank, financial institution, or any other external agency or party. We may have to revise our funding requirements and deployment schedule on account of a variety of factors such as our financial and market condition, business and strategy, competition, contractual terms and conditions and negotiation with lenders, variation in cost estimates and other external factors such as changes in the business environment and interest or exchange rate fluctuations, which may not be within the control of our management. This may entail rescheduling or revising the planned expenditure and funding requirements, including the expenditure for a particular purpose at the discretion of our management, subject to compliance with applicable laws. For details in relation to the discretion available to our management in respect of use of the Net Proceeds. For further details on the risks involved in our proposed fund utilization as well as executing our business strategies, please refer the section titled “*Risk Factors*” on page 30 of this Prospectus.

Our Company proposes to deploy the entire Net Proceeds towards the aforementioned Objects during Fiscal 2024-25. In the event that the estimated utilization of the Net Proceeds in scheduled fiscal years is not completely met, due to the reasons stated above, the same shall be utilized in the next fiscal year, as may be determined by the Board, in accordance with applicable laws. If the actual utilization towards any of the Objects is lower than the proposed deployment, such balance will be used towards general corporate purposes, to the extent that the total amount to be utilized towards general corporate purposes is within the permissible limits in accordance with the SEBI ICDR Regulations. Further, in case of variations in the actual utilization of funds earmarked for the purposes set forth above, increased fund requirements for a particular purpose may be financed by surplus funds, if any, available in respect of the other purposes for which funds are being raised in the Issue, subject to compliance with applicable laws.

All quotations mentioned in this section are valid as on the date of this Prospectus. However, we have not entered into any definitive agreements with any of these vendors and there can be no assurance that the same vendor would be engaged to eventually supply the plant and machineries at the same costs. We are yet to place orders for any of the components of the Proposed Objects. The Proposed Objects may be subject to the risk of unanticipated delays in implementation, cost overruns and other risks and uncertainties. Further, the Objects of the Issue includes orders for purchase of plant and machineries which have not yet been placed. There can be no assurance that we would be able to procure plant and machineries at the estimated costs. If we engage someone other than the vendors from whom we have obtained quotations or if the quotations obtained expire, such vendor’s estimates and actual costs for the services may differ from the current estimates. Some of the quotations mentioned above do not include cost of freight, insurance, goods and services tax (wherever applicable) and other applicable taxes as these can be determined only at the time of placing of orders. Such additional costs shall be funded from the Net Proceeds allocated towards general corporate purposes or through contingencies, if required. In case of increase in the estimated costs, such additional costs shall be incurred from our internal accruals.

MEANS OF FINANCE

The fund requirements set out for the aforesaid Objects are proposed to be met entirely from the Net Proceeds, internal accruals, net worth and existing debt financing. Accordingly, we confirm that there is no requirement for us to make firm arrangements of finance through verifiable means towards at least 75% of the stated means of finance, excluding the amount to be raised through the Net Proceeds and existing identifiable internal accruals.

DETAILS OF THE OBJECTS OF THE ISSUE

1. Funding of capital expenditure towards purchase of plant and machineries for expansion at the existing manufacturing facility

Our company intends to expand and upgrade our manufacturing capacities for existing formulations and new formulations currently in development and commercialization stages. As the company plans to enter the injectable section, particularly in the oncology field, we require new plants and machinery for manufacturing injectable sections comprising liquid vials and ampoules, as well as dry injections, particularly in the field of oncology. Regarding the current installed and utilized capacity of our manufacturing facility, we understand that it relates to those products currently being manufactured by our company. With the infusion of funds from the Objects of the Issue, we intend to enter the injectable section comprising

liquid vials and ampoules, as well as dry injections, particularly in the field of oncology. This move will pave our way to diversify our product portfolio and enter into new product lines.

Relating to government approval, we understand that our company already possesses the relevant government approval. We hold a Drugs Manufacturing License, License Form 28, with License No. 28/08/98 issued on November 13, 1998, by the Food & Drugs Control Administration, Madhya Pradesh. This license is required for the manufacturing of new products. For further details, kindly refer to the chapter titled, “Government and Statutory Approvals” on page 230 of this Prospectus.

Our Board in its meeting dated February 29, 2024 took note that an amount of ₹ 2,600.00 Lakhs is proposed to be utilised for purchase of machineries from the Net Proceeds. Our Company has received quotations from various suppliers for such machineries and is yet to place any orders or enter into definitive agreements for purchase of such machineries. Our Company intends to utilise ₹ 2,600.00 Lakhs from the Net Proceeds to purchase these machineries. The break-down of such estimated costs are set forth below:

(₹ in lakhs)

Description	Quantity	Amount *	Supplier	Date of Quotation	Validity	Installation Location
Vial Liquid Line - 300 <u>Machinery inclusive of</u> • Vertical Rotary Washing Machine • Sterilizing and Dehydrogenating Tunnel • Vial Filling & Stoppering Machine • Vial Cap Sealing Machine • SCADA (21 CFR Part 11 Compliant)	1	335.00	Snowbell Machines Private Limited	February 27, 2024	180 days from the date of quotation	Manufacturing Unit
Vial Liquid Line - 100 <u>Machinery inclusive of</u> • Vertical Rotary Washing Machine • Sterilizing and Dehydrogenating Tunnel • Vial Filling & Stoppering Machine • Vial Cap Sealing Machine • Isolator for Filling & Stoppering Machine • Isolator for Capping Machine • Air Handling Unit and Ducting for Isolator • VHP System Integration	1	1,635.00	Snowbell Machines Private Limited	February 27, 2024	180 days from the date of quotation	Manufacturing Unit

Description	Quantity	Amount *	Supplier	Date of Quotation	Validity	Installation Location
• SCADA (21 CFR Part 11 Compliant)						
Combi Ampoule Vial Powder – 400 / 240 <u>Machinery inclusive of</u> • Combi Vertical Rotary Ampoule Vial Washing Machine • Combi Sterilizing and Depyrogenating Tunnel - Ampoule Filling & Sealing Machine • Vial Powder Filling & Stoppering Machine • Vial Cap Sealing Machine • SCADA (21 CFR Part 11 Compliant)	1	630.00	Snowbell Machines Private Limited	February 27, 2024	180 days from the date of quotation	Manufacturing Unit
Total		2,600.00				

*Excluding GST. GST payable on such machineries will be paid from our internal accruals. Certain quotations are subject to additional costs including freight, installation and commissioning costs, transportation costs, packaging and forwarding costs, insurance, customs, duties and other government levies, as applicable shall be paid out of Internal Accruals.

2. **Funding working capital requirements**

Our business is working capital intensive. We fund the majority of our working capital requirements in the ordinary course of our business from our internal accruals and financing from banks. As on December 31, 2023, the aggregate amount sanctioned by the banks to our Company under the fund-based cash credit facilities amounted to ₹ 470.00 Lakhs. For details of facilities availed by us, see chapter titled “Financial Indebtedness” beginning on page 199 of this Prospectus. We propose to utilise ₹ 1,000.00 Lakhs from the Net Proceeds to fund the working capital requirements of our Company in Fiscal Year 2025.

Existing Working Capital requirements:

Considering our Company’s current Order Book as on May 02, 2024 of Rs. 2109.84 Lakhs and on the basis of our existing working capital requirements, our Board pursuant to its resolution dated February 29, 2024 has approved the estimated and projected working capital requirements for Fiscal 2024 and Fiscal 2025 as set forth below:

(₹ in Lakhs)

Sr. No.	Particulars	Actual	Actual	Actual	Actual
		December 31, 2023	Fiscal 2023	Fiscal 2022	Fiscal 2021
I	Current Assets				
	Inventories	1,157.33	1,115.72	108.72	82.80
	Trade Receivables	2,966.52	1,993.80	2,206.19	915.47
	Short Term Loans and Advances	134.84	241.35	206.97	152.28
	Other Current Assets	5.32	5.31	5.25	15.80
	Total (A)	4264.01	3,356.18	2,527.13	1,166.35
II	Current Liabilities				
	Trade payables	2294.66	2,460.24	1,704.71	796.67
	Other Current Liabilities	79.51	73.14	277.82	103.50
	Short term provisions	327.37	151.02	132.86	6.46

Sr. No.	Particulars	Actual	Actual	Actual	Actual
		December 31, 2023	Fiscal 2023	Fiscal 2022	Fiscal 2021
	Total (B)	2,701.54	2,684.40	2,115.39	906.63
III	Total Working Capital Gap (A-B)	1562.47	671.78	411.74	259.72
IV	Funding Pattern:				
	Short Term Borrowings	311.90	197.00	179.06	188.61
	Internal Accruals	1250.57	474.78	232.68	71.11

Basis of estimation of long-term working capital requirement:

On the basis of our existing working capital requirements, our Board pursuant to its resolution dated February 29, 2024 has approved the estimated and projected working capital requirements for Fiscal 2024 and Fiscal 2025 as set forth below*:

(₹ in Lakhs)

Sr. No.	Particulars	Provisional	Projected
		Fiscal 2023 -2024	Fiscal 2024 -2025
I	Current Assets		
	Inventories	2227.57	3100.39
	Trade Receivables	3723.87	5029.02
	Short Term Loans and Advances	256.85	339.20
	Other Current Assets	29.86	65.59
	Total (A)	6238.15	8534.20
II	Current Liabilities		
	Trade payables	2955.32	3283.61
	Other Current Liabilities	80.45	88.50
	Short Term Provisions	486.25	646.51
	Total (B)	3522.02	4018.62
III	Total Working Capital Gap (A-B)	2716.13	4515.58
IV	Funding Pattern		
	Internal Accruals & Short Borrowings	2716.13	3515.58
	IPO Proceeds	-----	1,000.00

*The projected working capital details as at March 31, 2024 and March 31, 2025 has been certified by our statutory auditor, M/s /s Shyam S. Gupta & Associates, Chartered Accountants pursuant to their certificate dated April 26, 2024.

Assumptions for working capital projections made by our Company:

We intend to expand and upgrade our manufacturing capacities for existing formulations and new formulations currently in development and commercialization stages. Our plan involves increasing production capacity by installing new plants and machinery at our existing manufacturing facility. We firmly believe that investing in these plants and machinery will augment our current installed capacity, enabling us to address demand in the pharmaceutical injectable sector, particularly in oncology. Our objective is to establish an injectable section comprising liquid vials and ampoules, as well as dry injections, including a lyophilizer line, to ensure efficient production processes.

We aim to expand and diversify our product portfolio by increasing its base and introducing new ranges of product lines. This expansion will allow us to capture future growth trends. We also intend to explore opportunities to expand our operations by developing new products and services within our existing lines of business. This will help us expand our customer base and increase revenue from operations.

Maintaining adequate working capital is crucial to ensuring that we can adequately stock raw materials and finished goods. It might be beneficial to analyze cash flow projections and explore options such as optimizing inventory management, negotiating favorable terms with suppliers, or securing additional financing if necessary. Expanding into new section necessitates a larger investment in inventory, as the products are typically priced higher and require quality control. The working capital increase is crucial to ensure we can adequately stock raw materials and packing material.

The table below sets forth the details of holding levels (in days) for Fiscal 2021, Fiscal 2022, Fiscal 2023 and for the period ended December 31, 2023 as well as projections for Fiscal 2024 and Fiscal 2025:

Particulars	Actual	Actual	Actual	Actual	Estimated	Projected
	FY 2020-21	FY 2021-22	FY 2022-23	Period ended 31.12.2023	FY 2023-24	FY 2024-25
Debtor Holding Days	99	96	124	131	127	159
Creditor Holding Days	131	103	182	158	188	175
Inventory Holding Days	38	8	53	80	116	149

The assumptions for working capital projections as at March 31, 2021, 2022, 2023, December 31, 2023 and March, 2024 has been certified by our statutory auditor, M/s /s Shyam S. Gupta & Associates, Chartered Accountants pursuant to their certificate dated April 26, 2024.

Justification:

Sr. No.	Particulars
Inventory:	Inventory includes raw materials, finished goods, and packing materials. The company had inventory days of around 53 days in Fiscal 2023 and is expecting them to increase to 116 days and 149 days in Fiscal 2024 and Fiscal 2025, respectively. This increase is primarily expected due to the company's plan to expand its operations by establishing a new oncology section. Thus, the company will require stocking raw materials to meet production demands and to receive cash/trade discounts and favorable pricing on its bulk purchases, resulting in increased inventory. Secondly, to penetrate new products of the oncology section into the market, we will need to keep stocks of finished goods and packing materials ready to make finished goods available at the appropriate time and place to capture the market.
Trade Receivable Days	Trade receivables days have shown a consistent increase over the years. In fiscal 2023, they amounted to 124 days, with projections indicating an increase to 127 days in fiscal 2024 and a further rise to 159 days in fiscal 2025. These figures suggest a trend of delayed payments from customers, which could potentially impact the company's liquidity and cash flow management. Revenue sources reveal a heavy reliance on income generated from government departments, constituting a significant portion of the company's overall revenue from operations. This concentration in government revenue poses a risk due to the considerable delays experienced in receiving payments. For instance, revenue from government departments accounted for approximately 66.64% of total revenue for the period ending December 31, 2023. Similar trends were observed for the financial years ending March 31, 2023, 2022, and 2021, where government revenue made up 61.93%, 51.11%, and 18.05% of total revenue, respectively. Despite the reliance on government revenue, the company is considering expansion plans, particularly through the establishment of a new oncology section. This strategic move may necessitate offering extended credit periods to customers to gain market share. However, such a strategy could potentially exacerbate the issue of delayed payments and further increase trade receivables days. In light of these considerations, it is imperative for the company to carefully manage its trade receivables and explore opportunities to diversify revenue sources. Additionally, as expansion plans unfold, the company must strike a balance between aggressive market capture strategies and prudent credit management practices to safeguard its financial stability in the face of payment delays and evolving market dynamics.
Trade Payables:	A combination of lesser credit terms and increased business volume with our suppliers will help us get better prices from them. This would enable us to offer competitive prices to our customers. With the company's expansion, there will be a need to increase purchases, resulting in a slight rise in trade payables. This increase in payables is necessary to accommodate the larger volume of purchases required to support business growth. Trade payables days in Fiscal 2023 were 182 days, and we expect to keep payables days at 188 days in fiscal 2024. The same will be reduced to 175 days in Fiscal 2025 to negotiate better rates with suppliers and to enjoy cash/trade discounts.
Short term loans and Advances	This includes mostly advances given to vendors and balances with government authorities. Since company is expanding its business and there will be need to make advance payments to enhance

Sr. No.	Particulars
	cost efficiency of products there will be increase in short term loan & advances. Secondly balance with government authorities includes GST credit receivables, excess TDS deducted etc. which tends to directly related to the increase in revenue.
Other current assets	Other current assets include relates to prepaid expenses like electricity expense, other office expense, insurance expenses etc. thus there is marginal increase in other current assets in Fiscal 2024 and Fiscal 2025.
Other current Liabilities	Other current liabilities include Salary payable as on period end, statutory dues and taxes payable like PT, PF, Bonus and salary payables, power and fuel payables audit fees etc. This figure is expected to increase due to increase in size of overall business of the company.
Short term Provisions	Short term provisions mainly include provision for taxation and gratuity expenses. These provisions are expected to increase due to increase in size of overall business of the company.

3. General Corporate Purpose

Our management will have flexibility to deploy the balance Net Proceeds of the Issue towards general corporate purposes, to be deployed towards including but not restricted to strategic initiatives, partnerships, joint ventures and acquisitions, meeting exigencies which our Company may face in the ordinary course of business, to renovate and refurbish certain of our existing Company owned/leased and operated facilities or premises, towards brand promotion activities or repayment of liabilities (on demand) if any or any other purposes as may be approved by our Board, subject to compliance with the necessary provisions of the Companies Act.

The quantum of utilization of funds towards any of the above purposes will be determined based on the amount actually available under this head and the business requirements of our Company, from time to time. This may also include rescheduling the proposed utilization of Net Proceeds. Our management, in accordance with the policies of our Board, will have flexibility in utilizing the proceeds earmarked for general corporate purposes. In the event that we are unable to utilize the entire amount that we have currently estimated for use out of Net Proceeds in a Fiscal, we will utilize such unutilized amount in the subsequent Fiscals.

We further confirm that in terms of the SEBI ICDR Regulations, the extent of the Net Proceeds proposed to be utilized for general corporate purposes shall not exceed 25.00% of the gross proceeds of the issue

ESTIMATED ISSUE RELATED EXPENSES

The details of the estimated issue related expenses are tabulated below:

(₹ in Lakhs)

Particulars	Amount	As a % of Estimates Issue Expenses	As a % of Issue Size
Book Running Lead Manager Fees including underwriting commission	225.00	59.50%	5.21%
Brokerage, selling, commission and upload fees	0.60	0.16%	0.01%
Registrar to the Issue	2.00	0.53%	0.05%
Legal Advisors	2.00	0.53%	0.05%
Advertising and Marketing expenses	3.00	0.79%	0.07%
Regulators including stock exchanges	3.75	0.99%	0.09%
Printing and distribution of offer stationery	1.00	0.26%	0.02%
Others, if any (market making, depositories, marketing fees, consultancy, secretarial, peer review etc.)	140.77	37.23%	3.26%
Total	378.12	100.00%	8.76%

The fund deployed out of internal accruals up to is ₹ 9.10 Lakhs towards issue expenses vide certificate dated April 26, 2024 having UDIN: 24075255BKAVHX6603 received from M/s Shyam S. Gupta & Associates, Chartered Accountants and the same will be recouped out of issue expenses.

Structure for commission and brokerage payment to the SCSBs Syndicate, RTAs, CDPs and SCSBs:

- 1) *SCSBs will be entitled to a processing fee of ₹10/- per Application Form for processing of the Application Forms only for the Successful Allotments procured by other Application Collecting Intermediary and submitted to them.*
- 2) *Selling commission payable to Registered broker, SCSBs, RTAs, CDPs on the portion directly procured from Retail Individual Investors and Non-Institutional Investors, would be 0.01% on the Allotment Amount.*
- 3) *No additional uploading/processing charges shall be payable to the SCSBs on the applications directly procured by them.*
- 4) *The commission and processing fees shall be released only after the SCSBs provide a written confirmation to the Book Running Lead Manager not later than 30 days from the finalization of Basis of Allotment by Registrar to the Issue in compliance with SEBI Circular no. SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021 read with SEBI Circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021 and SEBI Circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/51 dated April 20, 2022.*
- 5) *Amount Allotted is the product of the number of Equity Shares Allotted and the Issue Price.*

BRIDGE LOANS

Our Company has not raised any bridge loans from any bank or financial institution as on the date of this Prospectus, which are proposed to be repaid from the Net Proceeds of the Issue.

MONITORING OF UTILIZATION OF FUNDS

As this is a Fresh Issue for less than ₹10,000 lakhs, we are not required to appoint a monitoring agency for the purpose of the Issue in terms of the SEBI ICDR Regulations.

Our Board and Audit committee shall monitor the utilization of the net proceeds of the Issue. Our Company will disclose the utilization of the Net Proceeds under a separate head in our balance sheet along with the relevant details, for all such amounts that have not been utilized. Our Company will indicate investments, if any, of unutilized Net Proceeds in the balance sheet of our Company for the relevant financial years subsequent to the completion of the Issue.

Pursuant to SEBI LODR Regulations, our Company shall disclose to the Audit Committee of the Board of Directors the uses and applications of the Net Proceeds. Our Company shall prepare a statement of funds utilized for purposes other than those stated in this Prospectus and place it before the Audit Committee of the Board of Directors, as required under applicable law. Such disclosure shall be made only until such time that all the Net Proceeds have been utilized in full. The statement shall be certified by the statutory auditor of our Company. Furthermore, in accordance with the Regulation 32 of the SEBI LODR Regulations, our Company shall furnish to the Stock Exchange on a half yearly basis, a statement indicating (i) deviations, if any, in the utilization of the proceeds of the Issue from the Objects; and (ii) details of category wise variations in the utilization of the proceeds from the Issue from the Objects. This information will also be published in newspapers simultaneously with the interim or annual financial results, after placing the same before the Audit Committee of the Board of Directors.

INTERIM USE OF FUNDS

Pending utilization of the Net Proceeds for the purposes described above, our Company will deposit the Net Proceeds only with scheduled commercial banks included in the Second Schedule of the Reserve Bank of India Act, 1934, as amended, as may be approved by our Board. In accordance with Section 27 of the Companies Act, 2013, our company confirms that it shall not use the Net Proceeds for buying, trading or otherwise dealing in shares of any other listed company or for any investment in the equity markets or investing in any real estate product or real estate linked products.

VARIATION IN OBJECTS

In accordance with Sections 13(8) and 27 of the Companies Act and applicable rules, our Company shall not vary the Objects without our Company being authorized to do so by the Shareholders by way of a special resolution through a postal ballot. In addition, the notice offered to the Shareholders in relation to the passing of such special resolution (the "Postal Ballot Notice") shall specify the prescribed details as required under the Companies Act and applicable rules. The Postal Ballot Notice shall simultaneously be published in the newspapers, one in English and one in the vernacular language of the jurisdiction where our Registered Office is situated. Our Promoters or controlling Shareholders will be required to provide an exit opportunity to such shareholders who do not agree to the above stated proposal, at a price as may be prescribed by SEBI, in this regard.

OTHER CONFIRMATIONS / PAYMENT TO PROMOTERS AND PROMOTER'S GROUP FROM THE IPO PROCEEDS

There is no proposal whereby any portion of the Net Proceeds will be paid to Our Promoters, Promoter Group, Directors and Key Managerial Personnel, Group Companies, except in the ordinary course of business. Further, there are no existing or anticipated transactions in relation to the utilisation of the Net Proceeds entered into or to be entered into by our Company with Our Promoters, Promoter Group, Directors Group Companies, and/or Key Managerial Personnel.

BASIS FOR ISSUE PRICE

The Price Band and Issue Price shall be determined by our Company in consultation with the Book Running Lead Manager on the basis of the assessment of market demand for the Equity Shares through the Book Building Process and on the basis of the qualitative and quantitative factors as described in this section. The face value of the Equity Shares is ₹10/- each and the Issue Price is 9.3 times of the face value at the lower end of the Price Band and 9.7 times of the face value at the upper end of the Price Band.

Bidders should read the following basis with the section titled “Risk Factors” and chapters titled “Restated Financial Statements”, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Our Business” beginning on page 30, 196, 201 and 128 respectively, of this Prospectus to get a more informed view before making any investment decisions.

QUALITATIVE FACTORS

Some of the qualitative factors and our strengths which form the basis for the Issue Price are:

- Multi-product capability
- Revenue from Government institutions
- Product Portfolio
- Research and Development
- Quality assurance
- Experienced Promoter and management team
- Supply Chain Efficiency

For further details regarding some of the qualitative factors, which form the basis for computing the Issue Price, please see chapter titled “Our Business” beginning on page 128 of this Prospectus.

QUANTITATIVE FACTORS

The information presented in this chapter is derived from company’s Restated Financial Statements for the period ended December 31, 2023 and for the financial years ended March 31 2023, 2022 and 2021 prepared in accordance with Indian GAAP. For more details on financial information, investors please refer the chapter titled “Restated Financial Statements” beginning on page 196 of this Prospectus.

Investors should evaluate our Company taking into consideration its niche business segment and other qualitative factors in addition to the quantitative factors. Some of the quantitative factors which may form the basis for computing the price are as follows:

Some of the quantitative factors which may form the basis for computing the Issue Price are as follows:

1. Basic and Diluted Earnings / (Loss) Per Share (“EPS”), as adjusted for changes in capital

As per Restated Financial Statements – Post Bonus

Particulars	Basic & Diluted EPS (in ₹)	Weights
March 31, 2023	4.66	3
March 31, 2022	3.81	2
March 31, 2021	0.61	1
Weighted Average	3.70	
For the period ended December 31, 2023 (Not annualised)	7.18	

Notes:

- (1) Weighted average = Aggregate of year-wise weighted EPS divided by the aggregate of weights i.e. (EPS x Weight) for each year/Total of weights.
- (2) Earnings per Equity Share = Profit for the period/year / Weighted average number of equity shares outstanding during the period/year.
- (3) Basic and diluted Earnings per Equity Share are computed in accordance with Accounting Standard 20.

(4) The basic and diluted Earnings per Equity Share for the current period and previous period/year presented have been calculated/restated after considering the bonus issue.

(5) The face value of each Equity Share is ₹10/-.

2. Price Earnings Ratio ("P/E") in relation to Price Band of ₹ 93 to ₹ 97 per Equity Share

Particulars	(P/E) Ratio at the Floor Price* (no. of times)	(P/E) Ratio at the Cap Price (no. of times)
Based on Restated Financial Statements		
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2022-23	19.96	20.82
P/E ratio based on the Weighted Average Basic & Diluted EPS	25.14	26.22

Note: P/E ratio has been computed dividing the price per share by Earnings per Equity Share.

3. Industry P/E Ratio

Particulars	P/E Ratio
Highest	66.43
Lowest	14.69
Industry Composite	32.35

4. Return on Net worth (RoNW)

As per Restated Financial Statements

Particulars	RONW (%)	Weights
March 31, 2023	33.47%	3
March 31, 2022	41.08%	2
March 31, 2021	11.12%	1
Weighted Average	32.28%	
For the period ended December 31, 2023 (Not annualised)	34.03%	

Note: Return on Net Worth (%) = Profit for the period/ year / Average Net Worth at the end of the period/year.

5. Net Asset Value (NAV)

As per Restated Financial Statements – Post Bonus

Financial Year	NAV (₹)
March 31, 2023	13.93
March 31, 2022	9.26
March 31, 2021	5.46
For the period from April 01, 2023 to December 31, 2023 (Not annualised)	21.11
Net Asset Value per Equity Share after the Issue at Floor Price	38.95
Net Asset Value per Equity Share after the Issue at Cap Price	40.43
Issue Price	97.00

Notes:

(1) Net Asset Value per Equity Share (in ₹) = Net Worth at the end of the period/year / Number of equity shares outstanding at the end of the period/year.

(2) Issue Price per Equity Share will be determined on conclusion of the Book Building Process.

6. Comparison of accounting ratios with listed industry peers

Name of Company	CMP (₹)	Face Value (₹)	Basic & Diluted EPS (₹)	PE Ratio (times)	RoNW (%)	NAV per Share (₹)
Quest Laboratories Limited	97.00	10	4.66	20.82	33.47%	13.93
Peer Group						
Beta Drugs Limited	1300.00	10	19.57	66.43	19.55%	100.12
Alpa Laboratories Limited	93.95	10	5.90	15.92	8.59%	68.69

Name of Company	CMP (₹)	Face Value (₹)	Basic & Diluted EPS (₹)	PE Ratio (times)	RoNW (%)	NAV per Share (₹)
Zenith Drugs Limited	63.00	10	4.29	14.69	29.88%	14.37

Source: www.bseindia.com , www.nseindia.com.

Notes:

- (1) The figures for our company are based on Restated Financial Statements for the year ended March 31, 2023 after considering the bonus issue.
- (2) The figures for the Peer Group are based on the Standalone Financial Statements filed for the financial year ended March 31, 2023. (Expect for Zenith Drugs Limited Consolidated Financial Statements are considered for period ended March 31, 2023)
- (3) P/E Ratio has been computed based on their respective closing market price on May 06, 2024 as divided by the Basic EPS as on March 31, 2023.
- (4) Price Earning (P/E) Ratio in relation to the Issue Price of ₹ 97/- per share.

The face value of our share is ₹10/- per share and the Issue Price is of ₹ 97/- per share are 9.7 times of the face value.

Investor should read the above-mentioned information along with the section titled “Risk Factors” beginning on page 30 of this Prospectus and the financials of our Company including important profitability and return ratios, as set out in the chapter titled “Restated Financial Statements” beginning on 196 of this Prospectus

7. Key Performance Indicators (“KPIs”)

The KPIs disclosed below have been used historically by our Company to understand and analyse the business performance, which in result, help us in analysing the growth of various verticals in comparison to our peers. The KPIs disclosed below have been approved by a resolution of our Audit Committee dated April 17, 2024 and the members of the Audit Committee have verified the details of all KPIs pertaining to our Company. Further, the members of the Audit Committee have confirmed that there are no KPIs pertaining to our Company that have been disclosed to any investors at any point of time during the three years period prior to the date of filing of this Prospectus. Further, the KPIs herein have been certified by our Peer review Auditors, M/s. Shyam S Gupta & Associates, Chartered Accountants by their certificate dated April 17, 2024.

The KPIs of our Company have been disclosed in the chapters titled “Our Business” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Key Performance Indicators” on pages 128 and 201 of this Prospectus, respectively. We have described and defined the KPIs, as applicable, in “Definitions and Abbreviations” on page 1 of this Prospectus.

Our Company confirms that it shall continue to disclose all the KPIs included in this section on a periodic basis, at least once in a year (or any lesser period as determined by the Board of our Company), for a duration of one year after the date of listing of the Equity Shares on the Stock Exchange or till the complete utilisation of the proceeds of the Issue as per the disclosure made in the chapter titled “Objects of the Issue”, whichever is later or for such other duration as may be required under the SEBI ICDR Regulations. Further, the ongoing KPIs will continue to be certified by a member of an expert body as required under the SEBI ICDR Regulations.

a) Key Performance Indicators of our Company*

(₹ in Lakhs, otherwise mentioned)

Key Financial Performance	December 31, 2023	March 31, 2023	March 31, 2022	March 31, 2021
Revenue from Operations ⁽¹⁾	6207.98	6,164.06	5,948.39	3,036.35
EBITDA ⁽²⁾	1208.63	782.24	646.55	141.84
EBITDA Margin (%) ⁽³⁾	19.47%	12.69%	10.87%	4.67%
PAT	774.93	502.85	410.50	65.50
PAT Margin (%) ⁽⁴⁾	12.48%	8.16%	6.90%	2.16%
Return on equity (%) ⁽⁵⁾	34.03%	40.20%	51.69%	11.78%
Debt-Equity Ratio (times) ⁽⁶⁾	0.20	0.27	0.31	0.52
Current Ratio (times) ⁽⁷⁾	1.42	1.25	1.17	1.10

*As certified by M/s. Shyam S Gupta & Associates, Chartered Accountants by way of their certificate dated April 17, 2024

Notes:

- 1) Revenue from operation means revenue from sale of our products
- 2) EBITDA is calculated as Profit before tax + Depreciation + Finance Costs – Other Income

- 3) EBITDA Margin is calculated as EBITDA divided by Revenue from Operations
- 4) PAT Margin is calculated as PAT for the period/year divided by revenue from operations
- 5) Return on Equity is calculated by comparing the proportion of net income against the amount of average shareholder equity
- 6) Debt to Equity ratio is calculated as Total Debt divided by equity
- 7) Current Ratio is calculated by dividing Current Assets to Current Liabilities

b) Description on the historic use of the KPIs by our Company to analyse, track or monitor the operational and/or financial performance of our Company

In evaluating our business, we consider and use certain KPIs, as presented above, as a supplemental measure to review and assess our financial and operating performance. The presentation of these KPIs is not intended to be considered in isolation or as a substitute for the Financial Information. We use these KPIs to evaluate our performance. Some of these KPIs are not defined under applicable Accounting Standards and are not presented in accordance with applicable Accounting Standards. These KPIs have limitations as analytical tools. Further, these KPIs may differ from the similar information used by other companies and hence their comparability may be limited. Although these KPIs are not a measure of performance calculated in accordance with applicable accounting standards, our Company's management believes that it provides an additional tool for investors to use in evaluating our ongoing results, when taken collectively with financial measures prepared in accordance with applicable Accounting Standards.

Explanations for the certain financial data based on Restated Financial Statements

Key Financial Performance	Explanations
Financial KPIs	
Revenue from Operations	Revenue from Operations is used by our management to track the revenue profile of the business and in turn helps to assess the overall financial performance of our Company and volume of our business
EBITDA	EBITDA provides information regarding the operational efficiency of the business
EBITDA Margin	EBITDA Margin (%) is an indicator of the operational profitability and financial performance of our business
PAT	Profit after tax provides information regarding the overall profitability of the business
PAT Margin (%)	PAT Margin (%) is an indicator of the overall profitability and financial performance of the business
Return on equity (%)	Return on equity (ROE) is a measure of financial performance
Debt-Equity Ratio (times)	Debt / Equity Ratio is used to measure the financial leverage of the Company and provides comparison benchmark against peers
Current Ratio (times)	The current ratio is a liquidity ratio that measures our company's ability to pay short-term obligations or those due within one year

c) Comparison with Listed Industry Peers

As on March 31, 2023:

(₹ in Lakhs, otherwise mentioned)

Key Financial Performance	Quest Laboratories Limited	Beta Drugs Limited	Alpa Laboratories Limited	Zenith Drugs Limited
Revenue from Operations ⁽¹⁾	6,164.06	15,787.46	9,295.52	11,451.91
EBITDA ⁽²⁾	782.24	3,119.81	807.61	967.14
EBITDA Margin (%) ⁽³⁾	12.69%	19.76%	8.69%	8.45%
PAT	502.85	1,881.61	1,241.45	515.33
PAT Margin (%) ⁽⁴⁾	8.16%	11.92%	13.36%	4.50%
Return on Equity ⁽⁵⁾	40.20%	21.66%	8.99%	35.13%
Debt to Equity ⁽⁶⁾	0.27	0.04	0.02	1.51
Current Ratio ⁽⁷⁾	1.25	2.70	4.95	1.17

As on March 31, 2022:

(₹ in Lakhs, otherwise mentioned)

Key Financial Performance	Quest Laboratories Limited	Beta Drugs Limited	Alpa Laboratories Limited	Zenith Drugs Limited
Revenue from Operations ⁽¹⁾	5,948.39	12,484.68	11,226.64	9,165.50
EBITDA ⁽²⁾	646.55	2,518.37	1,068.65	683.12

Key Financial Performance	Quest Laboratories Limited	Beta Drugs Limited	Alpa Laboratories Limited	Zenith Drugs Limited
EBITDA Margin (%) ⁽³⁾	10.87%	20.17%	9.52%	7.45%
PAT	410.50	1,424.65	1,412.39	313.82
PAT Margin (%) ⁽⁴⁾	6.90%	11.41%	12.58%	3.42%
Return on Equity ⁽⁵⁾	51.69%	20.23%	11.34%	29.83%
Debt to Equity ⁽⁶⁾	0.31	0.07	0.04	1.56
Current Ratio ⁽⁷⁾	1.17	2.43	4.75	1.15

As on March 31, 2021:

(₹ in Lakhs, otherwise mentioned)

Key Financial Performance	Quest Laboratories Limited	Beta Drugs Limited	Alpa Laboratories Limited	Zenith Drugs Limited
Revenue from Operations ⁽¹⁾	3,036.35	7,945.64	9,755.42	7,340.17
EBITDA ⁽²⁾	141.84	1,531.00	770.84	702.82
EBITDA Margin (%) ⁽³⁾	4.67%	19.27%	7.90%	9.57%
PAT	65.50	697.78	728.60	302.92
PAT Margin (%) ⁽⁴⁾	2.16%	8.78%	7.47%	4.13%
Return on Equity ⁽⁵⁾	11.78%	11.64%	6.40%	40.73%
Debt to Equity ⁽⁶⁾	0.52	0.06	-	1.73
Current Ratio ⁽⁷⁾	1.10	2.39	3.69	1.20

Notes: -

- 1) Revenue from operation means revenue from sale of our products
- 2) EBITDA is calculated as Profit before tax + Depreciation + Finance Costs – Other Income
- 3) EBITDA Margin is calculated as EBITDA divided by Revenue from Operations
- 4) PAT Margin is calculated as PAT for the period/year divided by revenue from operations
- 5) Return on Equity is calculated by comparing the proportion of net income against the amount of average shareholder equity
- 6) Debt to Equity ratio is calculated as Total Debt divided by equity
- 7) Current Ratio is calculated by dividing Current Assets to Current Liabilities

8. Justification for Basis for Issue price

- a) The price per share of our Company based on the primary/ new issue of shares (equity / convertible securities), excluding shares issued under ESOP/ESOS and issuance of bonus shares**

Except as mentioned below, there has been no issuance of Equity Shares or convertible securities during the 18 months preceding the date of this Prospectus, excluding the shares issued under the ESOP Schemes and issuance of bonus shares, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-Issue capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of 30 days.

Date of Allotment	No. of Equity Shares allotted	Face Value (₹)	Issue Price (₹)	Nature of Consideration	Nature of Allotment	Total Consideration (₹ in lakhs)
January 01, 2024	11,50,000	10/-	30/-	Cash	Further Allotment	345.00
Weighted average cost of acquisition (WACA) Primary issuances (in ₹ per Equity Share)						30.00

*As certified by M/s. Shyam S Gupta & Associates, Chartered Accountants by way of their certificate dated February 24, 2024.

- b) The price per share of our Company based on the secondary sale / acquisition of shares (equity shares)**

Except as mentioned below, there have been no secondary sale / acquisitions of Equity Shares, where the promoters, members of the promoter group or shareholder(s) having the right to nominate director(s) in the board of directors of the Company are a party to the transaction (excluding gifts), during the 18 months preceding the date of this Prospectus, where either acquisition or sale is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre- issue share capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days.

Sr. No.	Name of Shareholder	Date of Transaction	Promoter/ Promoter Group/ Director	Number of Equity Shares Subscribed / Acquired	Number of Equity Shares Sold	Subscribed/ Acquired/ Transferred
1.	Anil Sabarwal	December 09, 2022	Promoter and Managing Director	70,000	-	Transfer from Ghanshyam Gupta
				19,300	-	Transfer from Ghanshyam Gupta
2.	Tejaswini Sabarwal	December 09, 2022	Promoter and Whole Time Director	40,000	-	Transfer from Ghanshyam Gupta
				7,00	-	Transfer from Ghanshyam Gupta
3.	Vinayak Sabarwal	January 01, 2024	Promoter Group	2,12,650	-	Transfer from Ashok Anand
Weighted average cost of acquisition (WACA) Secondary issuances (in ₹ per Equity Share)						22.41

*As certified by M/s. Shyam S Gupta & Associates, Chartered Accountants by way of their certificate dated February 24, 2024.

- c) Since there is an eligible transaction of our Company reported in (a) and (b) above in accordance with paragraph (9)(K)(4)(a) of the SEBI ICDR Regulations, the price per Equity Share of our Company based on the last five primary or secondary transactions in Equity Shares (secondary transactions where the Promoters/Promoter Group entities or Shareholders having the right to nominate director on the Board are a party to the transaction) not older than 3 years prior to the date of filing of this Prospectus has not been computed.

d) Weighted average cost of acquisition, Issue Price

Weighted average cost of acquisition of Equity Shares based on primary/ secondary transaction(s), as disclosed in paragraph above, are set out below:

Types of transactions	Weighted average cost of acquisition (₹ per Equity Share) **	Floor Price (₹ 93)	Cap Price (₹ 97)
Weighted average cost of acquisition of primary issuances as per paragraph 7(a) above	30.00	0.32	0.31
Weighted average cost of acquisition for secondary transactions as per paragraph 7(b) above	22.41	0.24	0.23

- e) **Explanation for Cap Price being 9.7 times of weighted average cost of acquisition of primary issuance price / secondary transaction price of Equity Shares (set out in 8 (d) above) along with our Company's key performance indicators and financial ratios for the Fiscals 2023, 2022 and 2021 and for the period ended December 31, 2023.**

We have approvals to manufacture more than 600 formulations. We routinely manufacture 250 to 300 types of formulations based on market demand and limited formulation lines. However, we have versatile manufacturing facility by which we can produce multiple products using a combination of processes. The flexible manufacturing infrastructure helps us change our product mix in response to changes in market demand. We have complete infrastructure of formulation development, pilot plant and validation studies and are able to develop efficient and cost-effective specialized processes at short notice.

Institutional and government business constitute a vital segment for our Company. The distribution of free drugs through initiatives by both state and central governments of India serves numerous critical objectives, encompassing equitable access to healthcare, poverty alleviation, public health initiatives, mortality and morbidity reduction, rural healthcare access, maternal and child health, chronic disease management, preventive care, response to public health emergencies, and fulfilment of international commitments. Our Company participates in government tenders, forging collaborations with major state and central government institutions. The advantages of government business include bulk quantity orders, committed volumes, and favorable purchase prices due to high-volume transactions.

A diverse and well-balanced product portfolio is another key competitive advantage for our Company. Our Company offers a comprehensive range of products, including generic drugs, branded pharmaceuticals, over-the-counter (OTC) products, and specialized medications. This diverse portfolio allows our company to cater to various market segments and respond effectively to changing market demands.

Our company maintains an efficient and well-managed supply chain. This efficiency results in reduced lead times, minimized inventory costs, and improved overall responsiveness to market changes. Such streamlined supply chain

operations provide a significant competitive advantage in the pharmaceutical industry, where timeliness and efficiency are crucial factors. By leveraging these competitive advantages, our Company continues to thrive in competitive pharmaceutical market, delivering high-quality products, satisfying customer needs, and driving its long-term success. In the pharmaceutical industry, where precision, timeliness, and compliance are critical, an optimized supply chain can indeed provide a substantial competitive advantage.

f) The Issue Price is 9.7 times of the face value of the equity shares

The face value of our share is ₹10/- per share and the Issue Price is of ₹ 97/- per share are 9.7 times of the face value. Our Company in consultation with the Book Running Lead Manager believes that the Issue Price of ₹ 97/- per share for the Public Issue is justified in view of the above quantitative and qualitative parameters. Investor should read the above-mentioned information along with the section titled “*Risk Factors*” beginning on page 30 of this Prospectus and the financials of our Company including important profitability and return ratios, as set out in the chapter titled “*Restated Financial Statements*” beginning on page 196 of this Prospectus.

STATEMENT OF POSSIBLE TAX BENEFITS

To,
The Board of Directors
Quest Laboratories Limited
(Formerly known as Quest Laboratories Private Limited)
Plot No. 45, Sector III, Pithampur, Dhar,
Madhya Pradesh- 454775

Dear Sir/Ma'am,

Subject - Statement of possible tax benefits ("the statement") available to Quest Laboratories Limited (Formerly known as Quest Laboratories Private Limited) (hereinafter referred as "the Company") and its shareholder prepared in accordance with the requirement in Point No. 9 (L) of Part A of Schedule VI to the Securities Exchange Board of India (Issue of Capital Disclosure Requirements) Regulations, 2018.

Reference - Initial Public Offer of Equity Shares by Quest Laboratories Limited (Formerly known as Quest Laboratories Private Limited).

We hereby confirm that the attached Annexure 1 and 2 (together "the Annexures"), prepared by the Quest Laboratories Limited (Formerly known as Quest Laboratories Private Limited) ('the Company'), provides the possible tax benefits available to the Company and to the shareholders of the Company under the Income-tax Act, 1961 ('the Act') as amended by the Finance Act 2023, Circulars and Notifications issued thereunder from time to time, as applicable for the Financial Year 2023-24 relevant to the Assessment Year 2024-25, the Central Goods and Services Tax Act, 2017/ the Integrated Goods and Services Tax Act, 2017 ("GST Act"), as amended by the Finance Act 2023, Circulars and Notifications issued from time to time, as applicable for the Financial Year 2023-24, presently in force in India (together, the "Tax Laws").

Several of these benefits are dependent on the Company or its shareholders fulfilling the conditions prescribed under the relevant provisions of the Tax Laws. Hence, the ability of the Company and/ or its shareholders to derive the tax benefits is dependent upon their fulfilling such conditions which, based on business imperatives the Company faces in the future, the Company or its shareholders may or may not choose to fulfil.

1. The benefits discussed in the attached Annexures are not exhaustive and the preparation of the contents stated is the responsibility of the management of the Company. We are informed that these Annexures are only intended to provide information to the investors and are neither designed nor intended to be a substitute for professional tax advice. In view of the individual nature of the tax consequences and the changing tax laws, each investor is advised to consult his or her own tax consultant with respect to the specific tax implications arising out of their participation in the proposed initial public offering.
2. We do not express any opinion or provide any assurance as to whether:
 - (i) the Company or its shareholders will continue to obtain these benefits in future;
 - (ii) the conditions prescribed for availing the benefits have been/ would be met with; and
 - (iii) the Revenue Authorities/Courts will concur with the views expressed herein.
3. The contents of the attached Annexures are based on information, explanations and representations obtained from the Company and on the basis of their understanding of the business activities and operations of the Company.
4. We do not give any assurance that the Revenue Authorities/ Courts will concur with the view expressed herein. Our views are solely based on existing provisions of law being force in India and implementation of such laws, which are subject to change from time to time. We do not assume any responsibility to updates the views consequent to such changes.
5. We shall not be liable to any claims, liabilities or expenses relating to this assignment except to the extent of fees relating to this assignment, as finally judicially determined to have resulted primarily from bad faith or intentional misconduct. We will not be liable to any other person in respect of this statement.
6. This certificate is provided solely for the purpose of assisting the addressee Company in discharging its responsibility under the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018

for inclusion in the Prospectus/ Prospectus in connection with the proposed issue of equity shares and is not be used, referred to or distributed for any other purpose without our written consent.

For M/s. Shyam S Gupta & Associates
Chartered Accountants
Firm's Reg No. 007309C

CA. Shyam Gupta
Partner
Membership No. 075255

Place: Indore
Date: February 24, 2024
UDIN: 24075255BKAVFT7335

ANNEXURE 1 TO THE STATEMENT OF TAX BENEFITS

The information provided below sets out the possible special tax benefits available to the Company and the Equity Shareholders under the Income Tax Act presently in force in India. It is not exhaustive or comprehensive and is not intended to be a substitute for professional advice. Investors are advised to consult their own tax consultant with respect to the tax implications of an investment in the Equity Shares particularly in view of the fact that certain recently enacted legislation may not have a direct legal precedent or may have a different interpretation on the benefits, which an investor can avail.

YOU SHOULD CONSULT YOUR OWN TAX ADVISORS CONCERNING THE INDIAN TAX IMPLICATIONS AND CONSEQUENCES OF PURCHASING, OWNING AND DISPOSING OF EQUITY SHARES IN YOUR PARTICULAR SITUATION

SPECIAL TAX BENEFITS TO THE COMPANY

The Company is not entitled to any special tax benefits under the Act.

B. SPECIAL TAX BENEFITS TO THE SHAREHOLDER

The Shareholders of the Company are not entitled to any special tax benefits under the Act.

Note:

1. All the above benefits are as per the current Tax Laws and will be available only to the sole/ first name holder where the shares are held by joint holders.
2. The above statement covers only certain relevant Direct Tax Law benefits and does not cover any Indirect Tax Law benefits or benefit under any other law.

We hereby give our consent to include our above referred opinion regarding the tax benefits available to the Company and to its shareholders in the Draft Red Herring Prospectus/ Red Herring Prospectus/Prospectus.

ANNEXURE 2 TO THE STATEMENT OF TAX BENEFITS

The information provided below sets out the possible special tax benefits available to the Company and the Equity Shareholders under the Goods and Service Tax Act (hereinafter referred to as 'GST Act') presently in force in India. It is not exhaustive or comprehensive and is not intended to be a substitute for professional advice. Investors are advised to consult their own tax consultant with respect to the tax implications of an investment in the Equity Shares particularly in view of the fact that certain recently enacted legislation may not have a direct legal precedent or may have a different interpretation on the benefits, which an investor can avail.

YOU SHOULD CONSULT YOUR OWN TAX ADVISORS CONCERNING THE INDIAN TAX IMPLICATIONS AND CONSEQUENCES OF PURCHASING, OWNING AND DISPOSING OF EQUITY SHARES IN YOUR PARTICULAR SITUATION

A. SPECIAL TAX BENEFITS TO THE COMPANY

The Company is not entitled to any special tax benefits under the GST Acts.

B. SPECIAL TAX BENEFITS TO THE SHAREHOLDER

The Shareholders of the Company are not entitled to any special tax benefits under the GST Acts.

Note:

1. All the above benefits are as per the current Tax Laws and will be available only to the sole/ first name holder where the shares are held by joint holders.
2. The above statement covers only certain relevant Indirect Tax Law benefits and does not cover any Direct Tax Law benefits or benefit under any other law.

We hereby give our consent to include our above referred opinion regarding the tax benefits available to the Company and to its shareholders in the Draft Red Herring Prospectus/ Red Herring Prospectus/Prospectus.

SECTION VI – ABOUT THE COMPANY

INDUSTRY OVERVIEW

The information in this chapter has been extracted from various websites and publicly available documents from various industry sources. The data may have been re-classified by us for the purpose of presentation. None of the Company and any other person connected with the Issue have independently verified this information. Industry sources and publications generally state that the information contained therein has been obtained from believed to be reliable, but their accuracy, completeness and underlying assumptions are not guaranteed, and their reliability cannot be assured. Industry sources and publications are also prepared based on information as of specific dates and may no longer be current or reflect current trends. Industry sources and publications may also base their information on estimates, projection forecasts and assumptions that may prove to be incorrect. Accordingly, investors should not place undue reliance on information.

GLOBAL ECONOMIC OVERVIEW

The baseline forecast is for global growth to slow from 3.5 percent in 2022 to 3.0 percent in 2023 and 2.9 percent in 2024, well below the historical (2000–19) average of 3.8 percent. Advanced economies are expected to slow from 2.6 percent in 2022 to 1.5 percent in 2023 and 1.4 percent in 2024 as policy tightening starts to bite. Emerging market and developing economies are projected to have a modest decline in growth from 4.1 percent in 2022 to 4.0 percent in both 2023 and 2024. Global inflation is forecast to decline steadily, from 8.7 percent in 2022 to 6.9 percent in 2023 and 5.8 percent in 2024, due to tighter monetary policy aided by lower international commodity prices. Core inflation is generally projected to decline more gradually, and inflation is not expected to return to target until 2025 in most cases.

Monetary policy actions and frameworks are key at the current juncture to keep inflation expectations anchored. It emphasizes the complementary role of monetary policy frameworks, including communication strategies, in helping achieve disinflation at a lower cost to output through managing agents' inflation expectations. Given increasing concerns about geoeconomic fragmentation.

Resilient Global Economy Is Limping Along, with Growing Divergences

The global economy continues to recover slowly from the blows of the pandemic, Russia's invasion of Ukraine, and the cost-of-living crisis. In retrospect, the resilience has been remarkable. Despite the disruption in energy and food markets caused by the war, and the unprecedented tightening of global monetary conditions to combat decades-high inflation, the global economy has slowed, but not stalled. Yet growth remains slow and uneven, with growing global divergences. The global economy is limping along, not sprinting.

According to the projections, global growth will slow from 3.5 percent in 2022 to 3 percent this year and 2.9 percent next year, a 0.1 percentage point downgrade for 2024 from our July projections. This remains well below the historical average. Headline inflation continues to decelerate, from 9.2 percent in 2022, on a year-over-year basis, to 5.9 percent this year and 4.8 percent in 2024. Core inflation, excluding food and energy prices, is also projected to decline, albeit more gradually than headline inflation, to 4.5 percent in 2024.


As a result, projections are increasingly consistent with a “soft landing” scenario, bringing inflation down without a major downturn in activity, especially in the United States, where the forecast increase in unemployment is very modest, from 3.6 to 3.9 percent by 2025.

Growing Global Divergences

After a strong initial rebound from the depths of the COVID-19 pandemic, the pace of recovery has moderated. Several forces are holding back the recovery. Some reflect the long-term consequences of the pandemic, Russia's war in Ukraine, and increasing geoeconomic fragmentation. Others are more cyclical, including the effects of monetary policy tightening necessary to reduce inflation, withdrawal of fiscal support amid high debt, and extreme weather events. Despite signs of economic resilience earlier this year and progress in reducing headline inflation, economic activity is still generally falling short of prepandemic (January 2020) projections, especially in emerging market and developing economies (Figure 1.1, panel 1).

The strongest recovery among major economies has been in the United States, where GDP in 2023 is estimated to exceed its prepandemic path. The euro area has recovered, though less strongly—with output still 2.2 percent below prepandemic projections, reflecting greater exposure to the war in Ukraine and the associated adverse terms-of-trade shock, as well as a spike in imported energy prices. In China, the pandemic-related slowdown in 2022 and the property sector crisis contribute to the larger output losses of about 4.2 percent, compared with prepandemic predictions. Other emerging market and

developing economies have seen even weaker recoveries, especially low-income countries, where output losses average more than 6.5 percent. Higher interest rates and depreciated currencies have exacerbated the difficulties of low-income countries, placing more than half either at high risk of distress or already in distress. Overall, global output for 2023 is estimated at 3.4 percent (or about \$ 3.6 trillion in 2023 prices) below prepandemic projections. Private consumption has also recovered faster in advanced economies than in emerging market and developing economies, owing to an earlier reopening in the former group facilitated by greater availability of effective vaccines, stronger safety nets, more ample policy stimulus, and greater feasibility of remote work. These factors supported livelihoods during the pandemic, and household consumption is now broadly back to prepandemic trends. Among advanced economies, private consumption has been stronger in the United States than in the euro area, with households receiving larger fiscal transfers early in the pandemic and spending the associated savings more quickly; being better insulated from the rise in energy prices resulting from the war in Ukraine; and feeling relatively confident amid historically tight US labor markets, which have supported real disposable incomes (Figure 1.1, panel 2). Among emerging market and developing economies, the consumption shortfall is particularly large in China, reflecting tight restrictions on mobility during the COVID-19 crisis.




Investment, on the other hand, has uniformly fallen short of prepandemic trends across regions. Businesses have shown less enthusiasm for expansion and risk taking amid rising interest rates, withdrawal of fiscal support, dimmer prospects for product demand, stricter lending conditions, and growing uncertainties. 75 million to 95 million more people were living in extreme poverty in 2022 compared with prepandemic estimates. Spikes in food prices and related insecurities following Russia's invasion of Ukraine, as well as bouts of extreme weather, have accentuated these difficulties. The global average temperature in July 2023 was the highest on record for any month, amid reports of catastrophic flooding, heat waves, and wildfires in many regions. Overall, the global prevalence of undernourishment is significantly higher than before the pandemic (FAO and others 2023).

Resilient Start to 2023, Signs of Slowdown

Despite these persistent challenges, several headwinds to global growth subsided earlier this year. The World Health Organization announced in May that it no longer considered COVID-19 a global health emergency, and infections and hospitalizations appear to remain relatively limited, despite a recent uptick in some regions. Supply chains, which the pandemic disrupted, have largely normalized, with shipping costs and suppliers' delivery times back to prepandemic levels. And global financial conditions eased after Swiss and US authorities took strong action in March to contain turbulence in their banking sectors.

Amid these conditions, global GDP expanded by 3.4 percent in the second quarter of 2023 compared with a year earlier outperforming forecasts, including those in the April 2023 WEO. The resilience reflected strong consumption amid tight labor markets in the United States and robust activity in economies with large travel and tourism sectors,




China: Slower Growth

China's growth momentum is fading following a COVID-19 reopening surge in early 2023. Growth slowed from 8.9 percent in the first quarter of 2023 (seasonally adjusted annualized quarterly rate) to 4.0 percent in the second quarter. With ample economic slack and declining energy and food prices, inflation fell to an estimated 0.2 percent (year over year) in the second quarter of 2023. Country Garden China's largest property developer and a major beneficiary of government support—is facing severe liquidity stress, a sign that real estate distress is spreading to stronger developers, despite policy easing measures. Meanwhile, real estate investment and housing prices continue to decline, putting pressure on local governments' revenues from land sales and threatening already fragile public finances. Commodity exporters and countries that are part of the Asian industrial supply chain are the most exposed to China's loss of momentum.



Tighter Monetary Policy, Tighter Credit

Acute stress in the banking sector has receded. The March 2023 banking scare remained contained and limited to problematic regional banks in the United States and Credit Suisse a Swiss globally systemically important bank on account of swift reaction by authorities in both countries. However, rapid rate hikes in major advanced economies over the past 18 months, a necessary response to rapidly rising inflationary pressures, have resulted in a tight monetary policy stance real rates above neutral rates that is expected to endure well into 2025.



INDIAN ECONOMY OVERVIEW

Introduction

Strong economic growth in the first quarter of FY23 helped India overcome the UK to become the fifth-largest economy after it recovered from the COVID-19 pandemic shock. Real GDP at constant prices in the second quarter of 2022–23 is estimated at US\$ 1.94 trillion (Rs. 160.06 trillion), showing a growth of 7.2% as compared to the First Revised Estimates of GDP for the year 2021-22 of US\$ 1.81 trillion (Rs. 149.26 trillion), indicating a strong start for India's recovery from the pandemic. Given the release of pent-up demand and the widespread vaccination coverage, the contact-intensive services sector will probably be the main driver of development in 2022–2023. In FY22, India's service exports stood at US\$ 254.4 billion. Furthermore, India's overall exports (services and merchandise) was estimated at US\$ 770.18 billion in FY23. Rising employment and substantially increasing private consumption, supported by rising consumer sentiment, will support GDP growth in the coming months.

Future capital spending of the government in the economy is expected to be supported by factors such as tax buoyancy, the streamlined tax system with low rates, a thorough assessment and rationalisation of the tariff structure, and the digitization of tax filing. In the medium run, increased capital spending on infrastructure and asset-building projects is set to increase growth multipliers, and with the revival in monsoon and the Kharif sowing, agriculture is also picking up momentum. The contact-based services sector has largely demonstrated promise to boost growth by unleashing the pent-up demand over the period of April-December 2022. The sector's success is being captured by a number of HFIs (High-Frequency Indicators) that are performing well, indicating the beginnings of a comeback.

India has emerged as the fastest-growing major economy in the world and is expected to be one of the top three economic powers in the world over the next 10-15 years, backed by its robust democracy and strong partnerships.


India's appeal as a destination for investments has grown stronger and more sustainable as a result of the current period of global unpredictability and volatility, and the record amounts of money raised by India-focused funds in 2022 are evidence of investor faith in the "Invest in India" narrative.

Market Size

India's nominal gross domestic product (GDP) at current prices is estimated to be at US\$ 3.31 trillion (Rs. 272.41 trillion) in FY22. Additionally, the Nominal GDP at current prices in Q3 of 2022-23 was US\$ 874.84 billion (Rs. 71.82 trillion), as against US\$ 792.3 billion (Rs. 65.05 trillion) in 2021-22, estimating a growth of 10.4%. With 115 unicorns valued at more than US\$ 350 billion, as of February 2023, India presently has the third-largest unicorn base in the world. The government is also focusing on renewable sources by achieving 40% of its energy from non-fossil sources by 2030. India is committed to achieving the country's ambition of Net Zero Emissions by 2070 through a five-pronged strategy, 'Panchamrit'. Moreover, India ranked 3rd in the renewable energy country attractive index.

According to the McKinsey Global Institute, India needs to boost its rate of employment growth and create 90 million non-farm jobs between 2023 and 2030 in order to increase productivity and economic growth. The net employment rate needs to grow by 1.5% per annum from 2023 to 2030 to achieve 8-8.5% GDP growth between 2023 and 2030. India's current account deficit (CAD), primarily driven by an increase in the trade deficit, stood at US\$ 1.3 billion, 0.2% of GDP in the fourth quarter of FY23.

Exports fared remarkably well during the pandemic and aided recovery when all other growth engines were losing steam in terms of their contribution to GDP. Going forward, the contribution of merchandise exports may waver as several of India's trade partners witness an economic slowdown. According to Mr. Piyush Goyal, Minister of Commerce and Industry, Consumer Affairs, Food and Public Distribution and Textiles, Indian exports are expected to reach US\$ 1 trillion by 2030.



Recent Developments

India is primarily a domestic demand-driven economy, with consumption and investments contributing to 70% of the economic activity. With an improvement in the economic scenario and the Indian economy recovering from the Covid-19 pandemic shock, several investments and developments have been made across various sectors of the economy. According to World Bank, India must continue to prioritise lowering inequality while also putting growth-oriented policies into place to boost the economy. In view of this, there have been some developments that have taken place in the recent past. Some of them are mentioned below.

- As of January 6, 2023, India's foreign exchange reserves stood at US\$ 561,583 million.
- 1,261 deals were recorded of more than US\$ 46 billion of Private Equity (PE) – Venture Capitalist (VC) investments in 2022. 111 mega transactions (rounds of US\$ 100 million or more) totalling US\$ 31 billion were completed in 2022.
- Merchandise exports in March 2023 stood at US\$ 38.38 billion, with total merchandise export of US\$ 447.46 billion during the period of April-March 2023. The overall exports (merchandise and service exports) in 2022-23 was estimated at US\$ 770.18, exhibiting a positive growth of 13.84%.
- India ranks 3rd position in the global number of scientific publications further improving India's Global Innovation Index (GII) rank from 81st in 2014 to 40th in 2022.
- PMI Services remained comfortably in the expansionary zone at 57.8 in the month of June 2023.
- In June 2023, the gross Goods and Services Tax (GST) revenue collection stood at US\$ 19.63 billion (Rs.1,61,497 crore), of which CGST is US\$ 3.77 billion (Rs. 31,013 crore), SGST is US\$ 4.65 billion (Rs. 38,292 crore), IGST is US\$ 9.76 billion (Rs. 80,292 crore).
- Between April 2000 – March 2023, cumulative FDI equity inflows to India stood at US\$ 9919.63 billion.
- In May 2023, the overall IIP (Index of Industrial Production) stood at 145. The Indices of Industrial Production for the mining, manufacturing and electricity sectors stood at 128.1, 142.3 and 201.6, respectively, in May 2023.
- According to data released by the Ministry of Statistics & Programme Implementation (MoSPI), India's Consumer Price Index (CPI) based retail inflation reached 4.81% in June 2023.
- In FY23, the Foreign Portfolio Investment (FPI) outflows stood at US\$ 14.81 billion (Rs. 1.21 trillion). As per depository data, Foreign Portfolio Investors (FPIs) invested Rs. 22,000 crore (US\$ 2.67 billion) in India during the first week of July 2023.
- The wheat procurement during RMS 2022-23 was estimated to be 262 lakh metric tonnes and the rice procured in KMS 2022-23 was 624.18 lakh metric tonnes (518 LMT for Kharif crop and 106.18 LMT for Rabi crop). Moreover, in the budget 2022-23, direct payment of (Maximum Selling Price) MSP was launched that estimated to be US\$ 31.74 billion (Rs. 2.37 trillion) in order to boost farmers' income.

Government Initiatives

Over the years, the Indian government has introduced many initiatives to strengthen the nation's economy. The Indian government has been effective in developing policies and programmes that are not only beneficial for citizens to improve their financial stability but also for the overall growth of the economy. Over recent decades, India's rapid economic growth has led to a substantial increase in its demand for exports. Besides this, a number of the government's flagship programmes, including Make in India, Start-up India, Digital India, the Smart City Mission, and the Atal Mission for Rejuvenation and Urban Transformation, is aimed at creating immense opportunities in India. In this regard, some of the initiatives taken by the government to improve the economic condition of the country are mentioned below:

- From April 1st, 2023, Foreign Trade Policy 2023 was unveiled to create an enabling ecosystem to support the philosophy of 'AtmaNirbhar Bharat' and 'Local goes Global'.
- In order to enhance India's manufacturing capabilities by increasing investment and production in the sector, the government of India has introduced the Production Linked Incentive Scheme (PLI) for Pharmaceuticals.

- Prime Minister's Development Initiative for North-East Region (PM-DevINE) was announced in the Union Budget 2022-23 with a financial outlay of US\$ 182.35 million (Rs. 1,500 crore).
- Prime Minister Mr Narendra Modi has inaugurated a new food security scheme for providing free food grains to Antodaya Ann Yojna (AAY) & Primary Household (PHH) beneficiaries, called Pradhan Mantri Garib Kalyan Ann Yojana (PMGKAY) from 1st January 2023.
- The Amrit Bharat Station scheme for Indian Railways envisages the development of stations on a continuous basis with a long-term vision, formulated on 29th December 2022 by the Ministry of Railways.
- On 7th October 2022, the Department for Promotion of Industry and Internal Trade (DPIIT) launched Credit Guarantee Scheme for Start-ups (CGSS) aiming to provide credit guarantees up to a specified limit by start-ups, facilitated by Scheduled Commercial Banks, Non-Banking Financial Companies and Securities and Exchange Board of India (SEBI) registered Alternative Investment Funds (AIFs).
- Telecom Technology Development Fund (TTDF) Scheme was launched in October 2022 by the Universal Service Obligation Fund (USOF), a body under the Department of Telecommunications. The objective is to fund R&D in rural-specific communication technology applications and form synergies among academia, start-ups, research institutes, and the industry to build and develop the telecom ecosystem.
- Home & Cooperation Minister Mr. Amit Shah laid the foundation stone and performed Bhoomi Pujan of Tanot Mandir Complex Project under Border Tourism Development Programme in Jaisalmer in September 2022.
- In August 2022, Mr. Narendra Singh Tomar, Minister of Agriculture and Farmers Welfare inaugurated four new facilities at the Central Arid Zone Research Institute (CAZRI), which has been rendering excellent services for more than 60 years under the Indian Council of Agricultural Research (ICAR).
- In August 2022, a Special Food Processing Fund of US\$ 242.72 million (Rs. 2,000 crore) was set up with National Bank for Agriculture and Rural Development (NABARD) to provide affordable credit for investments in setting up Mega Food Parks (MFP) as well as processing units in the MFPs.
- In July 2022, Deendayal Port Authority (DPA) announced plans to develop two Mega Cargo Handling Terminals on a Build-Operate-Transfer (BOT) basis under Public-Private Partnership (PPP) Mode at an estimated cost of Rs. 5,963 crore (US\$ 747.64 million).
- In July 2022, the Union Cabinet chaired by Prime Minister Mr. Narendra Modi, approved the signing of the Memorandum of Understanding (MoU) between India & Maldives. This MoU will provide a platform to tap the benefits of information technology for court digitization and can be a potential growth area for IT companies and start-ups in both countries.
- India and Namibia entered a Memorandum of Understanding (MoU) on wildlife conservation and sustainable biodiversity utilization on July 20, 2022, for establishing the cheetah into the historical range in India.
- In July 2022, the Reserve Bank of India (RBI) approved international trade settlements in Indian rupees (INR) in order to promote the growth of global trade with emphasis on exports from India and to support the increasing interest of the global trading community.
- The Agnipath Scheme aims to develop a young and skilled armed force backed by an advanced warfare technology scheme by providing youth with an opportunity to serve Indian Army for a 4-year period. It is introduced by the Government of India on 14 June 2022.
- In June 2022, Prime Minister Mr. Narendra Modi inaugurated and laid the foundation stone of development projects worth Rs. 21,000 crore (US\$ 2.63 billion) at Gujarat Gaurav Abhiyan at Vadodara.
- Mr. Rajnath Singh, Minister of Defence, launched 75 newly developed Artificial Intelligence (AI) products/technologies during the first-ever 'AI in Defence' (AIDef) symposium and exhibition organized by the Ministry of Defence in New Delhi on 11 July 2022.
- In June 2022, Prime Minister Mr. Narendra Modi laid the foundation stone of 1,406 projects worth more than Rs. 80,000 crore (US\$ 10.01 billion) at the ground-breaking ceremony of the UP Investors Summit in Lucknow. The

Projects encompass diverse sectors like Agriculture and Allied industries, IT and Electronics, MSME, Manufacturing, Renewable Energy, Pharma, Tourism, Defence & Aerospace, and Handloom & Textiles.

- The Indian Institute of Spices Research (IISR) under the Indian Council for Agricultural Research (ICAR) inked a Memorandum of Understanding (MoU) with Lysterra LLC, a Russia-based company for the commercialization of bio capsule, an encapsulation technology for bio-fertilization on 30 June 2022.
- As of April 2022, India signed 13 Free Trade Agreements (FTAs) with its trading partners including major trade agreements like the India-UAE Comprehensive Partnership Agreement (CEPA) and the India-Australia Economic Cooperation and Trade Agreement (IndAus ECTA).
- 'Mission Shakti' was applicable with effect from 1st April 2022, aimed at strengthening interventions for women's safety, security and empowerment.
- The Union Budget of 2022-23 was presented on February 1, 2022, by the Minister for Finance & Corporate Affairs, Ms. Nirmala Sitharaman. The budget had four priorities PM GatiShakti, Inclusive Development, Productivity Enhancement and Investment, and Financing of Investments. In the Union Budget 2022-23, effective capital expenditure is expected to increase by 27% at US\$ 142.93 billion (Rs. 10.68 trillion) to boost the economy. This will be 4.1% of the total Gross Domestic Production (GDP).
- Strengthening of Pharmaceutical Industry (SPI) was launched in March 2022 by the Ministry of Chemicals & Fertilisers to provide credit linked capital and interest subsidy for Technology Upgradation of MSME units in pharmaceutical sector, as well as support of up to Rs. 20 crore (US\$ 2.4 million) each for common facilities including Research centre, testing labs and ETPs (Effluent Treatment Plant) in Pharma Clusters, to enhance the role of MSMEs.
- Under PM GatiShakti Master Plan, the National Highway Network will develop 25,000 km of new highways network, which will be worth Rs. 20,000 crore (US\$ 2.67 billion). In 2022-23. Increased government expenditure is expected to attract private investments, with a production-linked incentive scheme providing excellent opportunities. Consistently proactive, graded, and measured policy support is anticipated to boost the Indian economy.
- In February 2022, The Ministry of Social Justice & Empowerment launched the Scheme for Economic Empowerment of Denotified/Nomadic/SemiNomadic tribal communities (DNTs) (SEED) to provide basic facilities like good quality coaching, and health insurance. livelihoods initiative at a community level and financial assistance for the construction of houses.
- In February 2022, Minister for Finance and Corporate Affairs Ms. Nirmala Sitharaman said that productivity linked incentive (PLI) schemes would be extended to 14 sectors to achieve the mission of AtmaNirbhar Bharat and create 60 lakh jobs with an additional production capacity of Rs. 30 trillion (US\$ 401.49 billion) in the next five years.
- In the Union Budget of 2022-23, the government announced funding for the production-linked incentive (PLI) scheme for domestic solar cells and module manufacturing of Rs. 24,000 crore (US\$ 3.21 billion).
- In the Union Budget of 2022-23, the government announced a production-linked incentive (PLI) scheme for Bulk Drugs which was an investment of Rs. 2,500 crore (US\$ 334.60 million).
- In the Union Budget of 2022, Minister for Finance & Corporate Affairs Ms. Nirmala Sitharaman announced that a scheme for design-led manufacturing in 5G would be launched as part of the PLI scheme.
- In September 2021, Union Cabinet approved major reforms in the telecom sector, which are expected to boost employment, growth, competition, and consumer interests. Key reforms include rationalization of adjusted gross revenue, rationalization of bank guarantees (BGs), and encouragement of spectrum sharing.
- In the Union Budget of 2022-23, the government has allocated Rs. 44,720 crore (US\$ 5.98 billion) to Bharat Sanchar Nigam Limited (BSNL) for capital investments in the 4G spectrum.
- Minister for Finance & Corporate Affairs Ms. Nirmala Sitharaman allocated Rs. 650 crore (US\$ 86.69 million) for the Deep Ocean mission that seeks to explore vast marine living and non-living resources.
- Department of Space (DoS) has got Rs. 13,700 crore (US\$ 1.83 billion) in 2022-23 for several key space missions like Gaganyaan, Chandrayaan-3, and Aditya L-1 (sun).

- In May 2021, the government approved the production-linked incentive (PLI) scheme for manufacturing advanced chemistry cell (ACC) batteries at an estimated outlay of Rs. 18,100 crore (US\$ 2.44 billion); this move is expected to attract domestic and foreign investments worth Rs. 45,000 crore (US\$ 6.07 billion).
- Minister for Finance & Corporate Affairs Ms Nirmala Sitharaman announced in the Union Budget of 2022-23 that the Reserve Bank of India (RBI) would issue Digital Rupee using blockchain and other technologies.
- In the Union Budget of 2022-23, Railway got an investment of Rs. 2.38 trillion (US\$ 31.88 billion) and over 400 new high-speed trains were announced. The concept of "One Station, One Product" was also introduced.
- To boost competitiveness, Budget 2022-23 has announced reforming the 16-year-old Special Economic Zone (SEZ) act.
- In June 2021, the RBI (Reserve Bank of India) announced that the investment limit for FPI (foreign portfolio investors) in the State Development Loans (SDLs) and government securities (G-secs) would persist unaffected at 2% and 6%, respectively, in FY22.
- In November 2020, the Government of India announced Rs. 2.65 trillion (US\$ 36 billion) stimulus package to generate job opportunities and provide liquidity support to various sectors such as tourism, aviation, construction, and housing. Also, India's cabinet approved the production-linked incentives (PLI) scheme to provide ~Rs. 2 trillion (US\$ 27 billion) over five years to create jobs and boost production in the country.
- Numerous foreign companies are setting up their facilities in India on account of various Government initiatives like Make in India and Digital India. Prime Minister of India Mr. Narendra Modi launched the Make in India initiative with an aim to boost the country's manufacturing sector and increase the purchasing power of the average Indian consumer, which would further drive demand and spur development, thus benefiting investors. The Government of India, under its Make in India initiative, is trying to boost the contribution made by the manufacturing sector with an aim to take it to 25% of the GDP from the current 17%. Besides, the government has also come up with the Digital India initiative, which focuses on three core components: the creation of digital infrastructure, delivering services digitally, and increasing digital literacy.
- On January 29, 2022, the National Asset Reconstruction Company Ltd (NARCL) will acquire bad loans worth up to Rs. 50,000 crore (US\$ 6.69 billion) about 15 accounts by March 31, 2022. India Debt Resolution Co. Ltd (IDRCL) will control the resolution process. This will clean up India's financial system and help fuel liquidity and boost the Indian economy.
- National Bank for Financing Infrastructure and Development (NaBFID) is a bank that will provide non-recourse infrastructure financing and is expected to support projects from the first quarter of FY23; it is expected to raise Rs. 4 trillion (US\$ 53.58 billion) in the next three years.
- By November 1, 2021, India and the United Kingdom hope to begin negotiations on a free trade agreement. The proposed FTA between these two countries is likely to unlock business opportunities and generate jobs. Both sides have renewed their commitment to boost trade in a manner that benefits all.
- In August 2021, Prime Minister Mr. Narendra Modi announced an initiative to start a national mission to reach the US\$ 400 billion merchandise export target by FY22.
- In August 2021, Prime Minister Mr. Narendra Modi launched a digital payment solution, e-RUPI, a contactless and cashless instrument for digital payments.
- In April 2021, Dr. Ahmed Abdul Rahman AlBanna, Ambassador of the UAE to India and Founding Patron of IFIICC, stated that trilateral trade between India, the UAE and Israel is expected to reach US\$ 110 billion by 2030.
- India is expected to attract investment of around US\$ 100 billion in developing the oil and gas infrastructure during 2019-23.
- The Government of India is expected to increase public health spending to 2.5% of the GDP by 2025.

Road Ahead

In the second quarter of FY23, the growth momentum of the first quarter was sustained, and high-frequency indicators (HFIs) performed well in July and August of 2022. India's comparatively strong position in the external sector reflects the country's generally positive outlook for economic growth and rising employment rates. India ranked fifth in foreign direct investment inflows among the developed and developing nations listed for the first quarter of 2022.

India's economic story during the first half of the current financial year highlighted the unwavering support the government gave to its capital expenditure, which, in FY23 (until August 2022), stood 46.8% higher than the same period last year. The ratio of revenue expenditure to capital outlay decreased from 6.4 in the previous year to 4.5 in the current year, signalling a clear change in favour of higher-quality spending. Stronger revenue generation because of improved tax compliance, increased profitability of the company, and increasing economic activity also contributed to rising capital spending levels.

Since India's resilient growth despite the global pandemic, India's exports climbed at the second-highest rate with a year-over-year (YoY) growth of 8.39% in merchandise exports and a 29.82% growth in service exports till April 2023. With a reduction in port congestion, supply networks are being restored. The CPI-C inflation reduction from June 2022 already reflects the impact. In June 2023 (Provisional), CPI-C inflation was 4.81%, down from 7.01% in June 2022. With a proactive set of administrative actions by the government, flexible monetary policy, and a softening of global commodity prices and supply-chain bottlenecks, inflationary pressures in India look to be on the decline overall.

(Source: <https://www.ibef.org/economy/indian-economy-overview>)

GLOBAL MANUFACTURING INDUSTRY

What is a manufacturing business model?

In simple words, a manufacturing business model refers to the way a manufacturer creates value and structures its operations to transform raw materials and components into finished products through a series of design, production, and logistics processes to create and deliver value to its customers as well as capture value for itself and its stakeholders. Business models are integral to a manufacturer's success and competitive edge as they provide a roadmap for creating value, generating revenue, managing costs, and adapting to a dynamic business environment¹. Manufacturing firms that strategically design and execute innovative business models are better positioned for long-term success.

A generic manufacturing business model can be described in terms of nine key building blocks⁴ that interact to configure different organizational resources, activities, and partners to create and deliver products and services to one or more customer segments through the proper channels and relations within a reasonable cost and gaining acceptable revenue and profits. These building blocks include Customer segments that represent the different groups of customers a manufacturing business serves with its products and services. These customer groups could include industrial clients, wholesalers, retailers, or end consumers. Identifying and understanding the specific needs and characteristics of each of these customer groups is crucial for tailoring the manufacturer's value propositions accordingly and for effectively configuring the required resources, activities, and partners for the design, manufacturing, and delivery of such value propositions through the proper channels. The value proposition that stands for the unique value (benefits) a manufacturing business can offer to its customers in terms of new product designs and features, superior quality and performance, mass customization or personalization options, or other value-added factors such as complementary services that set a manufacturer's products apart from those of its competitors.

Channels that determine the most effective ways to reach and sell to customers. These channels might involve direct sales, distribution through retailers, e-commerce platforms, or partnerships with other businesses. Channels also consider the supply chain and logistics aspects integral for delivering complete and timely product orders.

Customer relationships that outline how a manufacturing business will engage with its customers. This could include customer support, warranty services, and other post-sales interactions during a product's middle- and end-of-life as well as regular communications to understand and meet evolving customer needs.

Revenue streams that specify the sources of revenue for the manufacturing business. This could include product sales, maintenance contracts, licensing fees, or any other ancillary services that can contribute to the income streams.

Key resources that account for the critical resources and assets required to operate a manufacturing business from raw materials to production facilities and equipment to skilled labor.

Key activities that define the design, engineering, and manufacturing processes needed to conceptualize and develop a product.

Key partners that can enhance the manufacturing capabilities of the business or provide access to key resources and assets. These alliances might include suppliers, distributors, or joint ventures.

Cost structure that outlines the major costs associated with running a manufacturing business, including raw materials, labor, facilities, distribution, and overhead costs.

What is manufacturing business model innovation?

Manufacturing business model innovation refers to the process of strategically reimagining and redesigning one or more of the nine building blocks of a manufacturing firm's business model and/or the architecture linking this departure from traditional manufacturing approaches, encompassing significant changes in how a manufacturer designs, produces, sells, and supports its products along their lifecycles. Key areas for manufacturing business model innovation related to the nine building blocks of a generic manufacturing business model include but are not limited to:

New customer-centricity approaches place a strong emphasis on understanding and meeting the targeted customer segments' needs and engaging customers in value co-creation and co-innovation activities to ensure that the offered products and services align with their expectations.

New value propositions focus on creating new accustomed or personalized sustainable products, enhancing existing ones with new sustainable and smart features, or providing additional services to these to better meet evolving customer needs.

New sales channels such as online marketplaces and social media channels sell directly to consumers and bypass traditional retail channels, thus leading to better shopping experiences.

building blocks by looking at innovative ways of creating, delivering, and capturing new forms of value, enhancing competitiveness, and adapting to changing market and consumer dynamics.

New customer relationships priorities the customer through distinctive loyalty programmers, special promotions, and unique shopping experiences, tailored with customer data insights, which demonstrate a deeper understanding of customer pains.

New revenue streams beyond selling physical products explore new recurring income sources based on the offering of services and solutions, for instance, maintenance, upgrades, and performance-based contracts as well as leveraging data monetization opportunities.

New resources management practices based on the circular economy principles minimize the impact of finite resource consumption and create truly sustainable business models and value propositions.

New activities optimization efforts enhance efficiency, boost productivity, minimize waste, reduce costs, and improve product quality.

New partnership schemes based on collaborations with other manufacturers, suppliers, or even competitors create synergies and unlock new value propositions by integrating complementary products and/or services.

New cost structures analyses and better manage the various costs incurred in the design, manufacturing, and delivery of products and services to enhance profitability.

What are the challenges of manufacturing business model innovation?

While manufacturing business model innovation can bring about positive changes as discussed, it also comes with its set of challenges. Here are some common hurdles that manufacturing firms may face when attempting to innovate their business models:

Resistance to change is one of the primary challenges to manufacturing business model innovation as employees may be hesitant to adopt new technologies or ways of working.

High initial costs that come with the implementation of new technologies or processes that can require a significant upfront investment. Integration with legacy systems as new technologies may not be easily compatible.

Skills gaps as the adoption of advanced technologies may require new skill sets not available in the workforce.

Data security concerns as production equipment becomes more connected through the Internet of Things (IoT) and other digital technologies, there are increased concerns about cyber threats.

Regulatory compliance as new business models may require manufacturing firms to navigate complex regulatory landscapes, which can slow down the pace of innovation.

Uncertain return on investment (ROI) as manufacturing firms may hesitate to invest in new technologies without a clear understanding of the long-term benefits and financial returns.

Cultural shift towards a true culture of innovation can be difficult since it requires not only changes in processes and technologies but also a shift in the organizational mindset, embracing experimentation, learning from failures, and continuous improvement.

Lack of standardization can complicate the adoption process of new technologies.

Market acceptance when introducing new products or services through innovative business models may face challenges in gaining customers' and partners' acceptance. Long implementation timelines as significant changes in business models can take time. Overcoming these challenges requires strategic planning, effective change management, and a commitment to fostering a culture of innovation within a manufacturing firm.

(Source: https://worldmanufacturing.org/wp-content/uploads/27/6-WMF-Report-2023_E-Book.pdf)

INDIAN MANUFACTURING INDUSTRY

Introduction



Manufacturing is emerging as an integral pillar in the country's economic growth, thanks to the performance of key sectors like automotive, engineering, chemicals, pharmaceuticals, and consumer durables. The Indian manufacturing industry generated 16-17% of India's GDP pre-pandemic and is projected to be one of the fastest growing sectors.

The machine tool industry was literally the nuts and bolts of the manufacturing industry in India. Today, technology has stimulated innovation with digital transformation a key aspect in gaining an edge in this highly competitive market.

Technology has today encouraged creativity, with digital transformation being a critical element in gaining an advantage in this increasingly competitive industry. The Indian manufacturing

sector is steadily moving toward more automated and process-driven manufacturing, which is projected to improve efficiency and enhance productivity.

India has the capacity to export goods worth US\$ 1 trillion by 2030 and is on the road to becoming a major global manufacturing hub.

With 17% of the nation's GDP and over 27.3 million workers, the manufacturing sector plays a significant role in the Indian economy. Through the implementation of different programmes and policies, the Indian government hopes to have 25% of the economy's output come from manufacturing by 2025.

India now has the physical and digital infrastructure to raise the share of the manufacturing sector in the economy and make a realistic bid to be an important player in global supply chains.

A globally competitive manufacturing sector is India's greatest potential to drive economic growth and job creation this decade. Due to factors like power growth, long-term employment prospects, and skill routes for millions of people, India has a significant potential to engage in international markets. Several factors contribute to their potential. First off, these value chains are well positioned to benefit from India's advantages in terms of raw materials, industrial expertise, and entrepreneurship.

Second, they can take advantage of four market opportunities: expanding exports, localising imports, internal demand, and contract manufacturing. With digital transformation being a crucial component in achieving an advantage in this fiercely competitive industry, technology has today sparked creativity. Manufacturing sector in India is gradually shifting to a more automated and process driven manufacturing which is expected to increase the efficiency and boost production of the manufacturing industry.

India is gradually progressing on the road to Industry 4.0 through the Government of India's initiatives like the National Manufacturing Policy which aims to increase the share of manufacturing in GDP to 25 percent by 2025 and the PLI scheme for manufacturing which was launched in 2022 to develop the core manufacturing sector at par with global manufacturing standards.


Manufacturing has emerged as one of the high growth sectors in India. Prime Minister of India, Mr Narendra Modi, launched the 'Make in India' program to place India on the world map as a manufacturing hub and give global recognition to the Indian economy. Government aims to create 100 million new jobs in the sector by 2022.

Market Size

Manufacturing exports have registered highest ever annual exports of US\$ 447.46 billion with 6.03% growth during FY23 surpassing the previous year (FY22) record exports of US\$ 422 billion. By 2030, Indian middle class is expected to have the second-largest share in global consumption at 17%.

India's gross domestic product (GDP) at current prices stood at Rs. 51.23 lakh crore (US\$ 694.93 billion) in the first quarter of FY22, as per the provisional estimates of gross domestic product for the first quarter of 2021-22. The manufacturing GVA at current prices was estimated at US\$ 77.47 billion in the third quarter of FY22 and has contributed around 16.3% to the nominal GVA of during the past ten years. India has potential to become a global manufacturing hub and by 2030, it can add more than US\$ 500 billion annually to the global economy. As per the economic survey reports, estimated employment in manufacturing sector in

India was 5.7 crore in 2017-18, 6.12 crore in 2018-19 which was further increased to 6.24 crore in 2019-20. India's display panel market is estimated to grow from ~US\$ 7 billion in 2021 to US\$ 15 billion in 2025. As per the survey conducted by the Federation of Indian Chambers of Commerce and Industry (FICCI), capacity utilisation in India's manufacturing sector stood at 72.0% in the second quarter of FY22, indicating significant recovery in the sector.



Investment

Some of the major investments and developments in this sector in the recent past are:

- According to Department for Promotion of Industry and Internal Trade (DPIIT), India received a total foreign direct investment (FDI) inflow of US\$ 58.77 billion in FY22.
- Between April 2000-September 2022:
- The automobile sector received FDI inflows of US\$ 33,774 million.
- The chemical manufacturing sector (excluding fertilisers) received FDI inflows worth US\$ 20,759 million.
- The drug and pharmaceutical manufacturing sector received FDI inflows worth US\$ 20,104 million.
- The Food Processing Industries received FDI inflows worth US\$ 11,514 million.
- The combined index of eight core industries stood at 144.6 for Apr-Feb 2023 against 134.1 for Apr-Feb 2022.
- The Index of Industrial (Production IIP) from April-February 2023 stood at 137.1.
- In FY23, the Manufacturing Purchasing Managers' Index (PMI) in India stood at 55.6.
- In FY23 (until September 2022), export of top 10 major commodities (Engineering goods, Petroleum products, Gems and Jewellery, Organic and Inorganic chemicals, Drugs and Pharmaceuticals, Electronic goods, RMG of all Textiles, Cotton Yarn/Fabs./Madeups, Rice, Plastic and Linoleum) stood at US\$ 187.2 billion.
- In FY23 (until February 2023), EPFO added 131 lakh net subscribers. The Employees' Provident Fund Organisation (EPFO) added 1,396,185 in February 2023.

- In October 2021, information technology major Zoho, announced that it will invest Rs. 50–100 crore (US\$ 6.7-13.4 million) and form a new company, that will focus on research and development (R&D) in the manufacturing sector.
- In August 2021, Wistron Corp. collaborated with India's Optimus Electronics to manufacture products such as laptops and smartphones, giving a major boost to the 'Make in India' initiative and electronics manufacturing in the country.
- In April 2021, Samsung started manufacturing mobile display panels at its Noida plant and plans to ramp up manufacturing IT display panels soon.
- Samsung Display Noida, which has invested Rs. 4,825 crore (US\$ 650.42 million) to move its mobile and IT display manufacturing plant from China to Uttar Pradesh, has received special incentives from the state government.
- In April 2021, Bharti Enterprises Ltd. and Dixon Technologies (India) Ltd., formed a joint venture to take advantage of the government's PLI scheme for the manufacturing of telecom and networking products.

Government Initiatives

The Government of India has taken several initiatives to promote a healthy environment for the growth of manufacturing sector in the country. Some of the notable initiatives and developments are:

- In the Union Budget 2023-24:
- Startups incorporated within a time-period and meeting other conditions can deduct up to 100% of their profits; the end of this period has been extended from March 31, 2023 to March 31, 2024. In addition, the period within which losses of startups may be carried forward has been extended from seven to ten years.
- As per the Union Budget 2023 – 23, the income tax rate for new co-operative societies engaged in manufacturing activities has been lowered from 22% to 15% (plus 10% surcharge).
- The upper limit on turnover for MSMEs to be eligible for presumptive taxation has been raised from Rs. 2 crore (US\$ 2,43,044) to Rs. 3 crore (US\$ 3,64,528). The upper limit on gross receipts for professionals eligible for presumptive taxation has been raised from Rs. 50 lakh (US\$ 60,754) to Rs. 75 lakh (US\$ 91,132).
- Expenditure on fertilizer subsidy is estimated at Rs. 1,75,100 crore (US\$ 21.2 billion) in 2023-24. This is a decrease of Rs. 50,120 crore (US\$ 6.09 billion) (22.3%) from the revised estimate of 2022-23. Fertilizer subsidy for 2022-23 was increased substantially in response to a sharp increase in international prices of raw materials used in the manufacturing of fertilizers.
- The Centre will facilitate one crore farmers to adopt natural farming. For this, 10,000 Bio-Input Resource Centres will be set-up, creating a national-level distributed micro-fertilizer and pesticide manufacturing network.
- To avoid cascading of taxes on blended compressed natural gas, excise duty on GST-paid compressed bio-gas contained in it has been exempted from excise duty. Customs duty exemption has been extended to import of capital goods and machinery required for manufacture of lithium-ion cells for batteries used in electric vehicles.
- To further deepen domestic value addition in manufacture of mobile phones, the finance minister announced relief in customs duty on import of certain parts and inputs like camera lens. The concessional duty on lithium-ion cells for batteries will continue for another year. Basic customs duty on parts of open cells of TV panels has been reduced to 2.5%. The Budget also proposes changes in the basic customs duty to rectify inversion of duty structure and encourage manufacturing of electrical kitchen chimneys.
- Basic customs duty on seeds used in the manufacture of Lab Grown Diamonds has also been reduced.
- Ministry of Defence has set a target of achieving a turnover of US\$ 25 billion in aerospace and defence Manufacturing by 2025, which includes US\$ 5 billion exports. Till October 2022, a total of 595 Industrial Licences have been issued to 366 companies operating in Defence Sector.
- A new category of capital procurement 'Buy {Indian-IDD (Indigenously Designed, Developed and Manufactured)}' has been introduced in Defence Procurement Procedure (DPP)-2016.

- By 2030, the Indian government expects the electronics manufacturing sector to be worth US\$ 300 billion.
- Initiatives like Make in India, Digital India and Startup India have given the much needed thrust to the Electronics System Design and Manufacturing (ESDM) sector in India.
- Moreover, the government's endeavours such as Modified Special Incentive Scheme (M-SIPS), Electronics Manufacturing Clusters, Electronics Development Fund and National Policy on Electronics 2019 (NPE 2019) have been a huge success.
- The Scheme for Promotion of Manufacturing of Electronic Components and Semiconductors (SPECES) has been notified with an aim to strengthen the value chain for the manufacturing of electronic products in India.
- In the Union Budget 2022-23:
- Ministry of Defence has been allocated Rs. 525,166 crore (US\$ 67.66 billion)
- The government allocated Rs. 2,403 crore (US\$ 315 million) for Promotion of Electronics and IT Hardware Manufacturing.
- The PLI for semiconductor manufacturing is set at Rs. 760 billion (US\$ 9.71 billion), with the goal of making India one of the world's major producers of this crucial component.
- The government approved a PLI scheme for 16 plants for key starting materials (KSMs)/drug intermediates and active pharmaceutical ingredients (APIs). The establishment of these 16 plants would result in a total investment of Rs. 348.70 crore (US\$ 47.01 million) and generation of ~3,042 jobs. The commercial development of these plants is expected to begin by April 2023.
- In September 2022, the National Logistics Policy was launched by Prime Minister Mr. Narendra Modi which ensures quick last mile delivery, end transport-related challenges.
- In November 2021, the Experts' Advisory Committee (EAC) of the Department for Promotion of Industry and Internal Trade approved Rs. 3 crore (US\$ 403,293.54) for the Atal Incubation Centre (AIC), Pondicherry Engineering College Foundation (PECF), under the Start-up India Seed Fund scheme.
- In September 2021, Prime Minister Mr. Narendra Modi approved the production-linked incentive (PLI) scheme in the textiles sector—for man-made fibre (MMF) apparel, MMF fabrics and 10 segments/products of technical textiles—at an estimated outlay of Rs. 10,683 crore (US\$ 1.45 billion).
- India outlines a plan in August 2021 to reach its goal of US\$ 1 trillion in manufactured goods exports.
- In July 2021, the government launched six technology innovation platforms to develop technologies and thereby, boost the manufacturing sector in India to compete globally.
- To propagate Make in India, in July 2021, the Defence Ministry issued a tender of Rs. 50,000 crore (US\$ 6.7 billion) for building six conventional submarines under Project-75 India.
- In May 2021, the government approved a PLI scheme worth Rs. 18,000 crore (US\$ 2.47 billion) for production of advanced chemical cell (ACC) batteries; this is expected to attract investments worth Rs. 45,000 crore (US\$ 6.18 billion) in the country, and further boost capacity in core component technology and make India a clean energy global hub.
- In India, the market for grain-oriented electrical steel sheet manufacturing is witnessing high demand from power transformer producers, due to the rising demand for electric power and increasing adoption of renewable energy in the country.
- The Mega Investment Textiles Parks (MITRA) scheme to build world-class infrastructure will enable global industry champions to be created, benefiting from economies of scale and agglomeration. Seven Textile Parks will be established over three years.

- The government proposed to make significant investments in the construction of modern fishing harbours and fish landing centres, covering five major fishing harbours in Kochi, Chennai, Visakhapatnam, Paradip, and Petuaghat, along with a multipurpose Seaweed Park in Tamil Nadu. These initiatives are expected to improve exports from the textiles and marine sectors.
- The 'Operation Green' scheme of the Ministry of the Food Processing Industry, which was limited to onions, potatoes and tomatoes, has been expanded to 22 perishable products to encourage exports from the agricultural sector. This will facilitate infrastructure projects for horticulture products.

Road Ahead



India is an attractive hub for foreign investments in the manufacturing sector. Several mobile phone, luxury and automobile brands, among others, have set up or are looking to establish their manufacturing bases in the country. The manufacturing sector of India has the potential to reach US\$ 1 trillion by 2025. The implementation of the Goods and Services Tax (GST) will make India a common market with a GDP of US\$ 2.5 trillion along with a population of 1.32 billion people, which will be a big draw for investors. The Indian Cellular and Electronics Association (ICEA) predicts that India has the potential to scale up its cumulative laptop and tablet manufacturing capacity to US\$ 100 billion by 2025 through policy interventions. One of the initiatives by the Government of India's Ministry for Heavy Industries & Public Enterprises is SAMARTH Udyog Bharat 4.0, or SAMARTH Advanced Manufacturing and Rapid

Transformation Hubs. This is expected to increase competitiveness of the manufacturing sector in the capital goods market. With impetus on developing industrial corridors and smart cities, the Government aims to ensure holistic development of the nation. The corridors would further assist in integrating, monitoring and developing a conducive environment for the industrial development and will promote advance practices in manufacturing.

(Source: <https://www.ibef.org/industry/manufacturing-sector-india>)

GLOBAL PHARMACEUTICAL INDUSTRY

The trillion-dollar question for the bio/pharma industry is how will the industry perform in the near-term. A newly analysis issued this week (January 17, 2024) by the IQVIA Institute for Human Data Science shows market fundamentals trending in a positive direction and improving over recent forecasts. Global spending and demand for medicines is projected to increase over the next five years to approximately \$2.3 trillion by 2028 (based on list price levels), representing a compound annual growth rate (CAGR) of 5–8% CAGR through 2028, a growth rate raised by 2 percentage points compared to previous forecasts. The higher growth expectations come despite lower expectations for COVID-19 vaccines and therapeutics, which had been a major boon for the industry. COVID-19 continues to have an impact on pharmaceutical markets globally, but at a level much lower than previously estimated. The lower level of vaccinations seen to date and expected through 2028 have resulted in a \$200-billion reduction in the eight-year cumulative spending estimates. Despite this decline, overall, global use and spending on medicines is exceeding pre-pandemic growth rates and is expected to continue significantly above these trends through 2028, according to the IQVIA Institute's analysis.

In the US and the EU4 (France, Italy, Germany, and Spain) and the UK, list-price growth is projected at 6-9% and 4-7%, respectively while historic data suggest net payer spending will be about 2-5% for both, according to the IQVIA Institute's analysis. Spending and volume growth will follow diverging trends by region. The US market, on a net price basis, is forecast to grow 2-5% CAGR through 2028, an upward adjustment from the prior five-year forecast (through 2027) of -1–2% CAGR. This reflects the improved outlook for novel medicines and the expected early impact from the Inflation Reduction Act, legislation in the US that included drug pricing reforms. Spending in the five major European countries (France, Italy, Germany, Spain and the UK) is expected to increase by \$70 billion through 2028, driven by new brands. Latin America, Eastern Europe, and countries in Asia are expected to return to steady growth, outpacing the global market. Japan spending growth is projected to grow -1 to 2% through 2028 as brand growth is offset by a shift to annual price cuts, according to the IQVIA Institute's analysis.

Drug development: growth trends in therapeutic sectors and product segments In looking at growth in key therapy areas, oncology and obesity lead growth while immunology spending has slowed due to biosimilar availability and uptake, according to the IQVIA Institute's analysis. Many other classes will grow in mid-single digits. Demand for innovative oncology drugs will drive spending in this area to about \$440 billion by 2028, more than double the current level, as broader

and longer use of therapies, including 100 new drugs expected to be launched during that time. Global obesity spending is projected to grow 24-27% CAGR, reaching \$74 billion in 2028 – up from \$24 billion in 2023 – with some scenarios resulting in much higher or lower spending based on countries' reimbursement decisions, which are evolving rapidly. Immunology growth will slow significantly to 2-5% through 2028 with the arrival of new biosimilars despite robust volume growth. New therapies in rare neurological disorders, Alzheimer's and migraine are expected to drive spending growth in neurology, according to the IQVIA's Institute's analysis.

Another key trend is the continued rise of biologic-based medicines and specialty medicines. Biotech-based drugs will represent 39% of medicines spending globally through 2028, according to the IQVIA Institute's analysis, reflecting growth in traditional biotherapeutics, breakthrough cell and gene therapies, as well as a maturing biosimilar segment. The spending on global biotech is expected to exceed \$892 billion by 2028, with growth slowing to 9.5-12.5% from biosimilar savings. The outlook for next-generation biotherapeutics includes significantly uncertain clinical and commercial successes. Cell and gene therapies register high growth rates driven by wider usage and as many as 50 new therapies over the next five years, but are projected to represent only 1.5% of global spending in 2028, according to the IQVIA Institute's analysis.

Specialty medicines, as defined by the IQVIA Institute, as those medicines that treat chronic, complex, or rare diseases and possess additional distribution, care delivery, and/or cost characteristics, which require special management by stakeholders, are expected to see continued strong growth. Specialty medicines are projected to represent about 43% of global spending in 2028 and 55% of total spending in leading developed markets.

Manufacturing and supply: what's trending now and in the future During the pandemic and post-pandemic, improving supply-chain resiliency and security of supply of critical medicines became a key policy focus in both the US and Europe, and momentum continues to trend to more concrete action in this area. In the European Union (EU), the European Commission launched this week (January 16, 2024) a new initiative, the Critical Medicines Alliance, a consultative mechanism charged with developing recommendations and providing advice to the European Commission, EU member states, and other EU decision-makers on how to address long-standing medicines shortages.

The launch of the Critical Medicines Alliance builds on other recent action by EU authorities. Last month (December 2023), the European Medicines Agency published the first version of a list of critical medicines for the EU/European Economic Area (i.e. "the Union list"), which contains more than 200 active substances of medicines considered critical for healthcare systems across the EU/European Economic Area, for which continuity of supply is a priority and for which shortages should be avoided. The list contains active substances of innovator and generic drugs covering a wide range of therapeutic areas and includes vaccines and medicines for rare diseases. It reflects the outcome of a review of 600 active substances taken from six national lists of critical medicines. The list will be expanded in 2024 and will then be updated every year.

The Critical Medicines Alliance will work on a subset of active substances on the Union list before tackling the rest of the list by pooling the expertise and resources of its members to determine how vulnerabilities in the supply chains could be best addressed. A pilot by the European Commission will first analyze the vulnerabilities in the supply chains of an initial set of 10-20 substances from the Union list of critical medicines. The Alliance's efforts will initially focus on the outcomes of this analysis, expected to be published in April 2024. Once the pilot exercise is finalized, the European Commission will proceed with evaluating the remaining medicines in the Union list. It will then recommend priority actions for the near future and propose new tools to address the challenges it has identified. In particular, the recommendations will focus on mitigating structural risks, reinforcing supply by making demand more predictable, encouraging diversification, and boosting manufacturing.

The US is also pursuing policy and action to address the drug supply chain. In November (November 2023), President Joe Biden convened the inaugural meeting of the White House Council on Supply Chain Resilience, a cross-industry and government initiative to address the supply-chain challenges and vulnerabilities exposed during and post-pandemic and ways to strengthen US-based manufacturing and its supply chains. In all, the Biden Administration outlined 30 new actions to strengthen US supply chains and secure key sectors, which includes steps through the Defense Production Act to support US-based domestic manufacturing of essential medicines, new data collaboration to spot supply-chain risks sooner, and transportation and logistics initiatives to ensure the continued flow of supply chains. The implementation of these measures will be a key item to watch for in 2024.

Also on the horizon is how new technology, such on artificial intelligence (AI), will factor into drug manufacturing. Last March (March 2023), the US Food and Drug Administration (FDA) published a discussion paper, Artificial Intelligence in Drug Manufacturing, to outline areas for consideration and policy development identified by scientific and policy experts of the FDA's Center for Drug Evaluation and Research (CDER) for the application of AI in pharmaceutical manufacturing. The discussion paper included a series of questions to stimulate feedback from the public, including CDER and the Center for Biologics Evaluation and Research (CBER) stakeholders.

The discussion paper is part of a larger effort by the FDA in facilitating advanced manufacturing, a term that describes an innovative pharmaceutical manufacturing technology or approach that has the potential to improve the reliability and robustness of the manufacturing process and resilience of the supply chain. Advanced manufacturing can: integrate novel technological approaches, use established techniques in an innovative way, or apply production methods in a new domain where there are no defined best practices. Advanced manufacturing can be used for new or currently marketed large- or small-molecule drug products.

The FDA's discussion paper outlined four key areas in which AI in drug manufacturing has the potential to be applied: process design and scale-up; advanced process control; process monitoring and fault detection; and manufacturing trend monitoring.


In looking at these potential uses, the FDA, in its discussion paper, raised five key issues to be considered from both a regulatory and user perspective and asked for input from the industry and other stakeholders. These areas include: data integrity and data quality in cloud applications; the Internet of Things (IOT) and data-management practices; regulatory oversight of AI required in new drug or biologics license applications; process control and release testing; and real-time data in AI-based machine learning. The FDA extended the time for providing input on its discussion paper to November 2023.

The agency continues to address how AI in drug manufacturing may be used and regulated. Last September (September 2023), the FDA and the Product Quality Research Institute (PQRI) hosted a virtual workshop, The Regulatory Framework for the Utilization of Artificial Intelligence in Pharmaceutical Manufacturing. PQRI is a non-profit consortium of organizations working together to generate and share timely, relevant, and impactful information that advances global drug product quality, manufacturing and regulation. The workshop aimed to facilitate interaction among AI stakeholders on critical areas for development, implementation, and regulatory consideration, including uses in process development and control, operation of pharmaceutical quality systems, lifecycle approaches, and cGMP.

(Source: <https://www.dcatvci.org/features/whats-trending-on-the-industrys-radar-in-2024/>)

INDIAN PHARMACEUTICAL INDUSTRY

Introduction



India is the largest provider of generic drugs globally and is known for its affordable vaccines and generic medications. The Indian Pharmaceutical industry is currently ranked third in pharmaceutical production by volume after evolving over time into a thriving industry growing at a CAGR of 9.43% since the past nine years. Generic drugs, over-the-counter medications, bulk drugs, vaccines, contract research & manufacturing, biosimilars, and biologics are some of the major segments of the Indian pharma industry. India has the most number of pharmaceutical manufacturing facilities that are in compliance with the US Food and Drug Administration (USFDA) and has 500 API producers that make for around 8% of the worldwide API market.

Indian pharmaceutical sector supplies over 50% of global demand for various vaccines, 40% of generic demand in the US and 25% of all medicine in the UK. The domestic pharmaceutical industry includes a network of 3,000 drug companies and ~10,500 manufacturing units. India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers with a potential to steer the industry ahead to greater heights. Presently, over 80% of the antiretroviral drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome) are supplied by Indian pharmaceutical firms. India is rightfully known as the "pharmacy of the world" due to the low cost and high quality of its medicines.

Indian pharmaceutical industry is known for its generic medicines and low-cost vaccines globally. Transformed over the years as a vibrant sector, presently Indian Pharma ranks third in pharmaceutical production by volume. The Pharmaceutical industry in India is the third largest in the world in terms of volume and 14th largest in terms of value. The Pharma sector currently contributes to around 1.72% of the country's GDP.

According to a recent EY FICCI report, as there has been a growing consensus over providing new innovative therapies to patients, Indian pharmaceutical market is estimated to touch US\$ 130 billion in value by the end of 2030. Meanwhile, the global market size of pharmaceutical products is estimated to cross over the US\$ 1 trillion mark in 2023.

Market Size

Market size of India pharmaceuticals industry is expected to reach US\$ 65 billion by 2024, and ~US\$ 130 billion by 2030. According to the government data, the Indian pharmaceutical industry is worth approximately US\$ 50 billion with over US\$ 25 billion of the value coming from exports. About 20% of the global exports in generic drugs are met by India.

India is among the top 12 destinations for biotechnology worldwide and 3rd largest destination for biotechnology in Asia Pacific. In 2022, India's Biotechnology industry crossed US\$ 80.12 billion, growing 14% from the previous year.

During FY18 to FY23, the Indian pharmaceutical industry logged a compound annual growth rate (CAGR) of 6-8%, primarily driven by an 8% increase in exports and a 6% rise in the domestic market.

The Indian pharmaceutical industry has seen a massive expansion over the last few years and is expected to reach about 13% of the size of the global pharma market while enhancing its quality, affordability, and innovation.

The biosimilars market in India is estimated to grow at a compounded annual growth rate (CAGR) of 22% to become US\$ 12 billion by 2025. This would represent almost 20% of the total pharmaceutical market in India.

India is the 3rd largest producer of API accounting for an 8% share of the Global API Industry. About 500+ different APIs are manufactured in India, and it contributes 57% of APIs to prequalified list of the WHO.

The current market size of the medical devices sector in India is estimated to be US\$ 11 billion and its share in the global medical device market is estimated to be 1.5%.

The domestic pharmaceutical sector expects sales to grow 8-10% in the financial year 2023-24, indicated an analysis done by CRISIL, a global analytical research and rating agency.

Indian pharma companies have a substantial share in the prescription market in the US and EU. The largest number of FDA-approved plants outside the US is in India.

According to the Indian Economic Survey 2021, the domestic market is expected to grow 3x in the next decade. India's domestic pharmaceutical market stood at US\$ 42 billion in 2021 and is likely to reach US\$ 65 billion by 2024 and further expand to reach US\$ 120-130 billion by 2030. India's biotechnology industry comprises biopharmaceuticals, bio-services, bio-agriculture, bio-industry, and bioinformatics. The Indian biotechnology industry was valued at US\$ 70.2 billion in 2020 and is expected to reach US\$ 150 billion by 2025. India's medical devices market stood at US\$ 10.36 billion in FY20. The market is expected to increase at a CAGR of 37% from 2020 to 2025 to reach US\$ 50 billion. As of August 2021, CARE Ratings expect India's pharmaceutical business to develop at an annual rate of ~11% over the next two years to reach more than US\$ 60 billion in value.

In the global pharmaceuticals sector, India is a significant and rising player. India is the world's largest supplier of generic medications, accounting for 20% of the worldwide supply by volume and supplying about 60% of the global vaccination demand. The Indian pharmaceutical sector is worth US\$ 42 billion worldwide. In August 2021, the Indian pharmaceutical market increased at 17.7% annually, up from 13.7% in July 2020. According to India Ratings & Research, the Indian pharmaceutical market revenue is expected to be over 12% Y-o-Y in FY22.

Exports

Pharmaceutical is one of the top ten attractive sectors for foreign investment in India. The pharmaceutical exports from India reach more than 200 nations around the world, including highly regulated markets of the USA, West Europe, Japan, and Australia. India supplied around 45 tonnes and 400 million tablets of hydroxychloroquine to around 114 countries globally.

India's drugs and pharmaceuticals exports stood at Rs. 2,08,231 crore (US\$ 25.3 billion) for FY23, as per the data by Pharmexcil.

Exports of drugs and pharmaceuticals recorded a positive growth of 8.14% between April-October 2023.

Exports of Drugs & Pharmaceuticals was estimated to be at US\$ 2.42 billion in October 2023 and shared 7.21% of the total exports of the month.

India is the 12th largest exporter of medical goods in the world. Indian drugs are exported to more than 200 countries in the world, with US being the key market. Generic drugs account for 20% of the global export in terms of volume, making the country the largest provider of generic medicines globally. Indian drug & pharmaceutical exports stood at US\$ 24.60 billion in FY22 and US\$ 24.44 billion in FY21. Indian drug & pharmaceutical exports stood at US\$ 2.19 billion in September 2022.

Investments and Recent developments

The Indian Pharmaceuticals industry plays a prominent role in the global pharmaceuticals industry. India ranks third worldwide for production by volume and 14th by value.

In this regard the sector has seen a lot of investments and developments in the recent past.

- Up to 100%, FDI has been allowed through automatic route for Greenfield pharmaceuticals projects. For Brownfield pharmaceuticals projects, FDI allowed is up to 74% through automatic route and beyond that through government approval.
- The cumulative FDI equity inflow in the Drugs and Pharmaceuticals industry is US\$ 21.58 billion during the period April 2000-September 2023. This constitutes almost 3.3% of the total FDI inflow received across sectors.
- In August 2023, Union Minister for Labour & Employment and Environment, Forest and Climate Change Mr. Bhupender Yadav launched Chemotherapy Services in 30 ESIC Hospitals across the country.
- An MoU was signed on June 4, 2023, between the Indian Pharmacopoeia Commission (IPC), Ministry of Health & Family Welfare, Government of India and Ministry of Health, Government of Suriname for Recognition of Indian Pharmacopoeia (IP) in Suriname.
- In May 2023, the Ministry of Minority Affairs and the Ministry of Ayush joined hands to advance the Unani System of Medicine in India.
- Prime Minister Mr. Narendra Modi during his Independence Day 2023 speech said that the government has plans to increase the number of 'Jan Aushadhi Kendras' from 10,000 to 25,000.
- The Department of Pharmaceuticals will soon launch the Scheme for the Promotion of Research and Innovation in Pharma (PRIP) MedTech Sector. The scheme has been approved by the Union Cabinet for a period of five years starting from 2023-24 to 2027-28 with a total outlay of Rs. 5,000 crore (US\$ 604.5 million).
- Emcure Pharmaceuticals Limited (EPL) becomes the first ever company to launch Orofer FCM 750, a new extension of its parenteral iron brand containing Ferric carboxymaltose (FCM). The dose is suitable for the majority of Indian patients with iron deficiency and iron deficiency anemia.
- Japanese companies have been invited to invest in the Indian Pharmaceutical and Medical Device Industry. The cooperation between Pharmaceutical Traders Association and Japan Federation of Medical Devices Associations of the two countries can contribute to stabilize the global supply-chain especially of APIs and Medical Devices.
- Sun Pharmaceutical Industries Limited announced the successful completion of its acquisition of Concert Pharmaceuticals, Inc. on March 6, 2023, a late-stage clinical biopharmaceutical company that is developing deuruxolitinib, a novel, deuterated, oral JAK1/2 inhibitor, for the potential treatment of adult patients with moderate to severe alopecia areata.
- Glenmark Pharmaceuticals Ltd. (Glenmark), an innovation-driven, global pharmaceutical company, is the first to launch a unique I.V. injection formulation, Akynzeo I.V., in India for the prevention of chemotherapy-induced nausea and vomiting (CINV), under an exclusive licensing agreement with Helsinn, a Swiss biopharma group company.
- Entod Pharmaceuticals launched its new ocular aesthetic range focused on improving eye comfort and enhancing the aesthetics of the eyes.
- BDR Pharmaceutical launched the first generic apalutamide (brand name Apatide) in India to treat both metastatic castration sensitive prostate cancer as well as non-metastatic castration resistant prostate cancer. The product will be available across India.

- Anglo French Drugs & Industries Limited (AFDIL), a 99-year-old organization in the pharmaceutical sector, announced that it has entered into the fertility space with the launch of the LYBER range.
- Eli Lilly introduces Ramiven in India, for certain high-risk early breast cancer patients in November 2022.
- ICPA Health Products Ltd (ICPA), a leading pharma company in the oral healthcare segment, launched its latest product – Heximetro at the annual conference of the Indian Society of Periodontology (ISP) in November 2022.
- The FDI inflows in the Indian drugs and pharmaceuticals sector reached US\$ 19.90 billion between April 2000-June 2022.
- The Indian drugs and pharmaceuticals sector received cumulative FDIs worth US\$ 19.41 billion between April 2000-March 2022.
- The foreign direct investment (FDI) inflows in the Indian drugs and pharmaceuticals sector reached US\$ 1,414 million between in FY 2021-22.
- The Indian pharmaceutical industry generated a trade surplus of US\$ 15.81 billion in FY22.
- Medical Device industry is expected to reach US\$ 50 billion by 2030 growing at a CAGR of 15%.
- In November 2022, Sun Pharma and SPARC entered into a license agreement for commercialization of phenobarbital for injection in the US.
- Glenmark becomes the First Company in India to launch Teneligliptin + Dapagliflozin Fixed Dose Combination in October 2022.
- In October 2022, Lupin signed an agreement to acquire two inhalation brands from Sunovion Pharmaceuticals Inc.
- Dr. Reddy's Laboratories announced the launch of Lenalidomide Capsules in the U.S. with two of six strengths eligible for first-to-market, 180-day exclusivity in September 2022.
- In June 2022, Cipla partnered with Drugs for Neglected Diseases initiative (DNDi) to announce the launch of a 4-in-1 antiretroviral treatment for children living with HIV in South Africa.
- Glenmark becomes the first pharmaceutical company to launch Indacaterol + Mometasone fixed-Dose combination drug for Asthma in India.
- In May 2022, Sun Pharmaceutical Industries Limited through one of its wholly owned subsidiaries plans to launch Bempedoic Acid under the brand name Brillo, in India for reducing low-density lipoprotein (LDL) cholesterol.
- In May 2022, Dr. Reddy's Laboratories enters into exclusive partnership with HK inno.N Corporation to commercialise novel molecule Tegoprazan in India & select emerging markets.
- In April 2022, Dr Reddy's Laboratories Ltd. inked a pact with MediCane Health to announce the launch of medical cannabis products in Germany.
- The Union Cabinet have its nod for the amendment of existing Foreign Direct Investment (FDI) policy in the pharmaceutical sector in order to allow FDI up to 100% under the automatic route for manufacturing of medical devices subject to certain conditions.
- In March 2022, Themis Medicare Ltd. (Themis), announced the approval of its antiviral drug VIRALEX by the Drug Controller General of India (DCGI).
- The National Digital Health Blueprint has the potential to generate nearly US\$ 200 billion in added economic value for India's healthcare industry over the next 10 years.
- In October 2021, AstraZeneca India launched a Clinical Data and Insights (CDI) division to further strengthen its global presence and manage data-related aspects of its clinical trials.
- In September 2021, the Indian government contributed US\$ 4 billion to the pharmaceutical and medical industries.

- In August 2021, Uniza Group, an Ahmedabad-based pharmaceutical firm, signed an agreement with Lysulin Inc. (an US-based firm) to introduce Lysulin, a nutritional product for Indian consumers.
- In May 2021, Indian Immunologicals Ltd. (IIL) and Bharat Immunologicals and Biologicals Corporation (BIBCOL) inked technology transfer pacts with Bharat Biotech to develop the vaccine locally to boost India's vaccination drive. The two PSUs plan to start production of vaccines by September 2021.

Government Initiatives

Some of the initiatives taken by the Government to promote the pharmaceutical sector in India are as follows:

- As per the Union Budget 2023-24: A mission to eliminate sickle cell anemia by 2047 will be launched. It would involve raising awareness, conducting a comprehensive screening of seven crore individuals in the impacted tribal regions between the ages of 0 and 40, and providing counselling through coordinated efforts.
- For innovation in the pharmaceutical sector, through centres of excellence, a new initiative to encourage pharmaceutical research and innovation will be implemented. The government persuades business to spend money on R&D in a few chosen priority fields. At the grassroots level, government has also announced on building 157 nursing colleges in co-location with government medical colleges.
- The Union Cabinet, on April 26, 2023, approved the National Medical Devices Policy, 2023. The National Medical Devices Policy, 2023 is expected to facilitate an orderly growth of the medical device sector to meet the public health objectives of access, affordability, quality and innovation.
- Ayushman Bharat Digital Mission (ABDM):
- Under the ABDM, citizens will be able to create their ABHA (Ayushman Bharat Health Account) numbers, to which their digital health records can be linked. This will enable creation of longitudinal health records for individuals across various healthcare providers and improve clinical decision making by healthcare providers.
- The pilot of ABDM is completed in the six Union Territories of Ladakh, Chandigarh, Dadra & Nagar Haveli and Daman & Diu, Puducherry, Andaman and Nicobar Islands and Lakshadweep with successful demonstration of technology platform developed by the NHA.
- During the pilot, digital sandbox was created in which more than 774 partner solutions are undergoing integration. As of September 4, 2023, 450,164,619 Ayushman Bharat Health Accounts have been created and 224,967 doctors and 218,602 health facilities have been registered in ABDM.
- Scheme for Development of Pharma industry – Umbrella Scheme:
- The Department of Pharmaceuticals has prepared an Umbrella Scheme namely ‘Scheme for Development of Pharma industry’. Which comprises of the following sub schemes:
- Assistance to Bulk Drug Industry for Common Facilitation Centres
- Assistance to Medical Device Industry for Common Facilitation Centres
- Assistance to Pharmaceutical Industry (CDP-PS)
- Pharmaceutical Promotion and Development Scheme (PPDS)
- Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS)
- As per the Union Budget 2022-23:
- Rs. 3,201 crore (US\$ 419.2 million) has been set aside for research and Rs. 83,000 crore (US\$ 10.86 billion) has been allocated for the Ministry of Health and Family Welfare.
- Rs. 37,000 crore (US\$ 4.83 billion) has been allocated to the 'National Health Mission'.

- Rs. 10,000 crore (US\$ 1.28 billion) has been allocated to Pradhan Mantri Swasthya Suraksha Yojana.
- The Ministry of AYUSH has been allocated Rs. 3,050 crore (US\$ 399.4 million), up from Rs. 2,970 crore (US\$ 389 million).
- In March 2022, under the Strengthening of Pharmaceutical Industry (SPI) Scheme, a total financial outlay of Rs. 500 crore (US\$ 665.5 million) for the period FY22 to FY26 were announced.
- India could restart deliveries of COVID-19 shots to global vaccine-sharing platform COVAX in November-December 2021 for the first time since April 2021. The World Health Organization (WHO), which co-leads COVAX, has been pushing India to resume supplies for the programme, particularly after it sent ~4 million doses to neighbours and allies in October 2021.
- In November 2021, PM Mr. Narendra Modi inaugurated the first Global Innovation Summit of the pharmaceuticals sector. The summit will have 12 sessions and over 40 national and international speakers deliberating on a range of subjects including regulatory environment, funding for innovation, industry-academia collaboration and innovation infrastructure.
- In August 2021, Union Health Minister, Mr. Mansukh Mandaviya announced that an additional number of pharmaceutical companies in India are expected to commence manufacturing of anti-coronavirus vaccines by October-November 2021. This move is expected to further boost the vaccination drive across the country.
- In June 2021, Finance Minister Ms. Nirmala Sitharaman announced an additional outlay of Rs. 197,000 crore (US\$ 26,578.3 million) that will be utilised over five years for the pharmaceutical PLI scheme in 13 key sectors such as active pharmaceutical ingredients, drug intermediaries and key starting materials.
- To achieve self-reliance and minimise import dependency in the country's essential bulk drugs, the Department of Pharmaceuticals initiated a PLI scheme to promote domestic manufacturing by setting up greenfield plants with minimum domestic value addition in four separate 'Target Segments' with a cumulative outlay of Rs. 6,940 crore (US\$ 951.27 million) from FY21 to FY30.
- In May 2021, under Atmanirbhar Bharat 3.0, Mission COVID Suraksha was announced by the Government of India to accelerate development and production of indigenous COVID vaccines. To augment the capacity of indigenous production of Covaxin under the mission, the Department of Biotechnology, Government of India, provided financial support in the form of a grant to vaccine manufacturing facilities for enhanced production capacities, which is expected to reach >10 crore doses per month by September 2021.

Road Ahead



The pharmaceutical industry in India is a significant part of the nation's foreign trade and offers lucrative potential for investors. Millions of people around the world receive affordable and inexpensive generic medications from India, which also runs a sizable number of plants that adhere to Good Manufacturing Practices (GMP) standards set by the World Health Organization (WHO) and the United States Food and Drug Administration (USFDA). Among nations that produce pharmaceuticals, India has long held the top spot. Medicine spending in India is projected to grow 9-12% over the next five years, leading India to become one of the top 10 countries in terms of medicine spending. Going forward, better growth in domestic sales would also depend on the ability of companies to align their product portfolio towards chronic therapies for diseases such as cardiovascular, anti-diabetes, anti-depressants and anti-cancers, which are on the rise. The Indian Government has taken many steps to reduce costs and bring down healthcare expenses. The National Health Protection Scheme, which aims to offer universal healthcare, the ageing population, the rise in chronic diseases, and other government programmes, including the opening of pharmacies that offer inexpensive generic medications, should all contribute to boost the Indian pharmaceutical industry. Speedy introduction of generic drugs into the market has remained in focus and is expected to benefit the Indian pharmaceutical companies. In addition, the thrust on rural health programmes, lifesaving drugs and preventive vaccines also augurs well for the pharmaceutical companies.

(Source: <https://www.ibef.org/industry/pharmaceutical-india>).

OUR BUSINESS

This chapter should be read in conjunction with, and is qualified in its entirety by, the more detailed information about our Company and its financial statements, including the notes thereto, in the section titled “Risk Factors” and chapters titled “Restated Financial Statements” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” beginning on page 30, 196 and 199 respectively, of this Prospectus.

Unless otherwise indicated, the Restated Financial Statements included herein is based on our Restated Financial Statements for period ended December 31, 2023 and Financial Years ended on March 31, 2023, 2022 and 2021 included in this Prospectus. For further information, see “Restated Financial Statements” beginning on page 196 of this Prospectus.

OVERVIEW

Our Company, Quest Laboratories Limited is engaged in the business of manufacturing of pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. These formulations fall under the trademark “**Quest Laboratories Limited**”. The company produces a variety of products, comprising ethical drugs, generic drugs, and over-the-counter drugs (OTC). These products are available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids. This comprehensive approach allows our Company to address a wide range of medical needs and preferences among patients.

Our Company holds WHO Schedule M GMP, and GLP certifications, adhering to the stringent guidelines set by the World Health Organization. Our commitment to quality is further demonstrated by our ISO 9001:2015 certification and ISO/IEC 17025:2017 accreditation. With manufacturing under one roof, our company maintains stringent quality control standards throughout the entire manufacturing process. By doing so, we ensure that our products meet the relevant quality standards before they reach the market.

Our Company also possesses Good Laboratory Practice (GLP) certificate issued by Food & Drug Administration, Bhopal, Madhya Pradesh, indicating its commitment to maintaining high standards of quality and compliance in laboratory operations, particularly within the pharmaceutical sector. Our in-house laboratory is equipped with various equipment such as HPLC (High-Performance Liquid Chromatography), GC (Gas Chromatography), FTIR (Fourier Transform Infrared Spectroscopy), UV (Ultraviolet-Visible Spectroscopy), Dissolution apparatus, and other advanced instruments. This comprehensive suite of tools enables us to conduct a wide array of tests and analyses efficiently and accurately.

Furthermore, our professional staff ensures the reliability and credibility of our laboratory results and services. With their expertise, we maintain precision, adhere to protocols, and deliver results in a timely manner, all of which are paramount in pharmaceutical and related industries. Having these resources and capabilities in-house allows our Company to support various aspects of product development, quality control, and regulatory compliance. As a result, we have earned a reputation as a reliable and efficient laboratory service provider.

We currently have our manufacturing facility located at Plot No. 45, Sector III, Pithampur Industrial Area, Pithampur, Dhar - 454775, Madhya Pradesh, India. The total area of the facility is approximately 4,065 square meters. Our manufacturing facilities are well equipped with the required facilities including machinery, other handling equipment’s to facilitate smooth manufacturing process and easy logistics. We endeavour to maintain safety in our premises by adhering to key safety norms, established through our internal health and safety manual, accompanied by regular safety meetings.

Our Company have been receiving sales orders from the private sector & government institutions on regular basis. This collaborative approach offers benefits to the purchasers, including cost efficiency through bulk production, capacity scaling, regulatory compliance, reduced lead times, risk mitigation, access to specialized technologies, geographical expansion, cost effective compliance, and resource optimization.

Our company has successfully bid for government tender contracts over the past few years, collaborating with major state and central government institutions and corporations.

The key raw materials utilized in our manufacturing operations encompass Active Pharmaceutical Ingredients (APIs) for our formulations, key starting materials, and intermediaries for our internally manufactured APIs. We also acquire other materials such as excipients, manufacturing consumables, lab chemicals, and packaging materials. Furthermore, our procurement extends to packaging materials sourced from vendors situated across different geographical locations. In the domestic market, our company procures raw materials primarily from Madhya Pradesh, Maharashtra, Himachal Pradesh, Telangana, Uttarakhand, and Gujarat. We strive to maintain strong relationships with suppliers across these regions to ensure a steady supply chain and the quality of our products.

Our company operates in the domestic market across twelve (12) states and two (2) union territories namely Uttar Pradesh, Madhya Pradesh, Maharashtra, Delhi, Jharkhand, Assam, Karnataka, Jammu & Kashmir, Rajasthan, West Bengal Gujarat, Telangana, Haryana and Bihar based on sales made for the period ended December 31, 2023 and for the financial year ended March 31, 2023, 2022 and 2021.

Our company is promoted by Mr. Anil Kumar Sabarwal and Ms. Tejaswini Sabarwal, possessing around two decades and 5 years of experience, respectively, in the pharmaceutical industry. Our promoters have played pivotal roles in guiding, developing, growing, managing, and controlling the major aspects of our business operations, drawing upon their considerable expertise in the pharma sector. For more details, please see the chapter titled, “*Our Management*” and “*Our Promoter and Promoter Group*” on page 175 and 190 of this Prospectus. We attribute our success to sustained efforts over the years in key areas of our business, including product portfolio management, process improvements, and the expansion of our operational scale. Moreover, our company is managed by a team of industry veterans comprising individuals with technical, operational, and business development experience in the chemical and pharmaceutical sectors. We believe that the collective experience of our management team, coupled with their deep understanding of industry dynamics, regulatory affairs, manufacturing, quality control, sales, marketing, and finance, positions us to capitalize on current and future market opportunities both in India and internationally.

Our product mix has evolved over the past several years as we entered new product categories. We are consistently expanding our product portfolio through research and development of new pharmaceutical formulations. Our company maintains an in-house Department of Formulation Development, Quality Control, and Product Stability Studies. This department takes existing products and their dosages, then formulates different variations. Subsequently, they study these formulations, conducting Process Validations, Analytical Method Validations, and Cleaning Validation according to Standard Operating Procedures. This process ensures that we create and maintain quality pharmaceutical products, meeting regulatory standards and satisfying customer expectations.

Further, our company continues to benefit from the various initiatives extended by the government to support the MSME segment. Under the Madhya Pradesh MSME Yojna, specifically the MSME Promotion Scheme of 2016 and 2019, our company has received subsidies totalling ₹ 15.00 Lakhs and ₹ 26.79 Lakhs respectively, as Industrial Development Grants, for investments made in machinery. Additionally, under the Madhya Pradesh Interest Subsidy Scheme of 2023, we have been granted ₹ 20.00 Lakhs.

These subsidies serve as invaluable support, alleviating financial burdens associated with capital investments and interest payments. They enable our company to allocate resources more efficiently towards enhancing productivity, expanding operations, and contributing to economic growth and employment generation within the region. We remain committed to adhering to all terms and conditions associated with these subsidies to ensure continued benefit. Leveraging such government schemes not only underscores our dedication to innovation and sustainability but also reinforces our contribution to the local economy.

For period ended December 31, 2023 and for the Financial Years ended on March 31, 2023, 2022 and 2021, our revenue from operations was ₹ 6,207.98 Lakhs, ₹ 6,164.06 Lakhs, ₹ 5,948.39 Lakhs and ₹ 3,036.35 Lakhs, respectively. Our EBITDA (earnings before interest, depreciation and tax) for the Period ended December 31, 2023 and financial year ended March 31, 2023, 2022 and 2021 was ₹ 1208.63 Lakhs, ₹ 782.24 Lakhs, ₹ 646.55 Lakhs and ₹ 141.84 Lakhs, respectively, while our profit after tax for the Period ended December 31, 2023 and financial year ended March 31, 2023, 2022 and 2021 was ₹ 774.93 Lakhs, ₹ 502.85 Lakhs, ₹ 410.50 Lakhs and ₹ 65.50 Lakhs, respectively.

Key Performance Indicators of our Company.

As per Restated Financial Statements

(₹ in Lakhs, otherwise mentioned)

Key Financial Performance	December 31, 2023	March 31, 2023	March 31, 2022	March 31, 2021
Revenue from Operations ⁽¹⁾	6207.98	6,164.06	5,948.39	3,036.35
EBITDA ⁽²⁾	1208.63	782.24	646.55	141.84
EBITDA Margin (%) ⁽³⁾	19.47%	12.69%	10.87%	4.67%
PAT	774.93	502.85	410.50	65.50
PAT Margin (%) ⁽⁴⁾	12.48%	8.16%	6.90%	2.16%
Return on equity (%) ⁽⁵⁾	34.03%	40.20%	51.69%	11.78%
Debt-Equity Ratio (times) ⁽⁶⁾	0.20	0.27	0.31	0.52
Current Ratio (times) ⁽⁷⁾	1.42	1.25	1.17	1.10

*As certified by M/s Shyam S. Gupta & Associates, Chartered Accountants, by way of their certificate dated April 17, 2024.

Notes:

- 1) *Revenue from operation means revenue from sale of our products*
- 2) *EBITDA is calculated as Profit before tax + Depreciation + Finance Costs – Other Income*
- 3) *EBITDA Margin is calculated as EBITDA divided by Revenue from Operations*
- 4) *PAT Margin is calculated as PAT for the period/year divided by revenue from operations*
- 5) *Return on Equity is calculated by comparing the proportion of net income against the amount of average shareholder equity*
- 6) *Debt to Equity ratio is calculated as Total Debt divided by equity*
- 7) *Current Ratio is calculated by dividing Current Assets to Current Liabilities*

OUR STRENGTHS**1. Multi-product capability**

We have approvals to manufacture more than 600 formulations. We routinely manufacture 250 to 300 types of formulations based on market demand and limited formulation lines. However, we have versatile manufacturing facility by which we can produce multiple products using a combination of processes. The flexible manufacturing infrastructure helps us change our product mix in response to changes in market demand. We have complete infrastructure of formulation development, pilot plant and validation studies and are able to develop efficient and cost-effective specialized processes at short notice.

2. Revenue from Government institutions

Institutional and government business constitute a vital segment for our Company. The distribution of free drugs through initiatives by both state and central governments of India serves numerous critical objectives, encompassing equitable access to healthcare, poverty alleviation, public health initiatives, mortality and morbidity reduction, rural healthcare access, maternal and child health, chronic disease management, preventive care, response to public health emergencies, and fulfilment of international commitments. Our Company participates in government tenders, forging collaborations with major state and central government institutions. The advantages of government business include bulk quantity orders, committed volumes, and favorable purchase prices due to high-volume transactions.

3. Product Portfolio:

A diverse and well-balanced product portfolio is another key competitive advantage for our Company. Our Company offers a comprehensive range of products, including generic drugs, branded pharmaceuticals, over-the-counter (OTC) products, and specialized medications. This diverse portfolio allows our company to cater to various market segments and respond effectively to changing market demands.

4. Research and Development

Our Company is a technology-driven organization supported by extensive R&D department, coupled with well-equipped laboratories and the technical officials in the industry. Emphasis is placed on upgrading process technology, reducing costs, conducting pilot plant research, improving quality, optimizing resource utilization, and developing new products. In essence, improving the quality of formulations and developing newer and innovative dosage forms are ongoing tasks of the R&D department.

Our laboratory well is equipped for physical and metallurgical testing, microbiological testing, effective process controls, chemical testing, pharmacological testing, stability studies, and more. These capabilities ensure comprehensive evaluation and validation of products and processes, enabling us to maintain high standards of quality and innovation within its industry.

5. Quality assurance

Our Company holds Good Laboratory Practice (GLP) certificate from the Food & Drug Administration in Bhopal, Madhya Pradesh. With its own in-house Quality Control Laboratory, our Company ensures testing of both raw materials and finished goods. Our laboratory is equipped with advanced technology and staffed by technically qualified experts who can handle timely quality checks. This comprehensive testing process assures that all products manufactured by our Company meets relevant quality standards and adhere to regulatory requirements.

Our Company focuses on evaluating the quality of its systems and processes. This holistic approach ensures that every aspect of the manufacturing and quality control processes is assessed and optimized to deliver consistent and reliable results. Our company's commitment to quality is further reinforced by its certifications, including:

- a) WHO-GMP Certificate,
- b) GLP Certificate
- c) ISO 9001:2015 Certification
- d) ISO/IEC 17025:2017 Certification

For further details relating to quality certifications, kindly refer to the chapter titled, “*Our History and Certain Other Corporate Matters*” beginning on page 172 of this Prospectus.

6. Experienced Promoter and management team

We are led by qualified and experienced Board of Directors, Key Managerial Personnel and Senior Management, who we believe have knowledge and understanding of the pharmaceutical industry and have the expertise and vision to scale up our business.

Our Promoters have played a key role in guiding, developing, and growing our business, our promoter and managing director, Mr. Anil Kumar Sabarwal, has over two decades of experience in Pharma Industry and has been instrumental in crafting new avenues. For details, relating to the experience of our management, please see the chapters titled, “*Our Management*” and “*Our Promoter and Promoter Group*” on page 175 and 190 of this Prospectus. The team comprises of personnel having technical, operational, and business development experience in chemical and pharmaceutical industries. We believe that our management team’s experience and their understanding of the industry, regulatory affairs, manufacturing, quality control, sales, marketing, and finance will enable us to continue to take advantage of both current and future market opportunities within India and Abroad.

We believe our Promoters and Senior Management overall experience and vision will enable us to manage and grow our business in the existing markets and to enter new geographies with our competitive advantage. This will help us in addressing and mitigating various risks inherent in our business, including technical problems, facing the competitive landscape changes in global economy resulting in fluctuations in chemical and pharmaceutical pricing across the globe, etc.

7. Supply Chain Efficiency

Our company maintains an efficient and well-managed supply chain. This efficiency results in reduced lead times, minimized inventory costs, and improved overall responsiveness to market changes. Such streamlined supply chain operations provide a significant competitive advantage in the pharmaceutical industry, where timeliness and efficiency are crucial factors. By leveraging these competitive advantages, our Company continues to thrive in competitive pharmaceutical market, delivering high-quality products, satisfying customer needs, and driving its long-term success. In the pharmaceutical industry, where precision, timeliness, and compliance are critical, an optimized supply chain can indeed provide a substantial competitive advantage.

Furthermore, the ability to adapt to market changes swiftly is crucial in an industry where regulations, consumer preferences, and medical breakthroughs can significantly impact demand and production. A streamlined supply chain enables the company to adjust its operations promptly, ensuring it meets evolving customer needs. By consistently delivering high-quality products and maintaining customer satisfaction, our Company fosters long-term success in a challenging and dynamic industry landscape. As pharmaceutical market continues to evolve, leveraging these competitive advantages will be key to sustaining growth and staying ahead of competitors.

OUR STRATEGIES

1. Expansion and upgradation of our manufacturing facility

We intend to expand and upgrade our manufacturing capacities for existing formulations and new formulations that are currently in development and commercialization stages. Our plan involves increasing production capacity by installing new plants and machinery at our existing manufacturing facility. We firmly believe that our investment in these plants and machineries will augment our current installed capacity, thereby enabling us to address the demand in the pharmaceutical injectable sector, particularly in the field of oncology. Our objective is to establish an injectable section comprising liquid vials and ampoules, as well as dry injections, including a lyophilizer line, to ensure efficient production processes.

We plan to fund capital expenditure towards purchase of plant and machineries for expansion and upgradation at the existing manufacturing facility from net proceeds of the issue. For details, also see “Objects of the Issue” on page 81 We will

continue to pursue such opportunities where we believe they will add value to our business, our stakeholders and our customers.

2. Expand our Geographical Presence

We intend to focus on diversifying our customer base across both domestic and global markets. Our broad strategic initiatives for international markets include offering a wide product portfolio with a well-established pipeline to support growth in our existing markets, developing a comprehensive market penetration strategy, implementing territory-specific marketing, and establishing our presence in developed markets.

We believe that our growth in the domestic market will result from the increasing demand for generic drugs, access to affordable, high-quality medicine, and new product opportunities. We have presence in twelve (12) states and two (2) union territories namely Uttar Pradesh, Madhya Pradesh, Maharashtra, Delhi, Jharkhand, Assam, Karnataka, Jammu & Kashmir, Rajasthan, West Bengal, Gujarat, Telangana, Haryana and Bihar based on sales made for the period ended December 31, 2023 and for the financial year ended March 31, 2023, 2022 and 2021. As a business strategy, we intend to widen our reach by increasing our domestic presence and entering the international market. To meet the escalating demand in the pharmaceutical industry, we intend to expand and upgrade our manufacturing capacities and we believe that our investment in these plants and machinery will augment our current installed capacity, thereby enabling us to address the demand in the pharmaceutical injectable sector, particularly in the field of oncology which will facilitate entry in the international market and establish our presence in global pharmaceutical market.

3. Widen our product portfolio

Our Company aims to expand and diversify our product portfolio by increasing its product base and introducing new range of product lines. We plan to continue expanding our manufacturing capabilities in order to capture future growth trends. We intend to explore opportunities to expand our operations by developing new products and services within our existing lines of business. Our plan involves increasing production capacity by installing new plant and machineries at our existing manufacturing facility. We firmly believe that our investment in these plants and machineries will augment our current installed capacity, thereby enabling us to address the demand in the pharmaceutical injectable sector, particularly in the field of oncology. Our objective is to establish an injectable section comprising liquid vials and ampoules, as well as dry injections, employing technology, including a lyophilizer line, to ensure efficient production processes.

4. Continue to improve operating efficiencies through technology enhancements

Our Company is a technology-driven organization supported by extensive R&D department, coupled with well-equipped laboratories and the technical officials in the industry. Emphasis is placed on upgrading process technology, reducing costs, conducting pilot plant research, improving quality, optimizing resource utilization, and developing new products. In essence, improving the quality of formulations and developing newer and innovative dosage forms are ongoing tasks of the R&D department.

Our laboratory is equipped for physical and metallurgical testing, microbiological testing, effective process controls, chemical testing, pharmacological testing, stability studies, and more. These capabilities ensure comprehensive evaluation and validation of products and processes, enabling us to maintain high standards of quality and innovation within its industry. We believe that our in-house technology capabilities will continue to play a key role in effectively managing and expanding our operations, maintain strict operational and fiscal controls and continue to enhance customer service levels. We continue to further develop our technology systems to increase asset productivity, operating efficiencies and strengthen our competitive position.

REVENUE BIFURCATION

Following is the revenue bifurcation split between government institution and private sector as on December 31, 2023 and for the year ended March 2023, 2022 and 2021.

(₹ in Lakhs, otherwise mentioned)

Particulars*	Sales Distribution							
	December 31, 2023		March 31, 2023		March 31, 2022		March 31, 2021	
	Amount	%	Amount	%	Amount	%	Amount	%
Government Institutions	4,136.93	66.64	3,817.61	61.93	3,040.15	51.11	547.91	18.05
Private Sector	2,071.05	33.36	2,346.45	38.07	2,908.15	48.89	2,488.43	81.95
Total	6,207.98	100.00	6,164.06	100.00	5,948.30	100.00	3,036.34	100.00

*As certified by M/s Shyam S. Gupta & Associates, Chartered Accountant., by way of their certificate dated April 04, 2024.

GEOGRAPHICAL PRESENCE

We intend to focus on diversifying our customer base across both domestic and global markets. Our broad strategic initiatives for international markets include offering a wide product portfolio with a well-established pipeline to support growth in our existing markets, developing a comprehensive market penetration strategy, implementing territory-specific marketing, and establishing our presence in developed markets. We believe that our growth in the domestic market will result from the increasing demand for generic drugs, access to affordable, high-quality medicine, and new product opportunities. We have presence in twelve (12) states and two (2) union territories as mentioned below.

(₹ in Lakhs, otherwise mentioned)


Particulars	For the period / year ended							
	December 31, 2023		March 31, 2023		March 31, 2022		March 31, 2021	
	Value	In %	Value	In %	Value	In %	Value	In %
Uttar Pradesh	3412.08	54.96	1905.92	30.92	2596.77	43.65	250.83	8.26
Madhya Pradesh	2460.42	39.63	3119.75	50.61	1906.14	32.04	1315.68	43.33
Maharashtra	23.11	0.37	295.92	4.80	430.62	7.24	317.90	10.47
Delhi	14.52	0.23	20.88	0.34	4.03	0.07	272.80	8.98
Jharkhand	2.73	0.04	---	---	24.41	0.41	2.60	0.09
Assam	31.17	0.50	707.88	11.48	628.88	10.57	263.90	8.69
Rajasthan	---	---	0.62	0.01	---	---	6.35	0.21
Bihar	---	---	4.65	0.08	5.45	0.09	1.80	0.06
Karnataka	166.48	2.68	7.20	0.12	4.49	0.08	86.61	2.85
West Bengal	---	---	---	---	38.19	0.64	166.46	5.48
Gujarat	---	---	38.80	0.63	14.57	0.24	9.21	0.30
Jammu & Kashmir	97.47	1.57	62.45	1.01	---	---	51.31	1.69
Telangana	---	---	---	---	144.44	2.43	---	---
Haryana	---	---	---	---	1.15	0.02	---	---
Export	---	---	---	---	149.25	2.51	90.89	9.58
TOTAL	6,207.98	100.00	6,164.06	100.00	5,948.39	100.00	3,036.35	100.00

*As certified by M/s Shyam S. Gupta & Associates, Chartered Accountant., by way of their certificate dated April 04, 2024.



OUR PRODUCTS

1. TABLETS



Sr. No	Name of Tablets	Sr. No	Name of Tablets
1	Cetirizine Hydrochloride Tablet IP 10 mg	119	Aspirin Tab. USP
2	Zinc Sulphate Dispersible Tablet IP	120	Methyl Dopa Tablet Coated F/C
3	Diclofenac Sodium Tablet BP	121	Ferrous Fumarate and Folic Acid
4	Doxycycline Hyclate Tablet IP	122	Primaquine Tab. IP F/C
5	Calcium Gluconate Tablet IP	123	Primaquine Tab USP 7.5 mg
6	M - Vital Tablet	124	Folic Acid IP Tablet
7	Ibuprofen Tablet IP	125	Ascorbic Acid Tablet IP
8	Paracetamol Tablet IP	126	Dicyclomine Hydrochloride Tablet IP
9	Metronidazole Tablet IP	127	Sulphamethaxazole + Trimethoprim BP (Cotrim-SS)
10	Zinc Sulphate Dispersible Tablet USP	128	Sulphamethaxazole + Trimethoprim IP (Cotrim-DS)

Sr. No	Name of Tablets	Sr. No	Name of Tablets
11	Ferrous Sulphate & Folic Acid IP (E/C, F/C, S/C) Blue, Red	129	Albendazole Tablet IP
12	Nimesulide Tablet BP	130	Dicyclomine Hydrochloride Tablet IP
13	Dicyclomine Hydrochloride & Paracetamol Tablet BP	131	Norethisterone Tablet IP
14	Diclofenac Sodium & Paracetamol Tablet BP	132	Aceclofenac & Paracetamol Tab. IP (50+250 MG)
15	Multivitamin Tablet NFI (Sugar Coated Tablets) 2500 IU	133	Metformin Hydrochloride SR Tablets IP
16	Ferrous Sulphate & Folic Acid (E/C, F/C, S/C) Blue, Red	134	Azithromycin Tablet IP
17	Cefixime Trihydrate Tablet IP	135	Iron & Folic Tablet IP Large S/C, F/C S/C
18	Salbutamol Sulphate Tablet IP	136	Carisoprodol Tablets USP (Carmosin Red colour)
19	Primaquine Tablet IP F/C	137	Carisoprodol Tablets USP
20	Furazolidone Tablet	138	Diclofenac + Paracetamol + Chlorzoxazone IP Tablet
21	B-Complex Tablet	139	CARBAMAZEPINE TABLETS IP 400 MG
22	Diclofenac Sodium Tablet IP	140	Dried Aluminium Hydroxide Gel, Magnesium Hydroxide & Simethicone Chewable Tablets IP
23	Ciprofloxacin Tablet IP	141	Ofloxacin Tablet IP (Indocin)
24	Ibuprofen Tablet BP	142	Ofloxacin + Ornidazole Tablet IP (Indocin-OZ)
25	Furazolidone & Metronidazole Tablets IP	143	Amlodipine Tablets IP
26	Salbutamol Sulphate Tablet IP	144	Glibenclamide + Metformin
27	Ivermectin Tablets USP 12MG (Export)	145	Diclofenac Sodium + Paracetamol Tablets IP
28	Calcium & Vitamin D3 Tablet IP	146	Loperamide Hydrochloride Tablet IP
29	Quinine Sulphate Tablet USP	147	Betamethasone Sodium phosphate Tablet IP
30	Norfloxacin & Tinidazole Tablet	148	Dexamethasone Tablet IP
31	Metformin HCl, Glimepiride Tablets IP	149	Chlorpheniramine Maleate Tablets
32	Azithromycin Tablet IP 500mg (Round Shape)	150	Norfloxacin Tablets IP
33	Paracetamol Tablets IP 650 mg (Avg. Wt.-725 mg)	151	Aceclofenac Tablet IP
34	Tramadol Tablet BP F/C	152	Diclofenac Sodium + Paracetamol Tablets BP
35	Paracetamol & Phenylephrine Hydrochloride Chlorpheniramine Maleate Tablets	153	Diclofenac + Paracetamol Tablet IP (Dycloboon)
36	Levocetirizine HCl Tablets IP	154	Diclofenac + Paracetamol Tablet IP (Dycloboon-Forte)
37	Levonorgestrel Tablet BP (ELLE-72)	155	Loperamide Hydrochloride Tablet IP (Lomosafe)
38	Nimo Gold Plus Tablet	156	Ivermectin Tablets IP
39	Cold Hit Plus Tablet	157	Cyproheptadine Hydrochloride Tablet IP (Periton)
40	Sulfamethoxazole + Trimethoprim Tablet IP	158	Mebendazole Tablet IP
41	Carbamazepine Tablet BP	159	Paracetamol Tablet IP
42	Diclofenac Sodium SR Tablet IP	160	Paracetamol Tablets
43	Aluminium Hydroxide Gel Tablets IP	161	Paracetamol + Dicyclomine Tablet IP (Cyclonpar)
44	Diethylcarbamazine Tablet IP	162	Telmisartan Tablets IP
45	Ferrous Sulphate Tablet IP	163	Nimesulide + Paracetamol Tablet IP (SUMU)
46	Fluconazole Tablet IP	164	ASCORBIC ACID Tablets IP 100 mg
47	Dicyclomine Hydrochloride & Paracetamol Tablets IP	165	Azithromycin Tablet IP
48	Aceclofenac & Paracetamol Tablet IP	166	Chloroquine Phosphate Tablet f/c IP (MOSQUINE-250)
49	Poly vitamin Tablets NFI (Sugar Coated Tablets) 10000 IU	167	Chloroquine Phosphate Tablet f/c IP (MOSQUINE-500)
50	Vitamin B-Complex Tablets NFI (in Tartrazine Yellow)	168	Mefenamic acid + Dicyclomine IP (MEFCON SPAS)
51	Prochlorperazine Maleate & Acetaminophen Tablets	169	Mefenamic Acid and Dicyclomine Hydrochloride Tablets (MEF - SPAS)
52	Ranitidine Hydrochloride IP (Film coated)	170	Ibuprofen and Paracetamol Tablet IP
53	Tinidazole Tablets IP	171	Poly vitamin Tablets NFI (Sugar Coated Tablets) 2500 IU
54	Pantoprazole {E/C}	172	Carbamazepine Tablets IP 400 mg

Sr. No	Name of Tablets	Sr. No	Name of Tablets
55	Sildenafil & Carisoprodol Tablets 100mg	173	Mefenamic acid + Dicyclomine IP
56	B-Complex Tablet	174	Paracetamol Tablets IP (Avg. Wt.- 780mg)
57	Ferrous Sulphate (Iron) and Folic Acid Tablets (Red)	175	Paracetamol, Phenylephrine HCl, Cetirizine Dihydrochloride Tablets
58	Ferrous Sulphate (Iron) and Folic Acid Tablets (Blue)	176	Pyridoxine HCl 100mg (vitamin B6) tablets IP
59	Minitrim Tablet	177	POLY-VITAMIN TABLETS (9/32 PUNCH)
60	Ornidazole Tablets IP	178	Calcium carbonate tablets IP 400mg
61	Calcium, Zinc, Magnesium, Vitamin C, Vitamin D	179	Mifepristone tablets IP
62	Cefixime IP	180	Misoprostol tablets IP
63	Favipiravir Tablets 200mg	181	Calcium carbonate tablets IP 500mg
64	Carbamazepine TABLETS IP	182	Calcium carbonate tablets IP 625mg
65	Ondansetron IP 4mg	183	Calcium carbonate tablets IP 1000 mg
66	Carisoprodol Tablets USP (White colour)	184	Calcium carbonate tablets IP (1250 mg+500mg+250IU)
67	Paracetamol, Bromhexine, Chlorpheniramine Maleate, Guaiphenesin	185	Atenolol tablets IP 100mg
68	Sildenafil Citrate & Depoxitine Tablets BP	186	Ibuprofen & Paracetamol tablets
69	Favipiravir Tablets 400mg	187	Diclofenac + Paracetamol (50+325+10mg)
70	Favipiravir Tablets 800mg	188	Misoprostol tablets IP
71	Tramadol Hcl Tablet F/C	189	Clarithromycin tablets IP 500mg
72	N-Bion Tablets	190	Erythromycin Estolate tab. USP 250mg
73	Carisoprodol Tablets USP	191	Roxithromycin Tablets IP 150mg
74	Domperidone Tablets IP 10mg	192	Famotidine Tablets
75	Glimepiride Tablets IP 2mg	193	Paracetamol & Diclofenac Potassium
76	Coldflex (Parachloropheniramine Maleate & Caffeine Tablets IP)	194	NIMESULIDE MOUTH DISSOLVING TABLETS 100MG
77	Glimepiride Tablets IP 1mg	195	Tapentadol tablets 50 mg
78	Atenolol Tablets IP 50mg	196	Tapentadol tablets 100 mg
79	Hydroxychloroquine Sulphate	197	Calcium Citrate 500mg
80	Chlorpheniramine Maleate Tablets USP	198	Levocetirizine & Ambroxol
81	Dextromethorphan Hydrobromide BP	199	Famotidine Tablets 40 mg
82	Metformin Hydrochloride Tablet BP	200	Vitamin B - Complex Tablets (IN Carmoisine red Colour)
83	Azithromycin Tablet USP	201	Zinc Acetate Tablets
84	Vitamin-C (Ascorbic Acid) Tablets BP	202	Vitamin D Tablets (Cholecalciferol)
85	Diclofenac Sodium BP	203	Posaconazole Tablets
86	Ciprofloxacin BP	204	Activated Charcoal Tablets
87	Pantoprazole USP {E/C}	205	Aspirin Tab. IP
88	Levofloxacin Tablets USP 500mg	206	Carbimazole Tablets IP
89	Drotaverine Hydrochloride Tablets 40mg	207	Glibenclamide Tablets IP 5mg
90	Folic Acid Tablet IP 0.4mg	208	Glipizide Tablets IP 5mg
91	Telmisartan Tablets IP 40mg	209	Isosorbide Mononitrate Tablets IP
92	Carbamazepine Tablets IP 200 MG	210	Telmisartan Tablets IP
93	Ivermectin Tablets 12mg	211	Nitrofurantoin Tablets IP 100mg
94	Rabeprazole Gastro-Resistant Tablets IP	212	Quetiapine fumarate Tablets IP
95	Serratiopeptidase Tablet IP 10mg	213	Tramadol Tab. 50mg
96	Cefuroxime Tablets IP	214	Trihexyphenidyl Hydrochloride Tablets IP
97	Loperamide Hydrochloride & Simethicone Tablet	215	Vildagliptin Tablets 50mg
98	Myo-inositol & Folic Acid Tablets (1000mg+100mcg)	216	Bisacodyl Tablets IP 5 mg
99	Loperamide Hydrochloride Tablet USP	217	Nicotine Polacrilex Gum USP
100	Ursodeoxycholic Acid Tablets BP 300mg	218	Prednisolone Tablets IP 10 mg
101	Metformin HCl, Glimepiride & Pioglitazone Tablets	219	Alprazolam Tablets 0.5 mg

Sr. No	Name of Tablets	Sr. No	Name of Tablets
102	Tinidazole, Neomycin Sulphate, Nystatin & Prednisolone Sodium Tablets	220	Acyclovir tablets 400 mg
103	Ornidazole, Miconazole, Neomycin & Prednisolone Tablets	221	Folic Acid Tablets BP 5mg
104	Myo-Inositol, D-Chiro-Inositol, Metformin HCl, Calcium L-methyl folate & Methylcobalamin Tablets	222	Dextromethorphan Hydrobromide Tablets
105	Diclofenac Potassium, Betamethasone Sodium Phosphate & Hydroxocobalamin Sulphate Tablets	223	Enzyme Tablets
106	Ferrous Sulphate (Iron) and Folic Acid Tablets IP	224	Folic Acid Tablets BP 0.4 mg
107	Albendazole Tablets USP	225	Azithromycin Tablets BP 250mg
108	Levofloxacin Tablets IP 250mg	226	Azithromycin Tablets BP 500mg
109	Ferrous Ascorbate & Folic Acid Tablets	227	Levofloxacin Tablets IP 500mg
110	Trimethoprim & Sulfamethoxazole Tablets	228	Paracetamol Tablets BP
111	Metronidazole Tablets BP 500mg	229	Diclofenac Sodium & Paracetamol Tablets
112	Ranitidine Hydrochloride Tablets	230	Drotaverine Hydrochloride Tablets
113	Paracetamol Tablets BP	231	Aluminium Hydroxide, Magnesium Carbonate activated dimethicon Tablets.
114	Fluconazole Tablet BP	232	Ferrous Sulphate & Folic Acid IP (E/C-Blue) large
115	Azithromycin Tablets BP 1000 mg	233	Etophylline and Theophylline Prolonged - Release Tablets
116	Erythromycin Stearate Tablet IP 500mg		

2. DRY SYRUP & SUSPENSION:





Sr. No	NAMES OF DRY SYRUP AND SUSPENSION:	Sr. No	NAMES OF DRY SYRUP AND SUSPENSION:
1	Ferrous Sulphate & Folic Acid Syrup	60	Aluminium Hydroxide + Magnesium Hydroxide + Simethicone Suspension
2	Metronidazole Oral Suspension IP 100 mg/5ml	61	Haematinic Syrup with Vitamin B12, Iron folic acid and Sorbitol
3	Ibuprofen Oral Suspension BP	62	Acelofenac & Paracetamol Suspension
4	Paracetamol Oral Suspension IP	63	Furazolidone & Metronidazole Suspension
5	Albendazole Suspension IP	64	Cefixime Oral Suspension IP 100mg/5ml
6	Multivitamin Oral Syrup	65	Paracetamol Drop 150mg
7	Vitamin-A Paediatric Oral Solution IP	66	Ferrous Sulphate & Folic Acid Syrup Adult
8	Paracetamol Oral Syrup IP 250mg	67	Multivitamin Drops
9	Co-trimazole Oral Suspension BP	68	Ibuprofen Oral Suspension
10	Zinc Oral Solution USP	69	Ascorbic Acid (Vitamin - C) Drop Ip
11	Co-trimazole Oral Suspension IP	70	B-Complex (Vitamin B12 with L- Lysine Suspension)
12	Milk Of Magnesia USP	71	Paracetamol Oral Syrup IP 125 mg
13	Norfloxacin & Metronidazole Suspension	72	Kofgin Syrup
14	Bromhexine Hydrochloride Syrup	73	Salbutamol sulphate Syrup IP
15	Ambroxol HCL Syrup	74	Zinc Sulphate Oral Solution IP
16	Azithromycin oral suspension IP	75	Iron and Folic Acid with B12 Syrup
17	Cyproheptadine Hydrochloride Syrup	76	Metronidazole Oral Suspension IP
18	Ambroxole Hydrochloride Syrup	77	Lactulose Solution USP
19	Ferrous Sulphate Oral solution USP (34mg/5ml)	78	Calcium and vitamin D3 Suspension
20	Fungal Diastase, Cinamon Oil Caraway Oil & Cardamom Oil Syrup	79	Furazolidone Oral Suspension
21	Chlorpheniramine Maleate Oral Solution usp	80	Multivitamin Syrup
22	Metronidazole And Furazolidone Suspension IP	81	Cyproheptadine Hydrochloride & Tri choline Citrate Syrup (CYP up) (Z2mg + 55mg)
23	Ammonium chloride, Diphenhydramine HCL, Sodium citrate, Menthol Syrup (Benadryl)	82	Paracetamol Phenylephrine HCl, Chlorpheniramine Maleate, Sodium Citrate and Menthol Suspension
24	Cetirizine Syrup	83	Ofloxacin oral suspension IP 50mg
25	Ambroxol Hydrochloride Guaiphenesin Terbutaline Sulphate & Menthol Suspension (Kemkof - AT)	84	paracetamol suspension IP 250mg
26	Paracetamol Chlorpheniramine maleate And Phenylephrine hydrochloride Suspension	85	B complex syrup IP
27	Calcium phosphate, vitamin D3 & vitamin B12 Suspension (Cal- D3) (CLACI -D)	86	Ambroxol Hydrochloride, Guaiphenesin, Terbutaline Sulphate & Menthol Suspension
28	Alpha Amilase & Pepsine	87	Ondansetron HCL Oral Solution IP 2mg/5ml
29	Sucralfate Suspension	88	Dicyclomine hydrochloride Oral Solution

Sr. No	NAMES OF DRY SYRUP AND SUSPENSION:	Sr. No	NAMES OF DRY SYRUP AND SUSPENSION:
30	Cyproheptadine Hydrochloride & Tri choline Citrate Syrup (2mg + 275mg)	89	Cyproheptadine Hydrochloride, Sorbitol & Tri choline Citrate Syrup (2mg +3.575+275mg)
31	Lycopene Plus (Lycopene syrup Enriched with Vitamins & Minerals)	90	TERBUTALINE SULPHATE & BROMHEXINE HYDROCHLORIDE
32	Azithromycin Oral Suspension IP (Azomycin)	91	Dextromethorphan hydrobromide & CPM Syrup
33	Ferric Ammonium Citrate, Vitamin B12 & Folic Acid Syrup	92	Mefenamic acid & paracetamol syrup
34	Multivitamin L-Lysine Syrup	93	Metronidazole Benzoate Oral Suspension
35	Ferrous Fumarate Suspension	94	Potassium Chloride solution
36	Carbocisteine Syrup BP 2%	95	Multi Glycerophosphate with Vitamin B Complex Syrup
37	Aluminium hydroxide GEL (120 mg), magnesium hydro side, Simethicone Suspension	96	Paracetamol Oral Suspension BP
38	Domperidone Suspension IP	97	Cetirizine dihydrochloride, Ambroxol HCL syrup
39	DIPHENHYDRAMINE HCL IP 12.5mg	98	Levocetirizine hydrochloride syrup
40	Anti Tussive Cough Syrup	99	Levocetirizine hydrochloride, Ambroxol Hcl syrup
41	Expectorant	100	Paracetamol Suspension IP 100 mg
42	Hydroxyzine Hydrochloride Oral Solution	101	Mefenamic acid & paracetamol suspension
43	Calcium Carbonate with Vitamin D3 Oral Suspension	102	Mefenamic acid & Dicyclomine HCl suspension
44	Ferrous Sulphate Drops 125mg/ml	103	Furazolidone Suspension
45	Dicyclomine hydrochloride & Activated Dimethicone	104	Multi -Vitamin Drops
46	Aluminium hydroxide, magnesium hydro side & Simethicone Oral Suspension IP	105	Dextromethorphan Hydrobromide & Chlorpheniramine Maleate Syrup
47	Dextromethorphan hydrobromide Syrup IP 5ml/15mg	106	Ambroxol Hydrochloride Lev salbutamol Sulphate Guaiphenesin Syrup
48	Phenytoin Oral Suspension IP 30mg/5ml	107	Dextromethorphan Hydrobromide, Cetirizine Hydrochloride, Phenylephrine Hydrochloride & Chlorpheniramine Maleate Syrup
49	Carbamazepine Oral Suspension USP 5ml/100mg	108	Lev salbutamol Syrup
50	Erythromycin Estolate Oral Suspension 125mg/5ml	109	Calcium Phosphate IP
51	Multi -Vitamin Drops	110	Posaconazole Oral Suspension
52	Ondansetron HCL Oral Solution IP 4mg/5ml	111	Multivitamin Syrup
53	Ferrous Ascorbate & Folic Acid Syrup	112	Dextromethorphan Hydrobromide & Chlorpheniramine Maleate & Phenylephrine Hydrobromide Syrup
54	Erythromycin Stearate Oral Suspension IP 125mg/5ml	113	Ammonium chloride, Diphenhydramine HCL, Sodium citrate, Menthol Syrup (Cough syrup)
55	Iron Vitamin B12 & Folic Acid Syrup	114	Ferrous Sulphate and Folic Acid Syrup IP
56	Calcium, vitamin D3 & Vitamin B12 Suspension	115	Dicyclomine hydrochloride & Activated Dimethicone
57	Ferrous Fumarate & Folic Acid Syrup	116	Vitamin - B Complex Syrup
58	Dicyclomine hydrochloride & Activated Dimethicone Suspension	117	Paracetamol Oral Suspension BP
59	Metronidazole & Furazolidone Oral Suspension		

Sr. No.	NAMES OF DRY SYRUP AND SUSPENSION (EXTERNAL DEPARTMENT)	Sr. No.	NAMES OF DRY SYRUP AND SUSPENSION (EXTERNAL DEPARTMENT)
1	Benzyl Benzoate Application IP	24	Povidone iodine solution IP 10% W/V
2	Chlorhexidine Gluconate Solution 7.5 % + cetrimide 15% Conc. Antiseptic Lotion	25	Povidone iodine solution IP 2% W/V
3	Gamma Benzene Hexachloride BP	26	Isopropyl alcohol 70%
4	Povidone Iodine Solution IP	27	Chlorhexidine Gluconate Solution 0.2 %
5	Chlorhexidine Gluconate Sol.0.3%+Cetrimide 0.6% Lotion	28	Povidone iodine solution 1 % w/v
6	Formaldehyde Solution BP	29	2 Propanol 45%, 1 propanol 30% & Mecetronium Sulphate 0.2 %

Sr. No.	NAMES OF DRY SYRUP AND SUSPENSION (EXTERNAL DEPARTMENT)	Sr. No.	NAMES OF DRY SYRUP AND SUSPENSION (EXTERNAL DEPARTMENT)
7	Povidone Iodine Solution IP 5% W/V	30	Ethanol IP 80%, hydrogen per oxide IP 0.125% & Glycerol 1.45%
8	Gentian Violet Topical solution USP 1% W/V	31	Chlorhexidine Gluconate Solution 0.5 % & Ethanol IP 70%
9	Gamma Benzene Hexachloride lotion BP 0.1 % W/V	32	Ethanol 70%, glycerine 1%
10	Gamma Benzene Hexachloride & cetrimide 0.1 % W/V	33	Benzalkonium chloride 0.25%, chlorhexidine gluconate 0.25%, Benzyl alcohol
11	Povidone Iodine Solution BP 10% W/V	34	Chlorhexidine gluconate 0.250gm, benzalkonium chloride 0.025gm, Ethyl alcohol
12	clotrimazole mouth paint 1%	35	Benzalkonium chloride 0.2%, chlorhexidine gluconate 0.2% ethyl alcohol
13	Povidone Iodine Solution IP 7.5% W/V	36	hydrogen peroxide 4%
14	Ethanol 62%, carbomer, glycerine, Tri ethanol amine	37	Ethanol 80% hydrogen per oxide, Quaternary ammonium chloride
15	Ethanol 80% IP, hydrogen per oxide 0.125%, Glycerine	38	Ethanol IP 70% quaternary ammo. Comp ,0.02-0.09%, glycerine
16	Ethanol 70%, quaternary ammonium compound 0.02 to 0.009, glycerine	39	Sodium hypochlorite 10%
17	Ethanol 70%, chlorhexidine gluconate 2.5%, glycerine	40	Qettol Gel Lavender
18	Quat.am. comp. (N-alkyl dimethyl benzyl ammo.chl.0.105%, N-alkyl dimethyl ethyl. ---	41	Qettol Gel Lemon
19	Sodium hypochlorite 5%	42	Qettol Gel Rose
20	sodium hypochlorite 14%	43	Gentian Violet Topical solution USP 2% W/V
21	Ethanol 70%(v/v), glycerine 1%(v/v)	44	Qettol Gel Apple Green
22	Chlorhexidine Gluconate solution IP	45	Permethrin Lotion 1% W/V

3. OINTMENT



Sr. No.	NAMES OF OINTMENT	Sr. No.	NAMES OF OINTMENT
1	Silver Sulphadiazine Cream IP 1% w/w	16	Itraconazole, Clobetasol Propionate, Ofloxacin, Ornidazole Cream
2	Povidone Iodine Ointment USP 5 % w/w	17	Miconazole Cream IP
3	Povidone Iodine & Sucralfate Ointment	18	Aceclofenac, Linseed Oil, Methylsalicylate, Capsaicin, Menthol, Benzyl Alcohol Gel
4	Diclofenac Diethylamino IP Gel	19	Beclomethasone Dipropionate, Clotrimazole Cream
5	Salicylic Acid & Benzoic Acid IP Ointment (Whitefield Ointment)	20	Clobetasol Propionate, Gentamycin sulphate Tolnaftate, Idochlorhydroxyquin line, Clotrimazole, Chlorocresol Cream
6	Beclomethasone Dipropionate, Neomycin sulphate & Miconazole Nitrate Cream	21	Diclofenac Diethylamino, Linsed Oil, Menthol, Methylsalicylate Gel

Sr. No.	NAMES OF OINTMENT	Sr. No.	NAMES OF OINTMENT
7	Beclomethasone Dipropionate, Neomycin sulphate ointment	22	Clobetasol Propionate & Salicylic Acid Ointment
8	Clobetasol Propionate IP & Miconazole Nitrate Cream	23	Hydrocortisone Cream IP 0.01% w/w
9	Clobetasol Propionate, Gentamycin, Miconazole Nitrate & Clotrimazole Cream IP	24	Clotrimazole Cream IP 2 % W/W
10	Gentamycin Sulphate Cream USP 0.1 % w/w	25	Clobetasol Propionate, Gentamycin sulphate Tolnaftate, Iodochlorhydroxyquin line, Clotrimazole, Chlorocresol Cream
11	Neomycin sulphate Cream IP	26	Diclofenac Diethylamino, Linseed Oil, Menthol, methylsalicylate Gel
12	Beclomethasone Dipropionate, Neomycin sulphate & Clotrimazole Cream	27	Diclofenac Diethylamino, Virgin Linseed Oil, Menthol, Methylsalicylate, Benzyl Alcohol Gel
13	Nitrofurazone Cream USP	28	Sertaconazole nitrate BP 2% w/w Cream
14	Luliconazole Cream IP 1% w/w	29	Clotrimazole Cream IP 1% w/w
15	Mupirocin cream IP 2.0 % w/w	30	Clobetasol, Neomycin, Miconazole Cream

4. ORAL REHYDRATION SALT (ORS):




NAMES OF ORAL REHYDRATION SALT (ORS)	
Oral Rehydration Salts IP	D – Glucose & Vitamin D3 Powders
Oral Rehydration Salts BP	D – Glucose Powder IP

PRODUCTWISE WISE REVENUE*

(₹ in Lakhs)

Product Wise Sales		December 31, 2023			FY 2022-23			FY 2021-2022			FY 2020-2021		
Sr No.	Product	Units	Amount	% of Revenue	Units	Amount	% of Revenue	Units	Amount	% of Revenue	Units	Amount	% of Revenue
1	Tablets	97,51,05,327	3,996.62	64.38	8,96,80,700	4,906.20	79.59	3,72,14,100	4,367.55	73.42	2,73,14,125	2,494.80	82.16
2	Syrup	1,45,46,818	591.57	9.53	1,29,20,600	862.90	14.00	1,06,82,660	1,376.77	23.15	48,65,564	390.72	12.87
3	Suspension	20,84,502	203.25	3.27	21,38,701	170.38	2.76	24,70,000	86.45	1.45	5,64,145	50.83	1.67
4	ORS	3,87,27,068	786.71	12.67	15,25,000	38.13	0.62	3,65,934	9.51	0.16	21,51,455	38.99	1.28
5	Ointment	54976412	629.81	10.15	20,11,820	186.46	3.02	14,91,156	108.10	1.82	9,12,474	61.01	2.01
	Total	108,54,40,127	6,207.98	100.00	10,82,76,821	6,164.06	100.00	5,22,23,850	5,948.39	100.00	3,58,07,763	3,036.35	100.00


*As certified by M/s Shyam S. Gupta & Associates, Chartered Accountant., by way of their certificate dated April 04, 2024.



OUR MANUFACTURING PROCESS

1) TABLETS SECTION:

Flow Chart:



The tablet manufacturing process encompasses several distinct stages, each crucial for ensuring the quality, efficacy, and safety of the final product. One of the primary methods employed is the wet process. This method initiates with line clearance procedures mandated by the Quality Assurance (QA) department, which inspects and cleanses all machinery to prevent cross-contamination. Samples of rinse water from each machine are analysed to verify the absence of residues from previous batches, granting clearance for production to proceed. Once the QA department confirms the cleanliness and readiness of the equipment, batch process clearance is provided for the subsequent steps.

Raw materials, sieved to requisite sizes are then prepared for the production line. In the paste-making area, purified water is heated and combined with substances to create a paste. This paste, alongside the sieved raw materials, undergoes wet granulation in the Rapid Mixer Granulator (RMG) before being transferred to the Fluid Bed Dryer for drying at specific temperatures and durations. The dried granules are sifted, sized using the Multi Mill, and subjected to quality analysis before proceeding to the Octagonal Blender for lubrication and blending. Samples are sent to the Quality Control (QC) department for thorough analysis, including tap density and moisture content assessment, prior to quarantine.

Upon QC clearance, the granules are allocated to specified compression machines for tablet formation. In-process quality checks (IPQC) ensure the tablets meet predetermined standards for weight, size, friability, and disintegration throughout the compression process. Post-compression, tablets are quarantined until receiving final QC approval for storage or further processing. Uncoated tablets proceed to blister and strip packaging, while those requiring coating are transferred to the coating section for film, sugar, or enteric coating applications. Coated tablets undergo additional QC clearance before packaging and final analysis.

Alternatively, the roll compacting process offers a rapid and innovative method for direct granulation, streamlining tablet manufacturing. Similar to the wet process, line clearance is imperative before commencing production. Raw materials undergo sieving and are loaded into the Roll Compacter, producing granules subsequently processed through the Multi Mill for sizing. Granules are then blended, lubricated, and subjected to QC analysis before compression into tablets. IPQC checks ensure tablet quality at regular intervals, mirroring the procedures of the wet process.

Lastly, the powder section, characterized by strict temperature and humidity control, mandates meticulous line clearance and raw material preparation akin to previous processes. Octagonal Blenders facilitate powder mixing before undergoing QC analysis and pouch packaging. IPQC monitors pouch weight periodically, ensuring consistency and adherence to specifications before final analysis and transfer to bulk storage.

In conclusion, tablet manufacturing processes demand meticulous attention to detail, adherence to stringent quality standards, and robust quality control measures to ensure the production of safe, effective, and compliant pharmaceutical products.

2) DRY SYRUP & SUSPENSION:

Prior to initiating production, it is imperative to obtain line clearance from the Quality Assurance (QA) department. This clearance entails a thorough physical examination of all machines involved in the process, accompanied by a washing procedure. Rinse water samples are meticulously collected from each machine to assess any residues from prior batches. Upon receiving clearance from the Quality Control (QC) department, confirming the cleanliness and readiness of the machines, the QA department issues the necessary clearance for the next batch through the Batch Process Clearance form.


Raw materials approved for use are sourced from the Raw Material Stores and undergo sieving in the process section to meet the required mesh sizes. The sieved materials are then systematically collected in bins for transfer to the process area.

In the process area, the sifted materials are methodically added one by one, and the Octagonal Blender is activated for a specified duration. Subsequently, samples are extracted and forwarded to the QC section for comprehensive analysis before unloading the powder.

Following QC clearance, the process advances to filling the powder into bottles, ensuring precision and accuracy throughout the procedure. Samples of the filled bottles proceed to the Final Quality Control section for further analysis to ascertain adherence to quality standards.

In accordance with the In-Process Quality Control (IPQC) protocol, the weight of 10 pouches is assessed every 30 minutes, with data meticulously recorded on the Batch Manufacturing Record (BMR). Upon completion of the entire production process and subsequent quality assessments, the packed pouches undergo final analysis in the QC department. Upon receiving clearance, they are then directed to the Bulk Storage Room (BSR) for safekeeping until further distribution or use.

Flow Chart:




3) LIQUID ORAL SECTION:

The manufacturing process begins with line clearance from the QA department. The QA department physically *inspects all process and storage tanks and performs washing. Rinse water samples are collected from each machine to check for

residue from previous batches. After receiving clearance from QC that the machines are clean and ready for use, the QA department provides batch process clearance for the next batch. Approved raw materials are first issued from the Raw Material Stores, sieved in the process section with the requisite mesh sizes, and then collected in bins for transfer to the process area. EDTA and preservatives are added to the tank one by one until a clear solution is obtained and then sugar syrup and thickening agents are added.

The process tank is filled with purified water, and the sifted raw materials are dissolved and added slowly to the tank one by one according to the BMR. The pH of the process tank is monitored at each step to control the process. After adding color and flavor, the process tanks are filled with the required volume, and the final pH is measured. The entire batch is colloidized using a colloid machine and transferred to the holding tank. A sample of the batch is sent to QC for bulk analysis. QC examines the pH, clarity, weight per ml, and assay of the bulk. Once QC clears the batch, the filtration and filling processes begin. Filling, sealing, inspection, and labelling are performed online.

Flow Chart:



The IPQC section of the Liquid Oral Section conducts online inspections of the solution's pH and the volume of filled bottles. Samples of filled bottles are sent to QC for final analysis, and the filled bottles are placed in finished quarantine. Once QC approves the quality, the product is moved to the BSR (Batch Release Section).

LIQUID EXTERNAL SECTION:


Firstly, line clearance is essential from the QA department to initiate production. The QA department conducts physical inspections of all process and storage tanks, followed by thorough washing. Rinse water samples are collected from each machine to detect residues from previous batches. Upon receiving clearance from QC that the machines are clean and ready for use, the QA department issues batch process clearance for the next batch.

All approved raw materials are issued from the Raw Material Stores and sieved in the process section with the requisite mesh sizes before being collected in bins for transfer to the process area. EDTA and preservatives are added to the tank sequentially until a clear solution is obtained. Materials are then added one by one, and continuous stirring is performed as per the Batch Manufacturing Record (BMR).

Next, final volume adjustment is performed, and the PH is observed. A sample for QC bulk analysis is sent. The filling process commences after receiving QC results. Liquid is filled into the requisite containers. Subsequently, filled bottles are placed in quarantine until final QC results are received.

4) OINTMENT & CREAM SECTION:

Flow Chart



First of all, the Line clearance is must from QA department in order to start the production. The QA department observes all tanks of process and storage physically and washing is performed, and sample of Rinse water is sent from each and every machine in order to check the residue of the old batches. After getting the clearance from the QC that the machines are clean ready to use, the QA department provides the batch Process clearance form the next batch.

All the Approved raw material are issued from the Raw material Stores are Sieved in the process section with the requisite Mesh sizes and then the same is collected in the Bin to transfer in the process area. The Raw materials and excipients are dissolved, melted or heated as per process and added to the tanks as per BMR. Now pH is observed after final volume is performed and QC sample is sent for analysis Bulk.

The Filling is performed after receiving the QC result. The filling of the Ointment and Cream in requisite container or tube is done as per the BCR. Now the Filled Jars & Tubes are kept in Quarantine until final result from QC is received. After receiving the QC clearance, the Tubes and jar are sent to BSR for sales.

5) ORAL REHYDRATION SALT SECTION:

The manufacturing process begins with the cleaning and clearance of the production area to ensure a hygienic and safe working environment. Raw materials are then weighed and checked for quality before undergoing sieving to remove impurities and ensure uniform particle size. Following this, certain raw materials may be dried in an oven to achieve the desired moisture content.

After drying, the materials undergo another round of sieving to maintain uniformity. Subsequently, the raw materials are blended and mixed together to create the desired formulation. Once blended, the mixture undergoes another sieving process to ensure homogeneity.

The blended mixture is then transferred to bulk containers, with samples taken for quality control testing and labeling. These samples are scrutinized to ensure compliance with quality standards. The final product is then filled into pouches for packaging.

Before distribution, samples of the finished goods are once again taken for quality control purposes. Once approved, the finished goods are issued to the finished goods store for storage. Finally, the finished goods are dispatched to customers or distribution centers for sale and consumption. This sequential process ensures that raw materials are processed efficiently, quality standards are met at each stage, and the final product meets customer expectations.

OUR MANUFACTURING FACILITIES

Unit Name	Address
Registered Office & Manufacturing Unit	Plot No. 45, Sector III, Pithampur Industrial Area, Pithampur, Dhar - 454775, Madhya Pradesh, India.

For further details, kindly refer to the section titled; "Our Properties" mentioned below.



Registered Office and Manufacturing Unit



Raw Material Department



Packing Material Department



Tablet Coating Process



Powder Mixing Process



Tablet Compressor Processing



Tube Filling Process



Mass Mixer Machine Use for Powder Mixer



Blender Machine for Dry Granules Mixer



Blister Packaging Medicine



Liquid Filling Process



CAP Fitting Labelling Process



Suspension Filing



Labelling & Packaging Process



ORS Filing Process



Tablets Packing Process



In house Warehouses Facility

LIST OF MACHINERY, TESTING EQUIPMENT INSTALLED

Sr. No.	NAME OF EQUIPMENT	MAKE	MODEL/ SR NO.	ID. NO.
1.	ANALYTICAL BALANCE	OHAUS	PAG214C	QC/EQP-A/01
2.	OVEN	PATHAK ELECTRICAL WORK BOMBY-63	164	QC/EQP-A/03
3.	CONDUCTIVITY METER	EI	601	QC/EQP-A/04
4.	POLARIMETER	MEMORIAL SCIENTIFIC CORPORATION	-----	QC/EQP-A/05
5.	REFRACTOMETER	SCIENTECH TM	-----	QC/EQP-A/06
6.	FRIABILITY TESTER	PATHAK ELECTRICAL WORK BOMBY-63	104	QC/EQP-A/07
7.	CENTRIFUGE APPARATUS	LAB HOSP	-----	QC/EQP-A/08
8.	MUFFLE FURNANCE	NAVYUG	-----	QC/EQP-A/09
9.	LOD OVEN	LAB HOSP	-----	QC/EQP-A/10

Sr. No.	NAME OF EQUIPMENT	MAKE	MODEL/ SR NO.	ID. NO.
10.	DT APPARATUS	SCIENTECH INSTRUMENT DELHI	R-17010546	QC/EQP-A/11
11.	DISSOLUTION TEST APPARATUS	ELECTROLAB	TDT-08L	QC/EQP-A/12
12.	DISSOLUTION TEST APPARATUS	ELECTROLAB	TDT-08L	QC/EQP-A/13
13.	DISSOLUTION TEST APPARATUS	ELECTROLAB	TDT-08L	QC/EQP-A/14
14.	UV-VIS SPECTROPHOTOMETER	SHIMADZU	UV-1800	QC/EQP-A/15
15.	UV-VIS SPECTROPHOTOMETER	SHIMADZU	Bio Spec -1601	QC/EQP-A/16
16.	BULK DENSITY APPARATUS	PATHAK ELECTRICAL WORK BOMBY-63	Z02	QC/EQP-A/18
17.	TLC CHAMBER	MACRO SCIENTIFIC WORKS (R)	1139	QC/EQP-A/19
18.	UV CABINATE	MACRO SCIENTIFIC WORKS (R)	MSW-508	QC/EQP-A/20
19.	MELTING POINT APPARATUS	RADIX	4A055	QC/EQP-A/21
20.	LEAK TEST APPARATUS	EI	961	QC/EQP-A/22
21.	KARL FISCHER	VEEGO	51/0914ST	QC/EQP-A/23
22.	FLAME PHOTOMETER	LABTRONICS	LT-671	QC/EQP-A/24
23.	STABILITY CHAMBER (LONG TERM)	LABLINE	-----	QC/EQP-A/25
24.	STABILITY CHAMBER (ACCELERATED)	LABLINE	-----	QC/EQP-A/26
25.	HPLC PROMINENCE I LC 2030	SHIMADZU	LC 2030	QC/EQP-A/27
26.	COLUMN C18(250×4.6MM×5µm)	SHIMADZU	16J03236	QC/EQP-A/C-1
27.	COLUMN C18(250×4.6MM×5µm)	SHIMADZU	15L03519	QC/EQP-A/C-2
28.	ODS HYPERSIL Column	THERMO FISHER SCIENTIFIC	10555010	QC/EQP-A/C-3
29.	PEERLESS C18 (300mm×4.6mm×5µm)	PEERLESS	13071070805	QC/EQP-A/C-4
30.	COLUMN C18(250×4.6MM×5µm)	CHROMACHEMIC PURITAS	A18081701	QC/EQP-A/C-5
31.	COLUMN C18(4.6×250MM×5µm)	WELCH	60190501349	QC/EQP-A/C-6
32.	COLUMN C18(4.6×150MM×5µm)	WELCH	60191100826	QC/EQP-A/C-7
33.	COLUMN C18(4.6×250MM×5µm)	WELCH	60191101074	QC/EQP-A/C-8
34.	COLUMN C18(4.6×300MM×5µm)	WELCH	60191200166	QC/EQP-A/C-9
35.	COLUMN C18(4.6×250MM×5µm)	AGILENT	USNH050493	QC/EQP-A/C-10
36.	COLUMN C18(4.6×250MM×5µm)	SHIMADZU	22D53426	QC/EQP-A/C-11
37.	COLUMN C18(4.6×250MM×5µm)	SHIMADZU	22L69398	QC/EQP-A/C-12
38.	COLUMN C18(3.9×300MM×10µm)	WATERS	02393218813818	QC/EQP-A/C-13
39.	pH METER	HANNA (EDGE DEDICATED INSTRUMENT)	C04440C7	QC/EQP-A/28
40.	STABILITY CHAMBER (LONG TERM CONTINUITY)	LAB. HOSP	-----	QC/EQP-A/29
41.	VISCOMETER	LABMAN	LMDV-60	QC/EQP-A/30
42.	FT-IR SPECTROSCOPY	PERKINELMER	108138	QC/EQP-A/31
43.	BURSTING STRENGTH TESTER	UBIQUE	2053E	QC/EQP-A/32
44.	ELECTRONIC BALANCE	SARTORIUS	CP225D	QC/EQP-A/33
45.	HPLC I-SERIES LC-2050 C	SHIMADZU	LC-2050 C	QC/EQP-A/35
46.	ANALYTICAL BALANCE	METTLER TOLEDO	ME204	QC/EQP-A/01
47.	pH METER	EUTECH	2067492	QC/EQP-A/02
48.	OVEN	PATHAK ELECTRICAL WORK BOMBY-63	164	QC/EQP-A/03
49.	CONDUCTIVITY METER	EI	601	QC/EQP-A/04
50.	POLARIMETER	MEMORIAL SCIENTIFIC CORPORATION	-----	QC/EQP-A/05
51.	REFRACTOMETER	SCIENTECH TM	-----	QC/EQP-A/06

Sr. No.	NAME OF EQUIPMENT	MAKE	MODEL/ SR NO.	ID. NO.
52.	FRIABILITY TESTER	PATHAK ELECTRICAL WORK BOMBY-63	104	QC/EQP-A/07
53.	CENTRIFUGE APPARATUS	LAB HOPS	-----	QC/EQP-A/08
54.	MUFFLE FURNANCE	NAVYUG	-----	QC/EQP-A/09
55.	LOD OVEN	LAB HOPS	-----	QC/EQP-A/10
56.	DT APPARATUS	SCIENTECH INSTRUMENT DELHI	R-17010546	QC/EQP-A/11
57.	DISSOLUTION TEST APPARATUS	ELECTROLAB	TDT-08L	QC/EQP-A/12
58.	DISSOLUTION TEST APPARATUS	ELECTROLAB	TDT-08L	QC/EQP-A/13
59.	DISSOLUTION TEST APPARATUS	ELECTROLAB	TDT-06P	QC/EQP-A/14
60.	UV-VIS SPECTROPHOTOMETER	SHIMADZU	UV-1800	QC/EQP-A/15
61.	UV-VIS SPECTROPHOTOMETER	SHIMADZU	Bio Spec -1601	QC/EQP-A/16
62.	FT-IR	JASCO	FT/IR-200E	QC/EQP-A/17
63.	BULK DENSITY APPARATUS	PATHAK ELECTRICAL WORK BOMBY-63	Z02	QC/EQP-A/18
64.	TLC CHAMBER	MACRO SCIENTIFIC WORKS (R)	1139	QC/EQP-A/19
65.	UV CABINATE	MACRO SCIENTIFIC WORKS (R)	MSW-508	QC/EQP-A/20
66.	MELTING POINT APPARATUS	RADIX	MP-D	QC/EQP-A/21
67.	LEAK TEST APPRATUS	ASHOKA	-----	QC/EQP-A/22
68.	KARL FISCHER	VEEGO	51/0914ST	QC/EQP-A/23
69.	FLAME PHOTOMETER	ESICO	381	QC/EQP-A/24
70.	STABILITY CHAMBER (LONG TERM)	LABLINE	-----	QC/EQP-A/25
71.	STABILITY CHAMBER (ACCELERATED)	LABLINE	-----	QC/EQP-A/26
72.	HPLC PROMINENCE I LC 2030	SHIMADZU	LC 2030	QC/EQP-A/27
73.	COLUMN C18(250×4.6MM×5µm)	SHIMADZU	16J03236	QC/EQP-A/27-1
74.	COLUMN C18(250×4.6MM×5µm)	SHIMADZU	15L03519	QC/EQP-A/27-2
75.	ODS HYPERSIL Column	THERMO FISHER SCIENTIFIC	10555010	QC/EQP-A/27-3
76.	PEERLESS C18 (300mm×4.6mm×5µm)	PEERLESS	13071070805	QC/EQP-A/27-4
77.	COLUMN C18(250×4.6MM×5µm)	CHROMACHEMIC URITAS	A18081701	QC/EQP-A/27-5
78.	COLUMN C18(4.6×250MM×5µm)	WELCH	60190501349	QC/EQP-A/27-6
79.	COLUMN C18(4.6×150MM×5µm)	WELCH	60191100826	QC/EQP-A/27-7
80.	COLUMN C18(4.6×250MM×5µm)	WELCH	60191101074	QC/EQP-A/27-8
81.	COLUMN C18(4.6×300MM×5µm)	WELCH	60191200166	QC/EQP-A/27-9
82.	VISCOMETER	LABMAN	LMDV-60	QC/EQP-A/30
83.	FT-IR SPECTROSCOPY	PERKINELMER	108138	QC/EQP-A/31
84.	BURSTING STRENGTH TESTER	UBIQUE	2053E	QC/EQP-A/32
85.	ELECTRONIC BALANCE	SARTORIUS	CP225D	QC/EQP-A/33
86.	MUFFLE FURNANCE	I-THERM	AI-7982	QC/EQP-A/34

Sr. No.	NAME OF EQUIPMENT	MAKE	ID. NO.
1.	VERNIER'S CALIPER (Manual)	AERO SPACE	QC/EQP-B/01
2.	HARDNESS TESTER	TAB. MACHINES	QC/EQP-B/02
3.	SCREW GAUGE	INSIZE	QC/EQP-B/03
4.	SONICATOR (3.5 Lit.)	PCI (ANALYTICS)	QC/EQP-B/04
5.	SONICATOR (2.5 Lit.)	LABMAN	QC/EQP-B/05
6.	HOT PLATE	THERMOSTAT	QC/EQP-B/06
7.	HEATING MANTLE	KUMAR INDUSTRIES	QC/EQP-B/07

Sr. No.	NAME OF EQUIPMENT	MAKE	ID. NO.
8.	TEMPERATURE CONTROLLER (For Dissolution)	ELECTROLAB	QC/EQP-B/08
9.	MAGNETIC STIRRER	REMI EQUIPMENT	QC/EQP-B/09
10.	WATER BATH	LAB HOSP	QC/EQP-B/10
11.	REFRIGERATOR	GODREJ	QC/EQP-B/11
12.	DESICCATOR	---	QC/EQP-B/12
13.	DESICCATOR	----	QC/EQP-B/13
14.	DESICCATOR	----	QC/EQP-B/14
15.	DRY BOX	TECHNO SEARCH	QC/EQP-B/15
16.	VERNIER'S CALIPER (Digital)	AERO SPACE	QC/EQP-B/16
17.	DATA LOGGER (QC Lab.)	ERUOLAB	QC/EQP-B/17
18.	DATA LOGGER (LT Stability Chamber)	EASYLOG	QC/EQP-B/18
19.	SONICATOR (1.5 Lit.)	LABMAN	QC/EQP-B/19
20.	HPLC PC(DELL) WINDOW 10	DELL	QC/EQP-B/20
21.	SONICATOR (6.5 Lit.)	LABMAN	QC/EQP-B/21
22.	DIGITAL TECHNO METER	MICRO PROCESSOR	QC/EQP-B/22
23.	SIEVE (MESH NO. 22) 0.710 MM	JAYANT SCIENTIFIC	QC/EQP-B/23
24.	DESICCATOR	----	QC/EQP-B/24
25.	PC (LG) WINDOWS 7	LG	QC/EQP-B/25
26.	FTIR & UV PC (DELL) WINDOWS-7	DELL/VISION	QC/EQP-B/26
27.	DATA LOGGER (Short Term Stability Chamber)	ERUOLAB	QC/EQP-B/27
28.	WATER DISTILLATION APPARATUS	GENIST INTERNATIONAL	QC/EQP-B/28
29.	PC (LG) WINDOWS 7	LG	QC/EQP-B/29
30.	HOT PLATE	H.C MEMORIAL	QC/EQP-B/30
31.	HPLC - LC 2050 PC WINDOWS 10	ZEBRONICS/DELL	QC/EQP-B/31
32.	CANNON PRINTER	PIXMA	QC/EQP-B/32
33.	CANNON PRINTER	MF241D	QC/EQP-B/33
34.	EPSON PRINTER	M205	QC/EQP-B/34

Sr. No.	NAME OF EQUIPMENT	MAKE	ID. NO.
1.	HOT AIR OVEN (DRYING)	PATHAK ELECTRONICS WORKS BOMBAY/118	QL/MIC/01
2.	BOD INCUBATOR	NEWTRONICS	QL/MIC/02
3.	AUTOCLAVE (For Sterilization)	HC MEMORIAL SCIENTIFIC CORPORATION INDIA LTD.	QL/MIC/03
4.	BACTERIAL INCUBATOR	NAVYUG INDIA	QL/MIC/04
5.	PATHOGENS INCUBATOR	LAB HOSP CORPORATION BOMBAY INDIA	QL/MIC/05
6.	AUTOCLAVE (For Discarding)	REMI ELECTRONIC PVT. LTD.	QL/MIC/06
7.	DIGITAL BALANCE	PHOENIX NITIRAJ ENGINEERING PVT. LTD.	QL/MIC/07
8.	FUMIGATOR	REMI ELECTRONIC PVT. LTD.	QL/MIC/08
9.	ANTIBIOTICS ZONE READER	HC MEMORIAL SCIENTIFIC CORPORATION INDIA LTD.	QL/MIC/09
10.	MICROSCOPE	EVEREST OPTICS PVT. LTD.	QL/MIC/10
11.	INCUBATOR (FOR E. COLI) PATHOGENS	LAB TECH INSTRUMENT INDIA LTD.	QL/MIC/11
12.	COLONY COUNTER (DIGITAL)	REMI ELECTRONIC PVT. LTD.	QL/MIC/12
13.	CYCLOMIXER	REMI ELECTRONIC PVT. LTD.	QL/MIC/13
14.	LAMINAR AIR FLOW	-----	QL/MIC/14
15.	HEATING MENTAL	KUMAR INDUSTRIES	QL/MIC/15
16.	MAGNETIC STIRRER	ITEK PVT. LTD.	QL/MIC/16

RAW MATERIAL

The basic raw material required to manufacture formulation is basic drug / bulk drug comprising of both active and nonactive ingredients. The active raw materials are required in bulk quantities whereas non-active (diluent / excipients) are required in small quantities. The raw materials items are procured from time to time as per the production planning.

We procure raw materials essential to our business in the ordinary course of business from numerous suppliers. Our company procures raw materials from domestic markets within India. Our manufacturing processes involve a wide variety of raw materials, including APIs, emulsifying wax, dextrose anhydride, flavors, pharmaceutical - grade sugar, colorants, aqueous coating materials, and packaging materials such as primary, printed, and other materials. Our raw materials are mainly sourced in the domestic market from Uttar Pradesh, Madhya Pradesh, Maharashtra, Himachal Pradesh, Gujarat, Assam, Uttarakhand, Telangana, Delhi, Haryana, and Karnataka. Purchases made from our top 10 suppliers for the period ending December 31, 2023, and for the financial years ending March 31, 2023, 2022, and 2021 were ₹ 2,526.88 Lakhs, ₹ 1,700.88 Lakhs, ₹ 1,339.98 Lakhs, and ₹ 707.81 Lakhs, respectively, representing 62.73%, 32.78%, 29.94%, and 33.62% of our total raw material purchases.

We purchase these raw materials from a list of sources that we maintain, which has been approved by our internal quality control department following set standards and by our customers. We carefully assess the reliability of all materials purchased to ensure that they comply with the rigorous quality and safety standards required for our products. In an effort to manage risks associated with raw materials supply, we work closely with our suppliers to help ensure availability and continuity of supply while maintaining quality and reliability.

The following table illustrates the concentration of our revenues among our top Supplier:

(₹ in Lakhs)

Particulars	Suppliers							
	December 31, 2023		March 31, 2023		March 31, 2022		March 31, 2021	
	Amount	%	Amount	%	Amount	%	Amount	%
Top 5	1671.04	41.48	1377.77	21.93	1113.92	24.90	617.82	29.36
Top 10	2,526.88	62.73	1700.88	32.78	1339.98	29.94	707.81	33.62

*As certified by M/s Shyam S. Gupta & Associates, Chartered Accountants, by way of their certificate dated April 02, 2024.

CAPACITY AND CAPACITY UTILISATION

(Quantity in No's)

Sr No.	Product	December 31, 2023			FY 2022-23			FY 2021-2022			FY 2020-2021		
		Installed Capacity	Utilised Capacity	Utilization %	Installed Capacity	Utilised Capacity	Utilization %	Installed Capacity	Utilised Capacity	Utilization %	Installed Capacity	Utilised Capacity	Utilization %
1	Liquid Syrup	60 Lakh Litre	48.78 Lakhs Litre	81.30	60 Lakh Litre	42 Lakhs Litre	66.66	45 Lakh Litre	42 Lakh Litre	93.33	30 Lakh Litre	28 Lakhs Litre	93.33
2	Tablets	360 Crore	293.83 Crore	66.62	360 Crore	242 Crore	67.22	240 Crore	210 Crore	87.50	180 Crores	164 Crores	91.11
3	Dry Syrup	90000 Kg	27881 kg	30.97	90000 Kg	17000 kg	18.88	60000 Kg	45000 Kg	75.00	40000 Kg	38500 Kg	96.25
4	Powder ORS	2700 Ton	2719 Tons	80.70	2700 Ton	2150 Tons	79.62	2100 Ton	1950 Tons	92.85	1500 Ton	1388 Ton	92.53
5	External Liquid	12 Lakh Litre	2.97 Lakh Litre	24.75	12 Lakh Litre	4.19 Lakh Litre	18.00	10 Lakh Litre	8.85 Lakh Litre	88.50	6 Lakh Litre	5.850 Lakh Litre	97.5
6	Ointment	432 Tons	231.26 Tons	53.35	432 Tons	212 Tons	49.07	300 Tons	265 Tons	88.23	240 Tons	218 Tons	90.83

Note:

- Capacity utilization has been calculated on the basis of actual production during the relevant fiscal year/ period divided by the aggregate installed capacity of relevant manufacturing facilities as of at the end of the relevant fiscal year/ period.
- The above information is furnished on the basis of data provided and internal estimates and assumptions.
- The above information is certified by Chartered Engineer, Pradeep Chhabra, vide their certificate dated March 25, 2024.

PRICING

We determine the prices for our products based on various parameters, including market demand, transportation costs, raw materials costs, inventory levels, credit terms and sometimes it is fixed for particular customer to maintain the relationship. Our sales and marketing team takes into consideration the margins of intermediaries at different stages, in accordance with market practice, and applicable taxes to arrive at the list price of our offerings.

UTILITIES

Infrastructure Facilities

Our registered office and Manufacturing, site is well equipped with computer systems, internet connectivity, other communication equipment, security and other facilities, which are required for our business operations to function smoothly. Our manufacturing facility is equipped with requisite utilities and modern infrastructure including the following:

Power

Our manufacturing process requires uninterrupted supply of Electric & Power for our manufacturing facilities. We consume a substantial amount of power for our business operations. Our power requirements are met through State Electricity Board, i.e., Madhya Pradesh Paschim Kshetra Vidyut Vitaran Company Limited.

Water

Our company's registered office and manufacturing unit currently rely on a borewell to meet our water requirements for manufacturing operations, human consumption, and the general needs of our employees. As high purity water is essential in the pharmaceutical industry, our company has installed a water purification/processing system to ensure the required water purity.

Air Handling Unit

Our manufacturing facility is equipped with air handling units (AHUs) strategically installed to prevent cross-contamination and uphold precise control over relative humidity and temperature within our clean room environments. Each Clean Room AHU is outfitted with appropriate pre-filters followed by terminal High Efficiency Particulate Arrestance (HEPA) Air Filters, ensuring the removal of particulate matter and maintaining high air quality standards.

Our clean rooms are meticulously maintained at specific air pressures to prevent contamination, and we closely monitor relative humidity levels to ensure optimal manufacturing conditions. The implementation of positive or negative air pressure systems helps regulate the flow of air, minimizing the risk of contaminants entering or exiting the controlled environment.

This comprehensive approach underscores our commitment to maintaining stringent cleanliness standards, which is crucial for industries such as pharmaceuticals, electronics, biotechnology, and semiconductor manufacturing. Regular monitoring and maintenance of these systems are integral to sustaining optimal performance and upholding the highest quality standards across our manufacturing processes.

CUSTOMERS, SALES AND MARKETING

Our Company have been receiving sales orders from the private sector & government institutions on regular basis. Our company also engages in contract manufacturing, also known as white label manufacturing for pharmaceutical companies. This collaborative approach offers benefits to the purchasers, including cost efficiency through bulk production, capacity scaling, regulatory compliance, reduced lead times, risk mitigation, access to specialized technologies, geographical expansion, cost effective compliance, and resource optimization.

Our company monitors various sources to identify potential government tender opportunities. These sources may include government procurement websites, newspapers, trade publications, and specialized tender notification services. Once a tender opportunity is identified, our company carefully reviews the tender documents, which typically include the scope of work, pharmaceutical formulations, terms and conditions, evaluation criteria, and submission deadlines. Some government tenders may include pre-bid meetings or offer opportunities for bidders to seek clarifications on the tender documents.

Our company prepares the bid in accordance with the tender requirements. This process may involve developing proposals, cost estimates, project timelines, and other relevant documentation. After the submission of the bid, government agencies or procurement departments evaluate the received bids based on predetermined criteria, which may include factors such as compliances, price, qualifications, experience, and past performance. Once the evaluation process is complete, the

government agency or procurement department awards the contract to our company. The award decision is typically communicated to our company through mail or post. After the contract is awarded, it is signed by both parties, marking the official commencement of the production process.

The successful bidding for government tenders business and collaboration with major state and central government institutions and corporations over the past few years is a significant achievement for our company. This demonstrates our company's ability to compete effectively in the public procurement process and secure contracts to provide goods to government entities. Collaborating with major state and central government institutions and corporations further enhances our company's reputation and credibility in the market.

The efficiency of the marketing network is critical to the success of our Company. Our success lies in the strength of our relationship with our customers who have been associated with our Company. Our team through their vast experience owing to timely and quality delivery of services plays an instrumental role in creating and expanding a work platform for our Company. We have in-house team which looks after the sales and marketing of our products. Our in-house team work closely with our existing and prospective customers to understand their technical needs and specifications, evolving preferences and meet their requirements.

INVENTORY MANAGEMENT

Our finished products and raw materials are mainly stored on-site at our manufacturing facilities. We produce a quantity of finished products that is determined based on a combination of confirmed and expected orders. In some cases, according to customer demand we hold strategic stock, so our lead times can be reduced. These are in most cases according to a stocking policy with customers, but in some instances, these are pro-active steps taken by the organisation to ensure better supply chain management.

LOGISTICS

Our suppliers directly deliver raw materials to our manufacturing facilities. We outsource the delivery of our products to either third-party logistics companies or as mutually agreed shipment terms as decided between the customer and Company.

COMPETITION

Our company operates in the chemical and pharmaceutical sector, which faces competition from both domestic and international players, including organized and unorganized sectors, private and public companies. The primary competitive factors consist of quality, technology, prompt delivery, price, size of product portfolio, and customer service. Our competitors may also obtain regulatory approvals for their products more rapidly than we can, potentially resulting in them establishing a stronger market position before we enter the market. Many of the companies against which we compete, or may compete with in the future, have significantly greater financial resources and expertise in research and development, manufacturing, obtaining regulatory approvals, and marketing approved products than we do. Moreover, as we seek to diversify into new geographical areas globally, we may face competition from local companies, multinational corporations, and companies from other emerging markets operating in such markets. We compete with our competitors based on product quality, brand image, price, and reliability.

We continuously strive to increase our distribution channels to expand our domestic presence and increase our global reach. We intend to continue competing vigorously to capture more market share and manage our growth optimally by improving our brand image, expanding our product offerings, satisfying customer demands, achieving operating efficiencies, and more

INFORMATION TECHNOLOGY

We believe that an appropriate information technology infrastructure is important in order to support the growth of our business. Our manufacturing facilities is connected to our central IT network that facilitates monitoring of our operations and management of supply chain. Our IT infrastructure enables us to track procurement of raw materials, sale of finished goods, payments to vendors and receivables from customers.

REPAIR AND MAINTENANCE

We conduct periodic repair and maintenance programs for our manufacturing facilities. Our machinery and electrical repair teams carry out periodic maintenance and repair of the plant and machineries on as needed basis. In addition, our manufacturing facilities is periodically inspected by our technicians.

QUALITY CONTROL

Quality control encompasses two aspects: maintaining the quality of raw materials procured for captive consumption and ensuring the quality of the products we manufacture. The activities of this department include the collection and preparation of samples, testing of raw materials and other process inputs, inspection, testing, and quality certification of finished products, as well as providing feedback and assistance to the main production units to ensure control of process parameters and the timely implementation of corrective measures.

Conducting various tests on products to determine their purity and ensure they are free from impurities is fundamental. The tests conducted in our laboratories encompass chemical testing, biological testing, and instrumental testing.

Our company hold WHO Schedule M GMP, and GLP certifications, adhering to the stringent guidelines set by the World Health Organization. Our commitment to quality is further demonstrated by our ISO 9001:2015 certification and ISO/IEC 17025:2017 accreditation. Our Company also holds Good Laboratory Practice (GLP) certificate from the Food & Drug Administration in Bhopal, Madhya Pradesh, indicating its commitment to maintaining high standards of quality and compliance in laboratory operations, particularly within the pharmaceutical sector.

Further, the formulation development department has undertaken a series of strategic measures aimed at enhancing product yield while ensuring quality and efficiency throughout the manufacturing process. To begin with, specifications have been developed for raw materials, in-process materials, and finished products, laying down clear standards to maintain consistency and meet regulatory requirements.

Furthermore, the department has documented a master formula, serving as a standardized reference for manufacturing and packing operations, thus facilitating reproducibility and scalability across batches. In addition, the implementation of in-process controls allows for real-time monitoring and adjustment of critical parameters, minimizing the risk of production deviations and ensuring product integrity. A descriptive Batch Manufacturing Record (B.M.R.) has been established, detailing every aspect of the manufacturing process comprehensively, from equipment usage to operational conditions, ensuring thorough documentation for traceability, quality assurance, and regulatory compliance. These initiatives collectively underscore the department's commitment to continuous improvement and excellence in formulation development and manufacturing practices.

ENVIRONMENT, HEALTH & SAFETY

Our activities are subject to various environmental laws and regulations which govern, among other matters, air emissions, waste water discharges, the handling, storage and disposal of hazardous substances and wastes and employee health and employee safety. For further information, see *“Key Industry Regulations and Policies”* beginning on page 162 of this Prospectus. We continue to ensure compliance with applicable health and safety regulations and other requirements in our operations.

We have complied, and will continue to comply, with all applicable environmental and associated laws, rules and regulations. We have obtained, or are in the process of obtaining or renewing, all material environmental consents and licenses from the relevant governmental agencies that are necessary for us to carry on our business. For further information, see *“Government and Other Statutory Approvals”* beginning on page 230 of this Prospectus.

HUMAN RESOURCE

We believe that our employees are key contributors to our business success. We focus on attracting and retaining the best possible talent. Our Company looks for specific skill-sets, interests and background that would be an asset for its kind of business.

As of December 31, 2023, our registered office and manufacturing facility employ 83 individuals. These employees oversee various aspects of our manufacturing operations, including production, quality control, technical and engineering support services, inventory management, administration, accounting, secretarial duties, as well as other functions such as storage, packing, and dispatch.

Guided and supervised by our directors, our workforce comprises a balanced blend of experienced professionals and young talent. This combination affords us the dual advantage of stability and growth. The dedication of our team, along with their diverse skill sets ranging from skilled to semi-skilled and unskilled, coupled with our robust management team, has facilitated the successful implementation of our growth strategies.

At present, our employees are not unionized, and we have not encountered any work disruptions, strikes, lockouts, or other forms of employee unrest. The Company maintains that its relations with its employees are positive. We uphold stringent

safety standards in our facilities to ensure that our employees are not exposed to any hazards, prioritizing their well-being and security.

Sr. No	Category	No of Employees
1.	Production Department	52
2.	Quality Department	09
3.	Store Department	05
4.	Engineering Department	04
5.	Purchase Department & Sales Department	04
6.	Finance & Legal	03
7.	Housekeeping	04
8.	HR & Administration	02
Total		83

EXPORT AND EXPORT OBLIGATIONS

Our Company has identified certain key export markets for its products. As on the date, we do not have any export obligation.

COLLABORATION

As on date of this Prospectus, our Company has not entered into any technical or financial collaboration agreements.

INSURANCE

Our Company maintains insurance against various risks inherent in our business activities. While we believe that the insurance coverage which we maintain is in keeping with industry standards and would be reasonably adequate to cover the normal risks associated with the operation of our businesses, we cannot assure you that any claim under the insurance policies maintained by us will be honoured fully, in part or on time, or that we have taken out sufficient insurance to cover all our losses.

The following are the details of the insurance policies obtained by our Company:

Sr. No.	Name of the Insurance Company	Type of Policy	Validity Period up to	Policy No.	Sum Insured	Premium p.a.
1.	HDFC ERGO General Insurance Company Limited	Business Suraksha Classik Policy	21/09/2024	294920192061-2106000	₹ 3,82,81,000/-	₹ 65,153/-

PROPERTIES

Following Properties are owned / taken on lease / license by our company:

Date of Lease and License	Lessor/ Owner	Address	Period of Lease/ Rented /Owned	Area	Annual Charge	Purpose
August 13, 2010	Managing Director, Madhya Pradesh Audyogik Kendra Vikas Nigam Indore Limited	Plot No. 45, Sector III, Pithampur Industrial Area, Pithampur, Dhar - 454775, Madhya Pradesh, India.	30 Years	4,065 Square Meter.	₹ 36,788/- (Includes Maintenance charges)	Registered Office & Manufacturing Unit

INTELLECTUAL PROPERTY

Trademarks / patents / copyright/registered/objected/abandoned in the name of our company:

Sr. No	Brand Name/Logo Trademark	Class	Registration/ Application number	Owner	Authority	Date of Registration/ Application	Current Status
1.	 Quest LABORATORIES LIMITED	5	Application - 6278752	M/s. Quest Laboratories Limited,	Trade Mark Registry,	30/01/2024	Marked for Exam

DOMAIN:

Sr. No	Domain Name and ID	Sponsoring Registrar and ID	Registrant Name, ID and Address	Creation Date	Registry Expiry Date
1.	https://questlabltd.com/	ID:2843164808_DOMAIN_COM-VRSN	GoDaddy.com, LLC Registrar IANA ID: 146	January 04, 2024	January 04, 2025

KEY INDUSTRY REGULATIONS AND POLICIES

The following description is a summary of the relevant regulations and policies as prescribed by the GoI and other regulatory bodies that are applicable to our business. The information detailed below has been obtained from various legislations, including rules and regulations promulgated by regulatory bodies, and the bye laws of the respective local authorities that are available in the public domain. The regulations set out below may not be exhaustive and are merely intended to provide general information to the shareholders and neither designed, nor intended to substitute for professional legal advice. For details of government approvals obtained by us, see the section titled “Government and Other Approvals” on page 230 of this Prospectus.

THE COMPANIES ACT

The consolidation and amendment in the law relating to the Companies Act, 1956 made way to the enactment of the Companies Act, 2013 and rules made thereunder.

The Companies Act primarily regulates the formation, financing, functioning and restructuring of Companies as separate legal entities. The Act provides regulatory and compliance mechanism regarding all relevant aspects including organizational, financial and managerial aspects of companies. The provisions of the Act state the eligibility, procedure and execution for various functions of the company, the relation and action of the management and that of the shareholders. The law laid down transparency, corporate governance and protection of shareholders & creditors. The Companies Act plays the balancing role between these two competing factors, namely, management autonomy and investor protection.

SEBI REGULATIONS

Securities And Exchange Board of India is the regulatory body for securities market transactions including regulation of listing and delisting of securities. It forms various rules and regulations for the regulation of listed entities, transactions of securities, exchange platforms, securities market and intermediaries thereto. Apart from other rules and regulations, listed entities are mainly regulated by the SEBI Act, 1992, Securities Contract Regulation Act, 1956, Securities Contracts (Regulation) Rules, 1957, SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011 and SEBI (Prohibition of Insider Trading) Regulations, 2015.

TAX RELATED REGULATIONS

Income Tax Act, 1961

Income Tax Act, 1961 is applicable to every Domestic / Foreign Company whose income is taxable under the provisions of this Act or Rules made under it depending upon its “Residential Status” and “Type of Income” involved. U/s 139(1) every Company is required to file its Income tax return for every Previous Year by 31st October of the Assessment Year. Other compliances like those relating to Tax Deduction at Source, Advance Tax, Minimum Alternative Tax and like are also required to be complied by every Company.

Goods and Service Tax Act, 2017

The Central Goods and Services Tax Act, 2017 is an Act to make a provision for levy and collection of tax on intra-State supply of goods or services or both by the Central Government and for matters connected therewith or incidental thereto. In line with CGST Act, each state Government has enacted State Goods and Service Tax Act for respective states. Goods and Services Tax (GST) is a comprehensive indirect tax on manufacture, sale and consumption of goods and services throughout India to replace taxes levied by the central and state governments on goods and services. This method allows GST-registered businesses to claim tax credit to the value of GST they paid on purchase of goods or services or both as part of their normal commercial activity. The mechanism provides for two level taxation of interstate and intra state transactions. When the supply of goods or services happens within a state called as intra-state transactions, then both the CGST and SGST will be collected. Whereas if the supply of goods or services happens between the states called as interstate transactions and IGST will be collected. Exports are considered as zero-rated supply and imports are levied the same taxes as domestic goods and services adhering to the destination-based taxation principle in addition to the Customs Duty which has not been subsumed in the GST.

Customs Act, 1962

The provisions of the Customs Act, 1962 and rules made there under are applicable at the time of import of goods i.e. bringing into India from a place outside India or at the time of export of goods i.e. taken out of India to a place outside India. Any Company requiring to import or export any goods is first required to get it registered and obtain an IEC (Importer

Exporter Code) in terms of provisions of the Foreign Trade Development and Regulation Act, 1992. Imported goods in India attract basic customs duty, additional customs duty and cesses in terms of the provisions of the Customs Act, 1962, Customs Tariff Act, 1975 and the relevant provisions made thereunder. The rates of basic customs duty are specified under the Customs Tariff Act 1975. Customs duty is calculated on the assessable value of the goods. Customs duties are administered by Central Board of Indirect Taxes and Customs under the Ministry of Finance.

State Tax on Profession, Trades, Callings and Employment Rules, 1975

The professional tax slabs in India are applicable to those citizens of India who are either involved in any profession or trade. The State Government of each State is empowered with the responsibility of structuring as well as formulating the respective professional tax criteria and is also required to collect funds through professional tax. The professional taxes are charged on the incomes of individuals, profits of business or gains in vocations. The professional tax is charged as per the List II of the Constitution. The professional tax is classified under various tax slabs in India. The tax payable under the State Acts by any person earning a salary or wage shall be deducted by his employer from the salary or wages payable to such person before such salary or wages is paid to him, and such employer shall, irrespective of whether such deduction has been made or not when the salary and wage is paid to such persons, be liable to pay tax on behalf of such person and employer has to obtain the registration from the assessing authority in the prescribed manner.

BUSINESS/TRADE RELATED LAWS/REGULATIONS

Food Safety and Standards (Labelling and Display) Regulations 2020

The Food Safety and Standards Authority of India (FSSAI) has come up with the new Food Safety and Standards (Labelling and Display) Regulations, 2020. The new regulations emphasize on enabling consumers to make informed choices about their food purchases not only in the sphere of packaged food products but also on purchases from restaurants and ecommerce platforms. The new regime is set to be implemented from December 2021 except for a few provisions which are expected to be implemented a month later i.e. from January 2022. These regulations mandates several disclosures to be made on the packaging of the food items including display of certain information in a given manner for products sold on the e-commerce website.

Food Safety and Standards (Packaging) Regulations 2018

These regulations have been enacted to regulate the quality of packing materials being used for the packaging of food and food grade items. These regulations specifies the safety criteria to be used in the packaging of food items and aims to ensure that the packing material used for packaging of food and food grade items are safe for consumption and that the material used is able to withstand mechanical, chemical or thermal stresses encountered during normal transportation and specifies various packaging norms.

Drugs and Cosmetics Act, 1940 (“DCA”) and the Drugs and Cosmetics Rules, 1945 (“DCA Rules”)

The DCA regulates the import, manufacture, distribution and sale of drugs and cosmetics and prohibits the import, manufacture and sale of certain drugs and cosmetics which are, inter alia, misbranded, adulterated, spurious or harmful. The DCA Rules specify the requirement of a license for the manufacture or sale of any drug or cosmetic including for the purpose of examination, testing or analysis. It further mandates that every person holding a license must keep and maintain such records, registers and other documents as may be prescribed which may be subject to inspection by the relevant authorities.

Drugs (Prices Control) Order, 2013 (“DPCO”)

The DPCO prescribes inter alia the ceiling price of scheduled formulations, retail price of a new drug for existing manufacturers of scheduled formulations, maximum retail price of scheduled formulations. Under the DPCO, the Central Government may issue directions to the manufacturers of active pharmaceutical ingredients or bulk drugs and formulations to increase production or sell such active pharmaceutical ingredient or bulk drug to such manufacturers of formulations and direct the formulators to sell the formulations to institutions, hospitals or any agency. The DPCO specifies procedures for fixing the ceiling price of scheduled formulations of specified strengths or dosages, retail price of new drug for existing manufacturers of scheduled formulations, and penalties for contravention of its provisions.

The Narcotic Drugs and Psychotropic Substances Act, 1985 (“NDPS Act”)

The NDPS Act is a legal framework which seeks to control and regulate operations relating to narcotic drugs and psychotropic substances. It prohibits, inter alia, the cultivation, production, manufacture, possession, sale, purchase, transportation, warehousing, consumption, inter-state movement, transshipment and import and export of narcotic drugs and

psychotropic substances, except for medical or scientific purposes. It also controls and regulates controlled substances which can be used in the manufacturing of narcotic drugs and psychotropic substances. Offences under the NDPS Act are essentially related to violations of the various prohibitions imposed under the NDPS Act, punishable by both imprisonment and monetary fines.

Drugs, Medical Devices and Cosmetics Bill, 2023 (the “Drugs Bill, 2023”)

The Ministry of Health and Family Welfare, Government of India, released a of the Drugs Bill, 2023. The Drugs Bill, 2023 is proposed to amend and consolidate the laws relating to, inter alia, import, manufacture, distribution and sale of drugs and medical devices and cosmetics as well as the law relating clinical trials of new drugs and clinical investigation of investigational medical devices. The Drugs Bill, 2023 lays down the standards of the quality of imported drugs and cosmetics and circumstances under which these would be deemed to be adulterated, spurious and misbranded. Under the Drugs Bill, 2023, the central government has the power to prohibit or restrict or regulate the import of drugs and cosmetics in public interest including to meet the requirements of an emergency arising due to epidemic or natural calamities. Further, it lays down the standards of quality for manufacture, sale and distribution of drugs and cosmetics and clinical trial of drugs. The Drugs Bill, 2023 also proposes establishment of several boards and committees to assist and advise the Central and State Governments in the administration and regulation of drugs, cosmetics and medical devices.

Cosmetics Rules, 2020 (the “Cosmetic Rules”)

Under the Cosmetic Rules, no cosmetic shall be imported into India unless the product has been registered in accordance with these rules by the central licensing authority i.e., the Drugs Controller General of India, appointed by the Central Government. Further, any person who intends to manufacture cosmetics shall make an application for grant of a license or loan license to manufacture for sale or for distribution to the state licensing authority. Also, it needs to be ensured that if cosmetics are manufactured at more than one premises, a separate license is obtained for each such premises. Under the Cosmetic Rules, each batch of the raw materials used for manufacturing the cosmetics, and also each batch of the final product is required to be tested and the records or registers showing the particulars in respect of such tests is required to be maintained. The Cosmetic Rules further prescribes the labelling and packaging requirements to be followed for sale or distribution of cosmetics of Indian origin.

The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 (the “DMRA”)

The DMRA seeks to control advertisements of drugs in certain cases and prohibits advertisement of remedies that claim to possess magic qualities. In terms of the DMRA, advertisements include any notice, circular, label, wrapper or other document and any announcement made orally or by any means of producing or transmitting light, sound or smoke. It also specifies the ailments for which no advertisement is allowed. DMRA prohibits advertisements that give false impression regarding the true character of a drug, make false claims for a drug, or are otherwise false or misleading in any material particular. Further, the Drugs and Magic Remedies (Objectionable Advertisements) Rules, 1955 have been framed for effective implementation of the provisions of the DMRA.

National Pharmaceuticals Pricing Policy, 2012 (the “2012 Policy”)

The 2012 Policy intends to provide the principles for pricing of essential drugs specified in the National List of Essential Medicines – 2011 (“NLEM”) declared by the Ministry of Health and Family Welfare, Government of India and modified from time to time, in order to ensure the availability of such medicines at reasonable price, while providing sufficient opportunity for innovation and competition to support the growth of the industry. The prices are regulated based on the essential nature of the drugs. Further, the 2012 Policy regulates the price of formulations only, through market-based pricing which is different from the earlier principle of cost based pricing. Accordingly, the formulations will be priced by fixing a ceiling price and the manufacturers of such drugs will be free to fix any price equal to or below the ceiling price.

The New Drugs and Clinical Trial Rules, 2019 (the “NDC Rules”)

The clinical trials in India are controlled by the Directorate General (“DG”) of health services under the Ministry of Health and Family Welfare, Government of India. The NDC Rules lay down the process mechanics and guidelines for clinical trials, including procedure for approval for clinical trials. Clinical trials require obtaining of free, informed, and written consent from each study subject. The NDC Rules also provide for compensation in case of injury or death caused during the clinical trials. The Central Drugs Standard Control Organization has issued the guidance for industry for submission of clinical trial application for evaluating safety and efficacy, for the purpose of submission of clinical trial application as required under the NDC Rules. Further, under the NDC Rules, the ethics committee constituted thereunder is required to register itself with the central licensing authority in order to conduct any clinical trial, bioavailability study or bioequivalence study. The NDC Rules further provide for the composition and functions of the ethics committee and its

period of validity. The NDC Rules further mandate the maintenance of records for a period of five years after completion of the clinical trial, bioavailability study or bioequivalence study, as the case may be.

The Guidelines for Prevention of Misleading Advertisements and Endorsements for Misleading Advertisements, 2022 (“Advertisement Guidelines”)

The Advertisement Guidelines provide for the prevention of false or misleading advertisements and making endorsements relating thereto. The Advertisement Guidelines apply inter alia to a manufacturer and to all advertisements regardless of form, format or medium. The Advertisement Guidelines lay down the conditions for non-misleading and valid advertisement and prohibit surrogate or indirect advertisements of goods or services whose advertising is prohibited or restricted by law, by portraying it to be an advertisement for other goods or services, the advertising of which is not prohibited or restricted by law. Further, the Advertisement Guidelines lay down duties of inter alia a manufacturer and provide inter alia that every manufacturer shall ensure that all descriptions, claims and comparisons in an advertisement which relate to matters of objectively ascertainable facts shall be capable of substantiation. The Advertisement Guidelines further provide that any endorsement in an advertisement must reflect the genuine, reasonably current opinion of the individual, group or organization making such representation and must be based on adequate information about, or experience with, the identified goods, product or service and must not otherwise be deceptive.

The National List of Essential Medicines, 2022

The National List of Essential Medicines, 2022 (“NLEM”), has been introduced to replace the National List of Essential Medicines, 2015. This new list provides for 384 drugs as essential instead of the earlier 376. A total of 18 medicines have been added, 9 medicines have been deleted to finalize the new list. The medicines in National List of Essential Medicines (NLEM) should be available at affordable costs and with assured quality. The medicines used in the various national health programs emerging and re-emerging infections should be addressed in the list. The Government of India, Ministry of Health & Family Welfare (MOHFW) is mandated to ensure the quality healthcare system by assuring availability of safe and efficacious medicines for its population.

The Poisons Act, 1919 (“Poisons Act”)

The Poisons Act enables state governments to grant licenses for the possession, sale, wholesale or retail and fixing of the fee, if any, of poisons. The Poisons Act also enables state governments to regulate the classes of persons to whom such license may be granted, the maximum quantity of poison which may be permitted to be sold to any one person etc.

Good Manufacturing Practice Guidelines (GMP)

These guidelines are provided under Schedule T of Drug and Cosmetic Act, 1940. Good manufacturing practices (GMP) are the practices required in order to confirm the guidelines recommended by agencies that control authorization and licensing for manufacture and sale of food, drug products, and active pharmaceutical products. These guidelines provide minimum requirements that a pharmaceutical or a food product manufacturer must meet to assure that the products are of high quality and do not pose any risk to the consumer or public. Good manufacturing practices, along with good laboratory practices and good clinical practices, are overseen by regulatory agencies in various sectors in India.

The Bureau of Indian Standards Act, 1986

The Bureau of Indian Standards Act, 1986 (“BIS Act”) was established to provide for the establishment of a bureau (“Bureau”) for the harmonious development of the activities of standardization, marking and quality certification of goods and for matters connected therewith. “Indian Standard” means the standard (including any tentative or provisional standard) established and published by the Bureau, in relation to any article or process indicative of the quality and specification of such article or process and includes - (i) any standard recognized by the Bureau under clause (b) of section 10 of the BIS Act; and (ii) any standard established and published, or recognized, by the Indian Standards Institution and which is in force immediately before the date of establishment of the Bureau.

The Bureau of Indian Standards Act, 2016 (“BIS Act”) and Bureau of Indian Standards Rules, 2018 and amendments thereto

The BIS Act and rules made thereunder, establishes, publishes and regulates national standards to ensure conformity assessment, standardization, and quality assurance of goods, articles, processes, systems and services. The BIS Act empowers the Bureau of Indian Standards to inspect and monitor the quality of goods and materials to ensure conformity with the BIS Act. In furtherance of such powers, the officials may inspect the premises for evaluating a manufacturer’s compliance with use of standard marks. The BIS Act also enables the central government to appoint any authority to verify the conformity of products and services to a standard and issue certificate of conformity. Further, the BIS Act sets out inter

alia, liability for use of standard mark on products that do not conform to the relevant Indian Standard. Under the BIS Act, such products may be recalled from the market.

Legal Metrology Act, 2009

The Legal Metrology Act, 2009, as amended (the “Metrology Act”), was enacted with the objectives to establish and enforce standards of weights and measures, regulate trade and commerce in weights, measures and other goods which are sold or distributed by weight, measure or number and for matters connected therewith or incidental thereto. The Metrology Act states that any transaction/contract relating to goods/class of goods or undertakings shall be as per the weight/measurement/numbers prescribed by the Metrology Act. The specifications with respect to the exact denomination of the weight of goods to be considered in transactions are contained in rules by each state.

Standards of Weights and Measures Act, 1976

The Standards of Weights and Measures Act, 1976 (the “Act”) was enacted to regulate trade or commerce in weights, measures and other goods which are sold or distributed by weight, measure or number and to provide for such matters as may be connected thereto. The Act enumerates the specific base units to measure goods and products. Any offence under this Act is punishable with imprisonment or fine or with both based on the type of violation.

REGULATIONS RELATED TO FOREIGN TRADE AND INVESTMENT

The Foreign Direct Investment

The Government of India, from time to time, has made policy pronouncements on Foreign Direct Investment (“FDI”) through press notes and press releases. The Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce & Industry, Government of India makes policy pronouncements on FDI through Consolidated FDI Policy Circular/Press Notes/Press Releases which are notified by the Department of Economic Affairs (DEA), Ministry of Finance, Government of India as amendments to the Foreign Exchange Management (Non-Debt Instruments) Rules, 2019 under the Foreign Exchange Management Act, 1999 (42 of 1999) (FEMA). DPIIT has issued consolidated FDI Policy Circular of 2020 (“FDI Policy 2020”), which with effect from October 15, 2020, consolidates and supersedes all previous press notes, press releases and clarifications on FDI Policy that were in force. The Government proposes to update the consolidated circular on FDI policy once every year and therefore, FDI Policy 2020 will be valid until an updated circular is issued.

The reporting requirements for any investment in India by a person resident outside India under Foreign Exchange Management (Non-Debt Instruments) Rules, 2019 are specified by the RBI. Regulation 4 of the Foreign Exchange Management (Mode of Payment and Reporting of Non-Debt Instruments) Regulations, 2019 vide notification No. FEMA. 395/2019-RB dated 17.10.2019 issued by the RBI stipulates the reporting requirement for any investment in India by a person resident outside India. All the reporting is required to be done through the Single Master Form (SMF) available on the Foreign Investment Reporting and Management System (FIRMS) platform at <https://firms.rbi.org.in>.

Under the current FDI Policy of 2020, foreign direct investment in micro and small enterprises is subject to sectoral caps, entry routes and other sectoral regulations.

Foreign Exchange Management Act, 1999 (“FEMA”) and Regulations framed thereunder:

Foreign investment in India is governed primarily by the provisions of the FEMA which relates to regulation primarily by the RBI and the rules, regulations and notifications there under, and the policy prescribed by the Department of Promotion of Industry and Internal Trade, Ministry of Commerce & Industry, Government of India. As laid down by the FEMA Regulations no prior consents and approvals are required from the Reserve Bank of India, for Foreign Direct Investment under the ‘automatic route’ within the specified sectoral caps. In respect of all industries not specified as FDI under the automatic route, and in respect of investment in excess of the specified sectoral limits under the automatic route, approval may be required from the FIF and/or the RBI. The RBI, in exercise of its power under the FEMA, has notified the Foreign Exchange Management (Transfer or Issue of Security by a Person Resident Outside India) Regulations, 2017 (“FEMA Regulations”) to prohibit, restrict or regulate, transfer by or issue security to a person resident outside India and Foreign Exchange Management (Export of Goods and Services) Regulations, 2015 for regulation on exports of goods and services.

Ownership restrictions of FIIs

Under the portfolio investment scheme, the total holding of all FIIs together with their sub-accounts in an Indian company is subject to a cap of 24% of the paid-up capital of a company, which may be increased up to the percentage of sectoral cap on FDI in respect of the said company pursuant to a resolution of the board of directors of the company and the approval of the shareholders of the company by a special resolution in a general meeting. The total holding by each FII, or in case

an FII is investing on behalf of its sub-account, each sub-account should not exceed 10% of the total paid-up capital of a company

Laws related to Overseas Investment by Indian Entities:

Overseas investment by Indian Entities are governed under Foreign Exchange Management Act, 1999 under which the central Government of India have notified Foreign Exchange Management (Overseas Investment) Rules, 2022 in suppression of Foreign Exchange Management (Transfer or Issue of Any Foreign Security) Regulations, 2004 and the Foreign Exchange Management (Acquisition and Transfer of Immovable Property Outside India) Regulations, 2015. Followed by the rules, RBI has vide notification no. RBI/2022-2023/110, A.P. (DIR Series) Circular No.12 dated August 22, 2022 have issued Foreign Exchange Management (Overseas Investment) Directions, 2022 and Foreign Exchange Management (Overseas Investment) Regulations, 2022. These legislations frame the investment fields, mode and cap for various sectors and regions, by any person resident in India and the reporting requirements.

Foreign Trade Policy 2023:

The Central Government of India in exercise of powers conferred under Section 5 of the Foreign Trade (Development & Regulation) Act, 1992 (No. 22 of 1992) [FT (D&R) Act], as amended, has notified Foreign Trade Policy (FTP) 2023 which is effective from April 01, 2023 and shall continue to be in operation unless otherwise specified or amended. It provides for a framework relating to export and import of goods and services. All exports and imports made up to 31.03.2023 shall, accordingly, be governed by the relevant FTP, unless otherwise specified.

LAWS RELATED TO ENVIRONMENTAL LAWS

National Environmental Policy, 2006

The dominant theme of this policy is that while conservation of environmental resources is necessary to secure livelihoods and well-being of all, the most secure basis for conservation is to ensure that people dependent on particular resources obtain better livelihoods from the fact of conservation, than from degradation of the resource.

Environment (Protection) Act, 1986 as amended (“EPA”)

The EPA has been enacted for the protection and improvement of the environment. It stipulates that no person carrying on any industry, operation or process shall discharge or emit or permit to be discharged or emitted any environmental pollutant in excess of such standards as may be prescribed. Further, no person shall handle or cause to be handled any hazardous substance except in accordance with such procedure and after complying with such safeguards as may be prescribed. EPA empowers the Central Government to take all measures necessary to protect and improve the environment such as laying down standards for emission or discharge of pollutants, providing for restrictions regarding areas where industries may operate and generally to curb environmental pollution. Pollution control boards have been constituted in all states in India to exercise the powers and perform the functions provided for under these statutes for the purpose of preventing and controlling pollution. Companies are required to obtain consents of the relevant state pollution control boards for emissions and discharge of effluents into the environment.

Water (Prevention and Control of Pollution) Act, 1974 (the “Water Act”)

The Water Act provides for one Central Pollution Control Board, as well as state pollution control boards, to be formed to implement its provisions, including enforcement of standards for factories discharging pollutants into water bodies. The Water Act prohibits the use of any stream or well for the disposal of polluting matter, in violation of the standards set down by the State PCB. The Water Act also provides that the consent of the State PCB must be obtained prior to opening of any new outlets or discharges, which are likely to discharge sewage effluent. The Water Act prescribes specific amounts of fine and terms of imprisonment for various contraventions.

Hazardous and Other Wastes (Management and Transboundary Movement) Rules, 2016 (the “Hazardous Waste Rules”)

The Hazardous Waste Rules regulate the management, treatment, storage and disposal of hazardous waste. Under the Hazardous Waste Rules, “hazardous waste” inter alia means any waste which by reason of characteristics such as physical, chemical, biological, reactive, toxic, flammable, explosive or corrosive, causes danger or is likely to cause danger to health or environment, whether alone or in contact with other wastes or substances. Every occupier and operator of a facility generating hazardous waste must obtain authorization has been relevant state pollution control board. Further, the occupier, importer or exporter is liable for damages caused to the environment or third party resulting from the improper handling

and management and disposal of hazardous waste and must pay any financial penalty that may be levied by the respective state pollution control board.

The Noise Pollution (Regulation and Control) Rules, 2000

These Noise Pollution (Regulation and Control) Rules, 2000 (“Noise Pollution Rules”) were constituted to regulate and control noise producing and generating sources with the objective of maintaining the ambient air quality standards in respect of noise and were considered necessary as increasing ambient noise levels in public places from various sources, inter-alia, industrial activity, construction activity, (fire crackers, sound producing instruments), generator sets, loud speakers, public address systems, music systems, vehicular horns and other mechanical devices have deleterious effects on human health and psychological well-being of the people. The Noise Pollution Rules provide ambient air quality criteria with respect of noise for different areas/zones. The Noise Pollution Rules further provide powers to the authority to enforce the noise control measures in the areas/zones. The Noise Pollution Rules provide modes of making complaints to the authority in case noise levels exceed the ambient noise standards along with penalties and liabilities on account of violations in the silence zones/areas.

Environment Impact Assessment Notification of 2006

The Ministry of Environment, Forests and Climate Change has notified the Environment Impact Assessment Notification of 2006 in September 2006. The notification makes it mandatory for various projects to get environment clearance.

The Public Liability Insurance Act, 1991 (the “PLI Act”) and the Public Liability Insurance Rules, 1991(the “PLI Rules”)

The PLI Act imposes liability on the owner or controller of hazardous substances for any damage arising out of an accident involving such hazardous substances. A list of hazardous substances covered by the legislation has been enumerated by the government by way of a notification. Under the PLI Act, the owner or handler is also required to take out an insurance policy insuring against liability. The PLI Act also provides for the establishment of the Environmental Relief Fund, which shall be utilized towards payment of relief granted under the Public Liability Act. The PLI Rules mandate the employer to contribute a sum equal to the premium paid on the insurance policies towards the Environmental Relief Fund.

LAWS RELATING TO INTELLECTUAL PROPERTY

Trademarks Act, 1999

Under the Trademarks Act, 1999 (“Trademarks Act”), a trademark is a mark capable of being represented graphically and which is capable of distinguishing the goods or services of one person from those of others used in relation to goods and services to indicate a connection in the course of trade between the goods and some person having the right as proprietor to use the mark. A ‘mark’ may consist of a device, brand, heading, label, ticket, name signature, word, letter, numeral, shape of goods, packaging or combination of colors or any combination thereof.

The Patents Act, 1970:

The Patents Act, 1970 as amended from time to time, in India has been enacted to protect inventions. Patents provide the exclusive rights for the owner of a patent to make, use, exercise, distribute and sell a patented invention. The patent registration confers on the patentee the exclusive right to use, manufacture and sell his invention for the term of the patent.

LAWS RELATED TO EMPLOYMENT OF MANPOWER:

Code on Wages, 2019

The Code on Wages, 2019 regulates and amalgamates wage and bonus payments and subsumes four existing laws namely – the Payment of Wages Act, 1936, the Minimum Wages Act, 1948, the Payment of Bonus Act, 1965 and the Equal Remuneration Act, 1976 received the assent of the President of India on August 8, 2019. It regulates, inter alia, the minimum wages payable to employees, the manner of payment and calculation of wages and the payment of bonus to employees. Only few section of the Code has yet been notified vide notification no. S.O. 4604(E) dated December 18, 2020.

The Occupational Safety, Health and Working Conditions Code, 2020

The Occupational Safety, Health and Working Conditions Code, 2020 received the assent of the President of India on September 28, 2020 and proposes to subsume certain existing legislations, including the Factories Act, 1948, the Contract Labour (Regulation and Abolition) Act, 1970, the Inter-State Migrant Workmen (Regulation of Employment and

Conditions of Service) Act, 1979 and the Building and Other Construction Workers (Regulation of Employment and Conditions of Service) Act, 1996. The provisions of this code will be brought into force on a date to be notified by the Central Government. The Central Government has issued the draft rules under the Occupational Safety, Health and Working Conditions Code, 2020. The draft rules provide for operationalization of provisions in the Occupational Safety, Health and Working Conditions Code, 2020 relating to safety, health and working conditions of the dock workers, building or other construction workers, mines workers, inter-state migrant workers, contract labour, journalists, audio-visual workers and sales promotion employees.

The Industrial Relations Code, 2020

The Industrial Relations Code, 2020 received the assent of the President of India on September 28, 2020 and it proposes to subsume three existing legislations, namely, the Industrial Disputes Act, 1947, the Trade Unions Act, 1926 and the Industrial Employment (Standing Orders) Act, 1946. The provisions of this code will be brought into force on a date to be notified by the Central Government.

The Code on Social Security, 2020

The Code on Social Security, 2020 received the assent of the President of India on September 28, 2020 and it proposes to subsume certain existing legislations including the Employee's Compensation Act, 1923, the Employees' State Insurance Act, 1948, the Employees' Provident Funds and Miscellaneous Provisions Act, 1952, the Maternity Benefit Act, 1961, the Payment of Gratuity Act, 1972, the Building and Other Construction Workers' Welfare Cess Act, 1996 and the Unorganized Workers' Social Security Act, 2008. The provisions of this code will be brought into force on a date to be notified by the Central Government. The Central Government has issued the draft rules under the Code on Social Security, 2020. The draft rules provide for operationalization of provisions in the Code on Social Security, 2020 relating to employees' provident fund, employees' state insurance corporation, gratuity, maternity benefit, social security and cess in respect of building and other construction workers, social security for unorganized workers, gig workers and platform workers.

In addition to above, we are subject to wide variety of generally applicable labour laws concerning condition of working, benefit and welfare of our laborers and employees such as the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Employees (Provident Fund and Miscellaneous Provision) Act, 1952.

*The Code on Wages, 2019, The Code on Social Security, 2020, (enacted by the Parliament of India and assented to by the President of India) will come into force as may be notified in the Official Gazette by the Central Government of India, different dates may be appointed for different provisions of the Codes.

Employees Provident Fund and Miscellaneous Provisions Act, 1952

Under the Employees' Provident Funds and Miscellaneous Provisions Act, 1952 (EPF Act), compulsory provident fund, family pension fund and deposit linked insurance are payable to employees in factories and other establishments. The legislation provides that an establishment employing more than 20 (twenty) persons, either directly or indirectly, in any capacity whatsoever, is either required to constitute its own provident fund or subscribe to the statutory employee's provident fund. The employer of such establishment is required to make a monthly contribution to the provident fund equivalent to the amount of the employee's contribution to the provident fund. There is also a requirement to maintain prescribed records and registers and filing of forms with the concerned authorities. The EPF Act also prescribes penalties for avoiding payments required to be made under the abovementioned schemes.

Employees State Insurance Act, 1948, as amended (the "ESIC Act")

The ESI Act, provides for certain benefits to employees in case of sickness, maternity and employment injury. All employees in establishments covered by the ESI Act are required to be insured, with an obligation imposed on the employer to make certain contributions in relation thereto. In addition, the employer is also required to register itself under the ESI Act and maintain prescribed records and registers.

Payment of Gratuity Act, 1972, as amended (the "Gratuity Act")

The Gratuity Act establishes a scheme for the payment of gratuity to employees engaged in every factory, mine, oil field, plantation, port and railway company, every shop or establishment in which ten or more persons are employed or were employed on any day of the preceding twelve months and in such other establishments in which ten or more employees are employed or were employed on any day of the preceding twelve months, as notified by the Central Government from time to time. Penalties are prescribed for non-compliance with statutory provisions.

Under the Gratuity Act, an employee who has been in continuous service for a period of five years will be eligible for gratuity upon his retirement, resignation, superannuation, death or disablement due to accident or disease. However, the entitlement to gratuity in the event of death or disablement will not be contingent upon an employee having completed five years of continuous service. The maximum amount of gratuity payable may not exceed 1 million.

Certain other laws and regulations that may be applicable to our Company in India include the following:

- Minimum Wages Act, 1948 and Maharashtra Minimum Wages Rules, 1963 (“MWA Rules”)
- Public Liability Insurance Act, 1991 (“PLI Act”)
- Industrial (Development and Regulation) Act, 1951 (“IDRA”)
- Industrial Disputes Act, 1947 (“ID Act”)
- Payment of Bonus Act, 1965 (“POB Act”)
- Child Labour (Prohibition and Regulation) Act, 1986
- Inter-State Migrant Workers (Regulation of Employment and Conditions of Service) Act, 1979
- Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 (“SHWW Act”)
- Equal Remuneration Act, 1976 (“ER Act”)
- Contract Labour Regulation and Abolition Act, 1970 (CLRA) and Contract Labour (Regulation and Abolition) Central Rules, 1971 (Contract Labour Rules)
- Workmen Compensation Act, 1923 (“WCA”)
- Maternity Benefit Act, 1961 (“Maternity Act”)
- Industrial Employment Standing Orders Act, 1946
- Apprentice Act, 1961 read with The National Policy of Skill Development and Entrepreneurship 2015,

OTHER GENERAL REGULATIONS

The Micro, Small and Medium Enterprises Development Act, 2006 (“MSME Act”):

MSME Act was enacted to provide for facilitating the promotion and development and enhancing the competitiveness of micro, small and medium enterprises. Any person who intends to establish (a) a micro or small enterprise, at its discretion; (b) a medium enterprise engaged in providing or rendering of services may, at its discretion; or (c) a medium enterprise engaged in manufacture or production of goods pertaining to any industry specified in the First Schedule to the Industries (Development and Regulation) Act, 1951 is required to file a memorandum before such authority as specified by the State Government or the Central Government. The form of the memorandum, the procedure of its filing and other matters incidental thereto shall be such as may be specified by the Central Government, based on the recommendations of the advisory committee. Accordingly, in exercise of this power under the MSME Act, the Ministry of Micro, Small and Medium Enterprises notification dated September 18, 2015 specified that every micro, small and medium enterprises is required to file a Udyog Adhaar Memorandum in the form and manner specified in the notification.

State Laws

We operate in various states. Accordingly, legislations passed by the state governments are applicable to us in those states. These include legislations relating to, among others, Shops and Establishment Act, classification of fire prevention and safety measures and other local licensing. Further, we require several approvals from local authorities such as municipal bodies. The approvals required may vary depending on the state and the local area.

Municipality Laws

Pursuant to the Constitution (Seventy-Fourth Amendment) Act, 1992, the respective state legislatures in India have power to endow the municipalities with power to implement schemes and perform functions in relation to matters listed in the Twelfth Schedule to the Constitution of India. The respective states of India have enacted laws empowering the municipalities to issue trade license for operating eating outlets and implementation of regulations relating to such license along with prescribing penalties for non-compliance.

Approvals from Local Authorities

Setting up of a factory or manufacturing / housing unit entails the requisite planning approvals to be obtained from the relevant Local Panchayat(s) outside the city limits and appropriate Metropolitan Development Authority within the city limits. Consents are also required from the state pollution control board(s), the relevant state electricity board(s), the state excise authorities, sales tax, among others, are required to be obtained before commencing the building of a factory or the start of manufacturing operations.

Other regulations:

Apart from the above list of laws – which is inclusive in nature and not exhaustive - general laws like the Indian Contract Act 1872, Specific Relief Act 1963, Negotiable Instrument Act 1881, The Information Technology Act, 2000, Sale of Goods Act 1930 and Consumer Protection Act 1986, The Arbitration & Conciliation Act, 1996 are also applicable to the company.

PROPERTY RELATED LAWS

The Company is required to comply with central and state laws in respect of property. Central Laws that may be applicable to our Company's operations include the Land Acquisition Act, 1894, the Transfer of Property Act, 1882, Registration Act, 1908, Indian Stamp Act, 1899, and Indian Easements Act, 1882.

HISTORY AND CERTAIN CORPORATE MATTERS

BRIEF HISTORY OF OUR COMPANY

Our Company was originally incorporated under the name “*Quest Laboratories Private Limited*” under the provisions of the Companies Act, 1956 vide Certificate of Incorporation dated June 01, 1998, issued by the Registrar of Companies Madhya Pradesh, Gwalior. Subsequently, the status of the Company was changed to public limited and the name of our Company was changed to “*Quest Laboratories Limited*” vide Special Resolution passed by the Shareholders at the Extra Ordinary General Meeting of our Company held on January 11, 2024. The fresh certificate of incorporation consequent to conversion was issued on January 23, 2024, by Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies, Centralised Processing Centre. The Corporate Identification Number of our Company is U24232MP1998PLC012850.

Mr. Narendra Kumar Pamecha and Mr. Anil Kumar Sabarwal were the initial subscribers to the Memorandum of Association of our Company. Mr. Anil Kumar Sabarwal and Ms. Tejaswini Sabarwal are the current promoters of the company. For further details of our promoter please refer the chapter titled “*Our Promoters and Promoter Group*” beginning on page 190 of this Prospectus.

For information on our Company’s profile, activities, products, market, growth, technology, managerial competence, standing with reference to prominent competitors, major vendors and suppliers, please refer the chapter titled “*Our Business*”, “*Industry Overview*”, “*Our Management*”, “*Restated Financial Statements*” and “*Management’s Discussion and Analysis of Financial Condition and Results of Operations*” beginning on pages, 106, 175, 196 and 199 respectively of this Prospectus.

Our Company has 23 (Twenty-Three) shareholders as on the date of filing of this Prospectus.

CHANGES IN THE REGISTERED OFFICE OF OUR COMPANY

The following changes were made in the location of our Registered Office:

From	To	With effect from	Reason for Change
P-63, Onkar Marg, Gandhi Nagar, Indore 452001, Madhya Pradesh.	Plot No. 45 Sector III, Pithampur Dhar - 454775, Madhya Pradesh India.	March 25, 2019	Administrative Purpose

MAJOR EVENTS IN THE HISTORY OF OUR COMPANY

Year	Key Events/Milestones/Achievements
1998	Incorporation of our Company as Private Limited Company
1998	Good Manufacturing Practices Certificate
1998	Good Laboratory Practices Certificate
2022	ISO/IEC 17025:2017 for General Requirements for the Competence of Testing & Calibration Laboratories
2023	ISO 9001:2015 in accordance with the requirements Quality Management System standard
2023	Zed Bronze under MSME Sustainable (ZED) Certification
2024	Conversion of our Company from Private Limited to Public Limited Company

MAIN OBJECTS OF OUR COMPANY

The main objects of our Company as set forth in the Memorandum of Association of our Company are as follows:

1. To Carry on business as Manufacturers, importers, exporters, Buyers, Sellers, processors growers, makers, refiners inventor, formulators, analysts, druggist, chemist, stockists, Agents, Distributors and Inorganic Chemicals, Medicinal preparational drugs, Drug Intermediates, Drugs and Pharmaceutical formulations in usual dosage form i.e. vials, injections orals, syrups, Tablets, Capsules and in any such other forms for human as well as animal use, food products, Surgical goods, and Ayurvedic, Allopathic Homeopathic, and Unani products based on herbs, vegetables, fruits, plants and chemical compounds.
2. To manufacture all kinds of chemicals and fine chemicals and basic drugs required for and in the industries, relating to chemicals, photographic chemicals, textile chemicals pharmaceuticals and cosmetic chemicals, glues gums, colours, paints, pigments, paper chemicals, plastic and pesticides chemicals, metallurgical, agro based compound, substances and articles intended for or capable of being used in or connected with any such business as aforesaid.

AMENDMENTS TO THE MEMORANDUM OF ASSOCIATION OF OUR COMPANY SINCE INCORPORATION

The following changes have been made in the Memorandum of Association of our Company Since Incorporation:

Date of Meeting	Type	Nature of Amendment
March 25, 2004	EOGM	<u>Clause V of our Memorandum of Association was amended to reflect:</u> Increase in Authorised Share Capital of the company from ₹ 2,00,000 (Two Lakhs) divided into 20,000 equity shares of ₹10/- each to ₹ 15,00,000 (Fifteen Lakhs) divided into 1,50,000 equity shares of ₹10/- each.
February 01, 2008	EOGM	<u>Clause V of our Memorandum of Association was amended to reflect:</u> Increase in Authorised Share Capital of the company from ₹ 15,00,000 (Fifteen Lakhs) divided into 1,50,000 equity shares of ₹10/- each to ₹ 45,00,000 (Forty-Five Lakhs) divided into 4,50,000 equity shares of ₹10/- each.
March 25, 2010	EOGM	<u>Clause V of our Memorandum of Association was amended to reflect:</u> Increase in Authorised Share Capital of the company from ₹ 45,00,000 (Forty-Five Lakhs) divided into 4,50,000 equity shares of ₹10/- each to Rs. 1,00,00,000 (One Crore) divided into 10,00,000 equity shares of ₹10/- each.
June 30, 2016	EOGM	<u>Clause V of our Memorandum of Association was amended to reflect:</u> Increase in Authorised Share Capital of the company from ₹ 1,00,00,000 (One Crore) divided into 10,00,000 equity shares of ₹10/- each to ₹ 2,00,00,000 (Two Crore) divided into 20,00,000 equity shares of ₹10/- each.
August 19, 2023	EOGM	<u>Clause V of our Memorandum of Association was amended to reflect:</u> Increase in Authorised Share Capital of the company from ₹ 2,00,00,000 (Two Crore) divided into 20,00,000 equity shares of ₹10/- each to ₹ 12,00,00,000 (Twelve Crore) divided into 1,20,00,000 equity shares of ₹10/- each.
January 11, 2024	EOGM	<u>Clause V of our Memorandum of Association was amended to reflect:</u> Increase in Authorised Share Capital of the company from ₹ 12,00,00,000 (Twelve Crore) divided into 1,20,00,000 equity shares of ₹10/- each to ₹ 20,00,00,000 (Twenty Crore) divided into 2,00,00,000 equity shares of ₹10/- each.
January 11, 2024	EOGM	<u>Alteration in Name Clause pursuant to conversion:</u> Change in the name clause from “Quest Laboratories Private Limited” to “Quest Laboratories Limited”

OUR HOLDING COMPANY

As on the date of this Prospectus, our Company does not have any Holding Company.

OUR SUBSIDIARY COMPANY

As on the date of this Prospectus, our Company does not have any Subsidiary Company.

ACQUISITION OF BUSINESSES/UNDERTAKINGS, MERGER, AMALGAMATION OR REVALUATION OF ASSETS IN LAST 10 YEARS

Our Company has not made any material acquisitions or divestments of any business or undertaking, and has not undertaken any mergers, amalgamation or revaluation of assets in the last ten years.

SIGNIFICANT FINANCIAL OR STRATEGIC PARTNERSHIPS

We do not have any financial or strategic partnerships as on the date of this Prospectus.

SHAREHOLDERS' AGREEMENT

Our Company has not entered into any Shareholders Agreement as on the date of this Prospectus.

LOCK OUTS AND STRIKES

There have been no lock outs or strikes at any of the location of our Company as on the date of this Prospectus.

TIME/COST OVERRUN IN SETTING UP PROJECTS

There has been no time and cost overruns in the Company as on date of this Prospectus.

LAUNCH OF KEY PRODUCTS OR SERVICES, ENTRY OR EXIT IN NEW GEOGRAPHIES

For details of launch of key products or services, entry in new geographies or exit from existing markets, capacity or facility creation and the locations, please see chapter titled “*Our Business*” beginning on page 128 of this Prospectus.

CHANGES IN THE ACTIVITIES OF OUR COMPANY DURING THE LAST FIVE YEARS

There have been no changes in the activities of our Company during the last five years which may have had a material effect on the profits and loss account of our Company, including discontinuance of lines of business, loss of agencies or markets and similar factors.

DEFAULTS OR RESCHEDULING OF BORROWINGS WITH FINANCIAL INSTITUTIONS/BANKS

Our Company has not made any defaults / re-scheduling of its borrowings as on date of this Prospectus.

JOINT VENTURES

As on the date of this Prospectus, there are no joint ventures of our Company.

AGREEMENTS WITH KEY MANAGERIAL PERSONNEL, SENIOR MANAGEMENT, DIRECTOR, PROMOTERS OR ANY OTHER EMPLOYEE

Neither our Promoters, nor any of the Key Managerial Personnel, Senior Management, Directors or employees of our Company have entered into an agreement, either by themselves or on behalf of any other person, with any Shareholder or any other third party with regard to compensation or profit sharing in connection with the dealings of the securities of our Company.

MATERIAL AGREEMENTS

Except as disclosed above and in the chapter titled “*Our Business*” on page 128 of this Prospectus, we have not entered into any material agreement / contract as on the date of this Prospectus.

STRATEGIC PARTNERS

As of the date of this Prospectus, our Company does not have any Strategic Partners.

FINANCIAL PARTNERS

As on the date of this Prospectus, our Company does not have any other financial partners.

OUR MANAGEMENT

BOARD OF DIRECTORS

Under Articles of Association of our Company, the number of directors shall not be less than 3 (three) and not be more than 15 (Fifteen), subject to the applicable provisions of the Companies Act, 2013.

As of the date of this Prospectus, our Company has 6 (Six) Directors on the Board, 1 (One) as Chairman & Managing Director, 2 (Two) as Whole Time Directors, and 3 (Three) as Non-Executive Independent Directors. There is 1 (One) Woman Director in our Board.

The details of the Directors are as mentioned in the below table:

Name, Father's Name, Age, DOB, Designation, Address, Occupation, Nationality, Term and DIN	Date of Appointment/ Re appointment	Other Directorships
Name: Mr. Anil Kumar Sabarwal Father's Name: Mr. Satyapal Sabarwal Age: 56 years Date of Birth: May 13, 1967 Designation: Chairman & Managing Director Address: 121, Scheme No. 59, Amitesh Nagar, IDA, Indore - 452014, Madhya Pradesh, India. Occupation: Business Nationality: Indian Term: Re-appointed as Chairman and Managing Director for a period of 5 (five) years with effect from January 01, 2024. DIN: 00646133	Appointed as Director of the Company on June 01, 1998 Re-designated as Managing Director of the company on September 30, 2010 Re-appointed as Director of the company on February 21, 2022 Re-designated as Managing Director of the Company on January 01, 2024	Nil
Name: Ms. Tejaswini Sabarwal Father's Name: Mr. Shyam Kumar Chouhan Age: 28 years Date of Birth: August 15, 1995 Designation: Whole Time Director Address: 121, Amitesh Nagar, Scheme No 59, IDA, Indore 452 014, Madhya Pradesh, India. Occupation: Professional Nationality: Indian Term: Re-appointed as Whole Time Director for a period of 5 (five) years with effect from January 01, 2024 DIN: 09088283	Appointed as Additional Director of the company on March 05, 2021 Re-designated as Director of the company on March 30, 2021 Re-designated as Whole Time Director of the Company on January 01, 2024	Nil

Name, Father's Name, Age, DOB, Designation, Address, Occupation, Nationality, Term and DIN	Date of Appointment/ Re appointment	Other Directorships
Name: Mr. Rahul Dangi Father's Name: Mr. Pushpendra Dangi Age: 27 years Date of Birth: August 05, 1996 Designation: Whole Time Director Address: Gram Banshiya, Baronda Rehli, Sagar 470228, Madhya Pradesh, India Occupation: Professional Nationality: Indian Term: Re-appointed as Whole Time Director for a period of 5 (five) years with effect from January 01, 2024 DIN: 09088127	Appointed as Additional Director of the company on March 05, 2021 Re-designated as Director of the company on March 30, 2021 Re-designated as Managing Director of the company on August 14, 2021 Re-designated as Whole Time Director of the Company on January 01, 2024	Nil
Name: Mr. Gautam Kothari Father's Name: Mr. Hazarimal Kothari Age: 70 years Date of Birth: October 25, 1953 Designation: Non-Executive Independent Director Address: 231, Saket Nagar, Tilaknagar, Indore 452018, Madhya Pradesh, India. Occupation: Professional Nationality: Indian Term: Appointed as Non-Executive Independent Director with effect from February 09, 2024 for a period of 5 years DIN: 00115063	Appointed as Additional Director of the Company on January 10, 2024 Appointed as Non-Executive Independent Director of the Company on February 09, 2024	• Porwal Auto Components Limited
Name: Mr. Amit Ramesh Chandak Father's Name: Mr. Ramesh Mohanlal Chandak Age: 40 years Date of Birth: January 12, 1984 Designation: Non-Executive Independent Director Address: 302, Varad Vinayak Apartment, Siddheshwar Nagar, Dighori, Narsala, Nagpur- 440034 Maharashtra, India.	Appointed as Additional Director of the Company on January 10, 2024 Appointed as Non-Executive Independent Director of the Company on February 09, 2024	Nil

Name, Father's Name, Age, DOB, Designation, Address, Occupation, Nationality, Term and DIN	Date of Appointment/ Re appointment	Other Directorships
Occupation: Professional Nationality: Indian Term: Appointed as Non-Executive Independent Director with effect from February 09, 2024 for a period of 5 years DIN: 09419479		
Name: Mr. Basant Lal Menghwani Father's Name: Harpal Das Menghwani Age: 69 Years Date of Birth: February 12, 1955 Designation: Non-Executive Independent Director Address: 12/5 Jeevan Deep Colony, Indore 452001, Madhya Pradesh, India Occupation: Business Nationality: Indian Term: Appointed as Non-Executive Independent Director with effect from February 09, 2024 for a period of 5 years DIN: 10459081	Appointed as Additional Director of the Company on January 10, 2024 Appointed as Non-Executive Independent Director of the Company on February 09, 2024	Nil

BRIEF PROFILE OF OUR DIRECTORS

Mr. Anil Kumar Sabarwal, aged 56 years, is the Promoter, Chairman and Managing Director of our Company. He holds Secondary School Examination Certificate from Kendriya Vidyalaya Sriganaga Nagar, Cantt Raj School, in the year 1985. He is responsible for crafting and implementing the overall strategy of the company. He has been instrumental in managing & leading the operations of the company. He is responsible for the entire management and administration of the Company and brings about innovation through creation of new capacities, development of products, exploring and evaluating ways of penetrating existing markets and developing new markets in India and abroad. He has over 25 years of experience in our same company.

Ms. Tejaswini Sabarwal, aged 28 years, is the Promoter and Whole Time Director of our Company. She has completed her Bachelor of Pharmacy from Swami Vivekanand College of Pharmacy, Indore in the year 2017. She has an experience of around 5 Years in our Company. She looks after the day-to-day development and planning of Quality Control section of our Company.

Mr. Rahul Dangi, aged 27 years, is the Whole Time Director of our Company. He holds a Degree of Bachelor in Pharmacy from Vedic Institute of Pharmaceutical Education & Research, Sagar in the year 2017. He has an experience of around 4 years in our Company. He is responsible for handling Production Department of our Company.

Mr. Gautam Kothari, aged 70 years, is the Non-Executive Independent Director of our Company. He holds Master Degree in Commerce from Ravishankar Vishwavidyalaya in the year 1975. He holds Master Degree in Arts, Sociology from University of Indore in the year 1983. He holds Bachelor Degree in Law from Law College, Rajnandgaon from Ravishankar Vishwavidyalaya, Raipur in the year 1979. He was admitted as Fellow Chartered Accountant in The Institute of Chartered Accountants of India in the year 1986. He has around more than 44 years of experience in Accounting and Finance.

Mr. Amit Ramesh Chandak, aged 40 years, is the Non-Executive Independent Director of our Company. He holds Degree in Bachelors of Commerce from Amravati University in the year 2004. He was admitted as Fellow Chartered Accountant in The Institute of Chartered Accountants of India in the year 2015. He is having 14 years of experience in n the field of Taxation and Statutory Compliances and representations, Financial Reporting, Debts Syndication, Strategic Financial and Investment Consultancy and Regulatory Compliances.

Mr. Basant Lal Menghwani, aged 69 years, is the Non-Executive Independent Director of our Company. He has completed his Bachelors of Pharmacy from University of Indore in the year 1977. He has around 30 years of experience in pharmaceutical industry.

CONFIRMATIONS

As on the date of this Prospectus:

- None of the Directors of our Company are related to each other as per Section 2(77) of the Companies Act, 2013, except for that:
 - Mr. Anil Kumar Sabarwal and Ms. Tejaswini Sabarwal are related to each other as Husband and Wife.
- There are no arrangements or understanding with major shareholders, customers, suppliers or any other entity, pursuant to which any of the Directors were selected as a director or member of senior management.
- The directors of our Company have not entered into any service contracts with our Company which provides for benefits upon termination of employment.
- None of the Directors are categorized as a wilful defaulter or a fraudulent borrower, as defined under Regulation 2(1) (III) of SEBI ICDR Regulations.
- None of our Directors are or were directors of any listed Company whose shares have been/were suspended from trading by any of the stock exchange(s) during his/her tenure in that Company in the last five years or delisted from the stock exchange(s) during the term of their directorship in such companies.
- None of our Directors have been declared as fugitive economic offenders as defined in Regulation 2(1)(p) of the SEBI ICDR Regulations, nor have been declared as a 'fugitive economic offender' under Section 12 of the Fugitive Economic Offenders Act, 2018.
- None of the Promoters or Directors has been or is involved as a promoters or director of any other Company which is debarred from accessing the capital market under any order or directions made by SEBI or any other regulatory authority.
- No consideration, either in cash or shares or in any other form have been paid or agreed to be paid to any of our directors or to the firms, trusts or companies in which they have an interest in, by any person, either to induce them to become or to help them qualify as a director, or otherwise for services rendered by them or by the firm, trust or company in which he is interested, in connection with the promotion or formation of our Company.

DETAILS OF BORROWING POWERS

Pursuant to a Special Resolution passed at an Extra-Ordinary General Meeting of our Company held on February 09, 2024 and pursuant to provisions of Section 180(1)(c) and other applicable provisions, if any, of the Companies Act, 2013 and rules made thereunder, the Board of Directors of the Company are authorized to borrow monies from time to time, with or without security, any sum or sums of money, on such security and on such terms and conditions as the Board may deem fit, notwithstanding that the money to be borrowed together with the money already borrowed by our Company may exceed in the aggregate, its paid up capital and free reserves and security premium (apart from temporary loans obtained / to be obtained from bankers in the ordinary course of business), provided that the outstanding principal amount of such borrowing at any point of time shall not exceed in the aggregate of ₹ 20,000.00 Lakhs.

REMUNERATION OF OUR EXECUTIVE DIRECTORS

Mr. Anil Kumar Sabarwal

Mr. Anil Kumar Sabarwal, has been director of the Company since June 01, 1998. He was appointed as the Director of our Company on February 21, 2022, in the Boarding Meeting of the Company dated February 21, 2022. Further, at the Board Meeting of the Company dated January 01, 2024 and Shareholder's Resolution dated January 01, 2024, he was Re-designated as the Chairman & Managing Director of our Company for a period of five years with effect from January 01, 2024. The details of his remuneration as revised by our Board on January 01, 2024, for a period of five years, are as stated below:

Particulars	Terms of remuneration
Remuneration	₹ 5,00,000/- per month which shall be a sum of up to ₹ 60,00,000/- Lakhs per annum.
Other benefits	The director shall be entitled to reimbursement of expenses as decided by Board of Directors of Company from time to time and variable pay to be paid as decided from time to time and other terms and conditions of his employment be decided from time to time.

Ms. Tejaswini Sabarwal

Ms. Tejaswini Sabarwal has been a Director on the Board of our Company since March 05, 2021. She was appointed as Wholetime Director of the Company pursuant to a Board resolution dated January 01, 2024 and Shareholder's resolution dated January 01, 2024 for a period of 5 years with effect from January 01, 2024. The details of her remuneration as revised by our Board on January 01, 2024, for a period of five years, are as stated below:

Particulars	Terms of remuneration
Remuneration	₹ 2,00,000/- per month which shall be a sum of up to ₹ 24,00,000/- Lakhs per annum.
Other benefits	The director shall be entitled to reimbursement of expenses as decided by Board of Directors of Company from time to time and variable pay to be paid as decided from time to time and other terms and conditions of his employment be decided from time to time.

Mr. Rahul Dangi

Mr. Rahul Dangi has been a Director on the Board of our Company since March 05, 2021. He was appointed as Wholetime Director of the Company pursuant to a Board resolution dated January 01, 2024 and Shareholder's resolution dated January 01, 2024 for a period of 5 years with effect from January 01, 2024. The details of his remuneration as revised by our Board on January 01, 2024, for a period of five years, are as stated below:

Particulars	Terms of remuneration
Remuneration	₹ 75,000/- per month which shall be a sum of up to ₹ 9,00,000/- Lakhs per annum.
Other benefits	The director shall be entitled to reimbursement of expenses as decided by Board of Directors of Company from time to time and variable pay to be paid as decided from time to time and other terms and conditions of his employment be decided from time to time.

The compensation payable to our Directors will be governed as per the terms of their appointment and shall be subject to the provisions of Section 2(54), Section 2(94), Section 188, Section 196, Section 197, Section 198 and Section 203 and any other applicable provisions, if any of the Companies Act, 2013 read with Schedule V to the Companies Act, 2013 and the rules made there under (including any statutory modification(s) or re-enactment thereof or any of the provisions of the Companies Act, for the time being in force). The Remuneration / Sitting Fees paid to the Directors during the last F.Y. 2022 - 23 is as follows:

(₹ in Lakhs)

Sr. No.	Name	Designation	Remuneration paid
1.	Mr. Anil Kumar Sabarwal	Chairman & Managing Director	₹ 60.00
2.	Ms. Tejaswini Sabarwal	Whole Time Director	₹ 15.00
3.	Mr. Rahul Dangi	Whole Time Director	₹ 5.00

SITTING FEES

Pursuant to the Resolution passed by the Board of Directors of our Company on February 02 2024, the Non-Executive Independent Directors of our Company would be entitled to a sitting fee of ₹ 5,000 /- with effect from February 02 2024 for attending every meeting of Board and committees thereof.

REMUNERATION PAID OR PAYABLE TO OUR DIRECTORS BY OUR SUBSIDIARIES OR ASSOCIATES

As on the date of this Prospectus, we do not have any subsidiaries or associates.

PAYMENT OF BENEFITS (NON-SALARY RELATED)

Except as disclosed above, no amount or benefit has been paid or given within the two (2) years preceding the date of filing of this Prospectus or is intended to be paid or given to any of our directors except the remuneration for services rendered and/or sitting fees as Directors.

CONTINGENT AND DEFERRED COMPENSATION PAYABLE TO DIRECTORS

There is no contingent or deferred compensation payable to our directors, which does not form part of their remuneration.

BONUS OR PROFIT-SHARING PLAN FOR THE DIRECTORS

None of the Directors are party to any bonus or profit-sharing plan of our Company.

SHAREHOLDING OF OUR DIRECTORS

Our Articles of Association do not require our directors to hold any qualification shares.

The details of the shareholding of our directors as on the date of this Prospectus are as follows:

Sr. No.	Name of the Director	No. of Equity Shares	% of pre issue paid up capital	% of post issue paid up capital
1.	Mr. Anil Kumar Sabarwal	1,01,67,250	85.17%	62.04%
2.	Ms. Tejaswini Sabarwal	4,07,000	3.41%	2.48%

INTEREST OF OUR DIRECTORS

All our directors may be deemed to be interested to the extent of remuneration and reimbursement of expenses, if any, payable to them by our Company as well as sitting fees, if any, payable to them for attending meetings of our Board or Committees thereof payable to them.

Further our directors may be deemed to be interested to the extent of shareholding held by them in our Company or held by the entities in which they are associated as directors or partners, or that may be subscribed by or allotted to the companies, firms, ventures, trusts in which they are interested as promoters, directors, partners, proprietors, members or trustees, pursuant to the Issue and any dividend and other distributions payable in respect of such Equity Shares. For the shareholding of the Directors, please refer chapter titled “*Our Management – Shareholding of our Directors*” on page 175 of this Prospectus.

Further, relatives of certain of our directors are also shareholders and / or employees of our Company and may be deemed to be interested to the extent of the payment of remuneration made by our Company and dividends declared on the Equity Shares held by them, if any. For the payments that are made by our Company to such relatives of the Directors, see “*Restated Financial Statements – Annexure IX - Related Party Transactions*” on page 196 of this Prospectus.

Except mentioned in the Restated Financial Statements, no loans have been availed or extended by our directors from or to, our Company.

No sum has been paid or agreed to be paid to our directors or to firms or companies in which they may be members, in cash or shares or otherwise by any person either to induce them to become, or to qualify them as, a director, or otherwise for services rendered by them by such firm or company, in connection with the promotion or formation of our Company.

Except as stated in the heading titled “*Properties*” under the chapter titled “*Our Business*”, beginning on page 128 of this Prospectus, none of our directors have interest in any property acquired or proposed to be acquired by our Company, or in any transaction by our Company for acquisition of land, construction of building or supply of machinery.

Except as stated in the chapter titled “*Our Business*” and “*Restated Financial Statements*” beginning on page 128 and 196 respectively and to the extent of shareholding in our Company, if any, our directors do not have any other business interest in our Company.

Except Mr. Anil Kumar Sabarwal and Ms. Tejaswini Sabarwal, who are the Promoters of our Company, none of the other Directors are interested in the promotion of our Company.

CHANGES IN OUR BOARD OF DIRECTORS DURING THE LAST THREE YEARS

Sr. No.	Name of the Director	Date of Appointment / Change in designation	Reason for Change
1.	Mr. Ghanshyam Gupta	February 05, 2021	Appointed as Additional Director
2.	Late. Kavita Sabarwal	February 09, 2021	Cessation due to death
3.	Mr. Rahul Dangi	March 05, 2021	Appointed as Additional Director
4.	Mr. Sukhdev Pandagre	March 05, 2021	Appointed as Additional Director
5.	Ms. Tejaswini Chouhan	March 05, 2021	Appointed as Additional Director
6.	Mr. Ghanshyam Gupta	March 11, 2021	Cessation due to personal reason
7.	Mr. Anil Kumar Sabarwal	March 11, 2021	Cessation due to personal reason
8.	Mr. Sukhdev Pandagre	March 30, 2021	Change in Designation to Managing Director
9.	Mr. Rahul Dangi	March 30, 2021	Change in Designation to Director
10.	Ms. Tejaswini Chouhan	March 30, 2021	Change in Designation to Director
11.	Mr. Sukhdev Pandagre	August 14, 2021	Cessation due to personal reason
12.	Mr. Rahul Dangi	August 14, 2021	Change in Designation to Managing Director
13.	Mr. Anil Kumar Sabarwal	February 21, 2022	Appointed as Director
14.	Mr. Anil Kumar Sabarwal	January 01, 2024	Re-designated Managing Director
15.	Ms. Tejaswini Chouhan	January 01, 2024	Re-designated as Whole Time Director
16.	Mr. Rahul Dangi	January 01, 2024	Re-designated as Whole Time Director
17.	Mr. Gautam Chand Kothari	January 10, 2024	Appointed as Additional Non-Executive Independent Director
18.	Mr. Amit Ramesh Chandak	January 10, 2024	Appointed as Additional Non-Executive Independent Director
19.	Mr. Basant Lal Menghwani	January 10, 2024	Appointed as Additional Non-Executive Independent Director
20.	Mr. Gautam Chand Kothari	February 09, 2024	Regularised as Non-Executive Independent Director
21.	Mr. Amit Ramesh Chandak	February 09, 2024	Regularised as Non-Executive Independent Director
22.	Mr. Basant Lal Menghwani	February 09, 2024	Regularised as Non-Executive Independent Director

CORPORATE GOVERNANCE

We are in compliance with the requirements of the Companies Act in respect of corporate governance including constitution of the Board and committees thereof. Further, conditions of corporate governance as stipulated in Regulation 17 to 27 of the SEBI LODR Regulations is not applicable to our company in terms of the Regulation 15(2)(b) of the SEBI LODR Regulations. Our Board has been constituted in compliance with the Companies Act. The Board functions either as a full board or through various committees constituted to oversee specific functions.

Our Company stands committed to good corporate governance practices based on the principles such as accountability, transparency in dealing with our stakeholders, emphasis on communication and transparent report.

Our Board functions either as a full Board or through the various committees constituted to oversee specific operational areas. As on the date of this Prospectus, our Company has Six (6) Directors, 1 (One) as Chairman & Managing Director, 2 (Two) as Wholetime Director, and 3 (Three) as Non-Executive Independent Director. There is 1 (One) Woman Director in our Board.

COMMITTEES OF THE BOARD OF DIRECTORS

Our Board of Directors presently has four (4) committees which have been constituted in accordance with the relevant provisions of the Companies Act: (i) Audit Committee, (ii) Stakeholders' Relationship Committee, (iii) Nomination and Remuneration Committee, and (iv) Corporate Social Responsibility Committee.

Audit Committee: Our Board has constituted the Audit Committee vide Board Resolution dated February 02, 2024 which was in accordance with Section 177 of the Companies Act, 2013. The audit committee comprises of:

Name of the Directors	Nature of Directorship	Designation in Committee
Mr. Amit Ramesh Chandak	Non-Executive Independent Director	Chairman

Name of the Directors	Nature of Directorship	Designation in Committee
Mr. Gautam Kothari	Non-Executive Independent Director	Member
Mr. Anil Kumar Sabarwal	Chairman & Managing Director	Member

The Company Secretary & Compliance Officer of the Company will act as the Secretary of the Committee.

The role of Audit Committee shall include but shall not be restricted to the following:

1. Overseeing the Company's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible;
2. Recommending to the Board, the appointment, re-appointment and, if required, the replacement or removal of the statutory auditor and the fixation of audit fees;
3. Approving payments to statutory auditors for any other services rendered by the statutory auditors;
4. Reviewing, with the management, the annual financial statements before submission to the board for approval, with particular reference to:
 - (a) Matters required to be included in the Director's Responsibility Statement to be included in the Board's report in terms of clause (c) of sub-section 3 of Section 134 of the Companies Act, 2013;
 - (b) Changes, if any, in accounting policies and practices and reasons for the same;
 - (c) Major accounting entries involving estimates based on the exercise of judgment by management;
 - (d) Significant adjustments made in the financial statements arising out of audit findings;
 - (e) Compliance with listing and other legal requirements relating to financial statements;
 - (f) Disclosure of any related party transactions; g. Qualifications in the draft audit report;
 - (g) Qualifications in the draft audit report;
5. Reviewing with the management the quarterly financial statements before submission to the board for approval;
6. Reviewing, with the management, the statement of uses/application of funds raised through an offer (public issue, rights issue, preferential issue, etc.), the statement of funds utilized for purposes other than those stated in the offer document/notice and the report submitted by the monitoring agency monitoring the utilisation of proceeds of a public or rights issue, and making appropriate recommendations to the Board to take up steps in this matter;
7. Review and monitor the auditor's independence and performance, and effectiveness of audit process;
8. Reviewing, with the management, performance of statutory and internal auditors, and adequacy of the internal control systems;
9. Reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit;
10. Discussion with internal auditors any significant findings and follow up there on;
11. Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the board;
12. Discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern;
13. To look into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors;

14. To review the functioning of the Whistle Blower mechanism;
15. Approval of appointment of CFO (or the whole-time Finance Director or any other person heading the finance function or discharging that function) after assessing the qualifications, experience & background, etc. of the candidate;
16. Approval or any subsequent modification of transactions of the company with related parties;
17. Scrutiny of inter-corporate loans and investments;
18. Valuation of undertakings or assets of the Company, whenever it is necessary;
19. Evaluation of internal financial controls and risk management systems;
20. Review of management discussion and analysis report, management letters issued by the statutory auditors, etc;
21. Carrying out any other function as is mentioned in the terms of reference of the Audit Committee;
22. Reviewing the utilization of loans and/ or advances from/investment by the holding company in the subsidiary exceeding rupees 100 crore or 10% of the asset size of the subsidiary, whichever is lower including existing loans/ advances/ investments existing as on the date of coming into force of this provision; and
23. Consider and comment on rationale, cost-benefits and impact of schemes involving merger, demerger, amalgamation etc., on the listed entity and its shareholders.

Explanation (i): The term “related party transactions” shall have the same meaning as contained in the Ind AS 24, Related Party Transactions, issued by The Institute of Chartered Accountants of India.

Explanation (ii): If the issuer has set up an audit committee pursuant to provision of the Companies Act, the said audit committee shall have such additional functions / features as is contained in this clause.

The Audit Committee enjoys following powers:

- i) To investigate any activity within its terms of reference.
- ii) To seek information from any employee.
- iii) To obtain outside legal or other professional advice.
- iv) To secure attendance of outsiders with relevant expertise if it considers necessary.

The Audit Committee shall mandatorily review the following information:

- i) Management discussion and analysis of financial condition and results of operations;
- ii) Statement of significant related party transactions (as defined by the audit committee), submitted by management;
- iii) Management letters / letters of internal control weaknesses issued by the statutory auditors;
- iv) Internal audit reports relating to internal control weaknesses; and
- v) The appointment, removal and terms of remuneration of the internal auditor shall be subject to review by the Audit Committee.
- vi) statement of deviations: (a) half yearly statement of deviation(s) submitted to stock exchange(s) in terms of Regulation 32(1) of the SEBI LODR Regulations; and (b) annual statement of funds utilized for purposes other than those stated in the offer document/prospectus/notice in terms of Regulation 32(7) of the SEBI LODR Regulations.

The recommendations of the Audit Committee on any matter relating to financial management, including the audit report, are binding on the Board. If the Board is not in agreement with the recommendations of the Committee, reasons for disagreement shall have to be incorporated in the minutes of the Board Meeting and the same has to be communicated to the shareholders. The Chairman of the committee has to attend the Annual General Meetings of the Company to provide clarifications on matters relating to the audit.

Meeting of Audit Committee and Relevant Quorum

The Audit Committee shall meet at least four times in a year and not more than one hundred and twenty days shall elapse between two meetings. The quorum for audit committee meeting shall either be two members or one third of the members of the audit committee, whichever is greater, with at least two independent directors.

Stakeholders' Relationship Committee

Our Board has constituted the Stakeholders' Relationship Committee vide Board Resolution dated February 02, 2024 pursuant to Section 178 of the Companies Act, 2013. The Stakeholder's Relationship Committee comprises of:

Name of the Directors	Nature of Directorship	Designation in Committee
Mr. Basant Lal Menghwani	Non-Executive Independent Director	Chairman
Mr. Gautam Kothari	Non-Executive Independent Director	Member
Mr. Anil Kumar Sabarwal	Chairman & Managing Director	Member

The Company Secretary of the Company will act as the Secretary of the Committee.

This committee will address all grievances of Shareholders/Investors and its terms of reference include the following:

1. resolving the grievances of the security holders of the Company, including complaints related to transfer/transmission of shares, non-receipt of annual report, non-receipt of declared dividends, issue of new/duplicate certificates, general meetings, etc;
2. review of measures taken for effective exercise of voting rights by shareholders;
3. review of adherence to the service standards adopted by the Company in respect of various services rendered by the registrar and share transfer agent;
4. review of the various measures and initiatives taken by the Company for reducing the quantum of unclaimed dividends and ensuring timely receipt of dividend warrants/annual reports/statutory notices by the shareholders of the Company;
5. Formulate procedures in line with the statutory guidelines to ensure speedy disposal of various requests received from shareholders from time to time;
6. approve, register, refuse to register transfer or transmission of shares and other securities;
7. sub-divide, consolidate and or replace any share or other securities certificate(s) of the Company;
8. allotment and listing of shares;
9. authorise affixation of common seal of the Company;
10. issue duplicate share or other security(ies) certificate(s) in lieu of the original share/security(ies) certificate(s) of the Company;
11. approve the transmission of shares or other securities arising as a result of death of the sole/any joint shareholder;
12. dematerialize or rematerialize the issued shares;
13. ensure proper and timely attendance and redressal of investor queries and grievances;
14. carry out any other functions contained in the Companies Act, 2013 (including Section 178) and/or equity listing agreements (if applicable), as and when amended from time to time; and
15. further delegate all or any of the power to any other employee(s), officer(s), representative(s), consultant(s), professional(s), or agent(s).

Meeting of Stakeholders' Relationship Committee and Relevant Quorum

The stakeholders' Relationship committee shall meet at least four times in a year and shall report to the Board of Directors on a quarterly basis regarding the status of redressal of complaints received from the shareholders of the Company. The quorum for a meeting of the Stakeholder's Relationship Committee shall be two members present.

Nomination and Remuneration Committee

Our Board has constituted the Nomination and Remuneration Committee vide Board Resolution dated February 02 2024 pursuant to section 178 of the Companies Act, 2013.

The Nomination and Remuneration Committee comprises of:

Name of the Directors	Nature of Directorship	Designation in Committee
Mr. Basant Lal Menghwani	Non-Executive Independent Director	Chairman
Mr. Gautam Kothari	Non-Executive Independent Director	Member
Mr. Amit Ramesh Chandak	Non-Executive Independent Director	Member

The Company Secretary of our Company acts as the Secretary to the Committee.

The scope of Nomination and Remuneration Committee shall include but shall not be restricted to the following:

1. formulation of the criteria for determining qualifications, positive attributes and independence of a director and recommend to the Board a policy, relating to the remuneration of the directors, key managerial personnel and other employees;
2. for every appointment of an independent director, the Nomination and Remuneration Committee shall evaluate the balance of skills, knowledge and experience on the Board and on the basis of such evaluation, prepare a description of the role and capabilities required of an independent director. The person recommended to the Board for appointment as an independent director shall have the capabilities identified in such description. For the purpose of identifying suitable candidates, the Committee may:
 - i) use the services of an external agencies, if required;
 - ii) consider candidates from a wide range of backgrounds, having due regard to diversity; and
 - iii) consider the time commitments of the candidates.
3. formulation of criteria for evaluation of Independent Directors and the Board;
4. devising a policy on Board diversity;
5. identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down, and recommend to the Board their appointment and removal;
6. whether to extend or continue the term of appointment of the independent director, on the basis of the report of performance evaluation of independent directors; and
7. recommend to the board, all remuneration, in whatever form, payable to senior management.

Meeting of Nomination and Remuneration Committee and Relevant Quorum

The quorum necessary for a meeting of the Nomination and Remuneration Committee shall be two members. The Committee shall meet as and when required.

Corporate Social Responsibility Committee

Our Board has Re- constituted the Corporate Social Responsibility Committee vide Board Resolution dated February 02, 2024 pursuant to section 135 of the Companies Act, 2013.

The Corporate Social Responsibility Committee comprises of:

Name of the Directors	Nature of Directorship	Designation in Committee
Mr. Anil Kumar Sabarwal	Chairman & Managing Director	Chairman
Ms. Tejaswini Sabarwal	Non-Executive Independent Director	Member
Mr. Basant Lal Menghwani	Non-Executive Independent Director	Member

The scope of Corporate Social Responsibility Committee shall include but shall not be restricted to the following:

1. To formulate and recommend to the Board, a CSR policy which shall indicate the activities to be undertaken by the Company as per the Companies Act, 2013;
2. To review and recommend the amount of expenditure to be incurred on the activities to be undertaken by the company;
3. To monitor the CSR policy of the Company from time to time; and
4. Any other matter as the CSR Committee may deem appropriate after approval of the Board of Directors or as may be directed by the Board of Directors from time to time.


Meeting of Corporate Social Responsibility Committee and Relevant Quorum

The quorum necessary for a meeting of the Corporate Social Responsibility Committee shall be two members or one third of the members of the committee whichever is greater. The Committee shall meet at least once in a year.

POLICY ON DISCLOSURES AND INTERNAL PROCEDURE FOR PREVENTION OF INSIDER TRADING

The provisions of Regulation 9(1) of the SEBI PIT Regulations will be applicable to our Company immediately upon the listing of its Equity Shares on the NSE Emerge. We shall comply with the requirements of the SEBI PIT Regulations on listing of Equity Shares on stock exchange. Further, Board of Directors have formulated and adopted the code of conduct to regulate, monitor and report trading by its employees and other connected persons. The Company Secretary & Compliance Officer will be responsible for setting forth policies, procedures, monitoring and adherence to the rules for the preservation of price sensitive information and the implementation of the Code of Conduct under the overall supervision of the board.

ORGANIZATIONAL STRUCTURE



KEY MANAGERIAL PERSONNEL AND SENIOR MANAGEMENT

Our Company is managed by our Board of Directors, assisted by qualified and experienced professionals, who are permanent employees of our Company. Below are the details of the Key Managerial Personnel and senior management of our Company:

Key Managerial Personnel of our Company:

Mr. Anil Kumar Sabarwal is the Promoter, Chairman & Managing Director of the Company, Ms. Tejaswini Sabarwal is the Promoter, Whole Time Director of the company and Mr. Rahul Dangi is the Whole Time Director of the Company. For detailed profile, see para, “Brief Profile of our Directors” on page 175 of this Prospectus.

Mr. Ramkrishna Sharma, aged 36 years, is the Chief Financial Officer of our Company with effect from January 01, 2024. He has passed his Foundation Examination from The Institute of Chartered Accountant of India in the year 2006. He has completed Master in Personnel Management from University of Pune in the year 2012. He has completed his Master of Business Administration examination from Sikkim Manipal University in the year 2012. He is associated with our company from past 10 Years and currently he is responsible for accounts and finance of our company. He was paid ₹ 6.60 Lakhs as salary in the Fiscal Year 2022-23.

Mr. Jayesh Jain, aged 25 years, is the Company Secretary and Compliance Officer of our Company with effect from January 01, 2024. He has completed his apprenticeship from Agrawal Mundra & Associates. He is an Associate member of the Institute of Company Secretaries of India from 2023. He is responsible for the Secretarial and Compliance division of our Company. He was not paid any remuneration in the Fiscal Year 2022-23.

Senior Management Personnel of our Company:

In addition to the above, the details of our other Senior Management Personnel in terms of the SEBI ICDR Regulations, as of the date of this Prospectus are set forth below:

Mr. Gopal Krishan, aged 52 years, is the General Manager of our company. He has completed Bachelor of Law (Honours) from R C Jall Vidhi Mahavidyalaya, Mahu in the year 1996. He has been associated with our company since July 2015. He has around more than 8 years of experience in our company. He was paid ₹ 4.65 Lakhs as salary in the Fiscal Year 2022-23.

Mr. Dheeraj Vishwakarma, aged 27 years, is the QC Officer of our company. He has completed his Master of Science in Chemistry from Bhabha University, Bhopal in the year 2020. He has around 2 years of experience in Ives Drugs (India) Pvt Ltd as Ass. Chemist. He has been associated with our company since 2020. He has around more than 4 years of experience in our company. He was paid ₹ 3.00 Lakhs as salary in the Fiscal Year 2022-23.

Mr. Bishan Katare, aged 31 years, is the QC Officer of our company. He has completed his Master of Science in Chemistry from Devi Ahilya Vishwavidyalaya, Indore in the year 2018. He has been associated with our company since 2018. He has around more than 5 years of experience in our company. He was paid ₹ 1.92 Lakhs as salary in the Fiscal Year 2022-23.

Mr. Ravi Kumbhkar, aged 29 years, is the Production Officer of our company. He has completed his Bachelor in Pharmacy from Sagar Institute of Pharmacy & Technology, Bhopal in the year 2018. He has been associated with our company since 2019. He has around more than 4 years of experience in our company. He was paid ₹ 4.65 Lakhs as salary in the Fiscal Year 2022-23.

Mr. Dharmendra Shivshankar Sen, aged 28 years, is the Production Officer of our company. He has completed his Bachelor in Pharmacy from Charak Institute of Pharmacy, Mandleshwar, Khargone in the year 2018. He has been associated with our company since 2019. He has around more than 4 years of experience in our company. He was paid ₹ 2.16 Lakhs as salary in the Fiscal Year 2022-23.

Mr. Vinayak Sabarwal, aged 22 years, he is the institutional supplies and sales of our company. He has completed Bachelor of Arts in Journalism & Mass Communication from Devi Ahilya University, Indore in the year 2022. He has been associated with our company since 2020. He has around more than 4 years of experience in our company. He was paid ₹18.00 Lakhs as salary in the Fiscal Year 2022-23.

STATUS OF OUR KEY MANAGERIAL PERSONNEL AND SENIOR MANAGEMENT

All our Key Managerial Personnel and senior management are permanent employees of our Company.

RELATIONSHIP BETWEEN OUR DIRECTORS, KEY MANAGERIAL PERSONNEL AND SENIOR MANAGEMENT

None of our directors are related to each other or to our Key Managerial Personnel and Senior Management. Except as mentioned below:

- Mr. Anil Kumar Sabarwal and Ms. Tejaswini Sabarwal are related to each other as Husband and Wife.
- Mr. Anil Kumar Sabarwal and Mr. Vinayak Sabarwal are related to each other as Father and Son.
- Ms. Tejaswini Sabarwal and Mr. Vinayak Sabarwal are related to each other as Step Mother and Son.

SHAREHOLDING OF THE KEY MANAGEMENT PERSONNEL AND SENIOR MANAGEMENT

Except for the following, none of our KMPs or senior management hold any shares of our Company as on the date of this Prospectus.

Sr. No.	Name of the Director	Designation	No. of Equity Shares	Percentage of Pre-Issue Capital (%)
1.	Mr. Anil Kumar Sabarwal	Chairman & Managing Director	1,01,67,250	85.17%
2.	Ms. Tejaswini Sabarwal	Whole time Director	4,07,000	3.41%
3.	Mr. Vinayak Sabarwal	Senior Management Personnel	2,12,650	1.78%
4.	Mr. Gopal Krishan	Senior Management Personnel	100	Negligible

SERVICE CONTRACTS WITH KEY MANAGERIAL PERSONNEL AND SENIOR MANAGEMENT

Our Key Managerial Personnel or Senior Management have not entered into any service contracts with our Company which provide for any benefits upon termination of their employment in our Company.

INTEREST OF KEY MANAGERIAL PERSONNEL AND SENIOR MANAGEMENT

None of our Key Management Personnel or Senior Management has any interest in our Company except to the extent of their remuneration, benefits, reimbursement of expenses incurred by them in the ordinary course of business. Our Key Managerial Personnel or Senior Management may also be interested to the extent of Equity Shares, if any, held by them and any dividend payable to them and other distributions in respect of such Equity Shares in future.

ARRANGEMENT OR UNDERSTANDING WITH MAJOR SHAREHOLDERS/ CUSTOMERS/ SUPPLIERS

There is no arrangement or understanding with major shareholders, customers, suppliers or others, pursuant to which any of our Key Managerial Personnel or senior management have been selected as the Key Managerial Personnel or senior management of our Company.

BONUS OR PROFIT-SHARING PLAN OF THE KEY MANAGEMENT PERSONNEL AND SENIOR MANAGEMENT

There is no profit-sharing plan for the Key Managerial Personnel or senior management. However, our Company provides performance linked bonus payments, in accordance with their terms of appointment.

CONTINGENT AND DEFERRED COMPENSATION PAYABLE TO OUR KEY MANAGERIAL PERSONNEL AND SENIOR MANAGEMENT

There is no contingent or deferred compensation payable to our Key Managerial Personnel and senior management, which form part of their remuneration.

EMPLOYEE SHARE PURCHASE AND EMPLOYEE STOCK OPTION PLAN

Our Company does not have an employee stock option scheme as on the date of this Prospectus.

PAYMENT OR BENEFIT TO OUR KEY MANAGERIAL PERSONNEL AND SENIOR MANAGEMENT

No non salary related amount or benefit has been paid or given to any officer of our Company within the two years preceding the date of filing of this Prospectus or is intended to be paid or given, other than in the ordinary course of their employment.

CHANGES IN OUR KEY MANAGERIAL PERSONNEL AND SENIOR MANAGEMENT IN THE LAST THREE YEARS FROM THE DATE OF FILING OF THIS PROSPECTUS

The changes in our Key Managerial Personnel and Senior Management during the three years immediately preceding the date of filing of this Prospectus are set forth below:

Name	Designation	Date of Appointment/ Change in designation	Reason for Change
Mr. Sukhdev Pandagre	Managing Director	March 30, 2021	Change in Designation to Managing Director

Name	Designation	Date of Appointment/ Change in designation	Reason for Change
Mr. Sukhdev Pandagre	Managing Director	August 14, 2021	Cessation Due to personal reason
Mr. Rahul Dangi	Managing Director	August 14, 2021	Change in Designation to Managing Director
Mr. Anil Kumar Sabarwal	Chairman & Managing Director	January 01, 2024	Appointed as Chairman & Managing Director
Ms. Tejaswini Sabarwal	Whole Time Director	January 01, 2024	Appointed as Whole Time Director
Mr. Rahul Dangi	Whole Time Director	January 01, 2024	Appointed as Whole Time Director
Mr. Ramkrishna Sharma	Chief Financial Officer	January 01, 2024	Appointed as Chief Financial Officer
Mr. Jayesh Jain	Company Secretary and Compliance Officer	January 01, 2024	Appointed as Company Secretary and Compliance Officer

ATTRITION OF KEY MANAGERIAL PERSONNEL AND SENIOR MANAGEMENT

The attrition of Key Managerial Personnel and senior management is not high in our Company compared to the industry.

OUR PROMOTERS AND PROMOTER GROUP

As on the date of this Prospectus, our Promoters hold 1,05,74,250 Equity Shares, representing 88.58% of the pre-issued, subscribed and paid-up Equity Share capital of our Company. For details of the build-up of our Promoters' shareholding in our Company, please see "Capital Structure" beginning on page 73 of this Prospectus.

The details of our Promoters are as under:

Anil Kumar Sabarwal	
	Mr. Anil Kumar Sabarwal, aged 56 years is the Promoter, Chairman and Managing Director of our Company. For his complete profile along with the details of his date of birth, address, educational qualification, experience in the business, positions/posts held in past, directorships held, other ventures, special achievements, his business and financial activities, please refer to the chapter titled "Our Management" on page 175 of this Prospectus. Date of Birth: May 13, 1967 Nationality: Indian PAN: AKSPS7138K Residential Address: 121, Amitesh Nagar, Scheme No. 59, IDA, Indore -452 014, Madhya Pradesh, India. Other Interests: M/s Anil Sabarwal HUF
Tejaswini Sabarwal	
	Ms. Tejaswini Sabarwal, aged 28 years is the Promoter, Whole Time Director of our Company. For her complete profile along with the details of her date of birth, address, educational qualification, experience in the business, positions/posts held in past, directorships held, other ventures, special achievements, her business and financial activities, please refer to the chapter titled "Our Management" on page 175 of this Prospectus. Date of Birth: August 15, 1995. Nationality: Indian PAN: BSAPC0805N Residential Address: 121 Amitesh Nagar, Scheme No 59, IDA, Indore 452014, Madhya Pradesh, India, Other Interests: NIL

DECLARATION

- We confirm that the Permanent Account Number, Bank Account number, Passport number, Driving License number Aadhaar Card number of our Promoters shall be submitted to the Stock Exchange at the time of filing of the Prospectus with the Stock Exchange.
- Our Promoters and the members of our Promoter Group have confirmed that they have not been identified as wilful defaulters or fraudulent borrowers by the RBI or any other governmental authority.
- Our Promoters have not been declared as a fugitive economic offender under the provisions of section 12 of the Fugitive Economic Offenders Act, 2018.

4. No violations of securities law have been committed by our Promoters or members of our Promoter Group or any Group Companies in the past or is currently pending against them. None of (i) our Promoters and members of our Promoter Group or persons in control of or on the boards of bodies corporate forming part of our Group Companies (ii) the Companies with which any of our Promoters are or were associated as a promoter, director or person in control, are debarred or prohibited from accessing the capital markets or restrained from buying, selling, or dealing in securities under any order or directions passed for any reasons by the SEBI or any other authority or refused listing of any of the securities issued by any such entity by any stock exchange in India or abroad.

CHANGE IN CONTROL OF OUR COMPANY

There has not been any change in the control of our Company in the five years immediately preceding the date of this Prospectus.

EXPERIENCE OF OUR PROMOTERS IN THE BUSINESS OF OUR COMPANY

For details in relation to experience of our Promoters in the business of our Company, please refer the chapter “*Our Management*” beginning on page 175 of this Prospectus.

INTEREST OF OUR PROMOTERS

Our Promoters do not have any interest in our Company except to the extent of compensation payable / paid, rents on properties owned by them or their relatives but used by our company and reimbursement of expenses (if applicable) and to the extent of any equity shares held by them or their relatives and associates or held by the companies, firms and trusts in which they are interested as director, member, partner, and / or trustee, and to the extent of benefits arising out of such shareholding. For further details please see the chapters titled “*Capital Structure*”, “*Restated Financial Statements*” and “*Our Management*” beginning on pages 73, 196 and 175 of this Prospectus.

Except as stated otherwise in this Prospectus, we have not entered into any contract, agreements or arrangements in which our Promoters are directly or indirectly interested and no payments have been made to them in respect of the contracts, agreements or arrangements which are proposed to be made with them including the properties purchased by our Company and development rights entered into by our Company other than in the normal course of business. For further details, please see chapter titled “*Restated Financial Statements*” beginning on page 196 of this Prospectus.

Our Company is currently promoted by the Promoters in order to carry on its present business. Our Promoters are interested in our Company to the extent of their shareholding and directorship in our Company and the dividend declared, if any, by our Company. Our Promoters may also be deemed to be interested to the extent of Equity Shares held by them and their immediate relatives in our Company and also to the extent of any dividend payable to them and other distributions in respect of the said Equity Shares in our Company. For details regarding the shareholding of our Promoters in our Company, see the chapter titled “*Capital Structure*” on page 73 of this Prospectus.

Except as stated in the heading titled “*Properties*” under the chapter titled “*Our Business*” and “*Restated Financial Statements*” beginning on page 128 and 196 respectively, of this Prospectus, our Promoters have confirmed that they do not have any interest in any property acquired by our Company within three years preceding the date of this Prospectus or proposed to be acquired by our Company as on the date of this Prospectus.

Further, other than as mentioned in the chapter titled “*Our Business*” beginning on page 128 of this Prospectus Our Promoters does not have any interest in any land or property acquired by our Company in the three years preceding the date of this Prospectus or proposed to be acquired by our Company or in any transaction with respect to the acquisition of land, construction of building or supply of machinery or any other contract, agreement or arrangement entered into by our Company and no payments have been made or are proposed to be made in respect of these contracts, agreements or arrangements.

Our Promoters are not interested as member of a firm or company, and no sum has been paid or agreed to be paid to them or to such firm or company in cash or shares or otherwise by any person either to induce such person to become, or qualify them as a director, or otherwise for services rendered by them or by such firm or company in connection with the promotion or formation of our Company.

Our Promoters who are also the Directors of our Company may be deemed to be interested to the extent of remuneration, commission and reimbursement of expenses payable to them as per the terms of his appointment, the Articles of Association of our Company and relevant provisions of Companies Act. For further information on our Promoter’ compensation and other details please refer to the chapter titled “*Our Management*” on page 175 of this Prospectus.

Except as mentioned in this chapter and chapters titled “*Our Business*”, “*History and Certain Corporate Matters*”, “*Our Management*” and “*Restated Financial Statements*” beginning on pages 128, 172, 175 and 196, respectively, our Promoters do not have any other interest in our Company.

BUSINESS INTERESTS

Our Promoters are not interested as a member of a firm or company, and no sum has been paid or agreed to be paid to our Promoters or to such firm or company in cash or shares or otherwise by any person for services rendered by it or by such firm or company in connection with the promotion or formation of our Company.

Our Company has not entered into any contract, agreements or arrangements during the preceding two years from the date of filing of this Prospectus or proposes to enter into any such contract in which our Promoters are directly or indirectly interested and no payments have been made to it in respect of the contracts, agreements or arrangements which are proposed to be made with it.

PAYMENT OF AMOUNTS OR BENEFITS TO THE PROMOTERS OR PROMOTER GROUP DURING THE LAST TWO YEARS

Except as stated in the chapter titled “*Restated Financial Statements*” beginning on page 196 of this Prospectus, there has been no payment of benefits to our Promoters or Promoter Group during the two years preceding the date of this Prospectus nor is there any intention to pay or give any amount or benefit to our Promoter or members of our Promoter Group.

MATERIAL GUARANTEES GIVEN BY OUR PROMOTERS TO THIRD PARTY WITH RESPECT TO EQUITY SHARES

As on the date of this Prospectus, our Promoters have not given any material guarantees to any third party with respect to the Equity Shares.

OUR PROMOTER GROUP

Apart from our Promoters, as per Regulation 2(1)(pp) of the SEBI ICDR Regulations, the following individuals and entities shall form part of our Promoter Group:

A. Natural Persons who are Part of the Promoter Group

As per Regulation 2(1)(pp)(ii) of the SEBI ICDR Regulations, the following individuals form part of our Promoter Group:

Name of the Promoter	Name of the Relative	Relationship with the Promoter
Anil Kumar Sabarwal	Late. Satpal Sabarwal	Father
	Late. Motiyarani Sabarwal	Mother
	Ms. Tejaswini Sabarwal	Spouse
	Late. Rajkumar Sabarwal	Brothers
	Ms. Manju Singh	Sisters
	Ms. Kiran Sachdeva	
	Mr. Vinayak Sabarwal	Son
	Ms. Sakshi Sabarwal	Daughter
	Mr. Shyam Chouhan	Spouse's Father
	Ms. Padma	Spouse's Mother
	Mr. Vivek Chouhan	Spouse's Brother
	-	Spouse's Sisters
Tejaswini Sabarwal	Mr. Shyam Chouhan	Father
	Ms. Padma	Mother
	Mr. Anil Kumar Sabarwal	Spouse
	Mr. Vivek Chouhan	Brothers
	-	Sisters
	Mr. Vinayak Sabarwal	Son
	Ms. Sakshi Sabarwal	Daughter
	Late. Satpal Sabarwal	Spouse's Father
	Late. Motiyarani Sabarwal	Spouse's Mother
	Late. Rajkumar Sabarwal	Spouse's Brother
	Ms. Manju Singh	Spouse's Sisters

Name of the Promoter	Name of the Relative	Relationship with the Promoter
	Ms. Kiran Sachdeva	Spouse's Sisters

B. Companies / Corporate Entities Forming Part of the Promoter Group

As per Regulation 2(1)(pp)(iv) of the SEBI ICDR Regulations, the following Companies/Trusts/ Partnership firms/HUFs or Sole Proprietorships are forming part of our Promoter Group.

Sr. No.	Name of Promoter Group Entity/Company
1.	QAS Analytical Services Private Limited
2.	M/s Anil Sabarwal HUF

SHAREHOLDING OF THE PROMOTER GROUP IN OUR COMPANY

For details of shareholding of members of our Promoter Group as on the date of this Prospectus, please see the chapter titled “*Capital Structure*” beginning on page 73 of this Prospectus.

COMPANIES WITH WHICH THE PROMOTERS HAVE DISASSOCIATED IN THE LAST THREE YEARS

Our Promoters have not disassociated themselves from any companies, firms or entities during the last three years preceding the date of this Prospectus.

OUTSTANDING LITIGATIONS

There is no other outstanding litigation against our Promoters except as disclosed in the section titled “*Risk Factors*” and chapter titled “*Outstanding Litigations and Material Developments*” beginning on pages 30 and 221 respectively of this Prospectus.

OUR GROUP COMPANIES

The definition of '*Group Companies*' as per the SEBI ICDR Regulations, shall include such companies (other than promoters(s), holding Company and subsidiary/subsidiaries) with which there were related party transactions, during the period for which Financial Statements is disclosed, as covered under the applicable accounting standards, and also other companies as considered material by the board.

In terms of the SEBI ICDR Regulations and in terms of the policy of materiality defined by the Board pursuant to its resolution dated February 02, 2024 our Group Companies includes:

- (a) Those companies disclosed as related parties in accordance with Accounting Standard ("AS 18") issued by the Institute of Chartered Accountants of India, during the period for which Financial Information is disclosed.
- (b) All such companies which are deemed to be material by the Board of Directors. Accordingly, based on the parameters outlined above, our Company does not have any group company as on the date of this Prospectus.

DIVIDEND POLICY

Under the Companies Act, 2013 our Company can pay dividends upon a recommendation by our Board of Directors and approval by a majority of the shareholders at the General Meeting and as per provisions of Articles of Association of our Company. The shareholders of the Company have the right to decrease but not to increase the amount of dividend recommended by the Board of Directors. The dividends may be paid out of profits of our Company in the year in which the dividend is declared or out of the undistributed profits or reserves of previous fiscal years or out of both. The Articles of Association of our Company also gives the discretion to our Board of Directors to declare and pay interim dividends.

Our Company does not have any formal dividend policy for the Equity Shares. The dividend pay - out shall be determined by our Board after taking into account a number of factors, including but not limited to : (i) internal factors such as profits earned during the year, present and future capital requirements of the existing businesses, business acquisitions, expansion/modernization of existing businesses, availability of external finance and relative cost of external funds, additional investments in subsidiaries/associates/joint ventures of our Company and restrictions on loan agreement(s); and (ii) external factors such as economic and industry outlook, growth outlook, statutory/regulatory restrictions and covenants with lenders/bond holders. Any future determination as to the declaration and payment of dividends will be at the discretion of our Board.

For details of risks in relation to our capability to pay dividend, see Risk Factors – Our ability to pay Dividends in the future will depend on our future cash flows, working capital requirements, capital expenditures and financial condition.

Our Company has not paid / declared any dividend in six-month period ended December 31, 2023 and in last three years from date of this Prospectus.

SECTION VII – FINANCIAL INFORMATION

RESTATED FINANCIAL STATEMENTS

Sr No.	Particulars	Page No
1.	Restated Financial Statements	F-1 to F- 48

[THE REMAINDER OF THIS PAGE HAS INTENTIONALLY BEEN LEFT BLANK]

RESTATED FINANCIAL STATEMENTS

Independent Auditor's Report on Restated Financial Information of Quest Laboratories Limited (Formerly known as Quest Laboratories Private Limited)
(As required by Section 26 of Companies Act, 2013 read with Rule 4 of Companies (Prospectus and Allotment of Securities) Rules, 2014)

To,
The Board of Directors
Quest Laboratories Limited
(Formerly known as Quest Laboratories Private Limited)
Plot No. 45, Sector III,
Pithampur, Dhar,
Madhya Pradesh- 454775

Dear Sir/Ma'am,

1. We have examined the attached Restated Financial Information of **Quest Laboratories Limited (Formerly known as Quest Laboratories Private Limited)** (hereinafter referred as "the Company" or the "Issuer") comprising the Restated Statement of Assets and Liabilities of the Company as at December 31, 2023, March 31, 2023, March 31, 2022, and March 31, 2021, the Restated Statements of Profit and Loss of the company, the Restated Cash Flow Statement of the company for the period ended on December 31, 2023, March 31, 2023, March 31, 2022, and March 31, 2021, the Summary Statement of Significant Accounting Policies adopted by the company and notes to the restated financial information (collectively hereinafter referred as "Restated Financial Statement" or "Restated Financial Information"), as approved by the Board of Directors of the Company at their meeting held on 2nd February, 2024 for the purpose of inclusion in the Offer Document prepared by the Company in connection with its proposed SME Initial Public Offer of equity shares ("SME IPO") at SME Platform of NSE Limited ("NSE Emerge").
2. These restated Summary Statement have been prepared in terms of the requirements of:
 - a) Section 26 of Part I of Chapter III of the Companies Act, 2013 (the "Act");
 - b) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("ICDR Regulations"); and
 - c) The Guidance Note on Reports in Company Prospectuses (Revised 2019) issued by the Institute of Chartered Accountants of India ("ICAI"), as amended from time to time (the "Guidance Note").
3. The Company's Board of Directors is responsible for the preparation of the Restated Financial Information for the purpose of inclusion in the Offer Document to be filed with Securities and Exchange Board of India ("SEBI"), the relevant Stock Exchange ("NSE Emerge") and Registrar of Companies, Madhya Pradesh ("ROC") in connection with the proposed SME IPO. The Restated Financial Information of the company have been extracted and prepared by the management of the Company on the basis of preparation stated in Annexure IV to the Restated Financial Information. The Board of Directors of the Company responsibility includes designing, implementing and maintaining adequate internal control relevant to the preparation and presentation of the Restated Financial Information. The Board of Directors are also responsible for identifying and ensuring that the Company complies with the Act, ICDR Regulations and the Guidance Note.

4. We have examined such Restated Financial Information taking into consideration:
- a) The terms of reference and terms of our engagement agreed upon with you in accordance with our engagement letter dated 2nd February, 2024 in connection with the proposed IPO of equity shares of the Issuer;
 - b) The Guidance Note. The Guidance Note also requires that we comply with the ethical requirements of the Code of Ethics issued by the ICAI;
 - c) Concepts of test checks and materiality to obtain reasonable assurance based on verification of evidence supporting the Restated Financial Information; and
 - d) The requirements of Section 26 of the Act and the ICDR Regulations. Our work was performed solely to assist you in meeting your responsibilities in relation to your compliance with the Act, the ICDR Regulations and the Guidance Note in connection with the IPO.
5. This Restated Financial Information have been compiled by the management from:
- a) Audited financial statements of the Company as at and for the period ended December 31, 2023, March 31, 2023, March 31, 2022, and March 31, 2021, prepared in accordance with the Indian Accounting Standards (“Indian GAAP”) which have been approved by the Board of Directors at their meeting held on 3rd April, 2024, 2023, 4th September, 2023, 2nd September, 2022 and 6th October, 2021 respectively.
6. For the purpose of our examination, we have relied on:
- b) Auditors’ Report issued by M/s. Shyam S Gupta & Associates dated 3rd April, 2024, 4th September, 2023, 2nd September, 2022 and 6th October, 2021 on the financial statements of the company as at and for the period ended December 31, 2023, March 31, 2023, March 31, 2022 and March 31, 2021 respectively, as referred in Paragraph 5(a) above.

Reliance has been placed on the restated statement of assets and liabilities and the restated statements of profit and loss and cash flow statements, the Summary Statement of Significant Accounting Policies adopted by the company and notes to the restated financial information (collectively hereinafter referred as “Restated Financial Statement” or “Restated Financial Information”) examined by us for the said years.

7. Based on our examination and according to the information and explanations given to us, we report that:
- a) The “Restated Summary Statement of Assets and Liabilities” as set out in **Annexure I** to this report, of the Company as at and for period ended on December 31, 2023, March 31, 2023, March 31, 2022 and March 31, 2021 are prepared by the Company and approved by the Board of Directors. These Restated summary Statement of Assets and Liabilities have been arrived at after making such adjustments and regroupings to the individual financial statements of the Company, as in our opinion were appropriate and more fully described in Significant Accounting Policies and Notes to Accounts as set out in Annexure IV to this Report.
 - b) The “Restated Summary Statement of Profit and Loss” as set out in **Annexure II** to this report, of the Company as at and for the period ended December 31, 2023, March 31, 2023, March 31, 2022 and March 31, 2021 are prepared by the Company and approved by

the Board of Directors. These Restated summary Statement of Profit and Loss have been arrived at after making such adjustments and regroupings to the individual financial statements of the Company, as in our opinion were appropriate and more fully described in Significant Accounting Policies and Notes to Accounts as set out in Annexure IV to this Report.

- c) The “Restated Summary Statement of Cash Flow” as set out in **Annexure III** to this report, of the Company as at and for the period ended December 31, 2023, March 31, 2023, March 31, 2022 and March 31, 2021 are prepared by the Company and approved by the Board of Directors. These Restated summary Statement of Cash Flow have been arrived at after making such adjustments and regroupings to the individual financial statements of the Company, as in our opinion were appropriate and more fully described in Significant Accounting Policies and Notes to Accounts as set out in Annexure IV to this Report.
 - d) The Restated Standalone Summary Statement have been prepared in accordance with the Act, ICDR Regulations and the Guidance Note.
 - e) The Restated Summary Statements have been made after incorporating adjustments for prior period and other material amounts in the respective financial years to which they relate, if any and there are no qualifications which require adjustments;
 - f) Extra-ordinary items that need to be disclosed separately in the accounts has been disclosed wherever required;
 - g) There were no qualifications in the Audit Reports issued by the Statutory Auditors as at and for the period ended December 31, 2023, March 31, 2023 and March 31, 2022, March 31, 2021.
 - h) Profits and losses have been arrived at after charging all expenses including depreciation and after making such adjustments/restatements and regroupings as in our opinion are appropriate and are to be read in accordance with the Significant Accounting Policies and Notes to Accounts as set out in Annexure IV to this report;
 - i) Adjustments in Restated Summary Statements have been made in accordance with the correct accounting policies, which includes the impact of adjustments for Deferred Tax Assets/Liabilities made and which also includes the impact of provision of gratuity made on actuarial valuation basis in the Restated Summary Statements;
 - j) There are no revaluation reserves, which need to be disclosed separately in the Restated Financial Statements;
 - k) The company has not proposed any dividend in past effective for the said period.
8. We have also examined the following other financial information relating to the Company prepared by the Management and as approved by the Board of Directors of the Company and annexed to this report relating to the Company as at and for the period ended December 31, 2023, March 31, 2023 March 31, 2022 and March 31, 2021 proposed to be included in the Offer Document.

Annexure No.	Particulars
I	Restated Statement of Assets & Liabilities
II	Restated Statement of Profit & Loss
III	Restated Cash Flow Statement

Annexure No.	Particulars
IV (A)	Statement of Significant Accounting Policies & Notes
IV (B)	Reconciliation of Restated Profit
IV (C)	Reconciliation of Restated Equity/ Net Worth
V	Restated Statement of Share Capital
VI	Restated Statement of Reserves & Surplus
VII A	Restated Statement of Long/Short -Term Borrowings
VIII	Restated Statement of Long-Term Provisions
VII B	Nature of security & terms of repayment for long/ short term borrowings including current maturities
IX	Restated Statement of Trade Payable
X	Restated Statement of Other Current Liabilities
XI	Restated Statement of Short-Term Provisions
XII	Restated Statement of Tangible Assets
XIII	Restated Statement of Deferred tax Liabilities/ Assets
XIV	Restated Statement of Long-Term Loans and Advances
XV	Restated Statement of Non-current Investments
XVI	Restated Statement of Inventories
XVII	Restated Statement of Trade Receivable
XVIII	Restated Statement of Cash & Cash Equivalents
XIX	Restated Statement of Short-Term Loans and Advances
XX	Restated Statement of Other Current Assets
XXI	Restated Statement of Revenue from operations
XXII	Restated Statement of Other Income
XXIII	Restated Statement of Cost of Material Consumed
XXIV	Restated Statement of Changes in Inventories
XXV	Restated Statement of Employees Benefit Expenses
XXVI	Restated Statement of Financial Cost
XXVII	Restated Statement of Other Expenses
XXVIII	Restated Standalone Statement of Financial Ratio
XXIX	Restated Statement of Related Parties Transactions
XXX	Statement of Tax Shelter, As Restated
XXXI	Statement of Capitalization, As Restated
XXXII	Statement of Contingent Liabilities & Commitments, As Restated
XXXIII	Statement of Other Financial Information, As Restated
XXXIV	Notes to Standalone Restated Financial Statement

9. We, M/s. Shyam S Gupta & Associates, Chartered Accountants have been subjected to the peer review process of the Institute of Chartered Accountants of India ("ICAI") and hold a valid peer review certificate issued by the "Peer Review Board" of the ICAI which is valid till 31th March, 2027.
10. The Restated Financial Information do not reflect the effects of events that occurred subsequent to the respective dates of the reports on the special purpose interim financial statements and audited financial statements mentioned in paragraph 5 above.
11. This report should not in any way be construed as a reissuance or re-dating of any of the previous audit reports issued by the Auditor, nor should this report be construed as a new opinion on any of the financial statements referred to herein.
12. We have no responsibility to update our report for events and circumstances occurring after the date of the report.
13. Our report is intended solely for use of the Board of Directors for inclusion in the Offer Document to be filed with Securities and Exchange Board of India ("SEBI"), the relevant stock exchange ("NSE Emerge") and Registrar of Companies, Madhya Pradesh ("ROC")

in connection with the proposed SME IPO. Our report should not be used, referred to, or distributed for any other purpose except with our prior consent in writing. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this report is shown or into whose hands it may come without our prior consent in writing.

For M/s. Shyam S Gupta & Associates
Chartered Accountants
Firm's Reg No. 007309C

CA. Shyam Gupta
Partner
Membership No. 075255

Place: Indore
Date: 17/04/2024
UDIN: 2407525BKAVHE1264

QUEST LABORATORIES LIMITED
(FORMERLY KNOWN AS QUEST LABORATORIES PRIVATE LIMITED)

ANNEXURE – I

RESTATED STATEMENT OF ASSETS AND LIABILITIES

Particulars	Annexure	As at December 31, 2023	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
		(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)
EQUITY AND LIABILITIES					
Shareholders' funds					
(a) Share capital	V	1,078.76	107.88	107.88	107.88
(b) Reserves and surplus	VI	1,198.39	1,394.33	891.50	480.96
		2,277.15	1,502.21	999.38	588.84
Share application money pending allotment		345.00			
Non-current liabilities					
(a) Long-term Borrowings	VIIA	148.76	212.69	133.48	115.42
(b) Deferred tax liabilities (net)	XIII	73.93	59.84	45.89	35.10
(c) Long term provisions	VIII	10.81	8.58	6.66	5.03
		233.50	281.11	186.03	155.55
Current liabilities					
(a) Short term borrowings	VIIA	311.90	197.00	179.06	188.61
(b) Trade payables	IX				
(i) total outstanding dues of micro and small enterprises		-	-	-	-
(ii) total outstanding dues of creditors other than micro and small enterprises		2,294.66	2,460.24	1,704.71	796.67
(c) Other current liabilities	X	79.51	73.14	277.82	103.50
(d) Short-term provisions	XI	327.37	151.02	132.86	6.46
		3,013.44	2,881.40	2,294.45	1,095.24
TOTAL		5,869.09	4,664.72	3,479.86	1,839.63
ASSETS					
Non-current assets					
(a) Property, plant and equipment	XII	988.50	983.94	737.55	593.63
(b) Non-Current Investments	XV	8.75	8.75	8.75	8.75
(b) Deferred tax assets (net)	XIII	-	-	-	-
(c) Long-term loans and advances	XIV	603.29	66.16	49.52	29.26
		1,600.54	1,058.85	795.82	631.64
Current assets					
(a) Inventories	XVI	1,157.33	1,115.72	108.72	82.80
(b) Trade receivables	XVII	2,966.52	1,993.80	2,206.19	915.47
(c) Cash and bank balance	XVIII	4.54	249.69	156.91	41.64
(d) Short-term loans and advances	XIX	134.84	241.35	206.97	152.28
(e) Other Current Assets	XX	5.32	5.31	5.25	15.80
		4,268.55	3,605.87	2,684.04	1,207.99
TOTAL		5,869.09	4,664.72	3,479.86	1,839.63

As per our report of even date attached

For Shyam S Gupta & Associates
Chartered Accountants
FRN: 007309C

For and on behalf of the Board of Directors of
Quest Laboratories Limited
(Formerly Known as Quest Laboratories Private Limited)

CA Shyam Gupta
Partner
Membership No : 075255

Anil Kumar Sabarwal
DIN: 00646133
Director

Tejaswini Sabarwal
DIN: 9088283
Director

Place: Indore
Date: 17/04/2024
UDIN: 2407525BKAVHE1264

Place: Indore
Date: 17/04/2024

QUEST LABORATORIES LIMITED
(FORMERLY KNOWN AS QUEST LABORATORIES PRIVATE LIMITED)

ANNEXURE- II

RESTATED STATEMENT OF PROFIT AND LOSS

Particulars	Annexure	As at December 31, 2023	For the year ended March 31, 2023	For the year ended March 31, 2022	For the year ended March 31, 2021
		(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)
Income					
Revenue from operations	XXI	6,207.98	6,164.06	5,948.39	3,036.35
Other income	XXII	9.85	22.54	5.81	7.20
TOTAL INCOME		6,217.83	6,186.60	5,954.20	3,043.55
Expenses					
(a) Cost of Material Consumed	XXIII	3,996.13	4,173.79	4,427.41	2,443.19
(b) Purchase of stock-in-trade		-	-	-	-
(c) Increase/Decrease in Stock in trade	XXIV	(9.65)	7.77	21.97	3.28
(d) Employee benefits expense	XXV	329.96	356.79	346.44	253.08
(e) Finance costs	XXVI	62.50	53.84	29.65	30.71
(f) Depreciation and amortisation expense	XII	41.61	54.98	46.03	39.38
(g) Other expenses	XXVII	682.91	843.47	506.02	194.95
TOTAL EXPENSES		5,103.46	5,490.64	5,377.52	2,964.59
Profit / (Loss) before tax		1,114.37	695.96	576.68	78.95
Tax expenses:					
(a) Current tax expense		325.36	179.16	155.39	14.74
(b) Earlier year Tax		-	-	-	-
(c) Deferred tax expense / (benefit)		14.08	13.95	10.79	(1.29)
Net tax expense/(benefit)		339.44	193.11	166.18	13.45
Profit / (Loss) for the year		774.93	502.85	410.50	65.50
Earnings per share (of Rs. 10 each)					
(a) Basic & Diluted		7.18	4.66	3.81	0.61

As per our report of even date attached

For Shyam S Gupta & Associates
Chartered Accountants
FRN: 007309C

For and on behalf of the Board of Directors of
Quest Laboratories Limited
(Formerly Known as Quest Laboratories Private Limited)

CA Shyam Gupta
Partner
Membership No : 075255

Anil Kumar Sabarwal
DIN: 00646133
Director

Tejaswini Sabarwal
DIN: 9088283
Director

Place: Indore
Date: 17/04/2024
UDIN: 2407525BKAVHE1264

Place: Indore
Date: 17/04/2024

QUEST LABORATORIES LIMITED
(FORMERLY KNOWN AS QUEST LABORATORIES PRIVATE LIMITED)

ANNEXURE- III

RESTATED CASH FLOW STATEMENT

Particulars	As at December 31, 2023 (Rs. in lakhs)	As at March 31, 2023 (Rs. in lakhs)	As at March 31, 2022 (Rs. in lakhs)	As at March 31, 2021 (Rs. in lakhs)
A Cash flow from operating activities:				
Net profit before tax	1,114.37	695.96	576.68	78.95
Adjustments:				
Depreciation & Amortisation	41.61	54.98	46.03	39.38
Profit on sale of Fixed Assets	-	(0.40)	-	(0.17)
Interest Income	(9.64)	(9.75)	(3.70)	(1.03)
Finance cost	62.50	53.84	29.65	30.71
Provision for Gratuity	2.94	2.20	1.84	5.84
	97.41	100.87	73.82	74.73
Operating cash flow before working capital changes	1,211.78	796.83	650.50	153.68
Movement in working capital				
I. Adjustments for (Increase)/decrease in operating assets :				
Trade receivables	(972.72)	212.39	(1,290.72)	(181.19)
Inventories	(41.61)	(1,007.00)	(25.92)	341.17
Short-term loans & advance	136.01	(33.68)	(54.69)	5.82
Other Current Assets	(0.01)	(0.06)	10.55	(0.99)
II. Adjustments for (Increase)/decrease in operating liabilities :				
Trade payables	(165.58)	755.53	908.04	(153.73)
Other current liabilities	6.37	(204.68)	174.32	(19.02)
	(1,037.54)	(277.50)	(278.42)	(7.94)
Cash generated from operations	174.24	519.33	372.08	145.74
Net income taxes paid	(173.85)	(156.26)	(26.58)	(41.02)
Net cash (used in) / provided by oprating activities (A)	0.39	363.07	345.51	104.72
B Cash flows from investing activities:				
Purchase of fixed assets & including intangible assets	(51.52)	(306.72)	(193.07)	(120.70)
Sale of fixed assets & including intangible assets	-	-	0.55	-
Interest Received	9.64	9.75	3.70	1.03
Net cash provided by / (used in) investing activities (B)	(41.88)	(296.97)	(188.82)	(119.67)
C Cash flows from Financing activities:				
Proceeds from Long Term Borrowings	(63.93)	79.21	18.06	4.77
Issue of Share Capital	345.00			
Security Deposits paid	(537.13)	(16.64)	(20.26)	5.79
Proceeds from/(Repayment) of Short Term Borrowings	114.90	17.94	(9.55)	23.98
Interest paid	(62.50)	(53.84)	(29.65)	(30.71)
Net cash flow from/ (used in) financing activities (C)	(203.66)	26.67	(41.40)	3.83
Net increase / (decrease) in cash & cash equivalents (A+B+C)	(245.15)	92.77	115.29	(11.12)
Cash & cash equivalents as at the beginning of the year	249.69	156.92	41.63	52.75
Cash & cash equivalents as at the end of the year	4.54	249.69	156.92	41.63
Notes to Cash Flow Statement				
1 Component of cash and cash equivalent :				
- Cash in hand	0.44	9.33	3.20	5.99
- Balance with Bank	4.10	240.36	153.72	35.64
	4.54	249.69	156.92	41.63

As per our report of even date attached

For Shyam S Gupta & Associates
Chartered Accountants
FRN: 007309C

For and on behalf of the Board of Directors of
Quest Laboratories Limited
(Formerly Known as Quest Laboratories Private Limited)

CA Shyam Gupta
Partner
Membership No : 075255

Anil Kumar Sabarwal
DIN: 00646133
Director

Tejaswini Sabarwal
DIN: 9088283
Director

Place: Indore
Date: 17/04/2024
UDIN: 2407525BKAVHE1264

Place: Indore
Date: 17/04/2024

ANNEXURE IV (A)

STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES & NOTES TO RESTATED FINANCIAL STATEMENTS

1 COMPANY INFORMATION

Quest Laboratories Limited (Formerly Known as Quest Laboratories Private Limited) was incorporated on 1st June, 1998 and having its registered office at Plot No. 45, Sector III, Pithampur, Dhar, Madhya Pradesh- 454775. The Company is primarily engaged in the manufacturing of pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. The Company also produce variety of products, comprising ethical drugs, generic drugs, and over-the-counter drugs (OTC). The Company has been converted from Private Limited Company to Public Limited Company vide necessary resolution passed by shareholders and the name of company is this day changed to **Quest Laboratories Limited** pursuant to issuance of Fresh Certificate of Incorporation on 23rd January, 2024. Now, the CIN is **U24232MP1998PLC012850**.

SIGNIFICANT ACCOUNTING POLICIES

a) Accounting Convention

The Restated Summary Statement of Assets and Liabilities of the Company as at December 31, 2023, March 31, 2023, March 31, 2022 and March 31, 2021 and the related Restated Summary Statement of Profit and Losses and Cash Flows Statement for the period ended on December 31, 2023, March 31, 2023, March 31, 2022 and March 31, 2021 have been complied by management from the financial statements of the company for the period ended on December 31, 2023, March 31, 2023, March 31, 2022 and March 31, 2021.

The financial statements are prepared under the historical cost convention on the “Accrual Concept” and Going Concern assumption of accountancy in accordance with the accounting principles generally accepted in India and comply with the accounting standards as prescribed by Companies (Accounting Standard) Rules, 2006 or 2001 as may be applicable and with the relevant provisions of the Companies Act, 2013 and rules made there under

b) Use of Estimates

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amount of assets and liabilities on the date of the financial statement and the reported amount of revenues and expenses during the reporting period. Difference between the actual results and estimates are recognized in the period in which results are known/materialized.

c) Property, Plant and Equipment

Property, Plant and Equipment are stated at cost less accumulated depreciation. Cost comprises of all expenses incurred to bring the assets to its present location and condition. Borrowing cost directly attributable to the acquisition /construction are included in the cost of fixed assets. Adjustments arising from exchange rate variations attributable to the fixed assets are capitalized.

In case of new projects / expansion of existing projects, expenditure incurred during construction / preoperative period including interest and finance charge on specific / general purpose loans, prior to commencement of commercial production are capitalized. The same are allocated to the respective t on completion of construction / erection of the capital project / fixed assets.

Subsequent expenditures related to an item of tangible asset are added to its book value only if they increase the future economic benefits from the existing asset beyond its previously assessed standard of performance.

Capital assets (including expenditure incurred during the construction period) under erection / installation are stated in the Balance Sheet as “Capital Work in Progress.”

d) Impairment of Assets

At each balance sheet date, the Company reviews the carrying amount of its fixed assets to determine whether there is any indication that those assets suffered an impairment loss. If any such indication exists, the recoverable amount of the assets is estimated in order to determine the extent of impairment loss. Recoverable amount is the higher of an asset's net selling price and value in use. In assessing value in use, the estimated future cash flows expected from the continuing use of the assets and from its disposal are discounted to their present value using a pre-tax discount rate that reflects the current market assessments of time value of money and the risks specific to the assets.

e) Depreciation

All fixed assets, except capital work in progress, are depreciated on WDV Method. Depreciation is provided based on useful life of the assets as prescribed in Schedule II to the Companies Act, 2013. Depreciation on additions to / deletions from fixed assets made during the period is provided on pro-rata basis from / up to the date of such addition / deletion as the case may be

f) Investments

Investments are classified into current investments and non-current investments. Current investments i.e. investments that are readily realizable and intended to be held for not more than a year valued at cost. Any permanent reduction in the carrying amount or any reversals of such, reductions are charged or credited to the Statement of Profit & loss Account.

Non-current investments are stated at cost. Provision for diminution in the value of these investments is made only if such decline is other than temporary, in the opinion of the management.

g) Inventories

As per (AS) 2, The inventories are physically verified at regular intervals by the management. Raw Material Inventories are valued at the lower of cost and net realizable value

Finished goods, Stock-in-Trade and Work-in-Progress are valued at lower of cost and net realizable value. Cost of inventories comprises of cost of purchase, cost of conversion and other costs including manufacturing overheads net of recoverable taxes incurred in bringing them to their respective present location and condition.

Consumable stores and spares are valued at the lower of cost and net realizable value, as estimated by the management. Obsolete, defective, unserviceable and slow/non-moving stocks are duly provided for

h) Revenue Recognition

Sales revenue is recognized when property in the goods with all significant risk and rewards as well as the effective control of goods usually associated with ownership are transferred to the buyer. Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured

Revenue is recognized when it is earned and no significant uncertainty exists as to its realization or collection. Revenue from sale of goods or services are recognized on delivery of the products or services, when all significant contractual obligations have been satisfied, the property in the goods is transferred for price, significant risk and rewards of ownership are transferred to the customers and no effective ownership is retained.

In the financial statement, revenue from operation does not include Indirect taxes like Sales Tax And/ Or Goods & Service Tax

Sale of Goods

Sales are recognized, net of returns and trade discounts, on transfer of significant risk and rewards of ownership to the buyer, which generally coincide with the delivery of goods to the customers. The Company collects Goods and Service Tax (GST) and / or Tax Collected at source on behalf of the government and, therefore, these do not form a part of economic benefits flowing to the Company

Hence, they are excluded from revenue

Interest

Revenue is recognised on a time proportion basis taking into account the amount outstanding and the rate applicable.

Service Income

Income from service rendered is recognised based on the terms of the agreements as and when services are rendered and are net of Goods and Service Tax (GST)/ Service tax.

Dividend Income

Dividend income from investments, if any, is accounted on the receipt basis.

Insurance claims

Insurance claims are accounted for on the basis of claims admitted / expected to be admitted and to the extent that the amount recoverable can be measured reliably and it is reasonable to expect ultimate collection.

i) Borrowing Cost

Borrowing cost that are attributable to the acquisition, construction or production of qualifying assets are capitalized as part of the cost of such assets. A qualifying asset is one that necessarily takes a substantial period of time to get ready for its intended use. All other borrowing costs are charged to revenue.

j) Employee Benefits

Short – term employee benefits are recognized as an expense at the undiscounted amount in the profit & loss account of the year in which the related service is rendered.

Post-employment and other long term employee benefits are recognized as an expense in the profit & loss account for the year in which the liabilities are crystallized/accrued

k) Taxes on Income

Income tax expenses for the year comprises of current tax and deferred tax. Current tax provision is determined on the basis of taxable income computed as per the provisions of the Income Tax Act. Deferred tax is recognized for all timing differences that are capable of reversal in one or more subsequent periods subject to conditions of prudence and by applying tax rates that have been substantively enacted by the balance sheet date.

l) Foreign Currency Translation

i) Transaction denominated in foreign currencies are recorded at the exchange rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the year end are restated at closing rate.

ii) Any exchange difference on account of settlement of foreign currency transaction and restatement of monetary assets and liabilities denominated in foreign currency is recognized in the statement of Profit & loss Account.

m) Provision, Contingent Liabilities and Contingent Assets

Provisions involving substantial degree of estimation in measurement are recognized when there is a present obligation as a result of past events and it is probable that there will be an outflow of resources.

2 NOTES ON ACCOUNTS

a) The financial statements including financial information have been prepared after making such regroupings and adjustments, considered appropriate to comply with the same. As result of these regroupings and adjustments, the amount reported in the financial statements/information may not necessarily be same as those appearing in the respective audited financial statements for the relevant years

b) Provisions, Contingent Liabilities and Contingent Assets (AS 29)

Contingent liabilities and commitments (to the extent not provided for). There are no contingent liabilities as on December 31, 2023, March 31, 2023, March 31, 2022 & March 31, 2021 except as mentioned in Annexure-XXXII, for any of the years/ stub period covered by the statements.

c) Related Party Disclosure (AS 18)

Related party transactions are reported as per AS-18 of Companies (Accounting Standards) Rules, 2006 or 2001 as may be applicable, as amended, in the Annexure – J of the enclosed financial statements.

d) Accounting for Deferred Taxes on Income (AS 22)

(Rs. In Lakhs)

Particulars	For the Period from 1 st April to 31 st December 2023	As at 31st March		
		2023	2022	2021
WDV as per Companies Act, 2013 (A)	988.50	983.94	737.56	593.62
WDV as per Income tax Act, 1961 (B)	719.84	766.64	570.76	452.79
Difference in WDV (A-B)	268.66	217.30	166.80	140.83
Timing Difference due to Provision for Gratuity (DTA) (C)	2.94	2.20	1.84	5.84
Total Timing Difference (D)	265.72	215.10	164.95	134.99
Deferred Tax (Asset)/ Liability '(E)	73.92	59.84	45.89	35.10
Restated Closing Balance of Deferred Tax (Asset)/ Liability (E)	73.92	59.84	45.89	35.10
Deferred Tax (Assets)/ Liability as per Balance sheet of Previous Year	59.84	45.89	35.10	36.39
Deferred Tax (Assets)/ Liability charged to Profit & Loss	14.08	13.95	10.79	-1.30

(e) **Post Employment Benefits:** The Company has valued its obligations related to Gratuity as follows:

(Rs. In Lakhs)				
I. ASSUMPTIONS	For the Period Ended on December 31, 2023	For the Period Ended on March 31, 2023	For the Period Ended on March 31, 2022	For the Period Ended on March 31, 2021
Discount Rate	7.25%	7.50%	7.50%	7.50%
Expected Rate of Salary Increase	5.00%	5.00%	5.00%	5.00%
Withdrawal Rate	10.00%	10.00%	10.00%	10.00%
Mortality	IALM 2012-14	IALM 2012-14	IALM 2012-14	IALM 2012-14
Retirement	60 Years	60 Years	60 Years	60 Years
II. CHANGE IN THE PRESENT VALUE OF DEFINED BENEFIT OBLIGATIONS	For the Period Ended on December 31, 2023	For the Period Ended on March 31, 2023	For the Period Ended on March 31, 2022	For the Period Ended on March 31, 2021
Defined Benefit Obligation at beginning of the year	9.89	7.69	5.84	5.84
Current Service Cost	1.89	1.85	1.57	0
Interest cost	0.56	0.58	0.44	0
Actuarial (Gains)/Losses on Obligations - Due to Change in Financial Assumptions	0.48	-0.23	-0.16	0
Actuarial (Gains)/Losses on Obligations - Due to Experience Adjustment	-	-	-	-
Benefits Paid	-	-	-	-
Defined Benefit Obligation as at end of the year	12.82	9.89	7.69	5.84
III. AMOUNT RECOGNIZED IN THE BALANCE SHEET:	For the Period Ended on December 31, 2023	For the Period Ended on March 31, 2023	For the Period Ended on March 31, 2022	For the Period Ended on March 31, 2021
Net liability as at beginning of the year	9.89	7.69	5.84	5.84
Net expense recognized in the Statement of Profit and Loss	2.94	2.20	1.84	0
Benefits Paid	0	0	0	0
Net liability as at end of the year	12.82	9.89	7.69	5.84
IV. EXPENSE RECOGNIZED:	For the Period Ended on December 31, 2023	For the Period Ended on March 31, 2023	For the Period Ended on March 31, 2022	For the Period Ended on March 31, 2021
Current Service Cost	1.89	1.85	1.57	0
Interest Cost	0.56	0.58	0.44	0
Actuarial (Gains)/Losses on Obligations - Due to Change in Financial Assumptions and Due to Experience Adjustment	0.48	-0.23	-0.16	0
Expense charged to the Statement of Profit and Loss	2.94	2.20	1.84	5.84
V. BALANCE SHEET RECONCILIATION:	For the Period Ended on December 31, 2023	For the Period Ended on March 31, 2023	For the Period Ended on March 31, 2022	For the Period Ended on March 31, 2021
Opening net liability	9.89	7.69	5.84	5.84
Expense as above	2.94	2.98	4.59	0
Provision Related to Previous Year booked as Prior Period Items	0	0	0	0
Return on Plan Assets	0	0	0	0
Benefits Paid	0	0	0	0
Net liability/(asset) recognized in the balance sheet	12.82	10.67	10.43	5.84

MATERIAL ADJUSTMENT TO THE RESTATED FINANCIAL STATEMENT

1 Material Regrouping:

Appropriate adjustments have been made in the Restated Financial Statements of Assets and Liabilities, Profit and Losses and Cash Flows, wherever required, by reclassification of the corresponding items of income, expenses, assets and liabilities in order to bring them in line with the regroupings as per the audited financial statements of the company and the requirements of SEBI Regulations.

2 Material Adjustments:

The Summary of results of restatement made in the Audited Financial Statements for the respective period/years and its impact on the profit/ (loss) of the Company is as follows:

Particulars	For the Period from 1 st April 2023 to 31 st December 2023	(Rs. In Lakhs)		
		For the Period Ending 31 st March		
		2023	2022	2021
(A) Net Profits as per audited financial statements (A)	781.32	504.49	416.62	65.47
Add/(Less): Adjustments on account of -				
1) Difference on Account of Calculation in Provision for Income Tax				
2) Difference on Account of Calculation in Deferred Tax	-3.45	0.56	-4.28	5.87
3) Difference on account of Calculation in Gratuity	-2.94	-2.20	-1.84	-5.84
4) Difference on Account of Prepaid Expenses	-	-	-	-
5) Difference on Account of Provision for outstanding Expenses		-	-	-
Total Adjustments (B)				
Restated Profit/ (Loss) (A+B)	774.93	502.85	410.50	65.50

3 Notes on Material Adjustments pertaining to prior years

- Difference on Account of Provision for Current tax:** Since the Restated profit has been changed so that the Provision for current tax is also got changed
- Difference on Account of Change in Deferred Tax:** Deferred tax is calculated on the difference of WDV as per Companies Act & income tax Act in Restated financials but in Audited financials the same has been calculated between difference of Depreciation. Further Deferred Tax has been calculated on Timing difference arises due to Provision for Gratuity which was not considered in Audited Financial Statements
- Difference on Account of Provision for Gratuity:** Provision for Gratuity is provided in Restated Financials Statement which was not provided in Audited Financial Statements
- Difference on Account of Change in Prepaid Expenses:** Expenses Related to Next Accounting Period is transferred to Prepaid Expenses
- Difference on Account of Outstanding Expenses:** Expenses related to current accounting period has been provided as provision for outstanding expenses in current year itself

Reconciliation Statement between Restated Reserve & Surplus affecting Equity due to Adjustment made in Restated Financial Statements:

Particulars	For the Period from 1 st April 2023 to 31 st December 2023	(Rs. In Lakhs)		
		As at March 31		
		2023	2022	2021
(A) Total Equity as per audited financial statements (A)	2291.26	1509.95	1005.45	588.83
Add/(Less): Restatement Adjustments (B)	-0.62%	-0.51%	-0.60%	0.00%
Total Equity as per Restated Financial Statements (A+B)	2277.15	1502.21	999.38	588.84

(f) Trade Payable Ageing Summary

31.12.2023					(Rs. In Lakhs)
Particulars	Outstanding for following periods from due date of payment / Invoice date				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
(i) MSME	-	-	-	-	-
(ii) Others	2101.94	127.48	0.24	-	2229.66
(iii) Disputed dues - MSME	-	-	-	-	-
(iv) Disputed dues – Others	-	-	-	-	-
Total	2101.94	127.48	0.24	-	2229.66

31.03.2023					(Rs. In Lakhs)
Particulars	Outstanding for following periods from due date of payment / Invoice date				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
(i) MSME	-	-	-	-	-
(ii) Others	2229.04	196.38	34.82	-	2460.24
(iii) Disputed dues - MSME	-	-	-	-	-
(iv) Disputed dues – Others	-	-	-	-	-
Total	2229.04	196.38	34.82	-	2460.24

31.03.2022					(Rs. In Lakhs)
Particulars	Outstanding for following periods from due date of payment / Invoice date				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
(i) MSME	-	-	-	-	-
(ii) Others	1525.72	133.44	45.56	-	1704.71
(iii) Disputed dues - MSME	-	-	-	-	-
(iv) Disputed dues – Others	-	-	-	-	-
Total	1525.72	133.44	45.56	-	1704.71

31.03.2021					(Rs. In Lakhs)
Particulars	Outstanding for following periods from due date of payment / Invoice date				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
(i) MSME	-	-	-	-	-
(ii) Others	785.49	11.18	-	-	796.66
(iii) Disputed dues - MSME	-	-	-	-	-
(iv) Disputed dues – Others	-	-	-	-	-
Total	785.49	11.18	-	-	796.66

(g) Trade Receivable Ageing Summary

(Rs. In Lakhs)						
Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
31.12.2023						
(i) Undisputed Trade Receivable – considered good	2061.56	717.01	147.66	40.28	-	2966.51
(ii) Undisputed Trade Receivable – considered doubtful	-	-	-	-	-	-
(iii) Disputed Trade Receivable – considered good	-	-	-	-	-	-
(iv) Disputed Trade Receivable – considered doubtful	-	-	-	-	-	-
Total 31.12.2023	2061.56	717.01	147.66	40.28	-	2966.51
31.03.2023						
(i) Undisputed Trade Receivable – considered good	1444.91	295.81	135.80	117.28	-	1993.80
(ii) Undisputed Trade Receivable – considered doubtful	-	-	-	-	-	-
(iii) Disputed Trade Receivable – considered good	-	-	-	-	-	-
(iv) Disputed Trade Receivable – considered doubtful	-	-	-	-	-	-
Total 31.03.2023	1444.91	295.81	135.80	117.28	-	1993.80
31.03.2022						
(i) Undisputed Trade Receivable – considered good	1784.64	147.56	70.19	203.80	-	2206.19
(ii) Undisputed Trade Receivable – considered doubtful	-	-	-	-	-	-
(iii) Disputed Trade Receivable – considered good	-	-	-	-	-	-
(iv) Disputed Trade Receivable – considered doubtful	-	-	-	-	-	-
Total 31.03.2022	1784.64	147.56	70.19	203.80	-	2206.19
31.03.2021						
(i) Undisputed Trade Receivable – considered good	571.28	263.74	15.80	23.80	40.85	915.47
(ii) Undisputed Trade Receivable – considered doubtful	-	-	-	-	-	-
(iii) Disputed Trade Receivable – considered good	-	-	-	-	-	-
(iv) Disputed Trade Receivable – considered doubtful	-	-	-	-	-	-
Total 31.03.2021	571.28	263.74	15.80	23.80	40.85	915.47

(h) Restated Statement of Accounting Ratios:

S. No.	Particular	Numerator	December 31, 2023	March 31, 2023	March 31, 2022	March 31, 2021	Reason for Movements
		Denominator					
(a)	Current Ratio	Current Assets	1.42	1.25	1.17	1.10	Change is less than 25
		Current Liabilities					
(b)	Debt-Equity Ratio	Debt	1.68	1.32	1.42	0.41	Due to increase in equity as compared to the rate of increase in borrowings.
		Equity					
(c)	Debt Service Coverage Ratio	Net Operating Income	0.23	0.17	0.15	0.19	Due to increase in earnings available for service of debt consequent to increase in Net Profit.
		Total Debt Service					
(d)	Return on Equity Ratio	Profit After Tax	34.03%	40.20%	51.69%	11.78%	This ratio is decreased during 2022 and 2023 due to increase in Average shareholder equity getting increased not in the same ratio as profits. Further during period ended September 2023, it got increased due to increased profits.
		Average Shareholders' Equity					
(e)	Trade Receivables turnover ratio (in times)	Net Credit Sales	2.09	2.94	3.81	3.68	Due to increase in Net sales and corresponding increase in Accounts Receivable for the period.
		Average Trade Receivables					
(f)	Trade Payable Turnover Ratio (in times)	Net Credit Purchases	1.74	2.00	3.54	2.80	Due to decrease in Cost of Material Consumed but increase in Accounts Payable for the period.
		Average Trade Payables					
(g)	Net capital turnover ratio (in times)	Turnover	4.95	8.51	15.27	26.93	Due to increase in working capital as compared to the previous period.
		Net Working Capital					
(h)	Net profit ratio	Profit After Tax	12.48%	8.16%	6.90%	2.16%	Due to increase in Net Profit.
		Total Sales					
(i)	Return on Capital employed	Operating Profit	41.86%	38.03%	44.65%	11.82%	Due to increase in Capital Employed as compared to the previous period.
		Total Capital Employed					
(j)	Return on investment.	Profit After Tax	0.00%	0.00%	0.00%	0.00%	Change is less than 25%
		Initial Value of Investments					
(k)	Interest Service Coverage Ratio	EBIT	13.40	10.34	14.84	3.13	Due to increase in Net Profit
		Total Interest Service					

1. The ratios for the period ended on December 31, 2023 are not comparable

ANNEXURE- IV (B)

RECONCILIATION OF RESTATED PROFIT

Particulars	As at December 31, 2023	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)
Net Profit/ (loss) after tax as per audited statement of Profit & Loss	781.32	504.49	416.62	65.47
Adjustments for:				
(Increase)/ Decrease in Expenses				
Excess/ (Short) Provision for Tax	-	-		
Excess/ (Short) Provision for Gratuity	(2.94)	(2.20)	(1.84)	(5.84)
Deferred Tax (Liability)/ Assets Adjustment	(3.45)	0.56	(4.28)	5.87
Net Profit/ (loss) after tax as Restated Financial Statements	774.93	502.85	410.50	65.50

Explanatory Notes to the above restatements made in Audited Financial Statements of the Company for the respective periods.

To give Explanatory Notes regarding Adjustments

Appropriate adjustment have been made in the restated financial statements, wherever required, by reclassification of the corresponding items of income, expenses, assets & liabilities, in order to bring them in line with the groupings as per the audited financials of the Company for all the years & the requirements of the Securities & Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations, 2018.

ANNEXURE- IV (C)

RECONCILIATION OF RESTATED EQUITY/ NETWORTH

Particulars	As at December 31, 2023	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)
Equity/Networth as per audited financial Statements	2,291.26	1,509.95	1,005.45	588.83
Adjustments for:				
Differences pertaining to changes in Profit/(Loss) due to Restated Effect for the period covered in Restated Financials	(14.11)	(7.74)	(6.07)	0.01
Equity/Networth as Restated Financial Statements	2,277.15	1,502.21	999.38	588.84

Explanatory Notes to the above restatements made in Audited Financial Statements of the Company for the respective periods.

To give Explanatory Notes regarding Adjustments

Appropriate adjustment have been made in the restated financial statements, wherever required, by reclassification of the corresponding items of income, expenses, assets & liabilities, in order to bring them in line with the groupings as per the audited financials of the Company for all the years & the requirements of the Securities & Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations, 2018.

NOTES TO THE RESTATED FINANCIAL INFORMATION

ANNEXURE- V

DETAILS OF SHARE CAPITAL AS RESTATED

1. Statement of Share Capital:

Particulars	As at December 31, 2023		As at March 31, 2023		As at March 31, 2022		As at March 31, 2021	
	Number of shares	(Rs. in lakhs)	Number of shares	(Rs. in lakhs)	Number of shares	(Rs. in lakhs)	Number of shares	(Rs. in lakhs)
Authorised Capital								
Equity shares of Rs.10/- each with voting rights	1,20,00,000	1,200	20,00,000	200	20,00,000	200	20,00,000	200
Total	1,20,00,000	1,200	20,00,000	200	20,00,000	200	20,00,000	200
Issued, Subscribed and fully paid up								
Equity shares of Rs.10/- each with voting rights	1,07,87,600	1,079	10,78,760	108	10,78,760	108	10,78,760	108
Total	1,07,87,600	1,079	10,78,760	108	10,78,760	108	10,78,760	108

Terms/rights attached to equity share:

- As on date of report the company has only one class of equity shares.
- During the Financial Year 2023-24, the Company has increased its authorised share capital from Rs. 2,00,00,000 divided into 20,00,000 shares of Rs.10 each to Rs. 12,00,00,000 divided into 1,20,00,000 shares of Rs.10 each vide a resolution passed at EGM of the Company held at registered office of the Company on 19th August, 2023. Further, during the Financial Year 2023-24, the Company has increased its authorised share capital from Rs. 12,00,00,000 divided into 1,20,00,000 shares of Rs.10 each to Rs. 20,00,00,000 divided into 2,00,00,000 shares of Rs.10 each vide a resolution passed at EGM of the Company held at registered office of the Company on 11th January, 2024.

2. Reconciliation of the number of Shares outstanding at the beginning and at the end of the Period

Particulars	As at December 31, 2023	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
At the beginning of the Period	10,78,760	10,78,760	10,78,760	10,78,760
Additional Shares due to change in Face Value	-	-	-	-
Issued during the year	97,08,840	-	-	-
Redeemed or brought back during the year	-	-	-	-
Total	1,07,87,600	10,78,760	10,78,760	10,78,760

3. Details of shareholders holding more than 5% shares in the Company (in terms of No. of Shares)

Class of shares / Name of shareholder	Period ended on December 31, 2023		Year ended on March 31, 2023		Year ended on March 31, 2022		Year ended on March 31, 2021	
	Number of shares held	% holding in that class of shares	Number of shares held	% holding in that class of shares	Number of shares held	% holding in that class of shares	Number of shares held	% holding in that class of shares
Equity shares with voting rights								
Anil Sabarwal	1,01,67,250	94.25	10,16,725	94.25	10,48,700	97.21	3,17,175	29.40
Ghanshyam Gupta	-	-	-	-	30,000	2.78	1,30,000	12.05
Kavita Sabarwal	-	-	-	-	-	-	4,40,250	40.81
Motia Rani Sabarwal	-	-	-	-	-	-	1,70,000	15.76
Total	1,01,67,250	94.25	10,16,725	94.25	10,78,700	99.99	10,57,425	98.02

4. Shares held by promoters at the end of the year 31st December, 2023

Name of promoters	Period Ended on December 31, 2023			Year Ending on March 31, 2023		
	No. of Share	% of Total Share	% Change during the year	No. of Share	% of Total Share	% Change during the year
Equity shares with voting rights						
Anil Sabarwal	1,01,67,250	94.25%	0.00%	10,16,725	94.25%	-
Tejaswini Sabarwal	4,07,000	3.77%	0.00%	40,700	3.77%	-

5. Shares held by promoters at the end of the year 31st March 2022

Name of promoters	Year Ending on March 31, 2022			Year Ending on March 31, 2021		
	No. of Share	% of Total Share	% Change during the year	No. of Share	% of Total Share	% Change during the year
Equity shares with voting rights						
Anil Sabarwal	10,48,700	97.21%	224.10%	3,17,175	30.00%	-
Tejaswini Sabarwal	-	0.00%	0.00%	-	0.00%	-

Terms & Rights attached to Equity Shares

The Company has issued one class of equity shares having a face value of Rs. 10/- per share. Each shareholder is eligible for one vote per share held. The dividend, if any, proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting, except in case of interim dividend. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholding.

Notes:

- The figures disclosed above are based on the restated summary statement of assets & liabilities of the Company.
- The above statement should be read with the notes to restated summary statements of assets & liabilities, profit & losses, cash flows & significant accounting policies and notes appearing in Annexure I, II, III & IV respectively.
- The Company has allotted 97,08,840 equity shares via bonus issue in the Ratio of 9:1 having face value of Rs. 10 each, out of Reserves & Surplus, by way of passing Board Resolution for allotment of shares dated 30th September, 2023.
- The Company had undertake right issue and issued 11,50,000 equity shares having face value of Rs. 10 each at a premium of Rs. 20 per share, by way of passing Board Resolution for allotment of shares dated 1st January, 2024.

ANNEXURE- VI

DETAILS OF RESERVES & SURPLUS AS RESTATED

Particulars	As at December 31, 2023	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)
Surplus / (Deficit) in Statement of Profit and Loss				
Balance at the beginning of the period	1,234.56	731.71	321.21	255.70
Less: Bonus Issued	(811.10)			
Add: Profit / (Loss) of the period	774.93	502.85	410.50	65.50
Net surplus in the statement of profit and loss	1,198.39	1,234.56	731.71	321.20
Securities Premium				
Balance at the beginning of the period	159.78	159.78	159.78	159.78
Less: Bonus Issued	159.78	-	-	-
Additions during the Year	-	-	-	-
Balance at the end of the period	1,198.39	1,394.34	891.49	480.98

Notes:

1. The figures disclosed above are based on the restated summary statement of assets & liabilities of the Company.
2. The above statement should be read with the notes to restated summary statements of assets & liabilities, profit & losses, cash flows & significant accounting policies and notes appearing in Annexure I, II, III & IV respectively.
3. The Company has allotted 97,08,840 equity shares via bonus issue in the Ratio of 9:1 having face value of Rs. 10 each, out of Reserves & Surplus, by way of passing Board Resolution for allotment of shares dated 30th September, 2023.
4. The Company had undertake right issue and issued 11,50,000 equity shares having face value of Rs. 10 each at a premium of Rs. 20 per share, by way of passing Board Resolution for allotment of shares dated 1st January, 2024.

ANNEXURE- VIIA

DETAILS OF LONG/ SHORT TERM BORROWINGS AS RESTATED

Particulars	As at December 31, 2023	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)
LONG TERM BORROWINGS				
<u>Secured Loan</u>				
From Banks	147.08	185.94	131.80	102.47
<u>Unsecured Loan</u>				
From Directors	-	25.07	1.68	6.41
From Members	-	-	-	-
Others	1.68	1.68	1.68	6.54
Total	148.76	212.69	135.16	115.42
SHORT TERM BORROWINGS				
From Banks	311.90	197.00	179.06	188.61
From Directors	-	-	-	-
Total	311.90	197.00	179.06	188.61

Notes:

1. The figures disclosed above are based on the restated summary statement of assets & liabilities of the Company.
2. The above statement should be read with the notes to restated summary statements of assets & liabilities, profit & losses, cash flows & significant accounting policies and notes appearing in Annexure I, II, III & IV respectively.

ANNEXURE- VIII

DETAILS OF LONG TERM PROVISIONS AS RESTATED

Particulars	As at December 31, 2023	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)
Provision for employee benefits:				
- Gratuity	10.81	8.58	6.66	5.03
Total	10.81	8.58	6.66	5.03

Notes:

1. The Provisioning for Gratuity has been taken into account based on the Actuarial Valuer Report.
2. The figures disclosed above are based on the restated summary statement of assets & liabilities of the Company.
3. The above statement should be read with the notes to restated summary statements of assets & liabilities, profit & losses, cash flows & significant accounting policies and notes appearing in Annexure I, II, III & IV respectively.

ANNEXURE- VIIB

NATURE OF SECURITY & TERMS OF REPAYMENT FOR LONG/ SHORT TERM BORROWINGS INCLUDING CURRENT MATURITIES

(Rs. in lakhs)

S. No.	Lender	Type	Nature of Facility	Loan (Rs in Lakhs)	Amount Outstanding as at December 31, 2023	Rate of Interest	Repayment Terms	Security/Principal Terms & Condition
1	HDFC Bank	Long Term	Working Capital Term Loan	56.00	10.71	9.25% p.a.	Repayable in 49 monthly installment	Primary Security: 1) Industrial Plot No. 45, Sect. 3, Industrial Area- 454001 - Industrial Property used for Commercial Activity of Area 52,506 sq. feet. 2) FD Margin for L.C and Bank Guarantee @25%. 3) Hypothecation of Book Debts and Inventories both present and future. 4) Foreign Confirmed LCS, FD against Capex L.C. 5) Fixed Deposit for 35% margin for 200 Lakhs BG. Beyond above Personal Gurantee of Mr. Anil Kumar Sabarwal, Tejaswini Chouhan and Mr. Rahul Dangi has given. Collateral Security: 1) 25% FD Margin for L.C. and BG. 2) FD against Capex L.C. 3) Fixed Deposit for 35% margin for 200 Lakhs BG. Beyond above Personal Gurantee of Mr. Anil Kumar Sabarwal, Tejaswini Chouhan and Mr. Rahul Dangi has given.
2	HDFC Bank	Long Term	Term Loan	100.00	82.02	8.87% p.a.	Repayable in 61 monthly installment	
3	HDFC Bank	Short Term	Cash Credit	470.00	311.90	11.25% p.a.	-	
4	HDFC Bank	Long Term	Term Loan	75.00	48.63	9.5% p.a.	Repayable in 64 monthly installment	
5	HDFC Bank	Long Term	Auto Loan- Skoda	10.05	5.72	7.60% p.a.	Repayable in 39 monthly installment	
6	Viji Finance Limited	Long Term	Unsecured Loan*	1.68	1.68	-	-	

*The loan saction letter alongwith terms and conditions in relation to the loan taken from Viji Finance Limited is not traceable. However, the said loan has been repaid and is having NIL balance as on date of Restatement.

** The formal terms of repayment in realtion to the unsecured loans mentioned above, have been not defined as the loans taken from the related parties. Also, maturity profile has not been disclosed. Further, the Company is regularlly paying interest on such loans.

ANNEXURE- IX

DETAILS OF TRADE PAYABLES AS RESTATED

Particulars	As at December 31, 2023	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)
Other than Acceptances				
total outstanding dues of micro and small enterprises	-	-	-	-
total outstanding dues of creditors other than micro and small enterprises	2,294.66	2,460.24	1,704.71	796.67
Total	2,294.66	2,460.24	1,704.71	796.67

a. Unbilled

Particulars	As at December 31, 2023	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)
Unbilled - Other (Provision)	-	-	-	-
	-	-	-	-

Trade payable Ageing as Outstanding for following period from due date of payment

31st December, 2023

(Rs. in lakhs)

Particulars	Less than 1 Year	1 - 2 Year	2 - 3 Year	More than 3 Year	Total
- Micro, small and medium enterprises (MSME)	-	-	-	-	-
- Other	2,101.94	127.48	65.24	-	2,294.66
- Disputed Dues - MSME	-	-	-	-	-
- Disputed Dues - Other	-	-	-	-	-
Total	2,101.94	127.48	65.24	-	2,294.66

Trade payable Ageing as Outstanding for following period from due date of payment

31st March, 2023

(Rs. in lakhs)

Particulars	Less than 1 Year	1 - 2 Year	2 - 3 Year	More than 3 Year	Total
- Micro, small and medium enterprises (MSME)	-	-	-	-	-
- Other	2,229.04	196.38	34.82	-	2,460.24
- Disputed Dues - MSME	-	-	-	-	-
- Disputed Dues - Other	-	-	-	-	-
Total	2,229.04	196.38	34.82	-	2,460.24

31st March, 2022

(Rs. in lakhs)

Particulars	Less than 1 Year	1 - 2 Year	2 - 3 Year	More than 3 Year	Total
- Micro and small enterprises (MSME)	-	-	-	-	-
- Other	1,525.72	133.44	45.56	-	1,704.71
- Disputed Dues - MSME	-	-	-	-	-
- Disputed Dues - Other	-	-	-	-	-
Total	1,525.72	133.44	45.56	-	1,704.71

31st March, 2021

(Rs. in lakhs)

Particulars	Less than 1 Year	1 - 2 Year	2 - 3 Year	More than 3 Year	Total
- Micro and small enterprises (MSME)	-	-	-	-	-
- Other	785.49	11.18	-	-	796.67
- Disputed Dues - MSME	-	-	-	-	-
- Disputed Dues - Other	-	-	-	-	-
Total	785.49	11.18	-	-	796.67

Notes:

- The figures disclosed above are based on the restated summary statement of assets & liabilities of the Company.
- The above statement should be read with the notes to restated summary statements of assets & liabilities, profit & losses, cash flows & significant accounting policies and notes appearing in Annexure I, II, III & IV respectively.

ANNEXURE- X

DETAILS OF OTHER CURRENT LIABILITIES AS RESTATED

Particulars	As at December 31, 2023	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)
Statutory Dues:				
TDS Payable	4.44	6.33	9.20	2.15
TCS Payable	-	0.74	-	0.65
ESIC Payable	0.29	0.21	0.15	0.08
Profession Tax Payable	0.03	0.03	0.03	-
Provident Fund Payable	1.75	1.02	0.67	0.50
Bonus Payable	15.57	20.50	20.00	3.00
Salary Payable	37.62	31.47	101.34	45.29
Power and fuel payable	3.91	3.50	3.18	2.41
Advances from Customers	-	-	141.24	40.85
Telephone Expenses Payable	0.02	0.02	-	0.02
Audit Fees	2.00	2.00	2.00	0.45
GST- RCM	-	-	-	0.15
Interest on GST Payable	-	-	-	0.01
Interest on TDS Payable	-	-	0.01	0.03
Commission Payable	-	-	-	6.65
Directors Salary Payable	7.31	7.32	-	1.25
Total	72.94	73.14	277.82	103.49

Notes:

1. The figures disclosed above are based on the restated summary statement of assets & liabilities of the Company.
2. The above statement should be read with the notes to restated summary statements of assets & liabilities, profit & losses, cash flows & significant accounting policies and notes appearing in Annexure I, II, III & IV respectively.

ANNEXURE- XI

DETAILS OF SHORT TERM PROVISIONS AS RESTATED

Particulars	As at December 31, 2023	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)
Provision for Taxation	325.36	149.71	131.83	5.65
Gratuity	2.01	1.31	1.03	0.81
Total	327.37	151.02	132.86	6.46

Notes:

1. Provision for Income Tax have been adjusted against the Advance Tax, TDS & TCS Receivables, if any.
2. The figures disclosed above are based on the restated summary statement of assets & liabilities of the Company.
3. The above statement should be read with the notes to restated summary statements of assets & liabilities, profit & losses, cash flows & significant accounting policies and notes appearing in Annexure I, II, III & IV respectively.

ANNEXURE- XII

RECONCILIATION OF RESTATED TANGIBLE ASSETS

As at December 31, 2023

(Rs. in lakhs)

Particulars	Gross block				Accumulated depreciation				Net block	Net block
	Balance as at April 1, 2023	Additions	Disposals	Balance as at Dec. 31, 2023	Balance as at April 1, 2023	Depreciation/ amortisation expense for the year	Eliminated on disposal of assets	Balance as at Dec. 31, 2023	Balance as at Dec. 31, 2023	Balance as at Mar 31, 2023
(a) Land	10.43	-	-	10.43	-	-	-	-	10.43	10.43
(b) Plant and Machinery	469.72	11.90	5.36	476.26	161.59	18.29	-	179.89	296.38	308.13
(c) Furniture and Fixtures	30.24	-	-	30.24	16.11	1.21	-	17.32	12.92	14.13
(d) Office Equipment	8.74	0.83	-	9.57	4.00	0.62	-	4.62	4.95	4.74
(e) Computers and Printers	8.64	0.75	-	9.39	6.34	0.48	-	6.82	2.57	2.30
(f) Vehicles	68.92	-	-	68.92	35.73	4.36	-	40.09	28.83	33.20
(g) Analytical Equipments	27.63	-	-	27.63	12.54	1.97	-	14.50	13.12	15.09
(h) Buildings	681.88	38.05	-	719.93	85.96	14.69	-	100.64	619.29	595.92
Total	1,306.20	51.53	5.36	1,352.37	322.26	41.61	-	363.88	988.50	983.94

As at March 31, 2023

(Rs. in lakhs)

Particulars	Gross block				Accumulated depreciation				Net block	Net block
	Balance as at April 1, 2022	Additions	Disposals	Balance as at March 31, 2023	Balance as at April 1, 2022	Depreciation/ amortisation expense for the year	Eliminated on disposal of assets	Balance as at March 31, 2023	Balance as at March 31, 2023	Balance as at March 31, 2022
(a) Land	10.43	-	-	10.43	-	-	-	-	10.43	10.43
(b) Plant and Machinery	349.40	125.68	5.36	469.72	137.73	23.87	-	161.59	308.13	211.68
(c) Furniture and Fixtures	26.49	3.76	-	30.25	13.68	2.43	-	16.11	14.13	12.80
(d) Office Equipment	6.77	1.97	-	8.74	3.31	0.69	-	4.00	4.74	3.47
(e) Computers and Printers	7.31	1.33	-	8.64	5.93	0.42	-	6.34	2.30	1.38
(f) Vehicles	50.50	18.42	-	68.92	29.37	6.35	-	35.73	33.20	21.13
(g) Analytical Equipments	22.89	4.74	-	27.63	10.06	2.48	-	12.54	15.09	12.84
(h) Buildings	531.05	150.83	-	681.88	67.22	18.74	-	85.96	595.92	463.83
Total	1,004.84	306.73	5.36	1,306.21	267.30	54.98	-	322.27	983.94	737.55

As at March 31, 2022

Particulars	Gross block				Accumulated depreciation				Net block	Net block
	Balance as at April 1, 2021	Additions	Disposals	Balance as at March 31, 2022	Balance as at April 1, 2021	Depreciation/ amortisation expense for the year	Eliminated on disposal of assets	Balance as at March 31, 2022	Balance as at March 31, 2022	Balance as at March 31, 2021
(a) Land	10.43	-	-	10.43	-	-	-	-	10.43	10.43
(b) Plant and Machinery	285.19	64.22	-	349.41	117.91	19.82	-	137.73	211.68	167.27
(c) Furniture and Fixtures	25.82	0.66	-	26.48	11.39	2.29	-	13.68	12.80	14.43
(d) Office Equipment	6.12	0.65	-	6.77	2.56	0.75	-	3.31	3.46	3.57
(e) Computers and Printers	6.77	0.54	-	7.31	5.55	0.37	-	5.92	1.39	1.22
(f) Vehicles	53.62	-	3.12	50.50	23.83	5.55	-	29.38	21.12	29.80
(g) Analytical Equipments	22.89	-	-	22.89	7.88	2.17	-	10.05	12.84	15.01
(h) Buildings	404.06	127.00	-	531.06	52.15	15.07	-	67.22	463.84	351.91
Total	814.90	193.07	3.12	1,004.85	221.27	46.02	-	267.29	737.56	593.63

As at March 31, 2021

Particulars	Gross block				Accumulated depreciation				Net block	Net block
	Balance as at April 1, 2020	Additions	Disposals	Balance as at March 31, 2021	Balance as at April 1, 2020	Depreciation/ amortisation expense for the year	Eliminated on disposal of assets	Balance as at March 31, 2021	Balance as at March 31, 2021	Balance as at March 31, 2020
(a) Land	10.43	-	-	10.43	-	-	-	-	10.43	1,043.00
(b) Plant and Machinery	269.23	22.42	6.46	285.19	101.23	16.68	-	117.91	167.28	167.99
(c) Furniture and Fixtures	20.66	5.16	-	25.82	9.27	2.12	-	11.39	14.43	11.39
(d) Office Equipment	5.13	0.99	-	6.12	1.86	0.70	-	2.56	3.56	3.27
(e) Computers and Printers	6.63	0.13	-	6.76	4.98	0.57	-	5.55	1.21	1.65
(f) Vehicles	53.62	-	-	53.62	18.27	5.56	-	23.83	29.79	35.35
(g) Analytical Equipments	22.89	-	-	22.89	5.71	2.17	-	7.88	15.01	17.18
(h) Buildings	312.06	92.00	-	404.06	40.57	11.58	-	52.15	351.91	271.49
Total	700.65	120.70	6.46	814.89	181.89	39.38	-	221.27	593.62	1,551.32

ANNEXURE- XIII

DETAILS OF DEFERRED TAX LIABILITIES (NET) AS RESTATED

Particulars	As at December 31, 2023	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)
<u>Tax effect of items constituting Deferred tax liabilities</u>				
On difference between book balance and tax balance of property, plant and equipment	74.75	60.45	46.40	36.62
	74.75	60.45	46.40	36.62
<u>Tax effects of items Constituting Deferred Tax Asset</u>				
On difference between book balance and tax balance of property, plant and equipment	-	-	-	-
Unabsorbed tax losses & Depreciation	-	-	-	-
Provision for doubtful trade receivables	-	-	-	-
Disallowances u/s 40(a)(ia), 43B, 40(A)(7) of the Income Tax Act, 1961	(0.82)	(0.61)	(0.51)	(1.52)
	(0.82)	(0.61)	(0.51)	(1.52)
Net deferred tax asset / (liability)	73.93	59.84	45.89	35.10

Notes:

- The figures disclosed above are based on the restated summary statement of assets & liabilities of the Company.
- The above statement should be read with the notes to restated summary statements of assets & liabilities, profit & losses, cash flows & significant accounting policies and notes appearing in Annexure I, II, III & IV respectively.

ANNEXURE- XIV

DETAILS OF LONG TERM LOANS AND ADVANCES AS RESTATED

Particulars	As at December 31, 2023	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)
Security Deposits	603.29	66.16	49.52	29.26
Total	603.29	66.16	49.52	29.26

Notes:

- The figures disclosed above are based on the restated summary statement of assets & liabilities of the Company.
- The above statement should be read with the notes to restated summary statements of assets & liabilities, profit & losses, cash flows & significant accounting policies and notes appearing in Annexure I, II, III & IV respectively.

ANNEXURE- XV

DETAILS OF NON-CURRENT INVESTMENTS AS RESTATED

Particulars	As at December 31, 2023	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)
Quoted Investments				
i) Investments in Equity Instruments				
a) Choksi Laboratories Limited				
67,200 fully paid up shares of Rs. 10 each	8.75	8.75	8.75	8.75
Total	8.75	8.75	8.75	8.75

Notes:

- The investment in equity instruments of M/s. Choksi Laboratories Limited being Quoted Investment is valued at historical cost basis.

ANNEXURE- XVI

DETAILS OF INVENTORIES AS RESTATED

Particulars	As at December 31, 2023	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)
Raw Materials	504.66	792.58	66.35	33.12
Finished Goods (includes in transit)	12.11	2.46	10.23	32.20
Packing Materials	640.56	320.69	32.14	17.48
Total	1,157.33	1,115.73	108.72	82.80

Notes:

1. The figures disclosed above are based on the restated summary statement of assets & liabilities of the Company.
2. The above statement should be read with the notes to restated summary statements of assets & liabilities, profit & losses, cash flows & significant accounting policies and notes appearing in Annexure I, II, III & IV respectively.

ANNEXURE- XVII

DETAILS OF TRADE RECEIVABLES AS RESTATED

Particulars	As at December 31, 2022	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)
(Unsecured, considered good unless otherwise stated)				
(a) Trade receivables outstanding for a period exceeding six months from the date they were due for payment				
Considered good	2,966.52	1,993.80	2,064.95	874.62
Considered doubtful	-	-	-	-
	2,966.52	1,993.80	2,064.95	874.62
Less: Provision for doubtful trade receivables	-	-	-	-
	2,966.52	1,993.80	2,064.95	874.62
(b) Other Trade receivables	-	-	-	-
Total	2,966.52	1,993.80	2,064.95	874.62

Notes: Trade Receivable Ageing Schedule

(Rs. in lakhs)

Particulars	Less than 6 Months	6 Months to 1 year	1 - 2 Year	2 - 3 Year	More than 3 Year	Total
31st December, 2023						
(a) Undisputed Trade receivables-						
Considered good	2,061.56	717.01	147.66	40.28	-	2,966.51
Considered doubtful	-	-	-	-	-	-
(b) Disputed Trade receivables-						
Considered good	-	-	-	-	-	-
Considered doubtful	-	-	-	-	-	-
Total	2,061.56	717.01	147.66	40.28		2,966.51

(Rs. in lakhs)

Particulars	Less than 6 Months	6 Months to 1 year	1 - 2 Year	2 - 3 Year	More than 3 Year	Total
31st March, 2023						
(a) Undisputed Trade receivables-						
Considered good	1,444.91	295.81	135.80	117.28	-	1,993.80
Considered doubtful	-	-	-	-	-	-
(b) Disputed Trade receivables-						
Considered good	-	-	-	-	-	-
Considered doubtful	-	-	-	-	-	-
Total	1,444.91	295.81	135.80	117.28		1,993.80
31st March, 2022						
(a) Undisputed Trade receivables-						
Considered good	1,784.64	147.56	70.19	203.80	-	2,206.19
Considered doubtful	-	-	-	-	-	-
(b) Disputed Trade receivables-						
Considered good	-	-	-	-	-	-
Considered doubtful	-	-	-	-	-	-
Total	1,784.64	147.56	70.19	203.80	-	2,206.19
31st March, 2021						
(a) Undisputed Trade receivables-						
Considered good	571.28	263.74	15.80	23.80	40.85	915.47
Considered doubtful	-	-	-	-	-	-
(b) Disputed Trade receivables-						
Considered good	-	-	-	-	-	-
Considered doubtful	-	-	-	-	-	-
Total	571.28	263.74	15.80	23.80	40.85	915.47

Notes:

1. As per the view of the management of the company there is no doubtful debt & hence provision for doubtful debt has not been made.
2. The figures disclosed above are based on the restated summary statement of assets & liabilities of the Company.
3. The above statement should be read with the notes to restated summary statements of assets & liabilities, profit & losses, cash flows & significant accounting policies and notes appearing in Annexure I, II, III & IV respectively.

ANNEXURE- XVIII

DETAILS OF CASH & CASH EQUIVALENTS AS RESTATED

Particulars	As at December 31, 2023	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)
A. Cash and cash equivalents				
(a) Cash on hand	0.44	9.34	3.20	5.99
(b) Balances with banks				
(i) In current accounts	4.10	2.69	2.97	4.04
Total - Cash and cash equivalents (A)	4.54	12.03	6.17	10.03
B. Other bank balances				
(i) In other deposit accounts				
- original maturity more than 3 months*	-	237.66	150.74	31.61
Total - Other bank balances (B)	-	237.66	150.74	31.61
Total	4.54	249.69	156.91	41.64

* FD's created for the Bank Guarantee and Letter of Credit in accordance with the Letter of HDFC Bank for Sanction of Credit Facilities.

Notes:

1. The figures disclosed above are based on the restated summary statement of assets & liabilities of the Company.
2. The above statement should be read with the notes to restated summary statements of assets & liabilities, profit & losses, cash flows & significant accounting policies and notes appearing in Annexure I, II, III & IV respectively.

ANNEXURE- XIX

DETAILS OF SHORT TERM LOANS AND ADVANCES AS RESTATED

Particulars	As at December 31, 2023	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)
(Unsecured, considered good unless otherwise stated)				
Loans and Advances	-	-	-	-
- Advances to Others	-	6.70	6.70	7.66
- Loans to Others	7.47	6.85	6.85	9.35
Balance with statutory/government authorities				
-GST Receivable	46.02	199.76	155.88	126.13
-TDS- GST Receivable	49.86	25.68	35.90	3.11
-Duty Drawback Receivable	-	-	0.22	0.22
-VAT Receivable	-	-	-	4.66
-Income Tax Refund Receivable	1.86	1.86	1.16	1.16
Others	0.13	0.51	0.27	-
Total	105.33	241.36	206.97	152.28

Notes:

1. No Securities have been taken by the company against the advances given to the suppliers.
2. The figures disclosed above are based on the restated summary statement of assets & liabilities of the Company.
3. The above statement should be read with the notes to restated summary statements of assets & liabilities, profit & losses, cash flows & significant accounting policies and notes appearing in Annexure I, II, III & IV respectively.

ANNEXURE- XX

DETAILS OF OTHER CURRENT ASSETS AS RESTATED

Particulars	As at December 31, 2023	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)
Advance to Creditors	-	-	-	10.88
Interest Receivable	1.03	0.07	-	-
Prepaid Expenses	1.05	2.00	2.00	1.69
Income Tax- Mat Credit Entitlement	3.24	3.24	3.25	3.23
Total	5.32	5.31	5.25	15.80

Notes:

1. The figures disclosed above are based on the restated summary statement of assets & liabilities of the Company.
2. The above statement should be read with the notes to restated summary statements of assets & liabilities, profit & losses, cash flows & significant accounting policies and notes appearing in Annexure I, II, III & IV respectively.

ANNEXURE- XXI

DETAILS OF REVENUE FROM OPERATIONS AS RESTATED

Particulars	Period ended December 31, 2023	Year ended March 31, 2023	Year ended March 31, 2022	Year ended March 31, 2021
	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)
Revenue from Sale of products	6,207.98	6,164.06	5,948.39	3,036.35
Total	6,207.98	6,164.06	5,948.39	3,036.35

Revenue from Sale of products

Particulars	Period ended December 31, 2023	Year ended March 31, 2023	Year ended March 31, 2022	Year ended March 31, 2021
	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)
Domestic Sales	6,207.98	6,164.06	5,799.14	2,745.46
Foreign Sales	-	-	149.25	290.89
Total	6,207.98	6,164.06	5,948.39	3,036.35

Notes:

1. The figures disclosed above are based on the restated summary statement of assets & liabilities of the Company.
2. The above statement should be read with the notes to restated summary statements of assets & liabilities, profit & losses, cash flows & significant accounting policies and notes appearing in Annexure I, II, III & IV respectively.

ANNEXURE- XXII

DETAILS OF OTHER INCOME AS RESTATED

Particulars	Period ended December 31, 2023	Year ended March 31, 2023	Year ended March 31, 2022	Year ended March 31, 2021
	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)
Discount and Rebates	-	0.11	-	-
Subsidy	-	12.28	-	-
Interest Income	9.64	9.75	3.70	1.03
Refund of Duty Drawback	-	-	1.92	3.53
Profit on Sale of Fixed Assets	-	0.40	-	0.17
Interest on Electricity S.D.	0.21	-	0.18	0.19
Rate difference	-	-	-	2.28
Total	9.85	22.54	5.80	7.20

Notes:

1. The figures disclosed above are based on the restated summary statement of assets & liabilities of the Company.
2. The above statement should be read with the notes to restated summary statements of assets & liabilities, profit & losses, cash flows & significant accounting policies and notes appearing in Annexure I, II, III & IV respectively.

ANNEXURE- XXIII

DETAILS OF COST OF MATERIAL CONSUMED AS RESTATED

Particulars	Period ended December 31, 2023	Year ended March 31, 2023	Year ended March 31, 2022	Year ended March 31, 2021
	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)
Inventory at the beginning of the year	1,113.26	98.49	50.60	388.49
Add : Purchases	4,028.08	5,188.56	4,475.29	2,105.31
	5,141.34	5,287.05	4,525.89	2,493.80
Less : Inventory at the end of the year	1,145.22	1,113.26	98.49	50.60
Cost of material Consumed	3,996.12	4,173.79	4,427.40	2,443.20

Notes:

1. The figures disclosed above are based on the restated summary statement of assets & liabilities of the Company.
2. The above statement should be read with the notes to restated summary statements of assets & liabilities, profit & losses, cash flows & significant accounting policies and notes appearing in Annexure I, II, III & IV respectively.

ANNEXURE- XXIV

DETAILS OF CHANGE IN INVENTORIES OF WIP & FINISHED GOODS AS RESTATED

Particulars	Period ended December 31, 2023	Year ended March 31, 2023	Year ended March 31, 2022	Year ended March 31, 2021
	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)
Inventories at the end of the year				
- Semi Finished Goods	-	-	-	-
- Finished Goods	12.11	2.46	10.23	32.20
	12.11	2.46	10.23	32.20
Inventories at the beginning of the year				
- Semi Finished Goods	-	-	-	-
- Finished Goods	2.46	10.23	32.20	35.48
	2.46	10.23	32.20	35.48
Net (increase)/decrease	-9.65	7.77	21.97	3.28

Notes:

1. The figures disclosed above are based on the restated summary statement of assets & liabilities of the Company.
2. The above statement should be read with the notes to restated summary statements of assets & liabilities, profit & losses, cash flows & significant accounting policies and notes appearing in Annexure I, II, III & IV respectively.

ANNEXURE- XXV

DETAILS OF EMPLOYEE BENEFIT EXPENSES AS RESTATED

Particulars	Period ended December 31, 2023	Year ended March 31, 2023	Year ended March 31, 2022	Year ended March 31, 2021
	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)
Salaries and wages	248.47	243.97	269.71	189.27
Contribution to provident and other funds	8.05	6.46	4.82	3.26
Bonus	0.36	20.50	20.00	6.50
Managerial Remuneration	69.33	80.00	45.00	45.25
Gratuity Expenses	2.94	2.20	1.84	5.84
Staff welfare expenses	0.81	3.66	5.07	2.95
Total	329.96	356.79	346.44	253.07

Notes:

1. The figures disclosed above are based on the restated summary statement of assets & liabilities of the Company.
2. The above statement should be read with the notes to restated summary statements of assets & liabilities, profit & losses, cash flows & significant accounting policies and notes appearing in Annexure I, II, III & IV respectively.

ANNEXURE- XXVI

DETAILS OF FINANCE COST AS RESTATED

Particulars	Period ended December 31, 2023	Year ended March 31, 2023	Year ended March 31, 2022	Year ended March 31, 2021
	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)
Bank Charges	0.74	1.87	2.35	2.14
Interest expense on:				
- Borrowings	40.71	34.27	26.38	28.47
- Delayed payment of statutory dues	21.05	17.70	0.92	0.10
Total	62.50	53.84	29.65	30.71

Notes:

1. The figures disclosed above are based on the restated summary statement of assets & liabilities of the Company.
2. The above statement should be read with the notes to restated summary statements of assets & liabilities, profit & losses, cash flows & significant accounting policies and notes appearing in Annexure I, II, III & IV respectively.

ANNEXURE- XXVII
DETAILS OF OTHER EXPENSES AS RESTATED

Particulars	Period ended December 31, 2023	Year ended March 31, 2023	Year ended March 31, 2022	Year ended March 31, 2021
	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)	(Rs. in lakhs)
Analytical Expenses	9.73	17.08	4.67	5.08
Cylinder Charge	0.08	0.99	0.38	0.22
Factory Expenses	22.32	19.25	17.81	7.73
Insurance Expenses				
-Inward and Purchases	1.60	0.16	0.16	-
-General	2.89	2.30	3.16	3.59
-Keyman	10.23	15.68	-	-
Packing And Forwarding Expenses	-	0.83	0.51	2.95
Power & Fuel	13.71	60.48	57.60	39.66
Transport Charges	-	-	0.56	0.01
Excise Duty	-	-	-	1.50
Export Charges	0.02	-	-	0.10
Electrical Expenses	39.48	-	0.22	-
Jobwork Charges	-	-	-	0.30
Payment to Auditors	-	2.00	2.00	0.45
Association Fee	-	-	-	0.09
Business Promotion Expenses	-	8.47	-	-
Repair and Maintainance Expenses				
-Machinery	3.53	6.72	7.14	1.76
-Building	-	1.40	0.98	7.93
-Computer	0.56	0.51	1.22	0.50
-Vehicles	2.55	3.96	2.85	1.88
-General	5.98	-	0.33	0.35
Postage and Courier Charges	0.01	-	0.01	0.08
Consultancy Fees	1.38	52.70	18.65	0.18
CST Demand	-	-	0.09	0.41
Documenting Charges	-	-	-	0.26
Decoration Expenses	-	7.50	-	-
Diwali Gifts	-	10.29	-	-
Donation	-	0.03	-	1.25
Demurrage Charges	19.38	18.67	7.80	-
Electricity Fitting Expenses	-	-	-	0.71
Entry Tax Demand	-	-	-	2.24
Inspection Fee	-	-	-	0.05
Lease Rent	-	1.37	1.21	0.25
Legal & Professional Fees	13.18	1.97	3.27	0.67
Logistics Charges	6.07	-	-	-
License Renewal Fees	0.10	2.12	1.85	0.99
Maintainance Charge	-	-	-	-
Membership and Subscription Exp.	-	0.07	-	-
Miscellaneous Written Off	-	-	-	1.35
Office and General Expenses	-	29.62	2.49	1.51
Fines and Penalty	211.72	224.19	9.34	-
Pest Control	0.69	0.73	0.78	0.62
PNG Gas Consumption	7.82	9.48	8.38	3.77
Professional Tax	0.03	-	-	-
GST Registration Amendment	0.05	-	-	-
Professional Fees	7.60	-	-	-
Rates and Taxes	-	0.40	1.06	0.03
ROC Expenses	-	0.14	0.07	0.15
Service Charges	-	-	0.01	-
Loss on Sale of Fixed Assets	-	-	2.57	-
Stamp Charges	-	3.67	-	0.62
Printing and Stationery	1.99	1.48	1.48	0.40
Telephone Exp.	0.70	0.84	0.63	0.46
Travelling Exp	5.72	6.87	2.30	3.24
Tender Expenses	0.85	0.18	0.72	2.56
Bad Debts	-	-	112.90	22.82

RTO Charges	0.46	0.76	0.60	0.76
CSR Exp.	6.58	-	-	-
Advertisement Exps.	0.70	0.41	0.05	0.05
Commission	0.51	71.62	114.17	11.65
Unloading Charges	-	0.27	0.23	-
Freight Outward	284.86	258.11	111.80	63.69
Discount and Rate difference	(0.46)	0.14	2.38	-
Round Off	0.01	0.01	1.58	-
Total	682.63	843.47	506.01	194.87

Notes:

1. The figures disclosed above are based on the restated summary statement of assets & liabilities of the Company.
2. The above statement should be read with the notes to restated summary statements of assets & liabilities, profit & losses, cash flows & significant accounting policies and notes appearing in Annexure I, II, III & IV respectively.

ANNEXURE- XXVIII

RESTATED STANDALONE STATEMENT OF FINANCIAL RATIO

Sr. No.	Ratios	As at Decemeber 31, 2023	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
1	Current Assets	4,268.55	3,605.87	2,684.04	1,207.99
	Current Liabilities	3,013.44	2,881.40	2,294.45	1,095.24
	Current Ratio	1.42	1.25	1.17	1.10
	Variation	13.19%	6.98%	6.06%	
	Reason	Change is less than 25%			
2	Total Debt: Borrowings	460.66	409.69	312.54	304.03
	Equity	2,277.15	1,502.21	999.38	588.84
	Debt-Equity Ratio	0.20	0.27	0.31	0.52
	Variance	-25.82%	-12.79%	-39.43%	
	Reason	Due to increase in equity as compared to the rate of increase in borrowings.			
3	Earnings Available for Debt Service	879.04	611.67	486.18	135.59
	Debt Service	523.16	463.53	342.19	334.74
	Debt Service Coverage Ratio	1.68	1.32	1.42	0.41
	Variance	27.33%	-7.12%	250.76%	
	Reason	Due to increase in earnings available for service of debt consequent to increase in Net Profit.			
4	Net Profit After taxes	774.93	502.85	410.50	65.50
	Average Shareholders Equity	2,277.15	1,250.80	794.11	556.10
	Return on Equity (ROE)*	34.03%	40.20%	51.69%	11.78%
	Variance	-15.35%	-22.23%	338.88%	
	Reason	Due to increase in Net Profit after taxes and consequent increase in shareholders equity.			
5	Cost of Goods Sold	3,986.48	4,181.56	4,449.38	2,446.47
	Average Inventory	1,157.33	612.22	95.76	253.38
	Inventory Turnover Ratio*	3.44	6.83	46.46	9.66
	Variation	-49.57%	-85.30%	381.23%	
	Reason	Due to Increase in Inventory for the period and also increase in Cost of Goods sold.			
6	Net Sales	6,207.98	6,164.06	5,948.39	3,036.35
	Average Accounts Receivable	2,966.52	2,100.00	1,560.83	824.88
	Trade Receivables Turnover Ratio*	2.09	2.94	3.81	3.68
	Variation	-28.71%	-22.98%	3.53%	
	Reason	Due to increase in Net sales and corresponding increase in Accounts Receivable for the period.			
7	Cost of Materials Consumed	3,996.13	4,173.79	4,427.41	2,443.19
	Average Accounts Payables	2,294.66	2,082.48	1,250.69	873.53
	Trade Payables Turnover Ratio*	1.74	2.00	3.54	2.80
	Variation	-13.11%	-43.38%	26.57%	
	Reason	Due to decrease in Cost of Material Consumed but increase in Accounts Payable for the period.			
8	Revenue	6,207.98	6,164.06	5,948.39	3,036.35
	Working capital	1,255.11	724.47	389.59	112.75
	Net Capital Turnover Ratio	4.95	8.51	15.27	26.93
	Variation	-41.87%	-44.27%	-43.30%	
	Reason	Due to increase in working capital as compared to the previous period.			

9	Profit After Tax	774.93	502.85	410.50	65.50
	Revenue	6,207.98	6,164.06	5,948.39	3,036.35
	Net Profit Ratio	12.48%	8.16%	6.90%	2.16%
	Variation	53.02%	18.21%	219.91%	
	Reason	Due to increase in Net Profit.			
10	Profit before interest and tax	1,176.87	749.80	606.33	109.66
	Capital Employed	2,811.74	1,971.74	1,357.81	927.97
	Return on Capital employed (ROCE)	41.86%	38.03%	44.65%	11.82%
	Variation	10.07%	-14.84%	277.88%	
	Reason	Due to increase in Capital Employed as compared to the previous period.			
11	Share of Profits/ Return on Investment	0	0	0	0
	Investment in Companies	8.75	8.75	8.75	8.75
	Return on investment	0.00%	0.00%	0.00%	0.00%
	Variation		-	-	
	Reason	Change is less than 25%			

Note: Variation for December 31, 2023 and March 31, 2023 has not been calculated since both the data are not comparable.

*The Ratios for the Stub-Period have been calculated by taking the balances as at December 31, 2023 instead of Average Balances for the period.

The definitions of ratio / formulas used for actual computation are as follows:

- 1 Current Ratio = Current Assets/Current Liabilities
- 2 Debt Equity Ratio = Total Debt / Shareholders Equity
- 3 Debt Service Coverage Ratio = Earning available for Debt Service / Debt Service
- 4 Return on Equity (ROE) = Net Profit after taxes / Average Shareholders Equity
- 5 Inventory Turnover Ratio = Cost of goods sold / Average Inventory
- 6 Trade Receivables Turnover Ratio = Revenue from Operation / Average account receivable
- 7 Trade Payables Turnover Ratio = Cost of Material Consumed/ Average Trade Payables
- 8 Net Capital Turnover Ratio = Revenue from Operations / Working capital
- 9 Net Profit Ratio = Profit After Tax / Revenue from Operation
- 10 Return on Capital employed (ROCE) = Profit before interest and tax /(Networth+ Total Debt + Deferred tax liability)
- 11 Return on Investment = Net Gain on Sale of Investment / Cost of Investment

ANNEXURE- XXIX

DETAILS OF RELATED PARTIES TRANSACTIONS AS RESTATED

(a) Key Managerial Personnel (KMP):

Anil Sabarwal	Managing Director
Kavita Sabarwal	Director
Rahul Dangi	Whole time Director
Tejaswini Sabarwal	Whole time Director
Jayesh jain	Company secretary
Ramkrishna Sharma	Chief Financial officer

(b) Promoters & their Relatives having control:

Vinayak Sabarwal	Relative of Director
Sakshi Sabarwal	Relative of Director
Motia Rani Sabarwal	Relative of Director

(c) Relatives of Promoters who are under the employment of the company:

Vinayak Sabarwal	Relative of Director
Sakshi Sabarwal	Relative of Director

(d) Companies over which Directors have significant influence or control:

Vinayak Meditech Private Limited	Anil Sabarwal- Additional Director

(e) Other entities over which there is significant control:

B. Details of related party transactions during the year:

Particulars	Relationship	Ended on December 31, 2023	Ended on March 31, 2023	Ended on March 31, 2022	Ended on March 31, 2021
<u>Salary Expenses</u>					
Sakshi Sabarwal	Relative of Director	11.75	12.00	9.00	6.00
Vinayak Sabarwal	Relative of Director	14.84	18.00	9.00	6.00
<u>Director's Remuneration</u>					
Anil Sabarwal	Director	45.00	60.00	42.00	30.00
Tejaswini Sabarwal	Director	18.00	15.00	-	-
Kavita Sabarwal	Director	-	-	-	12.50
Rahul Dangi	Director	6.33	5.00	3.00	2.75
<u>Commission</u>					
Sakshi Sabarwal	Relative of Director	-	-	-	1.50
Vinayak Sabarwal	Relative of Director	-	-	-	1.50
<u>Loan Repaid</u>					
Anil Sabarwal	Director	73.07	-	6.41	23.49
<u>Loans Taken</u>					
Motia Rani Sabarwal	Relative of Director	-	-	-	0.51
Anil Sabarwal	Director	48.00	25.07	-	-

ANNEXURE- XXX

STATEMENT OF TAX SHELTER AS RESTATED

(Rs. in lakhs)

Particulars	As at Decemeber 31, 2023	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
Profit before tax, as restated (A)	1,114.37	695.96	576.68	78.95
Normal Corporate Tax Rate (%)	27.82%	27.82%	27.82%	26.00%
Minimum Alternate Tax Rate (%)	16.69%	16.69%	16.69%	15.60%
As per Section 115BAA Rate (%)	25.17%	25.17%	25.17%	25.17%
Adjustments:				
Permanent Differences				
<i>Expenses disallowed under Income Tax Act, 1961</i>				
Gratuity Provision	2.94	2.20	1.84	5.84
Other disallowance including u/s 36 & 37	-	1.70	5.08	3.93
Total Permanent Differences (B)	2.94	3.90	6.92	9.77
Income considered separately (C)	-9.64	-9.97	-3.70	-1.03
Timing Differences				
Depreciation as per Books	41.61	54.98	46.03	39.38
Depreciation as per Income Tax Act	99.33	110.84	71.08	57.00
Other disallowances including under section 43B	-	-	-	-
Total Timing Differences (D)	-57.72	-55.86	-25.05	-17.62
Net adjustments (E) = (B+C+D)	-64.42	-61.93	-21.83	-8.88
Tax expenses/(saving) thereon on net adjustment	-16.21	-15.59	-5.50	-2.24
Income from other sources (F)	9.64	9.97	3.70	1.03
Exempt Income/ Non-Taxable (G)	-	-	-	-
Income/ (Loss) (A+E+F-G)	1,059.59	644.00	558.55	71.10
Brought Forward Loss Set Off				
- Ordinary Business Loss & Unabsorbed Depreciation				
Taxable income/(loss)	1,059.59	644.00	558.55	71.10
Tax as per Normal Provisions	294.78	179.16	155.39	18.49
Tax as per Section 115BAA	266.70	162.09	140.59	17.90
Income as per MAT	1,114.37	695.96	576.68	78.95
Taxable Income/(Loss) as per MAT	482.67	835.99	623.42	84.79
Tax as per MAT	80.56	139.53	104.05	13.23
Tax Paid as per-	Normal Provisions	Normal Provisions	Normal Provisions	Normal Provisions

ANNEXURE- XXXI

RESTATED STATEMENT OF CAPITALIZATION AS AT DECEMBER 31, 2023

(Rs. in lakhs)		
Particulars	Pre Issue	Post Issue
Borrowings		
Short-Term Borrowings (A)	311.90	(*)
Long-Term Borrowings (B)	148.76	(*)
Total Borrowings (C)	460.66	(*)
Shareholder's Fund (Equity)		
Share Capital	1078.76	(*)
Reserve & Surplus	1198.39	(*)
Total Shareholder's Fund (D)	2277.15	(*)
Long-Term Borrowings/ Equity (B/D)	0.07	(*)
Total Borrowings/ Equity (C/D)	0.20	(*)

*The corresponding post issue figures are not determinable at this stage pending the completion of public issue and hence have not been furnished.

Notes:

1. The figures disclosed above are based on the restated summary of Profit & Loss of the Company.
2. The above statement should be read with the notes to restated summary statements of assets & liabilities, profit & losses, cash flows & significant accounting policies and notes appearing in Annexure I, II, III & IV respectively.

ANNEXURE- XXXII

DETAILS OF CONTINGENT LIABILITIES & COMMITMENTS AS RESTATED

(Rs. in lakhs)					
	Particulars	As at Decemeber 31, 2023	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
a.	Contingent liabilities				
	i) Bank Guarantee	768.98	682.94	282.94	282.94

ANNEXURE- XXXIII

OTHER FINANCIAL INFORMATION AS RESTATED

(Rs. in lakhs)				
Particulars	As at Decemeber 31, 2023	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
Restated PAT as per statement of Profit & Loss (For Basic EPS Purpose) (A)	774.93	502.85	410.50	65.50
Add: Depreciation	41.61	54.98	46.03	39.38
Add: Finance Cost	62.50	53.84	29.65	30.71
Add: Income Tax/ Deferred Tax	339.44	193.11	166.18	13.45
Less: Other Income	-9.85	-22.54	-5.81	-7.20
Restated Earnings Before Interest, Tax, Depreciation & Amortization (EBITDA)	1,208.63	782.24	646.55	141.84
EBITDA Margin (%)	19.47%	12.69%	10.87%	4.67%
Number of Equity Shares at the end of the period (B)	1,07,87,600	10,78,760	10,78,760	10,78,760
Number of Equity Shares considering Bonus Impact (C) (Post Bonus after restated period with retrospective effect)	1,07,87,600	1,07,87,600	1,07,87,600	1,07,87,600
Net Worth, as restated (D)	2,277.15	1,502.21	999.38	588.84
Earnings per Share				
Restated Basic EPS (Before Bonus) (A/B)	7.18	46.61	38.05	6.07
Restated Basic EPS (After Bonus) (A/C)	7.18	4.66	3.81	0.61
Return on Net Worth (%) (A/D)	34.03%	33.47%	41.08%	11.12%
Net Assets value per Equity Share (Before Bonus) (D/B)	21.11	139.25	92.64	54.58
Net Assets value per Equity Share (After Bonus) (D/C)	21.11	13.93	9.26	5.46

The definitions of ratio / formulas used for actual computation are as follows:

1. Restated EBITDA = Restated PAT+Depreciation+Finance cost+Income tax-other income
2. EBITDA Margin = EBITDA/ Revenue from Operations
3. Restated Basic EPS (Before Bonus) (A/B) = Restated PAT/No of shares at the end of period
4. Restated Basic EPS (After Bonus) (A/C) = Restated PAT/No of shares after bonus
5. Return on Net Worth (%) (A/D) = Restated PAT/Net Worth restated
6. Net Assets value per Equity Share (Before Bonus) (D/B) = Net worth restated/ No of equity shares at the end of the Period
7. Net Assets value per Equity Share (After Bonus) (D/C) = Net worth restated/ No of equity shares after Bonus Impact

Note: The company has allotted 97,08,840 Equity Shares as Bonus Share in the ratio of 9:1 on 30th September, 2023. As per Accounting Standard 20 (AS - 20), In case of a bonus issue or a share split, equity shares are issued to existing shareholders for no additional consideration. Therefore, the number of equity shares outstanding is increased without an increase in resources. The number of equity shares outstanding before the event is adjusted for the proportionate change in the number of equities shares outstanding as if the event had occurred at the beginning of the earliest period reported.

ANNEXURE- XXXIV

Notes to the Standalone Restated Financial Statements:

I. Long Term Employee Benefits [AS-15]- Defined Benefits Plans:

Accounting Standard (AS)- 15 issued by ICAI is mandatory. The Company has accounted for Long Term employee benefits based on Actuarial Valuation report.

Assumption used by Actuarial for Gratuity Provision

Particulars	For the period ended on			
	Decemeber 31, 2023	March 31, 2023	March 31, 2022	March 31, 2021
Discount Rate	7.25% per annum	7.50% per annum	7.50% per annum	7.50% per annum
Salary Growth Rate	5% per annum	5% per annum	5% per annum	5% per annum
Mortality	IALM 2012-14	IALM 2012-14	IALM 2012-14	IALM 2012-14
Expected rate of return	-	-	-	-
Withdrawal rate	10% per annum	10% per annum	10% per annum	10% per annum
Normal Retirement Age	60 Years	60 Years	60 Years	60 Years
Salary	Last drawn qualifying salary	Last drawn qualifying salary	Last drawn qualifying salary	Last drawn qualifying salary
Vesting Period	5 Years of service	5 Years of service	5 Years of service	5 Years of service
Benefits on Normal Retirement	15/26*Salary*Past Service (Yr.)	15/26*Salary*Past Service (Yr.)	15/26*Salary*Past Service (Yr.)	15/26*Salary*Past Service (Yr.)
Benefit on early exit due to death and disability	As above except that no vesting conditions apply	As above except that no vesting conditions apply	As above except that no vesting conditions apply	As above except that no vesting conditions apply
Limit	20,00,000	20,00,000	20,00,000	20,00,000

(Source: Based on Valuation report Mr. Ashok Kumar Garg (Fellow Member of Institute of Actuaries of India -00057))

ANNEXURE- XXXIV

II. Details on derivative instruments and unhedged foreign currency exposures

(Rs. in lakhs)

Particulars	Period Ending Decemeber 31, 2023	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
The year-end foreign currency exposures that have been hedged by a derivative instrument	NIL	NIL	NIL	NIL
The year-end foreign currency exposures that have not been hedged by a derivative instrument or otherwise	NIL	NIL	NIL	NIL

III. Income and Expenditure in Foreign Currency

i Income earned in foreign currency (accrual basis)

(Rs. in lakhs)

Particulars	Period Ending Decemeber 31, 2023	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
Sales of Products	-	-	149.25	290.89
Total	-	-	149.25	290.89

ii Expenditure incurred in foreign currency (accrual basis)

(Rs. in lakhs)

Particulars	Period Ending Decemeber 31, 2023	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
Purchases of Raw Material and Traded Goods	-	-	-	-
Total	-	-	-	-

IV. Segment Information

The Company operates in a single reportable segment which is governed by same set of risks and returns, thus the reporting requirements under Accounting Standard 17 'Operating Segments' have not been presented in the financial statements.

V. **Restated Standalone Statement of Earnings per Equity Share**

Particulars	Period Ending Decemeber 31, 2023	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
Before Exceptional Items				
1. Net Profit after tax as per Statement of Profit and Loss attributable to Equity Shareholders (Rs. in Lakhs)	774.93	502.85	410.50	65.50
2. Weighted Average number of equity shares used as denominator for calculating EPS (Pre-Bonus)	1,07,87,600	10,78,760	10,78,760	10,78,760
3. Weighted Average number of equity shares used as denominator for calculating EPS (Post-Bonus)	1,07,87,600	1,07,87,600	1,07,87,600	1,07,87,600
4. Basic and Diluted Earning per Share (On Face value of Rs. 10/per share) (Pre-Bonus)	7.18	46.61	38.05	6.07
5. Basic and Diluted Earning per Share (On Face value of Rs. 10/per share) (Post-Bonus)	7.18	4.66	3.81	0.61

VI. **Details of CSR**

(Rs. in lakhs)

Particulars	For the period ended on			
	December 31, 2023	March 31, 2023	March 31, 2022	March 31, 2021
1. Amount Required to be spent during the year	9.01	4.65	NA	NA
2. Amount of expenditure incurred	-	-	NA	NA
3. Shortfall at the end of the year	9.01	4.65	NA	NA
4. Total of previous years shortfall	4.65	NA	NA	NA
5. Reasons for shortfall	NA	NA	NA	NA
6. Nature of CSR Activities	-	-	NA	NA

VII. **Additional regulatory information**

(a) **Relationship with struck off companies**

The Company does not have any transactions with the companies struck off under section 248 of the Companies Act, 2013 or section 560 of the Companies Act, 1956 during the period ended on December 31, 2023 and for the year ended March 31, 2023, 2022 & 2021.

(b) **Compliance with approved scheme of arrangements**

The Company is not engaged in any scheme of arrangements.

(c) **Details of crypto currency or virtual currency**

The Company has neither traded nor invested in Crypto currency or Virtual Currency during the period ended on December 31, 2023 and for the year ended March 31, 2023, 2022 & 2021. Further, the Company has also not received any deposits or advances from any person for the purpose of trading or investing in Crypto Currency or Virtual Currency.

(d) **Undisclosed income**

During the Periods, the Company has not surrendered or disclosed as income any transactions not recorded in the books of accounts in the course of tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).

(e) **Compliance with numbers of layers of companies**

The Company is in compliance with the number of layers of companies in accordance with clause 87 of Section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017 during the period ended on December 31, 2023 and for the year ended March 31, 2023, 2022 & 2021.

(f) **Whistleblower Complaint**

The Company has not received any whistleblower complaint during the year. No frauds had been noticed by or reported to the Company.

(g) **Utilisation of borrowed funds and share premium**

During the year, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries") with the understanding, whether recorded in writing or otherwise, that the Intermediary shall lend or invest in party identified by or on behalf of the Company (Ultimate Beneficiaries). The Company has not received any fund from any party(s) (Funding Party) with the understanding that the Company shall whether, directly or indirectly lend or invest in other persons or entities identified by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries."

(h) **There are no proceedings initiated or pending against the Company for holding any Benami Property under the Benami Transactions (Prohibition) Act, 1988 and rules made thereunder.**

(i) **The Company has not been declared Willful Defaulter by any bank or financial institution or government or any government authority.**

VI. Material Regroupings:

Appropriate adjustments have been made in the restated summary statements of Assets and Liabilities Profits and Losses and Cash flows wherever required by reclassification of the corresponding items of income expenses assets and liabilities in order to bring them in line with the requirements of the SEBI Regulations.

VIII. Details of dues to Micro and Small Enterprises as defined under the MSMED Act, 2006

Based on the information available with the Company in respect of MSME (as defined in the Micro, Small and Medium Enterprises Development Act, 2006) and as confirmed to us there are no delays in payment of dues to such enterprise during the year.

The identification of Micro, Small and Medium Enterprises Suppliers as defined under "The Micro, Small and Medium Enterprises Development Act, 2006" is based on the information available with the management. As certified by the management, the amounts overdue as on December 31, 2023 and for the year ended March 31, 2023, 2022 & 2021 to Micro, Small and Medium Enterprises on account of principal amount together with interest, aggregate to Rs. Nil.

IX. Trade Receivables, Trade Payables, Borrowings, Loans & Advances and Deposits

Balances of Trade Receivables, Trade Payables, Borrowings and Loans & Advances and Deposits are subject to confirmation.

X. Re-grouping/re-classification of amounts

The figures have been grouped and classified wherever they were necessary.

XI. Pending Litigations

1. The Show Cause Notice has been issued u/s. 74 of the GST Act, 2017 intimating the assessee of net tax liability of Rs. 11.76 Lakhs determined during the scrutiny of returns for F.Y. 2017-18 on account of wrong utilization of ITC. Aggrieved by the order, the assessee has filed an appeal with the Appellate Authority in the matter and the same is pending.

2. There is outstanding demand of Rs. 172.28 Lakhs raised by the Income Tax Authorities under section 143(1) of the Income Tax Act, 1961 for the F.Y. 2022-23. However, the Company has disputed the said demand and is currently pending.

3. The Notice has been issued under section 148 of the Income Tax Act, 1961 for income escaping assessment for the F.Y. 2018-19 and reassessment proceedings are currently pending. The Notice has been issued on the grounds of suspicious transactions entered into by the assessee with one M/s. Richvib Exim Private Limited, Shri Pramod Sahu and Ms. Vibha Sahu in whose matters search was conducted u/s. 132 of the Act and who have allegedly accepted for having entered into bogus transactions.

4. There are outstanding demands of Rs. 8.60 Lakhs related to TDS defaults appearing on the TRACES portal as on date of preparation of the Restated Financial Statements. The defaults mainly relates to the short payment and short deduction of TDS and late filing fees, interest u/s 220 and 221 of Income Tax Act, 1961. The Income Tax Authorities has issued communication notices and the Authorities may at any time issue recovery notices in which event the same shall become payable.

5. The State of Andhra Pradesh represented by Drug Inspector being Complainant has filed petition against the Company alongwith its directors on the ground that they have taken sample of the Polyfol Forte tablest, Batch no. 13, Mfg. Date: 07/2010, Exp. Date: 12/2011, manufactured by the company, for test / analysis from the Central Drug Stores and they declared the sample of non-standard quality for the reason that the sample did not meet the I.P. specifications in respect of Description. The matter is pending with the Honourable Court of III Additional Judicial First Class Magistrate, Kakinada and later transferred to Honourable District & Sessions Judge, East Godavari, Rajahmahendravaram. Now, the matter is pending before the concerned court.

XII. Deferred Tax Asset / Liability: [AS-22]

The company has created Deferred Tax Asset / Liability as required by Accounting Standard (AS)-22.

OTHER FINANCIAL INFORMATION

ANNEXURE- XXXIII STATEMENT OF ACCOUNTING & OTHER RATIOS, AS RESTATED

The accounting ratios required under Clause 11 of Part A of Schedule VI of the SEBI ICDR Regulations, as derived from the Restated Financial Statements, are given below:

(₹ in Lakhs except the percentage % data)

Particulars	December 31, 2023	March 31, 2023	March 31, 2022	March 31, 2021
Restated PAT as per statement of Profit & Loss (For Basic EPS Purpose) (A)	774.93	502.85	410.50	65.50
Add: Depreciation	41.61	54.98	46.03	39.38
Add: Finance Cost	62.50	53.84	29.65	30.71
Add: Income Tax/ Deferred Tax	339.44	193.11	166.18	13.45
Less: Other Income	(9.85)	-22.54	-5.81	-7.20
Restated Earnings Before Interest, Tax, Depreciation & Amortization (EBITDA)	1208.63	782.24	646.55	141.84
EBITDA Margin (%)	19.47%	12.69%	10.87%	4.67%
Number of Equity Shares at the end of the period (B)	10787600	10,78,760	10,78,760	10,78,760
Number of Equity Shares considering Bonus Impact (C)	10787600	1,07,87,600	1,07,87,600	1,07,87,600
(Post Bonus after restated period with retrospective effect)				
Net Worth, as restated (D)	2277.15	1,502.21	999.38	588.84
Earnings per Share				
Restated Basic EPS (Before Bonus) (A/B)	7.18	46.61	38.05	6.07
Restated Basic EPS (After Bonus) (A/C)	7.18	4.66	3.81	0.61
Return on Net Worth (%) (A/D)	34.03%	33.47%	41.08%	11.12%
Net Assets value per Equity Share (Before Bonus) (D/B)	21.11	139.25	92.64	54.58
Net Assets value per Equity Share (After Bonus) (D/C)	21.11	13.93	9.26	5.46

The definitions of ratio / formulas used for actual computation are as follows:

1. Restated EBITDA = Restated PAT + Depreciation + Finance cost + Income tax-other income
2. EBITDA Margin = EBITDA/ Revenue from Operations
3. Restated Basic EPS (Before Bonus) (A/B) = Restated PAT/No of shares at the end of period
4. Restated Basic EPS (After Bonus) (A/C) = Restated PAT/No of shares after bonus
5. Return on Net Worth (%) (A/D) = Restated PAT/Net Worth restated
6. Net Assets value per Equity Share (Before Bonus) (D/B) = Net worth restated/No of equity shares at the end of the Period
7. Net Assets value per Equity Share (After Bonus) (D/C) = Net worth restated/No of equity shares after Bonus Impact

Note: The company has allotted 97,08,840 Equity Shares as Bonus Share in the ratio of 9:1 on 30th September, 2023. As per Accounting Standard 20 (AS - 20), In case of a bonus issue or a share split, equity shares are issued to existing shareholders for no additional consideration. Therefore, the number of equity shares outstanding is increased without an increase in resources. The number of equity shares outstanding before the event is adjusted for the proportionate change in the number of equities shares outstanding as if the event had occurred at the beginning of the earliest period reported.

CAPITALISATION STATEMENT

ANNEXURE - XXXI RESTATED STATEMENT OF CAPITALIZATION AS AT DECEMBER 31, 2023

The following table sets forth our capitalisation derived from our Restated Financial Statements as at December 31, 2023, and as adjusted for the Issue. This table should be read in conjunction with “*Management’s Discussion and Analysis of Financial Condition and Results of Operations*”, “*Restated Financial Information*” and “*Risk Factors*” on pages 199, 196, and 30, respectively of this Prospectus.

(₹ in Lakhs)

Particulars	Pre-Issue	Post Issue*
Borrowings		
Short-Term Borrowings (A)	311.90	311.90
Long-Term Borrowings (B)	148.76	148.76
Total Borrowings (C)	460.66	460.66
Shareholder’s Fund (Equity)		
Share Capital	1078.76	1638.72
Reserve & Surplus	1198.39	4921.42
Total Shareholder’s Fund (D)	2277.15	6560.14
Long-Term Borrowings/ Equity (B/D)	0.07	0.02
Total Borrowings/ Equity (C/D)	0.20	0.07

Notes:

1. The figures disclosed above are based on the restated summary of Profit & Loss of the Company.
2. The above statement should be read with the notes to restated summary statements of assets & liabilities, profit & losses, cash flows & significant accounting policies and notes appearing in Annexure I, II, III & IV respectively.

FINANCIAL INDEBTEDNESS

Our Company has availed borrowings in the ordinary course of our business. Set forth below is a brief summary of our aggregate outstanding borrowings as on December 31, 2023:

(₹. in Lakhs)

Nature of Borrowing#	Amount
Secured Borrowings	458.98
Unsecured Borrowings	1.68
Total	460.66

DETAILS OF SECURED BORROWINGS:

(₹ in Lakhs)

Name of Lender	Sanction Date	Nature of the Facility	Amt Sanctioned	Amt o/s as on December 31, 2023	Interest Rate & Repayment Terms	Security
HDFC Bank	June 24, 2020	Working Capital Term Loan	56.00	10.71	9.25% p.a. Repayable in 49 Monthly Instalments	Primary Security: 1) Industrial Plot No. 45, Sect. 3, Industrial Area- 454001- Industrial Property used for Commercial Activity of Area 52,506 sq. feet. 2) FD Margin for LC and Bank Guarantee @25%. 3) Hypothecation of Book Debts and Inventories both present and future. 4) Foreign Confirmed LCS, FD against Capex LC. 5) Fixed Deposit for 35% margin for 200 Lakhs BG. Beyond above Personal Guarantee of Mr. Anil Kumar Sabarwal, Tejaswini Chouhan and Mr. Rahul Dangi has given.
	October 20, 2022	Term Loan	100.00	82.02	8.87% p.a. Repayable in 61 Monthly Instalments	
	October 27, 2021	Term Loan	75.00	48.63	9.5% p.a. Repayable in 64 Monthly Instalments	
	September 04, 2017	Cash Credit	470.00	311.90	11.25% p.a.	Collateral Security: 1) 25% FD Margin for LC and BG. 2) FD against Capex LC. 3) Fixed Deposit for 35% margin for 200 Lakhs BG. Beyond above Personal Guarantee of Mr. Anil Kumar Sabarwal, Tejaswini Chouhan and Mr. Rahul Dangi has given.
	May 30, 2022	Auto Loan-Skoda	10.05	5.72	7.60% p.a. Repayable in 39 monthly instalments	Mortgaged of a Vehicle

DETAILS OF UNSECURED BORROWINGS:*(₹ in Lakhs)*

Name of Lender	Sanction Date	Nature of the Facility	Amount Sanctioned	Amount outstanding as on December 31, 2023	Interest Rate
Viji Finance Limited*	31/08/2018	Long Term	1.68	1.68	12% p.a.

**The loan sanction letter along with terms and conditions in relation to the loan taken from Viji Finance Limited is not traceable. As on the date of Prospectus this loan from Viji Finance Limited has been repaid.*

*** The formal terms of repayment in relation to the unsecured loans mentioned above, have been not defined as the loans taken from the related parties. Also, maturity profile has not been disclosed. Further, the Company is regularly paying interest on such loans.*

#As certified by M/s Shyam S. Gupta & Associates, Chartered Accountants, by way of their certificate dated April 26, 2024.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations for the period ended on December 31, 2023 and for the Fiscal Years 2023, 2022, and 2021 is based on, and should be read in conjunction with, our Restated Financial Statements, including the schedules, notes and significant accounting policies thereto, included in the chapter titled "Restated Financial Statements" beginning on page 196 of this Prospectus. Our Restated Financial Statements have been derived from our audited financial statements and restated in accordance with the SEBI ICDR Regulations and the ICAI Guidance Note. Our financial statements are prepared in accordance with AS.

You should read the following discussion of our financial condition and results of operations together with our restated financial statements included in this Prospectus. You should also read the section titled "Risk Factors" beginning on page 30 of this Prospectus, which discusses a number of factors, risks and contingencies that could affect our financial condition and results of operations. Our fiscal year ends on March 31 of each year, so all references to a particular fiscal year are to the twelve-month period ended March 31 of that year.

In this section, unless the context otherwise requires, any reference to "we", "us" or "our" refers to Quest Laboratories Limited, our Company. Unless otherwise indicated, financial information included herein are based on our "Restated Financial Statements" for the period ended on December 31, 2023 and for the Financial Years 2023, 2022, and 2021 included in this Prospectus beginning on page 196 of this Prospectus.

Note: Statement in the Management Discussion and Analysis Report describing our objectives, outlook, estimates, expectations or prediction may be "Forward Looking Statements" within the meaning of applicable securities laws and regulations. Actual results could differ materially from those expressed or implied. Important factors that could make a difference to our operations include, among others, economic conditions affecting demand/supply and price conditions in domestic and overseas market in which we operate, changes in Government Regulations, Tax Laws and other Statutes and incidental factors.

BUSINESS OVERVIEW

Our Company, Quest Laboratories Limited is engaged in the business of manufacturing of pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. These formulations fall under the trademark "**Quest Laboratories Limited**". The company produces a variety of products, comprising ethical drugs, generic drugs, and over-the-counter drugs (OTC). These products are available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids. This comprehensive approach allows our Company to address a wide range of medical needs and preferences among patients.

Our Company holds WHO Schedule M GMP, and GLP certifications, adhering to the stringent guidelines set by the World Health Organization. Our commitment to quality is further demonstrated by our ISO 9001:2015 certification and ISO/IEC 17025:2017 accreditation. With manufacturing under one roof, our company maintains stringent quality control standards throughout the entire manufacturing process. By doing so, we ensure that our products meet the relevant quality standards before they reach the market.

Our Company also possesses Good Laboratory Practice (GLP) certificate issued by Food & Drug Administration, Bhopal, Madhya Pradesh, indicating its commitment to maintaining high standards of quality and compliance in laboratory operations, particularly within the pharmaceutical sector. Our in-house laboratory is equipped with various equipment such as HPLC (High-Performance Liquid Chromatography), GC (Gas Chromatography), FTIR (Fourier Transform Infrared Spectroscopy), UV (Ultraviolet-Visible Spectroscopy), Dissolution apparatus, and other advanced instruments. This comprehensive suite of tools enables us to conduct a wide array of tests and analyses efficiently and accurately.

Furthermore, our professional staff ensures the reliability and credibility of our laboratory results and services. With their expertise, we maintain precision, adhere to protocols, and deliver results in a timely manner, all of which are paramount in pharmaceutical and related industries. Having these resources and capabilities in-house allows our Company to support various aspects of product development, quality control, and regulatory compliance. As a result, we have earned a reputation as a reliable and efficient laboratory service provider.

We currently have our manufacturing facility located at Plot No. 45, Sector III, Pithampur Industrial Area, Pithampur, Dhar - 454775, Madhya Pradesh, India. The total area of the facility is approximately 4,065 square meters. Our manufacturing facilities are well equipped with the required facilities including machinery, other handling equipment's to facilitate smooth manufacturing process and easy logistics. We endeavour to maintain safety in our premises by adhering to key safety norms, established through our internal health and safety manual, accompanied by regular safety meetings.

Our Company have been receiving sales orders from the private sector & government institutions on regular basis. This collaborative approach offers benefits to the purchasers, including cost efficiency through bulk production, capacity scaling, regulatory compliance, reduced lead times, risk mitigation, access to specialized technologies, geographical expansion, cost effective compliance, and resource optimization.

Our company has successfully bid for government tender contracts over the past few years, collaborating with major state and central government institutions and corporations.

The key raw materials utilized in our manufacturing operations encompass Active Pharmaceutical Ingredients (APIs) for our formulations, key starting materials, and intermediaries for our internally manufactured APIs. We also acquire other materials such as excipients, manufacturing consumables, lab chemicals, and packaging materials. Furthermore, our procurement extends to packaging materials sourced from vendors situated across different geographical locations. In the domestic market, our company procures raw materials primarily from Madhya Pradesh, Maharashtra, Himachal Pradesh, Telangana, Uttarakhand, and Gujarat. We strive to maintain strong relationships with suppliers across these regions to ensure a steady supply chain and the quality of our products.

Our company operates in the domestic market across twelve (12) states and two (2) union territories namely Uttar Pradesh, Madhya Pradesh, Maharashtra, Delhi, Jharkhand, Assam, Karnataka, Jammu & Kashmir, Rajasthan, West Bengal Gujarat, Telangana, Haryana and Bihar based on sales made for the period ended December 31, 2023 and for the financial year ended March 31, 2023, 2022 and 2021.

Our company is promoted by Mr. Anil Kumar Sabarwal and Ms. Tejaswini Sabarwal, possessing around 22 and 5 years of experience, respectively, in the pharmaceutical industry. Our promoters have played pivotal roles in guiding, developing, growing, managing, and controlling the major aspects of our business operations, drawing upon their considerable expertise in the pharma sector. For more details, please see the chapter titled, “*Our Management*” and “*Our Promoter and Promoter Group*” on page 175 and 190 of this Prospectus. We attribute our success to sustained efforts over the years in key areas of our business, including product portfolio management, process improvements, and the expansion of our operational scale.

Moreover, our company is managed by a team of industry veterans comprising individuals with technical, operational, and business development experience in the chemical and pharmaceutical sectors. We believe that the collective experience of our management team, coupled with their deep understanding of industry dynamics, regulatory affairs, manufacturing, quality control, sales, marketing, and finance, positions us to capitalize on current and future market opportunities both in India and internationally.

Our product mix has evolved over the past several years as we entered new product categories. We are consistently expanding our product portfolio through research and development of new pharmaceutical formulations. Our company maintains an in-house Department of Formulation Development, Quality Control, and Product Stability Studies. This department takes existing products and their dosages, then formulates different variations. Subsequently, they study these formulations, conducting Process Validations, Analytical Method Validations, and Cleaning Validation according to Standard Operating Procedures. This process ensures that we create and maintain quality pharmaceutical products, meeting regulatory standards and satisfying customer expectations.

Further, our company continues to benefit from the various initiatives extended by the government to support the MSME segment. Under the Madhya Pradesh MSME Yojna, specifically the MSME Promotion Scheme of 2016 and 2019, our company has received subsidies totalling ₹ 15.00 Lakhs and ₹ 26.79 Lakhs respectively, as Industrial Development Grants, for investments made in machinery. Additionally, under the Madhya Pradesh Interest Subsidy Scheme of 2023, we have been granted ₹ 20.00 Lakhs.

These subsidies serve as invaluable support, alleviating financial burdens associated with capital investments and interest payments. They enable our company to allocate resources more efficiently towards enhancing productivity, expanding operations, and contributing to economic growth and employment generation within the region. We remain committed to adhering to all terms and conditions associated with these subsidies to ensure continued benefit. Leveraging such government schemes not only underscores our dedication to innovation and sustainability but also reinforces our contribution to the local economy.

For period ended December 31, 2023 and for the Financial Years ended on March 31, 2023, 2022 and 2021, our revenue from operations was ₹ 6,207.98 Lakhs, ₹ 6,164.06 Lakhs, ₹ 5,948.39 Lakhs and ₹ 3,036.35 Lakhs, respectively. Our EBITDA (earnings before interest, depreciation and tax) for the Period ended December 31, 2023 and financial year ended March 31, 2023, 2022 and 2021 was ₹ 1208.63 Lakhs, ₹ 782.24 Lakhs, ₹ 646.55 Lakhs and ₹ 141.84 Lakhs, respectively, while our profit after tax for the Period ended December 31, 2023 and financial year ended March 31, 2023, 2022 and 2021 was ₹ 774.93 Lakhs, ₹ 502.85 Lakhs, ₹ 410.50 Lakhs and ₹ 65.50 Lakhs, respectively.

Key Performance Indicators of our Company.

As per Restated Financial Statements

(₹ in Lakhs, otherwise mentioned)

Key Financial Performance	December 31, 2023	March 31, 2023	March 31, 2022	March 31, 2021
Revenue from Operations ⁽¹⁾	6207.98	6,164.06	5,948.39	3,036.35
EBITDA ⁽²⁾	1208.63	782.24	646.55	141.84
EBITDA Margin (%) ⁽³⁾	19.47%	12.69%	10.87%	4.67%
PAT	774.93	502.85	410.50	65.50
PAT Margin (%) ⁽⁴⁾	12.48%	8.16%	6.90%	2.16%
Return on equity (%) ⁽⁵⁾	34.03%	40.20%	51.69%	11.78%
Debt-Equity Ratio (times) ⁽⁶⁾	0.20	0.27	0.31	0.52
Current Ratio (times) ⁽⁷⁾	1.42	1.25	1.17	1.10

*As certified by M/s Shyam S. Gupta & Associates, Chartered Accountants, by way of their certificate dated April 17, 2024

Notes:

- 1) Revenue from operation means revenue from sale of our products
- 2) EBITDA is calculated as Profit before tax + Depreciation + Finance Costs – Other Income
- 3) EBITDA Margin is calculated as EBITDA divided by Revenue from Operations
- 4) PAT Margin is calculated as PAT for the period/year divided by revenue from operations
- 5) Return on Equity is calculated by comparing the proportion of net income against the amount of average shareholder equity
- 6) Debt to Equity ratio is calculated as Total Debt divided by equity
- 7) Current Ratio is calculated by dividing Current Assets to Current Liabilities

SIGNIFICANT DEVELOPMENTS AFTER DECEMBER 31, 2023

In the opinion of the Board of Directors of our Company, since the date of the stub period as disclosed in this Prospectus, there have not arisen any circumstance that materially or adversely affect or are likely to affect the profitability of our Company or the value of its assets or its ability to pay its material liabilities within the next twelve months.

1. The Board of our Company has approved to increase the authorised share capital in the board meeting held on January 11, 2024.
2. The Board of our Company has approved to raise funds through right issue in the board meeting held on January 01, 2024.
3. The members of our Company approved proposal of Board of Directors to raise funds through initial public offering in the EOGM held on February 09, 2024.
4. The status of the Company was changed to public limited and the name of our Company was changed to “Quest Laboratories Limited” vide Special Resolution passed by the Shareholders at the Extra Ordinary General Meeting of our Company held on January 11, 2024. The fresh certificate of incorporation consequent to conversion was issued on January 23, 2024 by Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies, Centralised Processing Centre.

FACTORS AFFECTING OUR RESULTS OF OPERATIONS

Our business is subjected to various risks and uncertainties, including those discussed in the section titled “Risk Factors” beginning on page 30 of this Prospectus. Our results of operations and financial conditions are affected by numerous factors including the following:

1. Disruption in our manufacturing process.
2. Our ability to successfully implement our strategy, our growth and expansion, technological changes.
3. Fail to attract, retain and manage the transition of our management team and other skilled & unskilled employees;
4. Our ability to protect our intellectual property rights and not infringing intellectual property rights of other parties;

5. Ability to respond to technological changes;
6. Failure to comply with regulations prescribed by authorities of the jurisdictions in which we operate;
7. General economic and business conditions in the markets in which we operate and in the local, regional and national economies;
8. Our ability to effectively manage a variety of business, legal, regulatory, economic, social and political risks associated with our operations;
9. Changes in laws and regulations relating to the industries in which we operate;
Our ability to meet our capital expenditure requirements;
10. Failure to adapt to the changing technology in our industry of operation may adversely affect our business and financial condition;
11. Failure to obtain any approvals, licenses, registrations and permits in a timely manner;
12. Changes in political and social conditions in India or in countries that we may enter, the monetary and interest rate policies of India and other countries, inflation, deflation, unanticipated turbulence in interest rates, equity prices or other rates or prices;
13. Occurrence of natural disasters or calamities affecting the areas in which we have operations;
14. Conflicts of interest with affiliated companies, the promoter group and other related parties;
15. The performance of the financial markets in India and globally;
16. Any adverse outcome in the legal proceedings in which we are involved;
17. Our ability to expand our geographical area of operation;

SIGNIFICANT ACCOUNTING POLICIES

1. COMPANY INFORMATION

Quest Laboratories Limited (*Formerly Known as Quest Laboratories Private Limited*) was incorporated on June 01, 1998 and having its registered office at Plot No. 45, Sector III, Pithampur, Dhar, Madhya Pradesh- 454775. The Company is primarily engaged in the manufacturing of pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. The Company also produce variety of products, comprising ethical drugs, generic drugs, and over-the-counter drugs (OTC). The Company has been converted from Private Limited Company to Public Limited Company vide necessary resolution passed by shareholders and the name of company is this day changed to Quest Laboratories Limited pursuant to issuance of Fresh Certificate of Incorporation on January 23, 2024. The Corporate Identification Number is U24232MP1998PLC012850.

SIGNIFICANT ACCOUNTING POLICIES: -

(a) Basis of Preparation

The Restated Summary Statement of Assets and Liabilities of the Company as at December 31, 2023, March 31, 2023, March 31, 2022 and March 31, 2021 and the related Restated Summary Statement of Profit and Losses and Cash Flows Statement for the period ended on December 31, 2023, March 31, 2023, March 31, 2022 and March 31, 2021 have been complied by management from the financial statements of the company for the period ended on December 31, 2023, March 31, 2023, March 31, 2022 and March 31, 2021.

The financial statements are prepared under the historical cost convention on the “Accrual Concept” and Going Concern assumption of accountancy in accordance with the accounting principles generally accepted in India and comply with the accounting standards as prescribed by Companies (Accounting Standard) Rules, 2006 or 2001 as may be applicable and with the relevant provisions of the Companies Act, 2013 and rules made there under.

(b) Use of Estimates

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amount of assets and liabilities on the date of the financial statement and the reported amount of revenues and expenses during the reporting period. Difference between the actual results and estimates are recognized in the period in which results are known/materialized.

(c) Property, Plant and Equipment

Property, Plant and Equipment are stated at cost less accumulated depreciation. Cost comprises of all expenses incurred to bring the assets to its present location and condition. Borrowing cost directly attributable to the acquisition /construction are included in the cost of fixed assets. Adjustments arising from exchange rate variations attributable to the fixed assets are capitalized.

In case of new projects / expansion of existing projects, expenditure incurred during construction / preoperative period including interest and finance charge on specific / general purpose loans, prior to commencement of commercial production are capitalized. The same are allocated to the respective t on completion of construction / erection of the capital project / fixed assets.

Subsequent expenditures related to an item of tangible asset are added to its book value only if they increase the future economic benefits from the existing asset beyond its previously assessed standard of performance.

Capital assets (including expenditure incurred during the construction period) under erection / installation are stated in the Balance Sheet as “Capital Work in Progress.”

(d) Impairment of Assets

At each balance sheet date, the Company reviews the carrying amount of its fixed assets to determine whether there is any indication that those assets suffered an impairment loss. If any such indication exists, the recoverable amount of the assets is estimated in order to determine the extent of impairment loss. Recoverable amount is the higher of an asset’s net selling price and value in use. In assessing value in use, the estimated future cash flows expected from the continuing use of the assets and from its disposal are discounted to their present value using a pre-tax discount rate that reflects the current market assessments of time value of money and the risks specific to the assets.

(e) Depreciation

All fixed assets, except capital work in progress, are depreciated on WDV Method. Depreciation is provided based on useful life of the assets as prescribed in Schedule II to the Companies Act, 2013. Depreciation on additions to / deletions from fixed assets made during the period is provided on pro-rata basis from / up to the date of such addition /deletion as the case may be

(f) Investments

Investments are classified into current investments and non-current investments. Current investments i.e. investments that are readily realizable and intended to be held for not more than a year valued at cost. Any permanent reduction in the carrying amount or any reversals of such, reductions are charged or credited to the Statement of Profit & loss Account. Non-current investments are stated at cost. Provision for diminution in the value of these investments is made only if such decline is other than temporary, in the opinion of the management.

(g) Inventories

As per (AS) 2, The inventories are physically verified at regular intervals by the management. Raw Material Inventories are valued at the lower of cost and net realizable value.

Finished goods, Stock-in-Trade and Work-in-Progress are valued at lower of cost and net realizable value. Cost of inventories comprises of cost of purchase, cost of conversion and other costs including manufacturing overheads net of recoverable taxes incurred in bringing them to their respective present location and condition.

Consumable stores and spares are valued at the lower of cost and net realizable value, as estimated by the management. Obsolete, defective, unserviceable and slow/non-moving stocks are duly provided for.

(h) Revenue Recognition

Sales revenue is recognized when property in the goods with all significant risk and rewards as well as the effective control of goods usually associated with ownership are transferred to the buyer. Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured.

Revenue is recognized when it is earned and no significant uncertainty exists as to its realization or collection. Revenue from sale of goods or services are recognized on delivery of the products or services, when all significant contractual obligations have been satisfied, the property in the goods is transferred for price, significant risk and rewards of ownership are transferred to the customers and no effective ownership is retained.

In the financial statement, revenue from operation does not include Indirect taxes like Sales Tax And/ Or Goods & Service Tax.

Sale of Goods:

Sales are recognized, net of returns and trade discounts, on transfer of significant risk and rewards of ownership to the buyer, which generally coincide with the delivery of goods to the customers. The Company collects Goods and Service Tax (GST) and / or Tax Collected at source on behalf of the government and, therefore, these do not form a part of economic benefits flowing to the Company.

Hence, they are excluded from revenue.

Interest:

Revenue is recognised on a time proportion basis taking into account the amount outstanding and the rate applicable.

Service Income:

Income from service rendered is recognised based on the terms of the agreements as and when services are rendered and are net of Goods and Service Tax (GST)/ Service tax.

Dividend Income:

Dividend income from investments, if any, is accounted on the receipt basis.

Insurance claims

Insurance claims are accounted for on the basis of claims admitted / expected to be admitted and to the extent that the amount recoverable can be measured reliably and it is reasonable to expect ultimate collection.

(i) Borrowing Cost

Borrowing cost that are attributable to the acquisition, construction or production of qualifying assets are capitalized as part of the cost of such assets. A qualifying asset is one that necessarily takes a substantial period of time to get ready for its intended use. All other borrowing costs are charged to revenue.

(j) Employee benefits

Short-term employee benefits are recognized as an expense at the undiscounted amount in the profit & loss account of the year in which the related service is rendered.

Post-employment and other long term employee benefits are recognized as an expense in the profit & loss account for the year in which the liabilities are crystallized/accrued.

(k) Taxes on Income

Income tax expenses for the year comprises of current tax and deferred tax. Current tax provision is determined on the basis of taxable income computed as per the provisions of the Income Tax Act. Deferred tax is recognized for all timing differences that are capable of reversal in one or more subsequent periods subject to conditions of prudence and by applying tax rates that have been substantively enacted by the balance sheet date.

(l) Foreign Currency Translation

- i. Transaction denominated in foreign currencies are recorded at the exchange rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the year end are restated at closing rate.
- ii. Any exchange difference on account of settlement of foreign currency transaction and restatement of monetary assets and liabilities denominated in foreign currency is recognized in the statement of Profit & loss Account.

(m) Provision, Contingent Liabilities and Contingent Assets

Provisions involving substantial degree of estimation in measurement are recognized when there is a present obligation as a result of past events and it is probable that there will be an outflow of resources.

2. NOTES ON ACCOUNTS

- a) The financial statements including financial information have been prepared after making such regroupings and adjustments, considered appropriate to comply with the same. As result of these regroupings and adjustments, the amount reported in the financial statements/information may not necessarily be same as those appearing in the respective audited financial statements for the relevant years

b) Provisions, Contingent Liabilities and Contingent Assets (AS 29)

Contingent liabilities and commitments (to the extent not provided for). There are no contingent liabilities as on December 31, 2023, March 31, 2023, March 31, 2022 & March 31, 2021 except as mentioned in Annexure-XXXII, for any of the years/ stub period covered by the statements.

c) Related Party Disclosure (AS 18)

Related party transactions are reported as per AS-18 of Companies (Accounting Standards) Rules, 2006 or 2001 as may be applicable, as amended, in the Annexure – J of the enclosed financial statements.

d) Accounting for Deferred Taxes on Income (AS 22)

(₹ in lakhs)

Particulars	For the Period from 1 st April to 31 st December 2023	As at 31st March		
		2023	2022	2021
WDV as per Companies Act, 2013 (A)	988.50	983.94	737.56	593.62
WDV as per Income tax Act, 1961 (B)	719.84	766.64	570.76	452.79
Difference in WDV (A-B)	268.66	217.30	166.80	140.83
Timing Difference due to Provision for Gratuity (DTA) (C)	2.94	2.20	1.84	5.84
Total Timing Difference (D)	265.72	215.10	164.95	134.99
Deferred Tax (Asset)/ Liability (E)	73.92	59.84	45.89	35.10
Restated Closing Balance of Deferred Tax (Asset)/ Liability (E)	73.92	59.84	45.89	35.10
Deferred Tax (Assets)/ Liability as per Balance sheet of Previous Year	59.84	45.89	35.10	36.39
Deferred Tax (Assets)/ Liability charged to Profit & Loss	14.08	13.95	10.79	-1.30

- e) **Post Employment Benefits:** The Company has valued its obligations related to Gratuity as follows:

(₹ in lakhs)

I. ASSUMPTIONS	For the Period Ended on December 31, 2023	For the Period Ended on March 31, 2023	For the Period Ended on March 31, 2022	For the Period Ended on March 31, 2021
Discount Rate	7.25%	7.50%	7.50%	7.50%
Expected Rate of Salary Increase	5.00%	5.00%	5.00%	5.00%
Withdrawal Rate	10.00%	10.00%	10.00%	10.00%
Mortality	IALM 2012-14	IALM 2012-14	IALM 2012-14	IALM 2012-14
Retirement	60 Years	60 Years	60 Years	60 Years

II. CHANGE IN THE PRESENT VALUE OF DEFINED BENEFIT OBLIGATIONS	For the Period Ended on December 31, 2023	For the Period Ended on March 31, 2023	For the Period Ended on March 31, 2022	For the Period Ended on March 31, 2021
Defined Benefit Obligation at beginning of the year	9.89	7.69	5.84	5.84
Current Service Cost	1.89	1.85	1.57	0
Interest cost	0.56	0.58	0.44	0
Actuarial (Gains)/Losses on Obligations - Due to Change in Financial Assumptions	0.48	-0.23	-0.16	0
Actuarial (Gains)/Losses on Obligations - Due to Experience Adjustment	-	-	-	-
Benefits Paid	-	-	-	-
Defined Benefit Obligation as at end of the year	12.82	9.89	7.69	5.84
III. AMOUNT RECOGNIZED IN THE BALANCE SHEET:	For the Period Ended on December 31, 2023	For the Period Ended on March 31, 2023	For the Period Ended on March 31, 2022	For the Period Ended on March 31, 2021
Net liability as at beginning of the year	9.89	7.69	5.84	5.84
Net expense recognized in the Statement of Profit and Loss	2.94	2.20	1.84	0
Benefits Paid	0	0	0	0
Net liability as at end of the year	12.82	9.89	7.69	5.84
IV. EXPENSE RECOGNIZED:	For the Period Ended on December 31, 2023	For the Period Ended on March 31, 2023	For the Period Ended on March 31, 2022	For the Period Ended on March 31, 2021
Current Service Cost	1.89	1.85	1.57	0
Interest Cost	0.56	0.58	0.44	0
Actuarial (Gains)/Losses on Obligations - Due to Change in Financial Assumptions and Due to Experience Adjustment	0.48	-0.23	-0.16	0
Expense charged to the Statement of Profit and Loss	2.94	2.20	1.84	0.00
V. BALANCE SHEET RECONCILIATION:	For the Period Ended on December 31, 2023	For the Period Ended on March 31, 2023	For the Period Ended on March 31, 2022	For the Period Ended on March 31, 2021
Opening net liability	9.89	7.69	5.84	5.84
Expense as above	2.94	2.98	4.59	0
Provision Related to Previous Year booked as Prior Period Items	0	0	0	0
Return on Plan Assets	0	0	0	0
Benefits Paid	0	0	0	0
Net liability/(asset) recognized in the balance sheet	12.82	10.67	10.43	5.84

3. MATERIAL ADJUSTMENT TO THE RESTATED FINANCIAL STATEMENT

(i) Material Regrouping:

Appropriate adjustments have been made in the Restated Financial Statements of Assets and Liabilities, Profit and Losses and Cash Flows, wherever required, by reclassification of the corresponding items of income, expenses, assets and liabilities in order to bring them in line with the regroupings as per the audited financial statements of the company and the requirements of SEBI Regulations.

(ii) Material Adjustments:

The Summary of results of restatement made in the Audited Financial Statements for the respective period/years and its impact on the profit/ (loss) of the Company is as follows:

(₹ in lakhs)

Particulars	For the Period from 1 st April 2023 to 31 st December 2023	For the Period Ending 31 st March		
		2023	2022	2021
(A) Net Profits as per audited financial statements (A)	781.32	504.49	416.62	65.47
Add/(Less): Adjustments on account of -				
1) Difference on Account of Calculation in Provision for Income Tax	-	-	-	-
2) Difference on Account of Calculation in Deferred Tax	-3.45	0.56	-4.28	5.87
3) Difference on account of Calculation in Gratuity	-2.94	-2.20	-1.84	-5.84
4) Difference on Account of Prepaid Expenses	-	-	-	-
5) Difference on Account of Provision for outstanding Expenses	-	-	-	-
Total Adjustments (B)				
Restated Profit/ (Loss) (A+B)	774.93	502.85	410.50	65.50

(iii) Notes on Material Adjustments pertaining to prior years

- (a) **Difference on Account of Provision for Current tax:** Since the Restated profit has been changed so that the Provision for current tax is also got changed
- (b) **Difference on Account of Change in Deferred Tax:** Deferred tax is calculated on the difference of WDV as per Companies Act & income tax Act in Restated financials but in Audited financials the same has been calculated between difference of Depreciation. Further Deferred Tax has been calculated on Timing difference arises due to Provision for Gratuity which was not considered in Audited Financial Statements
- (c) **Difference on Account of Provision for Gratuity:** Provision for Gratuity is provided in Restated Financials Statement which was not provided in Audited Financial Statements
- (d) **Difference on Account of Change in Prepaid Expenses:** Expenses Related to Next Accounting Period is transferred to Prepaid Expenses
- (e) **Difference on Account of Outstanding Expenses:** Expenses related to current accounting period has been provided as provision for outstanding expenses in current year itself

Reconciliation Statement between Restated Reserve & Surplus affecting Equity due to Adjustment made in Restated Financial Statements:

(₹ in lakhs)

Particulars	For the Period from 1 st April 2023 to 31 st December 2023	As at March 31		
		2023	2022	2021
(A) Total Equity as per audited financial statements (A)	2291.26	1509.95	1005.45	588.83
Add/(Less): Restatement Adjustments (B)	-0.62%	-0.51%	-0.60%	0.00%
Total Equity as per Restated Financial Statements (A+B)	2277.15	1502.21	999.38	588.84

(f) Trade Payable Ageing Summary:

(₹ in lakhs)

31.12.2023					
Particulars	Outstanding for following periods from due date of payment / Invoice date				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
(i) MSME	-	-	-	-	-
(ii) Others	2101.94	127.48	65.24	-	2294.66
(iii) Disputed dues - MSME	-	-	-	-	-
(iv) Disputed dues – Others	-	-	-	-	-
Total	2101.94	127.48	65.24	-	2294.66

(₹ in lakhs)

31.03.2023					
Particulars	Outstanding for following periods from due date of payment / Invoice date				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
(i) MSME	-	-	-	-	-
(ii) Others	2229.04	196.38	34.82	-	2460.24
(iii) Disputed dues - MSME	-	-	-	-	-
(iv) Disputed dues – Others	-	-	-	-	-
Total	2229.04	196.38	34.82	-	2460.24

(₹ in lakhs)

31.03.2022					
Particulars	Outstanding for following periods from due date of payment / Invoice date				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
(i) MSME	-	-	-	-	-
(ii) Others	1525.72	133.44	45.56	-	1704.71
(iii) Disputed dues - MSME	-	-	-	-	-
(iv) Disputed dues – Others	-	-	-	-	-
Total	1525.72	133.44	45.56	-	1704.71

(₹ in lakhs)

31.03.2021					
Particulars	Outstanding for following periods from due date of payment / Invoice date				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
(i) MSME	-	-	-	-	-
(ii) Others	785.49	11.18	-	-	796.66
(iii) Disputed dues - MSME	-	-	-	-	-
(iv) Disputed dues – Others	-	-	-	-	-
Total	785.49	11.18	-	-	796.66

(g) Trade Receivable Ageing Summary

(₹ in lakhs)

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
31.12.2023						
Undisputed Trade Receivable – considered good	2061.56	717.01	147.66	40.28	-	2966.51
Undisputed Trade Receivable – considered doubtful	-	-	-	-	-	-
Disputed Trade Receivable – considered good	-	-	-	-	-	-
Disputed Trade Receivable – considered doubtful	-	-	-	-	-	-
Total	2061.56	717.01	147.66	40.28	-	2966.51
31.03.2023						
Undisputed Trade Receivable – considered good	1444.91	295.81	135.80	117.28	-	1993.80
Undisputed Trade Receivable – considered doubtful	-	-	-	-	-	-
Disputed Trade Receivable – considered good	-	-	-	-	-	-
Disputed Trade Receivable – considered doubtful	-	-	-	-	-	-
Total	1444.91	295.81	135.80	117.28	-	1993.80
31.03.2022						
Undisputed Trade Receivable – considered good	1784.64	147.56	70.19	203.80	-	2206.19

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
Undisputed Trade Receivable – considered doubtful	-	-	-	-	-	-
Disputed Trade Receivable – considered good	-	-	-	-	-	-
Disputed Trade Receivable – considered doubtful	-	-	-	-	-	-
Total	1784.64	147.56	70.19	203.80	-	2206.19
31.03.2021						
Undisputed Trade Receivable – considered good	571.28	263.74	15.80	23.80	40.85	915.47
Undisputed Trade Receivable – considered doubtful	-	-	-	-	-	-
Disputed Trade Receivable – considered good	-	-	-	-	-	-
Disputed Trade Receivable – considered doubtful	-	-	-	-	-	-
Total	571.28	263.74	15.80	23.80	40.85	915.47

(h) Restated Statement of Accounting Ratios:

(₹ in lakhs)

Sr. No.	Particular	Numerator	December 31, 2023	March 31, 2023	March 31, 2022	March 31, 2021	Reason for Movements
		Denominator					
(a)	Current Ratio	Current Assets Current Liabilities	1.42	1.25	1.17	1.10	Change is less than 25
(b)	Debt-Equity Ratio	Debt Equity	1.68	1.32	1.42	0.41	Due to increase in equity as compared to the rate of increase in borrowings.
(c)	Debt Service Coverage Ratio	Net Operating Income Total Debt Service	0.23	0.17	0.15	0.19	Due to increase in earnings available for service of debt consequent to increase in Net Profit.
(d)	Return on Equity Ratio	Profit After Tax Average Shareholders' Equity	34.03%	40.20%	51.69%	11.78%	This ratio is decreased during 2022 and 2023 due to increase in Average shareholder equity getting increased not in the same ratio as profits. Further during period ended September 2023, it got increased due to increased profits.
(e)	Trade Receivables turnover ratio (in times)	Net Credit Sales Average Trade Receivables	2.09	2.94	3.81	3.68	Due to increase in Net sales and corresponding increase in Accounts Receivable for the period.
(f)	Trade Payable Turnover Ratio (in times)	Net Credit Purchases Average Trade Payables	1.74	2.00	3.54	2.80	Due to decrease in Cost of Material Consumed but increase in Accounts Payable for the period.
(g)	Net capital turnover ratio (in times)	Turnover Net Working Capital	4.95	8.51	15.27	26.93	Due to increase in working capital as compared to the previous period.
(h)	Net profit ratio	Profit After Tax	12.48%	8.16%	6.90%	2.16%	

Sr. No.	Particular	Numerator	December 31, 2023	March 31, 2023	March 31, 2022	March 31, 2021	Reason for Movements
		Denominator					
		Total Sales					Due to increase in Net Profit.
(i)	Return on Capital employed	Operating Profit	41.86%	38.03%	44.65%	11.82%	Due to increase in Capital Employed as compared to the previous period.
		Total Capital Employed					
(j)	Return on investment.	Profit After Tax	0.00%	0.00%	0.00%	0.00%	Change is less than 25%
		Initial Value of Investments					

RESULTS OF OUR OPERATION

The following discussion on results of operations should be read in conjunction with the Restated Financial Statements of our Company for the period ended December 31, 2023 and financial years ended on 2023, 2022 and 2021:

(₹ in lakhs)

Particulars	For the Period ended/ For the Year Ended 31st March							
	December 31, 2023	% of Total Revenue	2023	% of Total Revenue	2022	% of Total Revenue	2021	% of Total Revenue
Revenue:								
Revenue from Operations	6207.98	99.84%	6,164.06	99.64%	5,948.39	99.90%	3,036.35	99.76%
Other income	9.85	0.16%	22.54	0.36%	5.81	0.10%	7.20	0.24%
Total revenue	6,217.83	100.00%	6,186.60	100.00%	5,954.20	100.00%	3,043.55	100.00%
Expenses:								
Cost of Material Consumed	3,996.13	64.27%	4,173.79	67.47%	4,427.41	74.36%	2,443.19	80.27%
Purchase of Stock in Trade	-	-	-	-	-	-	-	-
Increase/ Decrease in Stock in Trade	(9.65)	(0.16%)	7.77	0.13%	21.97	0.37%	3.28	0.11%
Employees Benefit Expenses	329.96	5.31%	356.79	5.77%	346.44	5.82%	253.08	8.32%
Finance costs	62.50	1.01%	53.84	0.87%	29.65	0.50%	30.71	1.01%
Depreciation and Amortization	41.61	0.67%	54.98	0.89%	46.03	0.77%	39.38	1.29%
Other expenses	682.91	10.98%	843.47	13.63%	506.02	8.50%	194.95	6.41%
Total Expenses	5103.46	82.08%	5,490.64	88.75%	5,377.52	90.31%	2,964.59	97.41%
Profit before exceptional and extraordinary items and tax	1114.37	17.92%	695.96	11.25%	576.68	9.69%	78.95	2.59%
Exceptional Items	-	-	-	-	-	-	-	-
Profit before extraordinary items and tax	1114.37	17.92%	695.96	11.25%	576.68	9.69%	78.95	2.59%
Extraordinary items	-	-	-	-	-	-	-	-
Profit before tax	1114.37	17.92%	695.96	11.25%	576.68	9.69%	78.95	2.59%
Tax expense:								
Current tax	325.36	5.23%	179.16	2.90%	155.39	2.61%	14.74	0.48%
Earlier year Tax	-	-	-	-	-	-	-	-
Deferred Tax	14.08	0.23%	13.95	0.23%	10.79	0.18%	(1.29)	(0.04%)
Net Total Tax Expenses	339.44	5.46%	193.11	3.12%	166.18	2.79%	13.45	0.44%
Profit /(Loss) for the period from continuing operations	774.93	12.46%	502.85	8.13%	410.50	6.89%	65.50	2.15%

KEY COMPONENTS OF COMPANY'S PROFIT AND LOSS STATEMENT

Revenue from operations: Revenue from operations mainly consists from Sales of products.

Other Income: Other Income Consist of Discount and Rebates, Subsidy, Interest Income, Refund of Duty Drawback, Profit on Sale of Fixed Assets, Interest on Electricity S.D and Rate difference.

Expenses: Company's expenses consist of, Cost of Material Consumed, Increase/Decrease in Stock in trade, Employee Benefit Expenses, Finance Cost, Depreciation and amortisation expense & Other Expenses.

Cost of Material Consumed: Cost of Material Consumed consist of Opening Stock, Purchase of Raw Material, Direct Expenses & Closing Stock.

Increase/Decrease in inventories: Changes in inventories of Finished Goods, Semi Finished Goods & Stock in Trade consist of difference between opening & closing Value of Stock.

Employee Benefits Expense: Employee benefit expenses includes Salaries and Wages, Contribution to provident and other funds, Bonus, Managerial Remuneration, Gratuity Expenses and Staff welfare expenses.

Finance Cost: Finance Cost includes Interest paid on borrowings, delayed payment of statutory dues& Bank Charges.

Depreciation and Amortization Expense: We recognize Depreciation and Amortization expense on a SLM Basis as per the rates set forth in the Companies Act, 2013/ Companies Act, 1956, as applicable.

Other Expenses: Other expenses include Factory Expenses, Power & Fuel, Repair and Maintenance Expenses, Freight Outward, etc.

REVIEW OF OPERATIONS FOR THE PERIOD ENDED ON DECEMBER 31, 2023:

Revenue from Operation

Revenue from operations for the period ended on December 31, 2023 amounting to ₹6207.98 lakhs represent 99.84% of Total Revenue.

Other Income

Other Income consisting of Interest on Deposits and rate differences amounting to ₹9.85 lakhs represent 0.16% of Total Revenue.

Cost of Material Consumed

Cost of Material Consumed for the period ended on December 31, 2023 amounting to ₹3996.13 lakhs represents 64.27% of Total Revenue.

Increase/ Decrease in Stock in trade

(Increase)/ Decrease in Stock in trade amounting to (₹9.65) lakhs represent (0.16%) of Total Revenue.

Employee Benefit Cost

Employee benefit expenses includes Salaries and Wages, Managerial Remuneration, Contribution to PF and other funds, Gratuity Expenses etc amounting to ₹329.96 Lakhs represents 5.31% of Total Revenue.

Finance Cost

Finance Cost includes Interest on Borrowings, Bank Charges and interest on delay in statutory dues payment amounting to ₹62.50 Lakhs represents 1.01% of Total Revenue.

Depreciation and Amortization

Depreciation is charged on WDV method amounting to ₹41.61 Lakhs represents 0.67% of Total Revenue.

Other Expenses

Other expenses include factory expenses, insurance expenses, power and fuel, repairs and maintenance, legal, professional and consultancy fees, printing and stationery, travelling expenses, freight outward etc. amounting to ₹682.91 lakhs represent 10.98% of Total Revenue.

Profit Before Tax

The Profit before tax for the period ended on December 31, 2023 was ₹1,114.37 lakhs representing 17.92% of Total Revenue.

Tax Expenses

Tax Expenses consisting of Current Tax & Deferred Tax for the period ended on December 31, 2023 was ₹325.36 lakhs and ₹14.08 lakhs respectively, representing 5.23% and 0.23% respectively of Total Revenue.

Profit After Tax

The Profit after tax for the period ended on December 31, 2023 was ₹774.93 lakhs representing 12.46% of Total Revenue.

Our Company achieved its revenue by positioning it favorably to negotiate prices for sourcing raw materials at relatively cheaper rates, thereby receiving quantity/trade discounts and cash discounts. In the current period, the effect of the learning curve remained constant, as evidenced by the percentage of employee costs to total revenue, which was 5.31% in the period ended December 31, 2023, and 5.77% in FY 2023. One of the reasons to be considered for the increase in PAT margin in December 31, 2023 as compared with FY 2022-2023 was the payment of a penalty for delay in delivery amounting to Rs 214.85 Lakhs in FY 2022-2023. Considering all these factors and the constant gross margin of 30%, the company booked a profit of 12.46%

FISCAL 2023 COMPARED WITH FISCAL 2022

Revenue from Operation

Revenue from operations increased by 3.63% from ₹5,948.39 lakhs in Fiscal 2022 to ₹6,164.06 lakhs in Fiscal 2023. This increase was primarily due to the rise in sales of products during the year, notably driven by increased orders from government departments in Madhya Pradesh. Revenue generated from these departments rose from ₹1,906.14 lakhs in fiscal 2022 to ₹3119.75 lakhs in fiscal 2023.

Other Income

Other income had increased from ₹5.81 lakhs in Fiscal 2022 to ₹22.54 lakhs in Fiscal 2023 due to increase in interest on deposits, discount and rebates received and subsidy received. The company's interest on deposits in the year 2022 was ₹3.70 lakhs which increased in the year 2023 to ₹9.75 lakhs. Further in the year 2023 the company has received subsidy amounting to ₹12.28 lakhs which was NIL in the fiscal year 2022.

Cost of Material Consumed

Cost of Material Consumed had decreased by 5.73% from ₹4,427.41 lakhs in Fiscal 2022 to ₹4,173.79 lakhs in Fiscal 2023. This decrease was primarily due to making bulk orders and thus received quantity discounts during the year.

Increase/ Decrease in stock in trade

Changes in Inventories of Finished Goods had decreased by 64.63% from ₹21.97 lakhs in Fiscal 2022 to ₹7.77 lakhs in Fiscal 2023.

Employee Benefit Expenses

Employee benefit expenses had increased by 2.99% from ₹346.44 lakhs in Fiscal 2022 to ₹356.79 lakhs in Fiscal 2023. This increase was primarily due to increase in contribution to provident and other funds from ₹4.82 lakhs in year 2022 to ₹6.46 lakhs in year 2023, increase in managerial remuneration from ₹45.00 lakhs in year 2022 to ₹80.00 lakhs in year 2023 & increase in gratuity expenses from ₹1.84 lakhs in year 2022 to ₹2.20 lakhs in year 2023.

Finance Cost

Finance Cost had increased by 81.59% from ₹29.65 lakhs in Fiscal 2022 to ₹53.84 lakhs in Fiscal 2023. This increase was primarily due to increase in Interest on borrowings from ₹26.38 lakhs in Fiscal 2022 to ₹34.27 lakhs in Fiscal 2023 and increase in the interest on delay payment of statutory dues from ₹0.92 lakhs in Fiscal 2022 to ₹17.70 lakhs in Fiscal 2023.

Depreciation and Amortization Expenses

Depreciation had increased by 19.44% from ₹46.03 lakhs in Fiscal 2022 to ₹54.98 lakhs in Fiscal 2023. This was primarily due to capital expenditure of ₹ 306.72 Lakhs during Fiscal 2023.

Other Expenses

In Fiscal 2023, other expenses experienced a substantial increase of 66.69%, surging from ₹506.02 lakhs in Fiscal 2022 to ₹843.47 lakhs. This escalation stemmed from several contributing factors. Firstly, factory expenses rose by ₹1.44 lakhs, while analytical expenses saw a notable uptick of ₹12.41 lakhs. Similarly, insurance expenses surged by ₹14.81 lakhs, and power and fuel expenses increased by ₹2.89 lakhs. Moreover, business promotion expenses climbed by ₹8.47 lakhs, and testing charges escalated by ₹10.87 lakhs. Additionally, freight outward expenses rose significantly, amounting to ₹146.32 lakhs. Alongside these operational cost increases, the company also incurred fines and penalties totalling ₹214.85 lakhs due to delays in scheduled delivery of goods to customers. This detailed breakdown underscores the diverse range of factors contributing to the rise in other expenses during Fiscal 2023, offering valuable insight into the company's expenditure dynamics and areas of focus.

Tax Expenses

The Company's tax expenses had increased by ₹26.93 lakhs from ₹166.18 lakhs in the Fiscal 2022 to ₹193.11 lakhs in Fiscal 2023. This was primarily due to increase in current tax expenses during the year which got increased from ₹155.39 Lakhs in the year 2022 to ₹179.16 lakhs in the year 2023 & increase in Deferred Tax Expenses from ₹10.79 lakhs in the year 2022 to ₹13.95 lakhs in the year 2023.

Profit after Tax

In FY 2023, the rise in margin was specifically due to the increase in revenue, as the company expanded its sales in the states of Madhya Pradesh and Uttar Pradesh. The company kept its gross margin constant at 30%. Since the company received repetitive orders, the initial fixed costs incurred for product development were not required in the current period. This can be observed as the employee costs were reduced to 5.77%, compared to 5.82% in FY 2022. Additionally, the cost of material consumed decreased to 67.47% in FY 2023 from 74.63% in FY 2022.

FISCAL 2022 COMPARED WITH FISCAL 2021

Revenue from Operation

In Fiscal 2021, revenue from operations amounted to ₹3,036.35 lakhs. In Fiscal 2022, this figure increased by 95.91% to ₹ 5,948.39 lakhs. The increase was primarily due to higher sales of products during the year, driven by increased orders from government departments in Uttar Pradesh and Madhya Pradesh. In Fiscal 2021, revenue generated from Uttar Pradesh and Madhya Pradesh was ₹250.83 lakhs and ₹1,315.68 lakhs respectively. These figures increased in Fiscal 2022 to ₹2,596.77 lakhs and ₹1,906.14 lakhs respectively.

Therefore, the increase in revenue from operations in Fiscal 2022 compared to Fiscal 2021 was significant in both Uttar Pradesh and Madhya Pradesh. Specifically, revenue from Uttar Pradesh increased by ₹2,345.94 lakhs, while revenue from Madhya Pradesh increased by ₹590.46 lakhs

Other Income

Other income had decreased by 19.31% from ₹7.20 lakhs in Fiscal 2021 to ₹5.81 lakhs in Fiscal 2022. This was primarily due to decrease in Duty Drawback by ₹1.60 Lakhs and in rate differences by ₹2.28 Lakhs.

Cost of Material Consumed

Cost of Material Consumed in the Fiscal 2022 was increased by 81.21% from ₹2443.19 lakhs in Fiscal 2021 to ₹4427.41 lakhs in Fiscal 2022. This decrease was primarily due to making bulk orders, thus received quantity discounts during the year.

Increase/Decrease in stock in trade

Changes in Inventories of Finished Goods was 569.82% from ₹3.28 lakhs in Fiscal 2021 to ₹21.97 lakhs in Fiscal 2022.

Employee Benefit Expenses

Employee benefit expenses had increased by 36.89% from ₹253.08 lakhs in Fiscal 2021 to ₹346.44 lakhs in Fiscal 2022. This increase was primarily due to increase in salary & wages from ₹189.27 lakhs in year 2021 to ₹269.71 lakhs in year 2022 and increase in bonus from ₹6.50 lakhs in year 2021 to ₹20.00 lakhs in year 2022.

Finance Cost

Finance Cost had decreased by 3.45% from ₹30.71 lakhs in Fiscal 2021 to ₹29.65 lakhs in Fiscal 2022. This decrease was primarily due to decrease in interest on borrowings by ₹2.09 lakhs in Fiscal 2022.

Depreciation and Amortization Expenses

Depreciation had increased by 16.89% from ₹39.38 lakhs in Fiscal 2021 to ₹46.03 lakhs in Fiscal 2022. This was primarily due to capital expenditure of ₹ 193.07 Lakhs during Fiscal 2022.

Other Expenses

Other expenses had increased by 159.56% from ₹194.95 lakhs in Fiscal 2021 to ₹506.02 lakhs in Fiscal 2022. The increase was primarily due to increase in factory expenses by ₹10.07 lakhs, power and fuel by ₹17.94 lakhs, auditor fees by ₹1.55 lakhs, professional and consultancy fees by ₹18.47 lakhs, testing charges by ₹7.80 lakhs, legal fees by ₹2.60 lakhs, fines and penalties by ₹9.33 lakhs, bad debts by ₹90.08, commission by ₹102.52 lakhs, freight outward by ₹48.11 lakhs etc. in Fiscal 2022.

Tax Expenses

The Company's tax expenses had increased by ₹152.73 lakhs from ₹13.45 lakhs in the Fiscal 2021 to ₹166.18 lakhs in Fiscal 2022. This was primarily due to increase in Current Tax Expenses from ₹14.74 Lakhs in Fiscal 2021 to ₹155.39 Lakhs in Fiscal 2022. The Current Tax Expenses has been increased due to higher profit during the year.

Profit after Tax

The profit margin for FY 2021 was significantly lower compared to FY 2022, FY 2023, and the stub period ending December 31, 2023. This decline can be attributed to several factors. Firstly, the company experienced minimal operations during FY 2020-21, likely due to the impact of COVID-19. Secondly, the cost of raw materials was substantially higher during this period. Lastly, despite low sales, the company incurred fixed costs, including rent and salaries. These factors collectively contributed to the decrease in profit margin. However, conditions improved in subsequent years, leading to higher profit margins

In Fiscal Year 2022, as the company gradually recovered from the pandemic, the costs of raw materials and packaging materials began to decline marginally. Additionally, there was a substantial increase in demand for medicines, likely due to heightened awareness surrounding health issues. These factors contributed to a significant rise in revenue during the fiscal period.

Moreover, as demand increased, the company was able to enhance its gross margin, which had previously ranged between 20% and 25%, to 30%. This improvement in gross margin was primarily attributed to the combination of reduced material costs and heightened sales.

Consequently, the company's overall margin for Fiscal 2022 surged from 2.15% to 6.89%. This marked increase underscores the company's successful adaptation to evolving market conditions and its ability to capitalize on emerging opportunities.

CASH FLOWS

(₹ in lakhs)

Particulars	December 31, 2023	March 31, 2023	March 31, 2022	March 31, 2021
Net Cash from Operating Activities	0.39	363.07	345.51	104.72
Net Cash from Investing Activities	(41.88)	(296.97)	(188.82)	(119.67)
Net Cash from Financing Activities	(203.66)	26.67	(41.40)	3.83

Cash Flows from Operating Activities

For the period ended December 31, 2023

Our net cash used from operating activities was ₹0.39 Lakhs for the period ended December 31, 2023. Our operating profit before working capital changes was ₹ 1,211.78 Lakhs for the period ended December 31, 2023 which was primarily adjusted against income tax of (₹173.85) Lakhs, increase in inventories ₹ (41.61) Lakhs, increase in trade receivables ₹ (972.72) Lakhs, decrease in short term loans & advances ₹ 136.01 Lakhs, increase in other current assets ₹ (0.01) Lakhs, increase in trade payables ₹ (165.58) Lakhs, decrease in other current liabilities ₹ 6.37 Lakhs.

For the financial year ended March 31, 2023

Our net cash used from operating activities was ₹ 363.08 Lakhs for the financial year ended March 31, 2023. Our operating profit before working capital changes was ₹ 796.83 Lakhs for the financial year ended March 31, 2023 which was primarily adjusted against income tax of ₹ (156.25) Lakhs, increase in inventories ₹ (1,007.00) Lakhs, decrease in trade receivables ₹ 212.39 Lakhs, increase in short term loans & advances ₹ (33.68) Lakhs, increase in other current assets ₹ (0.06) lakhs, decrease in trade payables ₹ 755.53 Lakhs, increase in other current liabilities ₹ (204.68) Lakhs.

For the financial year ended March 31, 2022

Our net cash used from operating activities was ₹ 345.49 Lakhs for the financial year ended March 31, 2022. Our operating profit before working capital changes was ₹ 650.50 Lakhs for the financial year ended March 31, 2022 which was primarily adjusted against income tax of ₹ (26.60) Lakhs, increase in inventories ₹ (25.92) Lakhs, increase in trade receivables ₹ (1,290.72) Lakhs, increase in short term loans & advances ₹ (54.69) Lakhs, decrease in other current assets ₹ 10.55 lakhs, increase in trade payables ₹ 908.04 Lakhs, increase in other current liabilities ₹ 174.32 Lakhs.

For the financial year ended March 31, 2021

Our net cash used from operating activities was ₹ 104.73 Lakhs for the financial year ended March 31, 2021. Our operating profit before working capital changes was ₹ 153.68 Lakhs for the financial year ended March 31, 2021 which was primarily adjusted against income tax of ₹ (41.01) Lakhs, decrease in inventories ₹ 341.17 Lakhs, increase in trade receivables ₹ (181.19) Lakhs, decrease in short term loans & advances ₹ 5.82 Lakhs, increase in other current assets ₹ (0.99) lakhs, decrease in trade payables ₹ (153.73) Lakhs, decrease in other current liabilities ₹ (19.02) Lakhs.

Cash Flows from Investment Activities

For the period ended December 31, 2023

Our net cash flow from investing activities was ₹(41.88) lakhs. This was mainly on account of Purchase of fixed assets & including intangible assets of ₹ (51.52) lakhs and interest received of ₹ 9.64 lakhs.

For the financial year ended March 31, 2023

Our net cash flow from investing activities was ₹ (296.97) lakhs. This was mainly on account of Purchase of fixed assets & including intangible assets of ₹ (306.72) lakhs and interest received of ₹ 9.75 lakhs.

For the financial year ended March 31, 2022

Our net cash flow from investing activities was ₹ (188.82) lakhs. This was mainly on account of Purchase of fixed assets & including intangible assets of ₹ (193.07) lakhs, Sale of fixed assets & including intangible assets of ₹ 0.55 lakhs and interest received of ₹ 3.70 lakhs.

For the financial year ended March 31, 2021

Our net cash flow from investing activities was ₹ (119.67) lakhs. This was mainly on account of Purchase of fixed assets & including intangible assets of ₹ (120.70) lakhs and interest received of ₹ 1.03 lakhs.

Cash Flows from Financing Activities

For the period ended December 31, 2023

Our net cash flow from financing activities was ₹ (203.66) lakhs. This was on account of proceeds from Long Term borrowings of ₹(63.93) lakhs, & Short-Term Borrowings of ₹ 114.90 lakhs, issue of share capital of ₹345.00 security deposits of ₹ (537.13) lakhs and interest paid of ₹ (62.50) lakhs.

For the financial year ended March 31, 2023

Our net cash flow from financing activities was ₹ 26.67 lakhs. This was on account of proceeds from Long Term borrowings of ₹ 79.21 lakhs, & Short-Term Borrowings of ₹17.94 lakhs, security deposits of ₹ (16.64) lakhs and interest paid of ₹ (53.84) lakhs.

For the financial year ended March 31, 2022

Our net cash flow from financing activities was ₹(41.40) lakhs. This was on account of proceeds from Long Term borrowings of ₹ 18.06 lakhs, & Short-Term Borrowings of ₹(9.55) lakhs, security deposits of ₹ (20.26) lakhs and interest paid of ₹(29.65) lakhs.

For the financial year ended March 31, 2021

Our net cash flow from financing activities was ₹ 3.83 lakhs. This was on account of proceeds from Long Term borrowings of ₹ 4.77 lakhs, & Short-Term Borrowings of ₹ 23.98 lakhs, security deposits of ₹ 5.79 lakhs and interest paid of ₹ (30.71) lakhs.

RELATED PARTY TRANSACTIONS

Related party transactions with certain of our promoter, directors and their entities and relatives primarily relate to remuneration, salary, commission and issue of Equity Shares. For further details of related parties kindly refer chapter titled “Restated Financial Statements” beginning on page 196 of this Prospectus.

OFF-BALANCE SHEET ITEMS

We do not have any other off-balance sheet arrangements, derivative instruments or other relationships with any entity that have been established for the purposes of facilitating off-balance sheet arrangements.

QUALIFICATIONS OF THE STATUTORY AUDITORS WHICH HAVE NOT BEEN GIVEN EFFECT TO IN THE RESTATED FINANCIAL STATEMENTS

There are no qualifications in the audit report that require adjustments in the Restated Financial Statements.

QUALITATIVE DISCLOSURE ABOUT MARKET RISK

Financial Market Risks

Market risk is the risk of loss related to adverse changes in market prices, including interest rate risk. We are exposed to interest rate risk, inflation and credit risk in the normal course of our business.

Interest Rate Risk

Our financial results are subject to changes in interest rates, which may affect our debt service obligations in future and our access to funds.

Effect of Inflation

We are affected by inflation as it has an impact on the salary, wages, etc. In line with changing inflation rates, we rework our margins so as to absorb the inflationary impact.

Credit Risk

We are exposed to credit risk on monies owed to us by our customers. If our customers do not pay us promptly, or at all, we may have to make provisions for or write-off such amounts.

OTHER MATTERS

Details of Default, if any, Including Therein the Amount Involved, Duration of Default and Present Status, in Repayment of Statutory Dues or Repayment of Debentures or Repayment of Deposits or Repayment of Loans from any Bank or Financial Institution

Except as disclosed in chapter titled “*Restated Financial Statements*” beginning on page 196 of this Prospectus, there have been no defaults in payment of statutory dues or repayment of debentures and interest thereon or repayment of deposits and interest thereon or repayment of loans from any bank or financial institution and interest thereon by the Company.

Material Frauds

There are no material frauds, as reported by our statutory auditor, committed against our Company, in the last three Fiscals.

Unusual or infrequent events or transactions

Except as described in this Prospectus, during the period/ years under review there have been no transactions or events, which in our best judgment, would be considered “unusual” or “infrequent”.

Significant Economic Changes that Materially Affected or are Likely to Affect Income from Continuing Operations

Indian rules and regulations as well as the overall growth of the Indian economy have a significant bearing on our operations. Major changes in these factors can significantly impact income from continuing operations. There are no significant economic changes that materially affected our Company’s operations or are likely to affect income from continuing operations except as described in chapter titled “*Risk Factors*” beginning on page 30 of this Prospectus.

Known trends or uncertainties that have had or are expected to have a material adverse impact on revenue or income from continuing operations

Other than as described in the section titled “*Risk Factors*” and chapter titled “*Management’s Discussion and Analysis of Financial Conditions and Results of Operations*”, beginning on page 30 and 199 of this Prospectus respectively to our knowledge there are no known trends or uncertainties that have or had or are expected to have a material adverse impact on revenues or income of our company from continuing operations.

Future relationship between Costs and Income

Other than as described in the section titled “*Risk Factors*” beginning on page 30 of this Prospectus, to our knowledge there are no factors, which will affect the future relationship between costs and income or which are expected to have a material adverse impact on our operations and finances.

The extent to which material increases in revenue or income from operations are due to increased volume, introduction of new products or services or increased prices

Changes in revenue in the last three financial years are as explained in the part “*Financial Year 2022-23 compared with financial year 2021-22 and Financial Year 2021-22 Compared with Financial Year 2020-21*” above.

Significant dependence on a single or few Suppliers or Customers

Significant proportion of our purchases have historically been derived from a limited number of suppliers. The % of Contribution of our supplier’s vis a vis the total purchases for the period ended December 31, 2023 and for the financial year ended March 31, 2023, 2022 and 2021 are as follows:

(₹ in lakhs)

Particulars	Suppliers							
	December 31, 2023		March 31, 2023		March 31, 2022		March 31, 2021	
	Amount	%	Amount	%	Amount	%	Amount	%
Top 5	1671.04	41.48	1,377.77	21.93	1,113.92	24.90	617.82	29.36
Top 10	2,526.88	62.73	1,700.88	32.78	1,339.98	29.94	707.81	33.62

Significant proportion of our total revenue have historically been derived from a limited number of customers. The % of Contribution of our Customers vis a vis the revenue from operations for the period ended December 31, 2023 and for the financial year ended March 31, 2023, 2022 and 2021 are as follows:

(₹ in lakhs)

Particulars	Customer							
	December 31, 2023		March 31, 2023		March 31, 2022		March 31, 2021	
	Amount	%	Amount	%	Amount	%	Amount	%
Top 5	5,807.98	93.56	5,339.17	86.62	4,516.79	75.93	1,185.62	39.05
Top 10	6,030.82	97.15	5,863.68	95.13	5,132.82	86.29	1,689.58	55.65

Status of any publicly announced new products or business segments

Please refer to the chapter titled “Our Business” beginning on page 128 of this Prospectus for new products or business segments.

The extent to which the business is seasonal

Our business is not seasonal in nature.

Competitive Conditions

We operate in a competitive atmosphere. Some of our competitors may have greater resources than those available to us. While product quality, brand value, distribution network, etc are key factors in client decisions among competitors, however, reliability and competitive pricing is the deciding factor in most cases. We face fair competition from both organized and unorganized players in the market.

We believe that our experience, and reliability record with our customers will be key to overcome competition posed by such organized and unorganized players. Although, a competitive market, there are not enough number of competitors offering services similar to us. We believe that we are able to compete effectively in the market with our quality of services and our reputation. We believe that the principal factors affecting competition in our business include client relationships, reputation, and the relative quality and price of the services.

SECTION VIII – LEGAL AND OTHER INFORMATION

OUTSTANDING LITIGATIONS AND MATERIAL DEVELOPMENTS

Except as stated below there is no (i) pending criminal litigation involving our Company, Directors, Promoter or Group Companies; (ii) actions taken by statutory or regulatory authorities involving our Company, Directors, Promoter or Group Companies; (iii) outstanding claims involving our Company, Directors, Promoter or Group Companies for any direct and indirect tax liabilities; (iv) outstanding proceedings initiated against our Company for economic offences; (v) defaults or non-payment of statutory dues by our Company; (vi) material fraud against our Company in the last five years immediately preceding the year of this Prospectus; (vii) inquiry, inspection or investigation initiated or conducted under the Companies Act 2013 or any previous companies law against our Company during the last five years immediately preceding the year of this Prospectus and if there were prosecutions filed (whether pending or not); (viii) fines imposed or compounding of offences for our Company in the last five years immediately preceding the year of this Prospectus; (ix) litigation or legal action against our Promoter by any ministry or Government department or statutory authority during the last five years immediately preceding the year of this Prospectus; (x) pending litigations involving our Company, Directors, Promoter, Group Companies or any other person, as determined to be material by the Company's Board of Directors in accordance with the SEBI (ICDR) Regulations; or (xi) outstanding dues to creditors of our Company as determined to be material by our Company's Board of Directors in accordance with the SEBI (ICDR) Regulations and dues to small scale undertakings and other creditors.

For the purpose of material litigation in (x) above, our Board has considered and adopted the following policy on February 02, 2024, materiality with regard to outstanding litigations to be disclosed by our Company in this Prospectus:

- a) All criminal proceedings, statutory or regulatory actions and taxation matters, involving our Company, Promoter, Directors, or Group Companies, as the case may be shall be deemed to be material;
- b) All pending litigation involving our Company, Promoter, Directors, or Group Companies as the case may be, other than criminal proceedings, statutory or regulatory actions and taxation matters, would be considered 'material' (a) the monetary amount of claim by or against the entity or person in any such pending matter(s) is in excess of 10% of the revenue of the Company for the most recent audited fiscal period;
- c) Notices received by our Company, Promoter, Directors, or Group Companies, as the case may be, from third parties (excluding statutory/regulatory authorities or notices threatening criminal action) shall, in any event, not be evaluated for materiality until such time that the Company / Directors / Promoter / Group Companies, as the case may be, are impleaded as parties in proceedings before any judicial forum.
- d) As per the materiality policy adopted by the Board of our Company in its meeting held on February 02, 2024, creditors of our Company The outstanding dues to creditors in excess of 10% of the trade payables of our company as per the audited previous full year financial statements will be considered material. Details of outstanding dues to creditors (including micro and small enterprises as defined under the Micro, Small and Medium Enterprises Development Act, 2006) as required under the SEBI Regulations have been disclosed on our website at www.questlabltd.com

Our Company, our Promoter and/or our Directors, have not been declared as wilful defaulters by the RBI or any governmental authority, have not been debarred from dealing in securities and/or accessing capital markets by the SEBI and no disciplinary action has been taken by the SEBI or any stock exchanges against our Company, our Promoter or our Directors, that may have a material adverse effect on our business or financial position, nor, so far as we are aware, are there any such proceedings pending or threatened.

OUTSTANDING TAXATION MATTERS INVOLVING OUR COMPANY, DIRECTORS, PROMOTER AND SUBSIDIARIES

PART 1: LITIGATION RELATING TO OUR COMPANY

A. FILED AGAINST OUR COMPANY

1) Litigation involving Criminal Laws

- (i) **The State of Andhra Pradesh (Represented by Drug Inspector) (Complainant) V/s. 1. M/s. Quest Laboratories Pvt. Ltd.; 2. Mr. Anil Sabarwal;**

P.R.C. No. 27/2013 filed and pending with the Honourable Court of III Additional Judicial First-Class Magistrate, Kakinada and later transferred to Honourable District & Sessions Judge, East Godavari, Rajahmahendravaram vide case no. (SC/159/2018)

As stated, M/s. Quest Laboratories Pvt. Ltd (the Company) represented by Mr. Anil Sabarwal, director is a manufacturer of Drugs and is having a manufacturing license under Form 25 & 28 bearing no. 25/18/98.

The complainant herein claims to have taken a sample on August 19, 2010 of Polyfol Forte tablest, Batch no. 13, Mfg. Date: 07/2010, Exp. Date: 12/2011, manufactured by the company, for test / analysis from the Central Drug Stores, APHMHIDC, 23-1-73/A, Old Bus Stand, Kakinada and the sample was sent to Govt. Analyst, drugs Control Laboratory, Vijaywada, as per the provisions of Drugs and Cosmetics Act, 1940. As alleged, the test report of the said sample received on June 29, 2011 declared the sample of non-standard quality for the reason that the sample did not meet the I.P. specifications in respect of Description. Upon receiving confirmation from the pharmacist of the Central Drug Store in question of having received the said drug from M/s. Quest Laboratories Pvt. Ltd., the Complainant herein alleged to have issued letter dated July 16, 2011 to the Company and several reminders thereof requiring the Company to provide Mfg. & Analytical records, Distribution particulars of the said batch and Drug and Manufacturing license to which the Complainant herein had allegedly not received any response. Resultantly, the instant petition was filed by the complainant, alleging the company to be a. guilty of manufacturing for sale and distribution of not of Standard quality drug, thereby contravening Section 18(a)(i) r/w. Section 16 punishable u/s. 27(d) of Drugs and Cosmetics (Amendment) Act, 2008 by manufacturing “NOT OF STANDARD QUALITY DRUG”; and b. failure to furnish the constitution particulars and batch manufacturing records of the products as required u/s. 24, 18-B & 22(1) of the Act, thus contravening the provisions of the Sections and punishable u/s. 28, 28-A and 22(3) of the Act, respectively and praying for committal to the Honourable Court of Sessions as per Section 32(2) of the Act and in the interest of Justice.

After considering the matter the Honourable ADJFC Magistrate, Kakinada vide its order dated March 08, 2018, considering it fit and proper case for committal to the Honourable Court of Sessions, committed the case to the Court of sessions, East Godavari, Rajahmahendravaram under section 209(a) of Criminal Procedure Code with directions that the Accused shall attend before Hon'ble Court of Sessions, East Godavari District, Rajamahendravaram after receipt of Court summons and the same order shall continue until further Orders of the Hon'ble Sessions Court as required under Sec.209 (b) Cr.P.C.

The matter is pending before the concerned court.

- (ii) **State Of Maharashtra (Complainant) V/s. 1) Anilkumar S/o Captain S. P. Sabharwal 2) Deependu Shekhar S/o. Hari Keshav Singh 3) Neha Goverdhan Bairagi; 4) M/s. Quest Laboratories Pvt. Ltd. (Parties 1 to 4 individually referred to as defendant no. 1, 2, 3 & 4 respectively and collectively as defendants)**

R.C.C./1390/2021; RCC- Reg. Criminal Case filed u/s. 18ai & 18c, 60 of Drugs & Cosmetic Act filed with Akola Dist & Session Court CJM Akola

As stated, M/s. Quest Laboratories Pvt. Ltd (the Company) represented by Mr. Anil Sabarwal, director is a manufacturer of Drugs and is having a manufacturing license under Form 25 & 28 bearing no. 25/18/98.

The complainant herein claims to have taken a sample of Chlorohexidine Gluconate Solution Hand Sanitizer B.No. E 1705, Mfg. Date: 03/2020, Exp. Date: 08-2021 (manufactured by M/s. Quest Laboratories Pvt. Ltd.) from M/s. Goyal Medical & General Store, New Radhakisan Plot, Akola, as per the provisions of Drugs and Cosmetics Act, 1940. As alleged, the test report no. NSQ/AUR/124775/2020 dated August 18, 2020 declared the sample of non-standard quality for the reason that the content of Chlorhexidine in the sample was less than the permissible limits.

Further as alleged, the name of the defendant no. 4 having been mentioned as manufacturer of the drugs in question, a detailed report as mentioned above was send to it requiring it to produce certain documents / details before the Complainant. Later the complainant filed the instant petition and the same is pending.

- (iii) **State thr. Kishore M. Rajne Drugs Inspector (Complainant) V/s. 1) Rahul Dangi thr. Managing Director M/s. Quest Laboratories Pvt. Ltd.; 2) Anil Kumar Sabarwal thr. Director M/s. Quest Laboratories Pvt. Ltd. 3) Tejaswini Chouhan; 4) Naval Gopal Sharma; 5) Umendra Ramkrishna Suthar; 6) Quest Laboratories Pvt. Ltd. (parties 1 to 6 respectively referred to as respondent no. 1, 2, 3, 4, 5 & 6 and collectively as Respondents)**

Regular criminal case, RCC/1997/2022 filed u/s. U/s. 18ai & 18c 161 34 under Drugs & Cosmetic Act with Vasai District & Addl sessions civil court, 12-4th JT CIVIL JUDGE J.D. J.M.F.C. Vasai

The complainant herein claims to have taken a sample on January 14, 2021 of Lomolok Tablets, Loperamide Hydrochloride Tablets I.P., Batch No. T8838, Mfg. Date: 07/2020, Exp. Date: 11/2023, manufactured by M/s. Quest Laboratories Pvt. Ltd. from the premises of M/s. AERO LIFE PHARMA, situated at shop no. 08, Laxmi Apartment, Waliv, Vasai (East), Dist. Palghar, for inspection and to draw routine samples for test / analysis.

As alleged, the test report of the said sample received on January 24, 2022 bearing no. NSQ/MUM/126825/2022 dated January 20, 2022, declared the samples so collected as of non-standard quality for the reason that the sample did not meet the I.P. specifications for dissolution test. Later, after due enquiry and having received the copy of order from the Joint Commissioner (Head Quarter) and Controlling Authority, Food and Drugs Administration, Mumbai, bearing no. Kathla/MUM/126825/74-22/10 dated February 11, 2022, directions were made to investigate the matter and file prosecution against the manufacturer of the drug and related.

Later, a notice bearing no. T Z-2/KMR/NSQ/126825/448/2022/2 dated June 23, 2022 was handed over to factory manager Mr. Gopal Chauhan upon the alleged visit to the premises of M/s. Quest Laboratories Pvt. Ltd., by the Complainant herein along with Drug Inspector, Bhopal (M.P.) for enquiry and investigation. Upon receipt of the said notice, the Respondent no. 1 herein submitted several papers and records with the complainant, which as per the Complainant, were not up to their satisfaction. On the basis of documents received from the respondents, the complainant held the respondent, liable of manufacturing Non-Standard Quality Drugs and accordingly framed several charges against them and filed the instant petition praying to initiate process against the respondents herein, in accordance with the law.

The matter is pending with the concerned court of jurisdiction.

2) Litigation Involving Actions by Statutory/Regulatory Authorities

NIL

3) Disciplinary Actions by Authorities

NIL

4) Litigation involving Tax Liability

Indirect Tax:

(i) GST: F.Y. 2017-18

M/s. QUEST LABORATORIES PVT. LTD (for GSTIN: **23AAACQ1040R1ZH**) (hereinafter referred to as the Assessee) has been served with a Show Cause Notice bearing reference No. **ZD2304220081823** dated April 27, 2022 issued u/s. 74 of the GST Act, 2017 intimating the Assessee of net tax liability of Rs. **11,76,582** /- (Rs. 5,21,766/- being Tax, Rs. 1,33,050/- being interest charged and Rs. 5,21,766/- being penalty) determined during the scrutiny of returns for F.Y. 2017-18 on account of wrong utilization of ITC. Aggrieved by the order, the Assessee has filed an appeal with the Appellate Authority in the matter and the same is pending.

Direct Tax:

1. Pending Demand of TDS:

As per details available on the TRACES an aggregate outstanding amount of Rs. **8,60,497/-** is determined to be paid from previous years till 2023-24 against **M/S. QUEST LABORATORIES PRIVATE LIMITED** (hereinafter referred to as the "Assessee") as default on account of short payment and short deduction of TDS and late filing fees u/s 234E Interest u/s 220 and 221 of the Income Tax Act. Although no action in respect of recovery of same has been taken by the department till date, except for issue of communication notices, the department may at any time issue recovery notices in which event the same shall become payable.

2. A.Y. 2023-24:

As per details available on the website of the Income Tax Department **M/S. QUEST LABORATORIES PRIVATE LIMITED** (hereinafter referred to as the "Assessee") have been issued with a demand notice bearing

no. **2023202337240267231C** dated January 12, 2024 passed u/s. 143(1) (a) of the Income Tax Act, 1961, raising a demand of Rs. 1,72,28,960 /- for A.Y. 2023-24 in addition to interest of Rs. 5,16,867/-, and the same has been disputed by the assessee and is pending.

3. A.Y. 2020-21:

As per details available on the website of the Income Tax Department **M/S. QUEST LABORATORIES PRIVATE LIMITED** (hereinafter referred to as the “Assessee”) have been issued with a notice bearing no. **ITBA/AST/S/148_1/2023-24/ 1063383366(1)** dated March 26, 2024 issued u/s. 148 of the income Tax Act, 1961 alleging the assessee of having escaped the assessment of its income for the A.Y. 2020-21, within the meaning of Section 147 of the Act and requiring the assessee to file its return for the A.Y. 2020-21 for the purpose of assessment / re-assessment within the meaning of Section 148 of the Act.

The notice has been issued based on an order bearing No. **ITBA/AST/F/148A/2023-24/ 1063381692(1)** dated March 26, 2023, passed u/s. 148(A)(d) of the Act on the grounds of suspicious transactions entered into by the assessee with one M/s. Richvib Exim Private Limited, Shri Pramod Sahu and Ms. Vibha Sahu in whose matters search was conducted u/s. 132 of the Act and who have allegedly accepted for having entered into bogus transactions.

The assessee is yet to submit its response in respect of the above notice.

4. A.Y. 2019-20:

As per details available on the website of the Income Tax Department **M/S. QUEST LABORATORIES PRIVATE LIMITED** (hereinafter referred to as the “Assessee”) have been issued with a notice bearing no. **ITBA/AST/S/148_1/2023-24/1052111053(1)** dated April 17, 2023 issued u/s. 148 of the income Tax Act, 1961 alleging the Assessee of having escaped the assessment of its income for the A.Y. 2019-20, within the meaning of Section 147 of the Act and requiring the Assessee to file its return for the A.Y. 2019-2020 for the purpose of assessment / re-assessment within the meaning of Section 148 of the Act.

The notice has been issued based on an order bearing No. **ITBA/AST/F/148A/2023-24/10521110574(1)** dated April 17, 2023, passed u/s. 148(A)(d) of the Act on the grounds of suspicious transactions entered into by the Assessee with one M/s. Richvib Exim Private Limited, Shri Pramod Sahu and Ms. Vibha Sahu in whose matters search was conducted u/s. 132 of the Act and who have allegedly accepted for having entered into bogus transactions.

In response to the aforementioned notice, the Assessee has filed a return for A.Y. 2019-20 and the same is pending for assessment.

5) Other Pending Litigation based on Materiality Policy of our Company

- (i) **Union of India Through Drugs Inspector Manoj Choudhary Jatav (Complainant) V/s. 1) M/ Quest Laboratories Pvt. Ltd. Through Director Anil Kumar Sabarwal 2) Anil Kumar Sabarwal (parties 1 & 2 respectively referred to as respondent no. 1& 2 and collectively as Respondents)**

Case No. Sc/336/2022 Rcs Civil Suit Case Class B, Dist Session Court Indore. 22-Additional Sessions Judge And Special Court No. 6 Under Electricity Act

The complainant herein claims to have taken a sample on November 26, 2020 of Ondansetron Tablets IP 4 mg., Batch No. T13104, date of Mfg. Feb 2020, Exp. Dtd. Jan/2022, manufactured by M/s. Quest Laboratories Pvt. Ltd., bearing smple no. SZI/SMP/MCJ/20202-21/A-002 from the premises of Civil Surgeon Store, MTH Compound, Palika Plaza, Phase-2, Indore-452001, for test and analysis under the provision of Section 23 of the Drugs and Cosmetics Act, 1940 and Rules made thereunder.

Allegedly one of the samples collected was sent to Government Analyst, Central Drug Testing Laboratory, which after test and analysis, vide its report no. FORM-18/20-21/102/1881 dated March 15, 2021, declared the alleged batch of drug sample to be Not of Standard Quality for the reason that “the sample received did not confirm the IP 2018 standard with respect to dissolution test.”

Upon receiving the alleged test report, a notice is alleged to have served to M/s. Civil Surgeon Store requiring them to stop the sale / distribution of the alleged drug and to disclose the name of the supplier and to furnish

several other details and a copy of the said notice is also allegedly said to have been served to the respondent herein.

Upon having allegedly traded the final supply, a notice vide reference no. SZI/2021/MCJ/NSQ/Ondamsetron/Quest/001/533 dated July 30, 2021 along with one sealed sample portion and test report was allegedly served to the respondent requiring them to submit their controversion if any. Later an investigation was carried out on December 09, 2021, at the premises of the Respondent and provided documents were collected.

The Complainant herein later received permission from Drugs Controller General (India) CDSCO, New Delhi vide its letter dated F.No. 09/Prosecution/2022 dated October 31, 2022, for launching prosecution against the respondent and resultantly the instant petition was filed by the Complainant herein, alleging the respondent of manufacturing, selling and distribution drugs of None of Standard Quality.

(ii) Ramnivas Sankhla (Complainant) V/s. 1) M/s Qwest Laboratories Private Limited Through Anil Shabarwal 2) M/S Quest Laboratory Private Limited Through Director Anil Shabarwal (parties 1 & 2 respectively referred to as respondent no. 1& 2 and collectively as Respondents)

Rcs-B-170/2022 Rcs Civil Suit Case Class B, filed with Dist Session Court Indore. 19-Iii Civil Judge Class-I under O7, R1, Civil Procedure Code 1908

The Complainant herein states to have been in the business of providing services of installation and fabrication of Tin Shades and have allegedly been contacted by the respondent no. 2 herein for fabrication and installation of tin shade at the premises of Respondent No. 1 herein at Plot No. 45, Sector-3, Pithampur, Dist. Dhar (alleged premises). The ratelist was allegedly shared and agreed to through whatsapp communication. Later, 2 (two) tin shades were allegedly fabricated and installed by the complainant at the premises of the respondent and the total invoice (including material and labour charges) was raised for Rs. 4,64,801/- out of which an amount of Rs. 3,59,000/- was received and a balance of Rs. 1,05,801/- (Alleged amount) was allegedly pending which was allegedly demanded vide letter dated November 12, 2021 payment of which was regularly deferred by the respondent on some account or the other. Later the complainant herein alleged to have served a demand notice dated January 05, 2022 requiring the respondent to pay the balance amount. However, having received no response from the respondent, the complainant herein filed the instant petition praying for recovery of the alleged amount and the same is pending before the concerned court of jurisdiction.

B. CASES FILED BY OUR COMPANY

1) Litigation involving Criminal Laws

NIL

2) Litigation Involving Actions by Statutory/Regulatory Authorities

NIL

3) Disciplinary Actions by Authorities

NIL

4) Litigation involving Tax Liability

NIL

5) Other Pending Litigation based on Materiality Policy of our Company

NIL

PART 2: LITIGATION RELATING TO OUR DIRECTORS AND PROMOTER OF THE COMPANY

A. LITIGATION AGAINST OUR DIRECTORS AND PROMOTER

1) Litigation involving Criminal Laws

(i) State of Jharkhand V/s. 1. Anil Sabarwal 2. Kavita Sabarwal

208 Case No. C.C. 131/2016 filed with the Judicial Magistrate Courts, Senior Division-II, Jamtara Court, filed u/s. 18(a)(i), 18(a)(vi) & 18(b) of the Drugs and Cosmetics Act.

A complaint was filed by Naseem Aslam, the drug inspector at Jamtara district in Jharkhand, against Mr. Anil Sabarwal, after finding that the samples of paracetamol oral suspension he collected from the drug store of Sadar Hospital in Jamtara on March 30, 2015 was not-of-standard-quality. From the details of invoices obtained by the drug inspector, the drugs were allegedly found to have been manufactured by M/s. Quest Laboratories Private Ltd in Indore for substantiating his charges leveled against the company, the Drug Inspector produced the laboratory test report of his samples in the court for evidence. The government drug testing laboratory (DTL) in Ranchi conducted the analytical test and the result was that the drug was Not of Standard Quality (NSQ).. The drug was supplied to the hospital by Mehsuk Enterprises, a pharma dealer at Paredih in Jamtara. Accordingly, the Jamtara court registered a case (131/2016) against Mr. Anil Sabarwal, managing director and Kavita Sabarwal, one of the directors of the company under Section 27 (d) of the D&C Act. In the course of time, the proceedings against Kavita Sabarwal had to be dropped because of her sudden death on February 9, 2021, but the case continued against Anil Sabarwal and he was put for hearing on 28.4.2023. The charges were explained to him and he was questioned by the court under section 313 of the Cr PC. He denied his complicity in the crime and stated that he was falsely implicated in the case. After being found guilty of manufacturing 'NSQ' drug, the Principal Sessions Judge at Jamtara in Jharkhand vide its order dated January 23, 2024, has ordered for conviction of Mr. Anil Sabarwal, the managing director of the Quest Laboratories Private Limited in Indore in Madhya Pradesh, for one year imprisonment and imposed a fine of Rs. 20,000, under Section 27 (d) of the Drugs and Cosmetics Act 1940. However, the court has granted him bail to enable him to appeal to the High Court of Ranchi and Mr. Anil Sabarwal has filed an appeal bearing no. Cr.A(SJ) 5225/2024 has been filed with Jharkhand High Court, Ranchi, on February 26, 2024 and the same is pending.

Matters which have been originally filed against the Company and our Director cum Promoter Mr. Anil Sabarwal has been made party to them in his capacity as the Director of the Company. For further details in respect of these matters please refer section titled "Matters against Our Company":

Sr. No.	Case Number and Type	Court Where Pending	Relevant Section and Act	Petitioner	Respondent	Stage of Case
1.	R.C.C./1390/2021 RCC - Reg. Criminal Case	Akola Dist & Session Court Cjm Akola	u/s. 18ai & 18c 60 of Drugs & Cosmetic Act	State of Maharashtra	1) Anilkumar S/o Captain S. P. Sabharwal 2) Deependu Shekhar S/o. Hari Keshav Singh 3) Neha Goverdhan Bairagi 4) M/s. Quest Laboratories Pvt. Ltd.	Summons Awaiting
2.	RCC/1997/2022 RCC - Regular Criminal Case	Vasai District & Addl sessions civil court 12-4th JT CIVIL JUDGE J.D. J.M.F.C. Vasai	U/s. 18ai & 18c 161 34 under Drugs & Cosmetic Act	State thr. Kishore M. Rajne Drugs Inspector	1) Rahul Dangi thr. Managing Director M/s. Quest Laboratories Pvt. Ltd.; 2) Anil Kumar Sabarwal thr. Director M/s. Quest Laboratories Pvt. Ltd. 3) Tejaswini Chouhan 4) Naval Gopal Sharma	Awaiting Summons

Sr. No.	Case Number and Type	Court Where Pending	Relevant Section and Act	Petitioner	Respondent	Stage of Case
					5) Umendra Ramkrishna Suthar 6) Quest Laboratories Pvt. Ltd.	

2) Litigation Involving Actions by Statutory/Regulatory Authorities

NIL

3) Disciplinary Actions by Authorities

NIL

4) Litigation involving Tax Liability

Indirect Tax:

NIL

Direct Tax:

NIL

5) Other Pending Litigation based on Materiality Policy of our Company

Matters which have been originally filed against the Company and our Director cum Promoter Mr. Anil Sabarwal has been made party to them in his capacity as the Director of the Company. For further details in respect of these matters please refer section titled "Matters against Our Company":

Sr. No.	Case Number and Type	Court Where Pending	Relevant Section and Act	Petitioner	Respondent	Stage of Case
1.	Sc/336/2022 RCS Civil Suit Case Class B	Dist. Session Court Indore. 22 - Additional Sessions Judge and Special Court No. 6 Under Electricity Act	Civil Procedure Code 1908 & Section 27(D) Of Drugs and Cosmetics Act, 1940	Union Of India Through Drugs Inspector Manoj Choudhary Jatav	1) M/ Quest Laboratories Pvt. Ltd. Through Director Anil Kumar Sabarwal 2) Anil Kumar Sabarwal	Matter Relating to Recording of Evidence in Criminal Matter
2.	Rcs-B-170/2022 RCS Civil Suit Case Class B	Dist. Session Court Indore. 19-Iii Civil Judge Class-I	O7, R1, Civil Procedure Code 1908	Ramnivas Sankhla	1) M/s Qwest Laboratories Private Limited Through Anil Shabarwal 2) M/S Quest Laboratory Private Limited Through Director Anil Shabarwal	Final Hearing / Final Argument Matters

B. LITIGATION FILED BY OUR DIRECTORS AND PROMOTER

1) Litigation involving Criminal Laws

NIL

2) Litigation Involving Actions by Statutory/Regulatory Authorities

NIL

3) Disciplinary Actions by Authorities

NIL

4) Litigation involving Tax Liability

NIL

5) Other Pending Litigation based on Materiality Policy of our Company

NIL

PART 3: LITIGATION RELATING TO OUR SUBSIDIARIES AND/OR GROUP COMPANIES

A. LITIGATION AGAINST OUR GROUP COMPANIES

1) Litigation involving Criminal Laws

NIL

2) Litigation Involving Actions by Statutory/Regulatory Authorities

NIL

3) Disciplinary Actions by Authorities

NIL

4) Litigation involving Tax Liability

Indirect Tax:

NIL

Direct Tax:

NIL

5) Other Pending Litigation based on Materiality Policy of our Company

NIL

DISCIPLINARY ACTION INCLUDING PENALTY IMPOSED BY SEBI OR STOCK EXCHANGES AGAINST THE PROMOTER, DIRECTORS, GROUP COMPANIES AND PROMOTOR GROUP DURING THE LAST 5 FINANCIAL YEARS

There are no disciplinary actions including penalty imposed by SEBI or Stock Exchanges against the Promoters, Directors or Group Companies during the last 5 financial years including outstanding actions except as disclosed above.

PAST INQUIRIES, INSPECTIONS OR INVESTIGATIONS

There have been no inquiries, inspections or investigations initiated or conducted under the Companies Act, 2013 or any previous company law in the last five years immediately preceding the year of this Prospectus in the case of our Company, Promoter, Directors. Other than as described above, there have been no prosecutions filed (whether pending or not) fines imposed, compounding of offences in the last five years immediately preceding the year of the Prospectus

OUTSTANDING LITIGATION AGAINST OTHER PERSONS AND COMPANIES WHOSE OUTCOME COULD HAVE AN ADVERSE EFFECT ON OUR COMPANY

As on the date of the Prospectus, there is no outstanding litigation against other persons and companies whose outcome could have a material adverse effect on our Company.

PROCEEDINGS INITIATED AGAINST OUR COMPANY FOR ECONOMIC OFFENCES

There are no proceedings initiated against our Company for any economic offences.

NON-PAYMENT OF STATUTORY DUES

As on the date of the Prospectus there have been no (i) instances of non-payment or defaults in payment of statutory dues by our Company, (ii) over dues to companies or financial institutions by our Company, (iii) defaults against companies or financial institutions by our Company, or (iv) contingent liabilities not paid for.

MATERIAL FRAUDS AGAINST OUR COMPANY

There have been no material frauds committed against our Company in the five years preceding the year of this Prospectus.

DISCLOSURES PERTAINING TO WILFUL DEFAULTERS

Neither our Company, nor our Promoters, nor Group Companies and nor Directors have been categorized or identified as wilful defaulters by any bank or financial institution or consortium thereof, in accordance with the guidelines on wilful defaulters issued by the Reserve Bank of India. There are no violations of securities laws committed by them in the past or are currently pending against any of them.

DISCLOSURES PERTAINING TO FRAUDULENT BORROWER

Our Company or any of our Promoters or Group Companies or Directors are not declared as 'Fraudulent Borrower' by the lending banks or financial institution or consortium, in terms of RBI master circular dated July 01, 2016.

MATERIAL DEVELOPMENTS OCCURRING AFTER LAST BALANCE SHEET DATE

Except as disclosed in Chapter titled "*Management's Discussion & Analysis of Financial Conditions & Results of Operations*" beginning on page 199 there have been no material developments that have occurred after the Last Balance Sheet Date.

OUTSTANDING DUES TO CREDITORS

There are no disputes with such entities in relation to payments to be made to our Creditors. The details pertaining to amounts due towards such creditors are available on the website of our Company.

Below are the details of the Creditors where outstanding amount as on December 31, 2023:

(₹ in Lakhs)

Name	Balance as on 31.12.2023
Total Outstanding dues to Micro and Small & Medium Enterprises	Nil
Total Outstanding dues to Creditors other than Micro and Small & Medium Enterprises	2,294.66

GOVERNMENT AND OTHER STATUTORY APPROVALS

We have received the necessary consents, licenses, permissions and approvals from the Government and various governmental agencies required for our present business (as applicable on date of this Prospectus) and except as mentioned below, no further approvals are required for carrying on our present business.

In view of the approvals listed below, we can undertake this Issue and our current/proposed business activities and no further major approvals from any governmental or regulatory authority or any other entity are required to be undertaken in respect of the Issue or to continue our business activities. It must be distinctly understood that, in granting these approvals, the Government of India does not take any responsibility for our financial soundness or for the correctness of any of the statements made or opinions expressed in this behalf. Unless otherwise stated, these approvals are all valid as of the date of this Prospectus.

The main objects clause of the Memorandum of Association and objects incidental to the main objects enable our Company to carry out its activities. The following are the details of licenses, permissions and approvals obtained by the Company under various Central and State Laws for carrying out its business:

APPROVALS IN RELATION TO OUR COMPANY'S INCORPORATION

1. Certificate of Incorporation dated June 01, 1998 from the Registrar of Companies, Madhya Pradesh, RoC- Gwalior, under the Companies Act, 1956 as “**QUEST LABORATORIES PRIVATE LIMITED**” (Corporate Identification No. **U24232MP1998PTC012850**)
2. Fresh Certificate of Incorporation dated January 23, 2024 from the Registrar of Companies, Assistant Registrar of Companies / Deputy Registrar of Companies / Registrar of Companies, Centralised Processing Centre, consequent to conversion of the Company from “**QUEST LABORATORIES PRIVATE LIMITED**” to “**QUEST LABORATORIES LIMITED**” (Corporate Identification No. – **U24232MP1998PLC012850**)

APPROVALS IN RELATION TO THE ISSUE

Corporate Approvals

1. Our Board of Directors has, pursuant to resolutions passed at its meeting held on February 02, 2024 authorized the Issue, subject to the approval by the shareholders of our Company under section 62(1)(c) of the Companies Act, 2013.
2. Our shareholders have, pursuant to a resolution dated February 09, 2024, under Section 62(1)(c) of the Companies Act, 2013, authorized the Issue.
3. Our Board of Directors has, pursuant to a resolution dated February 29, 2024 and May 07, 2024 authorized our Company to take necessary action for filing the Draft Red Herring Prospectus and Red Herring Prospectus respectively with NSE Emerge.

Approvals from Stock Exchange

1. Our Company has received in- principle listing approval from the NSE Emerge dated May 03, 2024 for listing of Equity Shares issued pursuant to the Issue.

Other Approvals

1. The Company has entered into a tripartite agreement dated March 01, 2024 with the Central Depository Services (India) Limited (CDSL) and the Registrar and Transfer Agent, who in this case is Bigshare Services Private Limited, for the dematerialization of its shares.
2. The Company has entered into an agreement dated February 20, 2024, with the National Securities Depository Limited (NSDL) and the Registrar and Transfer Agent, who in this case is Bigshare Services Private Limited, for the dematerialization of its shares.

APPROVALS / LICENSES / PERMISSIONS IN RELATION TO OUR BUSINESS:

Tax Related Approvals

Sr. No	Description	Address of Place of Business / Premises	Registration Number	Issuing Authority	Date of Issue	Date of Expiry
1.	Permanent Account Number (PAN)	NA	AAACQ1040R	Income Tax Department	June 01, 1998	Valid till Cancelled
2.	Tax Deduction and Collection Account Number (TAN)	M/s. Quest Laboratories Limited Line-1, Onkar Marg, Gandhi Nagar, Indore	BPLG01968B	Income Tax Department	---	Valid till Cancelled
3.	GST Registration Certificate (Madhya Pradesh)	M/s. Quest Laboratories Limited, Plot No.45, Sector No.3, Pithampur, Dhar, Madhya Pradesh, 454775	23AAACQ1040 R1ZH	Goods and Services Tax department	Valid from July 01, 2017 Certificate dated February 01, 2023	Valid till Cancelled
4.	Professions Tax Payer Enrolment certificate (P.T.E.C.)	M/s. Quest Laboratories Limited Plot No.45, Sector No.3, Pithampur, Dhar 454775, Madhya Pradesh, India	78309293217	Department of Commercial Tax, Pithampur Circle	February 23, 2024	Valid till Cancelled
5.	Professions Tax Payer Registration certificate (P.T.R.C.)	M/s. Quest Laboratories Limited Plot No.45, Sector No.3, Pithampur, Dhar 454775, Madhya Pradesh, India	79439026323	Department of Commercial Tax, Pithampur Circle	February 23, 2024	Valid till Cancelled

Registrations related to Labour Laws:

Sr. No.	Description	Address	License Number	Issuing Authority	Date of issue	Date of Expiry
1.	License To Work a Factory	M/s. Quest Laboratories Limited, Plot No: - 45, Opp. Kisan Pipe, Unit No. 4 & 5, Sector - 3, Pithampur, Dhar - 454 775, Madhya Pradesh.	License No. 187/15605/DHR /2m(i)/H Factory id: FAC1612120	Joint Director Industrial Safety and Health, Madhya Pradesh	November 04, 2022	December 31, 2027
2.	Registration under the Employees Provident fund (EPF)	M/s. Quest Laboratories Private Limited, P-63, Onkar Marg, Gandhi Nagar, Indore - 453112, Madhya Pradesh.	MPIND002312 1000	Employees Provident fund	July 06, 2018	Valid till Cancelled
3.	Registration under Employee State Insurance Act (ESIC)	M/S. Quest Laboratories Limited, Sector-3, Industrial Area, Opp. Of Kisan Pipe, Pithampur, Dist.- Dhar, M.P., 454775	1800028504000 0305	Employees' State Insurance Corporation,	October 04, 2017	Valid till Cancelled

Business Related Approvals:

Sr. No.	Description	Address of Premises	Registration Number	Issuing Authority	Date of issue	Date of Expiry
1.	Combined consent and authorization u/s. 25 of Water (Prevention & Control of Pollution) Act, 1947 and Section 21 of Air	M/s. Quest Laboratories Pvt. Ltd, Plot No 45, Sector 3, Industrial Area, Pithampur, Dist.: Dhar (M.P.)	Consent No: AWH-98402	M.P. Pollution Control Board- Dhar	March 17, 2022	Consent under Air and Water Act valid up to January 31, 2028 and Authorization under hazardous and other Waste

Sr. No.	Description	Address of Premises	Registration Number	Issuing Authority	Date of issue	Date of Expiry
	(Prevention and Control of Pollution) Act, 1984 and & Authorization under Hazardous and Other Waste (Management & Transboundary Movement) Rules, 2016					Management & Transboundary Movement) Rules, 2016 valid upto January 31, 2026
2.	Import Export Code (IEC)	M/s. Quest Laboratories Limited Plot No.45, Sector No.3, Pithampur, Dhar, Madhya Pradesh, 454775	1116902621	Ministry of Commerce and Industry Directorate General of Foreign Trade,	July 06,2016	Valid till Cancelled
3.	Drug Manufacturing License under Drugs & Cosmetic Act, 1940 & Rules	M/s. Quest Laboratories Limited, Plot No.45, Sector No. III, Pithampur, Dhar - 454775, Madhya Pradesh.	License Form 25 bearing LIC No. 25/18/98 Issue dated November 13,1998	Food & Drugs Control Administration, Madhya Pradesh	Renewed w.e.f. September 25, 2020	September 25, 2025
4.	Drug Manufacturing License under Drugs & Cosmetic Act, 1940 & Rules	M/s. Quest Laboratories Limited, Plot No.45, Sector No.III, Pithampur, Dhar, Madhya Pradesh, 454775	License Form 28, bearing LIC No. 28/08/98 Issue dated November 13,1998	Food & Drugs Control Administration, Madhya Pradesh	Renewed w.e.f. September 25, 2020	September 25, 2025
5.	Non-Conviction Certificate	M/s. Quest Laboratories Private Limited, Plot No.45, Sector No. III, Pithampur, Dhar - 454775, Madhya Pradesh.	DHRNC231366 (for License No. Form 25 bearing LIC No. 25/18/98)	Food & Drugs Control Administration, Madhya Pradesh	April 17, 2023	---
6.	Non-Conviction Certificate	M/s. Quest Laboratories Private Limited, Plot No.45, Sector No.III, Pithampur, Dhar, Madhya Pradesh, 454775	DHRNC231367 (for license no. 28, bearing Lic No. 28/08/98 Issue dated November 13,1998)	Food & Drugs Control Administration, Madhya Pradesh	April 17, 2023	---
7.	G.M.P Certificate	M/S. Quest Laboratories Private Limited, Plot No.45, Sector No. III, Pithampur, Dhar, Madhya Pradesh, 454775	DHRGMP202107559	Food & Drugs Control Administration, Madhya Pradesh	December 31, 2021	September 25, 2025
8.	G.M.P Certificate	M/S. Quest Laboratories Private Limited, Plot No.45, Sector No. III, Pithampur,	DHRGMP202112575	Food & Drugs Control Administration, Madhya Pradesh	December 31, 2021	September 25, 2025

Sr. No.	Description	Address of Premises	Registration Number	Issuing Authority	Date of issue	Date of Expiry
		Dhar - 454775, Madhya Pradesh.				
9.	G.L.P Certificate	M/s. Quest Laboratories Private Limited, Plot No.45, Sector No. III, Pithampur, Dhar - 454775, Madhya Pradesh.	DHRGLP202212466	Food & Drugs Control Administration, Madhya Pradesh	January 31, 2023	September 25, 2025
10.	ISO 9001:2015 Manufacturing, Marketing, Trading of Pharmaceutical Formulations (Tablets, Liquid Orals, Dry Syrup External Preparation, Ointments and Oral Powders Ors)	M/s. Quest Laboratories Limited, Plot No.45, Sector No.3, Pithampur, Dhar - 454775, Madhya Pradesh.	QUE23I2Q3I IN	United Accreditation Foundation	September 06, 2023	September 05, 2026
11.	Udhyam Registration Certificate	M/S. Quest Laboratories Limited, Plot No.45, Sector No.3, Pithampur, Dhar, Madhya Pradesh, 454775	UDYAM-MP-17 0001361	Ministry of Micro Small & Medium Enterprises	December 19, 2020	Valid till Cancelled
12.	MSME Zed Bronze Certificate for Manufacture of pharmaceuticals, medicinal chemical and botanical products	M/S. Quest Laboratories Private Limited, Flat No: - 45, Sector - 3, Pithampur, Dhar - 454775, Madhya Pradesh.	UDYAM-MP-1 7-0001361 Certificate No. 02092023_073834	Ministry of Micro Small & Medium Enterprises	September 02, 2023	Valid till Cancelled

INTELLECTUAL PROPERTY

Trademarks / patents / copyright/registered/objected/abandoned in the name of our company:

Sr. No	Brand Trademark	Name/Logo	Class	Registration/ Application number	Owner	Authority	Date of Registration/ Application	Current Status
1.		Quest LABORATORIES LIMITED	5	Application - 6278752	M/s. Quest Laboratories Limited	Trade Mark Registry	30/01/2024	Marked for Exam

DOMAIN:

Sr. No	Domain Name and ID	Sponsoring Registrar and ID	Registrant Name, ID and Address	Creation Date	Registry Expiry Date
1.	https://questlabltd.com/	ID:2843164808_DOMAIN_COM-VRSN	GoDaddy.com, LLC Registrar IANA ID: 146	January 04, 2024	January 04, 2025

In addition to above licenses and approvals and except as stated in this chapter, it is hereby mentioned that no application has been made for license / approvals required by the Company and no approval is pending in respect of any such application made with any of the authorities except that for change of name of the Company pursuant to change of its constitution from Private Limited to Public Limited and change of address at few places

OTHER REGULATORY AND STATUTORY DISCLOSURES

AUTHORITY FOR THE ISSUE

Our Board of Directors have vide resolution dated February 02, 2024 authorized the Issue, subject to the approval by the shareholders of our Company under Section 62(1)(c) of the Companies Act, 2013.

The shareholders have authorized the Issue, by passing a Special Resolution at the Extra Ordinary General Meeting held on February 09, 2024 in accordance with the provisions of Section 62(1)(c) of the Companies Act, 2013.

IN-PRINCIPLE LISTING APPROVALS

The Company has obtained approval from NSE vide letter dated May 03, 2024 to use the name of NSE in this Offer Document for listing of equity shares on the NSE Emerge. NSE is the designated stock exchange.

PROHIBITION BY SEBI OR OTHER GOVERNMENTAL AUTHORITIES

Further, our company, promoters, members of the promoter group, directors, are not debarred or prohibited from accessing the capital markets or debarred from buying, selling or dealing in securities under any order or direction passed by the Board or any securities market regulator in any other jurisdiction or any other authority/court as on the date of this Prospectus.

The listing of any securities of our Company has never been refused at any time by any of the stock exchanges in India.

None of the companies with which our Promoters and Directors are associated with as promoters, directors or persons in control have been debarred from accessing capital markets under any order or direction passed by SEBI or any other authorities.

None of our Directors are associated with securities market related business, in any manner and there have been no outstanding actions initiated by SEBI against our Directors in the five years preceding the date of this Prospectus.

Our Company, Promoters or Directors have not been declared as wilful defaulters by any bank or financial institution or consortium thereof in accordance with the guidelines on wilful defaulters offered by the RBI.

Our Promoters or Directors have not been declared as fugitive economic offenders under section 12 of the Fugitive Economic Offenders Act, 2018.

PROHIBITION BY RBI

Neither our Company nor any of our Promoters or Directors has been declared as willful defaulter(s) or fraudulent borrowers by the RBI or any other governmental authority.

DIRECTORS ASSOCIATED WITH THE SECURITIES MARKET

None of our Directors are associated with the securities market and there has been no outstanding action initiated by SEBI against them in the five years preceding the date of this Prospectus.

COMPLIANCE WITH THE COMPANIES (SIGNIFICANT BENEFICIAL OWNERSHIP) RULES, 2018

Our Company, Promoters and members of the Promoter Group confirm that they are in compliance with the Companies (Significant Beneficial Owners) Rules, 2018, to the extent applicable, as on the date of this Prospectus.

ELIGIBILITY FOR THE ISSUE

Our Company is an “Unlisted Issuer” in terms of the SEBI ICDR Regulations; and this Issue is an “Initial Public Offer” in terms of the SEBI ICDR Regulations.

This Issue is being made in terms of Regulation 229(2) of Chapter IX of the SEBI ICDR Regulations, as amended from time to time, whereby, an issuer whose post Issue face value capital is exceed ₹ 10 crores but does not exceed ₹ 25 crores rupees, shall issue shares to the public and propose to list the same on the Small and Medium Enterprise Exchange (in this case being the NSE Emerge).

As per Regulation 229 (3) of the SEBI ICDR Regulations, our Company satisfies track record and/or other eligibility conditions of NSE Emerge.

- a) Our Company was incorporated on June 01, 1998, under the Companies Act, 1956 with the Registrar of Companies, Gwalior. Hence, our Company is in existence for a period of 25 years on the date of filing the Prospectus with NSE.
- b) As on the date of this Prospectus, our Company has a total paid-up capital (face value) of ₹ 1193.76 Lakhs comprising 1,19,37,600 Equity Shares of ₹10/- each and the Post Issue paid-up Capital (face value) will be ₹ 1,638.72 Lakhs comprising 1,63,87,200 Equity Shares which shall be below ₹ 25 crores.
- c) Our Company confirms that it has track record of more than 3 years.
- d) As per the Restated Financial Statements, our company has operating profit (earnings before interest, depreciation and tax excluding other income) from operations of ₹ 1208.63 Lakhs for the period ended December 31, 2023 and ₹ 782.24 Lakhs in March 31, 2023, ₹ 646.55 Lakhs in Fiscal 2022, and ₹ 141.84 Lakhs in Fiscal 2021 i.e., in the stub period and all the 3 financial years preceding the date of this Prospectus and its net-worth is positive.
- e) Our Company has not been referred to Board for Industrial and Financial Reconstruction (BIFR) or no proceedings have been admitted under Insolvency and Bankruptcy Code against our company and promoting companies.
- f) There is no winding up petition against the company, which has been admitted by NCLT/ Court of competent jurisdiction or a liquidator has not been appointed.
- g) No material regulatory or disciplinary action has been taken by a stock exchange or regulatory authority in the past three years against our Company.
- h) Other Disclosures:
 - We have disclosed all material regulatory or disciplinary action by a stock exchange or regulatory authority in the past one year in respect of promoter/promoting company(ies), group companies, companies promoted by the promoter/promoting company(ies) of our company in the Prospectus.
 - There are no defaults in respect of payment of interest and/or principal to the debenture/bond/fixed deposit holders, banks, FIs by our company, promoter/promoting company(ies), group companies, companies promoted by the promoter/promoting company(ies) during the past three years except as mentioned in the Prospectus.
 - We have disclosed the details of our company, promoter/promoting company(ies), group companies, companies promoted by the promoter/promoting company(ies) litigation record, the nature of litigation, and status of litigation. For details, please refer the chapter “*Outstanding Litigations and Material Developments*” on page 221 of this Prospectus.
 - We have disclosed all details of the track record of the directors, the status of criminal cases filed or nature of the investigation being undertaken with regard to alleged commission of any offence by any of its directors and its effect on the business of the company, where all or any of the directors of offer have or has been charge-sheeted with serious crimes like murder, rape, forgery, economic offences etc. For Details, refer the chapter “*Outstanding Litigations and Material Developments*” on page 221 of this Prospectus.

As per Regulation 230 (1) of the SEBI ICDR Regulations, our Company has ensured that:

- a) The Prospectus has been filed with NSE and our Company has made an application to NSE for listing of its Equity Shares on the Emerge platform of NSE. NSE is the Designated Stock Exchange.
- b) Our Company has entered into an agreement dated February 20, 2024 with NSDL and agreement dated March 01, 2024 with CDSL for dematerialisation of its Equity Shares already issued and proposed to be issued.
- c) The entire pre-issue capital of our Company has fully paid-up Equity Shares and the Equity Shares proposed to be issued pursuant to this IPO are fully paid-up.
- d) The entire Equity Shares held by the Promoters are in dematerialized form.

- e) The fund requirements set out for the Objects of the Issue are proposed to be met entirely from the Net Proceeds. Accordingly, our Company confirms that there is no requirement to make firm arrangements of finance through verifiable means towards at least 75% of the stated means of finance, excluding the amount to be raised from the Issue as required under the SEBI ICDR Regulations. For details, please refer the chapter “*Objects of the Issue*” on page 86 of this Prospectus.

Our Company confirms that it will ensure compliance with the conditions specified in Regulation 230 (2) of the SEBI ICDR Regulations, to the extent applicable.

Further, our Company confirms that it is not ineligible to make the Issue in terms of Regulation 228 of the SEBI ICDR Regulations, to the extent applicable. The details of our compliance with Regulation 228 of the SEBI ICDR Regulations are as follows:

1. Neither our Company nor our Promoters, members of our Promoter group or our directors is debarred from accessing the capital markets by the SEBI.
2. None of our Promoters or Directors is Promoters or director of any other companies which are debarred from accessing the capital markets by the SEBI.
3. Neither our Company nor our Promoters or Directors is a wilful defaulter or a fraudulent borrower.
4. None of our Promoters or Directors is a fugitive economic offender.

We further confirm that we shall be complying with all other requirements as laid down for such issue under Chapter IX of SEBI ICDR Regulations, as amended from time to time and subsequent circulars and guidelines issued by SEBI and the Stock Exchange.

We further confirm that:

1. In accordance with Regulation 246 of the SEBI ICDR Regulations, the book running lead manager shall ensure that the issuer shall file copy of the Prospectus with SEBI along with relevant documents as required at the time of filing the Prospectus to SEBI.
2. In accordance with Regulation 260 of the SEBI ICDR Regulations, this issue has been one hundred percent (100%) underwritten and that the Book Running Lead Manager to the issue has underwritten at least 15% of the Total Issue Size. For further details, pertaining to said underwriting please see “*General Information*” beginning on page 61 of this Prospectus.
3. In accordance with Regulation 268 of the SEBI ICDR Regulations, we shall ensure that the total number of proposed allottees in the Issue is greater than or equal to fifty (50), otherwise, the entire application money will be unblocked forthwith. If such money is not unblocked within days from the date our Company becomes liable to unblock it, then our Company and every officer in default shall, on and from expiry of fourth day, be liable to unblock such application money with interest as prescribed under the SEBI ICDR Regulations, the Companies Act 2013 and applicable laws.

COMPLIANCE WITH PART A OF SCHEDULE VI OF THE SEBI ICDR REGULATIONS

Our Company is in compliance with the provisions specified in Part A of Schedule VI of the SEBI ICDR Regulations.

DISCLAIMER CLAUSE OF SEBI

IT IS TO BE DISTINCTLY UNDERSTOOD THAT SUBMISSION OF OFFER DOCUMENT TO SECURITIES AND EXCHANGE BOARD OF INDIA (SEBI) SHOULD NOT IN ANY WAY BE DEEMED OR CONSTRUED THAT THE SAME HAS BEEN CLEARED OR APPROVED BY SEBI. SEBI DOES NOT TAKE ANY RESPONSIBILITY EITHER FOR THE FINANCIAL SOUNDNESS OF ANY SCHEME OR THE PROJECT FOR WHICH THE ISSUE IS PROPOSED TO BE MADE OR FOR THE CORRECTNESS OF THE STATEMENTS MADE OR OPINIONS EXPRESSED IN THE OFFER DOCUMENT. THE BOOK RUNNING LEAD MANAGER HAS CERTIFIED THAT THE DISCLOSURES MADE IN THE OFFER DOCUMENT ARE GENERALLY ADEQUATE AND ARE IN CONFORMITY WITH THE REGULATIONS. THIS REQUIREMENT IS TO FACILITATE INVESTORS TO TAKE AN INFORMED DECISION FOR MAKING INVESTMENT IN THE PROPOSED ISSUE.

IT SHOULD ALSO BE CLEARLY UNDERSTOOD THAT WHILE THE ISSUER IS PRIMARILY RESPONSIBLE FOR THE CORRECTNESS, ADEQUACY AND DISCLOSURE OF ALL RELEVANT INFORMATION IN THIS OFFER DOCUMENT, THE BOOK RUNNING LEAD MANAGER IS EXPECTED TO EXERCISE DUE DILIGENCE TO ENSURE THAT THE ISSUER DISCHARGES ITS RESPONSIBILITY ADEQUATELY IN THIS BEHALF AND TOWARDS THIS PURPOSE, THE BOOK RUNNING LEAD MANAGER, SHRENI SHARES LIMITED (FORMERLY KNOWN AS SHRENI SHARES PRIVATE LIMITED) HAVE FURNISHED TO SEBI, A DUE DILIGENCE CERTIFICATE DATED MAY 08, 2024 IN THE FORMAT PRESCRIBED UNDER SCHEDULE V(A) OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018.

THE FILING OF THIS OFFER DOCUMENT DOES NOT, HOWEVER, ABSOLVE THE ISSUER FROM ANY LIABILITIES UNDER THE COMPANIES ACT, 2013 OR FROM THE REQUIREMENT OF OBTAINING SUCH STATUTORY AND OTHER CLEARANCES AS MAY BE REQUIRED FOR THE PURPOSE OF THE PROPOSED ISSUE. SEBI FURTHER RESERVES THE RIGHT TO TAKE UP, AT ANY POINT OF TIME, WITH THE BOOK RUNNING LEAD MANAGER ANY IRREGULARITIES OR LAPSES IN THIS OFFER DOCUMENT.

Note: All legal requirements pertaining to the Issue will be complied with at the time of filing of the Prospectus with the RoC in terms of Section 32 of the Companies Act. All legal requirements pertaining to the Issue will be complied with at the time of filing of the Prospectus with the RoC in terms of Sections 26, 33(1) and 33(2) of the Companies Act.

DISCLAIMER IN RESPECT OF JURISDICTION

This issue is being made in India to persons resident in India including Indian nationals resident in India (who are not minors, except through their legal guardian), Hindu Undivided Families (HUFs), companies, corporate bodies and societies registered under the applicable laws in India and authorized to invest in shares, Mutual Funds, Indian financial institutions, commercial banks, regional rural banks, co-operative banks (subject to RBI permission), Trusts registered under the Societies Registration Act, 1860, as amended from time to time, or any other trust law and who are authorised under their constitution to hold and invest in shares, permitted insurance companies and pension funds and to non-residents including NRIs and FIIs. This Prospectus does not, however, constitute an offer to sell or an invitation to subscribe to Equity Shares issued hereby in any other jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdiction. Any person into whose possession the Prospectus comes is required to inform himself or herself about, and to observe, any such restrictions. Any dispute arising out of this issue will be subject to the jurisdiction of appropriate court(s) in Mumbai only.

No action has been or will be taken to permit a public offering in any jurisdiction where action would be required for that purpose. Accordingly, the Equity Shares represented thereby may not be offered or sold, directly or indirectly, and the Prospectus may not be distributed, in any jurisdiction, except in accordance with the legal requirements applicable in such jurisdiction. Neither the delivery of the Prospectus nor any sale hereunder shall, under any circumstances, create any implication that there has been any change in the affairs of our Company since the date hereof or that the information contained herein is correct as of any time subsequent to this date.

No person outside India is eligible to Bid for Equity Shares in the Issue unless that person has received the preliminary offering memorandum for the Issue, which contains the selling restrictions for the Issue outside India.

Eligibility and Transfer Restrictions

The Equity Shares offered in the Issue have not been, and will not be, registered under the U.S. Securities Act and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and accordingly, the Equity Shares are being offered and sold (i) within the United States solely to persons who are reasonably believed to be “qualified institutional buyers” (as defined in Rule 144A under the U.S. Securities Act) in transactions exempt from the registration requirements of the U.S. Securities Act, and (ii) outside the United States in “offshore transactions” as defined in and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur.

The Equity Shares have not been, and will not be, registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

Bidders are advised to ensure that any Bid from them does not exceed investment limits or maximum number of Equity Shares that can be held by them under applicable law.

DISCLAIMER FROM OUR COMPANY, THE DIRECTORS AND THE BOOK RUNNING LEAD MANAGER

Our Company, our Directors and the Book Running Lead Manager accept no responsibility for statements made otherwise than in this Prospectus or in the advertisements or any other material issued by or at our Company's instance and anyone placing reliance on any other source of information, including our Company's website, www.questlabltd.com, or the website of any affiliate of our Company, would be doing so at his or her own risk.

The Book Running Lead Manager accept no responsibility, save to the limited extent as provided in the Issue Agreement and the Underwriting Agreement to be entered into between the Underwriter and our Company and Market Maker Agreement entered into among Market Maker and our Company.

All information shall be made available by our Company and the Book Running Lead Manager to the public and investors at large and no selective or additional information would be available for a section of the investors in any manner whatsoever including at road show presentations, in research or sales reports or at bidding centres elsewhere.

The Book Running Lead Manager and its associates and affiliates may engage in transactions with and perform services for, our Company and associates of our Company in the ordinary course of business and may in future engage in the provision of services for which they may in future receive compensation. Shreni Shares Limited (*Formerly known as Shreni Shares Private Limited*) is not an associate of the Company and is eligible to be appointed as the Book Running Lead Manager in this Issue, under SEBI MB Regulations.

Investors who apply in this Issue will be required to confirm and will be deemed to have represented to our Company and the Underwriter and their respective directors, officers, agents, affiliates and representatives that they are eligible under all applicable laws, rules, regulations, guidelines and approvals to acquire Equity Shares and will not issue, sell, pledge or transfer the Equity Shares to any person who is not eligible under applicable laws, rules, regulations, guidelines and approvals to acquire Equity Shares. Our Company and the Book Running Lead Manager and their respective directors, officers, agents, affiliates and representatives accept no responsibility or liability for advising any investor on whether such investor is eligible to acquire Equity Shares.

Neither our Company nor Book Running Lead Manager is liable for any failure in (i) uploading the Applications due to faults in any software/ hardware system or otherwise, or (ii) the blocking of the Application Amount in the ASBA Account on receipt of instructions from the Sponsor Bank on the account of any errors, omissions or non-compliance by various parties involved, or any other fault, malfunctioning, breakdown or otherwise, in the UPI Mechanism.

Bidders are advised to ensure that any Bid from them does not exceed the investment limits or maximum number of Equity Shares that can be held by them under applicable law.

DISCLAIMER CLAUSE OF THE NSE

As required, a copy of the Prospectus shall be submitted to the NSE Emerge. The Disclaimer Clause as intimated by the NSE Emerge to us, post scrutiny of the Prospectus, shall be included in the Prospectus and Prospectus prior to the filing with RoC.

“As required, a copy of this Offer Document has been submitted to National Stock Exchange of India Limited (hereinafter referred to as NSE). NSE has given vide its letter Ref.: NSE/LIST/3561 dated May 03, 2024, permission to the Issuer to use the Exchange's name in this Offer Document as one of the Stock Exchanges on which this Issuer's securities are proposed to be listed. The Exchange has scrutinized this draft offer document for its limited internal purpose of deciding on the matter of granting the aforesaid permission to this Issuer. It is to be distinctly understood that the aforesaid permission given by NSE should not in any way be deemed or construed that the offer document has been cleared or approved by NSE; nor does it in any manner warrant, certify or endorse the correctness or completeness of any of the contents of this offer document; nor does it warrant that this Issuer's securities will be listed or will continue to be listed on the Exchange; nor does it take any responsibility for the financial or other soundness of this Issuer, its promoters, its management or any scheme or project of this Issuer.

Every person who desires to apply for or otherwise acquire any securities of this Issuer may do so pursuant to independent inquiry, investigation and analysis and shall not have any claim against the Exchange whatsoever by reason of any loss which may be suffered by such person consequent to or in connection with such subscription /acquisition whether by reason of anything stated or omitted to be stated herein or any other reason whatsoever.”

LISTING

The Equity Shares issued through the Prospectus are proposed to be listed on the EMERGE Platform of NSE. Application have been made to the EMERGE Platform of NSE for obtaining permission for listing of the Equity Shares being issued and sold in the Issue on its NSE Emerge Platform after the allotment in the Issue. NSE is the Designated Stock Exchange, with which the Basis of Allotment will be finalized for the Issue.

Our company has obtained In-principle approval from NSE vide letter dated May 03, 2024 to use name of NSE in the Prospectus for listing of equity shares on NSE EMERGE.

If the permissions to deal in and for an official quotation of our Equity Shares are not granted by the NSE EMERGE the Company shall unblock, without interest, all moneys received from the applicants in pursuance of the Prospectus. Our Company shall ensure that all steps for the completion of the necessary formalities for listing and commencement of trading at the NSE EMERGE mentioned above are taken within three (3) Working Days of the Bid/Issue Closing Date or such period as may be prescribed by SEBI. If our Company does not allot Equity Shares pursuant to the Issue within 3 Working Days from the Bid/Issue Closing Date or within such timeline as prescribed by SEBI, it shall repay without interest all monies received from Bidders, failing which interest shall be due to be paid to the Bidders at the rate of 15% p. a, for the delayed period.

CONSENTS

Consents in writing of: (a) Directors, Promoters, the Chief Financial Officer, Company Secretary & Compliance Officer, the Statutory and Peer Review Auditors, (b) the Book Running Lead Manager, Registrar to the Issue, the Legal Advisors to the Issue, Bankers to the Issue, Bankers to the company, Market Maker and Underwriters to act in their respective capacities, have been obtained and shall be filed along with a copy of the Prospectus with the RoC, as required under Section 26 of the Companies Act, 2013.

In accordance with the Companies Act, 2013 and the SEBI ICDR Regulations, Peer Reviewed Auditors, M/s. Shyam S Gupta & Associates, Chartered Accountants, have provided their written consent to the inclusion of Restated Financial Statements dated February 24, 2024 and to the inclusion of their reports dated February 24, 2024 on Statement of Tax Benefits, which may be available to the Company and its shareholders, included in this Prospectus in the form and context in which they appear therein and such consents and reports have not been withdrawn up to the time of filing of this Prospectus.

EXPERT OPINION

Except as disclosed below, our Company has not obtained any expert opinions in connection with this Prospectus:

Our Company has received a written consent dated February 13, 2024 from our Peer Review Auditor, namely, M/s. Shyam S Gupta & Associates, Chartered Accountants, who hold a valid peer review certificate from ICAI, to include their name as required under section 26(5) of the Companies Act, 2013 read with SEBI ICDR Regulations, in this Prospectus, and as an “expert” as defined under section 2(38) of the Companies Act, 2013 to the extent and in their capacity as our Peer Review Auditor, and in respect of their (a) examination report dated April 17, 2024, on the Restated Financial Statements, and (b) report dated April 17, 2024 by the Peer Review Auditor on the statement of special tax benefits. Such consent has not been withdrawn as on the date of this Prospectus. However, the term “expert” and “consent” shall not be construed to mean an “expert” and “consent” as defined under the U.S. Securities Act.

Further, our Company has received written consent dated February 13, 2024, from M/s. Shyam S Gupta & Associates, Chartered Accountants, to include their name as required under Section 26 (5) of the Companies Act read with SEBI ICDR Regulations, in this Prospectus and as an “expert”, as defined under Section 2(38) of the Companies Act, 2013 to the extent and in their capacity as an Peer Review Auditor, in relation to the certificate dated February 24, 2024, certifying, *inter alia*, the details of the capital buildup of our company.

PREVIOUS PUBLIC OR RIGHTS OFFERS DURING THE LAST FIVE YEARS

We have not made any rights to the public and public offers in the past, and we are an “Unlisted Company” in terms of the SEBI ICDR Regulations and this Issue is an “Initial Public Offer” in terms of the SEBI ICDR Regulations.

COMMISSION AND BROKERAGE PAID ON PREVIOUS OFFERS OF OUR EQUITY SHARES IN LAST FIVE YEARS

Since this is an Initial Public Offer of the Company, no sum has been paid or has been payable as commission or brokerage for subscribing to or procuring or agreeing to procure subscription for any of the Equity Shares since inception of the Company.

CAPITAL OFFERS DURING THE LAST THREE YEARS BY OUR COMPANY, LISTED GROUP COMPANIES, SUBSIDIARIES & ASSOCIATES OF OUR COMPANY

Except as disclosed in Chapter titled “*Capital Structure*” on page 73 of Prospectus, our Company has not made any capital issue during the previous three years.

PERFORMANCE VIS-À-VIS OBJECTS

Except as stated in the chapter titled “*Capital Structure*” beginning on page 73 of this Prospectus, we have not made any previous rights and / or public issues during the last five (5) years and are an “Unlisted Issuer” in terms of SEBI ICDR Regulations and this Issue is an “Initial Public Offer” in terms of the SEBI ICDR Regulations, the relevant data regarding performance vis-à-vis objects is not available with the Company.

For details in relation to our group companies, please see chapter titled “*Our Group Company*” on page 176 of Prospectus.

PRICE INFORMATION OF THE PAST ISSUE HANDLED BY THE BOOK RUNNING LEAD MANAGER

Price information of past issues (during the current Financial Year and two Financial Years preceding the current Financial Year) handled by Shreni Shares Limited (Formerly known as Shreni Shares Private Limited):

Sr. No.	Issuer name	Issue size (₹ Crores)	Issue price (Rs.)	Listing Date	Opening price on Listing Date (in Rs.)	+/- change in closing price, [% change in closing benchmark] - 30 th calendar days from listing	+/- change in closing price, [% change in closing benchmark] - 90 th calendar days from listing	+/- change in closing price, [% change in closing benchmark] - 180 th calendar days from listing
Mainboard IPO Issues								
-	-	-	-	-	-	-	-	-
SME IPO Issues								
1.	Marco Cables & Conductors Limited	18.73	36.00	September 28, 2023	38.70	+45.83% [-2.44%]	+46.25% [+9.82%]	+20.00% [+13.18%]
2.	KK Shah Hospitals Limited^	8.78	45.00	November 06, 2023	56.10	+84.00% [+6.68%]	+56.67% [+10.97%]	+22.22% [+13.73%]
3.	Swasthik Plascon Limited	40.76	86.00	December 05, 2023	120.10	+20.00% [+2.97%]	+2.33% [+6.42%]	-
4.	Net Avenue Technologies Limited	10.25	18.00	December 08, 2023	42.00	+75.28% [+3.54%]	+10.56% [+7.18%]	-
5.	AIK Pipes and Polymers Limited	15.02	89.00	January 02, 2024	100.00	+33.34% [-0.20%]	+29.21% [+2.45%]	-
6.	Delaplex Limited	46.08	192.00	February 02, 2024	309.00	+43.65% [+2.40%]	+27.08% [+3.44%]	-
7.	Gabriel Pet Straps Limited	8.06	101.00	February 07, 2024	115.00	+32.67% [+2.73%]	+45.54% [+2.42%]	-
8.	Yash Optics & Lens Limited	53.15	81.00	April 08, 2024	90.00	+10.99% [-1.61%]	-	-
9.	Refractory Shapes Limited	18.60	31.00	May 14, 2024	75.00	-	-	-
10.	Silkflex Polymers (India) Limited	18.11	52.00	May 15, 2024	60.00	-	-	-

Source: www.bseindia.com / www.nseindia.com

Notes:

1. The BSE SENSEX and CNX NIFTY are considered as the Benchmark Index.
2. Price on BSE/NSE are considered for all the above calculations.
3. In case 30th, 90th and 180th day is not a trading day, closing price of the previous trading day has been considered.
4. In case 30th, 90th and 180th day, scripts are not traded then the last trading price has been considered.
5. Designated Stock Exchange as disclosed by the respective Issuer at the time of the issue has been considered for disclosing the price information.

As per SEBI Circular No. CIR/CFD/DIL/7/2015 dated October 30, 2015, the above table should reflect maximum 10 issues (Initial Public Offers) managed by the Lead Manager. Hence, disclosure pertaining to recent 10 issues handled by the lead manager are provided.

Summary statement of price information of past issues handled by Shreni Shares Limited (Formerly known as Shreni Shares Private Limited):

Financial Year	Total no. of IPOs	Total funds raised (₹ Crore s)	Nos. of IPOs trading at discount on as on 30th calendar days from listing date			Nos. of IPOs trading at premium on as on 30th calendar days from listing date			Nos. of IPOs trading at discount as on 180th calendar days from listing date			Nos. of IPOs trading at premium as on 180th calendar days from listing date		
			Over 50%	Between 25% 50%	Less than 25%	Over 50%	Between 25%- 50%	Less than 25%	Over 50%	Between 25%- 50%	Less than 25%	Over 50%	Between 25%- 50%	Less than 25%
2024-2025 [§]	3 ^{&}	89.86	-	-	-	-	-	1	-	-	-	-	-	-
2023-2024 [@]	13 ^{**}	260.67	-	-	-	6	6	1	-	-	-	6	-	2
2022-2023	10 ^{**}	156.29	-	-	-	5	2	3	-	-	1	5	-	4

******The script of Fidel Softech Limited, SKP Bearing Industries Limited, Olatech Solutions Limited, Ameya Precision Engineers Limited, DAPS Advertising Limited, Amiable Logistics (India) Limited, PNGS Gargi Fashion Jewellery Limited, Arihant Academy Limited, Srivasavi Adhesive Tapes Limited and Bright Outdoor Media Limited were listed on June 10, 2022, July 13, 2022, August 29, 2022, September 08, 2022, November 14, 2022, November 16, 2022, December 20, 2022, December 29, 2022, March 09, 2023 and March 24, 2023 respectively.

*******The script of Sancode Technologies Limited, Veefin Solutions Limited, Global Pet Industries Limited, AccelerateBS India Limited, C P S Shapers Limited, Meson Valves India Limited, Marco Cables & Conductors Limited, KK Shah Hospitals Limited, Swasthik Plascon Limited, Net Avenue Technologies Limited, AIK Pipes and Polymers Limited, Delaplex Limited and Gabriel Pet Straps Limited were listed on April 18, 2023, July 05, 2023, July 10, 2023, July 19, 2023, September 07, 2023, September 21, 2023, September 28, 2023, November 06, 2023, December 05, 2023, December 08, 2023, January 02, 2024, February 02, 2024 and February 07, 2024 respectively.

@ The script of Swasthik Plascon Limited, Net Avenue Technologies Limited, AIK Pipes and Polymers Limited, Delaplex Limited and Gabriel Pet Straps Limited have not completed 180 days from the date of listing.

§The script of Yash Optics & Lens Limited, Refractory Shapes Limited and Silkflex Polymers (India) Limited have not completed 180 days from the date of listing.

& The script of Yash Optics & Lens Limited, Refractory Shapes Limited and Silkflex Polymers (India) Limited were listed on April 08, 2024, May 14, 2024 and May 15, 2024 respectively.

^ In compliance with the proviso to Regulation 21A(1) of the Securities and Exchange Board of India (Merchant Bankers) Regulations, 1992, as amended, read with proviso to Regulation 244(3) of the SEBI ICDR Regulations, Shreni Shares Limited being associate of KK Shah Hospitals Limited and its role was limited to marketing of the Issue.

Note: Rights Issues lead managed by Shreni Shares Limited (Formerly known as Shreni Shares Private Limited) have not been included in the abovementioned Summary Statement of Disclosure as the disclosure is limited to IPOs only.

TRACK RECORD OF PAST OFFERS HANDLED BY BOOK RUNNING LEAD MANAGER

For details regarding track record of the Book Running Lead Manager to the Issue as specified in the Circular reference no. CIR/MIRSD/1/2012 dated January 10, 2012 issued by the SEBI, please refer the website of the Book Running Lead Manager at: www.shreni.in.

STOCK MARKET DATA OF EQUITY SHARES

This being an initial public offer of the Equity Shares of our Company, the Equity Shares are not listed on any stock exchange and accordingly, no stock market data is available for the Equity Shares.

MECHANISM FOR REDRESSAL OF INVESTOR GRIEVANCES

The Registrar Agreement provides for retention of records with the Registrar to the Issue for a period of three years from the date of listing and commencement of trading of the Equity Shares to enable the Bidders to approach the Registrar to the Issue for redressal of their grievances. The Registrar to the Issue shall obtain the required information from the SCSBs for addressing any clarifications or grievances of ASBA Bidders.

All grievances may be addressed to the Registrar to the Issue with a copy to the relevant Designated Intermediary with whom the ASBA Form was submitted, giving full details such as name of the sole or First Bidder, ASBA Form number, Bidder's DP ID, Client ID, PAN, address of Bidder, number of Equity Shares applied for, ASBA Account number in which the amount equivalent to the Bid Amount was blocked or the UPI ID (for UPI Bidders who make the payment of Bid Amount through the UPI Mechanism), date of ASBA Form and the name and address of the relevant Designated Intermediary where the Bid was submitted. Further, the Bidder shall enclose the Acknowledgment Slip or the application number from the Designated Intermediary in addition to the documents or information mentioned hereinabove. All grievances relating to Bids submitted through Registered Brokers may be addressed to the Stock Exchange with a copy to the Registrar to the Issue.

All grievances of the Anchor Investors may be addressed to the Registrar to the Issue, giving full details such as the name of the sole or First Bidder, Bid cum Application Form number, Bidders' DP ID, Client ID, PAN, date of the Bid cum Application Form, address of the Bidder, number of the Equity Shares applied for, Bid Amount paid on submission of the Bid cum Application Form and the name and address of the Book Running Lead Manager where the Bid cum Application Form was submitted by the Anchor Investor.

In case of any delay in unblocking of amounts in the ASBA Accounts exceeding Two Working Days from the Bid / Issue Closing Date, the Bidder shall be compensated at a uniform rate of ₹ 100 per day for the entire duration of delay exceeding Two Working Days from the Bid / Issue Closing Date by the intermediary responsible for causing such delay in unblocking. The BRLM shall, in their sole discretion, identify and fix the liability on such intermediary or entity responsible for such delay in unblocking.

The processing fees for applications made by UPI Bidders using the UPI Mechanism may be released to the remitter banks (SCSBs) only after such banks provide a written confirmation on compliance with SEBI Master Circular no. SEBI/HO/MIRSD/POD-1/P/CIR/2023/70 dated May 17, 2023 (to the extent applicable) and SEBI Master Circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023 (to the extent applicable).

In terms of SEBI circular SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021, as amended pursuant to SEBI circular SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021, the SEBI circular SEBI/HO/CFD/DIL2/CIR/P/2022/51 dated April 20, 2022, and SEBI master circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023, and subject to applicable law, any ASBA Bidder whose Bid has not been considered for Allotment, due to failure on the part of any SCSB, shall have the option to seek redressal of the same by the concerned SCSB within three months of the date of listing of the Equity Shares. SCSBs are required to resolve these complaints within 15 days, failing which the concerned SCSB would have to pay interest at the rate of 15% per annum for any delay beyond this period of 15 days.

Further, the investors shall be compensated by the SCSBs in accordance with SEBI circular SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021 in the events of delayed unblock for cancelled/withdrawn/deleted applications, blocking of multiple amounts for the same UPI application, blocking of more amount than the application amount, delayed unblocking of amounts for nonallotted/partially-allotted applications, for the stipulated period. In an event there is a delay in redressal of the investor grievance in relation to unblocking of amounts, the BRLMs shall compensate the investors at the rate higher of ₹100 or 15% per annum of the application amount for the period of such delay. Further, in terms of SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/51 dated April 20, 2022, the payment of processing fees to the SCSBs shall be undertaken pursuant to an application made by the SCSBs to the BRLMs, and such application shall be made only after (i) unblocking of application amounts for each application received by the

SCSB has been fully completed, and (ii) applicable compensation relating to investor complaints has been paid by the SCSB.

The following compensation mechanism has become applicable for investor grievances in relation to Bids made through the UPI Mechanism for public offers opening on or after May 1, 2021, for which the relevant SCSBs shall be liable to compensate the investor:

Scenario	Compensation amount	Compensation period
Delayed unblock for cancelled / withdrawn / deleted applications	₹100 per day or 15% per annum of the Bid Amount, whichever is higher	From the date on which the request for cancellation / withdrawal / deletion is placed on the bidding platform of the Stock Exchange till the date of actual unblock
Blocking of multiple amounts for the same Bid made through the UPI Mechanism	1. Instantly revoke the blocked funds other than the original application amount and 2. ₹100 per day or 15% per annum of the total cumulative blocked amount except the original Bid Amount, whichever is higher	From the date on which multiple amounts were blocked till the date of actual unblock
Blocking more amount than the Bid Amount	1. Instantly revoke the difference amount, i.e., the blocked amount less the Bid Amount and 2. ₹100 per day or 15% per annum of the difference amount, whichever is higher	From the date on which the funds to the excess of the Bid Amount were blocked till the date of actual unblock
Delayed unblock for non – Allotted / partially Allotted applications	₹100 per day or 15% per annum of the Bid Amount, whichever is higher	From the Working Day subsequent to the finalisation of the Basis of Allotment till the date of actual unblock

Further, in the event there are any delays in resolving the investor grievance beyond the date of receipt of the complaint from the investor, for each day delayed, the Book Running Lead Manager shall be liable to compensate the investor ₹ 100 per day or 15% per annum of the Bid Amount, whichever is higher. The compensation shall be payable for the period ranging from the day on which the investor grievance is received till the date of actual unblock.

Our Company, the BRLM and the Registrar to the Issue accept no responsibility for errors, omissions, commission or any acts of SCSBs including any defaults in complying with its obligations under applicable SEBI ICDR Regulations.

For helpline details of the Book Running Lead Manager pursuant to the SEBI/HO/CFD/DIL-2/OW/P/2021/2481/1/M dated March 16, 2021, see “General Information – Book Running Lead Manager” on page 61 of this Prospectus.

Further, the Bidder shall also enclose a copy of the Acknowledgment Slip duly received from the concerned Designated Intermediary in addition to the information mentioned hereinabove.

All grievances relating to Bids submitted with Registered Brokers may be addressed to the Stock Exchanges with a copy to the Registrar to the Issue. The Registrar to the Issue shall obtain the required information from the SCSBs and Sponsor Banks for addressing any clarifications or grievances of ASBA Bidders. Our Company, the BRLM and the Registrar to the Issue accept no responsibility for errors, omissions, commission or any acts of SCSBs including any defaults in complying with its obligations under the SEBI ICDR Regulations.

The Registrar to the Issue shall obtain the required information from the SCSBs and Sponsor Bank for addressing any clarifications or grievances of ASBA Applicants. Applicants can contact our Company Secretary and Compliance officer or the Registrar to the Issue in case of any pre-issue or post-issue related problems such as non-receipt of letters of Allotment, non-credit of Allotted Equity Shares in the respective beneficiary account, non-receipt of refund intimations and non-receipt of funds by electronic mode.

Anchor Investors are required to address all grievances in relation to the Issue to the BRLM.

Further, the Bidder shall also enclose a copy of the Acknowledgment Slip duly received from the concerned Designated Intermediary in addition to the information mentioned herein.

Our Company has also appointed Mr. Jayesh Jain, Company Secretary and Compliance officer for the Issue. For details, see “General Information” beginning on page 61 of this Prospectus.

STATUS OF INVESTOR COMPLAINTS

We confirm that we have not received any investor complaint during the three years preceding the date of this Prospectus and hence there are no pending investor complaints as on the date of this Prospectus.

DISPOSAL OF INVESTOR GRIEVANCES BY OUR COMPANY

Our Company estimates that the average time required by our Company or the Registrar to the Issue or the relevant Designated Intermediary, for the redressal of routine investor grievances shall be 7 (seven) days from the date of receipt of the complaint. In case of non-routine complaints and complaints where external agencies are involved, our Company will seek to redress these complaints within 30 days of receipt of complaint or upon receipt of satisfactory documents.

Our Company shall, after filing of this Prospectus, obtain authentication on the SCORES in terms of the SEBI circular bearing number CIR/OIAE/1/2013 dated April 17, 2013 read with SEBI circular bearing number SEBI/HO/OIAE/IGRD/CIR/P/2021/642 dated October 14, 2021 and shall comply with SEBI circular bearing number CIR/OIAE/1/2014 dated December 18, 2014 in relation to redressal of investor grievances through SCORES.

Further, our Board by a resolution on February 02, 2024, has also constituted a Stakeholders’ Relationship Committee. The composition of the Stakeholders’ Relationship Committee is as follows:

Name of the Directors	Nature of Directorship	Designation in Committee
Mr. Basant Lal Menghwani	Non-Executive Independent Director	Chairman
Mr. Gautam Kothari	Non-Executive Independent Director	Member
Mr. Anil Kumar Sabarwal	Chairman & Managing Director	Member

For further details, please see the chapter titled “Our Management” beginning on page 175 of this Prospectus.

EXEMPTION FROM COMPLYING WITH ANY PROVISIONS OF SECURITIES LAWS, IF ANY, GRANTED BY SEBI

Our company has not applied or received any exemption from complying with any provisions of securities laws by SEBI.

Other confirmations

No person connected with the Issue shall offer any incentive, whether direct or indirect, in any manner, whether in cash or kind or services or otherwise to any person for making an application in the Issue, except for fees or commission for services rendered in relation to the Issue.

SECTION IX – ISSUE INFORMATION

TERMS OF THE ISSUE

The Equity Shares being Issued are subject to the provisions of the Companies Act, SCRA, SCRR, SEBI (ICDR) Regulations, the SEBI Listing Regulations, our Memorandum and Articles of Association, the terms of this Prospectus, Prospectus, Application Form, any Confirmation of Allocation Note (“CAN”), the Revision Form, Allotment advices, and other terms and conditions as may be incorporated in the Allotment advices and other documents/certificates that may be executed in respect of the Issue. The Equity Shares shall also be subject to all applicable laws, guidelines, rules, notifications and regulations relating to the issue of capital and listing and trading of securities issued from time to time by SEBI, the GoI, the Stock Exchange, the RoC, the RBI and/or other authorities, as in force on the date of the Issue and to the extent applicable or such other conditions as may be prescribed by SEBI, RBI, the GoI, the Stock Exchange, the RoC and/or any other authorities while granting its approval for the Issue.

Please note that in terms of SEBI Circular No. CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, all the investors (except Anchor Investors) applying in a public Issue shall use only Application Supported by Blocked Amount (ASBA) process for application providing details of the bank account which will be blocked by the Self Certified Syndicate Banks (SCSBs) for the same. Further, pursuant to SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 01, 2018, Retail Individual Investors applying in public Issue may use either Application Supported by Blocked Amount (ASBA) facility for making application or also can use UPI as a payment mechanism with Application Supported by Blocked Amount for making application.

Further vide the said circular Registrar to the Issue and Depository Participants have been also authorized to collect the Bid-cum-Application forms. Investor may visit the official website of the concerned for any information on operational utilization of this facility of form collection by the Registrar to the Issue and Depository Participants as and when the same is made available.

AUTHORITY FOR THE ISSUE

This Issue has been authorized by a resolution of the Board passed at their meeting held on February 02, 2024 subject to the approval of shareholders through a special resolution to be passed pursuant to section 62(1)(c) of the Companies Act, 2013. The shareholders have authorized the Issue by a special resolution in accordance with Section 62(1)(c) of the Companies Act, 2013 passed at the Extra ordinary General Meeting of the Company held on February 09, 2024.

RANKING OF EQUITY SHARES

The Allottees upon Allotment of Equity Shares under the Issue will be entitled to dividend and other corporate benefits, if any, declared by our Company after the date of Allotment. The Equity Shares being issued and allotted shall be subject to the provisions of the Companies Act 2013, our Memorandum of Associations and Articles of Association shall rank pari passu in all respects with the existing Equity Shares including in respect of the rights to receive dividends and other corporate benefits, if any, declared by us after the date of Allotment. For further details, please see the section titled “Main Provisions of the Articles of Association” beginning on page 283 of this Prospectus.

MODE OF PAYMENT OF DIVIDEND

Our Company shall pay dividends, if declared, to the Shareholders in accordance with the provisions of the Companies Act, the Memorandum and Articles of Association and provisions of the SEBI Listing Regulations and any other guidelines or directions which may be issued by the Government in this regard. Dividends, if any, declared by our Company after the date of Allotment will be payable to the Bidders who have been allotted or transferred Equity Shares pursuant to the Issue, for the entire year, in accordance with applicable laws. For further details, in relation to dividends, see “Dividend Policy” and “Main Provisions of the Articles of Association” beginning on page 195 and 283, respectively of this Prospectus.

FACE VALUE, ISSUE PRICE, FLOOR PRICE AND PRICE BAND

The face value of each Equity Share is ₹ 10 and the Issue Price is ₹ 97/- per Equity Share. The Floor Price is ₹ 93/- per Equity Share and at the Cap Price is ₹ 97/- per Equity Share, being the Price Band. The Anchor Investor Issue Price is ₹ 97/- per Equity Share.

The Issue Price, Price Band and the minimum Bid Lot size for the Issue will be decided by our Company in consultation with the BRLM, and advertised in all editions of The Financial Express (a widely circulated English national daily newspaper), all editions of Jansatta (a widely circulated Hindi national daily newspaper) and a, Hindi regional newspaper

(Hindi being the regional language of Madhya Pradesh, where our Registered Office is located), each with wide circulation, at least two Working Days prior to the Bid/ Issue Opening Date and shall be made available to the Stock Exchanges for the purpose of uploading the same on their websites. The Price Band, along with the relevant financial ratios calculated at the Floor Price and at the Cap Price, shall be pre-filled in the Bid cum Application Forms available on the respective websites of the Stock Exchanges. The Issue Price shall be determined by our Company in consultation with the Book Running Lead Manager, after the Bid/ Issue Closing Date on the basis of assessment of market demand for the Equity Shares offered through the Book Building Process.

At any given point of time, there shall be only one denomination of Equity Shares, unless otherwise permitted by law.

COMPLIANCE WITH DISCLOSURE AND ACCOUNTING NORMS

Our Company shall comply with all disclosure and accounting norms as specified by SEBI from time to time.

RIGHTS OF THE EQUITY SHAREHOLDERS

Subject to applicable laws, rules, regulations and guidelines and our Articles of Association, our Shareholders shall have the following rights:

1. Right to receive dividends, if declared;
2. Right to receive Annual Reports and notices to members;
3. Right to attend general meetings and exercise voting rights, unless prohibited by law;
4. Right to vote on a poll either in person or by proxy and e-voting, in accordance with the provisions of the Companies Act;
5. Right to receive offers for rights shares and be allotted bonus shares, if announced;
6. Right to receive surplus on liquidation, subject to any statutory and preferential claim being satisfied;
7. Right of free transferability of the Equity Shares, subject to applicable laws including any RBI rules and regulations; and
8. Such other rights, as may be available to a shareholder of a listed public company under the Companies Act, the SEBI LODR Regulations, and our Memorandum of Association and Articles of Association.

For a detailed description of the main provisions of the Articles of Association of our Company relating to voting rights, dividend, forfeiture and lien, transfer, transmission and/or consolidation or splitting, see “*Main Provisions of the Articles of Association*” beginning on page 283 of this Prospectus.

ALLOTMENT ONLY IN DEMATERIALISED FORM

Pursuant to Section 29 of the Companies Act and the SEBI ICDR Regulations, the Equity Shares shall be Allotted only in dematerialised form. As per the SEBI ICDR Regulations, the trading of the Equity Shares shall only be in dematerialised form. In this context, two agreements have been signed amongst our Company, the respective Depositories and the Registrar to the Issue:

1. Tripartite agreement dated March 01, 2024 amongst our Company, CDSL and Bigshare Services Private Limited.
2. Tripartite agreement dated February 20, 2024 between our Company, NSDL and Bigshare Services Private Limited.

For details in relation to the Basis of Allotment, see “*Issue Procedure*” on page 259 of this Prospectus.

MINIMUM APPLICATION VALUE, MARKET LOT AND TRADING LOT

In accordance with Regulation 267 (2) of the SEBI ICDR Regulations, our Company shall ensure that the minimum application size shall not be less than ₹ 1,00,000/- (Rupees One Lakh) per application.

The trading of the Equity Shares will happen in the minimum contract size of 1,200 Equity Shares and the same may be modified by the Emerge platform of NSE from time to time by giving prior notice to investors at large.

Allocation and allotment of Equity Shares through this Issue will be done in multiples of 1,200 Equity Shares and is subject to a minimum allotment of 1,200 Equity Shares to the successful applicants in terms of the SEBI circular No. CIR/MRD/DSA/06/2012 dated February 21, 2012.

JOINT HOLDERS

Subject to the provisions contained in our Articles of Association, where two or more persons are registered as the holders of the Equity Shares, they shall be entitled to hold the same as joint tenants with benefits of survivorship.

JURISDICTION

The courts of Mumbai, Maharashtra, India will have exclusive jurisdiction in relation to this Issue.

The Equity Shares issued in the Issue have not been and will not be registered under the U.S. Securities Act or any state securities laws in the United States, and unless so registered, may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in accordance with any applicable U.S. state securities laws. Accordingly, the Equity Shares are being issued and sold outside the United States in 'offshore transactions' in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdictions where such offers and sales are made.

The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

Bidders are advised to ensure that any Bid from them does not exceed investment limits or the maximum number of Equity Shares that can be held by them under applicable law. Further, each Bidder where required must agree in the Allotment Advice that such Bidder will not sell or transfer any Equity Shares or any economic interest therein, including any off-shore derivative instruments, such as participatory notes, issued against the Equity Shares or any similar security, other than in accordance with applicable laws.

NOMINATION FACILITY TO BIDDERS

In accordance with Section 72 of the Companies Act read with the Companies (Share Capital and Debentures) Rules, 2014, as amended, the sole Bidder, or the first Bidder along with other joint Bidders, may nominate any one person in whom, in the event of the death of sole Bidder or in case of joint Bidders, death of all the Bidders, as the case may be, the Equity Shares Allotted, if any, shall vest. A person, being a nominee, entitled to the Equity Shares by reason of the death of the original holder(s), shall be entitled to the same advantages to which he or she would be entitled if he or she were the registered holder of the Equity Share(s). Where the nominee is a minor, the holder(s) may make a nomination to appoint, in the prescribed manner, any person to become entitled to Equity Share(s) in the event of his or her death during the minority. A nomination shall stand rescinded upon a sale, transfer or alienation of Equity Share(s) by the person nominating. A buyer will be entitled to make a fresh nomination in the manner prescribed. Fresh nomination can be made only on the prescribed form available on request at our Registered Office or to the registrar and transfer agents of our Company.

Any person who becomes a nominee by virtue of the provisions of Section 72 of the Companies Act shall upon the production of such evidence as may be required by our Board, elect either:

- a) to register himself or herself as the holder of the Equity Shares; or
- b) to make such transfer of the Equity Shares, as the deceased holder could have made.

Further, our Board may at any time give notice requiring any nominee to choose either to be registered himself or herself or to transfer the Equity Shares, and if the notice is not complied with within a period of 90 days, our Board may thereafter withhold payment of all dividends, bonuses or other monies payable in respect of the Equity Shares, until the requirements of the notice have been complied with.

Since the Allotment of Equity Shares in the Issue will be made only in dematerialised mode there is no need to make a separate nomination with our Company. Nominations registered with respective Depository Participant of the Bidder would prevail. If the Bidder wants to change their nomination, they are requested to inform their respective Depository Participant.

Our Company shall comply with such disclosure and accounting norms as may be specified by SEBI from time to time.

OPTION TO RECEIVE EQUITY SHARES IN DEMATERIALIZED FORM

Allotment of Equity Shares to successful Bidders will only be in the dematerialized form. Bidders will not have the option of Allotment of the Equity Shares in physical form. The Equity Shares on Allotment will be traded only in the dematerialized segment of the Stock Exchange.

WITHDRAWAL OF THE ISSUE

Our Company in consultation with the BRLM, reserve the right to not proceed with the Issue after the Issue Opening Date but before the Allotment. In such an event, our Company would issue a public notice in the newspapers in which the pre-Issue advertisements were published, within two (2) days of the Issue Closing Date or such other time as may be prescribed by SEBI, providing reasons for not proceeding with the Issue. The Book Running Lead Manager, through the Registrar to the Issue, shall notify the SCSBs to unblock the bank accounts of the ASBA Bidders within one (1) Working Day from the date of receipt of such notification. Our Company shall also inform the same to the Stock Exchanges on which Equity Shares are proposed to be listed.

The BRLM, through the Registrar to the Issue, shall notify the SCSBs and the Sponsor Banks (in case of UPI Bidders), to unblock the bank accounts of the ASBA Bidders within one Working Day from the date of receipt of such notification and also inform the Bankers to the Issue to process refunds to the Anchor Investors, as the case may be. The notice of withdrawal will be issued in the same newspapers where the pre-Issue advertisements have appeared, and the Stock Exchanges will also be informed promptly. In terms of the UPI Circulars, in relation to the Issue, the BRLM will submit reports of compliance with the applicable listing timelines and activities, identifying non-adherence to timelines and processes and an analysis of entities responsible for the delay and the reasons associated with it. Further, in case of any delay in unblocking of amounts in the ASBA Accounts (including amounts blocked through the UPI Mechanism) exceeding three Working Days from the Bid/ Issue Closing Date, the Bidder shall be compensated at a uniform rate of ₹100 per day for the entire duration of delay exceeding three Working Days from the Bid/ Issue Closing Date by the intermediary responsible for causing such delay in unblocking. The BRLM shall, in their sole discretion, identify and fix the liability on such intermediary or entity responsible for such delay in unblocking.

Notwithstanding the foregoing, this Issue is also subject to obtaining (i) the final listing and trading approvals of the Stock Exchange, which our Company shall apply for after Allotment, and (ii) the final ROC approval of the Prospectus after it is filed with the ROC. If our Company withdraws the Issue after the Issue Closing Date and thereafter determines that it will proceed with an Issue, our Company shall file a fresh Prospectus.

BID/ISSUE PROGRAM

An indicative timetable in respect of the Issue is set out below:

Event	Indicative Date
Bid/Issue Opens on	May 15, 2024 ⁽¹⁾
Bid/Issue Closes on	May 17, 2024 ⁽²⁾⁽³⁾
Finalization of Basis of Allotment with the Designated Stock Exchange	On or before May 21, 2024
Initiation of Refunds / unblocking of funds from ASBA Account*	On or before May 22, 2024
Credit of Equity Shares to demat account of the Allottees	On or before May 22, 2024
Commencement of trading of the Equity Shares on the Stock Exchange	On or before May 23, 2024

1. Our Company in consultation with the BRLM, may consider participation by Anchor Investors. The Anchor Investor Bid/Issue Period shall be one Working Day prior to the Bid/Issue Opening Date in accordance with the SEBI ICDR Regulations
2. Our Company in consultation with the BRLM, may consider closing the Bid/Issue Period for QIBs one day prior to the Bid/Issue Closing Date in accordance with the SEBI ICDR Regulations
3. UPI mandate end time and date shall be at 5:00 pm IST on Bid/ Issue Closing Date,

In case of any delay in unblocking of amounts in the ASBA Accounts (including amounts blocked through the UPI Mechanism) exceeding two Working Days from the Bid/Offer Closing Date for cancelled/withdrawn/deleted ASBA Forms, the Bidder shall be compensated at a uniform rate of ₹100 per day or 15% per annum of the Bid Amount, whichever is higher, for the entire duration of delay exceeding two Working Days from the Bid/Offer Closing Date by the intermediary responsible for causing such delay in unblocking. The BRLMs and shall, in their sole discretion, identify and fix the liability on such intermediary or entity responsible for such delay in unblocking. The Bidder shall be compensated by the manner

specified in the SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021 read with the SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021, SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/51 dated April 20, 2022 and SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/2022/75 dated May 30, 2022, and the SEBI ICDR Master Circular, which for the avoidance of doubt, shall be deemed to be incorporated in the deemed agreement of the Company with the Self Certified Syndicate Bank(s) (“SCSB”), to the extent applicable. The processing fees for applications made by UPI Bidders using the UPI Mechanism may be released to the remitter banks (SCSBs) only after such banks provide a written confirmation in compliance with SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021 read with SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021 and SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/51 dated April 20, 2022, SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/2022/75 dated May 30, 2022 read with SEBI master circular no. SEBI/HO/CFD/PoD- 2/P/CIR/2023/00094 dated June 21, 2023 and SEBI circular no. SEBI/HO/CFD/TPD1/CIR/P/2023/140 dated August 9, 2023, for which the avoidance of doubt, shall be deemed to be incorporated in the deemed agreement of the Company with the SCSBs, to the extent applicable. The processing fee for applications made by the UPI Bidders using the UPI Mechanism may be released to the remitter banks (SCSBs) only after such banks provide a written confirmation on compliance with SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021 read with SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021 and SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/51 dated April 20, 2022 and SEBI Circular no. SEBI/HO/CFD/DIL2/P/CIR/2022/75 dated May 30, 2022 read with SEBI master circular no. SEBI/HO/MIRSD/POD-1/P/CIR/2023/70 dated May 17, 2023.

The above timetable other than the Bid/Issue Closing Date, is indicative and does not constitute any obligation or liability on our Company or the BRLM.

Any circulars or notifications from the SEBI after the date of this Prospectus may result in changes to the timelines. Further, the Issue procedure is subject to change to any revised circulars issued by the SEBI to this effect.

Whilst our Company shall ensure that all steps for the completion of the necessary formalities for the listing and the commencement of trading of the Equity Shares on the Stock Exchanges are taken within such time as prescribed by SEBI, the timetable may be extended due to various factors, such as extension of the Bid/Issue Period by our Company in consultation with the BRLM, revision of the Price Band or any delay in receiving the final listing and trading approval from the Stock Exchanges. In terms of the SEBI master circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023, our Company shall within three days from the closure of the Issue, refund the subscription amount received in case of non – receipt of minimum subscription or in case our Company fails to obtain listing or trading permission from the Stock Exchanges for the Equity Shares. The commencement of trading of the Equity Shares will be entirely at the discretion of the Stock Exchange and in accordance with the applicable laws. The Shareholder, severally and not jointly, has specifically confirmed that it shall extend such reasonable support and co-operation required by our Company and the BRLM for completion of the necessary formalities for listing and commencement of trading of the Equity Shares at the Stock Exchange within such time as prescribed by SEBI.

The Registrar to the Issue shall submit the details of cancelled/withdrawn/deleted applications to the SCSB’s on daily basis within 60 minutes of the Bid closure time from the Bid/ Issue Opening Date till the Bid/Issue Closing Date by obtaining the same from the Stock Exchanges. The SCSB’s shall unblock such applications by the closing hours of the Working Day.

In terms of the UPI Circulars, in relation to the Issue, the BRLMs will be required to submit reports of compliance with timelines and activities prescribed by SEBI in connection with the allotment and listing procedure within such time as prescribed by SEBI, identifying non-adherence to timelines and processes and an analysis of entities responsible for the delay and the reasons associated with it.

Submission of Bids (other than Bids from Anchor Investors)

Bid/ Offer Period (except the Bid/ Offer Closing Date)	
Submission and Revision in Bids	Only between 10.00 a.m. and 5.00 p.m. (Indian Standard Time (“IST”))
Bid/Offer Closing Date*	
Submission of Electronic Applications (Online ASBA through 3-in-1 accounts) – For RIBs, Eligible Employees Bidding in the Employee Reservation Portion other than QIBs and NIIs	Only between 10.00 a.m. and up to 5.00 p.m. IST

Submission of Electronic Applications (Bank ASBA through Online channels like Internet Banking, Mobile Banking and Syndicate UPI ASBA applications where Bid Amount is up to ₹500,000)	Only between 10.00 a.m. and up to 4.00 p.m. IST
Submission of Electronic Applications (Syndicate Non-Retail, Non-Individual Applications)	Only between 10.00 a.m. and up to 3.00 p.m. IST
Submission of Physical Applications (Bank ASBA)	Only between 10.00 a.m. and up to 1.00 p.m. IST
Submission of Physical Applications (Syndicate Non-Retail, Non-Individual Applications where Bid Amount is more than ₹500,000)	Only between 10.00 a.m. and up to 12.00 p.m. IST
Modification/ Revision/cancellation of Bids	
Upward Revision of Bids by QIBs and Non-Institutional Bidders categories [#]	Only between 10.00 a.m. and up to 5.00 p.m. IST on Bid/ Offer Closing Date
Upward or downward Revision of Bids or cancellation of Bids by RIBs and Eligible Employees Bidding in the Employee Reservation Portion	Only between 10.00 a.m. and up to 5.00 p.m. IST

* UPI mandate and time and date shall be at 5:00 p.m. on Bid/Offer Closing Date

[#] QIBs and Non-Institutional Bidders can neither revise their bids downwards nor cancel/withdraw their bids.

On the Bid/Issue Closing Date, the Bids shall be uploaded until:

- i. 4.00 p.m. IST in case of Bids by QIBs and Non-Institutional Bidders, and
- ii. until 5.00 p.m. IST or such extended time as permitted by the Stock Exchange in case of Bids by RIBs.

On Bid/Issue Closing Date, extension of time will be granted by Stock Exchange only for uploading Bids received by RIBs after taking into account the total number of Bids received and as reported by the Book Running Lead Manager to the Stock Exchange.

The Registrar to the Offer shall submit the details of cancelled/withdrawn/deleted applications to the SCSB's on daily basis within 60 minutes of the Bid closure time from the Bid/ Offer Opening Date till the Bid/Offer Closing Date by obtaining the same from the Stock Exchanges. The SCSB's shall unblock such applications by the closing hours of the Working Day and submit confirmation to the BRLMs and the RTA on the daily basis.

It is clarified that Bids not uploaded on the electronic bidding system or in respect of which the full Bid Amount is not blocked by SCSBs or not blocked under the UPI Mechanism in the relevant ASBA Account, as the case may be, would be rejected.

Due to the limitation of time available for uploading the Bid-Cum- Application Forms on the Bid/Issue Closing Date, Bidders are advised to submit their applications one (1) day prior to the Bid/Issue Closing Date and, in any case, not later than 3.00 p.m. (IST) on the Bid/ Issue Closing Date. Any time mentioned in this Prospectus is IST. Bidders are cautioned that, in the event a large number of Bid-Cum- Application Forms are received on the Bid/ Issue Closing Date, as is typically experienced in public Issue, some Bid-Cum- Application Forms may not get uploaded due to the lack of sufficient time. Such Bid-Cum- Application Forms that cannot be uploaded will not be considered for allocation under this Issue. Applications will be accepted only on Working Days, i.e., Monday to Friday (excluding any public holidays). Neither our Company nor the BRLM is liable for any failure in uploading the Bid-Cum- Application Forms due to faults in any software/hardware system or otherwise; or blocking of application amount by SCSBs on receipt of instructions from the Sponsor Bank due to any errors, omissions, or otherwise non-compliance by various parties involved in, or any other fault, malfunctioning or breakdown in the UPI Mechanism.

Our Company in consultation with the Book Running Lead Manager, reserves the right to revise the Price Band during the Bid Period in accordance with the SEBI ICDR Regulations. The revision in the Price Band shall not exceed 20% on either side, i.e., the Floor Price can move up or down to the extent of 20% of the Floor Price and the Cap Price will be revised accordingly, but the Floor Price shall not be less than the Face Value of the Equity Shares.

In accordance with SEBI ICDR Regulations, QIBs and Non-Institutional Bidders are not allowed to withdraw or lower the size of their application (in terms of the quantity of the Equity Shares or the Application amount) at any stage. Retail Individual Bidders can revise or withdraw their Bid-Cum- Application Forms prior to the Bid/ Issue Closing Date. Allocation to Retail Individual Bidders, in this Issue will be on a proportionate basis.

In case of discrepancy in the data entered in the electronic book vis-à-vis the data contained in the physical Bid-Cum-Application Form, for a particular Bidder, the details as per the file received from Stock Exchange may be taken as the final data for the purpose of Allotment. In case of discrepancy in the data entered in the electronic book vis-à-vis the data contained in the physical or electronic Bid-Cum- Application Form, for a particular ASBA Bidder, the Registrar to the Issue shall ask the relevant SCSBs /RTAs / DPs / stock brokers, as the case may be, for the rectified data.

In case of revision in the Price Band, the Bid/Issue Period shall be extended for at least three additional Working Days after such revision, subject to the Bid/Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company in consultation with the BRLM, for reasons to be recorded in writing, may extend the Bid/Issue Period for a minimum of three Working Days, subject to the Bid/ Issue Period not exceeding 10 Working Days. Any revision in Price Band, and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges, by issuing a public announcement and also by indicating the change on the respective websites of the BRLM and at the terminals of the Syndicate Members and by intimation to the Designated Intermediaries and the Sponsor Bank(s), as applicable. In case of revision of Price Band, the Bid Lot shall remain the same.

In case of discrepancy in data entered in the electronic book vis-à-vis data contained in the Bid cum Application Form for a particular Bidder, the details as per the Bid file received from the Stock Exchanges shall be taken as the final data for the purpose of Allotment.

MINIMUM SUBSCRIPTION

This Issue is not restricted to any minimum subscription level and is 100% underwritten. As per Section 39 of the Companies Act, 2013, if the stated minimum amount has not been subscribed and the sum payable on application is not received within a period of 30 days from the date of the Prospectus, the application money has to be returned within such period as may be prescribed. If our Company does not receive the 100% subscription of the issue through the Issue Document including devolvement of Underwriters, if any, within sixty (60) days from the date of closure of the issue, our Company shall forthwith refund the entire subscription amount received. If there is a delay beyond Two days after our Company becomes liable to pay the amount, our Company and every officer in default will, on and from the expiry of this period, be jointly and severally liable to repay the money, with interest or other penalty as prescribed under the SEBI Regulations, the Companies Act 2013 and applicable law.

In accordance with Regulation 260 of the SEBI (ICDR) Regulations, our Issue shall be hundred percent underwritten. Thus, the underwriting obligations shall be for the entire hundred percent of the issue through the Prospectus and shall not be restricted to the minimum subscription level. For details of underwriting arrangement, kindly refer the chapter titled “*General Information - Underwriting*” on page 54 of this Prospectus.

Further, in accordance with Regulation 268(1) of the SEBI (ICDR) Regulations, our Company shall ensure that the number of prospective allottees to whom the Equity Shares will be allotted will not be less than 50 (Fifty).

Further, in accordance with Regulation 267(2) of the SEBI (ICDR) Regulations, our Company shall ensure that the minimum application size in terms of number of specified securities shall not be less than ₹ 1,00,000/- (Rupees One Lac only) per application.

The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be issued or sold, and applications may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

ARRANGEMENTS FOR DISPOSAL OF ODD LOTS

The trading of the Equity Shares will happen in the minimum contract size of 1,200 shares in terms of the SEBI circular No. CIR/MRD/DSA/06/2012 dated February 21, 2012. However, the Market Maker shall buy the entire shareholding of a shareholder in one lot, where value of such shareholding is less than the minimum contract size allowed for trading on the NSE Emerge.

RESTRICTIONS, IF ANY ON TRANSFER AND TRANSMISSION OF EQUITY SHARES

Except for the lock-in of the pre- Issue capital of our Company, lock-in of the Promoters’ minimum contribution and the Anchor Investor lock-in as provided in “*Capital Structure*” beginning on page 73 of this Prospectus and except as provided in our Articles of Association there are no restrictions on transfer of Equity Shares. Further, there are no restrictions on the transmission of shares/debentures and on their consolidation/splitting, except as provided in the Articles of Association. For details, see “*Main Provisions of the Articles of Association*” beginning on page 283 of this Prospectus.

The above information is given for the benefit of the Applicants. The Applicants are advised to make their own enquiries about the limits applicable to them. Our Company and the Book Running Lead Manager do not accept any responsibility for the completeness and accuracy of the information stated hereinabove. Our Company and the Book Running Lead Manager are not liable to inform the investors of any amendments or modifications or changes in applicable laws or regulations, which may occur after the date of this Prospectus. Applicants are advised to make their independent investigations and ensure that the number of Equity Shares Applied for do not exceed the applicable limits under laws or regulations.

NEW FINANCIAL INSTRUMENTS

As on the date of this Prospectus, there are no outstanding warrants, new financial instruments or any rights, which would entitle the shareholders of our Company, including our Promoters, to acquire or receive any Equity Shares after the Issue. Further, our Company is not issuing any new financial instruments through this Issue.

ALLOTMENT OF SECURITIES IN DEMATERIALIZED FORM

In accordance with the SEBI ICDR Regulations, Allotment of Equity Shares to successful applicants will only be in the dematerialized form. Applicants will not have the option of Allotment of the Equity Shares in physical form. The Equity Shares on Allotment will be traded only on the dematerialized segment of the Stock Exchange.

APPLICATION BY ELIGIBLE NRIS, FPIS OR VCFS REGISTERED WITH SEBI

It is to be understood that there is no reservation for Eligible NRIs, FPIs or VCF registered with SEBI. Such Eligible NRIs, FPIs or VCF registered with SEBI will be treated on the same basis with other categories for the purpose of Allocation.

AS PER THE EXTENT GUIDELINES OF THE GOVERNMENT OF INDIA, OCBS CANNOT PARTICIPATE IN THIS ISSUE

The current provisions of the Foreign Exchange Management (Transfer or Issue of Security by a Person Resident outside India) Regulations, 2000, provides a general permission for the NRIs, FPIs and foreign venture capital investors registered with SEBI to invest in shares of Indian companies by way of subscription in an IPO. However, such investments would be subject to other investment restrictions under the Foreign Exchange Management (Transfer or Issue of Security by a Person Resident outside India) Regulations, 2000, RBI and/or SEBI regulations as may be applicable to such investors. The Allotment of the Equity Shares to Non-Residents shall be subject to the conditions, if any, as may be prescribed by the Government of India/RBI while granting such approvals.

MIGRATION TO MAIN BOARD

SEBI vide Circular Nos. CIR/MRD/DSA/17/2010 dated May 18, 2010, has stipulated the requirements for migration from SME platform to main board. The migration policy of NSE was intimated vide circular Download Ref. No.: NSE/SME/26110 dated March 10, 2014, further revised vide circular Download Ref. No. NSE/SME/37551 dated April 18, 2018 and NSE/SME/47077 dated January 21, 2021. NSE has further reviewed and revised the migration policy effective from April 20, 2023 from NSE Emerge to NSE Main Board vide circular Download Ref. No.: NSE/SME/61057 dated March 07, 2024 to be effective from April 01, 2024 as follows:

1. The paid-up equity capital of the company shall not be less than ₹10 crores and the capitalisation of the company's equity shall not be less than ₹25 crores**

*** Explanation for this purpose, capitalisation will be the product of the price (average of the weekly high and low of the closing prices of the related shares quoted on the stock exchange during 3 months preceding the application date) and the post Issue number of equity shares*

2. The company should have positive cash accruals (Earnings before Interest, Depreciation and Tax) from operations for each of the 3 financial years preceding the migration application and has positive PAT in the immediate Financial Year of making the migration application to Exchange.
3. The company should have been listed on SME platform of the Exchange for at least 3 years.
4. The Company has not referred to the Board of Industrial & Financial Reconstruction (BIFR) &/OR No proceedings have been admitted under Insolvency and Bankruptcy Code against the issuer and Promoting companies.

5. The company has not received any winding up petition admitted by a NCLT.
6. The net worth of the company should be at least ₹50 crores.
7. Total number of public shareholders on the last day of preceding quarter from date of application should be at least 1000.
8. The company desirous of listing its securities on the main board of the Exchange should also satisfy the Exchange on the following:
 - a) The Company should have made disclosures for all material Litigation(s) / dispute(s) / regulatory action(s) to the stock exchanges where its shares are listed in adequate and timely manner.
 - b) Cooling period of two months from the date the security has come out of trade-to-trade category or any other surveillance action, by other exchanges where the security has been actively listed.
 - c) Redressal mechanism of Investor grievance.
 - d) PAN and DIN no. of Director(s) of the Company.
 - e) Change in Control of a Company/Utilisation of funds raised from public.

MARKET MAKING

The shares issued through this Issue are proposed to be listed on the NSE Emerge with compulsory market making through the registered Market Maker of the SME Exchange for a minimum period of three years or such other time as may be prescribed by the Stock Exchange, from the date of listing on NSE Emerge. For further details of the market making arrangement please refer the chapter titled “*General Information*” beginning on page 61 of this Prospectus.

ISSUE STRUCTURE

This Issue is being made in terms of Regulation 229 (2) of Chapter IX of SEBI (ICDR) Regulations, 2018, as amended from time to time, whereby, an issuer whose post issue paid up capital is more than ₹10 crores and up to ₹25 crores, shall issue equity shares to the public and propose to list the same on the Small and Medium Enterprise Exchange (“SME Exchange”, in this case being the Emerge Platform of NSE). For further details regarding the salient features and terms of such an issue, please refer chapter titled “*Terms of the Issue*” and “*Issue Procedure*” beginning on Page No. 246 and 259 respectively of this Prospectus.

ISSUE STRUCTURE

This Issue comprised of Initial Public Offering of 44,49,600 Equity Shares for Cash at an Issue Price of ₹ 97/- per Equity Share. The Issue comprises a reservation of 2,28,000 Equity Shares of face value of ₹10/- each for subscription by the designated Market Maker (“**the Market Maker Reservation Portion**”) and Net Issue to Public of 42,21,600 Equity Shares of face value of ₹10/- each (“**the Net Issue**”). The Issue and the Net Issue will constitute 27.15% and 25.76%, respectively of the post Issue paid-up equity share capital of the Company. The Issue is being made through the Book Building Process.

The Issue is being made through the Book Building Process.

Particulars	Market Maker Reservation Portion	QIBs ⁽¹⁾	Non - Institutional Investors/Bidders	Retail Individual Investors/Bidders
Number of Equity Shares available for allocation or allotment ⁽²⁾	2,28,000 Equity Shares	20,67,600 Equity Shares	6,55,200 Equity Shares available for allocation	14,98,800 Equity Shares available for allocation
Percentage of Issue Size available for Allocation	5.12% of the Issue Size	Not more than 50% of the Net Issue being available for allocation to QIB Bidders. However, up to 5% of the Net QIB Portion will be available for allocation proportionately to Mutual Funds only. Mutual Funds participating in the Mutual Fund Portion will also be eligible for allocation in the remaining QIB Portion (excluding the Anchor Investor Portion). The unsubscribed portion in the Mutual Fund Portion will be added to the Net QIB Portion	Not less than 15% of the Net Issue	Not less than 35% of the Net Issue
Basis of Allotment ⁽³⁾	Firm allotment	Proportionate as follows (excluding the Anchor Investor Portion): (a) 44,400 Equity Shares shall be available for allocation on a proportionate basis to Mutual Funds only; and	Proportionate basis subject to minimum allotment of 1,200 Equity Shares and further allotment in multiples of 1,200 Equity Shares. For details, see “ <i>Issue Procedure</i> ” beginning on page 259 of this Prospectus.	Proportionate basis subject to minimum allotment of 1,200 Equity Shares. For details, see “ <i>Issue Procedure</i> ” beginning on page 259 of this Prospectus.

Particulars	Market Maker Reservation Portion	QIBs ⁽¹⁾	Non - Institutional Investors/Bidders	Retail Individual Investors/Bidders
		(b) 20,67,600 Equity Shares shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds receiving allocation as per (a) above. (c) Up to 60% of QIB Portion (of 12,36,000 Equity Shares) allocated on a discretionary basis to Anchor Investors of which one-third shall be available for allocation to Domestic Mutual Funds only, subject to valid Bid received from Mutual Funds at or above the Anchor Investor Allocation Price		
Mode of Bid	Only through ASBA Process	ASBA only except for Anchor Investors ⁽⁴⁾	Only through ASBA Process	Through ASBA Process, Through Banks or by using UPI ID for payment
Mode of allotment	Compulsorily in dematerialized form			
Minimum Bid Size	2,28,000 Equity Shares	Such number of Equity Shares and in multiples of 1,200 Equity Shares that the Bid Amount exceeds ₹ 2.00 Lakhs	Such number of Equity shares in multiple of 1,200 Equity shares that Bid size exceeds ₹ 2.00 Lakhs	1,200 Equity Shares in multiple of 1,200 Equity shares so that the Bid Amount does not exceed ₹ 2.00 Lakhs
Maximum Bid Size	2,28,000 Equity Shares	Such number of Equity Shares in multiples of 1,200 Equity Shares not exceeding the size of the Net Issue, (excluding the Anchor portion), subject to limits applicable to each Bidder	Such number of Equity Shares in multiples of 1,200 Equity Shares not exceeding the size of the Net Issue (excluding the QIB portion), subject to applicable limits	Such number of Equity Shares in multiples of 1,200 Equity Shares so that the Bid Amount does not exceed ₹2.00 Lakhs
Bid Lot	1,200 Equity Shares and in multiples of 1,200 Equity Shares thereafter			
Trading Lot	1,200 Equity Shares, However the Market Maker may accept odd lots if any in the market as required under the SEBI ICDR Regulations	1,200 Equity Shares and in multiples thereof	1,200 Equity Shares and in multiples thereof	1,200 Equity Shares and in multiples thereof

Particulars	Market Maker Reservation Portion	QIBs ⁽¹⁾	Non - Institutional Investors/Bidders	Retail Individual Investors/Bidders
Who can apply? ⁽⁵⁾	Market Maker	Public financial institutions as specified in Section 2(72) of the Companies Act 2013, scheduled commercial banks, multilateral and bilateral development financial institutions, mutual funds registered with SEBI, FPIs other than individuals, corporate bodies and family offices, VCFs, AIFs, FVCIs, registered with SEBI, state industrial development corporation, insurance company registered with IRDAI, provident fund with minimum corpus of ₹2500 lakhs, pension fund with minimum corpus of ₹2500 lakhs, National Investment Fund set up by the Government of India, insurance funds set up and managed by army, navy or air force of the Union of India, insurance funds set up and managed by the Department of Posts, India and Systemically Important NBFCs, in accordance with applicable laws including FEMA Rules.	Resident Indian individuals, Eligible NRIs, HUFs (in the name of Karta), companies, corporate bodies, scientific institutions, societies, family offices, trusts, FPIs who are individuals, corporate bodies and family offices	Resident Indian individuals, HUFs (in the name of Karta) and Eligible NRIs applying for Equity Shares such that the Bid amount does not exceed ₹2.00 Lakhs in value
Terms of Payment	In case of all other Bidders: Full Bid Amount shall be blocked by the SCSBs in the bank account of the ASBA Bidder (other than Anchor Investors) or by the Sponsor Bank through the UPI Mechanism, that is specified in the ASBA Form at the time of submission of the ASBA Form. In case of Anchor Investors: Full Bid Amount shall be payable by the Anchor Investors at the time of submission of their Bids⁽⁶⁾			

(1) Our Company in consultation with the Book Running Lead Manager, may allocate up to 60% of the QIB Portion to Anchor Investors at the Anchor Investor Issue Price, on a discretionary basis, subject to there being (i) a maximum of two Anchor Investors, where allocation in the Anchor Investor Portion is up to ₹200.00 Lakhs, (ii) minimum of two and maximum of fifteen Anchor Investors, where the allocation under the Anchor Investor Portion is more than ₹200.00 Lakhs but up to ₹2,500.00 Lakhs under the Anchor Investor Portion, subject to a minimum Allotment of ₹100.00 Lakhs per Anchor Investor, and (iii) in case of allocation above ₹2,500.00 Lakhs under the Anchor Investor Portion, a minimum of five such investors and a maximum of fifteen Anchor Investors for allocation up to ₹2,500.00 Lakhs, and an additional ten Anchor Investors for every additional ₹2,500.00 Lakhs or part thereof will be permitted, subject to minimum allotment of ₹100.00 Lakhs per Anchor Investor. An Anchor Investor will make a minimum Bid of such number of Equity Shares, that the Bid Amount is at least ₹200.00 Lakhs. One-third of the Anchor Investor Portion will

be reserved for domestic Mutual Funds, subject to valid Bids being received at or above the price at which allocation is made to Anchor Investors.

- (2) *In terms of Rule 19(2) of the SCRR read with Regulation 252 of the SEBI ICDR Regulations, this is an Issue for at least 25% of the post Issue paid-up Equity share capital of the Company. This Issue is being made through Book Building Process, wherein allocation to the public shall be as per Regulation 252 of the SEBI ICDR Regulations.*
- (3) *Subject to valid Bids being received at or above the Issue Price, under subscription, if any, in any category, except in the QIB Portion, would be allowed to be met with spill-over from any other category or combination of categories of Bidders at the discretion of our Company in consultation with the Book Running Lead Manager and the Designated Stock Exchange, subject to applicable laws.*
- (4) *Anchor Investors are not permitted to use the ASBA process.*
- (5) *In the event that a Bid is submitted in joint names, the relevant Bidders should ensure that the depository account is also held in the same joint names and the names are in the same sequence in which they appear in the Bid cum Application Form. The Bid cum Application Form should contain only the name of the First Bidder whose name should also appear as the first holder of the beneficiary account held in joint names. The signature of only such First Bidder would be required in the Bid cum Application Form and such First Bidder would be deemed to have signed on behalf of the joint holders. Our Company reserves the right to reject, in its absolute discretion, all or any multiple Bids in any or all categories.*
- (6) *Full Bid Amount shall be payable by the Anchor Investors at the time of submission of the Anchor Investor Application Forms provided that any difference between the Anchor Investor Allocation Price and the Anchor Investor Issue Price shall be payable by the Anchor Investor Pay-In Date as indicated in the CAN.*
- (7) *SEBI vide its circular no. SEBI/HO/CFD/DIL2/P/CIR/2022/75 dated May 30, 2022 has mandated that ASBA applications in public issues shall be processed only after the application monies are blocked in the bank accounts of the Bidders. Accordingly, Stock Exchanges shall, for all categories of Bidders viz. QIBs, NIBs and RIBs and also for all modes through which the applications are processed, accept the ASBA applications in their electronic book building platform only with a mandatory confirmation on the application monies blocked.*

The Bids by FPIs with certain structures as described under “Issue Procedure” on page 259 of this Prospectus and having same PAN may be collated and identified as a single Bid in the Bidding process. The Equity Shares Allocated and Allotted to such successful Bidders (with same PAN) may be proportionately distributed.

Bidders will be required to confirm and will be deemed to have represented to our Company, the Underwriters, their respective directors, officers, agents, affiliates and representatives that they are eligible under applicable law, rules, regulations, guidelines and approvals to acquire the Equity Shares.

Subject to valid Bids being received at or above the Issue Price, under-subscription, if any, in the Non-Institutional Portion or the Retail Portion would be allowed to be met with spill-over from other categories or a combination of categories at the discretion of our Company in consultation with the BRLM and the Designated Stock Exchange, on a proportionate basis. However, under-subscription, if any, in the QIB Portion will not be allowed to be met with spill-over from other categories or a combination of categories. For further details, see “Terms of the Issue” on page 246.

In case of any revision in the Price Band, the Bid/ Issue Period shall be extended for at least three additional Working Days after such revision of the Price Band, subject to the total Bid/ Issue Period not exceeding 10 Working Days. Any revision in the Price Band, and the revised Bid/ Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges by issuing a public announcement and also by indicating the change on the websites of the BRLMs and at the terminals of the members of the Syndicate.

In case of discrepancy in the data entered in the electronic book vis-à-vis the data contained in the physical Bid cum Application Form for a particular Bidder, the details as per the Bid file received from the Stock Exchanges may be taken as the final data for the purpose of Allotment

ISSUE PROCEDURE

All Applicants should review the General Information Document for Investing in Public Issue, prepared and issued in accordance with the SEBI circular no CIR/CFD/DIL/12/2013 dated October 23, 2013 notified by SEBI and updated pursuant to SEBI Circular CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015, the SEBI Circular SEBI/HO/CFD/DIL/CIR/P/2016/26 dated January 21, 2016, SEBI circular SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 1, 2018 and updated pursuant to SEBI Circular SEBI/HO/CFD/DIL1/CIR/P/2020/37 dated March 17, 2020 (the "General Information Document") which highlights the key rules, processes and procedures applicable to public issues in general in accordance with the provisions of the Companies Act, the SCRA, the SCRR and the SEBI ICDR Regulations. The General Information Document is available on the websites of Stock Exchange, the Company and the Book Running Lead Manager. Please refer to the relevant provisions of the General Information Document which are applicable to the Issue.

Additionally, all Bidders may refer to the General Information Document for information in relation to (i) category of investors eligible to participate in the Issue; (ii) maximum and minimum Bid size; (iii) price discovery and allocation; (iv) payment instructions for ASBA Bidders/Applicants; (v) issuance of CAN and Allotment in the Issue; (vi) general instructions (limited to instructions for completing the Bid cum Application Form); (vii) submission of Bid cum Application Form; (viii) other instructions (limited to joint bids in cases of individual, multiple bids and instances when an application would be rejected on technical grounds); (ix) applicable provisions of the Companies Act, 2013 relating to punishment for fictitious applications; (x) mode of making refunds; (xi) Designated Date; (xii) disposal of applications; and (xiii) interest in case of delay in Allotment or refund.

SEBI vide its circular no. SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 1, 2018 read with its circular no. SEBI/HO/CFD/DIL2/CIR/P/2019/50 dated April 3, 2019, has introduced an alternate payment mechanism using Unified Payments Interface ("**UPI**") and consequent reduction in timelines for listing in a phased manner. From January 1, 2019, the UPI Mechanism for RIBs applying through Designated Intermediaries was made effective along with the existing process and existing timeline of T+6 days. ("**UPI Phase I**"). The UPI Phase I was effective until June 30, 2019.

With effect from July 1, 2019, SEBI vide its circular no. SEBI/HO/CFD/DIL2/CIR/P/2019/76 dated June 28, 2019, read with circular bearing number SEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019 with respect to Bids by UPI Bidders through Designated Intermediaries (other than SCSBs), the existing process of physical movement of forms from such Designated Intermediaries to SCSBs for blocking of funds has been discontinued and only the UPI Mechanism for such Bids with existing timeline of T+6 days was mandated for a period of three months or launch of five main board public issues, whichever is later ("**UPI Phase II**"). Subsequently, however, SEBI vide its circular no. SEBI/HO/CFD/DCR2/CIR/P/2019/133 dated November 8, 2019 extended the timeline for implementation of UPI Phase II till March 31, 2020. However, given the prevailing uncertainty due to the COVID-19 pandemic, SEBI vide its circular no. SEBI/HO/CFD/DIL2/CIR/P/2020/50 dated March 30, 2020, had decided to continue with the UPI Phase II till further notice. The final reduced timeline of T+3 days for the UPI Mechanism for applications by UPI Bidders ("**UPI Phase III**") and modalities of the implementation of UPI Phase III was notified by SEBI vide its circular no. SEBI/HO/CFD/TPD1/CIR/P/2023/140 dated August 9, 2023 and made effective on a voluntary basis for all issues opening on or after September 1, 2023 and on a mandatory basis for all issues opening on or after December 1, 2023. The Issue will be undertaken pursuant to the processes and procedures under UPI Phase III, subject to any circulars, clarification or notification issued by the SEBI from time to time.

The BRLMs shall be the nodal entity for any Issues arising out of the public issuance process. In terms of Regulation 23(5) and Regulation 52 of SEBI ICDR Regulations, the timelines and processes mentioned in SEBI RTA Master Circular, shall continue to form part of the agreements being signed between the intermediaries involved in the public issuance process and lead managers shall continue to coordinate with intermediaries involved in the said process.

Further, SEBI vide its circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021, as amended pursuant to SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021 and SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/51 dated April 20, 2022, has introduced certain additional measures for streamlining the process of initial public offers and redressing investor grievances, including the reduction of time period for unblocking of application monies from 15 days to four days. This circular is effective for initial public offers opening on/or after May 1, 2021, except as amended pursuant to SEBI circular SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021, and the provisions of this circular, as amended, are deemed to form part of this Prospectus.

Furthermore, pursuant to SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/P/2022/45 dated April 5, 2022, all individual bidders in initial public offerings (opening on or after May 1, 2022) whose application sizes are up to ₹5.00 lakhs shall use the UPI Mechanism and shall also provide their UPI ID in the Bid cum Application Form submitted with Syndicate Members, Registered Brokers, Collecting Depository Participants and Registrar has introduced certain additional measures for streamlining the process of initial public offers and redressing investor grievances. Pursuant to SEBI circular

no. SEBI/HO/CFD/DIL2/P/CIR/2022/75 dated May 30, 2022, applications made using the ASBA facility in initial public offerings shall be processed only after application monies are blocked in the bank accounts of investors (all categories).

In case of any delay in unblocking of amounts in the ASBA Accounts (including amounts blocked through the UPI Mechanism) exceeding three Working Days from the Bid/Issue Closing Date, in accordance with the SEBI master circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023, the Bidder shall be compensated at a uniform rate of ₹100 per day for the entire duration of delay exceeding three Working Days from the Bid/Issue Closing Date by the intermediary responsible for causing such delay in unblocking. The BRLM shall, in their sole discretion, identify and fix the liability on such intermediary or entity responsible for such delay in unblocking. Further, SEBI vide its master circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023, has reduced the timelines for refund of Application money to four days.

The BRLM shall be the nodal entity for any issues arising out of public issuance process.

Our Company and the BRLM, members of the syndicate do not accept any responsibility for the completeness and accuracy of the information stated in this section and the GID and are not liable for any amendment, modification or change in the applicable law which may occur after the date of this Prospectus. Bidders are advised to make their independent investigations and ensure that their Bids are submitted in accordance with applicable laws and do not exceed the investment limits or maximum number of the Equity Shares that can be held by them under applicable law or as specified in the Prospectus and the Prospectus, when filed.

Further, our Company and the Members of the Syndicate are not liable for any adverse occurrences consequent to the implementation of the UPI Mechanism for application in the Issue.

Pursuant to circular no. NSDL/CIR/II/28/2023 dated August 8, 2023 issued by NSDL and circular no. CDSL/OPS/RTA/POLICY/2023/161 dated August 8, 2023 issued by CDSL, our Company may request the Depositories to suspend/ freeze the ISIN in depository system till listing/ trading effective date. Pursuant to the aforementioned circulars, our Company may request the Depositories to suspend/ freeze the ISIN in depository system from or around the date of the Prospectus till the listing and commencement of trading of our Equity Shares. The shareholders who intend to transfer the pre-Offer shares may request our Company and/ or the Registrar for facilitating transfer of shares under suspended/ frozen ISIN by submitting requisite documents to our Company and/ or the Registrar. Our Company and/ or the Registrar would then send the requisite documents along with applicable stamp duty and corporate action charges to the respective depository to execute the transfer of shares under suspended ISIN through corporate action. The transfer request shall be accepted by the Depositories from our Company till one day prior to Bid/ Offer Opening Date.

BOOK BUILDING PROCEDURE

In terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (the “SCRR”) read with Regulation 252 of SEBI ICDR Regulations, the Issue is being made for at least 25% of the post- Issue paid-up Equity Share capital of our Company. The Issue is being made under Regulation 229 (2) of Chapter IX of SEBI ICDR Regulations via book building process wherein not more than 50% of the Issue shall be allocated on a proportionate basis to QIBs, provided that our Company and may, in consultation with the Book Running Lead Manager, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations, of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion. Further, 5% of the QIB Portion (excluding the Anchor Investor Portion) shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the QIB Portion shall be available for allocation on a proportionate basis to all QIBs (other than Anchor Investors), including Mutual Funds, subject to valid Bids being received at or above the Issue Price. Further, not less than 15% of the Issue shall be available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35% of the Issue shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price.

Subject to valid Bids being received at or above the Issue Price, under subscription, if any, in any category, except the QIB Portion, would be allowed to be met with spill-over from any other category or a combination of categories at the discretion of our Company in consultation with the Book Running Lead Manager, and the Designated Stock Exchange subject to receipt of valid Bids received at or above the Issue Price. However, undersubscription, if any, in the QIB Portion will not be allowed to be met with spillover from other categories or a combination of categories.

Bidders must ensure that their PAN is linked with Aadhaar and are in compliance with CBDT notification dated February 13, 2020 and press release dated June 25, 2021 read with press release dated September 17, 2021, and CBDT circular no.7 of 2022, dated March 30, 2022, read with press release dated March 28, 2023.

The Equity Shares, on Allotment, shall be traded only in the dematerialised segment of the Stock Exchange.

Bidders should note that the Equity Shares will be Allotted to all successful Bidders only in dematerialised form. The Bid cum Application Forms, which do not have the details of the Bidders' depository account, including DP ID, Client ID, UPI ID (in case of UPI Bidders using the UPI Mechanism) and PAN, shall be treated as incomplete and will be rejected. Bidders will not have the option of being Allotted Equity Shares in physical form. However, they may get the Equity Shares rematerialised subsequent to Allotment of the Equity Shares in the Issue, subject to applicable laws.

However, they may get the Equity Shares rematerialised subsequent to Allotment of the Equity Shares in the Issue, subject to applicable laws. Phased implementation of UPI.

PHASED IMPLEMENTATION OF UNIFIED PAYMENTS INTERFACE

SEBI has issued the UPI Circulars in relation to streamlining the process of public issue of inter alia, equity shares. Pursuant to the UPI Circulars, the UPI Mechanism has been introduced in a phased manner as a payment mechanism (in addition to mechanism of blocking funds in the account maintained with SCSBs under ASBA) for applications by RIBs through Designated Intermediaries with the objective to reduce the time duration from public issue closure to listing from six Working Days to up to three Working Days. Considering the time required for making necessary changes to the systems and to ensure complete and smooth transition to the UPI payment mechanism, the UPI Circulars have introduced the UPI Mechanism in three phases in the following manner:

Phase I: This phase was applicable from January 1, 2019 until March 31, 2019 or floating of five main board public issues, whichever was later. Subsequently, the timeline for implementation of Phase I was extended till June 30, 2019. Under this phase, an RIB had the option to submit the ASBA Form with any of the Designated Intermediary and use his/ her UPI ID for the purpose of blocking of funds. The time duration from public Issue closure to listing continued to be six Working Days. For further details, refer to the General Information Document available on the website of the Stock Exchange and the Book Running Lead Manager.

Phase II: This phase has become applicable from July 1, 2019. and was to initially continue for a period of three months or floating of five main board public issues, whichever is later. SEBI vide its circular no. SEBI/HO/CFD/DCR2/CIR/P/2019/133 dated November 8, 2019 has decided to extend the timeline for implementation of UPI Phase II until March 31, 2020. Subsequently, SEBI vide its circular no. SEBI/HO/CFD/DIL2/CIR/P/2020/50 dated March 30, 2020 extended the timeline for implementation of UPI Phase II until further notice. Under this phase, submission of the ASBA Form by RIBs through Designated Intermediaries (other than SCSBs) to SCSBs for blocking of funds has been discontinued and replaced by the UPI Mechanism. However, the time duration from public Issue closure to listing continues to be six Working Days during this phase.

Phase III: This phase has become applicable on a voluntary basis for all issues opening on or after September 1, 2023 and on a mandatory basis for all issues opening on or after December 1, 2023, vide SEBI circular bearing number SEBI/HO/CFD/TPD1/CIR/P/2023/140 dated August 9, 2023 ("T+3 Notification"). In this phase, the time duration from public Issue closure to listing has been reduced from six Working Days to three Working Days. The Issue shall be undertaken pursuant to the processes and procedures as notified in the T+3 Notification as applicable, subject to any circulars, clarification or notification issued by SEBI from time to time, including any circular, clarification or notification which may be issued by SEBI.

The Issue is being made under Phase III of the UPI (on a mandatory basis).

Individual investors bidding under the Non-Institutional Portion bidding for more than ₹ 200,000 and up to ₹ 500,000, using the UPI Mechanism, shall provide their UPI ID in the Bid-cum-Application Form for Bidding through Syndicate, sub-syndicate members, Registered Brokers, RTAs or CDPs, or online using the facility of linked online trading, demat and bank account (3 in 1 type accounts), provided by certain brokers.

Pursuant to the SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021 issued by SEBI, as amended by the SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021 and SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/51 dated April 20, 2022 (the "UPI Streamlining Circular"), SEBI has set out specific requirements for redressal of investor grievances for applications that have been made through the UPI Mechanism. The requirements of the UPI Streaming Circular include, appointment of a nodal officer by the SCSB and submission of their details to SEBI, the requirement for SCSBs to send SMS alerts for the blocking and unblocking of UPI mandates, the requirement for the Registrar to submit details of cancelled, withdrawn or deleted applications, and the requirement for the bank accounts of unsuccessful Bidders to be unblocked no later than one day from the date on which the Basis of Allotment is finalised. Failure to unblock the accounts within the timeline would result in the SCSBs being penalised under the relevant

securities law. Additionally, if there is any delay in the redressal of investors' complaints, the relevant SCSB as well as the post-issue BRLM will be required to compensate the concerned investor.

The processing fees for applications made by UPI Bidders using the UPI Mechanism may be released to the SCSBs only after such banks provide a written confirmation, in compliance with the SEBI RTA Master Circular in a format as prescribed by SEBI, from time to time, and such payment of processing fees to the SCSBs shall be made in compliance with circulars prescribed by SEBI and applicable law. The Issue will be made under UPI Phase III of the UPI Circular.

The processing fees for applications made by UPI Bidders using the UPI Mechanism may be released to the remitter banks (SCSBs) only after such banks provide a written confirmation on compliance with SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021 read with SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021 and SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/51 dated April 20, 2022.

All SCSBs offering facility of making application in public issues shall also provide facility to make application using UPI.

All SCSBs offering facility of making application in public issues shall also provide facility to make application using UPI. Our Company will be required to appoint one of the SCSBs as the Sponsor Bank(s) to act as a conduit between the Stock Exchanges and NPCI in order to facilitate collection of requests and / or payment instructions of the UPI Bidders.

Individual investors bidding under the Non-Institutional Portion bidding for more than ₹2.00 lakhs and up to ₹5.00 lakhs, using the UPI Mechanism, shall provide their UPI ID in the Bid-cum-Application Form for Bidding through Syndicate, sub syndicate members, Registered Brokers, RTAs or CDPs, or online using the facility of linked online trading, demat and bank account (3 in 1 type accounts), provided by certain brokers.

Pursuant to the SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021 as amended pursuant to SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021 and SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/51 dated April 20, 2022 ("UPI Streamlining Circular"), SEBI has set out specific requirements for redressal of investor grievances for applications that have been made through the UPI Mechanism. The requirements of the UPI Streamlining Circular include, appointment of a nodal officer by the SCSB and submission of their details to SEBI, the requirement for SCSBs to send SMS alerts for the blocking and unblocking of UPI mandates, the requirement for the Registrar to submit details of cancelled, withdrawn or deleted applications, and the requirement for the bank accounts of unsuccessful Bidders to be unblocked no later than one Working Day from the date on which the Basis of Allotment is finalised. Failure to unblock the accounts within the timeline would result in the SCSBs being penalised under the relevant securities law. Further, in terms of the UPI Circulars, the payment of processing fees to the SCSBs shall be undertaken pursuant to an application made by the SCSBs to the BRLMs, and such application shall be made only after (i) unblocking of application amounts for each application received by the SCSB has been fully completed, and (ii) applicable compensation relating to investor complaints has been paid by the SCSB.

For further details, refer to the General Information Document available on the websites of the Stock Exchange and the Book Running Lead Manager.

BID CUM APPLICATION FORM

Copies of the Bid cum Application Form (other than for Anchor Investors) and the abridged prospectus will be available at the offices of the Book Running Lead Manager, the Designated Intermediaries at Bidding Centres, and Registered Office of our Company. An electronic copy of the Bid cum Application Form will also be available for download on the website of the NSE (www.nseindia.com), at least one day prior to the Bid/Issue Opening Date.

Copies of the Bid cum Application Form (other than for Anchor Investors) and the abridged prospectus will be available with the Designated Intermediaries at the Bidding Centres, and our Registered and Corporate Office. An electronic copy of the Bid cum Application Form will also be available for download on the websites of NSE (www.nseindia.com) at least one day prior to the Bid/Issue Opening Date.

Copies of the Anchor Investor Application Form will be available at the offices of the Book Running Lead Manager.

UPI Bidders Bidding using the UPI Mechanism must provide the valid UPI ID in the relevant space provided in the Bid cum Application Form and the Bid cum Application Forms that do not contain the UPI ID are liable to be rejected. Applications made by the UPI Bidders using third party bank account or using third party linked bank account UPI ID are liable for rejection.

The ASBA Bidders, including UPI Bidders, shall ensure that they have sufficient balance in their bank accounts to be blocked through ASBA for their respective Bid as the application made by a Bidder shall only be processed after the Bid amount is blocked in the ASBA account of the Bidder pursuant to SEBI circular number SEBI/HO/CFD/DIL2/P/CIR/2022/75 dated May 30, 2022, which shall be effective from September 1, 2022.

ASBA Bidders (not using the UPI Mechanism) must provide bank account details and authorisation to block funds in their respective ASBA Accounts in the relevant space provided in the ASBA Form and the ASBA Forms that do not contain such details are liable to be rejected. The ASBA Bidders shall ensure that they have sufficient balance in their bank accounts to be blocked through ASBA for their respective Bid as the application made by a Bidder shall only be processed after the Bid amount is blocked in the ASBA account of the Bidder pursuant to SEBI circular number SEBI/HO/CFD/DIL2/P/CIR/2022/75 dated May 30, 2022, which shall be effective from September 1, 2022. All ASBA Bidders are required to provide either, (i) bank account details and authorizations to block funds in the ASBA Form; or (ii) the UPI ID (in case of UPI Bidders), as applicable, in the relevant space provided in the ASBA Form and the ASBA Forms that did not contain such details will be rejected. Applications made by the UPI Bidders using third party bank account or using third party linked bank account UPI ID are liable to be rejected. The UPI Bidders must provide the valid UPI ID in the relevant space provided in the Bid cum Application Form and the Bid cum Application Forms that do not contain the UPI ID are liable to be rejected. ASBA Bidders shall ensure that the Bids are made on ASBA Forms bearing the stamp of the Designated Intermediary, submitted at the Bidding Centres only (except in case of electronic ASBA Forms) and the ASBA Forms not bearing such specified stamp are liable to be rejected. UPI Bidders using UPI Mechanism, may submit their ASBA Forms, including details of their UPI IDs, with the Syndicate, sub-Syndicate members, Registered Brokers, RTAs or CDPs. RIBs authorising an SCSB to block the Bid Amount in the ASBA Account may submit their ASBA Forms with the SCSBs. ASBA Bidders must ensure that the ASBA Account has sufficient credit balance such that an amount equivalent to the full Bid Amount can be blocked by the SCSB or the Sponsor Banks, as applicable at the time of submitting the Bid. In order to ensure timely information to investors, SCSBs are required to send SMS alerts to investors intimating them about Bid Amounts blocked/ unblocked.

Since the Issue is made under Phase III, ASBA Bidders may submit the ASBA Form in the manner below:

- (a) RIBs (other than the UPI Bidders using UPI Mechanism) may submit their ASBA Forms with SCSBs (physically or online, as applicable), or online using the facility of linked online trading, demat and bank account (3 in 1 type accounts), provided by certain brokers.
- (b) UPI Bidders using the UPI Mechanism, may submit their ASBA Forms with the Syndicate, sub-syndicate members, Registered Brokers, RTAs or CDPs, or online using the facility of linked online trading, demat and bank account (3 in 1 type accounts), provided by certain brokers.
- (c) QIBs and NIIs may submit their ASBA Forms with SCSBs, Syndicate, sub-syndicate members, Registered Brokers, RTAs or CDPs.
- (d) ASBA Bidders are also required to ensure that the ASBA Account has sufficient credit balance as an amount equivalent to the full Bid Amount which can be blocked by the SCSB or the Sponsor Bank(s), as applicable, at the time of submitting the Bid. In order to ensure timely information to investors, SCSBs are required to send SMS alerts to investors intimating them about Bid Amounts blocked / unblocked.

In order to ensure timely information to investors, SCSBs are required to send SMS alerts to investors intimating them about Bid Amounts blocked/ unblocked. The prescribed colour of the Bid cum Application Form for the various categories is as follows:

Category	Colour of Bid cum Application form*
Resident Indians, including QIBs, Non-institutional Investors and Retail Individual Bidders, each resident in India and Eligible NRIs applying on a non-repatriation basis.	White
Non-Residents including Eligible NRIs, their sub-accounts (other than sub-accounts which are foreign corporates or foreign individuals under the QIB Portion), FPIs or FVCIs registered multilateral and bilateral development financial institutions applying on a repatriation basis	Blue
Anchor Investors**	White

* Excluding electronic Bid cum Application Form.

** Bid cum Application Forms for Anchor Investors will be made available at the office of the Book Running Lead Manager. Electronic Bid cum Application forms will also be available for download on the website of NSE (www.nseindia.com).

In case of ASBA forms, the relevant Designated Intermediaries (other than SCSBs) shall submit/deliver the Bid cum Application Form to the respective SCSB, where the Bidder has a bank account and shall not submit it to any non-SCSB bank or any Escrow Bank. Further, SCSBs shall upload the relevant Bid details (including UPI ID in case of ASBA Forms under the UPI Mechanism) in the electronic bidding system of the Stock Exchanges and the Stock Exchanges validate the electronic bids with the records of the CDP for DP ID/Client ID and PAN, on a real time basis and bring inconsistencies to the notice of the relevant Designated Intermediaries, for rectification and re-submission within the time specified by Stock Exchanges. The Stock Exchanges shall accept the ASBA applications in their electronic bidding system only with a mandatory confirmation on application monies blocked. For UPI Bidders, the Stock Exchanges shall allow modification of either DP ID/Client ID or PAN ID, bank code and location code in the Bid details already uploaded. The Stock Exchanges shall share the Bid details (including UPI ID) with the Sponsor Bank(s) on a continuous basis to enable the Sponsor Bank(s) to initiate UPI Mandate Request to UPI Bidders for blocking of funds. For ASBA Forms (other than UPI Bidders) Designated Intermediaries (other than SCSBs) shall submit/ deliver the ASBA Forms to the respective SCSB where the Bidder has an ASBA bank account and shall not submit it to any non-SCSB bank or any Escrow Collection Bank.

For UPI Bidders, the Stock Exchanges shall share the Bid details (including UPI ID) with the Sponsor Bank(s) on a continuous basis through API integration to enable the Sponsor Bank(s) to initiate UPI Mandate Request to UPI Bidders for blocking of funds. The Sponsor Bank(s) shall initiate request for blocking of funds through NPCI to UPI Bidders, who shall accept the UPI Mandate Request for blocking of funds on their respective mobile applications associated with UPI ID linked bank account. The NPCI shall maintain an audit trail for every Bid entered in the Stock Exchanges bidding platform, and the liability to compensate the UPI Bidders in case of failed transactions shall be with the concerned entity (i.e., the Sponsor Bank(s), NPCI or the Bankers to the Issue) at whose end the lifecycle of the transaction has come to a halt. The NPCI shall share the audit trail of all disputed transactions/ investor complaints to the Sponsor Bank(s) and the issuer bank. The Sponsor Bank(s) and the Bankers to the Issue shall provide the audit trail to the Book Running Lead Managers for analysing the same and fixing liability.

The Sponsor Bank(s) will undertake a reconciliation of Bid responses received from Stock Exchanges and sent to NPCI and will also ensure that all the responses received from NPCI are sent to the Stock Exchanges platform with detailed error code and description, if any. Further, the Sponsor Bank(s) will undertake reconciliation of all Bid requests and responses throughout their lifecycle on daily basis and share reports with the Book Running Lead Managers in the format and within the timelines as specified under the SEBI UPI Circulars. Sponsor Bank(s) and issuer banks shall download UPI settlement files and raw data files from the NPCI portal after every settlement cycle and do a three-way reconciliation with Banks UPI switch data, CBS data and UPI raw data. NPCI is to coordinate with issuer banks and Sponsor Bank(s) on a continuous basis.

For ensuring timely information to investors, SCSBs shall send SMS alerts for mandate block and unblock including details specified in SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021, as amended pursuant to SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021 and the SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/51 dated April 20, 2022. For all pending UPI Mandate Requests, the Sponsor Bank(s) shall initiate requests for blocking of funds in the ASBA Accounts of relevant Bidders with a confirmation cut-off time of 5:00 pm IST on the Bid/Issue Closing Date (**“Cut-Off Time”**). Accordingly, UPI Bidders should accept UPI Mandate Requests for blocking off funds prior to the Cut-Off Time and all pending UPI Mandate Requests at the Cut-Off Time shall lapse. Further, modification/cancellation of Bids (if any) shall be allowed in parallel during the Bid/Issue Period until the Cut-Off Time.

Pursuant to NSE circular dated August 3, 2022 with reference no. 25/2022, the following is applicable to all initial public offers opening on or after September 1, 2022:

- a) Cut-off time for acceptance of UPI mandate shall be up to 5:00 pm on the initial public offer closure date and existing process of UPI bid entry by syndicate members, registrars to the Issue and Depository Participants shall continue till further notice;
- b) There shall be no T+1 mismatch modification session for PAN-DP mismatch and bank/ location code on T+1 day for already uploaded bids. The dedicated window provided for mismatch modification on T+1 day shall be discontinued;
- c) Bid entry and modification/ cancellation (if any) shall be allowed in parallel to the regular bidding period up to 5 pm on the initial public offer closure day;

The Sponsor Bank(s) shall host a web portal for intermediaries (closed user group) from the date of Bid/ Issue Opening Date until the date of listing of the Equity Shares with details of statistics of mandate blocks/unblocks, performance of apps and UPI handles, down-time/network latency (if any) across intermediaries and any such processes having an impact/bearing on the Issue Bidding process.

The processing fees for applications made by UPI Bidders may be released to the remitter banks (SCSBs) only after such banks provide a written confirmation in accordance with SEBI circular no: SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021 read with SEBI circular no: SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021 and SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/51 dated April 20, 2022 and SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/2022/75 dated May 30, 2022 and any subsequent circulars or notifications issued by SEBI in this regard.

Pursuant to SEBI Circular No. CIR/CFD/POLICYCELL/11/2015 Dated November 10, 2015, an Investor, intending to subscribe to this Issue, shall submit a completed application form to any of the following intermediaries (Collectively called – Designated Intermediaries”):

1. An SCSB, with whom the bank account to be blocked, is maintained
2. A syndicate member (or sub-syndicate member)
3. A stock broker registered with a recognized stock exchange (and whose name is mentioned on the website of the stock exchange as eligible for this activity) (‘broker’)
4. A Depository Participant (“DP”) (whose name is mentioned on the website of the stock exchange as eligible for this activity)
5. A Registrar to an Issue and share transfer agent (“RTA”) (whose name is mentioned on the website of the stock exchange as eligible for this activity)

The aforesaid intermediary shall, at the time of receipt of application, give an acknowledgement to investor, by giving the counter foil or specifying the application number to the investor, as a proof of having accepted the application form, in physical or electronic mode, respectively.

The upload of the details in the electronic bidding system of stock exchange will be done by:

For Applications submitted by Investors to SCSBs:	After accepting the form, SCSB shall capture and upload the relevant details in the electronic bidding system as specified by the stock exchange and may begin blocking funds available in the bank account specified in the form, to the extent of the application money specified.
For applications submitted by investors to intermediaries other than SCSBs:	After accepting the application form, respective Intermediary shall capture and upload the relevant details in the electronic bidding system of the stock exchange. Post uploading, they shall forward a schedule as per prescribed format along with the application forms to designated branches of the respective SCSBs for blocking of funds within one day of closure of Issue.
For applications submitted by investors to intermediaries other than SCSBs with use of UPI for payment:	After accepting the application form, respective intermediary shall capture and upload the relevant application details, including UPI ID, in the electronic bidding system of stock exchange. Stock exchange shall share application details including the UPI ID with sponsor bank on a continuous basis, to enable sponsor bank to initiate mandate request on investors for blocking of funds. Sponsor bank shall initiate request for blocking of funds through NPCI to investor. Investor to accept mandate request for blocking of funds, on his/her mobile application, associated with UPI ID linked bank account.

Stock exchange shall validate the electronic bid details with depository’s records for DP ID/Client ID and PAN, on a real-time basis and bring the inconsistencies to the notice of intermediaries concerned, for rectification and re-submission within the time specified by stock exchange.

Stock exchange shall allow modification of selected fields viz. DP ID/Client ID or Pan ID (Either DP ID/Client ID or Pan ID can be modified but not BOTH), Bank code and Location code, in the bid details already uploaded.

Upon completion and submission of the Application Form to Application Collecting intermediaries, the Applicants are deemed to have authorized our Company to make the necessary changes in the Prospectus, without prior or subsequent notice of such changes to the Applicants. Applicants shall submit an Application Form either in physical or electronic form to the SCSB’s authorising blocking of funds that are available in the bank account specified in the Application Form used by ASBA Applicants. Designated Intermediaries (other than SCSBs) shall submit/deliver the ASBA Forms/ Application

Forms to the respective SCSB, where the Applicant has a bank account and shall not submit it to any non-SCSB bank or any Escrow Collection Bank.

Who Can Apply?

In addition to the category of Applicants set forth in the General Information Document, the following persons are also eligible to invest in the Equity Shares under all applicable laws, regulations and guidelines:

1. Indian nationals' resident in India who are not incompetent to contract under the Indian Contract Act, 1872, as amended, in single or as a joint application and minors having valid Demat account as per Demographic Details provided by the Depositories. Furthermore, based on the information provided by the Depositories, our Company shall have the right to accept the Applications belonging to an account for the benefit of minor (under guardianship);
2. Hindu Undivided Families or HUFs, in the individual name of the Karta. The Applicant should specify that the application is being made in the name of the HUF in the Application Form as follows: —Name of Sole or First applicant: XYZ Hindu Undivided Family applying through XYZ, where XYZ is the name of the Karta. Applications by HUFs would be considered at par with those from individuals;
3. Companies, corporate bodies and societies registered under the applicable laws in India and authorized to invest in the Equity Shares under their respective constitutional and charter documents;
4. Mutual Funds registered with SEBI;
5. Eligible NRIs on a repatriation basis or on a non-repatriation basis, subject to applicable laws. NRIs other than Eligible NRIs are not eligible to participate in this Issue;
6. Indian Financial Institutions, scheduled commercial banks, regional rural banks, co-operative banks (subject to RBI permission, and the SEBI Regulations and other laws, as applicable);
7. FIIs and sub-accounts of FIIs registered with SEBI, other than a sub-account which is a foreign corporate or a foreign individual under the QIB Portion;
8. Limited Liability Partnerships (LLPs) registered in India and authorized to invest in equity shares;
9. Sub-accounts of FIIs registered with SEBI, which are foreign corporate or foreign individuals only under the non-Institutional investor's category;
10. Venture Capital Funds and Alternative Investment Fund (I) registered with SEBI; State Industrial Development Corporations;
11. Foreign Venture Capital Investors registered with the SEBI;
12. Trusts/societies registered under the Societies Registration Act, 1860, as amended, or under any other law relating to Trusts and who are authorized under their constitution to hold and invest in equity shares;
13. Scientific and/or Industrial Research Organizations authorized to invest in equity shares;
14. Insurance Companies registered with Insurance Regulatory and Development Authority, India;
15. Provident Funds with minimum corpus of Rs. 25 Crores and who are authorized under their constitution to hold and invest in equity shares;
16. Pension Funds with minimum corpus of Rs. 25 Crores and who are authorized under their constitution to hold and invest in equity shares;
17. National Investment Fund set up by Resolution no. F. No. 2/3/2005-DDII dated November 23, 2005 of Government of India published in the Gazette of India;
18. Insurance funds set up and managed by army, navy or air force of the Union of India;
19. Multilateral and bilateral development financial institution;

20. Eligible QFIs;
21. Insurance funds set up and managed by army, navy or air force of the Union of India;
22. Insurance funds set up and managed by the Department of Posts, India;
23. Any other person eligible to apply in this Issue, under the laws, rules, regulations, guidelines and policies applicable to them.
24. Applications not to be made by:
 - a) Minors (except through their Guardians)
 - b) Partnership firms or their nominations
 - c) Foreign Nationals (except NRIs)
 - d) Overseas Corporate Bodies

ELECTRONIC REGISTRATION OF BIDS

- a) The Designated Intermediary may register the Bids using the on-line facilities of the Stock Exchanges. The Designated Intermediaries can also set up facilities for off-line electronic registration of Bids, subject to the condition that they may subsequently upload the off-line data file into the on-line facilities for Book Building on a regular basis before the closure of the Issue.
- b) On the Bid/Issue Closing Date, the Designated Intermediaries may upload the Bids till such time as may be permitted by the Stock Exchanges and as disclosed in the Prospectus.
- c) Only Bids that are uploaded on the Stock Exchanges Platform are considered for allocation/Allotment. The Designated Intermediaries are given till 5:00 pm on the Bid/Issue Closing Date to modify select fields uploaded in the Stock Exchange Platform during the Bid Period after which the Stock Exchange(s) send the bid information to the Registrar to the Issue for further processing.
- d) QIBs and Non-Institutional Investors can neither revise their bids downwards nor cancel/withdraw their bids.

PARTICIPATION BY PROMOTERS, PROMOTER GROUP, THE BOOK RUNNING LEAD MANAGER, THE SYNDICATE MEMBERS AND PERSONS RELATED TO PROMOTERS/PROMOTER GROUP/THE BOOK RUNNING LEAD MANAGER

The Book Running Lead Manager and the Syndicate Members shall not be allowed to purchase Equity Shares in this Issue in any manner, except towards fulfilling their underwriting obligations. However, the associates and affiliates of the Book Running Lead Manager and the Syndicate Members may Bid for Equity Shares in the Issue, either in the QIB Portion or in the Non-Institutional Portion as may be applicable to such Bidders, where the allocation is on a proportionate basis or in any other manner as introduced under applicable laws, and such subscription may be on their own account or on behalf of their clients. All categories of investors, including associates or affiliates of the Book Running Lead Manager and Syndicate Members, shall be treated equally for the purpose of allocation to be made on a proportionate basis.

Except as stated below, neither the Book Running Lead Manager nor any associate of the Book Running Lead Manager can apply in the Issue under the Anchor Investor Portion:

- (i) mutual funds sponsored by entities which are associate of the Book Running Lead Manager;
- (ii) insurance companies promoted by entities which are associate of the Book Running Lead Manager;
- (iii) AIFs sponsored by the entities which are associate of the Book Running Lead Manager; or
- (iv) FPIs other than individuals, corporate bodies and family offices sponsored by the entities which are associate of the Book Running Lead Manager.

Further, an Anchor Investor shall be deemed to be an “associate of the Book Running Lead Manager” if:

- (i) either of them controls, directly or indirectly through its subsidiary or holding company, not less than 15% of the voting rights in the other; or

- (ii) either of them, directly or indirectly, by itself or in combination with other persons, exercises control over the other;
or
- (iii) there is a common director, excluding nominee director, amongst the Anchor Investors, the Book Running Lead Manager.

BIDS BY MUTUAL FUNDS

With respect to Bids by Mutual Funds, a certified copy of their SEBI registration certificate must be lodged along with the Bid cum Application Form. Failing this, our Company in consultation with the Book Running Lead Manager, reserve the right to reject any Bid without assigning any reason thereof, subject to applicable law.

Bids made by asset management companies or custodians of Mutual Funds shall specifically state names of the concerned schemes for which such Bids are made.

In case of a Mutual Fund, a separate Bid can be made in respect of each scheme of the Mutual Fund registered with SEBI and such Bids in respect of more than one scheme of the Mutual Fund will not be treated as multiple Bids provided that the Bids clearly indicate the scheme concerned for which such Bid has been made.

No Mutual Fund scheme shall invest more than 10% of its NAV in equity shares or equity-related instruments of any single company, provided that the limit of 10% shall not be applicable for investments in case of index funds or sector or industry specific schemes. No Mutual Fund under all its schemes should own more than 10% of any company's paid-up share capital carrying voting rights.

BIDS BY ELIGIBLE NON-RESIDENT INDIANS

Eligible NRIs Bidding on non-repatriation basis are advised to use the Bid cum Application Form for residents (White in colour). Eligible NRIs Bidding on a repatriation basis are advised to use the Bid cum Application Form meant for Non-Residents (Blue in colour).

Eligible NRIs may obtain copies of Bid cum Application Form from the Designated Intermediaries. Only Bids accompanied by payment in Indian Rupees or freely convertible foreign exchange will be considered for Allotment. Eligible NRI Bidders Bidding on a repatriation basis by using the Non-Resident Forms should authorise their respective SCSB to block their NRE accounts, or Foreign Currency Non-Resident ("FCNR") Accounts, and eligible NRI Bidders Bidding on a non-repatriation basis by using Resident Forms should authorise their respective SCSB to block their NRO accounts for the full Bid Amount, at the time of the submission of the Bid cum Application Form. Eligible NRIs applying on a non-repatriation basis in the Issue through the UPI Mechanism are advised to enquire with their relevant bank, whether their account is UPI linked, prior to submitting a Bid cum Application Form.

In accordance with the FEMA Rules, the total holding by any individual NRI, on a repatriation basis, shall not exceed 5% of the total paid-up equity capital on a fully diluted basis or shall not exceed 5% of the paid-up value of each series of debentures or preference shares or share warrants issued by an Indian company and the total holdings of all NRIs and OCIs put together shall not exceed 10% of the total paid-up equity capital on a fully diluted basis or shall not exceed 10% of the paid-up value of each series of debentures or preference shares or share warrant. Provided that the aggregate ceiling of 10% may be raised to 24% if a special resolution to that effect is passed by the members of the Indian company in a general meeting.

NRIs will be permitted to apply in the Issue through Channel I or Channel II (as specified in the UPI Circulars). Further, subject to applicable law, NRIs may use Channel IV (as specified in the UPI Circulars) to apply in the Issue, provided the UPI facility is enabled for their NRE/ NRO accounts.

For details of restrictions on investment by NRIs, see "*Restrictions on Foreign Ownership of Indian Securities*" beginning on page 282 of this Prospectus.

Participation of Eligible NRIs in the Issue shall be subject to the FEMA Rules. Only Bids accompanied by payment in Indian rupees or fully converted foreign exchange will be considered for Allotment.

BIDS BY HUFs

Hindu Undivided Families or HUFs, in the individual name of the Karta. The Bidder should specify that the Bid is being made in the name of the HUF in the Bid cum Application Form/Application Form as follows: "Name of sole or first Bidder:

XYZ Hindu Undivided Family applying through XYZ, where XYZ is the name of the Karta. Bids/Applications by HUFs may be considered at par with Bids from individuals.

BIDS BY FPIs

In terms of applicable FEMA Rules and the SEBI FPI Regulations, investments by FPIs in the Equity Shares is subject to certain limits, i.e., the individual holding of an FPI (including its investor group (which means multiple entities registered as foreign portfolio investors and directly or indirectly, having common ownership of more than 50% or common control)) shall be below 10% of our post- Issue Equity Share capital on a fully diluted basis. In case the total holding of an FPI or investor group increases beyond 10% of the total paid-up Equity Share capital of our Company, on a fully diluted basis, the total investment made by the FPI or investor group will be re-classified as FDI subject to the conditions as specified by SEBI and the RBI in this regard and our Company and the investor will be required to comply with applicable reporting requirements. Further, the total holdings of all FPIs put together, with effect from April 1, 2020, can be up to the sectoral cap applicable to the sector in which our Company operates (i.e., up to 100%). In terms of the FEMA Rules, for calculating the aggregate holding of FPIs in a company, holding of all registered FPIs shall be included.

In case of Bids made by FPIs, a certified copy of the certificate of registration issued under the SEBI FPI Regulations is required to be attached to the Bid cum Application Form, failing which our Company reserves the right to reject any Bid without assigning any reason. FPIs who wish to participate in the Issue are advised to use the Bid cum Application Form for Non-Residents (Blue in colour).

In case the total holding of an FPI increases beyond 10% of the total paid-up Equity Share capital, on a fully diluted basis or 10% or more of the paid-up value of any series of debentures or preference shares or share warrants issued that may be issued by our Company, the total investment made by the FPI will be re-classified as FDI subject to the conditions as specified by SEBI and the RBI in this regard and our Company and the investor will be required to comply with applicable reporting requirements.

As specified in 4.1.4.2 (b)(i) and 4.1.4.2 (c)(iv) of the General Information Document, it is hereby clarified that bids received from FPIs bearing the same PAN shall be treated as multiple Bids and are liable to be rejected, except for Bids from FPIs that utilize the multiple investment manager structure in accordance with the Operational Guidelines for Foreign Portfolio Investors and Designated Depository Participants issued to facilitate implementation of SEBI FPI Regulations (“**MIM Structure**”), provided such Bids have been made with different beneficiary account numbers, Client IDs and DP IDs. Accordingly, it should be noted that multiple Bids received from FPIs, who do not utilize the MIM Structure, and bear the same PAN, are liable to be rejected. In order to ensure valid Bids, FPIs making multiple Bids using the same PAN, and with different beneficiary account numbers, Client IDs and DP IDs, are required to provide a confirmation along with each of their Bid cum Application Forms that the relevant FPIs making multiple Bids utilize the MIM Structure and indicate the name of their respective investment managers in such confirmation. In the absence of such confirmation from the relevant FPIs, such multiple Bids are liable to be rejected. Further, in the following cases, the bids by FPIs will not be considered as multiple Bids: involving (i) the MIM Structure and indicating the name of their respective investment managers in such confirmation; (ii) offshore derivative instruments (“**ODI**”) which have obtained separate FPI registration for ODI and proprietary derivative investments; (iii) sub funds or separate class of investors with segregated portfolio who obtain separate FPI registration; (iv) FPI registrations granted at investment strategy level/sub fund level where a collective investment scheme or fund has multiple investment strategies/sub-funds with identifiable differences and managed by a single investment manager; (v) multiple branches in different jurisdictions of foreign bank registered as FPIs; (vi) Government and Government related investors registered as Category 1 FPIs; and (vii) Entities registered as Collective Investment Scheme having multiple share classes.

With effect from the April 1, 2020, the aggregate limit shall be the sectoral caps applicable to the Indian company as prescribed in the FEMA Rules with respect to its paid-up equity capital on a fully diluted basis. While the aggregate limit as provided above could have been decreased by the concerned Indian companies to a lower threshold limit of 24%, 49% or 74% as deemed fit, with the approval of its board of directors and its shareholders through a resolution and a special resolution, respectively before March 31, 2020, our Company has not decreased such limit and accordingly the applicable limit with respect to our Company is 100%.

FPIs are permitted to participate in the Issue subject to compliance with conditions and restrictions which may be specified by the Government from time to time.

Subject to compliance with all applicable Indian laws, rules, regulations, guidelines and approvals in terms of Regulation 21 of the SEBI FPI Regulations, an FPI, may issue, subscribe to or otherwise deal in offshore derivative instruments (as defined under the SEBI FPI Regulations as any instrument, by whatever name called, which is issued overseas by a FPI against securities held by it in India, as its underlying) directly or indirectly, only in the event (i) such offshore derivative instruments are issued only by persons registered as Category I FPIs; (ii) such offshore derivative instruments are issued

only to persons eligible for registration as Category I FPIs; (iii) such offshore derivative instruments are issued after compliance with 'know your client' norms; and (iv) such other conditions as may be specified by SEBI from time to time.

An FPI issuing offshore derivative instruments is also required to ensure that any transfer of offshore derivative instruments issued by or on its behalf, is carried out subject to inter alia the following conditions:

- (a) such offshore derivative instruments are transferred only to persons in accordance with Regulation 22(1) of the SEBI FPI Regulations; and
- (b) prior consent of the FPI is obtained for such transfer, except when the persons to whom the offshore derivative instruments are to be transferred to are pre-approved by the FPI.

Participation of FPIs in the Issue shall be subject to the FEMA Rules

Please note that in terms of the General Information Document, the maximum Bid by any Bidder including QIB Bidder should not exceed the investment limits prescribed for them under applicable laws. Further, MIM Bids by an FPI Bidder utilising the MIM Structure shall be aggregated for determining the permissible maximum Bid. Further, please note that as disclosed in this Prospectus read with the General Information Document, Bid Cum Application Forms are liable to be rejected in the event that the Bid in the Bid cum Application Form *"exceeds the Issue size and/or investment limit or maximum number of the Equity Shares that can be held under applicable laws or regulations or maximum amount permissible under applicable laws or regulations, or under the terms of the Prospectus."*

For example, an FPI must ensure that any Bid by a single FPI and/ or an investor group (which means the same multiple entities having common ownership directly or indirectly of more than 50% or common control) (collective, the "FPI Group") shall be below 10% of the total paid-up Equity Share capital of our Company on a fully diluted basis. Any Bids by FPIs and/ or the FPI Group (including but not limited to (a) FPIs Bidding through the MIM Structure; or (b) FPIs with separate registrations for offshore derivative instruments and proprietary derivative instruments) for 10% or more of our total paid-up post Issue Equity Share capital shall be liable to be rejected.

BIDS UNDER POWER OF ATTORNEY

In case of Bids made pursuant to a power of attorney or by limited companies, corporate bodies, registered societies, eligible FPIs, AIFs, Mutual Funds, insurance companies, insurance funds set up by the army, navy or air force of India, insurance funds set up by the Department of Posts, India or the National Investment Fund and provident funds with a minimum corpus of ₹2,500.00 lakhs and pension funds with a minimum corpus of ₹2,500.00 lakhs (in each case, subject to applicable law and in accordance with their respective constitutional documents), a certified copy of the power of attorney or the relevant resolution or authority, as the case may be, along with a certified copy of the memorandum of association and articles of association and/or bye laws, as applicable must be lodged along with the Bid cum Application Form. Failing this, our Company reserve the right to accept or reject any Bid in whole or in part, in either case, without assigning any reasons thereof.

Our Company in consultation with the Book Running Lead Manager in their absolute discretion, reserve the right to relax the above condition of simultaneous lodging of the power of attorney along with the Bid cum Application Form.

BIDS BY SEBI REGISTERED VCFs, AIFs AND FVCIs

The SEBI FVCI Regulations, inter alia, prescribe the investment restrictions on VCFs and FVCIs registered with SEBI. Further, the SEBI AIF Regulations prescribe, amongst others, the investment restrictions on AIFs. Accordingly, the holding in any company by any individual VCF or FVCI registered with SEBI should not exceed 25% of the corpus of the VCF or FVCI. Further, subject to FEMA Rules, VCFs and FVCIs can invest only up to 33.33% of their investible funds in various prescribed instruments, including in public offerings.

Category I AIFs and Category II AIFs cannot invest more than 25% of the investible funds in one investee company. A category III AIF cannot invest more than 10% of the investible funds in one investee company. A VCF registered as a Category I AIF, as defined in the SEBI AIF Regulations, cannot invest more than one-third of its investible funds by way of subscription to an initial public offering of a venture capital undertaking. Pursuant to the repeal of the SEBI VCF Regulations, the VCFs which have not re-registered as an AIF under the SEBI AIF Regulations shall continue to be regulated by the SEBI VCF Regulations until the existing fund or scheme managed by the fund is wound up and such fund shall not launch any new scheme after the notification of the SEBI AIF Regulations. Our Company, the Book Running Lead Manager will not be responsible for loss, if any, incurred by the Bidder on account of conversion of foreign currency.

Participation of VCFs, AIFs or FVCIs in the Issue shall be subject to the FEMA Rules.

All non-resident investors should note that refunds (in case of Anchor Investors), dividends and other distributions, if any, will be payable in Indian Rupees only and net of bank charges and commission.

BIDS BY LIMITED LIABILITY PARTNERSHIPS

In case of Bids made by limited liability partnerships registered under the Limited Liability Partnership Act, 2008, a certified copy of certificate of registration issued under the Limited Liability Partnership Act, 2008, must be attached to the Bid cum Application Form. Failing this, our Company in consultation with the Book Running Lead Manager, reserve the right to reject any Bid without assigning any reason thereof.

BIDS BY BANKING COMPANIES

In case of Bids made by banking companies registered with the RBI, certified copies of (i) the certificate of registration issued by the RBI, and (ii) the approval of such banking company's investment committee are required to be attached to the Bid cum Application Form. Failing this, our Company in consultation with the Book Running Lead Manager, reserve the right to reject any Bid without assigning any reason thereof, subject to applicable law.

The investment limit for banking companies in non-financial services companies as per the Banking Regulation Act, 1949, as amended, (the "Banking Regulation Act"), and the Master Directions - Reserve Bank of India (Financial Services provided by Banks) Directions, 2016, as amended, is 10% of the paid-up share capital of the investee company, not being its subsidiary engaged in non-financial services, or 10% of the bank's own paid-up share capital and reserves, whichever is lower. Further, the aggregate investment by a banking company in subsidiaries and other entities engaged in financial services company cannot exceed 20% of the investee company's paid-up share capital and reserves. However, a banking company would be permitted to invest in excess of 10% but not exceeding 30% of the paid-up share capital of such investee company if (i) the investee company is engaged in non-financial activities permitted for banks in terms of Section 6(1) of the Banking Regulation Act, or (ii) the additional acquisition is through restructuring of debt/corporate debt restructuring/strategic debt restructuring, or to protect the bank's interest on loans/investments made to a company. The bank is required to submit a time-bound action plan for disposal of such shares within a specified period to the RBI. A banking company would require a prior approval of the RBI to make (i) investment in excess of 30% of the paid-up share capital of the investee company, (ii) investment in a subsidiary and a financial services company that is not a subsidiary (with certain exceptions prescribed), and (iii) investment in a non-financial services company in excess of 10% of such investee company's paid-up share capital as stated in 5(a)(v)(c)(i) of the Reserve Bank of India (Financial Services provided by Banks) Directions, 2016, as amended.

BIDS BY SCSBs

SCSBs participating in the Issue are required to comply with the terms of the circulars bearing numbers CIR/CFD/DIL/12/2012 and CIR/CFD/DIL/1/2013 dated September 13, 2012 and January 2, 2013, respectively, issued by SEBI. Such SCSBs are required to ensure that for making applications on their own account using ASBA, they should have a separate account in their own name with any other SEBI registered SCSBs. Further, such account shall be used solely for the purpose of making application in public issues and clear demarcated funds should be available in such account for such applications.

BIDS BY INSURANCE COMPANIES

In case of Bids made by insurance companies registered with the IRDAI, a certified copy of certificate of registration issued by IRDAI must be attached to the Bid cum Application Form. Failing this, our Company in consultation with the Book Running Lead Manager, reserve the right to reject any Bid without assigning any reason thereof, subject to applicable law.

The exposure norms for insurers are prescribed under the Insurance Regulatory and Development Authority of India (Investment) Regulations, 2016, as amended ("IRDAI Investment Regulations"), based on investments in the equity shares of a company, the entire group of the investee company and the industry sector in which the investee company operates. Insurance companies participating in the Issue are advised to refer to the IRDAI Investment Regulations for specific investment limits applicable to them and shall comply with all applicable regulations, guidelines and circulars issued by IRDAI from time to time.

BIDS BY PROVIDENT FUNDS/PENSION FUNDS

In case of Bids made by provident funds/pension funds with minimum corpus of ₹2,500.00 lakhs, subject to applicable law, a certified copy of a certificate from a chartered accountant certifying the corpus of the provident fund/pension fund must be attached to the Bid cum Application Form. Failing this, our Company in consultation with the Book Running Lead Manager, reserve the right to reject any Bid, without assigning any reason thereof.

BIDS BY SYSTEMICALLY IMPORTANT NON-BANKING FINANCIAL COMPANIES

In case of Bids made by Systemically Important Non-Banking Financial Companies registered with RBI, certified copies of: (i) the certificate of registration issued by RBI, (ii) certified copy of its last audited financial statements on a standalone basis, (iii) a net worth certificate from its statutory auditor, and (iv) such other approval as may be required by the Systemically Important Non-Banking Financial Companies, are required to be attached to the Bid cum Application Form. Failing this, our Company in consultation with the Book Running Lead Manager, reserves the right to reject any Bid without assigning any reason thereof, subject to applicable law. Systemically Important NBFCs participating in the Issue shall comply with all applicable regulations, guidelines and circulars issued by RBI from time to time.

The investment limit for Systemically Important NBFCs shall be as prescribed by RBI from time to time

BIDS BY ANCHOR INVESTORS

In accordance with the SEBI ICDR Regulations, in addition to details and conditions mentioned in this section, the key terms for participation by Anchor Investors are provided below.

- 1) Anchor Investor Application Forms will be made available for the Anchor Investors Portion at the offices of the Book Running Lead Manager.
- 2) The Bid must be for a minimum of such number of Equity Shares so that the Bid Amount is at least ₹200.00 lakhs. A Bid cannot be submitted for over 60% of the QIB Portion. In case of a Mutual Fund, separate Bids by individual schemes of a Mutual Fund will be aggregated to determine the minimum application size of ₹200.00 lakhs.
- 3) One-third of the Anchor Investor Portion will be reserved for allocation to domestic Mutual Funds.
- 4) Bidding for Anchor Investors will open one Working Day before the Bid/ Issue Opening Date and be completed on the same day.
- 5) Our Company in consultation with the Book Running Lead Manager, will finalize allocation to the Anchor Investors on a discretionary basis, provided that the minimum and maximum number of Allottees in the Anchor Investor Portion will be, as mentioned below:
 - where allocation in the Anchor Investor Portion is up to 200.00 Lakhs, maximum of 2 (two) Anchor Investors.
 - where the allocation under the Anchor Investor Portion is more than ₹200.00 Lakhs but up to ₹2,500.00 Lakhs, minimum of 2 (two) and maximum of 15 (fifteen) Anchor Investors, subject to a minimum Allotment of ₹100.00 Lakhs per Anchor Investor; and
 - where the allocation under the Anchor Investor portion is more than ₹2,500.00 Lakhs: (i) minimum of 5 (five) and maximum of 15 (fifteen) Anchor Investors for allocation up to ₹2,500.00 Lakhs; and (ii) an additional 10 Anchor Investors for every additional allocation of ₹2,500.00 Lakhs or part thereof in the Anchor Investor Portion; subject to a minimum Allotment of ₹100.00 Lakhs per Anchor Investor.
- 6) Allocation to Anchor Investors will be completed on the Anchor Investor Bidding Date. The number of Equity Shares allocated to Anchor Investors and the price at which the allocation is made will be made available in the public domain by the Book Running Lead Manager before the Bid/ Issue Opening Date, through intimation to the Stock Exchange.
- 7) Anchor Investors cannot withdraw or lower the size of their Bids at any stage after submission of the Bid.
- 8) If the Issue Price is greater than the Anchor Investor Allocation Price, the additional amount being the difference between the Issue Price and the Anchor Investor Allocation Price will be payable by the Anchor Investors within Anchor Investor Pay-in Date specified in the CAN. If the Issue Price is lower than the Anchor Investor Allocation Price, Allotment to successful Anchor Investors will be at the higher price, i.e., the Anchor Investor Issue Price.
- 9) The Equity Shares Allotted in the Anchor Investor Portion will be locked in, in accordance with the SEBI ICDR Regulations. 50% of the Equity Shares Allotted to Anchor Investors in the Anchor Investor Portion shall be locked in for a period of 90 days from the date of Allotment, while the remaining 50% of the Equity Shares Allotted to Anchor Investors in the Anchor Investor Portion shall be locked in for a period of 30 days from the date of Allotment.

- 10) Neither the (a) Book Running Lead Manager or any associate of the Book Running Lead Manager (other than mutual funds sponsored by entities which are associate of the Book Running Lead Manager or insurance companies promoted by entities which are associate of the Book Running Lead Manager or Alternate Investment Funds (AIFs) sponsored by the entities which are associates of the Book Running Lead Manager or FPIs, other than individuals, corporate bodies and family offices, sponsored by the entities which are associate of the Book Running Lead Manager) nor (b) the Promoters, Promoter Group or any person related to the Promoters or members of the Promoter Group shall apply under the Anchor Investors category.

For more information, please read the General Information Document.

The information set out above is given for the benefit of the Bidders. Our Company, the Book Running Lead Manager are not liable for any amendments or modification or changes to applicable laws or regulations, which may occur after the date of this Prospectus. Bidders are advised to make their independent investigations and ensure that any single Bid from them does not exceed the applicable investment limits or maximum number of the Equity Shares that can be held by them under applicable law or regulations, or as will be specified in the Prospectus.

Information for Bidders

The relevant Designated Intermediary will enter a maximum of three Bids at different price levels opted in the Bid cum Application Form and such options are not considered as multiple Bids. It is the Bidder's responsibility to obtain the acknowledgment slip from the relevant Designated Intermediary. The registration of the Bid by the Designated Intermediary does not guarantee that the Equity Shares shall be allocated/Allotted. Such Acknowledgement Slip will be non-negotiable and by itself will not create any obligation of any kind. When a Bidder revises his or her Bid, he /she shall surrender the earlier Acknowledgement Slip and may request for a revised acknowledgment slip from the relevant Designated Intermediary as proof of his or her having revised the previous Bid.

In relation to electronic registration of Bids, the permission given by the Stock Exchanges to use their network and software of the electronic bidding system should not in any way be deemed or construed to mean that the compliance with various statutory and other requirements by our Company and/or the Book Running Lead Manager are cleared or approved by the Stock Exchanges; nor does it in any manner warrant, certify or endorse the correctness or completeness of compliance with the statutory and other requirements, nor does it take any responsibility for the financial or other soundness of our Company, the management or any scheme or project of our Company; nor does it in any manner warrant, certify or endorse the correctness or completeness of any of the contents of this Prospectus or the Prospectus; nor does it warrant that the Equity Shares will be listed or will continue to be listed on the Stock Exchanges.

GENERAL INSTRUCTIONS

Please note that QIBs and Non-Institutional Bidders are not permitted to withdraw their Bid(s) or lower the size of their Bid(s) (in terms of quantity of Equity Shares or the Bid Amount) at any stage. RIBs can revise their Bid(s) during the Bid Period and withdraw or lower the size of their Bid(s) until Bid/Issue Closing Date. Anchor Investors are not allowed to withdraw their Bids after the Anchor Investor Bid Period.

Do's:

1. Check if you are eligible to apply as per the terms of the Prospectus and under applicable law, rules, regulations, guidelines and approvals;
2. Ensure that your PAN is linked with Aadhaar and you are in compliance with Central Board of Direct Taxes notification dated February 13, 2020 and press release dated June 25, 2021
3. All Bidders (other than Anchor Investors) should submit their Bids through the ASBA process only;
4. Ensure that you have Bid within the Price Band;
5. Read all the instructions carefully and complete the Bid cum Application Form in the prescribed form;
6. Ensure that you (other than the Anchor Investors) have mentioned the correct details of ASBA Account (i.e. bank account number or UPI ID, as applicable) in the Bid cum Application Form if you are not a UPI Bidder in the Bid cum Application Form and if you are a UPI Bidder ensure that you have mentioned the correct UPI ID (with maximum length of 45 characters including the handle), in the Bid cum Application Form;

7. Ensure that your Bid cum Application Form bearing the stamp of a Designated Intermediary is submitted to the Designated Intermediary at the relevant Bidding Centre (except in case of electronic Bids) within the prescribed time. Bidders (other than Anchor Investors) shall submit the Bid cum Application Form in the manner set out in the General Information Document;
8. UPI Bidders Bidding in the Issue shall ensure that they use only their own ASBA Account or only their own bank account linked UPI ID to make an application in the Issue and not ASBA Account or bank account linked UPI ID of any third party
9. UPI Bidders not using the UPI Mechanism, should submit their Bid cum Application Form directly with SCSBs and/or the designated branches of SCSBs;
10. Ensure that you mandatorily have funds equal to the Bid Amount in the ASBA Account maintained with the SCSB before submitting the ASBA Form to the relevant Designated Intermediaries;
11. Ensure that the signature of the first Bidder in case of joint Bids, is included in the Bid cum Application Forms. If the first Bidder is not the ASBA Account holder, ensure that the Bid cum Application Form is also signed by the ASBA Account holder;
12. Ensure that the names given in the Bid cum Application Form is/are exactly the same as the names in which the beneficiary account is held with the Depository Participant. In case of joint Bids, the Bid cum Application Form should contain the name of only the first Bidder whose name should also appear as the first holder of the beneficiary account held in joint names;
13. Ensure that you request for and receive a stamped acknowledgement in the form of a counterfoil or acknowledgment specifying the application number as a proof of having accepted the Bid cum Application Form for all your Bid options from the concerned Designated Intermediary;
14. Ensure that you submit the revised Bids to the same Designated Intermediary, through whom the original Bid was placed and obtain a revised acknowledgment.
15. Except for Bids (i) on behalf of the Central or State Governments and the officials appointed by the courts, who, in terms of the circular no. MRD/DoP/Cir-20/2008 dated June 30, 2008 issued by SEBI, may be exempt from specifying their PAN for transacting in the securities market, (ii) Bids by persons resident in the state of Sikkim, who, in terms of the circular dated July 20, 2006 issued by SEBI, may be exempted from specifying their PAN for transacting in the securities market, and (iii) persons/entities exempt from holding a PAN under applicable law, all Bidders should mention their PAN allotted under the IT Act. The exemption for the Central or the State Government and officials appointed by the courts and for investors residing in the State of Sikkim is subject to (a) the Demographic Details received from the respective depositories confirming the exemption granted to the beneficial owner by a suitable description in the PAN field and the beneficiary account remaining in "active status"; and (b) in the case of residents of Sikkim, the address as per the Demographic Details evidencing the same. All other applications in which PAN is not mentioned will be rejected;
16. Ensure that thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the Constitution of India are attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official seal;
17. Ensure that the category and the investor status is indicated in the Bid cum Application Form to ensure proper upload of your Bid in the electronic Bidding system of the Stock Exchanges;
18. Ensure that in case of Bids under power of attorney or by limited companies, corporates, trust, etc., relevant documents including a copy of the power of attorney, if applicable, are submitted;
19. Ensure that Bids submitted by any person outside India is in compliance with applicable foreign and Indian laws;
20. However, Bids received from FPIs bearing the same PAN shall not be treated as multiple Bids in the event such FPIs utilise the MIM Structure and such Bids have been made with different beneficiary account numbers, Client IDs and DP IDs.
21. FPIs making MIM Bids using the same PAN, and different beneficiary account numbers, Client IDs and DP IDs, are required to submit a confirmation that their Bids are under the MIM structure and indicate the name of their investment

managers in such confirmation which shall be submitted along with each of their Bid cum Application Forms. In the absence of such confirmation from the relevant FPIs, such MIM Bids shall be rejected;

22. Since the Allotment will be in dematerialised form only, ensure that the depository account is active, the correct DP ID, Client ID, UPI ID (for UPI Bidders Bidding through UPI mechanism) and the PAN are mentioned in their Bid cum Application Form and that the name of the Bidder, the DP ID, Client ID, UPI ID (for UPI Bidders Bidding through UPI mechanism) and the PAN entered into the online IPO system of the Stock Exchanges by the relevant Designated Intermediary, as applicable, matches with the name, DP ID, Client ID, UPI ID (for UPI Bidders Bidding through UPI mechanism) and PAN available in the Depository database;
23. In case of QIBs and NIIs, ensure that while Bidding through a Designated Intermediary, the ASBA Form is submitted to a Designated Intermediary in a Bidding Centre and that the SCSB where the ASBA Account, as specified in the ASBA Form, is maintained has named at least one branch at that location for the Designated Intermediary to deposit ASBA Forms (a list of such branches is available on the website of SEBI at www.sebi.gov.in);
24. Ensure that you have correctly signed the authorisation / undertaking box in the Bid cum Application Form, or have otherwise provided an authorisation to the SCSB or the Sponsor Banks, as applicable, via the electronic mode, for blocking funds in the ASBA Account equivalent to the Bid Amount mentioned in the Bid cum Application Form at the time of submission of the Bid. In case of UPI Bidders submitting their Bids and participating in the Issue through the UPI Mechanism, ensure that you authorise the UPI Mandate Request, including in case of any revision of Bids, raised by the Sponsor Banks for blocking of funds equivalent to Bid Amount and subsequent debit of funds in case of Allotment;
25. Ensure that the Demographic Details are updated, true and correct in all respects;
26. The ASBA Bidders shall use only their own bank account or only their own bank account linked UPI ID for the purposes of making Application in the Issue, which is UPI 2.0 certified by NPCI;
27. Bidders (except UPI Bidders) should instruct their respective banks to release the funds blocked in the ASBA account under the ASBA process. In case of RIBs, once the Sponsor Banks issues the Mandate Request, the RIBs would be required to proceed to authorize the blocking of funds by confirming or accepting the UPI Mandate Request to authorize the blocking of funds equivalent to application amount and subsequent debit of funds in case of Allotment, in a timely manner;
28. Bidding through UPI Mechanism shall ensure that details of the Bid are reviewed and verified by opening the attachment in the UPI Mandate Request and then proceed to authorize the UPI Mandate Request using his/her UPI pin. Upon the authorization of the mandate using his/her UPI pin, a UPI Bidder Bidding through UPI Mechanism shall be deemed to have verified the attachment containing the application details of the RIB Bidding through UPI Mechanism in the UPI Mandate Request and have agreed to block the entire Bid Amount and authorized the Sponsor Banks Issue a request to block the Bid Amount specified in the Bid cum Application Form in his/her ASBA Account;
29. UPI Bidders should mention valid UPI ID of only the Bidder (in case of single account) and of the first Bidder (in case of joint account) in the Bid cum Application Form;
30. UPI Bidders who have revised their Bids subsequent to making the initial Bid should also approve the revised UPI Mandate Request generated by the Sponsor Banks to authorize blocking of funds equivalent to the revised Bid Amount and subsequent debit of funds in case of Allotment in a timely manner;
31. Bids by Eligible NRIs for a Bid Amount of less than ₹2.00 lakhs would be considered under the Retail Category for the purposes of allocation and Bids for a Bid Amount exceeding ₹2.00 lakhs would be considered under the Non-Institutional Category for allocation in the Issue;
32. UPI Bidders using UPI Mechanism through the SCSBs and mobile applications shall ensure that the name of the bank appears in the list of SCSBs which are live on UPI, as displayed on the SEBI website. RIBs shall ensure that the name of the app and the UPI handle which is used for making the application appears in Annexure 'A' to the SEBI circular no. SEBI/HO/CFD/DIL2/COR/P/2019/85 dated July 26, 2019; and
33. Ensure that you have accepted the UPI Mandate Request received from the Sponsor Banks prior to 12:00 p.m. of the Working Day immediately after the Bid/ Issue Closing Date.
34. The ASBA bidders shall ensure that bids above ₹5.00 lakhs, are uploaded only by the SCSBs.

The Bid cum Application Form is liable to be rejected if the above instructions, as applicable, are not complied with. Application made using incorrect UPI handle or using a bank account of an SCSB or SCSBs which is not mentioned in the Annexure 'A' to the SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019 is liable to be rejected.

Don'ts:

1. Do not Bid for lower than the minimum Bid Lot;
2. Do not submit a Bid using UPI ID, if you are not a UPI Bidder;
3. Do not Bid for a Bid Amount exceeding ₹2.00 lakhs (for Bids by RIBs) and ₹5.00 lakhs for Bids by Eligible Employees Bidding in the Employee Reservation Portion;
4. Do not Bid on another Bid cum Application Form and the Anchor Investor Application Form, as the case may be, after you have submitted a Bid to any of the Designated Intermediary;
5. Do not Bid/ revise the Bid amount to less than the Floor Price or higher than the Cap Price;
6. Do not pay the Bid Amount in cheques, demand drafts or by cash, money order, postal order or by stock invest;
7. Do not send Bid cum Application Forms by post; instead submit the same to the Designated Intermediary only;
8. Do not Bid at Cut-off Price (for Bids by QIBs and Non-Institutional Bidders);
9. Do not instruct your respective banks to release the funds blocked in the ASBA Account under the ASBA process;
10. Do not submit the Bid for an amount more than funds available in your ASBA account;
11. Do not submit Bids on plain paper or on incomplete or illegible Bid cum Application Forms or on Bid cum Application Forms in a colour prescribed for another category of Bidder;
12. Do not submit a Bid in case you are not eligible to acquire Equity Shares under applicable law or your relevant constitutional documents or otherwise;
13. Do not Bid if you are not competent to contract under the Indian Contract Act, 1872 (other than minors having valid depository accounts as per Demographic Details provided by the depository);
14. Do not fill up the Bid cum Application Form such that the Equity Shares Bid for exceeds the Issue size and / or investment limit or maximum number of the Equity Shares that can be held under the applicable laws or regulations or maximum amount permissible under the applicable regulations or under the terms of the Prospectus;
15. Do not Bid for Equity Shares more than specified by respective Stock Exchanges for each category;
16. In case of ASBA Bidders (other than UPI Bidders using UPI mechanism), do not submit more than one Bid cum Application Form per ASBA Account;
17. Do not make the Bid cum Application Form using third party bank account or using third party linked bank account UPI ID;
18. Anchor Investors should not bid through the ASBA process;
19. Do not submit the Bid cum Application Form to any non-SCSB bank or our Company;
20. Do not Bid on another Bid cum Application Form and the Anchor Investor Application Form, as the case may be, after you have submitted a Bid to any of the Designated Intermediaries;
21. Do not submit the GIR number instead of the PAN;
22. Anchor Investors should submit Anchor Investor Application Form only to the Book Running Lead Manager;
23. Do not Bid on a Bid cum Application Form that does not have the stamp of a Designated Intermediary;

24. If you are a QIB, do not submit your Bid after 3 p.m. on the QIB Bid/ Issue Closing Date;
25. Do not withdraw your Bid or lower the size of your Bid (in terms of quantity of the Equity Shares or the Bid Amount) at any stage, if you are a QIB or a Non-Institutional Bidder. Retail Individual Bidders or Eligible Employees Bidding in the Employee Reservation Portion can revise or withdraw their Bids on or before the Bid/ Issue Closing Date;
26. Do not submit Bids to a Designated Intermediary at a location other than at the relevant Bidding Centres. If you are a UPI Bidder and are using UPI mechanism, do not submit the ASBA Form directly with SCSBs;
27. Do not submit the ASBA Forms to any Designated Intermediary that is not authorised to collect the relevant ASBA Forms or to our Company;
28. Do not submit incorrect details of the DP ID, Client ID, PAN and UPI ID details if you are a UPI Bidder. Further, do not provide details for a beneficiary account which is suspended or for which details cannot be verified to the Registrar to the Issue;
29. Do not submit the Bid without ensuring that funds equivalent to the entire Bid Amount are available for blocking in the relevant ASBA account;
30. Do not link the UPI ID with a bank account maintained with a bank that is not UPI 2.0 certified by the NPCI in case of Bids submitted by UPI Bidders using the UPI Mechanism;
31. Do not Bid if you are an OCB;
32. UPI Bidders using the incorrect UPI handle or using a bank account of an SCSB or a bank which is not mentioned in the list provided in the SEBI website is liable to be rejected; and
33. Do not submit more than one Bid cum Application Form for each UPI ID in case of UPI Bidders.
34. In case of ASBA Bidders (other than 3 in 1 Bids) Syndicate Members shall ensure that they do not upload any bids above ₹5.00 lakhs;

The Bid cum Application Form is liable to be rejected if the above instructions, as applicable, are not complied with.

GROUND FOR TECHNICAL REJECTION

In addition to the grounds for rejection of Bids on technical grounds as provided in the GID, Bidders are requested to note that Bids may be rejected on the following additional technical grounds:

1. Bids submitted without instruction to the SCSBs to block the entire Bid Amount;
2. Bids which do not contain details of the Bid Amount and the bank account details in the ASBA Form;
3. Bids submitted on a plain paper;
4. Bids submitted by UPI Bidders using the UPI Mechanism through an SCSBs and/or using a mobile application or UPI handle, not listed on the website of SEBI;
5. Bids under the UPI Mechanism submitted by UPI Bidders using third party bank accounts or using a third party linked bank account UPI ID (subject to availability of information regarding third party account from Sponsor Banks);
6. ASBA Form submitted to a Designated Intermediary does not bear the stamp of the Designated Intermediary;
7. Bids submitted without the signature of the First Bidder or sole Bidder;
8. The ASBA Form not being signed by the account holders, if the account holder is different from the Bidder;
9. ASBA Form by the RIBs by using third party bank accounts or using third party linked bank account UPI IDs;
10. Bids by persons for whom PAN details have not been verified and whose beneficiary accounts are “suspended for credit” in terms of SEBI circular CIR/MRD/DP/22/2010 dated July 29, 2010;

11. GIR number furnished instead of PAN;
12. Bids by RIBs with Bid Amount of a value of more than ₹2.00 lakhs;
13. Bids by persons who are not eligible to acquire Equity Shares in terms of all applicable laws, rules, regulations, guidelines and approvals;
14. Bids accompanied by stock invest, money order, postal order or cash; and
15. Bids uploaded by QIBs after 4.00 pm on the QIB Bid/ Issue Closing Date and by Non-Institutional Bidders uploaded after 4.00 p.m. on the Bid/ Issue Closing Date, and Bids by RIBs uploaded after 5.00 p.m. on the Bid/ Issue Closing Date, unless extended by the Stock Exchanges. On the Bid/ Issue Closing Date, extension of time may be granted by the Stock Exchanges only for uploading Bids received from Retail Individual Bidders, after taking into account the total number of Bids received up to closure of timings for acceptance of Bid-cum-Application Forms as stated herein and as informed to the Stock Exchanges.

For helpline details of the BRLM pursuant to the SEBI/HO.CFD.DIL2/CIR/P/2021/2480/1/M dated March 16, 2021, see “General Information – Book Running Lead Manager” on page 88. Further, in case of any pre-Offer or post Offer related issues regarding share certificates/demat credit/refund orders/unblocking etc., investors shall reach out the Company Secretary and Chief Compliance Officer. For details of the Company Secretary and Compliance Officer, see “General Information – Company Secretary and Compliance Officer” on page 87. In case of any delay in unblocking of amounts in the ASBA Accounts (including amounts blocked through the UPI Mechanism) exceeding the prescribed Working Days from the Bid/ Offer Closing Date, the Bidder shall be compensated in accordance with applicable law. Further, Investors shall be entitled to compensation in the manner specified in the SEBI Master Circular no. SEBI/HO/MIRSD/POD 1/P/CIR/2023/70 dated May 17, 2023 (to the extent applicable) in case of delays in resolving investor grievances in relation to blocking/unblocking of funds. The BRLM shall be the nodal entity for any issues arising out of public issuance process. In terms of Regulation 23(5) and Regulation 52 of SEBI ICDR Regulations, the timelines and processes mentioned in SEBI RTA Master Circular shall continue to form part of the agreements being signed between the intermediaries involved in the public issuance process and the BRLM shall continue to coordinate with intermediaries involved in the said process.

For details of grounds for technical rejections of a Bid cum Application Form, please see the General Information Document.

NAMES OF ENTITIES RESPONSIBLE FOR FINALISING THE BASIS OF ALLOTMENT IN A FAIR AND PROPER MANNER

The authorised employees of the Stock Exchange, along with the Book Running Lead Manager and the Registrar, shall ensure that the Basis of Allotment is finalised in a fair and proper manner in accordance with the procedure specified in SEBI ICDR Regulations.

ISSUANCE OF A CONFIRMATION NOTE (“CAN”) AND ALLOTMENT IN THE ISSUE

1. Upon approval of the basis of allotment by the Designated Stock Exchange, the BRLM or Registrar to the Issue shall send to the SCSBs a list of their Bidders who have been allocated Equity Shares in the Issue.
2. The Registrar will then dispatch a CAN to their Bidders who have been allocated Equity Shares in the Issue. The dispatch of a CAN shall be deemed a valid, binding and irrevocable contract for the Bidder

Issue Procedure for Application Supported by Blocked Account (ASBA) Bidders

In accordance with the SEBI Circular No. CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 all the Bidders have to compulsorily apply through the ASBA Process. Our Company and the Book Running Lead Manager are not liable for any amendments, modifications, or changes in applicable laws or regulations, which may occur after the date of this Prospectus. ASBA Bidders are advised to make their independent investigations and to ensure that the ASBA Bid Cum Application Form is correctly filled up, as described in this section. The lists of banks that have been notified by SEBI to act as SCSB (Self Certified Syndicate Banks) for the ASBA Process are provided on <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes>. For details on designated branches of SCSB collecting the Bid Cum Application Form, please refer the above-mentioned SEBI link.

Terms of payment

The entire Issue price of ₹ 97/- per share is payable on application. In case of allotment of lesser number of Equity Shares than the number applied, the Registrar shall instruct the SCSBs to unblock the excess amount paid on Application to the Bidders.

SCSBs will transfer the amount as per the instruction of the Registrar to the Public Issue Account, the balance amount after transfer will be unblocked by the SCSBs.

The Bidders should note that the arrangement with Bankers to the Issue or the Registrar is not prescribed by SEBI and has been established as an arrangement between our Company, Banker to the Issue and the Registrar to the Issue to facilitate collections from the Bidders.

Payment mechanism

The Bidders shall specify the bank account number in their Bid Cum Application Form and the SCSBs shall block an amount equivalent to the Application Amount in the bank account specified in the Bid Cum Application Form. The SCSB shall keep the Application Amount in the relevant bank account blocked until withdrawal/ rejection of the Application or receipt of instructions from the Registrar to unblock the Application Amount. However, Non-Retail Bidders shall neither withdraw nor lower the size of their applications at any stage. In the event of withdrawal or rejection of the Bid Cum Application Form or for unsuccessful Bid Cum Application Forms, the Registrar to the Issue shall give instructions to the SCSBs to unblock the application money in the relevant bank account within one day of receipt of such instruction. The Application Amount shall remain blocked in the ASBA Account until finalization of the Basis of Allotment in the Issue and consequent transfer of the Application Amount to the Public Issue Account, or until withdrawal/ failure of the Issue or until rejection of the Application by the ASBA Bidder, as the case may be.

Please note that, in terms of SEBI Circular No. CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, all the investors applying in a public Issue shall use only Application Supported by Blocked Amount (ASBA) process for application providing details of the bank account which will be blocked by the Self-Certified Syndicate Banks (SCSBs) for the same. Further, pursuant to SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 01, 2018, Retail Individual Investors applying in public Issue have to use UPI as a payment mechanism with Application Supported by Blocked Amount for making application.

METHOD OF ALLOTMENT AS MAY BE PRESCRIBED BY SEBI FROM TIME TO TIME

Our Company will not make any allotment in excess of the Equity Shares issued through this Offer document.

The allotment of Equity Shares to bidders other than to the RIBs, NIIs and Anchor Investors shall be on a proportionate basis within the respective investor categories and the number of securities allotted shall be rounded off to the nearest integer, subject to minimum allotment being equal to the minimum application size as determined and disclosed.

The allotment of Equity Shares to each Retail Individual Bidders shall not be less than the minimum bid lot, subject to the availability of shares in Retail Individual Bidders Portion and the remaining available shares, if any, shall be allotted on a proportionate basis. Further, not less than 15% of the Net Issue shall be available for allocation to Non-Institutional Bidders in accordance with the SEBI ICDR Regulations. Further, the allocation to each Non-Institutional Investor shall not be less than Minimum NIB Application Size, subject to availability of Equity Shares in the Non-Institutional Portion and the remaining available Equity Shares, if any, shall be allocated on a proportionate basis.

PAYMENT INTO ANCHOR INVESTOR ESCROW ACCOUNTS

Our Company in consultation with the Book Running Lead Manager will decide the list of Anchor Investors to whom the CAN will be sent, pursuant to which, the details of the Equity Shares allocated to them in their respective names will be notified to such Anchor Investors. For Anchor Investors, the payment instruments for payment into the Anchor Investor Escrow Account should be drawn in favor of:

- (a) In case of resident Anchor Investors: ***“Quest Laboratories Limited – Anchor Investor R Account”***
- (b) In case of Non-Resident Anchor Investors: ***“Quest Laboratories Limited – Anchor Investor NR Account”***

Anchor Investors should note that the escrow mechanism is not prescribed by SEBI and has been established as an arrangement between our Company, the Syndicate, the Escrow Collection Bank and the Registrar to the Issue to facilitate collections of Bid amounts from Anchor Investors.

PRE- ISSUE ADVERTISEMENT

Subject to Section 30 of the Companies Act, our Company shall, after filing the Prospectus with the RoC, publish a pre-Issue advertisement, in the form prescribed under the SEBI ICDR Regulations, in all editions of English national daily newspaper, Financial Express, all editions of Hindi national daily newspaper, Janasatta and Hamara Swaraj, a Hindi daily newspaper, (Hindi being the regional language of Madhya Pradesh where our Registered Office is located) each with wide circulation.

In the pre- Issue advertisement, we shall state the Bid/ Issue Opening Date and the Bid/ Issue Closing Date. This advertisement, subject to the provisions of Section 30 of the Companies Act, shall be in the format prescribed in Part A of Schedule X of the SEBI ICDR Regulations.

ALLOTMENT ADVERTISEMENT

Our Company, the Book Running Lead Manager and the Registrar shall publish an allotment advertisement before commencement of trading, disclosing the date of commencement of trading in all editions of English national daily newspaper, Financial Express, all editions of Hindi national daily newspaper, Janasatta and Hamara Swaraj, Hindi daily newspaper, (Hindi being the regional language of Madhya Pradesh, where our Registered Office is located) each with wide circulation.

The information set out above is given for the benefit of the Bidders. Our Company, the Book Running Lead Manager are not liable for any amendments or modification or changes in applicable laws or regulations, which may occur after the date of this Prospectus. Bidders are advised to make their independent investigations and ensure that the number of Equity Shares Bid for do not exceed the prescribed limits under applicable laws or regulations.

SIGNING OF THE UNDERWRITING AGREEMENT AND FILING WITH THE ROC

Our company has entered into an Underwriting Agreement dated April 25, 2023.

After signing the Underwriting Agreement, an updated Prospectus will be filed with the RoC in accordance with applicable law, which would then be termed as the Prospectus. The Prospectus will contain details of the Issue Price, the Anchor Investor Issue Price, the Issue size, and underwriting arrangements and will be complete in all material respects.

Depository Arrangements

The Allotment of the Equity Shares in the Issue shall be only in a dematerialised form, (i.e., not in the form of physical certificates but be fungible and be represented by the statement issued through the electronic mode). For more information, see “*Terms of the Issue*” on page 367 of this Prospectus.

IMPERSONATION

Attention of the bidders is specifically drawn to the provisions of sub-section (1) of Section 38 of the Companies Act, which is reproduced below:

“Any person who:

- a) makes or abets making of an application in a fictitious name to a company for acquiring, or subscribing for, its securities; or*
- b) makes or abets making of multiple applications to a company in different names or in different combinations of his name or surname for acquiring or subscribing for its securities; or*
- c) otherwise induces directly or indirectly a company to allot, or register any transfer of, securities to him, or to any other person in a fictitious name,*

shall be liable for action under Section 447.”

The liability prescribed under Section 447 of the Companies Act, for fraud involving an amount of at least ₹10.00 lakhs or 1% of the turnover of the Company, whichever is lower, includes imprisonment for a term which shall not be less than six months extending up to 10 years and fine of an amount not less than the amount involved in the fraud, extending up to three times such amount (provided that where the fraud involves public interest, such term shall not be less than three years.) Further, where the fraud involves an amount less than ₹10.00 lakhs or one per cent of the turnover of the company,

whichever is lower, and does not involve public interest, any person guilty of such fraud shall be punishable with imprisonment for a term which may extend to five years or with fine which may extend to ₹50.00 lakhs or with both.

UNDERTAKINGS BY OUR COMPANY

Our Company undertakes the following:

- adequate arrangements shall be made to collect all Bid cum Application Forms submitted by Bidders. the complaints received in respect of the Issue shall be attended to by our Company expeditiously and satisfactorily;
- all steps for completion of the necessary formalities for listing and commencement of trading at the Stock Exchanges where the Equity Shares are proposed to be listed shall be taken within three Working Days of the Bid/ Issue Closing Date or such other period as may be prescribed;
- if Allotment is not made within the prescribed time period under applicable law, the entire subscription amount received will be refunded/unblocked within the time prescribed under applicable law. If there is delay beyond the prescribed time, our Company shall pay interest prescribed under the Companies Act, the SEBI ICDR Regulations and applicable law for the delayed period;
- the funds required for making refunds (to the extent applicable) as per the mode(s) disclosed shall be made available to the Registrar to the Issue by our Company;
- where refunds (to the extent applicable) are made through electronic transfer of funds, a suitable communication shall be sent to the unsuccessful Bidder within three Working Days from the Bid/ Issue Closing Date or such other prescribed under applicable law, giving details of the bank where refunds shall be credited along with amount and expected date of electronic credit of refund;
- Promoters' contribution, if any, shall be brought in advance before the Bid/ Issue Opening Date and the balance, if any, shall be brought in on a pro rata basis before calls are made on the Allottees;
- that if our Company does not proceed with the Issue after the Bid/ Issue Closing Date but prior to Allotment, the reason thereof shall be given as a public notice within two days of the Bid/ Issue Closing Date. The public notice shall be issued in the same newspapers where the pre-Issue advertisements were published. The Stock Exchanges shall be informed promptly;

UTILISATION OF ISSUE PROCEEDS

Our Company, severally and not jointly, specifically confirm that all monies received out of the Issue shall be credited/transferred to a separate bank account other than the bank account referred to in sub-section (3) of Section 40 of the Companies Act.

Details of all monies utilized out of the Fresh Issue shall be disclosed, and continue to be disclosed till the time any part of the Net Proceeds remains unutilized, under an appropriate separate head in the balance sheet of our Company indicating the purpose for which such monies have been utilized; and

Details of all unutilized monies out of the Fresh Issue, if any shall be disclosed under an appropriate separate head in the balance sheet of our Company indicating the form in which such unutilized monies have been invested.

RESTRICTIONS ON FOREIGN OWNERSHIP OF INDIAN SECURITIES

Foreign investment in Indian securities is regulated through the Industrial Policy, 1991 of the Government of India and FEMA. While the Industrial Policy, 1991 prescribes the limits and the conditions subject to which foreign investment can be made in different sectors of the Indian economy, FEMA regulates the precise manner in which such investment may be made. Under the Industrial Policy, unless specifically restricted, foreign investment is freely permitted in all sectors of the Indian economy up to any extent and without any prior approvals, but the foreign investor is required to follow certain prescribed procedures for making such investment. The RBI and the concerned ministries/departments are responsible for granting approval for foreign investment. The Government has from time to time made policy pronouncements on FDI through press notes and press releases. The DPIIT issued, issued the Consolidated FDI Policy Circular of 2020 (“**FDI Policy**”), which, with effect from October 15, 2020, subsumes and supersedes all press notes, press releases, clarifications, circulars issued by the DPIIT, which were in force as on October 15, 2020. The FDI Policy will be valid until the DPIIT issues an updated circular.

The transfer of shares between an Indian resident and a non-resident does not require the prior approval of the RBI, provided that: (i) the activities of the investee company are under the automatic route under the foreign direct investment policy and transfer does not attract the provisions of the SEBI SAST Regulations; (ii) the non-resident shareholding is within the sectoral limits under the FDI policy; and (iii) the pricing is in accordance with the guidelines prescribed by the SEBI/RBI.

On October 17, 2019, Ministry of Finance, Department of Economic Affairs, had notified the FEMA Rules, which had replaced the Foreign Exchange Management (Transfer and Issue of Security by a Person Resident Outside India) Regulations 2017. Foreign investment in this Issue shall be on the basis of the FEMA Rules. Further, in accordance with Press Note No. 3 (2020 Series), dated April 17, 2020 issued by the DPIIT and the Foreign Exchange Management (Nondebt Instruments) Amendment Rules, 2020 which came into effect from April 22, 2020, any investment, subscription, purchase or sale of equity instruments by entities of a country which shares land border with India or where the beneficial owner of an investment into India is situated in or is a citizen of any such country, will require prior approval of the Government, as prescribed in the Consolidated FDI Policy and the FEMA Rules. Further, in the event of transfer of ownership of any existing or future foreign direct investment in an entity in India, directly or indirectly, resulting in the beneficial ownership falling within the aforesaid restriction/ purview, such subsequent change in the beneficial ownership will also require approval of the Government. Pursuant to the Foreign Exchange Management (Non-debt Instruments) (Fourth Amendment) Rules, 2020 issued on December 8, 2020, a multilateral bank or fund, of which India is a member, shall not be treated as an entity of a particular country nor shall any country be treated as the beneficial owner of the investments of such bank of fund in India.

As per the FDI policy, FDI in companies engaged in the sector in which our Company operates, is permitted up to 100% of the paid-up share capital of such company under the automatic route.

As per the existing policy of the Government of India, OCBs cannot participate in this Issue. For further details, see “*Issue Procedure*” on page 259 of this Prospectus. Each Bidder should seek independent legal advice about its ability to participate in the Issue. In the event such prior approval of the Government of India is required, and such approval has been obtained, the Bidder shall intimate our Company and the Registrar in writing about such approval along with a copy thereof within the Issue Period.

The Equity Shares issued in the Issue have not been and will not be registered under the U.S. Securities Act or any state securities laws of the United States and, unless so registered, may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws of the United States. Accordingly, the Equity Shares are only being issued and sold only outside the United States in offshore transactions in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdictions where those issues and sales occur.

The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be issued or sold, and Application may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

The above information is given for the benefit of the Bidders. Our Company and the Book Running Lead Manager are not liable for any amendments or modification or changes in applicable laws or regulations, which may occur after the date of this Prospectus. Bidders are advised to make their independent investigations, seek independent legal advice about its ability to participate in the Issue and ensure that the number of Equity Shares applied for do not exceed the applicable limits under laws or regulations.

SECTION X – MAIN PROVISIONS OF THE ARTICLES OF ASSOCIATION

#THE COMPANIES ACT, 2013

COMPANY LIMITED BY SHARES
(Incorporated under the Companies Act, 1956)

ARTICLES OF ASSOCIATION @

OF

*QUEST LABORATORIES LIMITED

1. CONSTITUTION OF THE COMPANY

a. Table “F” not to apply but company to be governed by these Articles

No regulations contained in Table “F” of Schedule I to the Companies Act, 2013 (“**Table F**”) as are applicable to a public company limited by shares, shall apply to the Company except: (a) so far as they are not inconsistent with any of the provisions contained in these articles or modifications thereof; or (b) to the extent that there is no specific provision in these articles. In case of any conflict between the provisions of these articles and table F, the provisions of these articles shall prevail.

b. Applicability of Stock Exchange Regulations

Notwithstanding anything contained herein in these Articles, any inconsistency as to clause or time stipulated therein with the regulations and conditions of listing agreement of applicable stock exchanges, where the shares/securities of the Company are listed, shall stand modified so as to be consistent with the regulations and conditions of the listing agreement as amended from time to time.

Where any regulations and conditions as modified from time to time of any recognized stock exchange/s, which are required to be stipulated and included in the articles of association of a company at the time of listing of shares / securities or thereafter, these Articles shall stand to have been modified or amended so as to include such regulation and condition without further requirement of alteration of the Articles of Association of the Company.

DEFINITIONS AND INTERPRETATION

In the interpretation of these Articles the following expressions shall have the following meanings, unless repugnant to the subject or context:

THE ACT

“The Act” means the Companies Act, 2013 and the rules and regulations prescribed thereunder, as now enacted or as amended from time to time and shall include any statutory modification or re-enactment thereof for the time being in force.

ARTICLES

The “Articles” or “Articles of Association” means these articles of association of the Company or as altered from time to time.

BOARD OR BOARD OF DIRECTORS

“Board” or “Board of Directors” means the board of directors of the Company, as constituted from time to time.

CHAIRMAN

“The Chairman” means the Chairman of the Board of Directors

THE COMPANY OR THIS COMPANY

“The Company” or “This Company” means **QUEST LABORATORIES LIMITED**

RULES

Rules means the applicable rules for the time being in force as prescribed under relevant sections of the Act.

LAW

“Law/Laws” shall mean all applicable provisions of all (i) constitutions, treaties, statutes, laws (including the common law), codes, rules, regulations, circulars, ordinances or orders of any governmental authority and SEBI, (ii) governmental approvals, (iii) orders, decisions, injunctions, judgments, awards and decrees of or agreements with any governmental Authority, (iv) rules or guidelines for compliance, of any stock exchanges, (v) international treaties, conventions and protocols, and (vi) Indian GAAP or Ind-AS or any other generally accepted accounting principles.

MONTH

“Month” means a calendar month.

PERSONS

“Person” or “person” shall mean any natural person, limited or unlimited liability company, body corporate or corporation, limited liability partnership, partnership (whether limited or unlimited), proprietorship, voluntary association, joint venture, unincorporated organization Hindu undivided family, trust, union, association, government or any agency or political subdivision thereof or any other entity, whether incorporated or not, that whether acting in an individual, fiduciary or other capacity may be treated as a person under applicable law.

GENDER

Words importing one gender also include the other gender(s).

SINGULAR NUMBER

Words importing the singular number include, where the context admits or requires, the plural number, and vice versa.

Unless the context otherwise requires, words or expressions contained in these regulations shall bear the same meaning as in the Act or any statutory modification thereof in force at the date at which these regulations become binding on the company.

SEBI

“SEBI” shall mean the Securities and Exchange Board of India, constituted under the Securities and Exchange Board of India Act, 1992.

SEBI LISTING REGULATIONS

“SEBI LISTING REGULATIONS” shall mean the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, any statutory amendment thereto and any listing agreement entered into by the Company with the Stock Exchanges.

SECURITIES” OR “SECURITIES

“SECURITIES” OR “SECURITIES” shall mean any Share (including Equity Shares), scrips, stocks, bonds, debentures, warrants or options whether or not, directly or indirectly convertible into, or exercisable or exchangeable into or for Equity Shares, and any other marketable securities.

SHARES” OR SHARES

“Shares” or “shares” shall mean any share issued in the Share Capital of the Company, including Equity Shares and preference shares.

SHAREHOLDER OR SHAREHOLDER OR MEMBER

“Shareholder” or “shareholder” or “member” shall mean any shareholder of the Company, from time to time.

SHAREHOLDERS’ MEETING

“Shareholders’ Meeting” shall mean any meeting of the Shareholders of the Company, including Annual General Meetings as well as Extraordinary General Meetings, convened from time to time in accordance with the Act, applicable Laws and the provisions of these Articles.

STOCK EXCHANGES

“Stock Exchanges” shall mean Bombay Stock Exchange Limited, the National Stock Exchange of India Limited and any other stock exchange in India where the Securities are listed.

EXPRESSION IN THE ACT TO BEAR THE SAME MEANING IN ARTICLES

Unless the context otherwise requires, words and expressions contained in these Articles shall bear the same meaning as in the Act. In these Articles, all capitalized items not defined herein below shall have the meanings assigned to them in the other parts of these Articles when defined.

Words and expressions occurring, but not defined, in these Articles and defined in the Act, SCRA, SEBI Act or regulations/notifications/circulars issued by SEBI (from time to time) shall have the same meanings respectively assigned to them thereunder or in any statutory.

2. PUBLIC COMPANY

The company is a public company as defined in Section 2(71) of the Act.

3. #CAPITAL, SHARES AND CERTIFICATES

The Authorized Share Capital of the Company is as stated in the **Clause 5th** of the Memorandum of Association with the rights, privileges and conditions attached thereto as provided in law for the time being in force with powers to the Company to issue share capital as provided under Section 43 of the Act and Applicable Law and divide share capital for the time being of the Company into several classes / kinds (being those specified in the Act) and to attach thereto respectively such preferential, qualified, differential or special rights, privileges or conditions as may be determined by or in accordance with the law or the Articles of Association of the Company for the time being in force and to vary, modify or abrogate any such rights, privileges or conditions in such manner as may for the time being be permitted by the law for the time being in force or provided by the Articles of Association of the Company.

Subject to the provision of the Act and Rules Applicable Law and these articles, the Board may issue and allot shares, in such proportion and in the capital of the Company in consideration of payment for any property or assets of any kind whatsoever sold or transferred, goods or machinery supplied or for services rendered to the Company in the conduct of its business or as sweat equity or ESOP or any other scheme and any shares which may be so allotted may be issued as fully paid up or partly paid up otherwise than cash and if so issued shall be deemed to be fully paid or partly paid up shares as the case may be or otherwise dispose of the same or any of them to such person in such proportion and on such terms and conditions and either at a premium or at par and at such time as they may from time to time think fit.

a. Increase of Capital by the Company

The Company in general meeting may from time to time, by ordinary resolution, increase the capital by creation of new shares and of such aggregate amount and to be divided into shares of such respective amounts as the resolution shall prescribe. The new shares shall be issued upon such terms and conditions and with such rights and privileges annexed thereto as the resolution shall prescribe, and in particular, such shares may be issued with a preferential or qualified right to dividends and in the distribution of assets of the Company and with a right of voting at a general meeting of the Company in conformity with Sections 47 of the Act.

b. Issue of Securities

Subject to the provisions of the Act and the rules and other applicable laws the Company shall have the right to issue any kind of shares/ securities / warrants having such rights as to conversion, redemption or otherwise and other terms and conditions and for consideration in cash or in consideration of any property or asset of any kind wherever sold or transferred goods or machinery supplied or for services rendered to the Company in the conduct of its business.

c. Preference Shares

Subject to the provisions of the Act, the Board shall have the power to issue or re-issue preference shares of one or more class which are liable to be redeemed or converted into equity shares on such terms and conditions and in such manner as may be determined by the Board in accordance with the Act and the Rules.

d. Shares under the control of the Board

Subject to the Section 62 of the Act and these Articles, the shares in the capital of the Company for the time being (including any shares forming part of any increased capital of the Company) shall be under the control of the Board who may issue, allot or otherwise dispose of the same or any of them to such persons, in such proportion and on such terms and conditions either at a premium or at par or at a discount (subject to the compliance with the provision of Section 53 of the Act) and at such times as it may from time to time think fit and proper, and with full power of the sanction of the Company in General Meeting, to give to any Person the option or right to call for any shares either at par or at a premium during such time and for such consideration as the Board thinks fit, and may issue and allot shares in the capital of the Company on payment in full or part of any property sold and transferred or for any services rendered to the Company in the conduct of its business and any shares which may be so allotted may be issued as fully paid up shares and is so issued, shall be deemed to be fully paid up shares.

Provided that the option or right to call of shares shall not be given to any persons except with the sanction of the Company in General Meeting.

e. Purchase / Buy Back of Shares

Notwithstanding anything contained in these Articles but subject to all applicable provisions of the Act or any other laws for the time being in force, the Company shall be entitled to purchase its own shares or other specified securities on such terms as deemed fit by way of a buy- back arrangement, in accordance with Sections 68, 69 and 70 of the Act, the Rules and subject to compliance with the applicable Laws.

f. Reduction of capital

The Company may (subject to the provisions of Section 52, 55, 66, 67 and/or other applicable provisions, if any, of the Act) from time to time by special resolution, reduce (a) its share capital, (b) any capital redemption, reserve account, or (c) any share premium account in any manner and with and subject to any incidents, authorise the consent required by law and in particular capital may be paid off on the footing that it may be called up again or otherwise. The Article is not to derogate from any power the Company would have if it were omitted.

g. Consolidation, Division, Sub-Division and Cancellation of Shares

Subject to the provisions of the Article and Section 61 of the Act, the Company in general meeting may from time to time by an ordinary resolution in General Meeting g from time to time, a alter the conditions of its Memorandum as follows that is to say:

- (a) consolidate and divide all or any of its share capital into shares of larger amount than its existing shares;
- (b) sub-divide its shares, or any of them into shares of smaller amount than is fixed by the Memorandum, so however, that in the sub-division, the proportion between the amount paid and the amount, if any, unpaid on each reduced share shall be the same as it was in the case of the share from which the reduced share is derived;
- (c) Cancel shares which, at the date of the passing of the resolution in that behalf, have not been taken or agreed to be taken by any person, and diminish the amount of its share capital by the amount of the shares so cancelled. A cancellation of shares in pursuance of this sub-clause shall not be deemed to be a reduction of share capital within the meaning of the Act.

h. Modification of Rights

- (i) Whenever the capital, by reason of the issue of shares including preference shares or otherwise, is divided into different classes of shares, all or any of the rights and privileges attached to each class may, subject to the provisions of Section 48 of the Act, be varied, modified, commuted, affected or abrogated, or dealt with, with the consent in writing of the holders of not less than three-fourths of the issued capital of that class or with the sanction of a special resolution passed at a separate general meeting of the holders of shares of that class, and all the provisions hereafter contained as to general meetings shall, *mutatis mutandis*, apply to every such meeting. This Article, is not to derogate from any power the Company would have if this Article was omitted.
- (ii) The rights conferred upon the holders of the shares (including preference shares, if any) of any class issued with preferred or other rights or privileges shall, unless otherwise expressly provided by the terms of the issue of shares of that class, be deemed not to be modified, commuted, affected, abrogated, dealt with or varied by the creation or issue of further shares ranking *pari passu* there with. This Article, is not to derogate from any power the Company would have if this Article was omitted.

i. Issue of Further Shares Not to Affect Rights of Existing Members

The rights conferred upon the holders of the shares of any class issued with preferred or other rights shall not, unless otherwise expressly provided by the terms of issue of the shares of that class, be deemed to be varied by the creation or issue of further shares ranking *pari passu* therewith. This Article, is not to derogate from any power the Company would have if this Article was omitted.

j. Further Issue of Shares/Securities

A further issue of shares/securities may be made in any manner whatsoever as the Board may determine including by way of preferential issue, private placement, rights issue, bonus issue, pursuant to employee stock options, sweat equity or in any other manner as permitted by the Act and at such time as the Board may from time-to-time think fit.

k. Issue of Shares to Employees

Subject to applicable rules and regulation, the Board may issue and allot shares/securities as sweat equity or under employees stock option scheme. The Board is authorised absolutely at its sole discretion to determine the terms and conditions of issue of such shares and modify the same from time to time.

l. Liability of Members

Every member, or his heirs, executors or administrators to the extent of his assets which come to their hands, shall be liable to pay to the Company the portion of the capital represented by his share or shares which may, for the time being, remain unpaid thereon in such amounts, at such time or times, and in such manner as the Board of Directors shall from time to time, in accordance with the Company's regulations, require or fix for the payment thereof.

m. Registers to be Maintained by the Company

The Company shall, in terms of the provisions of Section 88 of the Act, cause to be kept the following registers in terms of the applicable provisions of the Act:

- (I) A Register of Members indicating separately for each class of Equity Shares and preference shares held by each Shareholder residing in or outside India.
- (II) A register of Debenture holders; and
- (III) A register of any other security holders.

The Company may keep in any country outside India, a part of the registers referred above, called "foreign register" containing names and particulars of the Shareholders, Debenture holders or holders of other Securities or beneficial owners residing outside India.

The registers mentioned in this Article shall be kept and maintained in the manner prescribed under the Companies (Management and Administration) Rules, 2014.

n. Share Certificates

- (a) The Company shall cause to be kept a register of members in accordance with Section 88 of the Act and the Depositories Act, with the details of the shares held in Dematerialized forms in any medium as may be permitted by law including in any form of electronic medium.

Every person whose name is entered as a member in the register of members shall be entitled to receive, within two months after allotment (or within such other period as the conditions of issue shall provide), or within fifteen days after the application for the registration of transfer or transmission is received by the Company, without payment, certificate for all the shares registered in his name, every share certificate specifying the name of the person in whose favour it is issued, the share certificate number and the distinctive number(s) of the shares to which it relates and the amount paid up thereon. Such certificate shall be issued only in pursuance of a resolution passed by the Board and on surrender to the Company of its letter of allotment or its fractional coupons of requisite value, save in case of issues against letters of acceptance or of renunciation or in cases of issue of bonus shares provided that if the letter of allotment is lost or destroyed, the Board may impose such reasonable terms, if any, as it thinks fit, as to evidence and indemnity and the payment of out of pocket expenses incurred by the Company in investigating the evidence.

- (b) Certificate of title to shares shall be issued and shall be signed in conformity with the provisions of the Companies (Share Capital and Debentures) Rules, 2014 or any statutory modification or re-enactment thereof for the time being in force. Printing of blank forms to be used for issue of share certificates and maintenance of books and documents relating to issue of share certificates shall be in accordance with the provisions of aforesaid rules. Such certificates of title to shares shall be completed and kept ready for delivery within two months after the allotment unless the conditions of issue of shares provide otherwise.
- (c) Any two or more joint allottees or holders of share shall, for the purpose of this Article, be treated as a single member and the certificate of any share, which may be the subject of joint ownership, may be delivered to any one of such joint owners on behalf of all of them. In respect of any share or shares held jointly by several persons, the Company shall not be bound to issue more than one certificate and delivery of the certificate for a share to one of several joint shareholders shall be sufficient delivery to all such holder.

o. Fractional Certificates

- (a) If and whenever, as a result of issue of new shares on consolidation or sub-division of shares, any member becomes entitled to any fractional part of a share, the Board may subject to the provisions of the Act and these Articles and to the directions, if any, of the Company in General Meeting: -
 - (i) Issue to such member fractional certificate or certificates representing such fractional part. Such fractional certificate or certificates shall not be registered, nor shall they bear any dividend until exchanged with other fractional certificates for an entire share. The Directors may, however, fix the time within which such fractional certificates are to be exchanged for an entire share and may extend such time and if at the expiry of such time, any fractional certificates shall be deemed to be canceled and the Directors shall sell the shares represented by such canceled fractional certificates for the best price reasonably obtainable or
 - (ii) Sell the shares represented by all such fractional parts for the best price reasonably obtainable.
- (b) In the event of any shares being sold, in pursuance of sub-clause (a) above, the Company shall pay and distribute to and amongst the persons entitled, in due proportion the net sale proceeds thereof.
- (c) For the purpose of giving effect to any such sale, the Board may authorise any person to transfer the shares sold to the purchaser thereof, comprised in any such transfer and he shall not be bound to see to the application of purchase money nor shall his title to the shares be affected by any irregularity or invalidity in the proceedings in reference to the same.
- (d) The provisions of the foregoing Articles relating to issue of certificates shall mutatis mutandis apply to issue of certificates for any other securities including debentures (except where the Act otherwise requires) of the Company.

- (e) Notwithstanding the above, the Board shall have power to make such provision, by the issue of fractional certificates or by payment in cash or otherwise as it thinks fit, for the case of shares/securities becoming distributable in fractions.

p. Renewal of Share Certificate

No certificate of any share or shares shall be issued either in exchange for those which are sub-divided or consolidated or in replacement of those which are defaced, torn, or old, decrepit, worn out, or where the pages on the reverse for recording transfers have been duly utilised unless the certificate in lieu of which it is issued is surrendered to the Company.

Provided that no fee shall be charged for issue of new certificates in replacement of those which are old, decrepit or worn out or where the pages on the reverse for recording transfers have been fully utilised.

Provided further that in case of any share certificate being lost or destroyed or if there be no further space on the bank for endorsement of transfer, the Company may issue a duplicate certificate in place of the certificate so lost or destroyed on such terms as to evidence out of pocket expenses in regard to investigation of such evidence and on execution of indemnity as the Board may determine.

The Company shall issue certificates or receipts or advices, as applicable, of subdivision, split, consolidation, renewal, exchanges, endorsements, issuance of duplicates thereof or issuance of new certificates or receipts or advices, as applicable, in cases of loss or old decrepit or worn out certificates or receipts or advices, as applicable within a period of thirty days from the date of such lodgement.

Provided that notwithstanding what is stated above, the Board shall comply with such rules or regulation or requirements of any stock exchanges or the rules made under the Act or rules made under the Securities Contracts (Regulation) Act, 1956 or any other Act, or rules applicable thereof in this behalf.

The provisions of the foregoing Articles relating to issue of certificates shall mutatis mutandis apply to issue of certificates for any other securities including debentures (except where the Act otherwise requires) of the Company.

q. Company not bound to recognize any Interest in Share other than Registered Holder

Except as ordered by a Court of competent jurisdiction or as by law required the Company shall not be bound to recognise any equitable, contingent, future or partial interest in any share, or (except only as is by these Articles expressly provided) any right in respect of a share other than an absolute right thereto/ in accordance with these Articles, in the person whose name appears in the Register of Members as holder of shares or whose name appears as the beneficial owner of the shares in the records of the depository, but the Board shall be at liberty at their sole discretion to register any share in the joint names of any two or more persons or the survivor or survivors of them.

4. Company entitled to Dematerialise its Shares and Securities

Notwithstanding anything contained in the Articles of Association, the Company shall be entitled to dematerialize its shares, debenture and other securities in a dematerialised form held in the Depositories and/or to offer its fresh Securities in a dematerialized form pursuant to the Depositories Act, and the rules framed thereunder, if any.

If a Person opts to hold his Securities with a Depository, the Company shall intimate such Depository the details of allotment of the Securities and on receipt of the information, the Depository shall enter in its record the name of the allottee as the Beneficial Owner of the Securities.

All Securities held by a Depository shall be dematerialized and be held in fungible form. Nothing contained in Sections 88, 89 and 186 of the Act shall apply to a Depository in respect of the Securities held by it on behalf of the Beneficial Owners.

Subject to the applicable provisions of the Act, the Company may exercise an option to issue, dematerialize, hold the securities (including shares) with a Depository in electronic form and the certificates in respect thereof shall be dematerialized, in which event the rights and obligations of the parties concerned and matters connected therewith or incidental thereto shall be governed by the provisions of the Depositories Act.

The Company shall further be entitled to maintain a Register of Members with the details of members holding shares/securities both in material and dematerialised form in any media as permitted by law including any form of electronic media.

5. GENERAL AUTHORITY

Where in the Act, it has been provided that a company shall have any right, privilege or authority or that a company could carry out any transactions only if such company is so authorized by its articles of association, in every such case this Articles of Association hereby authorizes and empowers the Company, its Board, its Directors and/or its members to have such right, privilege or authority and to carry out such transaction as have been permitted by the Act without there being any specific provision in that behalf herein. Following are a few illustrations of such rights, privileges, authorities and transactions as set out with relevant Section numbers from the Act:

Section 40: to pay commission on issue of shares and debentures

Section 43: to issue shares with differential voting rights

Section 48: to alter rights of holders of special class of shares

Section 50: to accept amount on share capital although not called up

Section 51: to pay dividend in proportion to amount paid-up

Section 55: to issue preference shares.

Section 61: to alter the share capital of the company

Section 42: to issue shares on preferential basis

Section 62: to further issue shares/securities

Section 63: to issue bonus shares

Section 68: to buy back the shares of the Company

Section 88: to keep foreign register of members of debenture holders

Section 161: to appoint additional, alternate and nominee directors

The above authority does not include rights, privileges, authorities under Section 163 of the Act.

6. POWER TO PAY COMMISSION IN CONNECTION WITH SECURITIES ISSUED

The Company may exercise the powers of paying commissions conferred by the Act, to any person in connection with the subscription to its securities ,provided that the rate per cent or the amount of the commission paid or agreed to be paid shall be disclosed in the manner required by the Act and the Rules.

2. The rate or amount of the commission shall not exceed the rate or amount prescribed in the Act and the Rules.

3. The commission may be satisfied by the payment of cash or the allotment of fully or partly paid shares or partly in the one way and partly in the other.

7. BROKERAGE

The Company may on any issue of shares, debentures or any other securities pay such brokerage or commission as may be prescribed under the Act.

8. CALLS

a. BOARD MAY MAKE CALLS

Subject to the provisions of Section 49 of the Act, the Board of Directors may, from time to time, by a resolution passed at a meeting of the Board (and not by a circular resolution) make such calls as it thinks fit upon the members in respect of moneys unpaid on the shares, whether on account of the nominal value of the shares or by way of premium, held by them respectively and not by conditions of allotment thereof made payable at fixed times and each member shall pay the amount of every call so made on him to the person or persons and at the times and places appointed by the Board of Directors. A call may be made payable by installments. A call may be postponed or revoked as the Board may determine at any time.

b. NOTICE OF CALLS

At least Fourteen (14) days' notice in writing of any call shall be given by the Company specifying the time and place of payment, and the person or persons to whom such call shall be paid provided that before the time for payment of such call, the Board may revoke or postpone the same.

c. CALLS TO TAKE EFFECT FROM THE DATE OF RESOLUTION

A call shall be deemed to have been made at the time when the resolution authorising such call was passed at a meeting of the Board of Directors and may be made payable by the members whose names appear on the Register of Members on such date or at the discretion of the Board on such subsequent date as shall be fixed by the Board of Directors.

d. CALLS ON SHARES OF SAME CLASS TO BE ON UNIFORM BASIS

All calls shall be made on a uniform basis on all shares falling under the same class.

Explanation: Shares of different class having the same nominal value on which different amounts have been paid-up shall not be deemed to fall under the same class.

e. BOARD MAY EXTEND TIME

The Board of Directors may, from time to time at its discretion, extend the time fixed for the payments of any call, and may extend such times as to all or any of the members who, on account of residence at a distance or other cause, the Board of Directors may deem fairly entitled to such extension, but no member shall be entitled to such extension as of right except as a matter of grace and favour.

f. AMOUNT PAYABLE AT FIXED TIME OR BY INSTALLMENTS TO BE TREATED AS CALLS

If by the terms of issue of any share or otherwise any amount is made payable at any fixed time or by instalments at fixed time (whether on account of the amount of the share or by way of premium) every such amount or instalment shall be payable by the person who for the time being and from time to time is or shall be the registered holder of the shares or legal representative of a deceased registered shareholder, as if it were a call duly made by the Board and of which due notice has been given and all the provisions herein contained in respect of calls shall apply to such amount or installment accordingly.

g. Deposit and Call, etc. to be Debt Payable

The money (if any) which the Board of Directors shall, on the allotment of any shares being made by them, require or direct to be paid by way of deposit, call or otherwise, in respect of any shares allotted by them, shall, immediately on the inscription of the name of the allottee in the register of members as the name of the holder of such shares, become a debt due to and recoverable by the Company from the allottee thereof, and shall be paid by him accordingly.

h. Interest on Call or Instalment

If the sum payable in respect of any call or instalment is not paid on or before the day appointed for the payment thereof, the holder for the time being or allottee of the share in respect of which the call shall have been made or the installment shall be due, shall pay interest on the same at the rate as may be determined by the Board from the due date appointed for the payment thereof till the time of actual payment. However, the Board may waive payment of such interest wholly or in part. In case of non-payment, all the relevant provisions of these Articles as to payment of call, interest, expenses, forfeiture or otherwise shall apply as if such sum became payable by virtue of a call duly made and notified.

i. Partial Payment not to Preclude Forfeiture

Neither a judgment nor a decree in favour of the Company for calls or other moneys due in respect of any shares nor any part payment or satisfaction thereof nor the receipt by the Company of a portion of any money which shall from time-to-time be due from any member in respect of any shares either by way of principal or interest nor any indulgence granted by the Company in respect of payment of any such money shall preclude the forfeiture of such shares as herein provided.

j. PAYMENT IN ANTICIPATION OF CALLS MAY CARRY INTEREST

- (a) The Board of Directors may, if it thinks fit, subject to the provisions of the Act, agree to and receive from any member willing to advance the same, all or any part of the amount due upon the shares held by him beyond the sums actually called for and upon the moneys so paid in advance or upon so much thereof, from time to time, and at any time thereafter as exceeds the amount of the calls then made upon and due in respect of the shares on account of which such advances are made, the Company may pay or allow interest, at such rate as may be decided by the Board according to the provisions of the Act. The Board of Directors may agree to repay at any time any amount so advanced or may at any time repay the same upon giving to such members three months' notice in writing.
- (b) No member paying any such sum in advance shall be entitled to voting rights or dividend or to participate in profits in respect of the moneys so paid by him until the same would but for such payment, become presently payable.

The provisions of these Articles relating to calls on shares shall mutatis mutandis apply to any other securities including debentures of the Company.

9. LIEN

(a) Company to have Lien on Shares/ Debentures

The Company shall have a first and paramount lien upon all shares/debentures (other than fully paid up shares/debentures) registered in the name of each member (whether solely or jointly with others) and upon the proceeds of sale thereof, for all moneys (whether presently payable or not), called or payable at a fixed time in respect of such shares/debentures and no equitable interests in any such share/debentures shall be created except upon the footing and condition that this Article is to have full legal effect. Any such lien shall extend to all dividends and bonuses from time to time declared in respect of shares/ debentures.

Unless otherwise agreed, the registration of a transfer of such shares/ debentures shall operate as a waiver of the Company's lien if any, on such shares/ debentures. PROVIDED THAT the Board of Directors may, at any time, declare any share/ debentures to be wholly or in part exempt from the provisions of this Article.

(b) As to Enforcing Lien by Sale

The Company may sell, in such manner as the Board thinks fit, any shares on which the Company has a lien for the purpose of enforcing the same. PROVIDED THAT no sale shall be made:

- (a) Unless a sum in respect of which the lien exists is presently payable; or
- (b) Until the expiration of fourteen days after a notice in writing stating and demanding payment of such part of the amount in respect of which the lien exists as is presently payable has been given to the registered holder for the time being of the share or the person entitled thereto by reason of his death or insolvency. For the purpose of such sale the Board may cause to be issue a duplicate certificate in respect of such shares and may authorise one of the members to execute a transfer thereof on behalf of and in the name of such members.

(c) Transfer of Shares sold under Lien

- (1) To give effect to any such sale, the Board may authorise some person to transfer the shares sold to the purchaser thereto;
- (2) The Purchaser shall be registered as the holder of the shares comprised in any such transfer;

- (3) The receipt of the Company for the consideration (if any) given for the share on the sale thereof shall (subject, if necessary, to execution of an instrument of transfer or a transfer by relevant system, as the case may be) constitute a good title to the share and the purchaser shall be registered as the holder of the share.
- (4) The Purchaser shall not be bound to see to the application of the purchase money, nor shall his title to the shares be affected by any irregularity or invalidity in the proceedings in reference to the sale.

(d) Application of proceeds of sale

- (1) The net proceeds of any such sale shall be received by the Company and applied in or towards such part of the amount in respect of which the lien exists as is presently payable, and
- (2) The residue, if any, shall be paid to the person entitled to the shares at the date of the sale (subject to a like lien for sums not presently payable as existed on the share before the sale).

(e) Outsider's lien not to affect company's lien

In exercising its lien, the Company shall be entitled to treat the registered holder of any share as the absolute owner thereof and accordingly shall not (except as ordered by a court of competent jurisdiction or unless required by any statute) be bound to recognize any equitable or other claim to, or interest in, such share on the part of any other person, whether a creditor of the registered holder or otherwise. The Company's lien shall prevail notwithstanding that it has received notice of any such claim.

The provisions of these Articles relating to lien shall mutatis mutandis apply to any other securities including debentures of the Company.

10. JOINT HOLDERS

a. THE FIRST NAMED OF JOINT HOLDERS DEEMED SOLE HOLDER

If any share stands in the names of two or more persons, first named in the register shall, as regards receipts of dividends or bonus or service of notices and all or any other matter connected with the Company, except voting at meeting and the transfer of the shares, be deemed the sole holder thereof but the joint holder of a share shall, severally as well as jointly, be liable for the payment of all installments and calls due in respect of such share, and for all incidents thereof according to the Company's regulations.

Where two or more persons are registered as the holders of any share, they shall be deemed (so far as the Company is concerned) to hold the same as joint tenants with benefit of survivorship subject to the following and other provisions contained in these articles:-

b. NOT MORE THAN FOUR

- (a) The Company shall not be bound to register more than four persons as the holders of any share.
- (b) The joint holders of any share shall be liable severally as well as jointly for and in respect of all installments, calls and other payments which ought to be made in respect of such share.

c. TITLE OF SURVIVORS

On the death of any of such joint holder the survivor or survivors shall be the only person or persons recognised by the Company as having any title to the share but the Board may require such evidence of death as it may deem fit and nothing herein contained shall be taken to release the estate of a deceased joint holder from any liability on shares held by him jointly with any other person.

d. RECEIPT OF ONE SUFFICIENT

Any one of such joint holders may give effectual receipts of any dividends or other moneys payable in respect of such share.

e. DELIVERY OF CERTIFICATE AND GIVING OF NOTICE

Only the person whose name stands first in the Register of Members as one of the joint holders of any share unless otherwise directed by all of them in writing shall be entitled to delivery of certificate relating to such share or to receive any documents from the Company and any document served on or sent to such person shall be deemed service on all the joint holders.

The provisions of these Articles relating to joint holders of shares shall mutatis mutandis apply to any other securities including debentures of the Company registered in joint names.

11. FORFEITURE OF SHARES

a. IF MONEY PAYABLE ON SHARES NOT PAID NOTICE TO BE GIVEN TO MEMBER

If any member fails to pay any call or any installment of a call on or before the day appointed for the payment of the same or any such extension thereof as aforesaid, the Board of Directors may, at any time thereafter, give notice to him requiring him to pay the same together with any interest that may have accrued and all expenses that may have been incurred by the Company by reason of such non-payment.

b. ALLOTMENT MONEY SHALL BE DEEMED TO BE A CALL

For the purpose of provisions of these presents relating to forfeiture of shares, the sum payable upon allotment in respect of a share shall be deemed to be a call payable upon such share on the day of allotment.

c. EFFECT OF NONPAYMENT OF SUMS

In case of non-payment of such sum, all the relevant provisions of these Articles as to payment of interest and expenses, forfeiture or otherwise shall apply as if such sum had become payable by virtue of a call duly made and notified.

d. FORM OF NOTICE

The notice shall name a day (not being less than fourteen (14) days from the date of the notice) and a place or places on and at which such call or installment and such interest thereon at such rate and expenses as aforesaid are to be paid. The notice shall also state that, in the event of the non-payment at or before the time and at the place appointed the shares in respect of which the call was made or installment is payable will be liable to be forfeited.

e. IN DEFAULT OF PAYMENT SHARES TO BE FORFEITED

If the requirements of any such notice as aforesaid shall not be complied with, every or any share in respect of which such notice has been given may at any time thereafter before payment of all calls or installments interest and expenses due in respect thereof, be forfeited by a resolution of the Board of Directors to that effect. Such forfeiture shall include all dividends declared or any other moneys payable in respect by the forfeited shares and not actually paid before the forfeiture. Neither the receipt by the Company of a portion of any money which shall from time to time be due from any member to the Company in respect of his shares, either by way of principal or interest, nor any indulgence granted by the Company in respect of payment of any such money, shall preclude the Company from thereafter proceeding to enforce a forfeiture of such shares as herein provided.

f. NOTICE OF FORFEITURE TO A MEMBER

When any share shall have so forfeited, notice of the forfeiture shall be given to the member in whose name it stood immediately prior to the forfeiture, and an entry of the forfeiture, with the date thereof, shall forth with be made in the Register of Members, but no forfeiture shall be in any manner invalidated by any omission or neglect to give such notice or to make any such entry as aforesaid.

g. FORFEITED SHARE TO BE THE PROPERTY OF THE COMPANY AND MAY BE SOLD ETC.

Any share so forfeited, shall be deemed to be the property of the Company and may be sold, reallocated or otherwise disposed of, either to the original holder or to any other person, upon such terms and in such manner as the Board of Directors shall think fit.

h. CANCELLATION OF FORFEITURE

At any time before a sale or disposal as aforesaid, the Board may cancel the forfeiture on such terms as it thinks fit.

i. MEMBER STILL LIABLE TO PAY MONEY OWING AT THE TIME OF FORFEITURE AND INTEREST

Any member whose shares have been forfeited shall, notwithstanding the forfeiture, be liable to pay, and shall forthwith pay to the Company on demand all calls, installments, interest and expenses owing upon or in respect of such shares at the time of the forfeiture together with interest thereon from the time of forfeiture until payment, at such rate not exceeding twelve (12) per cent per annum as the Board of Directors may determine and the Board of Directors may enforce the payment of such moneys or any part thereof, if they think fit, but shall not be under any obligation so to do.

j. EFFECT OF FORFEITURE

The forfeiture of a share shall involve extinction at the time of the forfeiture of all interest in, and all claims and demands against the Company in respect of the share, and all other rights incidental to the share, except only such of those rights as by these Articles are expressly saved.

k. VALIDITY OF FORFEITURE

- 1) A duly verified declaration in writing that the declarant is a Director, the Managing Director or the Manager or Secretary of the Company, and that a share in the Company has been duly forfeited in accordance with these Articles, on a date stated in the declaration shall be conclusive evidence of the facts stated as against all persons claiming to be entitled to the share;
- 2) The Company may receive the consideration if any, given for the share on any sale, re-allotment or other disposal thereof and may execute a transfer of the share in favour of the person to whom the share is sold or disposed of;
- 3) The person to whom such share, is sold, re-allotted or disposed of shall thereupon be registered as the holder of the share;
- 4) Any such purchaser or allottee shall not (unless by express agreement) be liable to pay any calls, amounts, installments, interest and expenses owing to the Company prior to such purchase or allotment nor shall be entitled (unless by express agreement) to any of the dividends, interest and bonuses accrued or which might have accrued upon the share before the time of completing such purchase or before such allotment.
- 5) Such purchaser or allottee shall not be bound to see to the application of the purchase money, if any, nor shall his title to the share be affected by any irregularity or invalidity in the proceedings in reference to the forfeiture, sale re-allotment or other disposal of the share.

l. CANCELLATION OF SHARE CERTIFICATES IN RESPECT OF FORFEITED SHARES

Upon any sale, re-allotment or other disposal under the provisions of the preceding Articles, the certificates originally issued in respect of the relative shares shall (unless the same shall on demand by the Company have been previously surrendered to it by the defaulting member) stand cancelled and become null and void and of no effect, and the Board shall be entitled to issue a new certificate in respect of the said shares to the persons entitled thereto.

m. VALIDITY OF SALES

Upon any sale after forfeiture or for enforcing a lien in exercise of the powers hereinabove given, the Board may, if necessary, appoint some person to execute an instrument for transfer of the shares sold and cause the purchaser's name to be entered in the register of members in respect of the shares sold and after his name has been entered in the register of members in respect of such shares, the validity of the sale shall not be impeached by any person.

12. SURRENDER OF SHARES

The Board may, subject to the provisions of the Act, accept a surrender of any share from or for any member desirous of surrendering on such terms as they think fit.

The provisions of these Articles relating to forfeiture of shares shall mutatis mutandis apply to any other securities including debentures of the Company.

13. TRANSFER AND TRANSMISSION OF SHARES

a. INSTRUMENT OF TRANSFER TO BE EXECUTED BY TRANSFEROR AND TRANSFEREE

- 1) For shares in physical form, the instrument of transfer of any share in the Company shall be duly executed by or on behalf of both the transferor and transferee.
- 2) The transferor shall be deemed to remain a holder of the share until the name of the transferee is entered in the register of members in respect thereof.
- 3) The instrument of transfer shall be in writing and all the provisions of Section 56 of the Act and of any statutory modification thereof for the time being shall be duly complied with in respect of all transfers of shares and the registration thereof.

b. BOARD MAY REFUSE TO REGISTER TRANSFER

Subject to the provisions of Sections 58 and 59 of the Act, these Articles and other applicable provisions of the Act or any other law for the time being in force, the Board may, refuse to register the transfer of, or the transmission by operation of law of the right to, any securities or interest of a shareholder in the Company. Further, subject to the provisions of Section 56 of the Act and section 22A and other relevant provisions of the Securities Contracts (Regulation) Act, 1956, as amended, the Board may, at its absolute and uncontrolled discretion and by giving reasons, decline to register or acknowledge any transfer of shares whether fully paid or not and the right of refusal shall not be affected by the circumstances that the proposed transferee is already a shareholder of the Company. The Board shall, within one month from the date on which the instrument of transfer, or the intimation of such transmission, as the case may be, was delivered to the Company, send a notice of refusal to the transferee and transferor or to the person giving notice of such transmission, as the case may be, giving reasons for such refusal.

Provided that, registration of a transfer shall not be refused on the ground of the transferor being either alone or jointly with any other Person or Persons indebted to the Company on any account whatsoever except where the Company has a lien on shares. Transfer of shares / debentures in whatever lot shall not be refused.

c. BOARD MAY DECLINE TO RECOGNIZE INSTRUMENT OF TRANSFER

The Board may decline to recognize any instrument of transfer unless –

- a) the instrument of transfer is duly executed and is in the form as prescribed in the Rules made under the Act;
- b) the instrument of transfer is accompanied by the certificate of the shares to which it relates, and such other evidence as the Board may reasonably require to show the right of the transferor to make the transfer; and
- c) the instrument of transfer is in respect of only one class of shares.
- d) Nothing contained in Section 56 of the Act or these Articles shall apply to a transfer of Securities effected by transferor and transferee both of whom are entered as Beneficial Owners in the records of a Depository. In the case of transfer or transmission of shares or other Securities where the Company has not issued any certificates and where such shares or Securities are being held in any electronic or fungible form in a Depository, the provisions of the Depositories Act shall apply.
- e) Provisions of Articles to apply to Shares held in Depository:
Except as specifically provided in these Articles, the provisions relating to joint holders of shares, calls, lien on shares, forfeiture of shares and transfer and transmission of shares shall be applicable to shares held in Depository so far as they apply to shares held in physical form subject to the provisions of the Depositories Act.
- f) Certificate Number and other details of Securities in Depository:
Nothing contained in the Act or these Articles regarding the necessity of having certificate number/distinctive numbers for Securities issued by the Company shall apply to Securities held with a Depository

d. TRANSFER OF SHARES WHEN SUSPENDED

On giving of previous notice of at least seven (7) days or such lesser period in accordance with the Act and Rules made thereunder, the registration of transfers may be suspended at such times and for such periods as the Board may from time to time determine:

Provided that such registration shall not be suspended for more than thirty (30) days at any one time or for more than forty- five (45) days in the aggregate in any year.

e. TRANSFER OF PARTLY PAID SHARES

Where the application is made by the transferor and relates to partly paid shares, the transfer shall not be registered, unless the Company gives notice of the application to the transferee and the transferee makes no objection to the transfer within two weeks from the date of receipt of the notice.

f. TRANSFER TO MINORS, ETC.

- (a) No share shall in any circumstances be transferred to an insolvent or a person of unsound mind.
- (b) A minor may be admitted and registered as a member of the Company in respect of any fully paid up share or shares in his or her name. The father or the mother of a minor or a guardian appointed by a competent court shall have a right to represent and act for the minor in all respects including voting and/or giving proxy in respect of any share or shares held by such minor.

g. THE COMPANY NOT LIABLE FOR DISREGARD OF A NOTICE PROHIBITING REGISTRATION OF A TRANSFER

The Company shall incur no liability or responsibility whatever in consequence of its registering or giving effect to any transfer of shares made or purporting to be made by any apparent legal owner thereof as shown or appearing in the register of members to the prejudice of persons having or claiming any equitable right, title or interest to or in the said shares, notwithstanding that the Company may have had notice of such equitable right, or referred thereto in any book of the Company and the Company shall not be bound or required to regard or attend or give effect to any notice which may be given to it of any equitable right, title or interest, or be under any liability whatsoever for refusing or neglecting so to do, though it may have been entered or referred to in some books of the Company, but the Company shall nevertheless be at liberty to regard and attend to any such notice, and give effect thereto if the Board of Directors shall so think fit.

h. TITLE TO SHARES OF DECEASED MEMBER

The executors or administrators of a deceased member or the holder of a succession certificate or the legal representatives in respect of the shares of a deceased member (not being one of two or more joint holders) shall be the only persons recognised by the Company as having any title to the shares registered in the names of such members, and the Company shall not be bound to recognise such executors or administrators or holders of a succession certificate or the legal representatives unless such executors or administrators or legal representatives shall have first obtained Probate or Letters of Administration, or Succession certificate, as the case may be, from a duly constituted Court in the Union of India provided that in any case where the Board of Directors in its absolute discretion thinks fit, the Board may upon such terms as to indemnity or otherwise as the Directors may deem proper dispense with production of Probate or Letters of Administration or Succession Certificate and register under this Article the name of any person, who claims to be absolutely entitled to the shares standing in the name of a deceased member, as a member.

i. TITLE TO SHARES ON DEATH OF A MEMBER

On the death of a member, the survivor or survivors where the member was a joint holder, and his nominee or nominees or legal representatives where he was a sole holder, shall be the only persons recognized by the Company as having any title to his interest in the shares.

j. ESTATE OF DECEASED MEMBER LIABLE

Nothing shall release the estate of a deceased joint holder from any liability in respect of any share which had been jointly held by him with other persons.

k. TRANSMISSION CLAUSE

Any person becoming entitled to a share in consequence of the death or insolvency of a member may, upon such evidence being produced as may from time-to-time properly be required by the Board and subject as hereinafter provided, elect, either

a) to be registered himself as holder of the share; or

b) to make such transfer of the share as the deceased or insolvent member could have made.

l. BOARD'S RIGHT UNAFFECTED

The Board shall in either case have the same right to decline or suspend registration as it would have had, if the deceased or insolvent member had transferred the share before his death or insolvency.

m. INDEMNITY TO THE COMPANY

The Company shall be fully indemnified by such person from all liability, if any, by actions taken by the Board to give effect to such registration or transfer.

n. BOARD'S RIGHT UNAFFECTED

The Board shall, in either case, have the same right to decline or suspend registration as it would have had, if the deceased or insolvent member had transferred the share before his death or insolvency.

o. NO FEE ON TRANSFER OR TRANSMISSION

No fee shall be charged for registration of transfer, grant of probate, Succession Certificate and Letters of Administration, Certificates of Death or Marriage, Power of Attorney or similar other documents.

Notwithstanding anything contained in the Articles of Association, in the case of transfer of shares or other marketable securities, where the Company has not issued any certificates and where such shares or securities are being held in an electronic and fungible form, the provisions of the Depositories Act, 1996, shall apply.

The provisions of these Articles relating to transfer & transmission of shares shall mutatis mutandis apply to any other securities including debentures of the Company.

14. MEETINGS OF MEMBERS

a. ANNUAL GENERAL MEETING

The Company shall in each year hold in addition to any other meetings, a general meeting as its annual general meeting, except in the case where any extension of time for holding any annual general meeting is granted/availed under applicable laws. Not more than 15 (fifteen) months shall elapse between the date of one annual general meeting of the Company and that of the next. Nothing contained in the foregoing provisions shall be taken as affecting the right conferred upon the registrar under the provisions of Section 96 of the Act to extend the time within which any annual general meeting may be held. Every annual general meeting shall be called during business hours on a day that is not a national holiday and shall be held either at the registered office or at some other place within the city in which the office of the Company is situate through video conferencing or audio-visual means or teleconferencing /permitted mode, as the Board may determine.

b. EXTRAORDINARY GENERAL MEETING

All general meetings other than annual general meeting shall be called extra-ordinary general meeting.

The Board may, whenever they think fit, convene an extra-ordinary general meeting.

The Board shall on the requisition of such number of members of the Company as is specified in Section 100 of the Act, forthwith proceed to call an extra-ordinary general meeting of the Company and in respect of any such requisition and of any meeting to be called pursuant thereto, all other provisions of Section 100 of the Act shall for the time being apply through video conferencing or audio-visual means or teleconferencing/permitted mode.

c. CALLING GENERAL MEETING

A general meeting of the Company may be convened by giving not less than clear 21 (twenty-one) days' notice either in writing or through electronic/permitted mode in such manner as prescribed under the Act, provided that a general meeting may be called after giving a shorter notice if consent is given in writing or by electronic mode: (a) in the case of an annual general meeting, by not less than 95% (ninety-five percent) of the members entitled to vote

at such meeting, and (b) in the case of any other general meeting, by members holding, majority in number of members entitled to vote and who represent not less than 95% (ninety-five percent) of such part of the paid-up share capital of the Company as gives a right to vote at such meeting. Provided further that where any member is entitled to vote only on some resolution or resolutions to be moved at a general meeting and not on the others, that member shall be taken into account for the abovementioned purposes, in respect of the former resolution(s) and not in respect of the latter.

Notice of every general meeting shall be given to the members and to such other person or persons as required by and in accordance with Section 101 and 102 of the Act and it shall be served in the manner authorized by Section 20 of the Act.

The accidental omission to give notice of any meeting to or the non-receipt of any notice by any member or other person to whom it should be given shall not invalidate the proceedings at the meeting or the resolutions passed thereat.

d. NATURE OF BUSINESS

The ordinary business of an annual general meeting shall be to receive and consider the financial statements and the report of the Board and of the auditors, to reappointment of Directors retiring by rotation, to appointment of auditors and to declare dividends. All other business transacted at such meeting and all business transacted at an extra ordinary meeting shall be deemed special.

e. QUORUM

- 1) No business shall be transacted at any general meeting unless a quorum of members is present at the time when the meeting proceeds to business.
- 2) No business shall be discussed or transacted at any general meeting except election of Chairperson whilst the chair is vacant.
- 3) The quorum for a general meeting shall be as provided in the Act.

f. CHAIRMAN OF GENERAL MEETING

The chairman of the Board shall be entitled to take the chair at every general meeting, whether annual or extraordinary. If there be no such chairman of the Board, or if at any meeting he shall not be present within fifteen minutes of the time appointed for holding such meeting or if he shall be unable or unwilling to take the chair then the members present shall elect another Director as chairman, and if no Director be present or if all the Directors present decline to take the Chair, then the members present shall elect one of the members to be the chairman of that meeting.

g. BUSINESS CONFINED TO ELECTION OF CHAIRMAN WHILST CHAIR VACANT

No business shall be discussed at any general meeting except the election of a Chairman whilst the chair is vacant.

h. CHAIRMAN MAY ADJOURN MEETING

- (1) The Chairman may, suo moto, adjourn the meeting from time to time and from place to place.
- (2) In the event a quorum as required herein is not present within 30 (thirty) minutes of the appointed time, then subject to the provisions of Section 103 of the Act, the general meeting shall stand adjourned to the same place and time 7 (seven) days later, provided that the agenda for such adjourned general meeting shall remain the same. The said general meeting if called by requisitionists under Section 100 of the Act (read with provisions of these Articles) shall stand cancelled.
- (3) No business shall be transacted at any adjourned meeting other than the business left unfinished at the meeting from which the adjournment took place.
- (4) When a meeting is adjourned for thirty (30) days or more, notice of the adjourned meeting shall be given as in the case of an original meeting.

- (5) The required quorum at any adjourned general meeting shall be the same as that required at the original general meeting.
- (6) Save as aforesaid, it shall not be necessary to give any notice of an adjournment of or of the business to be transacted at any adjourned meeting.

i. CHAIRMAN'S DECLARATION OF RESULT OF VOTING ON SHOW OF HANDS

A declaration by the Chairman that on a show of hands, a resolution has or has not been carried either unanimously or by a particular majority, and an entry to that effect in the books containing the minutes of the proceedings of the Company shall be conclusive evidence of the fact, without proof of the number or proportion of votes in favour or against such resolution.

j. CHAIRMAN'S CASTING VOTE

In the case of an equality of votes, the chairman shall both on a show of hands and a poll (if any) have a second or casting vote in addition to the vote or votes to which he may be entitled as a member.

k. VOTING THROUGH ELECTRONIC MEANS

A member may exercise his vote at a meeting by electronic means in accordance with the Act and shall vote only once.

l. MEMBERS PAYING MONEY IN ADVANCE NOT TO BE ENTITLED TO VOTE IN RESPECT THEREOF

A member paying the whole or a part of the amount remaining unpaid on any share held by them although no part of that amount has been called up, shall not be entitled to any voting rights in respect of the moneys so paid by him until the same would but for such payment become presently payable.

m. NUMBER OF VOTES TO WHICH MEMBER ENTITLED

i) Subject to the provisions of the Act and these Articles and without prejudice to any special privileges or restrictions as to voting for the time being attached to any class of shares for the time being forming part of the capital of the Company, every Member, shall be entitled to vote in the manner prescribed under the Act and Articles.

ii) Subject to the provisions of this Act and this Articles any person entitled under the Transmission Clause to any shares may vote at any general meeting in respect thereof as if he was the registered holder of such shares, provided that at least 48 (forty eight) hours before the time of holding the meeting or adjourned meeting as the case may be, at which he proposes to vote, he shall duly satisfy the Board of his right to such shares unless the Board shall have previously admitted his right to vote at such meeting in respect thereof.

iii) Any member shall enjoy the same rights and be subject to the same liabilities as all other members of the same class.

n. VOTING IN PERSON OR BY PROXY

The instrument appointing a proxy and/or the power of attorney or other authority, if any, under which it is signed or a notarized copy of that power or authority, shall be deposited at the registered office of the Company not less than 48 (forty eight) hours before the time for holding the meeting or adjourned meeting at which the person named in the instrument proposes to vote; or in the case of a poll, not less than 24 (twenty four) hours before the time appointed for the taking of the poll; and in default the instrument of proxy shall not be treated as valid.

Any member entitled to attend and vote at a general meeting may do so either personally or through his constituted attorney or through another person as a proxy on his behalf, for that meeting.

An instrument appointing a proxy shall be in the form as prescribed under the Act and the rules framed thereunder.

The proxy so appointed shall have no right to speak at the meeting.

A vote given in accordance with the terms of an instrument of proxy shall be valid, notwithstanding the previous death or insanity of the principal or the revocation of the proxy or of the authority under which the proxy was

executed, or the transfer of the shares in respect of which the proxy is given, provided that no intimation in writing of such death, insanity, revocation or transfer shall have been received by the Company at its office before the commencement of the meeting or adjourned meeting at which the proxy is used.

Unless specifically provided as part of terms of preference shares, the preference shares shall not confer on the holders thereof the right to vote either in person or by proxy at any general meeting of the Company save to the extent and in the manner provided by Section 47(2) of the Act.

o. MEMBERS IN ARREARS NOT TO VOTE

No members shall exercise any voting right in respect of any shares registered in his name on which any calls or other sums presently payable by him have not been paid or in regard to which the Company has and has exercised any right of lien.

p. MINUTES OF PROCEEDINGS OF MEETINGS AND RESOLUTIONS PASSED BY POSTAL BALLOT

The Company shall cause minutes of the proceedings of every general meeting of any class of members or creditors and every resolution passed by postal ballot to be prepared and signed in such manner as may be prescribed under the Act and the Rules

q. INSPECTION OF MINUTE BOOKS OF GENERAL MEETING

The books containing the minutes of the proceedings of any general meeting of the Company or a resolution passed by postal ballot shall:

- a) be kept at the registered office of the Company; and
- b) be open to inspection of any member without charge, during 2 p.m. (IST) to 4.30 p.m. (IST) on all working days.

r. MEMBERS MAY OBTAIN COPY OF MINUTES

Any member shall be entitled to be furnished, within the time prescribed by the Act, after he has made a request in writing in that behalf to the Company and on payment of such fees as may be fixed by the Board, with a copy of any minutes of general meetings:

Provided that a member who has made a request for provision of a soft copy of the minutes of any previous general meeting held during the period immediately preceding three financial years, shall be entitled to be furnished with the same free of cost.

s. POWERS TO ARRANGE SECURITY AT MEETINGS

The Board, and also any person(s) authorized by it, may take any action before the commencement of any general meeting, or any meeting of a class of members in the Company, which they may think fit to ensure the security of the meeting, the safety of people attending the meeting, and the orderly conduct of the meeting. Any decision made in good faith under this Article shall be final, and rights to attend and participate in the meeting concerned shall be subject to such decision.

15. DIRECTORS

a. NUMBER OF DIRECTORS

- a) Until otherwise determined by a general meeting of the Company and subject to the provisions of Section 149 of the Act, the number of Directors (excluding Debenture Directors, Government Directors, Ex-officio Directors, if any) shall be not less than 3 and not more than 15. However, maximum number can exceed 15 by passing special resolution as required under the Act.

- b) The first Directors of the Company were and Mr. Narendra Kumar Pamecha and Mr. Anil Kumar Sabarwal.

- (c) It shall not be necessary for a Director to hold any share in the Company.

b. DIRECTORS NOT LIABLE TO RETIRE BY ROTATION

The shareholders/ members shall have the power to determine the Directors whose period of office is or is not liable to determination by retirement of Directors by rotation subject to compliance of the Act and the Rules made thereunder. Each of them shall be entitled to hold the office until he resigns on his own accord.

Subject to provisions of the relevant laws and these Articles, not less than 2/3rd of the total number of Directors for the time being shall be those whose period of office is liable for determination of retirement by rotation save as otherwise expressly provided in this Act, be appointed by the company in general meeting. For the purposes of this article, the total number of Directors shall not include independent directors, Nominee Director, whether appointed under the Act or any other law for the time being in force, on the Board.

The Directors to retire by rotation at every annual general meeting shall be those who have been longest in office since their last appointment, but as between persons who became Directors on the same day, those who are to retire shall, in default of and subject to any agreement among themselves, be determined by lot. Further this will also be governed by the provisions of Listing Regulations.

A retiring Director shall be eligible for re-election.

c. SAME INDIVIDUAL MAY BE CHAIRPERSON AND MANAGING DIRECTOR/ CHIEF EXECUTIVE OFFICER

The same individual may, at the same time, be appointed as the Chairperson of the Company as well as the Managing Director or Chief Executive Officer of the Company.

d. APPOINTMENT OF ALTERNATE DIRECTOR

The Board may appoint an Alternate Director to act for a Director (hereinafter called “the original Director”) during his absence for a period of not less than three months from the India which meetings of the Board are ordinarily held. Every such Alternate Director shall, subject to his giving to the Company an address in India at which notice may be served on him, be entitled to notice of meeting of Board and to attend and vote as a Director and be counted for the purposes of a quorum and generally at such meetings to have and exercise all powers and duties and authorities of the original Director. The Alternate Director appointed under this Article shall vacate office as and when original Director returns to the India. If the terms of office of the original Director is determined before he returns to the India, any provision in the Act or in this Article for the automatic re-appointment of retiring Director in default of another appointment shall apply to the original Director and not to the Alternate Director.

e. APPOINTMENT OF SPECIAL DIRECTOR

- (i) The Company shall, subject to the provisions of the Act, be entitled to agree with the Central or State Government, or any person, firm, corporation or authority that he or it shall have the right to appoint his or its nominees on the Board of Directors of the Company upon such terms and conditions as the Directors may deem fit. Such nominees and their successors in office appointed under this Article shall be called Special Directors. Special Directors shall be entitled to hold office until requested to retire by authority, person, firm or corporation who may have appointed them and will not be bound to retire by rotation. As and whenever a Special Director vacates office, whether upon request as aforesaid or by death, resignation or otherwise, the authority, person, firm or corporation who appointed such Special Director may, if the agreement so provides, appoint another Director in his place.
- (ii) The Special Directors, appointed under sub-clause (i) above, shall be entitled to hold office until requested to retire by the person, firm or corporation who may have appointed them and will not be bound to retire by rotation. As and whenever a Special Director vacates office whether upon request as aforesaid or by death, resignation or otherwise, the person, firm or corporation who have appointed such special Director may appoint any other Director in his place. The Special Director may at any time by notice in writing to the Company resign his office. Subject as aforesaid a Special Director shall be entitled to the same rights and privileges and be subject to the same obligations as any other Director of the Company.

f. APPOINTMENT OF DEBENTURE DIRECTORS

Any Trust Deed for securing debentures or debenture stocks may, if so agreed, provide for the appointment, from time to time, by the Trustees thereof, or by the holders of debentures or debenture stocks, of some person to be a Director

and may empower such Trustees or holder of debentures or debentures stocks, from time to time, to remove and re-appoint any Director so appointed. The Director so appointed under this Article herein referred to as “Debenture Director” and the term “Debenture Director” means the Director for the time being in office under this Article. The Debenture Director shall not be liable to retire by rotation or be removed by the Company. The Trust Deed may contain such ancillary provision as may be agreed between the Company and the Trustees and all such provisions shall have effect notwithstanding any of the other provisions herein contained.

g. APPOINTMENT OF NOMINEE DIRECTORS

- (i) Notwithstanding anything to the contrary contained in these Articles, so long as any money remain owing by the Company to financial institutions, financing company or body or credit corporation, out of any loans granted by them to the Company or so long as the financial institution, financing company or body corporate or Credit Corporation (each of the financial institutions, financing company or body or credit corporation is hereinafter in this Article referred to as “The Corporation”) continue to hold debentures in the Company by direct subscription or private placement, or so long as the Corporation holds shares in the Company as result of underwriting or direct subscription or so long as any liability of the Company arising out of any guarantee furnished by the Corporation on behalf of the Company remains outstanding, the Corporation shall have a right to appoint from time to time, any person or persons as a Director or Directors, whole time or non-whole time, (which Directors or Directors is/are hereinafter referred to as “Nominee Director/s”) on the Board of the Company and to remove from such office any person or persons so appointed and to appoint any person or persons in his or their place/s in terms of the agreement executed with such Corporation/ provisions of the respective statute/ or otherwise agreed to by the Board.
- (ii) The Board of Directors of the Company shall have no power to remove from office the Nominee Director/s. At the option of the Corporation, such Nominee Director/s shall not be required to hold any share qualification in the Company. Also, at the option of the Corporation, such Nominee Director/s shall not be liable to retirement by rotation of Directors. Subject as aforesaid, the Nominee Director/s shall be entitled to the same rights and privileges and be subject to the same obligations as any other Director of the Company.
- (iii) The Nominee Director/s so appointed shall hold the said office only so long as any money remain owing by the Company to the Corporation or so long as the Corporation holds Debentures in the Company as result of direct subscription or private placement or so long as the Corporation holds shares in the Company as a result of underwriting or direct subscription or the liability of the Company arising out of the Guarantee is outstanding and the Nominee Director/s so appointed in exercise of the said power shall ipso facto vacate such office immediately the money owing by the Company to the Corporation are paid off or on the Corporation ceasing to hold debentures/shares in the Company or on the satisfaction of the liability of the Company arising out of the Guarantee furnished by the Corporation.
- (iv) The Nominee Director/s appointed under this Article shall be entitled to receive all notices of and attend to General Meetings, Board Meetings and of the Meetings of the Committee of which the Nominee Director/s is/are member/s as also the minutes of such meetings. The Corporation shall also be entitled to receive all such notices and minutes.
- (v) The Company shall pay to the Nominee Director/s sitting fees and expenses to which the other Directors of the Company are entitled, but if any other fees, commission, money or remuneration in any form is payable to the Directors of the Company, the fees, commission, money and remuneration in relation to such Nominee Director/s shall accrue to the Corporation and same shall accordingly be paid by the Company directly to the Corporation.
- (vi) Any expenses that may be incurred by the Corporation or such Nominee Director/s in connection with their appointment or Directorship shall also be paid or reimbursed by the Company to the Corporation or, as the case may be, to such Nominee Director/s. Provided that if any such Nominee Director/s is an officer of the Corporation, the sitting fees in relation to such Nominee Director/s shall also accrue to the Corporation and the same shall accordingly be paid by the Company directly to the Corporation or as per rules and regulations/or agreement entered into with such corporation
- (vii) In the event of the Nominee Director/s being appointed as Whole-time Director/s, such Nominee Director/s shall exercise such powers and have such rights as are usually exercised or available to a whole-time Director in the management of the affairs of the Company. Such Whole time Director/s shall be entitled to receive such remuneration, fees, commission and money as may be approved by the Corporation.

h. DIRECTORS MAY FILL VACANCIES

The Directors shall have power at any time and from time to time to appoint any person to be a Director to fill a casual vacancy. Such casual vacancy shall be filled by the Board of Directors at a meeting of the Board. Any person so appointed shall retain his office only upto the date upto which the Director in whose place he is appointed would have held office, if it had not been vacated as aforesaid but he shall then be eligible for re-election.

i. APPOINTMENT OF ADDITIONAL DIRECTORS

The Directors shall also have power at any time and from time to time to appoint any other person to be a Director as an addition to the Board under Section 161 of the Act but so that the total number of Directors shall not at any time exceed the maximum fixed. Any person so appointed as an addition to the Board shall retain his office only upto the date of the next annual general meeting but shall be eligible for election at such meeting.

j. APPOINTMENT OF OTHER DIRECTORS

The Board shall appoint Woman Director and Independent Director in the manner required under the provisions of Act and other applicable laws.

k. APPOINTMENT OF MANAGING DIRECTOR OR MANAGING DIRECTOR(S) OR WHOLE TIME DIRECTOR OR WHOLE TIME DIRECTOR(S)

Subject to the provisions of Section 196 / 203 and other applicable provisions of the Act and these Articles, the Board shall have power to appoint or reappoint from time to time Managing Director or Managing Directors or whole time Director or whole time Directors of the Company for such term not exceeding five years at a time as they may think fit to manage the affairs and business of the Company and may from time to time (subject to the provisions of any contract between him or them and the Company) remove or dismiss or reappoint him or them from office and appoint another or others in his or their place or places.

16. REMUNERATION OF DIRECTORS

- 1) The remuneration of the Directors shall, in so far as it consists of a monthly payment, be deemed to accrue from day-to-day.
- 2) The remuneration payable to the Directors, including any managing or whole-time director or manager, if any, shall be determined, in accordance with and subject to the provisions of the Act.
- 3) In addition to the remuneration payable to them in pursuance of the Act, the Directors may be paid all travelling, hotel, sitting fees and other expenses properly incurred by them –
 - a) in attending, and returning from meetings of the Board of Directors or any committee thereof or general meetings of the Company; or
 - b) in connection with the business of the Company
 - c) Subject to the provisions of the Act, every Director shall be paid out of the funds of the Company such sum as the Board may from time to time determine for attending every meeting of the Board or any committee of the Board, subject to the ceiling prescribed under the Act.
- 4) All cheques, promissory notes, drafts, hundis, bills of exchange and other negotiable instruments, and all receipts for monies paid to the Company, shall be signed, drawn, accepted, endorsed, or otherwise executed, as the case may be, by such person and in such manner as the Board shall from time to time by resolution determine.

17. PROCEEDING OF THE BOARD OF DIRECTORS

a. MEETINGS OF DIRECTORS

- (a) The conducting of Meetings of the Board of Directors is governed by Secretarial Standards issued by ICSI and approved by the Ministry of Corporate Affairs.
- (b) A meeting of the Board of Directors shall be held at least four (4) times every year and not more than 120 days shall lapse between two (2) Board meetings.

- (c) No business shall be conducted at any meeting of the Directors unless a quorum is present. The quorum for the meeting of the Board shall be one third of its total strength or 2 (two) Directors, whichever is higher, and the participation of the Directors by video conferencing or by other audio-visual means or any other means (to the extent permitted under the Act and the rules framed thereunder or otherwise provided by the Ministry of Corporate Affairs), in each case from time to time, shall also be counted for the purposes of quorum, provided that where at any time the number of interested Directors is equal to or exceeds two-thirds of the total strength of the Board, the number of remaining Directors, that is to say the number of Directors who are not interested and present at the meeting being not less than 2 (two), shall be the quorum during such time.
- (d) If quorum is found to be not present within 30 (thirty) minutes from the time when the meeting should have begun or if during the meeting, valid quorum no longer exists, the meeting shall be reconvened at the same time and at the same place 7 (seven) days later. At the reconvened meeting, the Directors present and not being less than 2 (two) persons shall constitute the quorum and may transact the business for which the meeting was called and any resolution duly passed at such meeting shall be valid and binding on the Company.

b. WHEN MEETING TO BE CONVENED

- i) The Chairperson or any one Director with the previous consent of the Chairperson may, or the company secretary on the direction of the Chairperson shall, at any time, summon a meeting of the Board.
- ii) The participation of Directors in a meeting of the Board may be either in person or through video conferencing or audio-visual means or teleconferencing, as may be prescribed by the Rules or permitted under law.

c. QUORUM

The quorum for the Board meeting shall be as provided above.

d. CHAIRMAN

The Chairperson of the Company shall be the Chairperson at meetings of the Board. In his/her absence, the Board may elect a Chairperson of its meetings and determine the period for which he is to hold office. If no such Chairperson is elected, or if at any meeting the Chairperson is not present within fifteen minutes after the time appointed for holding the meeting, the Directors present may choose one of the Directors to be Chairperson of the meeting.

e. QUESTIONS AT BOARD MEETING HOW DECIDED

Subject to provisions of the Act, questions arising at any meeting of the Board shall be decided by a simple majority of votes, and in case of equality of votes, the chairman shall have second or casting vote.

f. CIRCULAR RESOLUTION

Save as otherwise expressly provided in the Act, a resolution in writing, signed, whether manually or by secure electronic mode, by a majority of the members of the Board or of a Committee thereof, for the time being entitled to receive notice of a meeting of the Board or Committee, shall be valid and effective as if it had been passed at a meeting of the Board or Committee, duly convened and held provided that a draft of such resolution together with the information required to make a fully-informed good faith decision with respect to such resolution and appropriate documents required to evidence passage of such resolution, if any necessary papers, if any, was sent to all of the Directors or members of the committee (as the case may be) at their addresses registered with the Company in India by hand delivery or by post or by courier, or through such electronic means as may be prescribed under the Act, and has been approved by a majority of the Directors or members who are entitled to vote on the resolution.

g. ACTS OF BOARD OR COMMITTEE VALID NOTWITHSTANDING DEFECT IN APPOINTMENT

All acts, done by any meeting of the Board or by a Committee of the Board or by any person acting as a Director shall, notwithstanding that it shall afterwards be discovered that there was some defect in the appointment of one or more of such Directors or any person acting as aforesaid, or that they or any of them were disqualified or had vacated office or that the appointment of any of them is deemed to be terminated by virtue of any provisions contained in

the Act or in these Articles, be as valid as if every such person had been duly appointed and was qualified to be a Director. Provided nothing in this Article shall be deemed to give validity to acts done by a director after his appointment has been shown to the Company to be invalid or to have been terminated.

Every Director shall at the first meeting of the Board in which he participates as a Director and thereafter at the first meeting of the Board in every financial year or whenever there is any change in the disclosures already made, then the first meeting held after such change, disclose his concern or interest in any company, companies or bodies corporate, firms or other associations of individuals which shall include the shareholding in such manner as may be prescribed under the Act and the rules framed thereunder.

h. GENERAL POWERS OF THE COMPANY VESTED IN BOARD

The management of the business of the Company shall be vested in the Board and the Board may exercise all such powers, and do all such acts and things, as the Company is by the memorandum of association or otherwise authorized to exercise and do, and, not hereby or by the statute or otherwise directed or required to be exercised or done by the Company in general meeting but subject nevertheless to the provisions of the Act and other laws and of the memorandum of association and these Articles and to any regulations, not being inconsistent with the memorandum of association and these Articles or the Act, from time to time made by the Company in general meeting provided that no such regulation shall invalidate any prior act of the Board which would have been valid if such regulation had not been made. The Board shall also undertake the corporate social responsibility activities under the provisions of the Act.

The Board may at any time and from time to time by authority letter, board resolution, power of attorney or otherwise appoint any person or persons to be the authorized persons, delegates or attorneys of the Company for such purposes and with such powers, authorities and discretions (not exceeding those vested in or exercisable by the Board) and for such periods and subject to such conditions as the Board may from time to time think fit, and may contain powers enabling such authorized persons, delegates or attorneys as aforesaid to sub-delegate/authorise all or any of the powers, authorities and discretions for the time being vested in them.

i. BORROWING POWERS

Subject to the provisions of the Act and these Articles, the Board of Directors may, from time to time at its discretion by a resolution passed at a meeting of the Board, borrow money from time to time including but not limited to fund based and non-fund based credit facilities from Bankers and other eligible lenders, loans, fixed deposits etc. for the purpose of the business of the Company to be secured in such manner and upon such terms and conditions as the Board of Directors may think fit.

j. ISSUE OF DEBENTURES

The Board has power to issue debentures of various kinds from time to time.

The Board may, from time to time, at its discretion raise for the purpose of the Company's business such of money as they think fit. The Board may raise any such sums as aforesaid by the issue, at such price as it may think fit, of debentures of debentures-stock, either charged upon the whole or any part of the property and assets of the Company or not so charged or in such other way as the Board may think expedient.

k. DELEGATE POWERS

Subject to the provisions of the Act including Section 179, as applicable, the Board may, from time to time, and at any time, delegate to any persons so appointed any of the powers, authorities, and discretions for the time being vested in the Board, other than its power to make calls or to make loans or borrow moneys; and to authorise the member for the time being of any such Local Board, or any of them, to fill up any vacancies therein and to act notwithstanding vacancies, and such appointment or delegation may be made on such terms subject to such conditions as the Board may think fit, and the Board may at any time remove any person so appointed, and may annul or vary any such delegation.

18. BOARD MAY APPOINT COMMITTEES

- i) The Board of Directors may subject to the provisions of Section 179 and other relevant provisions of the Act and of these Articles appoint committee of the Board, and delegate any of the powers other than the powers to make calls and to issue debentures to such committee or committees and may from time to time revoke and discharge any such committees of the Board either wholly or in part and either as to the persons or purposes, but every committee

of the Board so formed shall in exercise of the powers so delegated confirms to any regulation that may from time to time be imposed on it by the Board of Directors. All acts done by any such committee of the Board in conformity with such regulations and in fulfillment of the purpose of their appointment, but not otherwise, shall have the like force and effect, as if done by the Board.

- ii) The participation of Directors in a meeting of the Committee may be either in person or through video conferencing or audio-visual means or teleconferencing, as may be prescribed by the Rules or permitted under law.

a. CHAIRMAN OF COMMITTEE OF DIRECTORS

- i) Committee may elect a Chairperson of its meetings unless the Board, while constituting a Committee, has appointed a Chairperson of such Committee.
- ii) If no such Chairperson is elected, or if at any meeting the Chairperson is not present within five minutes after the time appointed for holding the meeting, the members present may choose one of their members to be Chairperson of the meeting.

b. FUNCTIONING OF THE COMMITTEE

- 1) A Committee may meet and adjourn as it thinks fit.
- 2) Questions arising at any meeting of a Committee shall be determined by a simple majority of votes of the members present.
- 3) In case of an equality of votes, the Chairperson of the Committee shall have a second or casting vote.

19. CHIEF EXECUTIVE OFFICER, MANAGER, COMPANY SECRETARY AND CHIEFFINANCIAL OFFICER

Subject to the provisions of the Act;

- i) A chief executive officer, manager, company secretary and chief financial officer may be appointed by the Board for such term, at such remuneration and upon such conditions as it may think fit; and any chief executive officer, manager, company secretary and chief financial officer so appointed may be removed by means of a resolution of the Board; the Board may appoint one or more chief executive officers for its multiple businesses.
- ii) A director may be appointed as chief executive officer, manager, company secretary or chief financial officer.

The Board shall have the power to appoint an individual as the chairperson of the Company as well as the managing director or chief executive officer of the Company at the same time.

A whole time director / chief financial officer / company secretary of the Company are severally authorised to sign any document or proceeding requiring authentication by the Company or any contract made by or on behalf of the Company.

Any provision of the Act or these regulations requiring or authorising a thing to be done by or to a director and chief executive officer, manager, company secretary or chief financial officer shall not be satisfied by its being done by or to the same person acting both as Director and as, or in place of, chief executive officer, manager, company secretary or chief financial officer.

20. STATUTORY REGISTERS

The Company shall keep and maintain at its registered office all statutory registers namely, register of charges, register of members, register of debenture holders, register of any other security holders, the register and index of beneficial owners and annual return, register of loans, guarantees, security and acquisitions, register of investments not held in its own name and register of contracts and arrangements for such duration as the Board may, unless otherwise prescribed, decide, and in such manner and containing such particulars as prescribed by the Act and the Rules. The registers and copies of annual return shall be open for inspection during 11.00 a.m. to 1.00 p.m. on all working days, other than Saturdays, at the registered office of the Company only by the persons entitled thereto under the Act, on payment, where required, of such fees as may be fixed by the Board but not exceeding the limits prescribed by the Rules. Subject to aforesaid the Board shall have a power to refuse inspection to any other person, at its discretion.

21. FOREIGN REGISTERS

The Company may exercise the powers conferred on it by the Act with regard to the keeping of a foreign register; and the Board may (subject to the provisions of the Act) make and vary such Articles as it may think fit respecting the keeping of any such register. The foreign register shall be open for inspection and may be closed, and extracts may be taken therefrom and copies thereof may be required, in the same manner, mutatis mutandis, as is applicable to the register of members.

22. DIVIDENDS AND RESERVE

- i. Company in general meeting may declare dividends.

The Company in general meeting may declare dividends, but no dividend shall exceed the amount recommended by the Board but the Company in general meeting may declare a lesser dividend.

- ii. Interim dividends

Subject to the provisions of the Act, the Board may from time-to time pay to the members such interim dividends of such amount on such class of shares and at such times as it may think fit.

- iii. Dividends only to be paid out of profits

The Board may, before recommending any dividend, set aside out of the profits of the Company such sums as it thinks fit as a reserve or reserves which shall at the discretion of the Board, be applied for any purpose to which the profits of the Company may be properly applied, including provision for meeting contingencies or for equalizing dividends; and pending such application, may, at the like discretion, either be employed in the business of the Company or be invested in such investments (other than shares of the Company) as the Board may, from time-to-time, think fit.

- iv. Carry forward of profits

The Board may subject to provisions of the Act also carry forward any profits which it may consider necessary not to divide, without setting them aside as a reserve.

- v. Payments in Advance

No amount paid or credited as paid on a share in advance of calls shall be treated for the purposes of this Article as paid on the share.

- vi. Dividends to be Apportioned

All dividends shall be apportioned and paid proportionately to the amounts paid or credited as paid on the shares during any portion or portions of the period in respect of which the dividend is paid; but if any share is issued on terms providing that it shall rank for dividend as from a particular date such share shall rank for dividend accordingly.

- vii. No member to receive dividend whilst indebted to the Company and Company's right to reimbursement therefrom

The Board may deduct from any dividend payable to any member all sums of money, if any, presently payable by him to the Company on account of calls or otherwise in relation to the shares of the Company.

- viii. Retention of dividends

The Board may retain dividends payable upon shares in respect of which any person is, under the Transmission Clause herein before contained, entitled to become a member, until such person shall become a member in respect of such shares.

- ix. Dividend how Remitted

A dividend, interest or other monies payable in cash in respect of shares may be paid by electronic mode or by cheque or warrant sent through the post directed to the registered address of the holder or, in the case of joint holders, to the registered address of that one of the joint holders who is first named on the register of members, or to such person and to such address as the holder or joint holders may in writing direct.

Every such cheque or warrant shall be made payable to the order of the person to whom it is sent.

x. Discharge to Company

Payment in any way whatsoever shall be made at the risk of the person entitled to the money paid or to be paid. The Company will not be responsible for a payment which is lost or delayed. The Company will be deemed to having made a payment and received a good discharge for it if a payment using any of the foregoing permissible means is made.

xi. Receipt of one holder sufficient

Any one of two or more joint holders of a share may give effective receipts for any dividends, bonuses or other monies payable in respect of such share.

xii. No interest on Dividends

No dividend shall bear interest against the Company.

xiii. Waiver of Dividends

The waiver in whole or in part of any dividend on any share by any document (whether or not under seal) shall be effective only if such document is signed by the member (or the person entitled to the share in consequence of the death or bankruptcy of the holder) and delivered to the Company and if or to the extent that the same is accepted as such or acted upon by the Board.

23. Winding up

The Company may be wound up in accordance with the Act and the Insolvency and Bankruptcy Code, 2016 (to the extent applicable).

24. Accounts

Subject to the provisions of the Act, the Company shall keep at its registered office, proper books of accounts and other relevant books and papers and financial statement for every financial year which give a true and fair view of the state of the affairs of the Company, including that of its branch office or offices, if any, and explain the transactions effected both at the registered office and its branches and such books shall be kept on accrual basis and according to the double entry system of accounting, provided that all or any of the books of account aforesaid may be kept at such other place in India as the Board may decide and when the Board so decides the Company shall, within 7 (seven) days of the decision file with the registrar a notice in writing giving the full address of that other place, provided further that the Company may keep such books of accounts or other relevant papers in electronic mode in such manner as provided in Section 128 of the Act and the rules framed thereunder.

The Board shall be entitled from time to time to determine whether and to what extent and at what times and places and under what conditions or regulations, the accounts and books of the Company, or any of them, shall be open to the inspection of members not being Directors. Each Director shall be entitled to examine the books, accounts and records of the Company, and shall have free access, at all reasonable times and with prior written notice, to any and all properties and facilities of the Company. The Company shall provide such information relating to the business, affairs and financial position of the Company as any Director may reasonably require.

No member (not being a Director) shall have any right of inspecting any account or book or document of the company except as conferred by law or authorised by the Board.

All the aforesaid books shall give a true and fair view of the Company's affairs with respect to the matters aforesaid and explain its transactions.

The books of accounts of the Company relating to past periods shall be preserved in good order in compliance with applicable laws.

25. Unpaid or unclaimed dividend

Where the Company has declared a dividend which has not been paid or the dividend warrant in respect thereof has not been posted or sent within thirty days from the date of declaration to any shareholder entitled to payment of the dividend, the Company shall transfer the total amount of dividend, which remained unpaid or unclaimed within seven days from the date of expiry of the said period of thirty days to a special account to be opened by the Company in that behalf in any scheduled bank to be called the “unpaid dividend account”. No unclaimed dividend shall be forfeited by the Board before the claim becomes barred by law and such forfeiture, if effected, shall be annulled in appropriate cases.

Any money so transferred to the unpaid dividend account of the Company which remains unpaid or unclaimed for a period of seven years from the date of such transfer, shall be transferred by the Company to the fund established under sub-section (1) of Section 125 of the Act, viz. “investors education and protection fund”.

26. INDEMNITY AND INSURANCE

Directors and officers right to indemnity

- (a) Subject to the provisions of the Act, every director, managing director, whole-time director, manager, chief executive officer, chief financial officer, company secretary and officer of the Company shall be indemnified by the Company out of the funds of the Company, to pay all costs, losses and expenses (including travelling expense) which such director, manager, company secretary and officer may incur or become liable for by reason of any contract entered into or act or deed done by him in his capacity as such director, manager, company secretary or officer or in anyway in the discharge of his duties in such capacity except such suits, proceedings, cost, charges, losses, damage and expenses, if any, that such director, manager, company secretary and officer shall incur or sustain, by or through his own willful neglect or default.
- (b) Subject as aforesaid, every director, managing director, manager, chief executive officer, chief financial officer, company secretary and officer of the Company shall be indemnified against any liability incurred by him in defending any proceedings, whether civil or criminal in which judgment is given in his favour or in which he is acquitted or discharged or in connection with any application under applicable provisions of the Act in which relief is given to him by the Court.

Provided, however, that such indemnification shall not apply in respect of any cost or loss or expenses to the extent it is finally judicially determined to have resulted from the gross negligence, willful misconduct or bad faith acts or omissions of such director, managing director, manager, chief executive officer, chief financial officer, company secretary or officer.

27. INSURANCE

The Company may take and maintain any insurance as the Board may think fit on behalf of its present and / or former Directors and key managerial personnel for indemnifying all or any of them against any liability for any acts in relation to the Company for which they may be liable but have acted honestly and reasonably.

28. CAPITALISATION

- 1) The Company in General Meeting by Ordinary Resolution may, upon the recommendation of the Board, resolve:
 - (a) that it is desirable to capitalise any part of the amount for the time being standing to the credit of the Company’s reserve accounts, or to the credit of the Profit and Loss Account or otherwise available for distribution;

And

 - (b) that such sum be accordingly set free for distribution in the manner specified in clause no. 2 amongst the members who would have been entitled thereto, if distributed by way of dividend and in the same proportions.
- 2) The sum aforesaid shall not be paid in cash but shall be applied, subject to the provisions contained in clause no. 3 either in or towards:-

- (a) paying up any amount for the time being unpaid on any shares held by such members respectively;
 - (b) paying up in full un-issued shares of the Company to the allocated and distributed, credited as fully paid up, to and amongst such members in the proportions aforesaid; or
 - (c) partly in the way specified in sub-clause (a) and partly in that specified in sub-clause (b).
- 3) A share premium account and a Capital Redemption Reserve Account may, for the purposes of this regulation, only be applied in the paying up of unissued share to be issued to members of the Company as fully paid Bonus Shares.
 - 4) the Board shall give effect to the resolution passed by the Company in pursuance of this regulation.
 - 5) Any agreement made under such authority shall be effective and binding on such members.

29. **SECURITY CLAUSE**

Every director, manager, auditor, secretary, treasurer, trustee, member of a committee, officer, servant, agent, accountant or other person employed in the business of the Company shall, if so required, by the Director, before and any time after entering upon his duties, sign a declaration pledging himself to observe a strict secrecy respecting all transactions, operations, business and affairs of the Company and shall by such declaration pledge himself not to reveal any of the matters which may come to his knowledge in the discharge of his duties except when required to do so by the Board or by law.

30. **NO MEMBER TO ENTER THE PREMISES OF THE COMPANY WITHOUT PERMISSION**

No member or other person (not being a Director) shall, without the prior written permission of the Chairperson of the Company or Managing Director be entitled to visit or inspect any property or premises of the Company or to require discovery of or any information respecting any detail of the Company's trading, operation or business, or any matter which is or may be in the nature of a trade secret, mystery of trade, secret process, or any other matter which may relate to the conduct of the business of the Company and which in the opinion of the Chairperson/Managing Director, it would be inexpedient in the interest of the Company to disclose.

—x—

Alteration of Articles of Association for increase in Authorised Capital to Rs. 15,00,000/- vide passing special resolution at the Members Extra Ordinary General Meeting held on 25th March, 2004.

Alteration of Articles of Association for increase in Authorised Capital to Rs. 45,00,000/- vide passing special resolution at the Members Extra Ordinary General Meeting held on 01st February, 2008.

Alteration of Articles of Association for increase in Authorised Capital to Rs. 100,00,000/- vide passing special resolution at the Members Extra Ordinary General Meeting held on 25th March, 2010.

Alteration of Articles of Association for increase in Authorised Capital to Rs. 200,00,000/- vide passing special resolution at the Members Extra Ordinary General Meeting held on 30th June 2016.

Alteration of Articles of Association for increase in Authorised Capital to Rs. 12,00,00,000/- vide passing special resolution at the Members Extra Ordinary General Meeting held on 19th August 2023.

Alteration of Articles of Association for increase in Authorised Capital to Rs. 20,00,00,000/- vide passing special resolution at the Members Extra Ordinary General Meeting held on 11th January, 2024.

@ Adopted whole new set of Articles of Association vide passing special resolution at the Members Extra Ordinary General Meeting held on 11th January, 2024.

****Conversion of Private Company into Public Company vide passing Special Resolution at the Extra Ordinary General meeting of the Members held on 11th January, 2024.***

Adopted whole new set of Articles of Association vide passing special resolution at the Members Extra Ordinary General Meeting held on 09th February, 2024.

SECTION XI – OTHER INFORMATION

MATERIAL CONTRACTS AND DOCUMENTS FOR INSPECTION

The copies of the following documents and contracts which have been entered or are to be entered into by our Company (not being contracts entered into in the ordinary course of business carried on by our Company) which are or may be deemed material will be attached to the copy of the Prospectus which will be filed with the RoC. Copies of the contracts and documents for inspection referred to hereunder, may be inspected at our Registered Office between 10 a.m. to 5 p.m. on all Working Days from date of the Prospectus until the Bid/ Issue Closing Date. The copies of the contracts and documents for inspection referred to hereunder will be uploaded on the website of our Company at, and will be available for inspection from date of the Prospectus until the Bid/ Issue Closing Date (except for such agreements executed after the Bid/ Issue Closing Date).

MATERIAL CONTRACTS

1. Issue Agreement dated February 20, 2024 between our Company and the Book Running Lead Manager.
2. Registrar Agreement dated February 20, 2024 between our Company and the Registrar to the Issue.
3. Banker to the Issue agreement dated March 26, 2024 between our Company, Book Running Lead Manager, Registrar to the Issue and Public Issue Bank/refund Bank/Sponsor bank.
4. Market Making Agreement dated April 25, 2024 between our Company and the Book Running Lead Manager and Market Maker.
5. Underwriting Agreement dated April 25, 2024 between our Company and Book Running Lead Manager and the Underwriter.
6. Syndicate Agreement dated March 26, 2024 amongst our Company, the Book Running Lead Manager, and Syndicate Members.
7. Tripartite agreement between the CDSL, our Company and the Registrar to the Issue dated March 01, 2024.
8. Tripartite agreement between the NSDL, our Company and the Registrar to the Issue dated February 20, 2024.

MATERIAL DOCUMENTS

1. Certified true copies of the Memorandum and Articles of Association of our Company, as amended from time to time.
2. Copy of Certificate of Incorporation dated June 01, 1998, issued under the name Quest Laboratories Private Limited, issued by Registrar of Companies, Madhya Pradesh, Gwalior.
3. Copy of Fresh Certificate of Incorporation dated January 23, 2024, issued by Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies, Centralised Processing Centre, consequent to name change from Quest Laboratories Private Limited to Quest Laboratories Limited pursuant to the conversion of our Company into a Public Limited Company.
4. Resolution of the Board of Directors dated February 02, 2024 in relation to the Issue.
5. Resolution of the Shareholders of our Company, passed at the Extra Ordinary General Meeting held on February 09, 2024 in relation to the Issue.
6. Examination report for Restated Financial Statements dated April 17, 2024 from our Peer Review Auditor included in this Prospectus.
7. The Statement of Possible Tax Benefits dated February 24, 2024 from our Peer Review Auditor included in this Prospectus.
8. Copies of Audited Financial Statements of the Company for the period ended December 31, 2023 and for the financial year ended March 31, 2023, 2022, and 2021.

9. Consents of our Directors, Promoters, Company Secretary and Compliance Officer, Chief Financial Officer, Senior Management Personnel, Statutory Auditor, Chartered Engineer, Peer Review Auditor, Banker(s) to the Company, Book Running Lead Manager, Legal Advisor to the Issue, Registrar to the Issue, Banker to the Issue, Syndicate Member, Underwriter and Market Maker to act in their respective capacities.
10. Certificate on KPI's issued by the Statutory Auditor Shyam S Gupta & Associates, Chartered Accountants, by way of their certificate dated April 17, 2024.
11. Board Resolution dated February 29, 2024 for approval of Draft Red Herring Prospectus and dated for May 07, 2024 approval of Red Herring Prospectus.
12. Due Diligence Certificate dated May 08, 2024 to SEBI by the Book Running Lead Manager
13. In Approval from NSE vide letter dated May 03, 2024 to use the name of NSE in this Offer Document for listing of Equity Shares on the NSE Emerge

Any of the contracts or documents mentioned in this Prospectus may be amended or modified at any time if so, required in the interest of our Company or if required by the other parties, without the consent of shareholders subject to compliance of the provisions contained in the Companies Act and other relevant statutes.

DECLARATION

We hereby declare that all relevant provisions of the Companies Act, 2013 and the guidelines or regulations issued by the Government and / or the guidelines or regulations issued by the Securities and Exchange Board of India, as the case may be, have been complied with and no statement made in this Prospectus is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts (Regulation) Rules, 1957, amended, or the rules made thereunder or Guidelines / Regulations issued, as the case may be. We further certify that all statements and disclosures made in this Prospectus are true and correct.

SIGNED BY THE DIRECTORS OF OUR COMPANY

Sd/- Mr. Anil Kumar Sabarwal Chairman & Managing Director DIN: 00646133	Sd/- Ms. Tejaswini Sabarwal Whole Time Director DIN: 09088283
Sd/- Mr. Rahul Dangi Non-Executive Independent Director DIN: 09088127	Sd/- Mr. Gautam Kothari Non-Executive Independent Director DIN: 00115063
Sd/- Mr. Amit Ramesh Chandak Non-Executive Independent Director DIN: 09419479	Sd/- Mr. Basant Lal Menghwani Non-Executive Independent Director DIN: 10459081

SIGNED BY THE CFO AND CS OF OUR COMPANY

Sd/- Mr. Ram Krishna Sharma Chief Financial Officer	Sd/- Mr. Jayesh Jain Company Secretary and Compliance Officer

Date: May 20, 2024

Place: Madhya Pradesh